Aims	O
Coeliac	B-DIS
disease	I-DIS
CD	B-DIS
is	O
an	O
autoimmune	B-DIS
disorder	I-DIS
with	O
a	O
prevalence	B-EPI
≤2	B-STAT
%	I-STAT
that	O
causes	O
an	O
immune	O
reaction	O
to	O
gluten	O
.	O

Growth	O
retardation	O
GR	O
generally	O
accompanies	O
CD	B-DIS
due	O
to	O
gastrointestinal	O
complications	O
and	O
should	O
be	O
treated	O
as	O
early	O
as	O
possible	O
along	O
with	O
initiation	O
of	O
a	O
gluten	O
-	O
free	O
diet	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
indicators	O
of	O
GR	O
in	O
patients	O
with	O
CD	O
.	O

Methods	O
This	O
single	O
-	O
centre	O
retrospective	O
study	O
included	O
paediatric	O
outpatients	O
with	O
CD	O
.	O

All	O
patients	O
were	O
diagnosed	O
with	O
CD	O
via	O
serological	O
analysis	O
and	O
upper	B-DIS
gastrointestinal	I-DIS
endoscopy	I-DIS
if	O
necessary	O
.	O

Patient	O
records	O
were	O
obtained	O
from	O
Adana	O
City	O
Training	O
and	O
Research	O
Hospital	O
.	O

Patients	O
that	O
were	O
diagnosed	O
with	O
GR	O
accompanying	O
CD	O
were	O
given	O
oral	O
nutritional	O
supplements	O
and	O
followed	O
-	O
up	O
every	O
3	O
-	O
6	O
months	O
.	O

Statistical	O
relationships	O
between	O
demographics	O
and	O
anthropometric	O
measurements	O
duration	O
of	O
breastfeeding	O
gluten	O
contact	O
time	O
diet	O
duration	O
presenting	O
complaints	B-DIS
and	O
serological	O
findings	O
were	O
evaluated	O
.	O

Results	O
This	O
study	O
included	O
169	O
paediatric	O
outpatients	O
between	O
ages	O
1	O
and	O
18	O
.	O

Longer	O
symptom	O
duration	O
and	O
shorter	O
breastfeeding	O
duration	O
were	O
significantly	O
correlated	O
with	O
GR	O
accompanying	O
CD	O
P	O
=	O
0.007	O
and	O
P	O
=	O
0.029	O
respectively	O
.	O

Vomiting	B-DIS
was	O
the	O
only	O
symptom	O
that	O
was	O
correlated	O
with	O
the	O
presence	O
of	O
GR	O
P	O
=	O
0.010	O
.	O

Helicobacter	O
pylori	B-DIS
infection	I-DIS
was	O
not	O
correlated	O
with	O
the	O
presence	O
of	O
GR	O
P	O
=	O
0.277	O
.	O

Conclusions	O
GR	O
should	O
be	O
treated	O
as	O
early	O
as	O
possible	O
to	O
reduce	O
the	O
severity	O
of	O
CD	O
and	O
a	O
6	O
months	O
sole	O
breastfeeding	O
followed	O
by	O
solid	O
foods	O
accompanied	O
by	O
breastfeeding	O
for	O
2	O
years	O
is	O
crucial	O
for	O
preventing	O
GR	O
.	O

Moreover	O
vomiting	B-DIS
as	O
a	O
presenting	O
complaint	O
in	O
patients	O
with	O
CD	O
might	O
be	O
indicative	O
of	O
the	O
presence	O
of	O
GR	O
.	O

The	O
Australian	O
Cattle	B-DIS
dog	O
ACD	O
is	O
one	O
of	O
many	O
breeds	O
predisposed	O
to	O
congenital	B-DIS
sensorineural	I-DIS
deafness	I-DIS
CSD	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
estimate	O
CSD	B-DIS
prevalence	B-EPI
and	O
investigate	O
any	O
association	O
with	O
phenotype	O
in	O
the	O
ACD	O
in	O
the	O
UK	B-LOC
.	O

The	O
database	O
of	O
the	O
authors	O
'	O
institution	O
was	O
searched	O
for	O
ACD	O
puppies	O
undergoing	O
brainstem	O
auditory	O
evoked	O
response	O
BAER	O
testing	O
for	O
CSD	O
screening	O
1999	O
-	O
2019	O
.	O

Inclusion	O
criteria	O
were	O
BAER	O
performed	O
at	O
4	O
-	O
10	O
weeks	O
of	O
age	O
testing	O
of	O
complete	O
litters	O
and	O
available	O
phenotypic	O
data	O
.	O

The	O
age	O
sex	O
coat	O
and	O
iris	O
colour	O
presence	O
and	O
location	O
of	O
face	O
and	O
body	O
patches	O
hearing	O
status	O
and	O
BAER-	O
determined	O
parental	O
hearing	O
status	O
of	O
each	O
puppy	O
were	O
recorded	O
.	O

A	O
multivariable	O
mixed	O
-	O
effects	O
logistic	O
regression	O
model	O
was	O
used	O
to	O
calculate	O
odds	O
ratios	O
and	O
95	O
%	O
confidence	O
intervals	O
to	O
determine	O
whether	O
any	O
of	O
these	O
variables	O
were	O
significantly	O
associated	O
with	O
CSD	O
while	O
adjusting	O
for	O
clustering	O
at	O
litter	O
level	O
.	O

Inclusion	O
criteria	O
were	O
met	O
for	O
524	O
puppies	O
.	O

Hearing	O
was	O
bilaterally	O
normal	O
in	O
464	O
puppies	O
88.6	B-STAT
%	I-STAT
.	O

The	O
prevalence	B-EPI
of	O
unilateral	O
and	O
bilateral	O
CSD	B-DIS
was	O
9.7	B-STAT
%	I-STAT
and	O
1.7	B-STAT
%	I-STAT
respectively	O
.	O

On	O
the	O
basis	O
of	O
multivariable	O
analysis	O
the	O
presence	O
of	O
a	O
pigmented	O
face	O
patch	O
was	O
the	O
only	O
phenotypic	O
variable	O
significantly	O
associated	O
with	O
CSD	B-DIS
and	O
was	O
linked	O
to	O
a	O
reduced	O
risk	O
of	O
the	O
condition	O
.	O

The	O
prevalence	B-EPI
was	O
similar	O
to	O
that	O
reported	O
in	O
an	O
Australian	O
population	O
of	O
ACDs	O
.	O

The	O
key	O
findings	O
from	O
this	O
study	O
were	O
that	O
overall	O
CSD	O
prevalence	B-EPI
in	O
the	O
ACD	O
population	O
in	O
the	O
UK	B-LOC
was	O
11.4	B-STAT
%	I-STAT
and	O
puppies	O
with	O
a	O
face	O
patch	O
were	O
at	O
reduced	O
risk	O
of	O
the	O
condition	O
.	O

Despite	O
the	O
importance	O
of	O
Culex	O
species	O
as	O
major	O
vectors	O
of	O
Rift	B-LOC
Valley	I-LOC
fever	B-DIS
virus	O
West	B-LOC
Nile	I-LOC
virus	O
and	O
the	O
microfilariae	O
that	O
cause	O
lymphatic	O
filariasis	O
information	O
on	O
these	O
mosquitoes	O
in	O
Sudan	B-LOC
is	O
limited	O
to	O
works	O
published	O
65	O
years	O
ago	O
in	O
the	O
former	O
Anglo	O
-	O
Egyptian	O
Sudan	B-LOC
where	O
some	O
species	O
were	O
only	O
recorded	O
from	O
areas	O
of	O
the	O
territory	O
now	O
known	O
as	O
South	B-LOC
Sudan	I-LOC
.	O

In	O
this	O
paper	O
we	O
provide	O
updated	O
information	O
on	O
Culex	O
mosquitoes	O
collected	O
indoors	O
during	O
surveillance	O
studies	O
conducted	O
along	O
the	B-LOC
Nile	I-LOC
River	I-LOC
in	O
central	O
and	O
northern	O
areas	O
of	O
Sudan	B-LOC
between	O
2012	O
and	O
2019	O
.	O

Of	O
3411	O
female	O
mosquitoes	O
collected	O
in	O
Khartoum	B-LOC
and	O
northern	O
states	O
along	O
the	O
river	O
2560	O
75	B-STAT
%	I-STAT
were	O
specimens	O
of	O
Culex	O
belonging	O
to	O
12	O
species	O
Cx	O
.	O

Culex	O
antennatus	B-DIS
Becker	I-DIS
1903	O
Cx	O
.	O

Cux	O
.	O

laticinctus	O
Edwards	O
1913	O
Cx	O
.	O

Cux	O
.	O

neavei	O
Theobald	O
1906	O
Cx	O
.	O

Cux	O
.	O

pipiens	O
Linnaeus	O
1758	O
Cx	O
.	O

Cux	O
.	O

perexiguus	O
Theobald	O
1903	O
Cx	O
.	O

Cux	O
.	O

poicilipes	O
Theobald	O
1903	O
Cx	O
.	O

Cux	O
.	O

quinquefasciatus	O
Say	O
1823	O
Cx	O
.	O

Cux	O
.	O

simpsoni	O
Theobald	O
1905	O
Cx	O
.	O

Cux	O
.	O

sinaiticus	O
Kirkpatrick	O
1925	O
Cx	O
.	O

Cux	O
.	O

theileri	O
Theobald	O
1903	O
Cx	O
.	O

Cux	O
.	O

tritaeniorhynchus	O
Giles	O
1901	O
and	O
Cx	O
.	O

Culiciomyia	O
macfiei	O
Edwards	O
1923	O
.	O

This	O
is	O
the	O
first	O
record	O
for	O
Cx	O
.	O

tritaeniorhynchus	O
and	O
Cx	O
.	O

macfiei	O
in	O
central	O
Sudan	B-LOC
.	O

The	O
relative	O
abundance	O
of	O
each	O
species	O
varied	O
in	O
different	O
areas	O
and	O
seasons	O
but	O
Cx	O
.	O
antennatus	O
and	O
Cx	O
.	O
quinquefasciatus	O
were	O
the	O
most	O
abundant	O
indoor	O
resting	O
species	O
.	O

We	O
provide	O
an	O
updated	O
dichotomous	O
key	O
for	O
the	O
identiﬁcation	O
of	O
the	O
adults	O
of	O
Culex	O
mosquitoes	O
known	O
to	O
occur	O
in	O
the	O
Republic	B-LOC
of	I-LOC
the	I-LOC
Sudan	I-LOC
.	O

Objectives	O
Few	O
studies	O
have	O
investigated	O
the	O
prognostic	O
factors	O
for	O
idiopathic	B-DIS
inflammatory	I-DIS
myopathy	I-DIS
-	O
associated	O
interstitial	B-DIS
lung	I-DIS
disease	I-DIS
IIM	B-DIS
-	O
ILD	B-DIS
across	O
different	O
clinical	O
/	O
serological	O
phenotypes	O
.	O

Methods	O
We	O
conducted	O
a	O
retrospective	O
analysis	O
of	O
patients	O
diagnosed	O
with	O
IIM	B-DIS
between	O
January	O
2012	O
and	O
December	O
2017	O
.	O

Results	O
Of	O
the	O
760	O
IIM	B-DIS
cases	O
registered	O
679	O
adult	O
cases	O
were	O
included	O
in	O
this	O
study	O
.	O

ILD	B-DIS
was	O
present	B-EPI
in	O
508	O
cases	O
and	O
the	O
presence	B-EPI
of	O
ILD	B-DIS
in	O
the	O
clinically	O
amyopathic	O
DM	O
DM	O
and	O
PM	O
groups	O
was	O
92.7	B-STAT
73.6	B-STAT
and	O
55.1	B-STAT
%	I-STAT
respectively	O
P	O
<	O
0.01	O
.	O

The	O
prevalence	B-EPI
of	O
ILD	B-DIS
in	O
the	O
anti	O
-	O
synthetase	O
antibody	O
ASA	O
+	O
-IIM	B-DIS
group	O
was	O
higher	O
than	O
that	O
in	O
ASA	B-DIS
--	O
IIM	O
group	O
95.2	B-STAT
vs	O
72.4	B-STAT
%	I-STAT
P	O
<	O
0.01	O
;	O
no	O
such	O
difference	O
was	O
found	O
between	O
the	O
anti	O
-	O
histidyl	O
-	O
tRNA	O
synthetase	O
Jo-1	O
+	O
-IIM	O
and	O
Jo-1	O
-	O
ASA+-IIM	O
groups	O
93.0	B-STAT
vs	O
98.5	B-STAT
%	I-STAT
0.05	O
.	O

The	O
prevalence	B-EPI
of	O
ILD	B-DIS
in	O
the	O
melanoma	B-DIS
differentiation	O
-	O
associated	O
protein-5	O
MDA-5	O
+	O
-IIM	O
group	O
was	O
higher	O
than	O
that	O
in	O
MDA-5	O
--	O
IIM	O
group	O
97.8	B-STAT
vs	O
72.1	B-STAT
%	I-STAT
P	O
<	O
0.01	O
.	O

Among	O
adults	O
with	O
IIM	B-DIS
men	O
with	O
concurrent	O
ILD	B-DIS
who	O
were	O
older	O
than	O
50	O
years	O
were	O
most	O
likely	O
to	O
die	O
.	O

No	O
significant	O
difference	O
was	O
found	O
in	O
the	O
all	O
-	O
cause	O
mortality	O
rates	O
between	O
DM	O
-	O
ILD	O
and	O
clinically	O
amyopathic	O
DM	O
-	O
ILD	O
groups	O
33.3	B-STAT
vs	O
23	B-STAT
%	I-STAT
0.05	O
although	O
both	O
were	O
higher	O
than	O
that	O
in	O
PM	O
group	O
13.2	B-STAT
%	I-STAT
P	O
=	O
0.01	O
and	O
P	O
<	O
0.05	O
respectively	O
.	O

No	O
difference	O
was	O
found	O
in	O
the	O
all	O
-	O
cause	O
mortality	O
rates	O
between	O
MDA5	O
-	O
ASA	O
--	O
IM	O
-	O
ILD	O
and	O
MDA5	O
-	O
ASA+-IM	O
-	O
ILD	O
groups	O
17.2	O
vs	O
12.8	B-STAT
%	I-STAT
0.05	O
and	O
both	O
were	O
lower	O
than	O
that	O
in	O
MDA5+ASA	O
--	O
IM	O
-	O
ILD	O
group	O
33.7	B-STAT
%	I-STAT
P	O
<	O
0.05	O
.	O

Conclusion	O
The	O
prevalence	B-EPI
of	O
ILD	B-DIS
in	O
IIM	B-DIS
and	O
the	O
prognosis	O
of	O
IIM	O
-	O
ILD	O
patients	O
may	O
vary	O
depending	O
on	O
the	O
statuses	O
of	O
the	O
ASA	O
and	O
MDA-5	O
antibodies	O
.	O

Clinical	O
disorders	O
known	O
to	O
affect	O
inherited	O
gamma	O
-	O
amino	O
butyric	O
acid	O
GABA	O
metabolism	O
are	O
autosomal	O
recessively	O
inherited	O
succinic	O
semialdehyde	O
dehydrogenase	O
and	O
GABA	O
-	O
transaminase	O
deficiency	O
.	O

The	O
clinical	O
presentation	O
of	O
succinic	O
semialdehyde	O
dehydrogenase	O
deficiency	O
includes	O
intellectual	B-DIS
disability	I-DIS
ataxia	I-DIS
obsessive	I-DIS
-	I-DIS
compulsive	O
disorder	B-DIS
and	O
epilepsy	O
with	O
a	O
nonprogressive	O
course	O
in	O
typical	O
cases	O
although	O
a	O
progressive	O
form	O
in	O
early	O
childhood	O
as	O
well	O
as	O
deterioration	O
in	O
adulthood	O
with	B-DIS
worsening	O
epilepsy	O
are	O
reported	O
.	O

GABA	O
-	O
transaminase	O
deficiency	O
is	O
associated	O
with	O
a	B-DIS
severe	I-DIS
neonatal	I-DIS
-	O
infantile	O
epileptic	O
encephalopathy	O
.	O

The	O
deficiency	O
of	O
21	B-DIS
-	O
hydroxylase	O
due	O
to	O
CYP21A2	O
pathogenic	O
variants	O
is	O
a	O
rather	O
frequent	O
disease	O
with	O
serious	O
consequences	O
going	O
from	O
a	O
real	O
mortality	O
risk	B-DIS
to	O
infertility	O
and	O
to	O
milder	O
symptoms	O
nevertheless	O
important	O
for	O
affecting	O
the	O
patients	O
'	O
self	O
-	O
esteem	O
.	O

In	O
the	O
most	O
severe	O
cases	O
life	B-DIS
-	I-DIS
threatening	I-DIS
adrenal	I-DIS
salt	O
wasting	O
crises	O
may	O
occur	O
.	O

Significant	O
morbidity	O
including	O
the	O
possibility	O
of	O
mistaken	O
gender	O
determination	O
precocious	O
puberty	B-DIS
infertility	I-DIS
and	O
growth	O
arrest	O
with	O
consequent	O
short	O
stature	B-DIS
may	O
also	O
affect	O
these	O
patients	O
.	O

In	O
the	O
less	O
severe	O
cases	O
milder	O
symptoms	O
like	O
hirsutism	B-DIS
will	O
likely	O
affect	O
the	O
image	O
of	O
the	O
self	O
with	O
strong	O
psychological	O
consequences	O
.	O

Its	O
diagnosis	O
is	O
confirmed	O
by	O
17OH	O
-	O
progesterone	O
dosages	O
exceeding	O
the	O
cut	O
-	O
off	O
value	O
of	O
10/15	O
ng	O
/	O
ml	O
but	O
genotyping	O
is	O
progressively	O
assuming	O
an	O
essential	O
role	O
in	O
the	O
study	O
of	O
these	O
patients	O
particularly	O
in	O
confirming	O
difficult	O
cases	O
determining	O
some	O
aspects	O
of	O
the	O
prognosis	O
and	O
allowing	O
a	O
correct	O
genetic	O
counseling	O
.	O

Genotyping	O
is	O
a	O
difficult	O
process	O
due	O
to	O
the	O
occurrence	O
of	O
both	O
a	O
gene	O
and	O
a	O
highly	O
homologous	O
pseudo	O
gene	O
.	O

However	O
new	O
tools	O
are	O
opening	O
new	O
possibilities	O
to	O
this	O
analysis	O
and	O
improving	O
the	O
chances	O
of	O
a	O
correct	O
diagnosis	O
and	O
better	O
understanding	O
of	O
the	O
underlying	O
mechanisms	O
of	O
the	O
disease	O
.	O

Beyond	O
the	O
10	O
classic	O
pathogenic	O
variants	O
usually	O
searched	O
for	O
in	O
most	O
laboratories	O
a	O
correct	O
analysis	O
of	O
21OH	O
-	O
deficiency	O
cases	O
implies	O
completely	O
sequencing	O
of	O
the	O
entire	O
gene	O
and	O
the	O
determination	O
of	O
gene	O
duplications	O
.	O

These	O
are	O
now	O
recognized	O
to	O
occur	O
frequently	O
and	O
can	O
be	O
responsible	O
for	O
some	O
false	O
positive	O
cases	O
.	O

And	O
finally	O
because	O
gene	O
conversions	O
can	O
include	O
several	O
pathogenic	O
variants	O
one	O
can	O
not	O
be	O
certain	O
of	O
identifying	O
that	O
both	O
alleles	O
are	O
affected	O
without	O
studying	O
parental	O
DNA	O
samples	O
.	O

A	O
complete	O
genotype	O
characterization	O
should	O
be	O
considered	O
essential	O
in	O
the	O
preparation	O
for	O
pregnancy	O
even	O
in	O
the	O
case	O
of	O
parents	O
with	O
milder	O
forms	O
of	O
the	O
disease	O
or	O
even	O
just	O
carriers	O
since	O
it	O
has	O
been	O
reported	O
that	O
giving	O
birth	O
to	O
progeny	O
with	O
the	O
severe	O
classic	O
forms	O
occurs	O
with	O
a	O
much	O
higher	O
frequency	O
than	O
expected	O
.	O

Barth	B-DIS
syndrome	I-DIS
BTHS	B-DIS
is	O
a	O
rare	O
X	O
-	O
linked	O
recessive	O
infantile	O
-	O
onset	O
debilitating	O
disorder	O
characterized	O
by	O
early	O
-	O
onset	O
cardiomyopathy	O
skeletal	O
muscle	O
myopathy	O
growth	O
delay	O
and	O
neutropenia	O
with	O
a	O
worldwide	O
incidence	B-EPI
of	O
1/300	B-STAT
000	I-STAT
-	I-STAT
400000	I-STAT
live	O
births	O
.	O

The	O
high	O
mortality	O
rate	O
throughout	O
infancy	O
in	O
BTHS	B-DIS
patients	O
is	O
related	O
primarily	O
to	O
progressive	O
cardiomyopathy	B-DIS
and	O
a	O
weakened	O
immune	O
system	O
.	O

BTHS	B-DIS
is	O
caused	O
by	O
defects	O
in	O
the	O
TAZ	O
gene	O
that	O
encodes	O
tafazzin	O
a	O
transacylase	O
responsible	O
for	O
the	O
remodeling	O
and	O
maturation	O
of	O
the	O
mitochondrial	O
phospholipid	O
cardiolipin	O
CL	O
which	O
is	O
critical	O
to	O
normal	O
mitochondrial	O
structure	O
and	O
function	O
i.e	O
.	O

ATP	O
generation	O
.	O

A	O
deficiency	O
in	O
tafazzin	O
results	O
in	O
up	O
to	O
a	O
95	B-STAT
%	I-STAT
reduction	O
in	O
levels	O
of	O
structurally	O
mature	O
CL	O
.	O

Because	O
the	O
heart	O
is	O
the	O
most	O
metabolically	O
active	O
organ	O
in	O
the	O
body	O
with	O
the	O
highest	O
mitochondrial	O
content	O
of	O
any	O
tissue	O
mitochondrial	B-DIS
dysfunction	I-DIS
plays	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
heart	B-DIS
failure	I-DIS
in	O
patients	O
with	O
BTHS	B-DIS
.	O

Changes	O
in	O
mitochondrial	O
oxidative	O
phosphorylation	O
reduce	O
the	O
ability	O
of	O
mitochondria	O
to	O
meet	O
the	O
ATP	O
demands	O
of	O
the	O
human	O
heart	O
as	O
well	O
as	O
skeletal	O
muscle	O
namely	O
ATP	O
synthesis	O
does	O
not	O
match	O
the	O
rate	O
of	O
ATP	O
consumption	O
.	O

The	O
presence	O
of	O
several	O
cardiomyopathic	O
phenotypes	O
have	O
been	O
described	O
in	O
BTHS	B-DIS
including	O
dilated	B-DIS
cardiomyopathy	I-DIS
left	O
ventricular	B-DIS
noncompaction	I-DIS
either	O
alone	O
or	O
in	O
conjunction	O
with	O
other	O
cardiomyopathic	O
phenotypes	O
endocardial	O
fibroelastosis	O
hypertrophic	B-DIS
cardiomyopathy	I-DIS
and	O
an	O
apical	O
form	O
of	O
hypertrophic	B-DIS
cardiomyopathy	I-DIS
among	O
others	O
all	O
of	O
which	O
can	O
be	O
directly	O
attributed	O
to	O
the	O
lack	O
of	O
CL	O
synthesis	O
remodeling	O
and	O
maturation	O
with	O
subsequent	O
mitochondrial	B-DIS
dysfunction	I-DIS
.	O

Several	O
mechanisms	O
by	O
which	O
these	O
cardiomyopathic	O
phenotypes	O
exist	O
have	O
been	O
proposed	O
thereby	O
identifying	O
potential	O
targets	O
for	O
treatment	O
.	O

Dysfunction	O
of	O
the	O
sarcoplasmic	O
reticulum	O
Ca	O
2	O
+	O
<	O
/s	O
-ATPase	O
pump	O
and	O
inflammation	B-DIS
potentially	O
triggered	O
by	O
circulating	O
mitochondrial	O
components	O
have	O
been	O
identified	O
.	O

Currently	O
treatment	O
modalities	O
are	O
aimed	O
at	O
addressing	O
symptomatology	O
of	O
HF	O
in	O
BTHS	B-DIS
but	O
do	O
not	O
address	O
the	O
underlying	O
pathology	O
.	O

One	O
novel	O
therapeutic	O
approach	O
includes	O
elamipretide	O
which	O
crosses	O
the	O
mitochondrial	O
outer	O
membrane	O
to	O
localize	O
to	O
the	O
inner	O
membrane	O
where	O
it	O
associates	O
with	O
cardiolipin	O
to	O
enhance	O
ATP	O
synthesis	O
in	O
several	O
organs	O
including	O
the	O
heart	O
.	O

Encouraging	O
clinical	O
results	O
of	O
the	O
use	O
of	O
elamipretide	O
in	O
treating	O
patients	O
with	O
BTHS	B-DIS
support	O
the	O
potential	O
use	O
of	O
this	O
drug	O
for	O
management	O
of	O
this	O
rare	O
disease	O
.	O

In	O
recent	O
years	O
a	O
growing	O
body	O
of	O
research	O
has	O
shown	O
sex	O
differences	O
in	O
the	O
prevalence	B-EPI
and	O
symptomatology	O
of	O
psychopathologies	B-DIS
such	O
as	O
depression	B-DIS
anxiety	I-DIS
and	O
fear	B-DIS
-	I-DIS
related	O
disorders	O
all	O
of	O
which	O
show	B-EPI
high	O
incidence	O
rates	O
in	O
early	O
life	O
.	O

This	O
has	O
highlighted	O
the	O
importance	O
of	O
including	O
female	O
subjects	O
in	O
animal	O
studies	O
as	O
well	O
as	O
delineating	O
sex	O
differences	O
in	O
neural	O
processing	O
across	O
development	O
.	O

Of	O
particular	O
interest	O
is	O
the	O
corticolimbic	O
system	O
comprising	O
the	O
hippocampus	O
amygdala	O
and	O
medial	O
prefrontal	O
cortex	O
.	O

In	O
rodents	O
these	O
corticolimbic	O
regions	O
undergo	O
dynamic	O
changes	O
in	O
early	O
life	O
and	O
disruption	O
to	O
their	O
normative	O
development	O
is	O
believed	O
to	O
underlie	O
the	O
age	O
and	O
sex	O
-	O
dependent	O
effects	O
of	O
stress	O
on	O
affective	O
processing	O
.	O

In	O
this	O
review	O
we	O
consolidate	O
research	O
on	O
sex	O
differences	O
in	O
the	O
hippocampus	O
amygdala	O
and	O
medial	O
prefrontal	O
cortex	O
across	O
early	O
development	O
.	O

First	O
we	O
briefly	O
introduce	O
current	O
principles	O
on	O
sexual	O
differentiation	O
of	O
the	O
rodent	O
brain	O
.	O

We	O
then	O
showcase	O
corticolimbic	O
regional	O
sex	O
differences	O
in	O
volume	O
morphology	O
synaptic	O
organization	O
cell	O
proliferation	O
microglia	O
and	O
GABAergic	O
signaling	O
and	O
explain	O
how	O
these	O
differences	O
are	O
influenced	O
by	O
perinatal	O
and	O
pubertal	O
gonadal	O
hormones	O
.	O

In	O
compiling	O
this	O
research	O
we	O
outline	O
evidence	O
of	O
what	O
and	O
when	O
sex	O
differences	O
emerge	O
in	O
the	O
developing	O
corticolimbic	O
system	O
and	O
illustrate	O
how	O
temporal	O
dynamics	O
of	O
its	O
maturational	O
trajectory	O
may	O
differ	O
in	O
male	O
and	O
female	O
rodents	O
.	O

This	O
will	O
help	O
provide	O
insight	O
into	O
potential	O
neural	O
mechanisms	O
underlying	O
sex	O
-	O
specific	O
critical	O
windows	O
for	O
stress	O
susceptibility	O
and	O
behavioral	O
emergence	O
.	O

Background	O
As	O
a	O
result	O
of	O
the	O
current	O
global	O
pandemic	O
the	O
dental	O
profession	O
has	O
utilized	O
teledentistry	O
to	O
reduce	O
footfall	O
in	O
the	O
hospitals	O
and	O
clinics	O
where	O
possible	O
.	O

Pediatric	O
dental	O
consultants	O
form	O
a	O
vital	O
part	O
of	O
a	O
multidisciplinary	O
team	O
and	O
regularly	O
monitor	O
the	O
dental	O
growth	O
and	O
development	O
of	O
patients	O
with	O
cleft	B-DIS
lip	I-DIS
and	O
palate	B-DIS
.	O

Objective	O
To	O
assess	O
the	O
effectiveness	O
of	O
the	O
service	O
provided	O
by	O
pediatric	O
dental	O
consultants	O
in	O
the	O
South	O
Thames	O
Cleft	B-DIS
Service	O
at	O
Evelina	O
Children	O
's	O
Hospital	O
during	O
the	O
COVID-19	O
pandemic	O
through	O
virtual	O
clinics	O
.	O

Design	O
Data	O
were	O
collected	O
retrospectively	O
and	O
include	O
all	O
cleft	B-DIS
patients	O
contacted	O
via	O
the	O
virtual	O
clinic	O
during	O
May	O
to	O
July	O
2020	O
.	O

Patients	O
were	O
prioritized	O
by	O
the	O
Red	O
Amber	O
Green	O
RAG	O
scale	O
to	O
highlight	O
the	O
urgency	O
of	O
their	O
next	O
face	O
-	O
to	O
-	O
face	O
appointment	O
.	O

Results	O
A	O
total	O
of	O
215	O
patients	O
were	O
contacted	O
during	O
this	O
period	O
with	O
a	O
97	O
%	O
response	O
rate	O
.	O

Patients	O
given	O
a	O
RAG	O
score	O
of	O
GREEN	O
86	O
%	O
meant	O
no	O
urgent	O
requirement	O
for	O
a	O
face	O
-	O
to	O
-	O
face	O
consultation	O
and	O
AMBER	O
8	B-STAT
%	I-STAT
patients	O
required	O
treatment	O
that	O
was	O
deemed	O
nonurgent	O
.	O

However	O
3	B-STAT
%	I-STAT
of	O
patients	O
received	O
a	O
RED	O
rating	O
as	O
they	O
required	O
urgent	O
input	O
.	O

Conclusion	O
Through	O
these	O
virtual	O
clinics	O
the	O
pediatric	O
team	O
was	O
able	O
to	O
reach	O
208	O
patients	O
and	O
provided	O
advice	O
and	O
reassurance	O
.	O

The	O
need	O
for	O
face	O
-	O
to	O
-	O
face	O
appointment	O
was	O
eliminated	O
for	O
11	O
%	O
of	O
patients	O
who	O
were	O
discharged	O
to	O
their	O
local	O
dental	O
practitioners	O
thereby	O
reducing	O
the	O
risk	O
of	O
spreading	O
COVID-19	O
.	O

BACKGROUND	O
Intellectual	B-DIS
disability	I-DIS
ID	B-DIS
affects	O
1	B-STAT
-	I-STAT
3	I-STAT
%	I-STAT
of	O
the	O
Western	B-LOC
population	I-LOC
and	O
is	O
heterogeneous	O
in	O
origin	O
.	O

Mutations	O
in	O
X	O
-	O
linked	O
genes	O
represent	O
5	B-STAT
-	I-STAT
10	I-STAT
%	I-STAT
of	O
ID	B-DIS
in	O
males	O
.	O

Fragile	B-DIS
X	I-DIS
syndrome	I-DIS
due	O
to	O
the	O
silencing	O
of	O
the	O
FMR1	O
gene	O
is	O
the	O
most	O
common	O
form	O
of	O
ID	O
with	O
a	O
prevalence	B-EPI
of	O
around	O
15000	O
males	O
.	O

Females	O
are	O
usually	O
non-	O
or	O
mildly	O
affected	O
carriers	O
and	O
in	O
a	O
few	O
rare	O
cases	O
the	O
only	O
gender	O
affected	O
.	O

Array	O
comparative	O
genome	O
hybridization	O
aCGH	O
and	O
next	O
-	O
generation	O
sequencing	O
NGS	O
have	O
dramatically	O
changed	O
the	O
nature	O
of	O
human	O
genome	O
analysis	O
leading	O
to	O
the	O
identification	O
of	B-DIS
new	I-DIS
X	I-DIS
-	I-DIS
linked	O
intellectual	O
disability	O
syndromes	O
and	O
disease	O
-	O
causing	O
genes	O
.	O

SOURCES	O
OF	O
DATAOriginal	O
papers	O
reviews	O
guidelines	O
and	O
experiences	O
of	O
the	O
diagnostic	O
laboratories	O
.	O

AREAS	O
OF	O
AGREEMENTFamily	O
history	O
and	O
clinical	O
examination	O
still	O
are	O
essential	O
to	O
choose	O
the	O
appropriate	O
diagnostic	O
tests	O
including	O
a	O
disease	O
-	O
specific	O
genetic	O
test	O
aCGH	O
or	O
FMR1	O
molecular	O
analysis	O
.	O

If	O
negative	O
NGS	O
approaches	O
like	O
well	O
-	O
defined	O
gene	O
panels	O
whole	O
exome	O
or	O
even	O
whole	O
genome	O
sequencing	O
are	O
increasingly	O
being	O
used	O
improving	O
diagnostics	O
and	O
leading	O
to	O
the	O
identification	O
of	O
novel	O
disease	O
mechanisms	O
.	O

AREAS	O
OF	O
CONTROVERSYThe	O
main	O
challenge	O
in	O
the	O
era	O
of	O
NGS	O
is	O
filtering	O
and	O
interpretation	O
of	O
the	O
data	O
generated	O
by	O
the	O
analysis	O
of	O
a	O
single	O
individual	O
.	O

In	O
X	O
-	O
linked	O
cases	O
assessing	O
pathogenicity	O
is	O
particularly	O
challenging	O
even	O
more	O
when	O
the	O
variant	O
is	O
found	O
to	O
be	O
inherited	O
from	O
a	O
healthy	O
carrier	O
mother	O
or	O
when	O
a	O
heterozygous	O
X	O
-	O
linked	O
mutation	O
is	O
found	O
in	O
an	O
impaired	O
female	O
.	O

GROWING	O
POINTSAt	O
present	O
variant	O
interpretation	O
remains	O
a	O
challenging	O
task	O
especially	O
in	O
X	B-DIS
-	I-DIS
linked	O
disorders	O
.	O

We	O
review	O
the	O
main	O
difficulties	O
and	O
propose	O
a	O
comprehensive	O
overview	O
that	O
might	O
aid	O
in	O
variant	O
interpretation	O
.	O

Establishing	O
a	O
genetic	O
diagnosis	O
facilitates	O
counseling	O
and	O
allows	O
better	O
delineation	O
of	O
clinical	O
phenotypes	O
.	O

AREAS	O
TIMELY	O
FOR	O
DEVELOPING	O
RESEARCHTo	O
improve	O
variant	O
interpretation	O
there	O
is	O
need	O
to	O
refine	O
in	O
silico	O
predictions	O
with	O
specific	O
criteria	O
for	O
each	O
gene	O
and	O
to	O
develop	O
cost	O
-	O
effective	O
functional	O
tools	O
which	O
can	O
be	O
easily	O
transferred	O
to	O
diagnostics	O
.	O

Background	O
Vitiligo	B-DIS
is	O
a	O
disfiguring	O
skin	B-DIS
disease	I-DIS
with	O
profound	O
psychosocial	O
impacts	O
such	O
as	O
anxiety	B-DIS
but	O
the	O
reported	O
effect	O
sizes	O
of	O
associations	O
vary	O
.	O

We	O
aimed	O
to	O
conduct	O
a	O
meta	O
-	O
analysis	O
to	O
quantify	O
the	O
strength	O
of	O
association	B-DIS
between	O
anxiety	B-DIS
and	O
vitiligo	O
and	O
to	O
estimate	B-EPI
the	O
prevalence	B-DIS
of	O
anxiety	O
among	O
individuals	B-DIS
with	O
vitiligo	O
.	O

Methods	O
A	O
systematic	O
literature	O
search	O
was	O
performed	O
in	O
five	O
online	O
databases	O
MEDLINE	O
Embase	O
Web	O
of	O
Science	O
Cochrane	O
Library	O
and	O
PsycINFO	O
from	O
inception	O
until	O
March	O
202020	O
.	O

All	O
of	O
the	O
eligible	O
studies	O
were	O
comprehensively	O
reviewed	O
and	O
all	O
of	O
the	O
available	O
data	O
were	O
analyzed	O
according	O
to	O
our	O
predefined	O
criteria	O
.	O

Results	O
Twenty	O
-	O
one	O
studies	O
involving	O
3259	O
patients	O
in	O
11	O
countries	O
were	O
included	O
in	O
this	O
meta	O
-	O
analysis	O
.	O

Compared	O
with	O
the	O
healthy	O
control	O
group	O
patients	O
with	O
vitiligo	B-DIS
often	O
had	O
concomitant	O
anxiety	B-DIS
OR	B-EPI
=	O
6.14	B-STAT
[	O
95	O
%	O
CI	O
3.35	O
-	O
11.24	O
]	O
I	O
2	O
<	O
/s	O
=	O
30.1	B-STAT
%	I-STAT
.	O

The	O
pooled	O
prevalence	B-EPI
of	O
anxiety	B-DIS
in	O
female	O
patients	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
males	O
OR	B-EPI
=	O
2.24	B-STAT
[	O
95	O
%	O
CI	O
1.31	O
-	O
3.84	O
]	O
I	O
2	O
<	O
/s	O
=	O
0.0	B-STAT
%	I-STAT
.	O

Subgroup	O
analysis	O
showed	O
that	O
the	O
pooled	O
prevalence	B-EPI
of	O
clinical	O
anxiety	B-DIS
disorder	I-DIS
and	O
anxiety	O
symptoms	O
was	O
12	B-STAT
%	I-STAT
95	O
%	O
CI	O
7	O
%	O
-16	O
%	O
I	O
2	O
<	O
/s	O
=	O
76.3	B-STAT
%	I-STAT
and	O
34	B-STAT
%	I-STAT
95	O
%	O
CI	O
21	O
%	O
-46	O
%	O
I	O
2	O
<	O
/s	O
=	O
94.7	B-STAT
%	I-STAT
respectively	O
.	O

No	O
publication	O
bias	O
has	O
been	O
detected	O
by	O
Begg	O
's	O
funnel	O
plot	O
and	O
Egger	O
's	O
test	O
.	O

Conclusion	O
Patients	O
with	O
vitiligo	B-DIS
have	O
high	O
anxiety	B-DIS
comorbidity	O
with	O
female	O
predominance	O
.	O

Dermatologists	O
and	O
psychiatrists	O
should	O
be	O
vigilant	O
to	O
the	O
presence	O
of	O
anxiety	B-DIS
apply	O
appropriate	O
interventions	O
to	O
reduce	O
the	O
psychological	O
impacts	O
in	O
a	O
timely	O
manner	O
and	O
thus	O
promote	O
recovery	O
in	O
vitiligo	B-DIS
patients	O
.	O

However	O
due	O
to	O
some	O
objective	O
limitations	O
poor	O
information	O
about	O
the	O
OR	O
and	O
diversity	O
in	O
assessment	O
tools	O
among	O
included	O
studies	O
findings	O
should	O
be	O
interpreted	O
with	O
caution	O
.	O

Objective	O
Tarsal	O
coalition	O
is	O
known	O
to	O
cause	O
abnormal	B-DIS
talocrural	I-DIS
stress	I-DIS
hindfoot	I-DIS
malalignment	I-DIS
and	O
ankle	O
sprains	O
.	O

These	O
can	O
all	O
be	O
associated	O
with	O
osteochondritis	B-DIS
dissecans	O
OCD	B-DIS
of	O
the	O
talar	O
dome	O
.	O

We	O
present	O
the	O
first	O
detailed	O
description	O
of	O
a	O
series	O
of	O
talar	B-DIS
OCDs	I-DIS
occurring	O
in	O
patients	O
with	O
tarsal	O
coalition	O
with	O
the	O
goal	O
of	O
determining	O
whether	O
there	O
is	O
an	O
increased	O
prevalence	B-EPI
of	O
OCDs	B-DIS
among	O
patients	O
with	O
tarsal	O
coalition	O
.	O

Materials	O
and	O
methods	O
We	O
studied	O
ankle	O
MRIs	O
in	O
57	O
patients	O
with	O
tarsal	O
coalitions	O
excluding	O
those	O
with	O
a	O
reported	O
inciting	O
traumatic	B-DIS
event	O
.	O

The	O
MRIs	O
were	O
performed	O
on	O
magnetic	O
field	O
strengths	O
ranging	O
from	O
0.3	O
to	O
1.5	O
T	O
and	O
included	O
axial	O
coronal	O
and	O
sagittal	O
T1	O
and	O
T2	O
or	O
PD	O
fat	O
-	O
suppressed	O
sequences	O
.	O

We	O
evaluated	O
the	O
morphology	O
and	O
location	O
of	O
classically	O
described	O
OCDs	B-DIS
in	O
these	O
patients	O
type	O
and	O
location	O
of	O
concomitant	O
tarsal	O
coalition	O
and	O
when	O
available	O
the	O
presence	O
of	O
pes	O
planus	B-DIS
and	O
hindfoot	B-DIS
valgus	I-DIS
on	O
weight	O
-	O
bearing	O
radiographs	O
.	O

Chi	O
-	O
squared	O
analysis	O
was	O
used	O
to	O
compare	O
categorical	O
variables	O
and	O
a	O
Student	O
's	O
t	O
test	O
was	O
used	O
for	O
parametric	O
continuous	O
variables	O
.	O

Additionally	O
logistic	O
regression	O
was	O
used	O
to	O
compute	O
the	O
odds	O
ratio	O
of	O
talar	B-DIS
OCD	I-DIS
associated	O
with	O
patient	O
age	O
gender	O
laterality	O
pes	O
planus	O
status	O
hindfoot	O
valgus	O
status	O
and	O
coalition	O
type	O
.	O

Results	O
Eighty	B-STAT
-	I-STAT
nine	I-STAT
percent	I-STAT
of	O
tarsal	O
coalitions	O
were	O
non	O
-	O
osseous	O
coalitions	O
and	O
the	O
calcaneonavicular	O
space	O
was	O
the	O
most	O
common	O
site	O
of	O
abnormal	O
tarsal	O
connection	O
54.4	B-STAT
%	I-STAT
.	O

In	O
the	O
29	O
patients	O
with	O
tarsal	O
coalitions	O
and	O
talar	B-DIS
OCDs	I-DIS
OCDs	I-DIS
commonly	O
occurred	O
medially	O
75.9	B-STAT
%	I-STAT
.	O

In	O
the	O
sagittal	O
plane	O
talar	O
OCDs	O
occurred	O
centrally	O
with	O
only	O
one	O
case	O
sparing	O
the	O
central	O
talar	O
dome	O
.	O

The	O
mean	O
surface	O
area	O
of	O
the	O
29	O
OCDs	B-DIS
was	O
89.7	O
mm	O
2	O
<	O
/s	O
.	O

Both	O
osseous	B-DIS
coalition	I-DIS
and	I-DIS
hindfoot	I-DIS
valgus	I-DIS
were	O
associated	O
with	O
smaller	O
talar	B-DIS
OCD	I-DIS
mean	O
surface	O
area	O
p	O
=	O
0.015	O
and	O
p	O
=	O
0.0001	O
respectively	O
.	O

There	O
was	O
no	O
association	O
between	O
depth	O
and	O
surface	O
area	O
of	O
talar	B-DIS
OCD	I-DIS
with	O
either	O
coalition	O
location	O
or	O
presence	O
of	O
pes	O
planus	O
coalition	O
location	O
p	O
=	O
0.455	O
for	O
depth	O
and	O
p	O
=	O
0.295	O
for	O
surface	O
area	O
;	O
presence	O
of	O
pes	O
planus	O
p	O
=	O
0.593	O
for	O
depth	O
and	O
p	O
=	O
0.367	O
for	O
surface	O
area	O
.	O

Conclusion	O
Talar	O
OCD	B-DIS
prevalence	B-EPI
is	O
higher	O
in	O
patients	O
with	O
tarsal	O
coalition	O
than	O
that	O
reported	O
for	O
the	O
general	O
population	O
.	O

This	O
occurrence	O
may	O
relate	O
to	O
altered	O
biomechanics	O
and	O
repetitive	B-DIS
talocrural	I-DIS
stress	I-DIS
owing	O
to	O
altered	O
subtalar	O
motion	O
particularly	O
given	O
the	O
findings	O
of	O
increased	O
odds	O
of	O
talar	B-DIS
OCD	I-DIS
in	O
older	O
patients	O
as	O
well	O
as	O
weak	O
associations	O
between	O
OCD	B-DIS
surface	O
area	O
and	O
both	O
non	O
-	O
osseous	O
coalition	O
and	O
hindfoot	O
alignment	O
.	O

However	O
we	O
did	O
not	O
find	O
any	O
specific	O
OCD	B-DIS
morphologic	O
features	O
attributable	O
to	O
the	O
precise	O
location	O
of	O
the	O
tarsal	O
coalition	O
.	O

Objective	O
To	O
study	O
the	O
genetic	O
cause	O
of	O
Mayer	B-DIS
-	I-DIS
Rokitansky	I-DIS
-	O
Kuster	O
-	O
Hauser	O
syndrome	O
MRKH	O
.	O

Although	O
a	O
few	O
candidate	O
genes	O
and	O
genomic	O
domains	O
for	O
have	O
been	O
reported	O
for	O
MRKH	B-DIS
the	O
genetic	O
underpinnings	O
remain	O
largely	O
unknown	O
.	O

Some	O
of	O
the	O
top	O
candidate	O
genes	O
are	O
WNT4	O
HNF1B	O
and	O
LHX1	O
.	O

The	O
goals	O
of	O
this	O
study	O
were	O
to	O
1	O
determine	O
the	O
prevalence	B-EPI
of	O
WNT4	O
HNF1B	O
and	O
LHX1	O
point	O
mutations	O
as	O
well	O
as	O
new	O
copy	O
number	O
variants	O
CNVs	O
in	O
people	O
with	O
MRKH	B-DIS
;	O
and	O
2	O
identify	O
and	O
characterize	O
MRKH	B-DIS
cohorts	O
.	O

Design	O
Laboratory-	O
and	O
community	O
-	O
based	O
study	O
.	O

Setting	O
Academic	O
medical	O
centers	O
.	O

Patient	O
s	O
A	O
total	O
of	O
147	O
MRKH	B-DIS
probands	O
and	O
available	O
family	O
members	O
.	O

Interventions	O
s	O
DNA	O
sequencing	O
of	O
WNT4	O
HNF1B	O
and	O
LHX1	O
in	O
100	O
MRKH	B-DIS
patients	O
chromosomal	O
microarray	O
analysis	O
in	O
31	O
North	O
American	O
MRKH	B-DIS
patients	O
and	O
characterization	O
and	O
sample	O
collection	O
of	O
147	O
North	O
American	O
and	O
Turkish	O
MRKH	B-DIS
probands	O
and	O
their	O
families	O
.	O

Main	O
outcome	O
measure	O
s	O
DNA	O
sequence	O
variants	O
and	O
CNVs	O
;	O
pedigree	O
structural	O
analysis	O
.	O

Result	O
s	O
We	O
report	O
finding	O
CNVs	O
in	O
6/31	B-STAT
people	O
∼19	B-STAT
%	I-STAT
with	O
MRKH	B-DIS
but	O
no	O
point	O
mutations	O
or	O
small	O
indels	O
in	O
WNT4	O
HNF1B	B-LOC
or	O
LHX1	O
in	O
100	O
MRKH	B-DIS
patients	O
.	O

Our	O
MRKH	B-DIS
families	O
included	O
43	O
quads	O
26	O
trios	O
and	O
30	O
duos	O
.	O

Of	O
our	O
MRKH	B-DIS
probands	O
87/147	B-STAT
59	B-STAT
%	I-STAT
had	O
MRKH	B-DIS
type	I-DIS
1	I-DIS
and	I-DIS
60/14741	B-STAT
%	I-STAT
had	O
type	O
2	O
with	O
additional	O
anomalies	B-DIS
.	O

Conclusion	O
s	O
Although	O
the	O
prevalence	B-EPI
of	O
WNT4	O
HNF1B	O
and	O
LHX1	O
point	O
mutations	O
is	O
low	O
in	O
people	O
with	O
MRKH	B-DIS
the	O
prevalence	B-EPI
of	O
CNVs	O
was	O
∼19	O
%	O
.	O

Further	O
analysis	O
of	O
our	O
large	O
familial	O
cohort	O
of	O
patients	O
will	O
facilitate	O
gene	O
discovery	O
to	O
better	O
understand	O
the	O
complex	O
etiology	O
of	O
MRKH	B-DIS
.	O

The	O
end	O
-	O
of	O
-	O
outbreak	O
declaration	O
is	O
an	O
important	B-DIS
step	I-DIS
in	O
controlling	O
infectious	O
disease	O
outbreaks	O
.	O

Objective	O
estimation	O
of	O
the	O
confidence	O
level	O
that	O
an	O
outbreak	O
is	O
over	O
is	O
important	O
to	O
reduce	O
the	O
risk	O
of	O
postdeclaration	O
flare	O
-	O
ups	O
.	O

We	O
developed	O
a	O
simulation	O
-	O
based	O
model	O
with	O
which	O
to	O
quantify	O
that	O
confidence	O
and	O
tested	O
it	O
on	B-DIS
simulated	I-DIS
Ebola	I-DIS
virus	O
disease	O
data	O
.	O

We	O
found	O
that	O
these	O
confidence	O
estimates	O
were	O
most	O
sensitive	O
to	O
the	O
instantaneous	O
reproduction	O
number	O
the	O
reporting	O
rate	O
and	O
the	O
time	O
between	O
the	O
symptom	O
onset	O
and	O
death	B-DIS
or	O
recovery	O
of	O
the	O
last	O
detected	O
case	O
.	O

For	O
Ebola	B-DIS
virus	I-DIS
disease	I-DIS
our	O
results	O
suggested	O
that	O
the	O
current	O
World	O
Health	O
Organization	O
criterion	O
of	O
42	O
days	O
since	O
the	O
recovery	O
or	O
death	B-DIS
of	O
the	O
last	O
detected	O
case	O
is	O
too	O
short	O
and	O
too	O
sensitive	O
to	O
underreporting	O
.	O

Therefore	O
we	O
suggest	O
a	O
shift	O
to	O
a	O
preliminary	O
end	O
-	O
of	O
-	O
outbreak	O
declaration	O
after	O
63	O
days	O
from	O
the	O
symptom	O
onset	O
day	O
of	O
the	O
last	O
detected	O
case	O
.	O

This	O
preliminary	O
declaration	O
should	O
still	O
be	O
followed	O
by	O
90	O
days	O
of	O
enhanced	O
surveillance	O
to	O
capture	O
potential	O
flare	O
-	O
ups	O
of	O
cases	O
after	O
which	O
the	O
official	O
end	O
of	O
the	O
outbreak	O
can	O
be	O
declared	O
.	O

This	O
sequence	O
corresponds	O
to	O
more	O
than	O
95	O
%	O
confidence	O
that	O
an	O
outbreak	O
is	O
over	O
in	O
most	O
of	O
the	O
scenarios	O
examined	O
.	O

Our	O
framework	O
is	O
generic	O
and	O
therefore	O
could	O
be	O
adapted	O
to	O
estimate	O
end	O
-	O
of	O
-	O
outbreak	B-DIS
confidence	I-DIS
for	O
other	O
infectious	O
diseases	O
.	O

Background	O
A	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
were	O
made	O
of	B-EPI
the	O
incidence	O
of	O
recurrences	O
in	O
patients	O
with	B-DIS
proliferative	I-DIS
verrucous	I-DIS
leukoplakia	O
PVL	O
subjected	O
to	O
different	O
types	O
of	O
treatment	O
.	O

Methods	O
The	O
study	O
was	O
carried	O
out	O
following	O
the	O
Preferred	O
Reporting	O
Items	O
for	O
Systematic	O
Reviews	O
and	O
Meta	O
-	O
Analyses	O
PRISMA	O
statement	O
guidelines	O
.	O

A	O
literature	O
search	O
was	O
made	O
in	O
the	O
Medline	O
PubMed	O
EMBASE	O
and	O
Web	O
of	O
Science	O
databases	O
together	O
with	O
a	O
manual	O
search	O
covering	O
the	O
period	O
from	O
1985	O
to	O
January	O
2020	O
with	O
no	O
language	O
restrictions	O
.	O

Studies	O
were	O
included	O
if	O
they	O
described	O
treatments	O
applied	O
to	O
at	O
least	O
10	O
patients	O
with	O
the	O
corresponding	O
outcomes	O
.	O

Methodological	O
quality	O
was	O
evaluated	O
using	O
Jadad	B-LOC
scale	O
and	O
Newcastle	B-LOC
-	O
Ottawa	B-LOC
tool	O
.	O

Global	O
incidence	B-EPI
was	O
calculated	O
by	O
random	O
effects	O
meta	O
-	O
analysis	O
using	O
the	O
Comprehensive	O
Meta	O
-	O
analysis	O
version	O
3.0	O
software	O
.	O

Publication	O
bias	O
was	O
assessed	O
using	O
funnel	O
plots	O
and	O
the	O
Duval	O
and	O
Tweedie	O
trim	O
and	O
fill	O
method	O
.	O

Results	O
Of	O
the	O
922	O
identified	O
articles	O
12	O
were	O
found	O
to	O
meet	O
the	O
inclusion	O
criteria	O
.	O

Most	O
of	O
them	O
presented	O
moderate	O
or	O
low	O
risk	O
of	O
bias	O
.	O

A	O
total	O
of	O
397	O
patients	O
were	O
analyzed	O
.	O

The	O
mean	O
age	O
was	O
62.34	O
years	O
and	O
248	O
were	O
women	O
62.5	O
%	O
.	O

The	O
mean	O
follow	O
-	O
up	O
was	O
79.3	O
months	O
.	O

The	O
most	O
frequent	O
treatment	O
was	O
surgical	O
removal	O
with	O
a	O
cold	O
scalpel	O
or	O
laser	O
339	O
patients	O
.	O

A	O
total	O
of	O
232	O
subjects	O
presented	O
lesion	O
recurrence	O
.	O

The	O
combination	O
of	O
proportions	O
global	O
effect	O
meta	O
-	O
analysis	O
yielded	O
a	O
recurrence	B-EPI
rate	I-EPI
of	O
67.2	B-STAT
%	I-STAT
95	O
%	O
CI	O
48.3	O
-	O
81.8	O
with	O
the	O
absence	O
of	O
publication	O
bias	O
.	O

Conclusions	O
There	O
is	O
not	O
enough	O
scientific	O
evidence	O
to	O
conclude	O
that	O
any	O
treatment	O
strategy	O
is	O
able	O
to	O
reduce	O
the	O
recurrence	O
in	O
PVL	B-DIS
.	O

Aim	O
To	O
investigate	O
the	O
point	O
prevalence	B-EPI
of	O
hereditary	B-DIS
neuromuscular	I-DIS
disorders	I-DIS
on	O
January	O
12020	O
in	O
Northern	B-LOC
Norway	I-LOC
.	O

Methods	O
From	O
January	O
11999	O
until	O
January	O
12020	O
we	O
screened	O
medical	O
and	O
genetic	O
hospital	O
records	O
in	O
Northern	B-LOC
Norway	I-LOC
for	O
hereditary	B-DIS
neuromuscular	I-DIS
disorders	I-DIS
.	O

Results	O
We	O
identified	O
542	O
patients	O
with	O
a	O
hereditary	B-DIS
neuromuscular	I-DIS
disorder	I-DIS
living	O
in	O
Northern	B-LOC
Norway	I-LOC
giving	O
a	O
point	O
prevalence	B-EPI
of	O
111.9/100000	B-STAT
on	O
January	O
1	O
2020	O
.	O

The	O
prevalence	B-EPI
of	O
children	O
<	O
18	O
years	O
old	O
and	O
adults	O
≥18	O
years	O
old	O
were	O
57.8/100000	B-STAT
and	O
125.1/100000	B-STAT
respectively	O
.	O

Inherited	O
neuropathies	B-DIS
had	O
a	O
prevalence	B-EPI
of	O
38.8/100000	B-STAT
.	O

Charcot	B-DIS
-	I-DIS
Marie	I-DIS
-	I-DIS
Tooth	I-DIS
and	O
hereditary	B-DIS
neuropathy	I-DIS
with	I-DIS
liability	I-DIS
to	I-DIS
pressure	I-DIS
palsies	I-DIS
had	O
a	O
prevalence	B-EPI
of	O
29.9/100000	B-STAT
and	O
8.3/100000	B-STAT
respectively	O
.	O

We	O
calculated	O
a	O
prevalence	B-EPI
of	O
3.7/100000	B-STAT
for	O
spinal	B-DIS
muscular	I-DIS
atrophies	I-DIS
and	O
2.4/100000	B-STAT
for	O
Kennedy	O
disease	O
.	O

Inherited	O
myopathies	B-DIS
were	O
found	O
in	O
67.7/100000	B-STAT
.	O

Among	O
these	O
we	O
registered	O
13.4/100000	B-STAT
myotonic	B-DIS
dystrophy	I-DIS
type	O
1	O
6.8/100000	B-STAT
myotonic	O
dystrophy	O
type	O
2	O
7.3/100000	B-STAT
Duchenne	B-DIS
muscular	I-DIS
dystrophy	I-DIS
1.6/100000	B-STAT
Becker	B-DIS
muscular	I-DIS
dystrophy	I-DIS
3.7/100000	B-STAT
facioscapulohumeral	B-DIS
muscular	I-DIS
dystrophy	I-DIS
12.8/100000	B-STAT
limb	B-DIS
-	I-DIS
girdle	I-DIS
muscular	I-DIS
dystrophy	I-DIS
2.5/100000	B-STAT
hypokalemic	B-DIS
periodic	I-DIS
paralysis	I-DIS
and	O
11.4/100000	B-STAT
myotonia	B-DIS
congenita	I-DIS
.	O

Conclusion	O
Our	O
total	O
prevalence	B-EPI
was	O
higher	O
than	O
previously	O
hypothesized	O
in	O
European	O
population	O
-	O
based	O
studies	O
.	O

The	O
prevalence	B-EPI
was	O
especially	O
high	O
for	O
myotonia	B-DIS
congenita	I-DIS
and	O
limb	B-DIS
-	I-DIS
girdle	I-DIS
muscular	O
dystrophy	O
.	O

The	O
prevalence	B-EPI
of	O
Charcot	B-DIS
-	I-DIS
Marie	I-DIS
-	I-DIS
Tooth	I-DIS
polyneuropathy	I-DIS
was	O
higher	O
than	O
in	O
most	O
European	O
studies	O
but	O
lower	O
than	O
previously	O
reported	O
in	O
epidemiological	O
studies	O
in	O
other	O
regions	O
of	O
Norway	B-LOC
.	O

The	O
treatment	O
of	O
Graves	B-DIS
'	I-DIS
disease	I-DIS
is	O
based	O
on	O
three	O
therapies	O
medical	O
treatment	O
with	O
synthetic	O
antithyroid	O
agents	O
surgery	O
and	O
radioactive	O
-	O
iodine	O
therapy	O
.	O

The	O
purpose	O
of	O
our	O
study	O
was	O
to	O
study	O
the	O
role	O
and	O
effectiveness	O
of	O
radioactive	O
-	O
iodine	O
therapy	O
for	O
the	O
treatment	B-DIS
of	I-DIS
Graves	I-DIS
'	O
disease	O
.	O

We	O
conducted	O
a	O
retrospective	O
descriptive	O
study	O
of	O
the	O
epidemiological	O
clinical	O
paralclinical	O
and	O
therapeutic	O
features	O
of	O
54	O
patients	O
with	O
Graves	B-DIS
'	I-DIS
disease	I-DIS
managed	O
and	O
treated	O
with	O
iodine-131	O
as	O
well	O
as	O
of	O
their	O
short-	O
and	O
medium	O
-	O
term	O
remission	O
rate	O
.	O

The	O
sex	O
ratio	O
was	O
0.45	O
.	O

The	O
average	O
age	O
of	O
patients	O
was	O
3833	O
±	O
12.7	O
years	O
.	O

The	O
most	O
common	O
functional	O
signs	O
were	O
weight	B-DIS
loss	I-DIS
tremors	I-DIS
and	O
palpitations	B-DIS
.	O

Mean	O
FT4	O
was	O
5451	O
±	O
1956	O
ng	O
/	O
dl	O
ranging	O
from	O
890	O
and	O
100	O
.	O

Mean	O
TSHus	O
was	O
0074	O
±	O
029	O
µIU	O
/	O
ml	O
.	O

Synthetic	O
antithyroid	O
drugs	O
were	O
used	O
in	O
49	O
patients	O
;	O
8367	B-STAT
%	I-STAT
of	O
cases	O
had	O
persistent	O
hyperthyroidism	B-DIS
.	O

Radioactive	O
-	O
iodine	O
therapy	O
was	O
used	O
as	O
first	O
-	O
line	O
therapy	O
in	O
93	B-STAT
%	I-STAT
of	O
cases	O
and	O
as	O
second	O
-	O
line	O
therapy	O
in	O
907	B-STAT
%	I-STAT
of	O
cases	O
.	O

Mean	O
activity	O
was	O
1329	O
mCi	O
±	O
146	O
ranging	O
from	O
10	O
to	O
15	O
mCi	O
.	O

The	O
first	O
assessment	O
of	O
hormonal	O
status	O
was	O
performed	O
after	O
an	O
average	O
post	O
-	O
treatment	O
period	O
of	O
191	O
months	O
;	O
29	O
patients	O
537	B-STAT
%	I-STAT
achieved	O
remission	O
eu-	B-DIS
or	O
hypo	O
-	O
thyroidism	O
.	O

After	O
a	O
12	O
month	O
-	O
follow	O
-	O
up	O
patients	O
'	O
course	O
was	O
marked	O
by	O
remission	O
in	O
8888	B-STAT
%	I-STAT
of	O
cases	O
euthyroidism	B-DIS
in	O
148	B-STAT
%	I-STAT
and	O
hypothyroidism	B-DIS
in	O
74	B-STAT
%	I-STAT
of	O
cases	O
.	O

Radioactive	O
-	O
iodine	O
therapy	O
is	O
an	O
effective	O
treatment	B-DIS
for	I-DIS
Graves	I-DIS
'	O
disease	O
.	O

High	O
radioactive	O
iodine	O
dose	O
provides	O
high	O
remission	O
rate	O
.	O

Background	O
/	O
aim	O
This	O
study	O
analysed	B-EPI
the	O
prevalence	O
of	O
the	O
characteristics	O
evaluated	O
in	O
dermatoscopy	O
for	O
melanocytic	O
infiltrations	O
of	O
the	O
conjunctiva	O
with	O
various	O
degrees	B-DIS
of	O
malignancy	O
.	O

Patients	O
and	O
methods	O
A	O
total	O
of	O
160	O
conjunctival	O
pigmented	O
lesions	O
were	O
studied	O
.	O

Each	O
lesion	O
was	O
scored	O
using	O
dermatoscopic	O
patterns	O
and	O
the	O
characteristics	O
of	O
malignancy	B-DIS
described	O
by	O
Kittler	O
.	O

Also	O
the	O
Authors	O
'	O
own	O
clues	O
were	O
added	O
to	O
the	O
evaluation	O
.	O

Results	O
In	O
melanomas	O
the	O
following	O
characteristics	O
were	O
identified	O
asymmetry	O
of	O
the	O
pattern	O
and	O
colour	O
larger	O
average	O
number	O
of	O
colours	O
the	O
presence	O
of	O
grey	B-DIS
colour	I-DIS
structureless	I-DIS
area	O
polymorphic	O
vessels	O
and	O
feeder	O
vessels	O
.	O

A	O
pattern	O
of	O
black	O
dots	O
and	O
a	O
black	O
colour	O
was	O
typical	O
of	O
malignant	O
lesions	O
and	O
pre	B-DIS
-	I-DIS
cancerous	I-DIS
premalignant	I-DIS
lesions	I-DIS
-	I-DIS
primary	I-DIS
acquired	I-DIS
melanosis	O
PAM	O
with	O
atypia	O
.	O

Cysts	O
were	O
observed	O
only	O
in	O
the	O
group	O
of	O
naevi	O
.	O

Conclusion	O
The	O
patterns	O
evaluated	O
with	O
dermatoscopy	O
are	O
present	O
in	O
pigmented	O
lesions	O
of	O
the	O
conjunctiva	O
.	O

There	O
are	O
however	O
some	O
characteristics	O
which	O
allow	O
differentiation	O
between	O
melanoma	B-DIS
and	O
pigmented	O
naevus	O
and	O
melanosis	B-DIS
and	O
also	O
between	O
PAM	B-DIS
.	O

Hearing	B-DIS
loss	I-DIS
is	O
one	O
of	O
the	O
most	O
common	O
birth	B-DIS
disorders	I-DIS
in	O
humans	O
with	O
an	O
estimated	O
prevalence	B-EPI
of	O
1	B-STAT
-	I-STAT
3	I-STAT
in	I-STAT
every	I-STAT
1000	I-STAT
newborns	O
.	O

This	O
study	O
investigates	O
the	O
molecular	O
etiology	O
of	O
a	O
hearing	B-DIS
loss	I-DIS
cohort	O
using	O
a	O
stepwise	O
strategy	O
to	O
effectively	O
diagnose	O
patients	O
and	O
address	O
the	O
challenges	O
posed	O
by	O
the	O
genetic	O
heterogeneity	O
and	O
variable	O
mutation	O
spectrum	O
of	O
hearing	B-DIS
loss	I-DIS
.	O

In	O
order	O
to	O
target	O
known	O
pathogenic	O
variants	O
multiplex	O
PCR	O
plus	O
next	O
-	O
generation	O
sequencing	O
was	O
applied	O
in	O
the	O
first	O
step	O
;	O
patients	O
which	O
did	O
not	O
receive	O
a	O
diagnosis	O
from	O
this	O
were	O
further	O
referred	O
for	O
exome	O
sequencing	O
.	O

A	O
total	O
of	O
92	O
unrelated	O
patients	O
with	O
nonsyndromic	B-DIS
hearing	I-DIS
loss	I-DIS
were	O
enrolled	O
in	O
the	O
study	O
.	O

In	O
total	O
64	B-STAT
%	I-STAT
59/92	B-STAT
of	O
the	O
patients	O
were	O
molecularly	O
diagnosed	O
44	O
of	O
them	O
in	O
the	O
first	O
step	O
by	O
multiplex	O
PCR	O
plus	O
sequencing	O
.	O

Exome	O
sequencing	O
resulted	O
in	O
eleven	O
diagnoses	O
23	B-STAT
%	I-STAT
11/48	B-STAT
and	O
four	O
probable	O
diagnoses	O
8	B-STAT
%	I-STAT
4/48	B-STAT
among	O
the	O
48	O
patients	O
who	O
were	O
not	O
diagnosed	O
in	O
the	O
first	O
step	O
.	O

The	O
rate	O
of	O
secondary	O
findings	O
from	O
exome	O
sequencing	O
in	O
our	O
cohort	O
was	O
3	B-STAT
%	I-STAT
2/58	B-STAT
.	O

This	O
research	O
presents	O
a	O
molecular	O
diagnosis	O
spectrum	O
of	O
92	O
non	B-DIS
-	I-DIS
syndromic	I-DIS
hearing	O
loss	O
patients	O
and	O
demonstrates	O
the	O
benefits	O
of	O
using	O
a	O
stepwise	O
diagnostic	O
approach	O
in	O
the	O
genetic	O
testing	B-DIS
of	I-DIS
nonsyndromic	I-DIS
hearing	O
loss	O
.	O

Summary	O
Multiple	O
endocrine	B-DIS
neoplasia	I-DIS
type	O
1	O
MEN1	B-DIS
is	O
a	O
rare	O
inherited	O
endocrine	B-DIS
disorder	I-DIS
with	O
a	O
high	O
rate	O
of	O
penetrance	O
.	O

The	O
incidence	B-EPI
of	O
MEN1	B-DIS
is	O
1/30000	B-STAT
in	O
the	O
general	O
population	O
;	O
however	O
it	O
is	O
quite	O
rare	O
for	O
a	O
patient	O
to	O
present	O
for	O
medical	O
attention	O
with	O
MEN1	B-DIS
for	O
the	O
first	O
time	O
in	O
pregnancy	O
.	O

Primary	B-DIS
hyperparathyroidism	I-DIS
PHPT	I-DIS
is	O
one	O
of	O
the	O
most	O
common	O
features	O
of	O
MEN1	B-DIS
.	O

The	O
incidence	B-EPI
of	O
PHPT	B-DIS
occurring	O
in	O
pregnancy	O
is	O
1	B-STAT
%	I-STAT
.	O

Despite	O
advances	O
in	O
the	O
medical	O
surgical	O
and	O
obstetric	O
care	O
over	O
the	O
years	O
management	O
of	O
this	O
condition	O
during	O
pregnancy	O
may	O
be	O
challenging	O
.	O

It	O
can	O
be	O
difficult	O
to	O
identify	O
pregnant	O
women	O
with	O
PHPT	B-DIS
requiring	O
intervention	O
and	O
to	O
monitor	O
safely	O
.	O

Hypercalcemia	B-DIS
can	O
result	O
in	O
significant	O
maternal	O
and	O
fetal	O
adverse	O
outcomes	O
including	O
miscarriage	B-DIS
intrauterine	O
growth	O
restriction	O
preterm	O
delivery	O
neonatal	O
hypocalcaemia	B-DIS
pre	I-DIS
-	O
eclampsia	O
and	B-DIS
maternal	O
nephrolithiasis	O
.	O

Herein	O
we	O
present	O
a	O
case	O
study	O
of	O
a	O
lady	O
with	O
a	O
strong	O
family	O
history	O
of	O
MEN1	B-DIS
who	O
was	O
biochemically	O
proven	O
to	O
have	O
PHPT	B-DIS
and	O
evidence	O
of	O
Zollinger	B-DIS
Ellison	I-DIS
Syndrome	I-DIS
ZE	I-DIS
on	O
endoscopy	O
.	O

This	O
patient	O
delayed	O
her	O
assisted	O
pregnancy	O
plans	O
for	O
in	O
vitro	O
fertilization	O
IVF	O
until	O
completion	O
of	O
the	O
MEN1	B-DIS
workup	O
;	O
nevertheless	O
she	O
spontaneously	O
achieved	O
an	O
unplanned	O
pregnancy	O
.	O

As	O
a	O
result	O
she	O
required	O
intervention	O
with	O
parathyroidectomy	O
in	O
the	O
second	O
trimester	O
of	O
her	O
pregnancy	O
as	O
her	O
calcium	O
level	O
continued	O
to	O
rise	O
.	O

This	O
case	O
study	O
highlights	O
the	O
workup	O
follow	O
up	O
and	O
management	O
of	O
MEN1	B-DIS
presenting	O
with	O
PHPT	B-DIS
and	O
ZE	B-DIS
in	O
pregnancy	O
.	O

Learning	O
points	O
Women	O
of	O
childbearing	O
age	O
who	O
are	O
suspected	O
to	O
have	O
a	O
diagnosis	O
of	O
primary	B-DIS
hyperparathyroidism	I-DIS
ideally	O
should	O
have	O
genetic	O
testing	O
and	O
avoid	O
pregnancy	O
until	O
definitive	O
plans	O
are	O
in	O
place	O
.	O

Zollinger	B-DIS
Ellison	I-DIS
syndrome	I-DIS
in	O
pregnancy	O
means	O
off	O
-	O
label	O
use	O
of	O
high	O
dose	O
of	O
proton	O
pump	O
inhibitors	O
PPI	O
.	O

Use	O
of	O
PPI	O
in	O
pregnancy	O
is	O
considered	O
to	O
be	O
safe	O
based	O
on	O
retrospective	O
studies	O
.	O

Omeprazole	O
however	O
is	O
FDA	O
class	O
C	O
drug	O
because	O
of	O
lack	O
of	O
large	O
prospective	O
studies	O
or	O
large	O
case	O
series	O
during	O
pregnancy	O
.	O

Calcium	O
supplements	O
in	O
the	O
form	O
of	O
calcium	O
carbonate	O
must	O
be	O
converted	O
to	O
calcium	O
chloride	O
by	O
gastric	O
acid	O
in	O
order	O
to	O
be	O
absorbed	O
however	O
patients	O
rendered	O
achlorhydric	O
as	O
a	O
result	O
of	O
PPI	O
use	O
will	O
have	O
impaired	O
absorption	O
of	O
calcium	O
.	O

Therefore	O
use	O
of	O
calcium	O
citrate	O
might	O
be	O
considered	O
a	O
better	O
option	O
in	O
this	O
case	O
.	O

Recessive	O
mutations	O
in	O
genes	O
encoding	O
mitochondrial	O
DNA	O
replication	O
machinery	O
lead	O
to	O
mitochondrial	O
DNA	O
depletion	O
syndromes	O
.	O

This	O
genetically	O
and	O
phenotypically	O
heterogeneous	O
group	O
includes	O
infantile	O
onset	O
spinocerebellar	B-DIS
ataxia	I-DIS
OMIM	I-DIS
#	O
271245	O
a	O
neurodegenerative	B-DIS
disease	I-DIS
caused	O
by	O
mutations	O
in	O
the	O
mtDNA	O
helicase	O
gene	O
c10orf2	O
with	O
an	O
increased	O
frequency	O
in	O
the	O
Finnish	O
population	O
due	O
to	O
a	O
founder	O
mutation	O
.	O

We	O
describe	O
a	O
child	O
of	O
English	O
descent	O
who	O
presented	O
with	O
a	O
severe	O
phenotype	O
of	O
IOSCA	B-DIS
as	O
a	O
result	O
of	O
two	O
-	O
novel	O
mutations	O
in	O
the	O
c10orf2	O
gene	O
.	O

This	O
paper	O
expands	O
the	O
phenotypic	O
spectrum	O
of	O
IOSCA	B-DIS
and	O
adds	O
further	O
evidence	O
for	O
the	O
presence	O
of	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
among	O
patients	O
with	O
recessive	O
mutations	O
in	O
this	O
gene	O
.	O

BACKGROUNDAdrenocortical	O
carcinoma	B-DIS
ACC	O
is	O
a	O
rare	O
endocrine	B-DIS
malignancy	I-DIS
often	O
with	O
an	O
unfavorable	O
prognosis	O
.	O

Radical	O
adrenalectomy	O
is	O
the	O
gold	O
standard	O
of	O
treatment	O
of	O
localized	O
disease	O
.	O

CASE	O
DESCRIPTIONWe	O
report	O
a	O
case	O
of	O
a	O
23	O
-	O
year	O
-	O
old	O
male	O
patient	O
who	O
presented	O
with	B-DIS
persistent	O
left	B-DIS
flank	O
pain	O
and	O
urticaria	O
for	O
3	O
months	O
.	O

Imaging	O
studies	O
confirmed	O
the	O
presence	O
of	O
a	O
large	O
left	B-DIS
adrenal	I-DIS
mass	I-DIS
with	I-DIS
malignant	I-DIS
features	I-DIS
.	O

The	O
biochemical	O
workup	O
was	O
unremarkable	O
.	O

Open	O
left	O
radical	O
adrenalectomy	O
was	O
performed	O
the	O
final	O
pathologic	O
examination	O
showed	O
ACC	O
with	O
negative	O
surgical	O
margins	O
.	O

The	O
patient	O
remained	O
disease	O
-	O
free	O
for	O
eighteen	O
months	O
period	O
of	O
follow	O
up	O
after	O
surgery	O
.	O

DISCUSSIONACC	O
is	O
a	O
rare	O
neoplasm	O
with	O
poor	O
prognosis	O
and	O
with	O
an	O
incidence	B-EPI
of	O
one	O
in	O
one	O
million	O
population	O
.	O

There	O
is	O
a	O
slight	O
female	O
predilection	O
.	O

The	O
ACC	O
may	O
be	O
functional	O
with	O
a	O
clinically	O
pure	O
endocrine	B-DIS
syndrome	I-DIS
like	O
Cushing	B-DIS
syndrome	I-DIS
.	O

Most	O
of	O
patients	O
with	O
ACC	O
present	O
with	O
symptoms	O
and	O
signs	O
of	O
hormonal	O
secretion	O
.	O

Adrenal	O
computed	O
tomography	O
CT	O
scanning	O
and	O
magnetic	O
resonance	O
imaging	O
MRI	O
are	O
the	O
imaging	O
studies	O
of	O
choice	O
in	O
ACC	O
.	O

When	O
feasible	O
total	O
resection	O
remains	O
the	O
treatment	O
of	O
choice	O
for	O
the	O
definitive	O
treatment	O
of	O
ACC	O
.	O

The	O
benefit	O
of	O
the	O
use	O
of	O
mitotane	O
as	O
an	O
adjuvant	O
treatment	O
has	O
been	O
considered	O
controversial	O
.	O

Adjuvant	O
mitotane	O
significantly	O
decreases	O
the	O
recurrence	O
and	O
mortality	O
rate	O
after	O
resection	O
of	O
ACC	O
in	O
patients	O
without	O
distant	O
metastasis	B-DIS
as	O
proved	O
by	O
some	O
studies	O
but	O
these	O
findings	O
need	O
further	O
validation	O
.	O

CONCLUSIONACC	O
is	O
a	O
rare	O
neoplasm	O
characterized	O
by	O
a	O
high	O
risk	O
of	O
recurrence	O
after	O
surgical	O
resection	O
.	O

Pneumocystis	B-DIS
jirovecii	I-DIS
pneumonia	O
PJP	B-DIS
is	O
an	O
opportunistic	B-DIS
infectious	I-DIS
disease	I-DIS
well	O
described	O
in	O
patients	O
living	O
with	O
HIV	O
PLHIV	O
but	O
that	O
can	O
occur	O
in	O
other	O
immunosuppressed	B-DIS
patients	O
.	O

Currently	O
its	O
incidence	B-EPI
decreases	O
in	O
PLHIV	O
but	O
increases	O
in	O
non	O
-	O
HIV	O
immunosuppressed	O
patients	O
particularly	O
in	O
case	B-DIS
of	I-DIS
hematological	O
diseases	O
.	O

Thus	O
in	O
elderly	O
the	O
diagnosis	O
of	O
PJP	B-DIS
should	O
be	O
evoked	O
in	O
case	O
of	O
subacute	O
pneumonia	B-DIS
rapidly	O
evolving	O
to	O
an	O
acute	O
respiratory	B-DIS
distress	I-DIS
with	O
or	O
without	O
interstitial	B-DIS
pneumonia	I-DIS
at	O
chest	O
radiography	O
and	O
a	O
context	O
of	O
immunosuppression	O
.	O

Introduction	O
Neuromyelitis	B-DIS
optica	I-DIS
spectrum	I-DIS
disorders	I-DIS
NMOSD	I-DIS
is	O
an	O
inflammatory	O
and	O
heterogeneous	O
astrocyte	O
disorder	O
of	O
the	O
central	O
nervous	O
system	O
with	O
the	O
characteristic	O
of	O
higher	O
incidence	B-EPI
in	O
women	O
and	O
Asian	O
people	O
.	O

Most	O
patients	O
with	O
NMOSD	B-DIS
have	O
a	O
course	O
of	O
recurrence	O
and	O
remission	O
that	O
is	O
prone	O
to	O
cause	O
paralysis	B-DIS
and	O
blindness	B-DIS
.	O

Several	O
studies	O
have	O
confirmed	O
the	O
efficacy	O
and	O
promising	O
prospect	O
of	O
mycophenolate	O
mofetil	O
MMF	O
in	O
the	O
treatment	O
of	O
NMOSD	B-DIS
.	O

Yet	O
its	O
therapeutic	O
effect	O
and	O
safety	O
are	O
controversial	O
.	O

Although	O
there	O
has	O
been	O
two	O
published	O
literature	O
that	O
is	O
relevant	O
to	O
the	O
topic	O
of	O
this	O
study	O
both	O
of	O
them	O
have	O
certain	O
defects	O
and	O
they	O
can	O
only	O
provide	O
answers	O
about	O
the	O
efficacy	O
or	O
safety	O
of	O
MMF	O
in	O
the	O
treatment	O
of	O
NMOSD	B-DIS
from	O
partial	O
perspectives	O
or	O
conclusions	O
.	O

This	O
research	O
aims	O
to	O
perform	O
a	O
direct	O
and	O
comprehensive	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
to	O
evaluate	O
MMF	O
's	O
effectiveness	O
and	O
safety	O
in	B-DIS
treating	O
NMOSD	O
.	O

Methods	O
and	O
analysis	O
This	O
systematic	O
review	O
will	O
cover	O
all	O
comparative	O
researches	O
from	O
randomised	O
controlled	O
trials	O
to	O
cohort	O
studies	O
and	O
case	O
-	O
control	O
study	O
.	O

A	O
relevant	O
literature	O
search	O
will	O
be	O
conducted	O
in	O
PubMed	O
Web	O
of	O
Science	O
EMBASE	O
the	O
Cochrane	O
Library	O
China	O
National	O
Knowledge	O
Infrastructure	O
Wanfang	O
Database	O
China	O
Science	O
and	O
Technology	O
Journal	O
Database	O
and	O
Chinese	O
Biomedical	O
Literature	O
Database	O
from	O
their	O
inception	O
to	O
31	O
June	O
2020	O
.	O

We	O
will	O
also	O
search	O
registers	O
of	O
clinical	O
trials	O
potential	O
grey	O
literature	O
and	O
abstracts	O
from	O
conferences	O
.	O

There	O
are	O
no	O
limits	O
on	O
language	O
and	O
publication	O
status	O
.	O

The	O
reporting	O
quality	O
and	O
risk	O
of	O
bias	O
will	O
be	O
assessed	O
by	O
two	O
researchers	O
independently	O
.	O

Expanded	O
Disability	O
Status	O
Scales	O
and	O
annualised	O
relapse	O
rate	O
will	O
be	O
evaluated	O
as	O
the	O
primary	O
outcome	O
.	O

The	O
secondary	O
outcomes	O
will	O
consist	O
of	O
the	O
frequency	O
and	O
severity	O
of	O
adverse	O
events	O
best	O
-	O
corrected	O
visual	O
acuity	O
relapse	O
-	O
free	O
rate	O
and	O
time	O
to	O
the	O
next	O
attack	O
.	O

A	O
meta	O
-	O
analysis	O
will	O
be	O
performed	O
using	O
RevMan	O
V.5.3	O
software	O
provided	O
by	O
the	O
Cochrane	O
Collaboration	O
and	O
Stata	O
V.12.0	O
.	O

Ethics	O
and	O
dissemination	O
Because	O
the	O
data	O
used	O
for	O
this	O
systematic	O
review	O
will	O
be	O
exclusively	O
extracted	O
from	O
published	O
studies	O
ethical	O
approval	O
and	O
informed	O
consent	O
of	O
patients	O
will	O
not	O
be	O
required	O
.	O

The	O
systematic	O
review	O
will	O
be	O
published	O
in	O
a	O
peer	O
-	O
reviewed	O
journal	O
presented	O
at	O
conferences	O
and	O
will	O
be	O
shared	O
on	O
social	O
media	O
platforms	O
.	O

Prospero	O
registration	O
number	O
CRD42020164179	O
.	O

Background	O
Methylmalonic	B-DIS
acidemia	I-DIS
MMA	I-DIS
and	O
propionic	O
acidemia	O
PA	O
are	O
two	O
kinds	O
of	O
diseases	O
caused	O
by	O
inborn	B-DIS
errors	I-DIS
of	O
metabolism	O
.	O

So	O
far	O
the	O
epidemiological	O
data	O
on	O
them	O
are	O
limited	O
in	O
China	B-LOC
.	O

The	O
aim	O
of	O
our	O
study	O
is	O
to	O
investigate	O
the	O
proportion	O
and	O
characteristics	O
of	O
hospitalized	O
pediatric	O
patients	O
with	O
MMA	O
and	O
PA	O
in	O
China	B-LOC
.	O

Methods	O
The	O
data	O
in	O
this	O
study	O
were	O
obtained	O
from	O
the	O
Hospital	O
Quality	O
Monitoring	O
System	O
a	O
national	O
inpatient	O
database	O
in	O
China	B-LOC
with	O
information	O
on	O
the	O
patients	O
hospitalized	O
during	O
the	O
period	O
from	O
2013	O
to	O
2017	O
.	O

We	O
identified	O
the	O
data	O
related	O
to	O
the	O
patients	O
who	O
were	O
under	O
18	O
years	O
old	O
and	O
were	O
diagnosed	O
with	O
MMA	O
/	O
PA	O
and	O
extracted	O
the	O
information	O
on	O
demographic	O
characteristics	O
hospital	O
location	O
total	O
cost	O
and	O
other	O
related	O
clinical	O
presentations	O
from	O
the	O
data	O
.	O

Results	O
Among	O
all	O
hospitalized	O
pediatric	O
patients	O
with	O
liver	B-DIS
diseases	I-DIS
there	O
were	O
increasing	O
trends	O
in	O
the	O
proportion	O
of	O
individuals	O
diagnosed	O
with	O
MMA	O
or	O
PA	O
during	O
the	O
period	O
from	O
20130.76	B-STAT
%	I-STAT
for	O
MMA	O
;	O
0.13	B-STAT
%	I-STAT
for	O
PA	O
to	O
20171.61	B-STAT
%	I-STAT
for	O
MMA	O
;	O
0.32	B-STAT
%	I-STAT
for	O
PA	O
.	O

For	O
both	O
MMA	O
and	O
PA	O
children	O
under	O
2	B-DIS
-	O
year	O
-	O
old	O
accounted	O
for	O
the	O
highest	O
proportion	O
.	O

The	O
median	O
of	O
total	O
cost	O
per	O
hospitalization	O
was	O
relatively	O
high	O
RMB	O
7388.53	O
for	O
MMA	O
;	O
RMB	O
4999.66	O
for	O
PA	O
.	O

Moreover	O
most	O
patients	O
hospitalized	O
in	O
tertiary	O
class	O
A	O
hospitals	O
MMA	O
80.96	B-STAT
%	I-STAT
PA	O
76.21	B-STAT
%	I-STAT
;	O
and	O
a	O
majority	O
of	O
pediatric	O
patients	O
admitted	O
in	O
the	O
hospitals	O
in	O
Shanghai	B-LOC
and	O
Beijing	B-LOC
are	O
from	O
outside	O
districts	O
.	O

Manifestations	O
of	O
nervous	O
system	O
-	O
related	O
symptoms	B-DIS
and	I-DIS
metabolic	O
acidosis	B-DIS
or	O
anemia	O
in	O
laboratory	O
findings	O
were	O
more	O
common	O
during	O
hospitalization	O
.	O

Conclusions	O
The	O
study	O
is	O
the	O
first	O
nationwide	O
one	O
in	O
providing	O
epidemiological	O
and	O
clinical	O
information	O
on	O
hospitalized	O
pediatric	O
patients	O
with	O
MMA	O
/	O
PA	O
.	O

An	O
increasing	O
hospitalization	O
with	O
various	O
presentations	O
and	O
a	O
heavy	O
financial	O
burden	O
were	O
observed	O
.	O

In	O
addition	O
geographically	O
the	O
medical	O
resources	O
in	O
China	B-LOC
have	O
been	O
unevenly	O
distributed	O
.	O

Background	O
Many	O
epidemiological	O
studies	O
have	O
indicated	O
that	O
inbreeding	O
has	O
little	O
or	O
no	O
effect	O
on	O
the	O
incidence	B-EPI
of	O
cancer	B-DIS
.	O

Due	O
to	O
the	O
high	O
prevalence	B-EPI
of	O
consanguinity	B-DIS
in	O
Qatar	B-LOC
54	B-STAT
%	I-STAT
its	O
influence	O
may	O
nevertheless	O
be	O
of	O
special	O
importance	O
.	O

Aim	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
whether	O
parental	O
consanguinity	B-DIS
affects	O
the	O
risk	O
of	O
cancer	B-DIS
in	O
a	O
local	O
Arab	O
highly	O
inbred	O
population	O
.	O

Design	O
Matched	O
case	O
-	O
control	O
study	O
.	O

Setting	O
The	O
study	O
was	O
carried	O
out	O
in	O
Al	O
-	B-DIS
Amal	O
cancer	O
hospital	O
and	O
primary	O
health	O
care	O
centers	O
in	O
Qatar	B-LOC
over	O
a	O
period	O
from	O
August	O
2008	O
to	O
February	O
2009	O
.	O

Subjects	O
and	O
methods	O
The	O
study	O
included	O
370	O
Qataris	O
and	O
other	O
Arab	O
expatriates	O
with	O
various	O
types	O
of	O
cancers	B-DIS
and	O
635	O
controls	O
matched	O
by	O
age	O
and	O
ethnicity	O
.	O

A	O
questionnaire	O
that	O
included	O
socio	O
-	O
demographic	O
information	O
type	B-DIS
of	O
consanguinity	O
medical	O
history	B-DIS
and	O
tumor	O
grade	O
was	O
designed	O
to	O
collect	O
the	O
information	O
of	O
cases	O
and	O
controls	O
.	O

Results	O
The	O
study	O
revealed	O
that	O
the	O
rate	O
of	O
parental	O
consanguinity	B-DIS
was	O
similar	O
in	O
both	O
cases	O
29.5	B-STAT
%	I-STAT
and	O
controls	O
29.9	B-STAT
%	I-STAT
with	O
a	O
higher	O
inbreeding	O
coefficient	O
in	O
controls	O
0.017-/+0.03	O
compared	O
to	O
cancer	B-DIS
patients	O
0.0155-/+0.03	O
.	O

Other	O
Arab	B-LOC
expatriates	I-LOC
had	O
a	O
higher	O
incidence	B-EPI
of	O
cancer	B-DIS
61.1	B-STAT
%	I-STAT
than	O
Qataris	B-LOC
38.9	B-STAT
%	I-STAT
.	O

The	O
inbreeding	O
coefficient	O
was	O
higher	O
in	O
male	O
cancer	B-DIS
patients	O
0.0189-/+0.03	O
but	O
lower	O
in	O
female	O
cancer	B-DIS
patients	O
0.014-/+0.03	O
as	O
compared	O
to	O
controls	O
.	O

Controls	O
were	O
more	O
inbred	O
in	O
the	O
overall	O
studied	O
subjects	O
23.6	B-STAT
%	I-STAT
and	O
women	O
23.8	B-STAT
%	I-STAT
than	O
cases	O
.	O

The	O
coefficient	O
of	O
inbreeding	O
was	O
lower	O
in	O
patients	O
with	O
breast	B-DIS
0.014	I-DIS
skin	I-DIS
0.012	I-DIS
thyroid	I-DIS
0.008	I-DIS
and	I-DIS
female	I-DIS
genital	I-DIS
0.014	I-DIS
cancers	I-DIS
whereas	O
it	O
was	O
higher	O
in	O
cases	O
for	O
leukemia	B-DIS
and	I-DIS
lymphoma	I-DIS
0.018	I-DIS
colorectal	I-DIS
0.025	I-DIS
and	I-DIS
prostate	I-DIS
0.017	O
with	O
no	O
significant	O
difference	O
between	O
cases	O
and	O
controls	O
.	O

No	O
significant	O
differences	O
were	O
observed	O
between	O
cases	O
and	O
controls	O
in	O
the	O
parental	O
consanguinity	O
mean	O
coefficient	O
of	O
inbreeding	O
and	O
proportion	O
of	O
more	O
inbred	O
subjects	O
.	O

Conclusions	O
The	O
study	O
findings	O
revealed	O
that	O
although	O
the	O
consanguinity	O
rate	O
is	O
high	O
in	O
our	O
Arab	O
population	O
it	O
has	O
no	O
effect	O
on	O
the	O
incidence	B-EPI
of	O
cancers	B-DIS
overall	O
.	O

However	O
there	O
was	O
an	O
increased	O
risk	O
found	O
for	O
leukemia	B-DIS
and	I-DIS
lymphoma	I-DIS
colorectal	I-DIS
and	I-DIS
prostate	I-DIS
cancer	I-DIS
groups	O
but	O
a	O
reduced	O
risk	O
in	O
breast	B-DIS
skin	I-DIS
thyroid	I-DIS
and	O
female	O
genital	B-DIS
cancer	I-DIS
groups	O
.	O

The	O
clinical	O
presentation	O
of	O
optic	B-DIS
neuritis	I-DIS
is	O
quite	O
characteristic	O
and	O
the	O
epidemiology	O
differential	O
diagnosis	O
and	O
treatment	O
protocol	O
are	O
well	O
established	O
.	O

However	O
when	O
the	O
presentation	O
of	O
optic	B-DIS
neuritis	I-DIS
is	O
atypical	O
bilateral	O
and	O
intravenous	O
steroid	O
-	O
resistant	O
the	O
treatment	O
guidelines	O
are	O
quite	O
nebulous	O
.	O

We	O
present	O
a	O
case	O
of	O
bilateral	O
severe	O
double	B-DIS
-	I-DIS
seronegative	I-DIS
optic	O
neuritis	B-DIS
with	I-DIS
catastrophic	I-DIS
vision	O
loss	O
and	O
intravenous	O
steroid	O
resistance	O
.	O

After	O
an	O
exhaustive	O
investigation	O
we	O
empirically	O
treated	O
our	O
patient	O
with	O
plasma	O
exchange	O
therapy	O
and	O
obtained	O
a	O
dramatic	O
recovery	O
of	O
vision	O
.	O

When	O
an	O
immune	O
etiology	O
is	O
suspected	O
this	O
case	O
is	O
instructive	O
vis	O
-	O
a	O
-	O
vis	O
the	O
utility	O
of	O
plasma	O
exchange	O
in	B-DIS
refractory	I-DIS
cases	O
of	O
optic	O
neuritis	O
despite	O
seronegativity	O
.	O

The	O
definition	O
of	O
congenital	B-DIS
anomalies	I-DIS
of	O
the	O
kidney	O
and	O
urinary	B-DIS
tract	I-DIS
CAKUT	O
is	O
the	O
disease	O
of	O
structural	B-DIS
malformations	I-DIS
in	O
the	O
kidney	O
and/or	O
urinary	O
tract	O
containing	O
vesicoureteral	B-DIS
reflux	I-DIS
VUR	I-DIS
.	O

These	O
anomalies	B-DIS
can	O
cause	O
pediatric	O
chronic	B-DIS
kidney	I-DIS
disease	I-DIS
.	O

However	O
the	O
pathogenesis	O
of	O
CAKUT	B-DIS
is	O
not	O
well	O
understood	O
because	O
identifying	O
the	O
genetic	O
architecture	O
of	O
CAKUT	O
is	O
difficult	O
due	O
to	O
the	O
phenotypic	O
heterogeneity	O
and	O
multifactorial	O
genetic	O
penetrance	O
.	O

We	O
describe	O
the	O
current	O
genetic	O
basis	O
and	O
mechanisms	O
of	O
CAKUT	O
including	O
VUR	B-DIS
via	O
approaching	O
the	O
steps	O
and	O
signaling	O
pathways	O
of	O
kidney	O
developmental	O
processes	O
.	O

We	O
also	O
focus	O
on	O
the	O
newly	O
developed	O
strategies	O
and	O
challenges	O
to	O
fully	O
address	O
the	O
role	O
of	O
the	O
associated	O
genes	O
in	O
the	O
pathogenesis	O
of	O
the	O
disease	O
.	O

Recent	O
expansion	O
of	O
arboviruses	O
such	O
as	O
West	B-LOC
Nile	I-LOC
WNV	I-LOC
Usutu	I-LOC
USUV	O
and	O
tick	B-DIS
-	I-DIS
borne	O
encephalitis	O
TBEV	O
over	O
their	O
natural	O
range	O
of	O
distribution	O
needs	O
strengthening	O
their	O
surveillance	O
.	O

As	O
common	O
viral	O
vertebrate	O
hosts	O
birds	O
and	O
horses	O
deserve	O
special	O
attention	O
with	O
routine	O
serological	O
surveillance	O
.	O

Here	O
we	O
estimated	O
the	O
seroprevalence	O
of	O
WNV	B-DIS
USUV	I-DIS
and	O
TBEV	B-DIS
in	O
160	O
migrating	O
/	O
resident	O
birds	O
and	O
60	O
horses	O
sampled	O
in	O
Mazandaran	B-LOC
Golestan	I-LOC
North	I-LOC
Khorasan	I-LOC
Kordestan	I-LOC
provinces	I-LOC
and	O
Golestan	B-LOC
province	I-LOC
of	O
Iran	B-LOC
respectively	O
.	O

ELISA	O
results	O
showed	O
that	O
of	O
220	O
collected	O
samples	O
32	O
samples	O
14.54	B-STAT
%	I-STAT
including	O
22	O
birds	O
and	O
10	O
horses	O
were	O
positive	O
.	O

Microsphere	O
immunoassay	O
results	O
showed	O
that	O
16.7	B-STAT
%	I-STAT
10/60	B-STAT
of	O
horse	O
blood	O
samples	O
collected	O
in	O
Golestan	B-LOC
province	I-LOC
were	O
seropositive	O
against	O
WNV	B-DIS
7	O
;	O
11.7	B-STAT
%	I-STAT
Flavivirus	B-DIS
2	I-DIS
;	O
3.3	B-STAT
%	I-STAT
and	O
seropositive	O
for	O
USUV	B-DIS
or	O
WNV	B-DIS
1	O
;	O
1.7	B-STAT
%	I-STAT
.	O

Furthermore	O
micro	O
virus	O
neutralization	O
tests	O
revealed	O
that	O
four	O
of	O
seven	O
ELISA	O
-	O
positive	O
bird	O
blood	O
samples	O
were	O
seropositive	B-DIS
against	O
WNV	O
two	O
Egyptian	O
vultures	O
and	O
one	O
long	O
-	O
legged	O
buzzard	O
collected	O
in	O
Golestan	O
province	O
as	O
well	O
as	O
a	O
golden	O
eagle	O
collected	O
in	O
North	B-LOC
Khorasan	I-LOC
province	O
.	O

No	O
evidence	O
of	O
seropositivity	O
with	O
TBEV	B-DIS
was	O
observed	O
in	O
collected	O
samples	O
.	O

We	O
showed	O
that	O
WNV	B-DIS
responsible	O
for	O
neuroinvasive	O
infection	B-DIS
in	O
vertebrates	O
is	O
circulating	O
among	O
birds	O
and	O
horses	O
in	O
Iran	B-LOC
recommending	O
a	O
sustained	O
surveillance	O
of	O
viral	B-DIS
infections	I-DIS
in	O
animals	O
and	O
anticipating	O
future	O
infections	B-DIS
in	O
humans	O
.	O

Background	O
Orbital	B-DIS
hypertelorism	I-DIS
OHT	O
represents	O
a	O
congenital	O
condition	O
defined	O
by	O
lateralization	O
of	O
the	O
bony	O
orbit	O
unlike	O
soft	O
tissue	O
telecanthus	B-DIS
in	O
which	O
there	O
is	O
an	O
increase	O
in	O
intercanthal	O
distance	O
without	O
true	O
bony	O
lateralization	O
.	O

Existing	O
literature	O
remains	O
very	O
limited	O
in	O
its	O
postoperative	O
assessment	O
of	O
bony	O
versus	O
soft	O
tissue	O
relapse	O
which	O
may	O
both	O
clinically	O
present	O
as	O
telecanthus	B-DIS
.	O

We	O
performed	O
a	O
critical	O
appraisal	O
of	O
the	O
literature	O
to	O
determine	O
the	O
postoperative	O
incidence	B-EPI
of	O
bony	O
versus	O
soft	O
tissue	O
relapse	O
following	O
OHT	O
repair	O
.	O

Methods	O
The	O
PubMed	O
MEDLINE	O
EMBASE	O
Scopus	O
Cochrane	O
Central	O
Register	O
of	O
Controlled	O
Trials	O
and	O
clinicaltrials.org	O
were	O
searched	O
systematically	O
for	O
all	O
English	O
studies	O
published	O
in	O
any	O
time	O
frame	O
reporting	O
relapse	O
rates	O
following	O
primary	O
OHT	O
repair	O
.	O

The	O
primary	O
outcome	O
was	O
incidence	B-EPI
of	O
bony	O
and	O
soft	O
tissue	O
relapse	O
defined	O
as	O
orbital	O
lateralization	O
and	O
medial	O
canthal	O
drift	O
respectively	O
.	O

The	O
secondary	O
outcome	O
measures	O
include	O
postoperative	O
complications	O
predictors	O
of	O
postoperative	O
complications	O
timing	O
and	O
type	O
of	O
surgery	O
and	O
revision	O
rates	O
.	O

Results	O
Eleven	O
articles	O
were	O
included	O
.	O

A	O
total	O
of	O
84	O
35.3	B-STAT
%	I-STAT
patients	O
experienced	O
bony	B-DIS
relapse	I-DIS
while	O
43	O
27.2	B-STAT
%	I-STAT
patients	O
experienced	O
soft	O
tissue	O
relapse	O
.	O

Age	O
at	O
time	O
of	O
intervention	O
p	O
<	O
0.92	O
severity	O
at	O
presentation	O
p	O
<	O
0.90	O
and	O
surgical	O
technique	O
p	O
<	O
0.09	O
were	O
not	O
found	O
be	O
significantly	O
associated	O
with	O
relapse	O
rate	O
.	O

Methods	O
for	O
long	O
-	O
term	O
follow	O
-	O
up	O
were	O
not	O
standardized	O
and	O
there	O
was	O
no	O
consistent	O
measure	B-DIS
to	O
objectively	O
assess	O
telecanthus	O
.	O

Conclusions	O
There	O
is	O
no	O
general	O
consensus	O
on	O
predictive	O
factors	O
of	O
long	O
-	O
term	O
relapse	O
following	O
OHT	O
repair	O
in	O
the	O
form	O
of	O
box	O
osteotomy	O
or	O
facial	O
bipartition	O
.	O

These	O
findings	O
call	O
for	O
cross	O
-	O
sectional	O
outcome	O
standardization	O
to	O
better	O
understand	O
long	O
-	O
term	O
outcomes	O
across	O
institutional	O
provider	O
and	O
patient	O
differences	O
.	O

Zika	O
virus	O
ZIKV	O
is	O
a	O
vectorborne	O
infectious	O
agent	O
of	O
global	O
public	O
health	O
significance	O
due	O
to	O
its	O
potential	O
to	O
cause	O
severe	O
teratogenic	O
outcomes	O
.	O

The	O
question	O
of	O
whether	O
health	O
systems	O
should	O
consider	O
adopting	O
screening	O
programmes	O
for	O
ZIKV	B-DIS
infections	I-DIS
during	O
pregnancy	O
warrants	O
consideration	O
.	O

In	O
this	O
analysis	O
we	O
apply	O
the	O
Wilson	O
-	O
Jungner	O
framework	O
to	O
appraise	O
the	O
potential	O
utility	O
of	O
a	O
prenatal	O
ZIKV	O
screening	O
programme	O
outline	O
potential	O
screening	O
strategies	O
within	O
the	O
case	O
-	O
finding	O
pathway	O
and	O
consider	O
other	O
epidemiological	O
factors	O
that	O
may	O
influence	O
the	O
planning	O
of	O
such	O
a	O
screening	O
programme	O
.	O

Our	O
evaluation	O
of	O
a	O
potential	O
prenatal	O
ZIKV	O
screening	O
programme	O
highlights	O
factors	O
affirming	O
its	O
usefulness	O
including	O
the	O
importance	O
of	O
Congenital	B-DIS
Zika	I-DIS
Syndrome	I-DIS
as	O
a	O
public	O
health	O
problem	O
and	O
the	O
existence	O
of	O
analogous	O
congenital	O
prenatal	O
screening	O
programmes	O
for	O
STORCH	O
agents	O
syphilis	O
toxoplasmosis	B-DIS
others	O
eg	O
human	B-DIS
immunodeficiency	I-DIS
virus	I-DIS
varicella	I-DIS
-	I-DIS
zoster	I-DIS
virus	I-DIS
parvovirus	I-DIS
B19	I-DIS
rubella	I-DIS
cytomegalovirus	O
and	O
herpes	O
simplex	O
virus	O
.	O

However	O
our	O
assessment	O
also	O
reveals	O
key	O
barriers	O
to	O
implementation	O
such	O
as	O
the	O
need	O
for	O
more	O
accurate	O
diagnostic	O
tests	O
effective	O
antiviral	O
treatments	O
increased	O
social	O
service	O
capacity	O
and	O
surveillance	O
.	O

Given	O
that	O
the	O
reemergence	O
of	O
ZIKV	O
is	O
likely	O
we	O
provide	O
a	O
guiding	O
framework	O
for	O
policymakers	O
and	O
public	O
health	O
leaders	O
that	O
can	O
be	O
further	O
elaborated	O
and	O
adapted	O
to	O
different	O
contexts	O
in	O
order	O
to	O
reduce	O
the	O
burden	O
of	O
adverse	O
ZIKV	O
-	O
related	O
birth	O
outcomes	O
during	O
future	O
outbreaks	O
.	O

The	O
genetic	O
basis	O
of	O
Japanese	O
autosomal	B-DIS
recessive	I-DIS
retinitis	I-DIS
pigmentosa	I-DIS
ARRP	I-DIS
remains	O
largely	O
unknown	O
.	O

Herein	O
we	O
applied	O
a	O
2	O
-	O
step	O
genome	O
-	O
wide	O
association	O
study	O
GWAS	O
in	O
640	O
Japanese	O
patients	O
.	O

Meta	O
-	O
GWAS	O
identified	O
three	O
independent	O
peaks	O
at	O
P	O
<	O
5.0	O
×	O
10	O
-8	O
<	O
/s	O
all	O
within	O
the	O
major	O
ARRP	O
gene	O
EYS	O
.	O

Two	O
of	O
the	O
three	O
were	O
each	O
in	O
linkage	O
disequilibrium	O
with	O
a	O
different	O
low	O
frequency	O
variant	O
allele	O
frequency	O
<	O
0.05	O
;	O
a	O
known	O
founder	O
Mendelian	O
mutation	O
c.4957dupA	O
p.	O
S1653Kfs	O
*	O
2	O
and	O
a	O
non	O
-	O
synonymous	O
variant	O
c.2528	O
A	O
p.	O
G843E	O
of	O
unknown	O
significance	O
.	O

mRNA	O
harboring	O
c.2528	O
A	O
failed	O
to	O
restore	O
rhodopsin	O
mislocalization	O
induced	O
by	O
morpholino	O
-	O
mediated	O
knockdown	B-DIS
of	O
eys	O
in	O
zebrafish	O
consistent	O
with	O
the	O
variant	O
being	O
pathogenic	O
.	O

c.2528	O
A	O
solved	O
an	B-STAT
additional	I-STAT
7.0	I-STAT
%	I-STAT
of	O
Japanese	B-LOC
ARRP	B-DIS
cases	O
.	O

The	O
third	O
peak	O
was	O
in	O
linkage	O
disequilibrium	O
with	O
a	O
common	O
non	O
-	O
synonymous	O
variant	O
c.7666	O
T	O
p.	O
S2556C	O
possibly	O
representing	O
an	O
unreported	O
disease	O
-	O
susceptibility	O
signal	O
.	O

GWAS	O
successfully	O
unraveled	O
genetic	O
causes	O
of	O
a	O
rare	O
monogenic	B-DIS
disorder	I-DIS
and	O
identified	O
a	O
high	O
frequency	O
variant	O
potentially	O
linked	O
to	O
development	O
of	O
local	O
genome	O
therapeutics	O
.	O

Li	B-DIS
-	I-DIS
Fraumeni	O
syndrome	O
LFS	O
is	O
an	B-DIS
inherited	I-DIS
cancer	O
syndrome	O
characterized	O
by	O
an	O
early	O
onset	O
of	O
various	O
types	B-DIS
of	O
cancers	O
.	O

LFS	O
is	O
associated	O
with	O
a	O
germline	O
mutation	O
in	O
the	O
TP53	O
gene	O
.	O

The	O
risk	O
of	O
developing	O
skin	B-DIS
cancer	I-DIS
in	O
patients	O
with	O
LFS	B-DIS
is	O
unknown	O
.	O

To	O
evaluate	O
the	O
cumulative	O
risk	O
of	O
skin	B-DIS
cancer	I-DIS
in	O
patients	O
with	O
LFS	B-DIS
and	O
to	O
compare	O
this	O
risk	O
to	O
the	O
general	O
Dutch	O
population	O
.	O

In	O
this	O
retrospective	O
cohort	O
study	O
all	O
proven	O
TP53	O
mutation	O
carriers	O
in	O
the	O
Netherlands	O
Cancer	B-DIS
Institute	O
were	O
included	O
from	O
their	O
first	O
visit	O
to	O
the	O
Institute	O
until	O
June	O
2017	O
.	O

Medical	O
charts	O
and	O
pathology	O
reviews	O
cross	O
-	O
referenced	O
with	O
PALGA	O
the	O
nationwide	O
network	O
and	O
registry	O
of	O
histo-	O
and	O
cytopathology	O
were	O
used	O
to	O
identify	B-DIS
incident	I-DIS
skin	O
cancers	O
.	O

Cumulative	O
risks	O
were	O
calculated	O
by	O
Kaplan	O
-	O
Meier	O
analysis	O
.	O

Seventy	O
-	O
one	O
patients	O
59	B-STAT
%	I-STAT
female	O
from	O
33	O
families	O
were	O
included	O
.	O

Ten	O
patients	O
14	B-STAT
%	I-STAT
developed	O
a	O
total	O
of	O
19	O
skin	B-DIS
cancers	I-DIS
at	O
a	O
median	O
age	O
of	O
4125	O
-	O
65	O
years	O
.	O

The	O
cumulative	O
risk	O
of	O
skin	B-DIS
cancer	I-DIS
is	O
10.4	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
4.4	B-STAT
-	I-STAT
23.5	I-STAT
%	I-STAT
at	O
age	O
4025.2	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
12.3	O
-	O
47.6	O
%	O
at	O
age	O
60	O
and	O
a	O
at	O
age	O
70	O
this	O
risk	O
is	O
44.6	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
22.9	O
-	O
73.9	B-STAT
%	I-STAT
.	O

The	O
cumulative	O
risks	O
of	O
melanoma	B-DIS
and	O
basal	B-DIS
cell	I-DIS
carcinoma	I-DIS
at	O
age	O
70	O
are	O
increased	O
compared	O
to	O
the	O
general	O
Dutch	O
population	O
namely	O
12.6	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
3.6	B-STAT
-	I-STAT
38.4	I-STAT
%	I-STAT
and	O
34.6	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
15.4	B-STAT
-	I-STAT
66.2	I-STAT
%	I-STAT
respectively	O
.	O

Patients	O
with	O
LFS	B-DIS
have	O
an	O
increased	O
risk	O
of	O
developing	O
skin	B-DIS
cancer	I-DIS
.	O

A	O
dermatological	O
consultation	O
may	O
be	O
considered	O
at	O
least	O
once	O
in	O
individuals	O
with	O
LFS	O
to	O
raise	O
awareness	O
for	O
skin	B-DIS
cancer	I-DIS
and	O
inform	O
about	O
risk	O
factors	O
.	O

Background	O
Neuromyelitis	B-DIS
optica	I-DIS
spectrum	I-DIS
disorders	I-DIS
NMOSD	I-DIS
is	O
an	O
increasing	O
diagnostic	O
and	O
therapeutic	O
challenge	O
in	O
Latin	B-LOC
America	I-LOC
LATAM	O
.	O

Despite	O
the	O
heterogeneity	O
of	O
this	O
population	O
ethnic	O
and	O
socioeconomic	O
commonalities	O
exist	O
and	O
epidemiologic	O
studies	O
from	O
the	O
region	O
have	O
had	O
a	O
limited	O
geographic	O
and	O
population	O
outreach	O
.	O

Identification	O
of	O
some	O
aspects	O
from	O
the	O
entire	O
region	O
are	O
lacking	O
.	O

Objectives	O
To	O
determine	O
ethnic	O
clinical	O
characteristics	O
and	O
utilization	O
of	O
diagnostic	O
tools	O
and	O
types	O
of	O
therapy	O
for	O
patients	O
with	O
NMOSD	B-DIS
in	O
the	O
entire	O
Latin	O
American	O
region	O
.	O

Methods	O
The	O
Latin	O
American	O
Committee	O
for	O
Treatment	O
and	O
Research	O
in	O
MS	O
LACTRIMS	O
created	O
an	O
exploratory	O
investigational	O
survey	O
addressed	O
by	O
Invitation	O
to	O
NMOSD	B-DIS
Latin	O
American	O
experts	O
identified	O
through	O
diverse	O
sources	O
.	O

Data	O
input	O
closed	O
after	O
30	O
days	O
from	O
the	O
initial	O
invitation	O
.	O

The	O
questionnaire	O
allowed	O
use	O
of	O
absolute	O
numbers	O
or	O
percentages	O
.	O

Multiple	O
option	O
responses	O
covering	O
25	O
themes	O
included	O
definition	O
of	O
type	O
of	O
practice	O
;	O
number	O
of	O
NMOSD	B-DIS
cases	O
;	O
ethnicity	O
;	O
utilization	O
of	O
the	O
2015	O
International	O
Panel	O
criteria	O
for	O
the	O
diagnosis	O
of	O
Neuromyelitis	B-DIS
optica	I-DIS
IPDN	O
;	O
clinical	O
phenotypes	O
;	O
methodology	O
utilized	O
for	O
determination	O
of	O
anti	O
-	O
Aquaporin-4	O
anti-	O
AQP4	O
antibodies	O
serological	O
testing	O
and	O
if	O
this	O
was	O
performed	O
locally	O
or	O
processed	O
abroad	O
;	O
treatment	O
of	O
relapses	O
and	O
long	O
-	O
term	O
management	O
were	O
surveyed	O
.	O

Results	O
We	O
identified	O
62	O
investigators	O
from	O
21	O
countries	O
reporting	O
information	O
from	O
2154	O
patients	O
utilizing	O
the	O
IPDN	O
criteria	O
in	O
93.9	B-STAT
%	I-STAT
of	O
cases	O
which	O
were	O
categorized	O
in	O
two	O
geographical	O
regions	O
North	B-LOC
-	I-LOC
Central	I-LOC
including	O
the	B-DIS
Caribbean	O
NCC	O
and	O
South	B-LOC
America	I-LOC
SA	I-LOC
.	O

Ethnic	O
identification	O
disclosed	O
Mestizos	O
61.4	B-STAT
%	I-STAT
as	O
the	O
main	O
group	O
.	O

The	O
most	O
common	O
presenting	O
symptoms	O
were	O
concomitant	O
presence	O
of	O
optic	B-DIS
neuritis	I-DIS
and	O
transverse	B-DIS
myelitis	I-DIS
in	O
31.8	B-STAT
%	I-STAT
p=0.95	O
;	O
only	O
optic	B-DIS
neuritis	I-DIS
in	O
31.4	B-STAT
%	I-STAT
more	O
common	O
in	O
SA	O
p	O
<	O
0.001	O
;	O
involvement	O
of	O
the	O
area	O
postrema	O
occurred	O
in	O
21.5	B-STAT
%	I-STAT
and	O
brain	O
stem	O
in	O
8.3	B-STAT
%	I-STAT
both	O
were	O
more	O
frequent	O
in	O
the	O
South	O
American	O
cases	O
p	O
<	O
0.001	O
.	O

Anti	O
-	O
AQP4	O
antibodies	O
were	O
positive	O
in	O
63.9	B-STAT
%	I-STAT
and	O
anti	O
-	O
Myelin	O
Oligodendrocyte	O
Glycoprotein	O
MOG	O
antibodies	O
in	O
4.8	B-STAT
%	I-STAT
of	O
total	O
cases	O
.	O

The	O
specific	O
laboratorial	O
method	O
employed	O
was	O
not	O
known	O
by	O
23.8	B-STAT
%	I-STAT
of	O
the	O
investigators	O
.	O

Acute	O
relapses	O
were	O
identified	O
in	O
81.6	B-STAT
%	I-STAT
of	O
cases	O
and	O
were	O
treated	O
in	O
93.9	B-STAT
%	I-STAT
of	O
them	O
with	O
intravenous	O
steroids	O
IVS	O
;	O
62.1	B-STAT
%	I-STAT
with	O
plasma	O
exchange	O
PE	O
and	O
40.9	B-STAT
%	I-STAT
with	O
intravenous	O
immunoglobulin	O
-	O
G	O
IVIG	O
.	O

Therapy	O
was	O
escalated	O
in	O
some	O
cases	O
due	O
to	O
suboptimal	O
initial	O
response	O
.	O

Respondents	O
favored	O
Rituximab	O
as	O
long	O
-	O
term	O
therapy	O
86.3	B-STAT
%	I-STAT
whereas	O
azathioprine	O
was	O
also	O
utilized	O
on	O
81.8	B-STAT
%	I-STAT
of	O
the	O
cases	O
either	O
agent	O
used	O
indistinctly	O
by	O
the	O
investigators	O
according	O
to	O
treatment	O
accessibility	O
or	O
clinical	O
judgement	O
.	O

There	O
were	O
no	O
differences	O
among	O
the	O
geographic	O
regions	O
.	O

Conclusions	O
This	O
is	O
the	O
first	O
study	O
including	O
all	O
countries	O
of	O
LATAM	O
and	O
the	O
largest	O
cohort	O
reported	O
from	O
a	O
multinational	O
specific	O
world	O
area	O
.	O

Ethnic	O
distributions	O
and	O
phenotypic	O
features	O
of	O
the	O
disease	O
in	O
the	O
region	O
challenges	O
in	O
access	O
to	O
diagnostic	O
tools	O
and	O
therapy	O
were	O
identified	O
.	O

The	O
Latin	O
American	O
neurological	O
community	O
should	O
play	O
a	O
determinant	O
role	O
encouraging	O
and	O
advising	O
local	O
institutions	O
and	O
health	O
officials	O
in	O
the	O
availability	O
of	O
more	O
sensitive	O
and	O
modern	O
diagnostic	O
methodology	O
in	O
facilitating	O
the	O
the	O
access	O
to	O
licensed	O
medications	O
for	O
NMOSD	B-DIS
and	O
addressing	O
concerns	O
on	O
education	O
diagnosis	O
and	O
management	O
of	O
the	O
disease	O
in	O
the	O
community	O
.	O

The	O
field	O
of	O
gene	O
therapy	O
is	O
striving	O
more	O
than	O
ever	O
to	O
define	O
a	O
path	O
to	O
the	O
clinic	O
and	O
the	O
market	O
.	O

Twenty	O
gene	O
therapy	O
products	O
have	O
already	O
been	O
approved	O
and	O
over	O
two	O
thousand	O
human	O
gene	O
therapy	O
clinical	O
trials	O
have	O
been	O
reported	O
worldwide	O
.	O

These	O
advances	O
raise	O
great	O
hope	O
to	O
treat	O
devastating	O
rare	O
and	O
inherited	O
diseases	O
as	O
well	O
as	O
incurable	O
illnesses	O
.	O

Understanding	O
of	O
the	O
precise	O
pathomechanisms	O
of	O
diseases	O
as	O
well	O
as	O
the	O
development	O
of	O
efficient	O
and	O
specific	O
gene	O
targeting	O
and	O
delivery	O
tools	O
are	O
revolutionizing	O
the	O
global	O
market	O
.	O

Currently	O
human	O
cancers	B-DIS
and	O
monogenic	B-DIS
disorders	I-DIS
are	O
indications	O
number	O
one	O
.	O

The	O
elevated	O
prevalence	B-EPI
of	O
genetic	O
disorders	O
and	O
cancers	B-DIS
clear	O
gene	O
manipulation	O
guidelines	O
and	O
increasing	O
financial	O
support	O
for	O
gene	O
therapy	O
in	O
clinical	O
trials	O
are	O
major	O
trends	O
.	O

Gene	O
therapy	O
is	O
presently	O
starting	O
to	O
become	O
commercially	O
profitable	O
as	O
a	O
number	O
of	O
gene	O
and	O
cell	O
-	O
based	O
gene	O
therapy	O
products	O
have	O
entered	O
the	O
market	O
and	O
the	O
clinic	O
.	O

This	O
article	O
reviews	O
the	O
history	O
and	O
development	O
of	O
twenty	O
approved	O
human	O
gene	O
and	O
cell	O
-	O
based	O
gene	O
therapy	O
products	O
that	O
have	O
been	O
approved	O
up	O
-	O
to	O
-	O
now	O
in	O
clinic	O
and	O
markets	O
of	O
mainly	O
North	B-LOC
America	I-LOC
Europe	I-LOC
and	O
Asia	B-LOC
.	O

Objective	O
To	O
analyze	O
the	O
results	O
and	O
follow	O
up	O
data	O
of	O
screening	O
for	O
newborn	O
organic	O
aciduria	O
in	O
Zhejiang	B-LOC
province	I-LOC
.	O

Methods	O
The	O
results	O
and	O
follow	O
-	O
up	O
data	O
of	O
1861262	O
newborns	O
from	O
Zhejiang	B-LOC
province	O
undergoing	O
screening	B-DIS
for	I-DIS
organic	O
aciduria	O
during	O
January	O
2009	O
and	O
December	O
2016	O
were	O
retrospectively	O
analyzed	O
.	O

The	O
acylcarnitine	O
spectrum	O
in	O
urine	O
samples	O
was	O
detected	O
by	O
tandem	O
mass	O
spectrum	O
MS	O
/	O
MS	O
and	O
the	O
positive	O
patients	O
were	O
confirmed	O
by	O
urine	O
gas	O
chromatography	O
mass	O
spectrometry	O
and/or	O
gene	O
analysis	O
.	O

Results	O
Ninety	O
two	O
cases	O
of	O
organic	B-DIS
aciduria	I-DIS
were	O
confirmed	O
with	O
a	O
prevalence	B-EPI
of	O
120200	O
.	O

Among	O
40	O
cases	O
of	O
methylmalonic	B-DIS
academia	I-DIS
MMA	I-DIS
1332.5	B-STAT
%	I-STAT
were	O
of	O
MMA	O
simple	O
type	O
and	O
2767.5	B-STAT
%	I-STAT
were	O
combined	O
type	O
.	O

Genetic	O
analysis	O
showed	O
6	O
cases	O
of	O
MUT	O
type	O
and	O
1	O
case	O
of	O
CblB	O
type	O
out	O
of	O
7	O
patients	O
with	O
MMA	O
simple	O
type	O
10	O
cases	O
of	O
CblC	B-DIS
and	O
1	O
case	O
of	O
CblF	O
out	O
of	O
11	O
patients	O
with	O
combined	O
type	O
respectively	O
.	O

Six	O
patients	O
had	O
propionic	O
academia	O
with	O
a	O
prevalence	B-EPI
of	O
13102007	O
had	O
isovaleric	O
academia	O
12659006	O
had	O
glutaric	B-DIS
academia	O
type	O
11310200	O
27	O
had	O
3	O
-	B-DIS
methylcrotonyl	I-DIS
-	I-DIS
CoA	I-DIS
carboxylase	O
deficiency	B-DIS
MCC	I-DIS
1689001	I-DIS
had	O
3	O
-	O
hydroxy-3	O
-	O
methylglutaric	O
aciduria	O
11861300	O
2	O
had	O
β	O
-	O
ketothiolase	O
deficiency	O
1960600	O
and	O
3	O
had	O
biotinidase	O
deficiency	O
/	O
holocarboxylase	O
synthetase	O
deficiency	O
1620400	O
.	O

Thirty	O
-	O
one	O
patients	O
had	O
a	O
disease	O
onset	O
at	O
neonatal	O
period	O
and	O
15	O
at	O
post	O
-	O
neonatal	O
period	O
.	O

Thirty	O
-	O
three	O
patients	B-DIS
had	I-DIS
brain	I-DIS
involvements	I-DIS
or	I-DIS
cranial	I-DIS
imaging	O
disorders	O
.	O

Three	O
patients	O
with	O
MMA	O
had	O
kidney	B-DIS
diseases	I-DIS
or	O
heomlytic	O
uremic	B-DIS
syndrome	I-DIS
and	O
3	O
had	O
myocardial	B-DIS
impairments	I-DIS
.	O

Twenty	O
patients	O
died	O
during	O
the	O
follow	O
-	O
up	O
.	O

Conclusions	O
MMA	O
is	O
the	O
most	O
common	O
newborn	O
organic	O
aciduria	O
in	O
Zhejiang	B-LOC
province	I-LOC
.	O

Except	O
MCC	O
most	O
organic	B-DIS
aciduria	I-DIS
may	O
lead	O
to	O
metabolism	O
decompensation	B-DIS
complications	O
or	O
even	O
death	B-DIS
.	O

Objectives	O
Generally	O
neuropathies	B-DIS
of	O
peripheral	O
nerves	O
are	O
a	O
frequent	O
condition	O
prevalence	B-EPI
2	B-STAT
-	I-STAT
3	I-STAT
%	I-STAT
and	O
most	O
frequently	O
due	O
to	O
alcoholism	B-DIS
diabetes	I-DIS
renal	I-DIS
insufficiency	I-DIS
malignancy	I-DIS
toxins	O
or	O
drugs	O
.	O

However	O
the	O
vast	O
majority	O
of	O
neuropathies	B-DIS
has	O
orphan	O
status	O
.	O

This	O
review	O
focuses	O
on	O
the	O
etiology	O
frequency	O
diagnosis	O
and	O
treatment	O
of	O
orphan	O
neuropathies	B-DIS
.	O

Methods	O
Literature	O
reviewResultsRareness	O
of	O
diseases	O
is	O
not	O
uniformly	O
defined	O
but	O
in	O
the	O
US	B-LOC
an	O
orphan	O
disease	O
is	O
diagnosed	O
if	O
the	O
prevalence	B-EPI
is	O
<	O
1200000	O
in	O
Europe	B-LOC
if	O
<	O
510000	O
.	O

Most	O
acquired	O
and	O
hereditary	B-DIS
neuropathies	I-DIS
are	O
orphan	O
diseases	O
.	O

Often	O
the	O
causative	O
variant	O
has	O
been	O
reported	O
only	O
in	O
a	O
single	O
patient	O
or	O
family	O
particularly	O
the	O
ones	O
that	O
are	O
newly	O
detected	O
e.g	O
.	O

SEPT9	O
SORD	O
.	O

Among	O
the	O
complex	O
neuropathies	B-DIS
hereditary	I-DIS
multisystem	I-DIS
disorders	I-DIS
with	O
concomitant	O
neuropathies	B-DIS
orphan	O
forms	O
have	O
been	O
reported	O
among	O
mitochondrial	B-DIS
disorders	I-DIS
e.g	O
.	O

NARP	B-DIS
MNGIE	I-DIS
SANDO	I-DIS
spinocerebellar	I-DIS
ataxias	I-DIS
e.g	O
.	O

TMEM240	B-LOC
hereditary	B-DIS
spastic	I-DIS
paraplegias	I-DIS
e.g	O
UBAP1	O
lysosomal	O
storage	O
disease	O
e.g	O
.	O

Schindler	B-DIS
disease	I-DIS
peroxisomal	I-DIS
disorders	I-DIS
porphyrias	I-DIS
and	O
other	O
types	O
e.g	O
.	O

giant	O
axonal	B-DIS
neuropathy	I-DIS
Tangier	I-DIS
disease	I-DIS
.	O

Orphan	O
acquired	O
neuropathies	B-DIS
include	O
the	O
metabolic	B-DIS
neuropathies	I-DIS
e.g	O
.	O

vitamin	O
-	O
B1	O
folic	O
acid	O
toxic	O
neuropathies	O
e.g	O
.	O

copper	O
lithium	O
lead	O
arsenic	O
thallium	O
mercury	O
infectious	O
neuropathies	O
immune	O
-	O
mediated	O
e.g	O
.	O

Bruns	B-DIS
-	I-DIS
Garland	O
syndrome	B-DIS
and	I-DIS
neoplastic	O
/	O
paraneoplastic	O
neuropathies	O
.	O

Conclusions	O
Though	O
orphan	O
neuropathies	B-DIS
are	O
rare	O
per	O
definition	O
they	O
constitute	O
the	O
majority	O
of	O
neuropathies	B-DIS
and	O
should	O
be	O
considered	O
as	O
some	O
of	O
them	O
are	O
easy	O
to	O
identify	O
and	O
potentially	O
treatable	O
as	O
clarification	O
of	O
the	O
underlying	O
cause	O
may	O
contribute	O
to	O
the	O
knowledge	O
about	O
etiology	O
and	O
pathophysiology	O
of	O
these	O
conditions	O
and	O
as	O
the	O
true	O
prevalence	B-EPI
may	O
become	O
obvious	O
only	O
if	O
all	O
ever	O
diagnosed	O
cases	O
are	O
reported	O
.	O

Papillon	B-DIS
-	I-DIS
Lefevre	O
syndrome	O
PLS	O
is	O
a	O
rare	O
disease	O
characterized	O
by	O
skin	O
lesions	O
which	B-DIS
includes	I-DIS
palmar	O
-	B-DIS
plantar	O
hyperkeratosis	O
and	B-DIS
hyperhidrosis	I-DIS
with	O
severe	O
periodontal	O
destruction	O
involving	O
both	O
the	O
primary	O
and	O
the	O
permanent	O
dentitions	O
.	O

It	O
is	O
transmitted	O
as	O
an	O
autosomal	B-DIS
-	O
recessive	O
condition	O
and	O
consanguinity	O
of	O
parents	O
is	O
evident	O
in	O
about	O
one	O
-	O
third	O
of	O
the	O
cases	O
.	O

This	O
paper	O
describes	O
a	O
13	O
-	O
year	O
-	O
old	O
male	O
patient	O
who	O
presented	O
to	O
the	O
department	O
of	O
pedodontics	B-DIS
with	O
rapidly	O
progressing	O
periodontitis	O
.	O

A	O
general	O
physical	O
examination	O
revealed	O
scaling	O
on	O
the	O
hands	O
and	O
feet	O
which	O
had	O
been	O
medically	O
diagnosed	O
as	O
PLS	O
.	O

The	O
incidence	B-EPI
of	O
this	O
rare	O
entity	O
is	O
increasing	O
in	O
the	O
recent	O
times	O
which	O
is	O
associated	O
with	O
irreparable	O
periodontal	O
destruction	O
at	O
an	O
early	O
age	O
with	O
not	O
so	O
prominent	O
skin	O
lesions	O
in	O
some	O
cases	O
.	O

In	O
such	O
instances	O
the	O
dentist	O
has	O
a	O
more	O
important	O
role	O
in	O
diagnosing	O
treatment	O
planning	O
and	O
preservation	O
of	O
the	O
periodontal	O
tissues	O
and	O
at	O
the	O
same	O
time	O
referring	O
for	O
the	O
treatment	O
of	O
the	O
skin	O
lesions	O
.	O

This	O
paper	O
emphasizes	O
the	O
combined	O
effort	O
of	O
the	O
two	O
specialities	O
in	O
order	O
to	O
maintain	O
skin	O
as	O
well	O
as	O
dental	O
conditions	O
in	O
health	O
by	O
early	O
intervention	O
and	O
a	O
synergistic	O
treatment	O
approach	O
.	O

The	O
reported	O
incidence	B-EPI
of	O
COVID-19	O
among	O
cohorts	O
of	O
patients	O
with	O
inflammatory	B-DIS
bowel	I-DIS
and	I-DIS
skin	I-DIS
diseases	I-DIS
under	O
treatment	O
with	O
biologicals	O
is	O
low	O
.	O

Treatment	O
may	O
further	O
modify	O
disease	O
severity	O
as	O
some	O
biological	O
modifiers	O
such	O
as	O
anakinra	O
are	O
also	O
proposed	O
for	O
the	O
management	O
of	O
COVID-19	O
patients	O
potentially	O
providing	O
HS	O
patients	O
with	O
an	O
advantage	O
.	O

The	O
above	O
preliminary	O
evidence	O
suggests	O
that	O
hidradenitis	B-DIS
suppurativa	I-DIS
HS	O
does	O
probably	O
not	O
provide	O
an	O
increased	O
susceptibility	O
for	O
COVID-19	O
and	O
that	O
any	O
susceptibility	O
is	O
unlikely	O
to	O
be	O
modified	O
negatively	O
by	O
treatment	O
with	O
biologicals	O
.	O

On	O
the	O
occasion	O
of	O
its	O
10th	O
International	O
Conference	O
experts	O
of	O
the	O
European	O
Hidradenitis	B-DIS
Suppurativa	O
Foundation	O
e.	O
V	O
.	O

have	O
prepared	O
a	O
consensus	O
statement	O
regarding	O
anti	O
-	O
COVID-19	O
measurements	O
for	O
HS	O
patients	O
.	O

Based	O
on	O
the	O
available	O
knowledge	O
patients	O
with	O
HS	O
may	O
be	O
vaccinated	O
against	O
SARS	O
-	O
CoV2	O
and	O
patients	O
affected	B-DIS
by	I-DIS
metabolic	O
syndrome	O
constitute	O
a	O
high	O
-	O
risk	O
group	O
for	O
COVID-19	O
and	O
should	O
be	O
vaccinated	O
at	O
the	O
earliest	O
convenient	O
point	O
in	O
time	O
.	O

HS	O
patients	O
on	O
treatment	O
with	O
adalimumab	O
can	O
be	O
vaccinated	O
with	O
non	O
-	O
living	O
virus	O
anti	O
-	O
SARS	O
-	O
CoV2	O
vaccines	O
.	O

A	O
possible	O
suboptimal	O
effect	O
of	O
the	O
vaccine	O
may	O
be	O
suspected	O
but	O
might	O
not	O
be	O
expected	O
universally	O
.	O

The	O
management	O
of	O
the	O
biological	O
treatment	O
in	O
HS	O
patients	O
is	O
at	O
the	O
discretion	O
of	O
the	O
dermatologist	O
/	O
responsible	O
physician	O
.	O

Background	O
Target	O
organ	B-DIS
damage	I-DIS
mainly	I-DIS
cardiac	I-DIS
and	I-DIS
renal	I-DIS
damage	I-DIS
is	O
easy	O
to	O
evaluate	O
in	O
outpatient	O
clinics	O
and	O
offers	O
valuable	O
information	O
about	O
patient	O
's	O
cardiovascular	O
risk	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
using	O
simple	O
methods	O
the	O
prevalence	B-EPI
of	O
cardiac	B-DIS
and	I-DIS
renal	I-DIS
damage	I-DIS
and	O
its	O
relationship	O
to	O
the	O
presence	O
of	O
established	O
cardiovascular	B-DIS
disease	I-DIS
CVD	O
in	O
patients	O
with	O
hypertension	B-DIS
HT	I-DIS
and	O
type	B-DIS
2	I-DIS
diabetes	I-DIS
mellitus	I-DIS
DM	I-DIS
.	O

Methods	O
The	O
RICARHD	O
study	O
is	O
a	O
multicentre	O
cross	O
-	O
sectional	O
study	O
made	O
by	O
293	O
investigators	O
in	O
Nephrology	O
and	O
Internal	O
Medicine	O
Spanish	O
outpatient	O
clinics	O
and	O
included	O
patients	O
aged	O
55	O
years	O
or	O
more	B-DIS
with	O
HT	O
and	O
type	O
2	O
DM	O
with	O
more	O
than	O
six	O
months	O
of	O
diagnosis	O
.	O

Demographic	O
clinical	O
and	O
biochemical	O
data	O
and	O
CVD	O
were	O
collected	O
from	O
the	O
clinical	O
records	O
.	O

Cardiac	B-DIS
damage	I-DIS
was	O
defined	O
by	O
the	O
presence	O
of	O
electrocardiographic	O
left	O
ventricular	B-DIS
hypertrophy	I-DIS
ECG	I-DIS
-	O
LVH	B-DIS
and	I-DIS
renal	O
damage	O
by	O
a	O
calculated	O
glomerular	O
filtration	O
rate	O
GFR	O
of	O
<	O
60	O
ml	O
/	O
min/1.73	O
m2	O
and/or	O
the	O
presence	O
of	O
an	O
albumin	O
/	O
creatinine	O
rati	O
or	O
=	O
30	O
mg	O
/	O
g	O
;	O
or	O
an	O
urinary	O
albumin	O
excretion	O
UAE	O
or	O
=	O
30	O
mg/24	O
hours	O
.	O

Results	O
2339	O
patients	O
mean	O
age	O
68.9	O
years	O
48.2	B-STAT
%	I-STAT
females	O
51.3	B-STAT
%	I-STAT
with	O
established	O
CVD	O
were	O
included	O
.	O

ECG	O
-	O
LVH	O
was	O
present	O
in	O
22.9	B-STAT
%	I-STAT
of	O
the	O
sample	O
GFR	O
<	O
60	O
ml	O
/	O
min/1.73	O
m2	O
in	O
45.1	B-STAT
%	I-STAT
and	O
abnormal	O
UAE	O
in	O
58.7	B-STAT
%	I-STAT
.	O

Compared	O
with	O
the	O
reference	O
patients	O
those	O
without	O
neither	O
cardiac	B-DIS
nor	I-DIS
renal	I-DIS
damage	I-DIS
patients	O
with	O
ECG	B-DIS
-	O
LVH	O
alone	O
OR	O
2.20	B-STAT
[	I-STAT
95	I-STAT
%	I-STAT
CI	O
1.43	O
-	O
3.38	O
]	B-DIS
or	I-DIS
kidney	O
damage	O
alone	O
OR	O
1.41	O
[	O
1.13	O
-	O
1.75	O
]	O
showed	O
an	B-EPI
increased	O
prevalence	O
of	O
CVD	O
.	O

The	O
presence	O
of	O
both	O
ECG	B-DIS
-	O
LVH	B-DIS
and	I-DIS
renal	O
damage	O
was	O
associated	O
with	O
the	B-EPI
higher	O
prevalence	O
OR	O
3.12	O
[	O
2.33	O
-	O
4.19	O
]	O
.	O

After	O
stratifying	O
by	O
gender	O
this	O
relationship	O
was	O
present	O
for	O
both	O
men	O
and	O
women	O
.	O

Conclusion	O
In	O
patients	O
with	O
HT	B-DIS
and	O
type	O
2	O
DM	O
ECG	O
-	O
LVH	O
or	O
renal	O
damage	O
evaluated	O
using	O
simple	O
methods	O
are	O
associated	O
with	O
an	B-EPI
increased	O
prevalence	O
of	O
established	O
CVD	O
.	O

The	O
simultaneous	O
presence	O
of	O
both	O
cardiac	B-DIS
and	I-DIS
renal	I-DIS
damage	I-DIS
was	O
associated	O
to	O
the	O
higher	O
prevalence	B-EPI
of	O
CVD	O
affording	O
complementary	O
information	O
.	O

A	O
systematic	O
assessment	O
of	O
cardiac	B-DIS
and	I-DIS
renal	I-DIS
damage	I-DIS
complements	O
the	O
risk	O
assessment	O
of	O
these	O
patients	O
with	O
HT	B-DIS
and	O
type	O
2	O
DM	O
.	O

The	O
mermaid	B-DIS
syndrome	I-DIS
sirenomelia	I-DIS
is	O
an	O
extremely	O
rare	O
anomaly	B-DIS
an	O
incidence	B-EPI
of	O
1	B-STAT
in	I-STAT
100000	I-STAT
births	O
in	O
which	O
a	O
newborn	O
born	O
with	O
legs	O
joined	O
together	O
featuring	O
a	O
mermaid	O
-	O
like	B-DIS
appearance	I-DIS
head	I-DIS
and	I-DIS
trunk	I-DIS
like	O
humans	O
and	O
tail	O
like	O
fish	O
and	O
in	O
most	O
cases	O
die	O
shortly	O
after	O
birth	O
.	O

Gastrointestinal	B-DIS
and	I-DIS
urogenital	I-DIS
anomalies	I-DIS
and	O
single	O
umbilical	O
artery	O
are	O
clinical	O
outcome	O
of	O
this	O
syndrome	O
.	O

There	O
are	O
two	O
important	O
hypotheses	O
for	O
pathogenesis	O
of	O
mermaid	B-DIS
syndrome	I-DIS
vitelline	I-DIS
artery	I-DIS
steal	I-DIS
hypothesis	O
and	O
defective	O
blastogenesis	O
hypothesis	O
.	O

The	O
cause	O
of	O
the	O
mermaid	B-DIS
syndrome	I-DIS
is	O
unknown	O
but	O
there	O
are	O
some	O
possible	O
factors	O
such	O
as	O
age	O
younger	O
than	O
20	O
years	O
and	O
older	O
than	O
40	O
years	O
in	O
mother	O
and	O
exposure	O
of	O
fetus	O
to	O
teratogenics	O
.	O

Here	O
we	O
introduced	O
19	O
-	O
year	O
-	O
old	O
mother	O
's	B-DIS
first	I-DIS
neonate	O
with	O
mermaid	O
syndrome	O
.	O

The	O
mother	O
had	O
gestational	O
diabetes	B-DIS
mellitus	I-DIS
and	O
neonate	O
was	O
born	O
with	O
single	O
lower	O
limb	O
ambiguous	O
genitalia	O
and	O
thumb	O
anomalies	O
and	O
4	O
days	O
after	O
birth	B-DIS
the	I-DIS
neonate	I-DIS
died	O
due	O
to	O
multiple	O
anomalies	B-DIS
and	O
imperforated	B-DIS
anus	I-DIS
.	O

Scurvy	B-DIS
is	O
a	O
disease	O
caused	O
by	O
chronic	O
vitamin	O
C	O
deficiency	O
.	O

The	O
greater	O
prevalence	B-EPI
was	O
found	O
in	O
the	O
paediatric	O
population	O
with	O
neurodevelopmental	B-DIS
disorders	I-DIS
such	O
as	O
autism	B-DIS
spectrum	I-DIS
disorders	I-DIS
due	O
to	O
their	O
restricted	O
dietary	O
intake	O
.	O

Our	O
case	O
reported	O
a	O
child	O
with	O
autism	B-DIS
who	O
presented	O
with	O
arthralgia	B-DIS
and	O
anaemia	B-DIS
.	O

Systemic	B-DIS
lupus	I-DIS
erythematosus	I-DIS
was	O
the	O
first	O
diagnostic	O
impression	O
resulting	O
in	O
over	O
investigation	O
and	O
delayed	O
diagnosis	O
of	O
vitamin	O
C	O
deficiency	O
.	O

After	O
the	O
child	O
was	O
treated	O
with	O
ascorbic	O
acid	O
the	O
child	O
's	O
symptoms	O
resolved	O
.	O

This	O
case	O
highlighted	O
the	O
importance	O
of	O
developmental	O
and	O
nutritional	O
history	O
taking	O
in	O
the	O
paediatric	O
population	O
.	O

Furthermore	O
parents	O
and	O
physicians	O
should	O
be	O
concerned	O
about	O
nutritional	O
status	O
especially	O
in	O
children	O
with	O
restrictive	O
dietary	O
intake	O
.	O

Objective	O
The	O
diagnosis	O
of	O
childhood	B-DIS
-	I-DIS
onset	I-DIS
cerebellar	O
ataxia	O
CA	O
is	O
often	O
challenging	O
due	O
to	O
variations	O
in	O
symptoms	B-DIS
and	O
etiologies	O
.	O

Despite	O
the	O
known	O
regional	O
differences	O
in	O
the	O
prevalence	B-EPI
of	O
etiologies	O
underlying	O
CA	O
the	O
frequency	O
and	O
characteristics	O
of	O
CA	O
in	O
Japan	B-LOC
remain	O
unclear	O
.	O

We	O
conducted	O
a	O
questionnaire	O
-	O
based	O
survey	O
to	O
identify	O
the	O
clinical	O
characteristics	B-DIS
of	O
childhood	O
-	O
onset	O
CA	O
in	O
the	O
Japanese	O
population	O
.	O

Materials	O
and	O
methods	O
Questionnaires	O
were	O
sent	O
to	O
1103	O
board	O
-	O
certified	O
pediatric	O
neurologists	O
in	O
Japan	B-LOC
from	O
2016	O
to	O
2017	O
.	O

The	O
primary	O
survey	O
requested	O
the	O
number	O
of	O
patients	O
with	O
CA	O
under	O
care	O
and	O
the	O
follow	O
-	O
up	O
secondary	O
questionnaire	O
requested	O
additional	O
clinical	O
characteristics	O
of	O
the	O
patients	O
.	O

Results	O
The	O
primary	O
survey	O
obtained	O
578	O
responses	O
response	O
rate	O
52.4	B-STAT
%	I-STAT
on	O
385	O
patients	O
with	O
CA	O
including	O
171	O
diagnosed	O
and	O
214	O
undiagnosed	O
cases	O
diagnostic	O
rate	O
44.4	B-STAT
%	I-STAT
.	O

The	O
most	O
frequent	O
etiology	O
was	O
dentatorubropallidoluysian	B-DIS
atrophy	I-DIS
DRPLA	O
followed	O
by	O
mitochondrial	B-DIS
disorders	I-DIS
and	O
encephalitis	B-DIS
.	O

The	O
secondary	O
survey	O
obtained	O
the	O
clinical	O
characteristics	O
of	O
252	O
cases	O
119	O
diagnosed	O
and	O
133	O
undiagnosed	O
cases	O
.	O

Multiple	O
logistic	O
regression	O
analysis	O
revealed	O
that	O
a	O
younger	O
age	O
at	O
onset	O
hearing	O
issues	O
and	O
short	O
stature	B-DIS
were	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
remaining	O
undiagnosed	O
with	O
CA	O
in	O
Japan	B-LOC
.	O

Conclusions	O
The	O
diagnostic	O
rate	O
of	O
childhood	B-DIS
-	O
onset	O
CA	O
in	O
the	O
current	O
study	O
was	O
comparable	O
to	O
those	O
reported	O
in	O
other	O
countries	O
.	O

The	O
high	O
prevalence	B-EPI
of	O
autosomal	B-DIS
dominant	O
ataxia	B-DIS
especially	O
DRPLA	B-DIS
was	O
a	O
signature	O
of	O
CA	O
in	O
Japan	B-LOC
.	O

These	O
data	O
offer	O
insights	O
into	O
the	O
characteristics	O
of	O
childhood	B-DIS
-	O
onset	O
CA	O
in	O
the	O
Japanese	O
population	O
.	O

The	O
Global	O
Atmospheric	O
Passive	O
Sampling	O
GAPS	O
network	O
initiated	O
in	O
2005	O
across	O
55	O
global	O
sites	O
supports	O
the	O
global	O
monitoring	O
plan	O
GMP	O
of	O
the	O
Stockholm	O
Convention	O
on	O
Persistent	O
Organic	O
Pollutants	O
POPs	O
by	O
providing	O
information	O
on	O
POP	O
concentrations	O
in	O
air	O
on	O
a	O
global	O
scale	O
.	O

These	O
data	O
inform	O
assessments	O
of	O
the	O
long	O
-	O
range	O
transport	O
potential	O
of	O
POPs	O
and	O
the	O
effectiveness	O
evaluation	O
of	O
chemical	O
regulation	O
efforts	O
by	O
observing	O
changes	O
in	O
concentrations	O
over	O
time	O
.	O

Currently	O
measurements	O
spanning	O
5	O
-	O
10	O
sampling	O
years	O
are	O
available	O
for	O
40	O
sites	O
from	O
the	O
GAPS	O
Network	O
.	O

This	O
study	O
was	O
the	O
first	O
time	O
that	O
POP	O
concentrations	O
in	O
air	O
were	O
reported	O
on	O
a	O
global	O
scale	O
for	O
an	O
extended	O
time	O
period	O
and	O
the	O
first	O
to	O
evaluate	O
worldwide	O
trends	O
with	O
an	O
internally	O
consistent	O
sample	O
set	O
.	O

For	O
consistency	O
between	O
sampling	O
years	O
site-	O
and	O
sample	O
specific	O
sampling	O
rates	O
were	O
calculated	O
with	O
a	O
new	O
public	O
online	O
model	O
which	O
accounts	O
for	O
the	O
effects	O
of	O
wind	O
speed	O
variability	O
.	O

Concentrations	O
for	O
legacy	O
POPs	O
in	O
air	O
between	O
2005	O
and	O
2014	O
show	O
different	O
trends	O
for	O
different	O
organochlorine	O
pesticides	O
OCPs	O
and	O
polychlorinated	O
biphenyls	O
PCBs	O
.	O

The	O
POPs	O
discussed	O
in	O
this	O
study	O
were	O
chosen	O
due	O
to	O
being	O
the	O
most	O
frequently	O
detected	O
with	O
detection	O
at	O
the	O
majority	O
of	O
sites	O
.	O

PCB	O
endosulfan	O
and	O
hexachlorocyclohexane	O
HCH	O
concentrations	O
in	O
air	O
are	O
decreasing	O
at	O
most	O
sites	O
.	O

The	O
global	O
trends	O
reflect	O
global	O
sources	O
and	O
recycling	O
of	O
HCH	O
ongoing	O
emissions	O
from	O
old	O
stockpiles	O
for	O
PCBs	O
and	O
recent	O
use	O
restrictions	O
for	O
endosulfan	O
.	O

These	O
chlorinated	O
OCPs	O
continue	O
to	O
present	O
exposure	O
threat	O
to	O
humans	O
and	O
ecosystems	O
worldwide	O
.	O

Concentrations	O
of	O
other	O
OCPs	O
such	O
as	O
chlordanes	O
heptachlor	O
and	O
dieldrin	O
are	O
steady	O
and/or	O
declining	O
slowly	O
at	O
the	O
majority	O
of	O
sites	O
reflecting	O
a	O
transition	O
from	O
primary	O
to	O
secondary	O
sources	O
i.e	O
.	O

re	O
-	O
emission	O
from	O
reservoirs	O
where	O
these	O
POPs	O
have	O
accumulated	O
historically	O
which	O
now	O
control	O
ambient	O
air	O
burdens	O
.	O

As	O
the	O
HIV	O
epidemic	O
in	O
sub	O
-	O
Saharan	B-LOC
Africa	I-LOC
matures	O
evidence	O
about	O
the	O
age	O
distribution	O
of	B-DIS
new	I-DIS
HIV	O
infections	O
and	O
how	O
this	O
distribution	O
has	O
changed	O
over	O
the	O
epidemic	O
is	O
needed	O
to	O
guide	O
HIV	O
prevention	O
.	O

We	O
aimed	O
to	O
assess	O
trends	O
in	O
age	O
-	O
specific	B-EPI
HIV	O
incidence	O
in	O
six	O
population	O
-	O
based	O
cohort	O
studies	O
in	O
eastern	O
and	O
southern	O
Africa	B-LOC
reporting	O
changes	O
in	B-DIS
mean	O
age	O
at	O
infection	O
age	B-DIS
distribution	O
of	O
new	O
infections	O
and	B-EPI
birth	O
cohort	O
cumulative	O
incidence	O
.	O

We	O
used	O
a	O
Bayesian	O
model	O
to	O
reconstruct	O
age	O
-	O
specific	B-EPI
HIV	O
incidence	O
from	O
repeated	O
observations	O
of	O
individuals	O
'	O
HIV	O
serostatus	O
and	O
survival	O
collected	O
among	O
population	O
HIV	O
cohorts	O
in	O
rural	O
Malawi	B-LOC
South	B-LOC
Africa	I-LOC
Tanzania	I-LOC
Uganda	B-LOC
and	O
Zimbabwe	B-LOC
in	O
a	O
collaborative	O
analysis	O
of	O
the	O
ALPHA	O
network	O
.	O

We	O
modelled	O
HIV	O
incidence	B-EPI
rates	O
by	O
age	O
time	O
and	O
sex	O
using	O
smoothing	O
splines	O
functions	O
.	O

We	O
estimated	O
incidence	B-EPI
trends	O
separately	O
by	O
sex	O
and	O
study	O
.	O

We	O
used	O
estimated	O
incidence	B-EPI
and	O
prevalence	B-EPI
results	O
for	O
2000	O
-	O
17	O
standardised	O
to	O
study	O
population	O
distribution	O
to	O
estimate	O
mean	O
age	O
at	O
infection	B-DIS
and	O
proportion	O
of	O
new	O
infections	B-DIS
by	O
age	O
.	O

We	O
also	O
estimated	O
cumulative	O
incidence	B-EPI
lifetime	O
risk	O
of	O
infection	B-DIS
by	O
birth	O
cohort	O
.	O

Age	O
-	B-EPI
specific	O
incidence	O
declined	O
at	O
all	O
ages	O
although	O
the	O
timing	O
and	O
pattern	O
of	O
decline	O
varied	O
by	O
study	O
.	O

The	O
mean	O
age	O
at	O
infection	B-DIS
was	O
higher	O
in	O
men	O
cohort	O
mean	O
27·8	O
-	O
34·6	O
years	O
than	O
in	O
women	O
24·8	O
-	O
29·6	O
years	O
.	O

Between	O
2000	O
and	O
2017	O
the	O
mean	O
age	O
at	O
infection	B-DIS
per	O
cohort	O
increased	O
slightly	O
0·5	O
to	O
2·8	O
years	O
among	O
men	O
and	O
-0·2	O
to	O
2·5	O
years	O
among	O
women	O
.	O

Across	O
studies	O
between	B-STAT
38	I-STAT
%	I-STAT
and	I-STAT
63	I-STAT
%	I-STAT
cohort	O
medians	O
of	O
the	O
infections	B-DIS
in	O
women	O
were	O
among	O
those	O
aged	O
15	O
-	O
24	O
years	O
and	O
between	B-STAT
30	I-STAT
%	I-STAT
and	I-STAT
63	I-STAT
%	I-STAT
of	O
infections	B-DIS
in	O
men	O
were	O
in	O
those	O
aged	O
20	O
-	O
29	O
years	O
.	O

Lifetime	O
risk	O
of	O
HIV	O
declined	O
for	O
successive	O
birth	O
cohorts	O
.	O

HIV	O
incidence	B-EPI
declined	O
in	O
all	O
age	O
groups	O
and	O
shifted	O
slightly	O
to	O
older	O
ages	O
.	O

Disproportionate	B-DIS
new	I-DIS
HIV	I-DIS
infections	I-DIS
occur	O
among	O
women	O
aged	O
15	O
-	O
24	O
years	O
and	O
men	O
aged	O
20	O
-	O
29	O
years	O
supporting	O
focused	O
prevention	O
in	O
these	O
groups	O
.	O

However	O
40	B-STAT
-	I-STAT
60	I-STAT
%	I-STAT
of	O
infections	B-DIS
were	O
outside	O
these	O
ages	O
emphasising	O
the	O
importance	O
of	O
providing	O
appropriate	O
HIV	O
prevention	O
to	O
adults	O
of	O
all	O
ages	O
.	O

Bill	O
&	O
Melinda	O
Gates	O
Foundation	O
.	O

The	O
prevalence	B-EPI
of	O
congenital	B-DIS
hydrocephalus	I-DIS
has	O
been	O
estimated	O
at	O
1.1	O
per	O
1000	O
infants	O
when	O
including	O
cases	O
diagnosed	O
before	O
1	O
year	O
of	O
age	O
after	O
exclusion	O
of	O
neural	O
tube	O
defects	O
.	O

Classification	O
criteria	O
are	O
based	O
either	O
on	O
CSF	O
dynamics	O
pathophysiological	O
mechanisms	O
or	O
associated	O
lesions	O
.	O

Whereas	O
inherited	O
syndromic	B-DIS
hydrocephalus	I-DIS
has	O
been	O
associated	O
with	O
more	O
than	O
100	O
disease	O
-	O
causing	O
genes	O
only	O
four	O
genes	O
are	O
currently	O
known	O
to	O
be	O
linked	B-DIS
to	I-DIS
congenital	O
hydrocephalus	O
either	O
isolated	O
or	O
as	O
a	O
major	O
clinical	O
feature	O
L1CAM	O
AP1S2	O
MPDZ	B-DIS
and	O
CCDC88C	O
.	O

In	O
the	O
past	O
10	O
years	O
pathogenic	O
variants	O
in	O
CCDC88C	B-DIS
have	O
been	O
documented	O
but	O
the	O
neuropathology	B-DIS
remains	O
virtually	O
unknown	O
.	O

We	O
report	O
the	O
neuropathology	B-DIS
of	O
two	O
foetuses	O
from	O
one	O
family	O
harbouring	O
two	O
novel	O
compound	O
heterozygous	O
pathogenic	O
variants	O
in	O
the	O
CCDC88C	B-DIS
gene	O
a	O
maternally	O
inherited	O
indel	O
in	O
exon	O
22	O
c.3807_3809delinsACCT	O
;	O
p.	O
Gly1270Profs	O
*	O
53	O
and	O
a	O
paternally	O
inherited	O
deletion	O
of	O
exon	O
23	O
c.3967-	O
?	O

_	O
c.4112-	O
?	O

;	O
p	O
.	O

Leu1323Argfs	O
*	O
10	O
.	O

Medical	O
termination	O
of	O
pregnancy	O
was	O
performed	O
at	O
18	O
and	O
23	O
weeks	O
of	O
gestation	O
for	O
severe	O
bilateral	O
ventriculomegaly	B-DIS
.	O

In	O
both	O
fetuses	O
brain	O
lesions	O
consisted	O
of	O
multifocal	O
atresia	O
-	O
forking	O
along	O
the	O
aqueduct	O
of	O
Sylvius	O
and	O
the	O
central	O
canal	O
of	O
the	O
medulla	B-DIS
periventricular	I-DIS
neuronal	O
heterotopias	B-DIS
and	I-DIS
choroid	I-DIS
plexus	O
hydrops	O
.	O

The	O
second	O
fetus	O
also	O
presented	O
lumbar	B-DIS
myelomeningocele	I-DIS
left	I-DIS
diaphragmatic	I-DIS
hernia	I-DIS
and	O
bilateral	O
renal	B-DIS
agenesis	I-DIS
.	O

CCDC88C	B-DIS
encodes	O
the	O
protein	O
DAPLE	O
which	O
contributes	O
to	O
ependymal	O
cell	O
planar	O
polarity	O
by	O
inhibiting	O
the	O
non	O
-	O
canonical	O
Wnt	O
signaling	O
pathway	O
and	O
interacts	O
with	O
MPDZ	O
and	O
PARD3	O
.	O

Interestingly	O
heterozygous	O
variants	O
in	O
PARD3	O
result	O
in	O
neural	O
tube	O
defects	O
by	O
defective	O
tight	O
junction	O
formation	O
and	O
polarization	O
process	O
of	O
the	O
neuroepithelium	O
.	O

Besides	O
during	O
organ	O
formation	O
Wnt	O
signalling	O
is	O
a	O
prerequisite	O
for	O
planar	O
cell	O
polarity	O
pathway	O
activation	O
and	O
mutations	O
in	O
planar	O
cell	O
polarity	O
genes	O
lead	O
to	O
heart	B-DIS
lung	I-DIS
and	I-DIS
kidney	I-DIS
malformations	I-DIS
.	O

Hence	O
candidate	O
variants	O
in	O
CCDC88C	B-DIS
should	O
be	O
carefully	O
considered	O
whether	O
brain	O
lesions	O
are	O
isolated	O
or	O
associated	O
with	O
malformations	B-DIS
suspected	O
to	O
result	O
from	O
disorders	O
of	O
planar	O
cell	O
polarity	O
.	O

Intellectual	B-DIS
disability	I-DIS
ID	O
has	O
an	O
estimated	O
prevalence	B-EPI
of	O
1.5	B-STAT
%	I-STAT
-2	I-STAT
%	I-STAT
.	O

Whole	O
exome	O
sequencing	O
WES	O
studies	O
have	O
identified	O
a	O
multitude	O
of	O
novel	O
causative	O
gene	O
defects	O
and	O
have	O
shown	O
that	O
sporadic	O
ID	O
cases	O
result	O
from	O
de	O
novo	O
mutations	O
in	O
genes	O
associated	O
with	O
ID	O
.	O

Here	O
we	O
report	O
on	O
a	O
10	O
-	O
year	O
-	O
old	O
girl	O
who	O
has	O
been	O
regularly	O
presented	O
in	O
our	O
neuropediatric	O
and	O
genetic	O
outpatient	O
clinic	O
.	O

A	O
median	O
cleft	B-DIS
palate	I-DIS
and	O
a	O
heart	O
defect	O
were	O
surgically	O
corrected	O
in	O
infancy	O
.	O

Apart	O
from	O
ID	O
she	O
has	O
behavioral	B-DIS
anomalies	I-DIS
muscular	I-DIS
hypotonia	I-DIS
scoliosis	I-DIS
and	O
hypermobile	B-DIS
joints	I-DIS
.	O

The	O
facial	O
phenotype	O
is	O
characterized	O
by	O
arched	O
eyebrows	O
mildly	O
upslanting	B-DIS
long	I-DIS
palpebral	I-DIS
fissures	I-DIS
prominent	O
nasal	O
tip	O
and	O
large	O
protruding	O
ears	O
.	O

Trio	O
WES	O
revealed	O
a	O
de	O
novo	O
missense	O
variant	O
in	O
MEIS2	O
c.99	O
A	O
;	O
p.	O
Arg333Lys	O
.	O

Haploinsufficiency	O
of	O
MEIS2	O
had	O
been	O
discussed	O
as	O
the	O
most	O
likely	O
mechanism	O
of	O
the	O
microdeletion	O
5q14	O
-	O
associated	O
complex	O
phenotype	B-DIS
with	I-DIS
ID	I-DIS
cleft	O
palate	O
and	O
heart	O
defect	O
.	O

Recently	O
four	O
studies	O
including	O
in	O
total	O
17	O
individuals	O
with	O
intragenic	O
MEIS2	O
variants	O
were	O
reported	O
.	O

Here	O
we	O
present	O
the	O
evolution	O
of	O
the	O
clinical	O
phenotype	O
and	O
compare	O
with	O
the	O
data	O
of	O
known	O
individuals	O
.	O

Enamel	B-DIS
renal	I-DIS
syndrome	I-DIS
is	O
a	O
unique	O
syndrome	O
associated	O
with	O
kidney	B-DIS
agenesis	I-DIS
associated	O
with	O
kidney	B-DIS
agenesis	I-DIS
amelogenesis	I-DIS
imperfecta	I-DIS
and	O
gingival	B-DIS
hyperplasia	I-DIS
.	O

The	O
prevalence	B-EPI
rate	O
of	O
this	O
rare	O
syndrome	O
is	O
<	O
1/1000	B-STAT
000	O
.	O

A	O
17	O
-	O
year	O
-	O
old	O
male	O
patient	O
came	O
to	O
the	O
department	O
of	O
periodontics	O
with	O
a	O
chief	O
complaint	O
of	O
dislodged	O
crown	O
in	O
the	O
anterior	O
teeth	O
region	O
.	O

On	O
clinical	O
examination	O
the	O
patient	O
had	O
teeth	O
with	O
mottled	O
enamel	O
and	O
gingival	B-DIS
enlargement	I-DIS
.	O

The	O
orthopantomograph	O
and	O
gingival	O
biopsy	O
revealed	O
pulpal	B-DIS
calcification	I-DIS
and	O
gingival	B-DIS
calcification	I-DIS
respectively	O
.	O

Furthermore	O
the	O
renal	O
ultrasonography	O
revealed	O
absence	O
/	O
agenesis	O
of	O
the	O
left	O
kidney	O
.	O

Thus	O
based	O
on	O
radiographical	O
histological	O
and	O
ultrasound	O
investigations	O
the	O
patient	O
was	O
diagnosed	O
with	O
nephrocalcinosis	B-DIS
syndrome	O
.	O

The	O
patient	O
was	O
treated	O
with	O
periodontal	O
therapy	O
and	O
prosthodontic	O
full	O
-	O
mouth	O
rehabilitation	O
.	O

This	O
case	O
report	O
highlights	O
the	O
need	O
of	O
a	O
periodontist	O
to	O
be	O
acquainted	O
about	O
the	O
signs	O
and	O
symptoms	O
of	O
the	O
syndrome	O
to	O
benefit	O
an	O
individual	O
in	O
the	O
right	O
diagnosis	O
and	O
treatment	O
plan	O
.	O

The	O
escalating	O
prevalence	B-EPI
of	O
coronavirus	B-DIS
disease	I-DIS
2019	O
COVID-19	O
worldwide	O
with	O
an	O
increased	O
rate	O
of	O
morbidity	O
and	O
mortality	O
highlights	O
an	O
urgent	O
need	O
to	O
develop	O
more	O
effective	O
therapeutic	O
interventions	O
.	O

Despite	O
the	O
authorized	O
treatment	O
against	O
COVID-19	O
by	O
the	O
European	O
Union	O
EU	O
the	O
safety	O
and	O
effectiveness	O
of	O
this	O
therapeutic	O
strategy	O
for	O
a	O
wide	O
variety	O
of	O
patients	O
have	O
remained	O
a	O
significant	O
challenge	O
.	O

In	O
this	O
respect	O
micronutrients	O
such	O
as	O
vitamins	O
and	O
minerals	O
as	O
essential	O
factors	O
can	O
be	O
considered	O
for	O
improving	O
the	O
function	O
of	O
the	O
immune	O
system	O
and	O
accelerating	O
the	O
treatment	O
procedure	O
.	O

Dietary	O
supplements	O
can	O
attenuate	O
vascular	O
and	O
inflammatory	O
manifestations	O
related	O
to	O
infectious	B-DIS
diseases	I-DIS
in	O
large	O
part	O
due	O
to	O
their	O
anti	O
-	O
inflammatory	O
and	O
antioxidant	O
properties	O
.	O

Recently	O
it	O
has	O
been	O
revealed	O
that	O
poor	O
nutritional	O
status	O
may	O
be	O
one	O
of	O
the	O
notable	O
risk	O
factors	O
in	O
severe	O
COVID-19	B-DIS
infections	I-DIS
.	O

In	O
the	O
current	O
review	O
we	O
focus	O
on	O
the	O
micronutrient	O
therapy	O
of	O
COVID-19	O
patients	O
and	O
provide	O
a	O
comprehensive	O
insight	O
into	O
the	O
essential	O
vitamins	O
/	O
minerals	O
and	O
their	O
role	O
in	O
controlling	O
the	O
severity	O
of	B-DIS
the	I-DIS
COVID-19	O
infection	O
.	O

We	O
also	O
discuss	O
the	O
recent	O
advancements	O
challenges	O
negative	O
and	O
positive	O
outcomes	O
in	O
relevance	O
to	O
this	O
approach	O
.	O

Background	O
Neuroendocrine	O
tumors	O
NETs	O
are	O
rare	O
but	O
their	O
worldwide	O
incidence	B-EPI
is	O
gradually	O
increasing	O
.	O

NETs	O
are	O
generally	O
heterogeneous	O
;	O
however	O
in	O
rare	O
cases	O
they	O
have	O
been	O
shown	O
to	O
change	O
their	O
phenotype	O
i.e	O
.	O

nonfunctional	O
to	O
functional	O
or	O
one	O
functional	O
phenotype	O
to	O
the	O
addition	O
of	O
another	O
functional	O
phenotype	O
.	O

Here	O
we	O
present	O
two	O
cases	O
of	O
liver	B-DIS
metastatic	I-DIS
NETs	I-DIS
with	O
phenotype	O
transformation	O
at	O
the	O
advanced	O
stage	O
that	O
led	O
to	O
life	O
-	O
threatening	O
events	O
.	O

Case	O
presentation	O
A	O
73	O
-	O
year	O
-	O
old	O
woman	O
had	O
a	O
small	O
intestinal	B-DIS
nonfunctional	I-DIS
NET	O
with	O
liver	O
metastasis	O
.	O

After	O
uncontrollable	O
liver	B-DIS
metastasis	I-DIS
at	O
the	O
advanced	O
stage	O
she	O
developed	O
duodenal	B-DIS
perforation	I-DIS
with	O
hypergastremia	O
.	O

The	O
patient	O
was	O
treated	O
with	O
octreotide	O
and	O
proton	O
pump	O
inhibitors	O
and	O
underwent	O
endoscopic	O
closure	O
for	O
duodenal	B-DIS
perforation	I-DIS
but	O
her	O
general	O
condition	O
gradually	O
deteriorated	O
and	O
she	O
died	O
2	O
weeks	O
after	O
duodenal	B-DIS
perforation	I-DIS
.	O

Another	O
patient	O
a	O
50	O
-	O
year	O
-	O
old	O
man	O
had	O
a	O
functional	B-DIS
NET	I-DIS
gastrinoma	O
with	B-DIS
liver	I-DIS
metastasis	O
and	O
duodenal	O
ulcer	O
.	O

After	O
uncontrollable	O
liver	B-DIS
metastasis	I-DIS
at	O
the	O
advanced	O
stage	O
he	O
developed	O
hypoglycemia	B-DIS
.	O

Although	O
octoreotide	O
and	O
diazoxide	O
were	O
administrated	O
for	O
hyperalimentation	O
his	O
hypoglycemia	B-DIS
was	O
uncontrollable	O
and	O
he	O
died	O
after	O
4	O
months	O
owing	O
to	O
general	O
deterioration	O
.	O

Conclusion	O
The	O
present	O
cases	O
show	O
that	O
advanced	O
NETs	O
with	O
treatment	O
-	B-DIS
uncontrollable	I-DIS
liver	O
metastasis	O
can	O
transform	O
their	O
phenotype	O
specifically	O
from	O
a	O
nonfunctional	O
NET	O
into	O
a	O
functional	O
NET	O
and	O
from	O
one	O
functional	O
NET	O
into	O
the	O
addition	O
of	O
another	O
functional	O
NET	O
.	O

These	O
experiences	O
suggest	O
that	O
the	O
presence	O
of	O
treatment	B-DIS
-	I-DIS
resistant	I-DIS
liver	O
metastasis	O
might	O
be	O
a	O
hallmark	O
of	O
the	O
potential	O
to	O
gain	O
novel	O
functions	O
.	O

Limb	O
deficiency	B-DIS
disorders	I-DIS
are	O
rare	O
etiologically	O
heterogeneous	O
skeletal	O
dysplasias	O
that	O
occur	O
as	O
an	O
isolated	O
anomaly	B-DIS
or	O
as	O
a	O
part	O
of	O
a	O
syndrome	O
.	O

The	O
term	O
limb	O
deficiency	O
incorporates	O
both	O
absence	O
and	O
size	O
reduction	O
of	O
any	O
of	O
the	O
120	O
human	O
limb	O
bones	O
with	O
around	O
205	O
identified	O
abnormalities	O
.	O

Congenital	O
absence	O
of	O
tibia	O
is	O
a	O
rare	O
and	O
severe	O
lower	O
limb	O
malformation	O
with	O
an	O
incidence	B-EPI
of	O
approximately	O
11000000	O
live	O
births	O
.	O

Absence	O
of	O
tibia	O
with	O
ectrodactyly	B-DIS
lobster	O
claw	O
deformity	O
or	O
tibial	B-DIS
hemimelia	I-DIS
with	O
split	O
hand	B-DIS
/	I-DIS
foot	O
malformation	O
TH	B-DIS
-	O
SHFM	O
or	O
Gollop	O
-	O
Wolfgang	O
complex	O
is	O
a	O
rarer	O
malformation	O
with	O
highly	O
variable	O
manifestations	O
.	O

Objective	O
We	O
sought	O
to	O
determine	O
the	O
risk	O
factors	O
incidence	B-EPI
and	O
mortality	O
of	O
very	O
late	O
onset	O
bacterial	B-DIS
infection	I-DIS
blood	O
urine	O
or	O
cerebrospinal	O
fluid	O
culture	O
positive	O
occurring	O
after	O
day	O
of	O
life	O
120	O
in	O
preterm	O
infants	O
.	O

Study	O
design	O
A	O
retrospective	O
observational	O
cohort	O
study	O
of	O
all	O
very	O
low	O
birth	O
weight	O
infants	O
cared	O
for	O
between	O
day	O
of	O
life	O
120	O
and	O
365	O
in	O
292	O
neonatal	O
intensive	O
care	O
units	O
in	O
the	B-LOC
United	I-LOC
States	I-LOC
from	O
1997	O
to	O
2008	O
.	O

Results	O
We	O
identified	O
3918	O
infants	O
who	O
were	O
hospitalized	O
beyond	O
120	O
days	O
of	O
life	O
.	O

Of	O
these	O
102726	B-STAT
%	I-STAT
were	O
evaluated	O
with	O
at	O
least	O
1	O
culture	O
blood	O
urine	O
or	O
cerebrospinal	O
fluid	O
and	O
27627	B-STAT
%	I-STAT
of	O
the	O
evaluated	O
infants	O
had	O
414	O
episodes	O
of	O
culture	B-DIS
-	I-DIS
positive	O
infection	O
.	O

Gram	O
-	O
positive	O
organisms	O
caused	O
most	O
of	B-DIS
the	O
infections	O
48	B-STAT
%	I-STAT
.	O

The	O
risk	O
of	O
death	B-DIS
was	O
higher	O
in	O
infants	O
with	O
positive	O
cultures	O
odds	O
ratio	O
;	O
10.595	B-STAT
%	I-STAT
confidence	O
interval	O
[	O
7.2	O
-	O
15.5	O
]	O
or	O
negative	O
cultures	O
4.8	O
[	O
3.5	O
-	O
6.7	O
]	O
compared	O
to	O
infants	O
that	O
were	O
never	O
evaluated	O
with	O
a	O
culture	O
p	O
<	O
0.001	O
.	O

Mortality	O
was	O
highest	O
with	O
fungal	B-DIS
infections	I-DIS
8/2433	B-STAT
%	I-STAT
followed	O
by	O
Gram	O
-	O
positive	B-STAT
cocci	O
40/14228	B-STAT
%	I-STAT
.	O

Conclusions	O
Important	O
predictive	O
risk	O
factors	O
for	O
early	O
and	O
late	O
onset	O
sepsis	B-DIS
birth	O
weight	O
and	O
gestational	O
age	O
did	O
not	O
contribute	O
to	O
risk	O
of	O
developing	O
very	O
late	O
onset	O
infection	B-DIS
.	O

Evaluation	O
for	O
infection	B-DIS
whether	O
positive	O
or	O
negative	O
was	O
a	O
significant	O
risk	O
factor	O
for	O
death	B-DIS
.	O

GPC	O
and	O
fungal	B-DIS
infections	I-DIS
were	O
associated	O
with	O
high	O
mortality	O
.	O

Background	O
Nonarteritic	B-DIS
anterior	I-DIS
ischemic	I-DIS
optic	I-DIS
neuropathy	I-DIS
NAION	O
in	O
young	O
patients	O
age	O
≤50	O
accounts	O
for	O
a	O
minority	O
of	O
all	O
cases	O
of	O
NAION	B-DIS
and	O
is	O
more	O
highly	O
associated	O
with	O
crowding	O
of	O
the	O
optic	O
nerves	O
and	O
bilateral	O
involvement	O
than	O
NAION	B-DIS
in	O
older	O
patients	O
.	O

Optic	B-DIS
disc	I-DIS
drusen	I-DIS
ODD	I-DIS
are	O
likewise	O
associated	O
with	O
crowded	O
optic	O
nerves	O
and	O
are	O
located	O
in	O
the	O
prelaminar	B-DIS
optic	I-DIS
nerve	I-DIS
head	I-DIS
where	O
they	O
could	O
contribute	O
to	O
NAION	B-DIS
pathogenesis	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
prevalence	B-EPI
of	O
ODD	B-DIS
in	O
the	O
eyes	O
of	O
young	O
NAION	B-DIS
patients	O
using	O
modern	O
imaging	O
methods	O
and	O
to	O
compare	O
it	O
to	O
the	O
baseline	O
1.8	B-STAT
%	I-STAT
-2.0	O
%	O
prevalence	B-EPI
of	O
ODD	B-DIS
in	O
the	O
general	O
population	O
.	O

Methods	O
In	O
this	O
retrospective	O
study	O
all	O
young	O
NAION	B-DIS
patients	O
ages	O
18	O
-	O
50	O
years	O
inclusive	O
seen	O
in	O
2	O
tertiary	O
care	O
neuro	O
-	O
ophthalmology	O
clinics	O
in	O
London	B-LOC
Canada	B-LOC
and	O
Copenhagen	B-LOC
Denmark	B-LOC
in	O
the	O
ten	O
-	O
year	B-DIS
interval	O
between	O
April	O
12009	O
and	O
March	O
312019	O
were	O
identified	O
and	O
their	O
medical	O
charts	O
reviewed	O
.	O

Patients	O
were	O
included	O
in	O
the	O
study	O
if	O
ODD	B-DIS
were	O
diagnosed	O
by	O
any	O
method	O
including	O
ophthalmoscopy	O
ultrasound	O
[	O
US	B-LOC
]	O
fundus	O
autofluorescence	O
[	O
FAF	O
]	O
computed	O
tomography	O
[	O
CT	O
]	O
or	O
any	O
optical	O
coherence	O
tomography	O
[	O
OCT	O
]	O
method	O
or	O
if	O
ODD	B-DIS
were	O
excluded	O
by	O
enhanced	O
-	O
depth	O
imaging	O
OCT	O
EDI	O
-	O
OCT	O
using	O
the	O
ODD	O
Studies	O
ODDS	O
Consortium	O
protocol	O
.	O

The	O
presence	O
or	O
absence	O
of	O
ODD	B-DIS
was	O
recorded	O
for	O
each	O
eye	O
.	O

Results	O
There	O
were	O
37	O
eligible	O
patients	O
74	O
eyes	O
.	O

Mean	O
age	O
of	O
NAION	B-DIS
onset	O
was	O
38.5	O
±	O
10.0	O
years	O
and	O
23	O
patients	O
62	B-STAT
%	I-STAT
were	O
men	O
.	O

Patients	O
had	O
undergone	O
the	O
following	O
methods	O
of	O
ODD	B-DIS
detection	O
ophthalmoscopy	O
37	O
patients	O
EDI	O
-	O
OCT	O
36	O
patients	O
FAF	O
31	O
patients	O
US	B-LOC
9	O
patients	O
and	O
CT	O
orbits	O
8	O
patients	O
.	O

We	O
found	O
a	O
prevalence	B-EPI
of	O
ODD	B-DIS
of	I-DIS
56.7	B-STAT
%	I-STAT
in	O
NAION	B-LOC
-	O
affected	O
patients	O
and	O
53.3	B-STAT
%	I-STAT
in	O
NAION	B-LOC
-	O
affected	O
eyes	O
.	O

Only	B-STAT
35.9	I-STAT
%	I-STAT
of	O
ODD	B-DIS
were	O
visible	O
on	O
ophthalmoscopy	O
.	O

Twenty	O
of	O
21	O
ODD	B-DIS
patients	O
95.2	B-STAT
%	I-STAT
had	O
bilateral	O
ODD	B-DIS
.	O

Age	O
of	O
onset	O
and	O
sex	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
ODD	O
-	O
positive	O
group	O
and	O
the	O
ODD	O
-	O
negative	O
group	O
.	O

EDI	O
-	O
OCT	O
outperformed	O
any	O
combination	O
of	O
ophthalmoscopy	O
US	B-LOC
FAF	O
and	O
CT	O
at	B-DIS
detecting	O
ODD	O
.	O

Conclusion	O
ODD	B-DIS
were	O
found	O
with	O
much	O
higher	O
prevalence	B-EPI
in	O
young	O
patients	O
with	O
NAION	B-DIS
than	O
in	O
the	O
general	O
population	O
and	O
were	O
usually	O
bilateral	O
and	O
buried	O
.	O

ODD	B-DIS
may	O
contribute	O
to	O
NAION	B-DIS
pathogenesis	O
by	O
exacerbating	O
an	O
underlying	O
compartment	B-DIS
syndrome	I-DIS
in	O
the	O
crowded	O
`	O
`	O
disc	O
at	O
risk	O
.	O
''	O

EDI	O
-	O
OCT	O
may	O
be	O
the	O
best	O
imaging	O
modality	B-DIS
for	O
ODD	O
detection	O
in	O
future	O
studies	O
.	O

Marfan	B-DIS
syndrome	I-DIS
MFS	O
is	O
a	O
heritable	O
connective	B-DIS
tissue	I-DIS
disorder	I-DIS
HCTD	I-DIS
caused	O
by	O
pathogenic	O
variants	O
in	O
FBN1	O
that	O
frequently	O
occur	O
de	O
novo	O
.	O

Although	O
individuals	O
with	O
somatogonadal	O
mosaicisms	B-DIS
have	O
been	O
reported	O
with	O
respect	O
to	O
MFS	O
and	O
other	O
HCTD	B-DIS
the	O
overall	O
frequency	O
of	O
parental	O
mosaicism	B-DIS
in	O
this	O
pathology	O
is	O
unknown	O
.	O

In	O
an	O
attempt	O
to	O
estimate	O
this	O
frequency	O
we	O
reviewed	O
all	O
the	O
333	O
patients	O
with	O
a	O
disease	O
-	O
causing	O
variant	O
in	O
FBN1	O
.	O

We	O
then	O
used	O
direct	O
sequencing	O
combined	O
with	O
High	O
Resolution	O
Melting	O
Analysis	O
to	O
detect	O
mosaicism	B-DIS
in	O
their	O
parents	O
complemented	O
by	O
NGS	O
when	O
a	O
mosaicism	B-DIS
was	O
objectivized	O
.	O

We	O
found	O
that	O
1	O
the	O
number	O
of	O
apparently	O
de	O
novo	O
events	O
is	O
much	O
higher	O
than	O
the	O
classically	O
admitted	O
number	O
around	B-STAT
50	I-STAT
%	I-STAT
of	O
patients	O
and	O
not	O
25	B-STAT
%	I-STAT
as	O
expected	O
for	O
FBN1	B-DIS
and	I-DIS
2	I-DIS
around	I-DIS
5	I-DIS
%	I-STAT
of	O
the	O
FBN1	O
disease	O
-	O
causing	O
variants	O
were	O
not	O
actually	O
de	O
novo	O
as	O
anticipated	O
but	O
inherited	O
in	O
a	O
context	O
of	B-DIS
somatogonadal	O
mosaicisms	O
revealed	O
in	O
parents	O
from	O
three	O
families	O
.	O

High	O
Resolution	O
Melting	O
Analysis	O
and	O
NGS	O
were	O
more	O
efficient	O
at	O
detecting	O
and	O
evaluating	O
the	O
level	O
of	O
mosaicism	B-DIS
compared	O
to	O
direct	O
Sanger	O
sequencing	O
.	O

We	O
also	O
investigated	O
individuals	O
with	O
a	O
causal	O
variant	O
in	O
another	O
gene	O
identified	O
through	O
our	O
`	O
`	O
aortic	O
diseases	O
genes	O
''	O
NGS	O
panel	O
and	O
report	O
for	O
the	O
first	O
time	O
on	O
an	O
individual	O
with	O
a	O
somatogonadal	O
mosaicism	O
in	O
COL5A1	O
.	O

Our	O
study	O
shows	O
that	O
parental	O
mosaicism	B-DIS
is	O
not	O
that	O
rare	O
in	O
Marfan	B-DIS
syndrome	I-DIS
and	O
should	O
be	O
investigated	O
with	O
appropriate	O
methods	O
given	O
its	O
implications	O
in	O
patient	O
's	O
management	O
.	O

Organ	B-DIS
damage	I-DIS
in	O
sickle	B-DIS
cell	I-DIS
disease	I-DIS
SCD	I-DIS
is	O
a	O
crucial	O
determinant	O
for	O
disease	O
severity	O
and	O
prognosis	O
.	O

In	O
a	O
previous	O
study	O
we	O
analyzed	O
the	O
prevalence	B-EPI
of	O
SCD	B-DIS
-	I-DIS
related	I-DIS
organ	O
damage	O
and	O
complications	O
in	O
adult	O
sickle	O
cell	O
patients	O
.	O

We	O
now	O
describe	O
a	O
seven	O
-	O
year	O
follow	O
-	O
up	O
of	O
this	O
cohort	O
.	O
All	O
patients	O
from	O
the	O
primary	O
analysis	O
in	O
2006	O
n	O
=	O
104	O
were	O
included	O
for	O
follow	O
-	O
up	O
.	O

Patients	O
were	O
screened	O
for	O
SCD	O
-	B-DIS
related	I-DIS
organ	O
damage	O
and	B-DIS
complications	I-DIS
microalbuminuria	I-DIS
renal	O
failure	O
elevated	O
tricuspid	O
regurgitation	O
flow	O
velocity	O
TRV	O
≥2.5	O
m	O
/	B-DIS
seconds	I-DIS
retinopathy	I-DIS
iron	I-DIS
overload	O
cholelithiasis	B-DIS
avascular	O
osteonecrosis	B-DIS
leg	I-DIS
ulcers	O
acute	B-DIS
chest	I-DIS
syndrome	O
ACS	O
stroke	O
priapism	O
and	O
admissions	O
for	O
vaso	O
-	O
occlusive	O
crises	O
VOC	O
biannually	O
.	O

Upon	O
7	O
years	O
of	O
follow	O
-	O
up	O
progression	O
in	B-EPI
the	O
prevalence	B-DIS
of	I-DIS
avascular	O
osteonecrosis	O
from	O
12.5	B-STAT
%	I-STAT
to	O
20.4	B-DIS
%	I-DIS
renal	O
failure	O
from	O
6.7	B-STAT
%	I-STAT
to	O
23.4	B-DIS
%	I-STAT
retinopathy	O
from	O
39.7	B-STAT
%	I-STAT
to	O
53.8	B-STAT
%	I-STAT
was	O
observed	O
in	O
the	O
whole	O
group	O
.	O

In	O
HbSS	B-LOC
/	O
HbSβ	O
0	O
<	O
/s	O
-thal	O
patients	O
also	O
progression	O
in	O
microalbuminuria	O
from	O
34	B-STAT
%	I-STAT
to	I-STAT
45	I-STAT
%	I-STAT
and	O
elevated	O
TRV	O
from	O
40	B-STAT
%	I-STAT
to	I-STAT
48	I-STAT
%	I-STAT
was	O
observed	O
while	O
hardly	O
any	O
progression	O
in	B-EPI
the	O
prevalence	B-DIS
of	I-DIS
cholelithiasis	I-DIS
priapism	O
stroke	O
or	B-DIS
chronic	O
ulcers	O
was	O
seen	O
.	O

The	O
proportion	O
of	O
patients	O
with	O
at	O
least	O
one	O
episode	O
of	O
ACS	O
increased	O
in	O
the	O
group	O
of	O
HbSS	B-LOC
/	O
HbSβ	O
0	O
<	O
/s	O
-thal	O
patients	O
from	O
32	B-STAT
%	I-STAT
to	O
49.1	B-STAT
%	I-STAT
.	O

In	O
conclusion	O
62	B-STAT
%	I-STAT
of	O
the	O
sickle	O
cell	O
patients	O
in	O
this	O
prospective	O
cohort	O
study	O
developed	O
a	O
new	O
SCD	O
-	O
related	O
complication	O
in	O
a	O
comprehensive	O
care	O
setting	O
within	O
7	O
years	O
of	O
follow	O
-	O
up	O
.	O

Although	O
the	O
hospital	O
admission	O
rate	O
for	O
VOC	O
remained	O
stable	O
multiple	O
forms	O
of	O
organ	B-DIS
damage	I-DIS
increased	O
substantially	O
.	O

These	O
observations	O
underline	O
the	O
need	O
for	O
continued	O
screening	O
for	O
organ	B-DIS
damage	I-DIS
in	O
all	O
adult	O
patients	O
with	O
SCD	B-DIS
.	O

Objective	O
Myotonia	B-DIS
Congenita	I-DIS
MC	I-DIS
is	O
a	O
hereditary	B-DIS
neuromuscular	I-DIS
disorder	I-DIS
caused	O
by	O
a	O
mutation	O
in	O
chloride	O
voltage	O
-	O
gated	O
channel	O
1	O
CLCN1	O
gene	O
.	O

The	O
incidence	B-EPI
of	O
MC	B-DIS
is	O
estimated	O
as	O
1	O
in	O
100.000	O
.	O

The	O
absence	O
of	O
left	O
main	O
coronary	O
artery	O
LMCA	O
is	O
a	O
rare	O
coronary	B-DIS
anomaly	I-DIS
.	O

Here	O
we	O
present	O
a	O
family	O
with	O
four	O
members	O
who	O
have	O
MC	O
variation	O
carrier	O
and	O
cardiovascular	O
risk	O
.	O

Method	O
The	O
demographic	O
features	O
laboratory	O
findings	O
anthropometric	O
measurements	O
and	O
cardiological	O
examination	O
of	O
the	O
cases	O
were	O
recorded	O
.	O

In	O
addition	O
CLCN1	O
gene	O
was	O
sequenced	O
by	O
NGS	O
Next	O
Generation	O
Sequencing	O
Method	O
and	O
possible	O
causes	O
of	O
inherited	O
thrombophilia	B-DIS
risk	O
including	O
MTHFR	B-DIS
A1298C	I-DIS
Factor	I-DIS
V	I-DIS
Leiden	I-DIS
G1691A	I-DIS
Factor	I-DIS
II	I-DIS
G20210A	I-DIS
MTHFR	B-DIS
C677	I-DIS
T	I-DIS
Factor	O
V	O
Cambridge	O
G1091C	O
plasminogen	O
activator	O
inhibitor	O
1	O
PAI-1	O
4G/5	B-STAT
G	O
APOE	O
APOB	O
ITGB	O
ACE	O
ins	O
/	O
del	O
FVHR2	O
and	O
FGB	O
gene	O
alterations	O
were	O
evaluated	O
.	O

Results	O
Case	O
1	O
had	O
homozygous	O
c.188	O
C	O
p.	O
Leu629Pro	O
alteration	O
in	O
CLCN1	O
gene	O
and	O
also	O
coronary	B-DIS
artery	I-DIS
disease	I-DIS
myocardial	I-DIS
infarction	I-DIS
MI	O
history	O
hyperlipidemia	B-DIS
primary	O
hypertension	B-DIS
vertigo	I-DIS
lomber	I-DIS
disc	I-DIS
herniation	I-DIS
and	O
hearing	B-DIS
loss	I-DIS
.	O

LMCA	O
was	O
not	O
detected	O
in	O
coronary	O
angiography	O
in	O
Case	O
1	O
.	O

Cases	O
23	O
and	O
4	O
had	O
heterozygous	O
c.188	O
C	O
p.	O
Leu629Pro	O
alteration	O
with	O
normal	O
electrocardiographic	O
and	O
echocardiographic	O
findings	O
.	O

Additionally	O
all	O
of	O
family	O
members	O
had	O
genetic	O
risk	O
factors	O
for	O
the	O
related	O
gene	O
which	O
lead	O
to	O
an	O
increased	O
risk	O
of	O
cardiovascular	B-DIS
disease	I-DIS
.	O

Conclusion	O
Since	O
alteration	O
of	O
chloride	O
channels	O
in	O
cardiomyocytes	O
leads	O
to	O
variable	O
myocardial	O
involvement	O
cases	O
with	O
MC	O
should	O
be	O
regularly	O
followed	O
for	O
cardiovascular	O
risk	O
.	O

Moreover	O
the	O
cases	O
with	O
MC	O
and	O
with	O
genetic	O
profile	O
associated	O
with	O
high	O
cardiovascular	O
risk	O
should	O
also	O
be	O
regularly	O
followed	O
up	O
by	O
cardiologists	O
.	O

Background	O
The	O
combination	O
of	O
esophageal	B-DIS
atresia	I-DIS
congenital	I-DIS
duodenal	I-DIS
obstruction	I-DIS
and	O
anorectal	B-DIS
malformation	I-DIS
has	O
seldom	O
been	O
reported	O
.	O

We	O
describe	O
the	O
largest	O
series	O
of	O
patients	O
with	O
such	O
association	O
which	O
we	O
summed	O
up	O
with	O
the	O
mnemonic	O
acronym	O
DATE	O
[	O
D	O
-	O
duodenal	O
obstruction	O
A	O
-	O
anorectal	O
malformation	B-DIS
ARM	O
and	B-DIS
TE	I-DIS
-	O
tracheoesophageal	O
fistula	O
with	O
esophageal	O
atresia	O
]	O
.	O

Methods	O
This	O
was	O
a	O
multicenter	O
retrospective	O
review	O
of	O
13	O
patients	O
recruited	O
from	O
8	O
institutions	O
over	O
a	O
nearly	O
5	O
-	O
decade	O
period	O
1968	O
-	O
2017	O
.	O

Information	O
gathered	O
included	O
type	O
of	O
DATE	O
malformations	O
other	O
associated	O
anomalies	B-DIS
type	O
and	O
timing	O
of	O
surgery	O
and	O
clinical	O
outcomes	O
.	O

Results	O
The	O
DATE	O
association	O
consisted	O
of	O
type	O
C	O
esophageal	B-DIS
atresia	I-DIS
13	O
complete	O
9	O
or	O
incomplete	O
4	O
congenital	B-DIS
duodenal	I-DIS
obstruction	I-DIS
CDO	I-DIS
and	O
high	O
or	O
intermediate	O
8	O
or	O
low	O
5	O
ARM	B-DIS
.	O

Eight	O
patients	O
had	O
at	O
least	O
one	O
additional	O
component	O
feature	O
of	O
VACTERL	O
association	O
.	O

A	O
total	O
of	O
6	O
patients	O
died	O
.	O

Overall	O
9	O
patients	O
achieved	O
complete	O
restoration	O
of	O
gastrointestinal	O
continuity	O
7	O
of	O
whom	O
are	O
alive	O
at	O
a	O
median	O
follow	O
-	O
up	O
of	O
4	O
y	B-STAT
range	I-STAT
1	I-STAT
to	O
9	O
.	O

Survivors	B-DIS
received	O
a	O
median	O
of	O
6	O
major	O
operations	O
range	O
4	O
to	O
14	O
to	O
overcome	O
their	O
anomalies	B-DIS
and	O
surgical	O
complications	O
.	O

Two	O
incomplete	O
duodenal	B-DIS
obstructions	I-DIS
were	O
initially	O
overlooked	O
.	O

All	O
survivors	O
with	O
high	O
or	O
intermediate	O
ARM	B-DIS
defects	O
required	O
some	O
form	O
of	O
bowel	O
management	O
to	O
keep	O
them	O
clean	O
.	O

Conclusions	O
The	O
DATE	O
association	O
is	O
a	O
low	O
-	O
frequency	O
entity	O
often	O
occurring	O
among	O
the	O
wider	O
spectrum	O
of	O
VACTERL	O
association	O
.	O

Functional	O
outcomes	O
largely	O
depend	O
on	O
the	O
severity	O
of	O
ARM	O
or	O
other	O
major	O
associated	O
malformations	B-DIS
.	O

Awareness	O
of	O
the	O
DATE	O
association	O
may	O
avoid	O
untoward	O
diagnostic	O
delays	O
of	O
subtler	O
component	O
features	O
of	O
the	O
spectrum	O
such	O
as	O
an	O
incomplete	O
CDO	O
.	O

The	O
use	O
of	O
Drosophila	O
melanogaster	O
as	O
a	O
model	O
for	O
studying	O
human	B-DIS
disease	I-DIS
is	O
well	O
established	O
reflected	O
by	O
the	O
steady	O
increase	O
in	O
both	O
the	O
number	O
and	O
proportion	O
of	O
fly	O
papers	O
describing	O
human	B-DIS
disease	I-DIS
models	O
in	O
recent	O
years	O
.	O

In	O
this	O
article	O
we	O
highlight	O
recent	O
efforts	O
to	O
improve	O
the	O
availability	O
and	O
accessibility	O
of	O
the	O
disease	O
model	O
information	O
in	O
FlyBase	O
http//flybase.org	O
the	O
model	O
organism	O
database	O
for	O
Drosophila	O
.	O

FlyBase	O
has	O
recently	O
introduced	O
Human	O
Disease	O
Model	O
Reports	O
each	O
of	O
which	O
presents	O
background	O
information	O
on	O
a	O
specific	O
disease	O
a	O
tabulation	O
of	O
related	O
disease	O
subtypes	O
and	O
summaries	O
of	O
experimental	O
data	O
and	O
results	O
using	O
fruit	O
flies	O
.	O

Integrated	O
presentations	O
of	O
relevant	O
data	O
and	O
reagents	O
described	O
in	O
other	O
sections	O
of	O
FlyBase	O
are	O
incorporated	O
into	O
these	O
reports	O
which	O
are	O
specifically	O
designed	O
to	O
be	O
accessible	O
to	O
non	O
-	O
fly	O
researchers	O
in	O
order	O
to	O
promote	O
collaboration	O
across	O
model	O
organism	O
communities	O
working	O
in	O
translational	O
science	O
.	O

Another	O
key	O
component	O
of	O
disease	O
model	O
information	O
in	O
FlyBase	O
is	O
that	O
data	O
are	O
collected	O
in	O
a	O
consistent	O
format	O
--	O
-	O
using	O
the	O
evolving	O
Disease	O
Ontology	O
an	O
open	O
-	O
source	O
standardized	O
ontology	O
for	O
human	O
-	O
disease	O
-	O
associated	O
biomedical	O
data	O
-	O
to	O
allow	O
robust	O
and	O
intuitive	O
searches	O
.	O

To	O
facilitate	O
this	O
FlyBase	O
has	O
developed	O
a	O
dedicated	O
tool	O
for	O
querying	O
and	O
navigating	O
relevant	O
data	O
which	O
include	O
mutations	O
that	O
model	O
a	O
disease	O
and	O
any	O
associated	O
interacting	O
modifiers	O
.	O

In	O
this	O
article	O
we	O
describe	O
how	O
data	O
related	O
to	O
fly	O
models	O
of	O
human	B-DIS
disease	I-DIS
are	O
presented	O
in	O
individual	O
Gene	O
Reports	O
and	O
in	O
the	O
Human	O
Disease	O
Model	O
Reports	O
.	O

Finally	O
we	O
discuss	O
search	O
strategies	O
and	O
new	O
query	O
tools	O
that	O
are	O
available	O
to	O
access	O
the	O
disease	O
model	O
data	O
in	O
FlyBase	O
.	O

Bernard	O
-	O
Soulier	O
syndrome	O
is	O
a	O
rare	O
autosomal	B-DIS
recessive	I-DIS
bleeding	O
disorder	O
and	O
has	O
a	B-EPI
low	O
incidence	O
.	O

Bernard	O
-	O
Soulier	O
syndrome	O
is	O
caused	O
by	O
the	O
deficiency	O
of	O
glycoprotein	O
GPIb	O
-	O
V	O
-	O
IX	O
complex	O
a	O
receptor	O
for	O
von	O
Willebrand	B-DIS
factor	O
and	O
is	O
characterized	B-DIS
by	O
thrombocytopenia	O
giant	O
platelets	O
and	O
bleeding	O
tendency	O
.	O

We	O
are	O
reporting	O
three	O
members	O
of	O
a	O
same	O
family	O
with	O
variable	O
phenotypic	O
clinical	O
presentation	O
.	O

The	O
index	O
case	O
is	O
a	O
20	O
-	O
year	O
-	O
old	O
boy	O
who	O
has	O
a	B-DIS
frequent	O
presentation	O
with	O
epistaxis	O
and	O
low	O
platelet	B-STAT
counts	O
25	O
×	O
109	O
/	O
l	O
.	O

He	O
had	O
been	O
hospitalized	O
multiple	O
times	O
and	O
received	O
platelet	O
transfusions	O
.	O

His	O
brother	O
and	O
cousin	O
reported	O
bleeding	B-DIS
symptoms	O
with	O
less	O
frequent	O
medical	O
intervention	O
.	O

Genetic	O
analysis	O
by	O
next	O
-	O
generation	O
sequencing	O
identified	O
a	O
homozygous	O
GP1BB	O
variant	O
c.42	O
Ap	O
.	O
Cys141Ter	O
which	O
segregated	O
amongst	O
the	O
family	O
members	O
.	O

The	O
results	O
led	O
us	O
to	O
an	O
improved	O
insight	O
into	O
the	O
disease	O
for	O
this	O
family	O
with	O
variable	O
phenotypic	O
expression	O
in	O
addition	O
to	O
the	O
identification	O
of	O
a	O
variant	O
for	O
further	O
structural	O
and	O
functional	O
characterization	O
.	O

Background	O
Birth	O
defect	O
is	O
widely	O
used	O
as	O
a	O
term	O
for	O
congenital	B-DIS
anomalies	I-DIS
.	O

Children	O
with	O
cleft	B-DIS
lip	I-DIS
and	O
palate	B-DIS
may	O
have	O
serious	O
speech	O
hearing	O
nutrition	O
and	O
mental	O
and	O
social	O
development	O
disorders	O
;	O
therefore	O
this	O
study	O
was	O
designed	O
to	O
determine	O
the	O
overall	O
prevalence	B-EPI
of	O
cleft	B-DIS
palate	I-DIS
lip	I-DIS
and	O
cleft	B-DIS
palate	I-DIS
through	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
.	O

Methods	O
In	O
this	O
study	O
systematic	O
review	O
and	O
meta	O
-	O
analysis	O
of	O
data	O
from	O
studies	O
on	B-EPI
the	O
prevalence	B-DIS
of	I-DIS
cleft	O
lip	B-DIS
and	O
palate	O
in	O
Scopus	O
Embase	O
Magiran	O
Web	O
of	O
Science	O
WoS	O
PubMed	O
and	O
Science	O
Direct	O
databases	O
were	O
extracted	O
between	O
January	O
2000	O
and	O
June	O
2020	O
.	O

In	O
order	O
to	O
perform	O
the	O
analysis	O
of	O
qualified	O
studies	O
the	O
model	O
of	O
random	O
effects	O
was	O
used	O
and	O
the	O
inconsistency	O
of	O
studies	O
with	O
I	O
2	O
<	O
/s	O
index	O
was	O
investigated	O
.	O

Data	O
analysis	O
was	O
performed	O
with	O
Comprehensive	O
Meta	O
-	O
Analysis	O
software	O
Version	O
2	O
.	O

Results	O
According	O
to	O
the	O
results	O
of	O
the	O
present	O
study	O
on	O
cleft	B-DIS
palate	I-DIS
the	O
total	O
number	O
of	O
samples	O
entered	O
in	O
the	O
study	O
in	O
59	O
studies	O
were	O
21088517	O
individuals	O
the	O
prevalence	B-EPI
of	O
cleft	B-DIS
palate	I-DIS
based	O
on	O
the	O
meta	O
-	O
analysis	O
of	O
the	O
reviewed	O
studies	O
in	O
every	O
1000	O
live	O
births	O
was	O
obtained	O
0.3395	B-STAT
%	I-STAT
CI	O
0.28	O
-	O
0.38	O
.	O

In	O
the	O
case	O
of	O
cleft	B-DIS
lip	I-DIS
the	O
total	O
number	O
of	O
samples	O
entered	O
in	O
the	O
57	O
reviewed	O
studies	O
were	O
17907569	O
individuals	O
.	O

The	O
prevalence	B-EPI
of	O
cleft	B-DIS
lip	I-DIS
obtained	O
based	O
on	O
the	O
meta	O
-	O
analysis	O
of	O
the	O
reviewed	O
studies	O
was	O
0.3	O
in	O
every	O
1000	O
live	O
births	O
95	B-STAT
%	I-STAT
CI	O
0.26	O
-	O
0.34	O
and	O
in	O
the	O
case	B-DIS
of	I-DIS
cleft	O
lip	B-DIS
and	O
palate	O
the	O
total	O
number	O
of	O
samples	O
entered	O
in	O
the	O
55	O
reviewed	O
studies	O
was	O
17894673	O
.	O

The	O
prevalence	B-EPI
of	O
cleft	B-DIS
lip	I-DIS
and	O
palate	B-DIS
based	O
on	O
the	O
meta	O
-	O
analysis	O
of	O
the	O
studies	O
reviewed	O
in	O
each	O
1000	O
live	O
births	O
was	O
0.4595	B-STAT
%	I-STAT
CI	O
0.38	O
-	O
0.52	O
.	O

Conclusion	O
Due	O
to	O
the	O
high	O
prevalence	B-EPI
of	O
oral	O
clefts	O
such	O
as	O
cleft	B-DIS
palate	I-DIS
cleft	I-DIS
lip	I-DIS
and	O
cleft	B-DIS
lip	I-DIS
and	O
palate	B-DIS
;	O
health	O
system	O
policymakers	O
need	O
to	O
take	O
precautionary	O
measures	O
to	O
reduce	O
the	O
number	O
of	O
patients	O
as	O
well	O
as	O
diagnostic	O
and	O
therapeutic	O
measures	O
to	O
reduce	O
the	O
effects	O
of	O
this	O
disorder	O
in	O
children	O
.	O

Background	O
The	O
evidence	O
of	O
an	O
association	O
between	O
statins	O
and	O
amyotrophic	B-DIS
lateral	I-DIS
sclerosis	I-DIS
ALS	I-DIS
is	O
heterogeneous	O
and	O
inconclusive	O
.	O

Methods	O
We	O
performed	O
a	O
population	O
-	O
based	O
cohort	O
study	O
consisting	O
of	O
974304	O
statin	O
initiators	O
aged	O
≥40	O
years	O
and	O
1948606	O
matched	O
general	O
population	O
comparators	O
identified	O
from	O
Danish	O
nationwide	O
registries	O
1996	O
-	O
2016	O
.	O

We	O
computed	O
incidence	B-EPI
rates	O
and	O
hazard	O
ratios	O
HRs	O
of	O
a	O
first	O
-	O
time	O
hospital	O
-	B-DIS
based	O
diagnosis	O
of	O
ALS	O
.	O

HRs	O
were	O
controlled	O
for	O
sex	O
birth	O
year	O
calendar	O
year	O
medically	O
diagnosed	O
comorbidities	O
and	O
concomitant	O
medications	O
.	O

Results	O
During	O
a	O
median	O
follow	O
-	O
up	O
of	O
7.7	O
years	B-DIS
852	O
ALS	O
events	O
occurred	O
among	O
statin	O
initiators	O
11.3	O
[	O
95	B-STAT
%	I-STAT
CI	O
10.6	O
-	O
12.1	O
]	O
events	O
per	O
100000	O
person	O
-	O
years	O
and	O
1679	O
among	O
non	O
-	O
initiators	O
11.4	O
[	O
95	B-STAT
%	I-STAT
CI	O
10.9	O
-	O
12.0	O
]	O
events	O
per	O
100000	O
person	O
-	O
years	O
.	O

The	O
overall	O
adjusted	O
HR	O
indicated	O
a	O
slight	O
association	O
between	O
statin	O
initiation	O
and	O
ALS	B-DIS
1.11	O
[	O
95	B-STAT
%	I-STAT
CI	O
1.00	O
-	O
1.23	O
]	O
.	O

In	O
the	O
first	O
year	O
after	O
initiation	O
the	O
HR	O
was	O
1.4095	B-STAT
%	I-STAT
CI	O
1.09	O
-	O
1.79	O
for	O
both	O
sexes	O
combined	O
1.0095	B-STAT
%	I-STAT
CI	O
0.70	O
-	O
1.42	O
for	O
men	O
and	O
1.9295	B-STAT
%	I-STAT
CI	O
1.30	O
-	O
2.82	O
for	O
women	O
.	O

The	O
associations	O
diminished	O
to	O
approximately	O
null	O
after	O
the	O
first	O
year	O
of	O
follow	O
-	O
up	O
for	O
both	O
sexes	O
combined	O
and	O
for	O
men	O
but	O
point	O
estimates	O
were	O
above	O
1	O
for	O
women	O
until	O
10	O
years	O
after	O
initiation	O
.	O

Conclusions	O
Statin	O
initiation	O
was	O
largely	O
unassociated	O
with	O
ALS	B-DIS
diagnosis	O
but	O
was	O
associated	O
with	O
an	O
elevated	O
risk	O
of	O
ALS	B-DIS
in	O
women	O
especially	O
in	O
the	O
first	O
year	O
after	O
initiation	O
.	O

The	O
association	O
could	O
be	O
explained	O
by	O
reverse	O
causation	O
detection	O
bias	O
early	O
neurotoxic	B-DIS
effects	O
of	O
statins	O
that	O
affect	O
women	O
more	O
than	O
men	O
or	O
a	O
combination	O
thereof	O
.	O

Background	O
The	O
state	O
of	O
newborn	O
screening	O
NBS	O
programmes	O
for	O
organic	B-DIS
acidurias	I-DIS
in	O
Europe	B-LOC
was	O
assessed	O
by	O
a	O
web	O
-	O
based	O
questionnaire	O
in	O
the	O
EU	O
programme	O
of	O
Community	O
Action	O
in	O
Public	B-STAT
Health	O
2010/2011	O
among	O
the	O
-	O
at	O
that	O
time	O
-	O
27	O
EU	O
member	O
states	O
candidate	O
countries	O
potential	O
candidates	O
and	O
three	O
EFTA	O
countries	O
.	O

Results	O
Thirty	O
-	O
seven	O
data	O
sets	O
from	O
39	O
target	O
countries	O
were	O
analysed	O
.	O

Newborn	O
screening	O
for	O
glutaric	B-DIS
aciduria	I-DIS
type	I-DIS
I	I-DIS
GA	I-DIS
-	O
I	O
was	O
performed	O
in	O
ten	O
for	O
isovaleric	O
aciduria	O
IVA	O
in	O
nine	O
and	B-DIS
for	I-DIS
methylmalonic	O
aciduria	B-DIS
including	I-DIS
cblA	I-DIS
cblB	O
cblC	B-DIS
and	O
cblD	O
MMACBL	O
as	O
well	O
as	O
for	O
propionic	O
aciduria	O
PA	O
in	O
seven	O
countries	O
.	O

Samples	O
were	O
obtained	O
at	O
a	O
median	O
age	O
of	O
2.5	O
days	O
and	O
laboratory	O
analysis	O
began	O
at	O
median	O
age	O
of	O
4.5	O
days	O
.	O

Positive	O
screening	O
results	O
were	O
mostly	O
confirmed	O
in	O
specialised	O
centres	O
by	O
analysis	O
of	O
organic	O
acids	O
in	O
urine	O
.	O

Confirmation	O
of	O
a	O
positive	O
screening	O
result	O
usually	O
did	O
not	O
start	O
before	O
the	O
second	O
week	O
of	O
life	O
median	O
ages	O
9.5	O
days	O
[	O
IVA	O
]	O
9	O
days	O
[	O
GA	B-DIS
-	O
I	O
]	O
8.5	O
days	O
[	O
PA	O
MMACBL	O
]	O
and	O
was	O
completed	O
early	O
in	O
the	O
third	O
week	O
of	O
life	O
median	O
ages	O
15	O
days	O
[	O
IVA	O
PA	O
MMA	O
]	O
14.5	O
days	B-DIS
[	O
GA	O
-	O
I	O
]	O
.	O

Treatment	O
was	O
initiated	O
in	O
GA	B-DIS
-	O
I	O
and	O
IVA	O
at	O
a	O
median	O
age	O
of	O
14	O
days	O
and	O
in	O
MMACBL	B-LOC
and	O
PA	O
at	O
a	O
median	O
age	O
of	O
15	O
days	O
.	O

Conclusion	O
NBS	O
for	O
organic	B-DIS
acidurias	I-DIS
in	O
Europe	B-LOC
is	O
variable	O
and	O
less	O
often	O
established	O
than	O
for	O
amino	O
acid	O
disorders	O
.	O

While	O
for	O
GA	B-DIS
-	O
I	O
its	O
benefit	O
has	O
already	O
been	O
demonstrated	O
there	O
is	O
room	O
for	O
debate	O
of	O
NBS	O
for	O
IVA	O
and	O
especially	O
PA	O
and	O
MMACBL	O
.	O

Congenital	B-DIS
hypothyroidism	I-DIS
CH	I-DIS
is	O
a	O
thyroid	B-DIS
hormone	I-DIS
deficiency	I-DIS
syndrome	I-DIS
in	O
newborns	O
resulting	O
from	O
incomplete	O
thyroid	O
development	O
and	O
decreased	B-DIS
thyroid	I-DIS
hormone	I-DIS
biosynthesis	I-DIS
or	O
thyroid	O
-	O
stimulating	O
hormone	O
secretion	O
.	O

Without	O
early	O
treatment	O
newborns	O
with	O
CH	O
have	O
irreversible	O
neurological	B-DIS
deficits	I-DIS
and	O
long	O
-	O
term	O
metabolic	O
complications	O
.	O

Therefore	O
several	O
countries	O
have	O
implemented	O
widespread	O
newborn	O
screening	O
to	O
identify	O
and	O
treat	O
CH	O
in	O
newborns	O
.	O

Although	O
newborn	O
screening	O
has	O
improved	O
diagnosis	O
and	O
treatment	O
outcomes	O
for	O
CH	O
several	O
questions	O
remain	O
concerning	O
the	O
etiology	O
and	O
increased	O
incidence	B-EPI
of	O
CH	O
in	O
different	O
populations	O
.	O

Moreover	O
the	O
increase	O
in	O
the	O
number	O
of	O
preterm	B-DIS
low	I-DIS
-	I-DIS
birth	O
-	O
weight	O
newborns	O
and	O
of	O
newborns	O
admitted	O
to	O
the	O
neonatal	O
intensive	O
care	O
unit	O
presenting	O
with	O
CH	O
requires	O
additional	O
research	O
to	O
detect	O
and	O
treat	O
all	O
forms	O
of	O
CH	O
.	O

Hyperthyroidism	B-DIS
in	O
pregnancy	O
is	O
associated	O
with	O
a	O
increased	O
incidence	B-EPI
of	O
low	O
birth	O
weight	O
preterm	O
birth	O
and	O
admission	O
to	O
the	O
neonatal	O
intensive	O
care	O
unit	O
.	O

However	O
available	O
treatment	O
options	O
are	O
limited	O
.	O

In	O
this	O
report	O
we	O
present	O
a	O
case	O
of	O
fetal	O
gastroschisis	B-DIS
with	O
a	O
history	O
of	O
intrauterine	O
exposure	O
to	O
methimazole	O
.	O

A	O
37	O
-	O
year	O
-	O
old	O
woman	B-DIS
was	I-DIS
diagnosed	I-DIS
with	I-DIS
Grave	O
's	O
disease	O
3	O
years	O
before	O
her	O
pregnancy	O
.	O

She	O
had	O
a	O
poor	O
response	O
to	O
propylthiouracil	O
and	O
required	O
high	O
-	O
dose	O
methimazole	O
before	O
her	O
pregnancy	O
.	O

During	O
the	O
first	O
trimester	O
she	O
received	O
methimazole	O
120	O
mg	O
/	O
day	O
.	O

After	O
her	O
12th	O
week	O
of	O
pregnancy	O
she	O
received	O
block	O
-	O
and	O
-	O
replace	O
therapy	O
levothyroxine	O
[	O
LT4	O
]	O
50	O
µg	O
/	O
day	B-DIS
because	O
of	O
the	O
risk	O
of	O
hypothyroidism	O
and	O
the	O
dose	O
of	O
methimazole	O
was	O
downtitrated	O
to	O
60	O
mg	O
/	O
day	O
.	O

Fetal	O
ultrasonography	O
showed	O
fetal	O
growth	O
retardation	O
and	O
gastroschisis	B-DIS
at	O
gestational	O
week	O
33	O
.	O

The	O
relationship	O
between	O
the	O
very	O
high	O
doses	O
of	O
methimazole	O
in	O
the	O
first	O
trimester	O
of	O
pregnancy	O
and	O
the	O
incidence	B-EPI
of	O
gastroschisis	B-DIS
in	O
this	O
patient	O
was	O
not	O
fully	O
understood	O
because	O
evidence	O
of	O
a	O
relationship	O
between	O
the	O
use	O
of	O
antithyroid	O
drugs	O
in	O
the	O
first	O
trimester	O
and	O
congenital	B-DIS
abnormalities	I-DIS
in	O
the	O
fetus	O
is	O
lacking	O
.	O

Furthermore	O
block	O
-	O
and	O
-	O
replace	O
therapy	O
is	O
not	O
recommended	O
in	O
pregnancy	O
because	O
it	O
requires	O
a	O
higher	O
dose	O
of	O
methimazole	O
.	O

We	O
recommend	O
preconception	O
counseling	O
and	O
early	O
screening	O
of	O
thyroid	O
function	O
.	O

The	O
counseling	O
should	O
include	O
the	O
best	O
timeline	O
for	O
pregnancy	O
and	O
a	O
discussion	O
of	O
the	O
risks	O
and	O
benefits	O
of	O
hyperthyroidism	B-DIS
treatment	O
options	O
.	O

Distal	O
renal	B-DIS
tubular	I-DIS
acidosis	I-DIS
dRTA	I-DIS
or	O
RTA	O
type	O
1	O
a	O
rare	O
inherited	O
or	O
acquired	O
disease	O
is	O
a	O
disorder	B-DIS
of	I-DIS
the	I-DIS
distal	I-DIS
tubule	I-DIS
caused	O
by	O
impaired	B-DIS
urinary	I-DIS
acid	I-DIS
secretion	O
.	O

Due	O
to	O
associated	O
conditions	O
and	O
nonspecific	O
symptoms	O
dRTA	B-DIS
may	O
go	O
undetected	O
.	O

This	O
analysis	O
aims	O
to	O
estimate	O
the	O
prevalence	B-EPI
of	O
dRTA	B-DIS
in	O
the	O
UK	O
Clinical	O
Practice	O
Research	O
Datalink	O
CPRD	O
databases	O
and	O
extrapolate	O
it	O
to	O
European	O
Union	O
Five	O
EU5	O
populations	O
.	O

A	O
retrospective	O
analysis	O
was	O
conducted	O
using	O
the	O
CPRD	O
GOLD	O
database	O
and	O
linked	O
Hospital	O
Episode	O
Statistics	O
HES	O
data	O
to	O
identify	O
diagnosed	O
and	O
potentially	O
undiagnosed	O
or	O
miscoded	O
patients	O
suspected	O
patients	O
.	O

Patients	O
'	O
records	O
with	O
at	O
least	O
one	O
diagnosis	O
code	O
for	O
dRTA	B-DIS
RTA	B-DIS
specific	I-DIS
autoimmune	I-DIS
diseases	I-DIS
or	O
renal	B-DIS
disorders	I-DIS
recorded	O
between	O
January	O
1987	O
and	O
November	O
2017	O
were	O
obtained	O
and	O
analyzed	O
.	O

An	O
algorithm	O
was	O
developed	O
to	O
detect	O
potentially	O
undiagnosed	O
/	B-DIS
miscoded	O
dRTA	O
based	O
on	O
associated	O
conditions	O
and	O
prescriptions	O
.	O

A	O
total	O
of	O
216	O
patients	O
with	O
diagnosis	O
of	O
RTA	O
or	O
dRTA	B-DIS
were	O
identified	O
with	O
98	O
linked	O
to	O
hospital	O
data	O
and	O
447	O
patients	O
were	O
identified	O
as	O
having	O
suspected	O
dRTA	B-DIS
.	O

dRTA	B-DIS
prevalence	B-EPI
for	O
2017	O
was	O
estimated	O
between	O
0.46	O
recorded	O
cases	O
of	O
which	O
22.1	B-STAT
%	I-STAT
were	O
considered	O
primary	O
and	O
1.60	O
when	O
including	O
suspected	O
cases	O
7.6	B-STAT
%	I-STAT
primary	O
per	O
10000	O
people	O
.	O

Prescription	O
and	O
clinical	O
records	O
of	O
diagnosed	O
patients	O
revealed	O
a	O
wide	O
range	O
of	O
comorbidities	O
and	O
a	O
need	O
for	O
pharmacological	O
treatment	O
to	O
manage	O
associated	O
symptoms	O
.	O

The	O
study	O
provides	O
new	O
estimates	O
of	O
dRTA	B-DIS
prevalence	B-EPI
in	O
Europe	B-LOC
and	O
suggests	O
that	O
patients	O
may	O
often	O
be	O
unreported	O
or	O
miscoded	O
potentially	O
confounding	O
appropriate	O
disease	O
management	O
.	O

Our	O
knowledge	O
about	O
inherited	O
susceptibility	O
to	O
adrenocortical	B-DIS
carcinoma	I-DIS
ACC	O
almost	O
exclusively	O
stems	O
from	O
experiences	O
with	O
familial	B-DIS
cancer	I-DIS
susceptibility	O
syndromes	O
which	O
are	O
caused	O
by	O
single	O
gene	O
mutations	O
e.g	O
.	O

Li	B-DIS
-	I-DIS
Fraumeni	O
syndrome	O
LFS	O
.	O

Population	O
-	O
based	O
studies	O
are	O
largely	O
unavailable	O
.	O

ACC	O
diagnosed	O
during	O
childhood	O
is	O
known	O
to	O
be	O
commonly	O
part	O
of	O
hereditary	B-DIS
cancer	I-DIS
syndromes	I-DIS
.	O

Childhood	O
ACC	O
is	O
part	O
of	O
the	O
classical	O
tumor	B-DIS
spectrum	O
of	O
LFS	O
and	O
Beckwith	B-DIS
-	I-DIS
Wiedemann	I-DIS
syndrome	O
BWS	O
.	O

In	O
adults	O
ACC	O
has	O
been	O
reported	O
in	O
patients	O
with	O
multiple	B-DIS
endocrine	I-DIS
neoplasia	I-DIS
MEN1	I-DIS
familial	I-DIS
adenomatous	I-DIS
polyposis	I-DIS
coli	O
FAP	B-DIS
and	O
neurofibromatosis	B-DIS
type	I-DIS
1	I-DIS
NF1	I-DIS
.	O

However	O
the	O
evidence	O
associating	O
ACC	O
with	O
these	O
syndromes	O
is	O
less	O
well	O
substantiated	O
.	O

Here	O
we	O
will	O
review	O
the	O
evidence	O
for	O
genetic	O
predisposition	O
in	O
general	O
and	O
the	O
association	O
with	O
known	O
familial	B-DIS
cancer	I-DIS
susceptibility	O
syndromes	O
in	O
particular	O
.	O

We	O
will	O
also	O
review	O
current	O
recommendations	O
regarding	O
screening	O
and	O
surveillance	O
of	O
these	O
patients	O
as	O
they	O
apply	O
to	O
a	O
specialized	O
ACC	O
or	O
endocrine	B-DIS
cancer	I-DIS
clinic	O
.	O

Aim	O
Sentinel	O
lymph	O
node	O
biopsy	O
SLNB	O
is	O
the	O
accepted	O
approach	O
to	O
stage	O
the	O
clinically	O
negative	O
axilla	O
.	O

The	O
incidence	B-EPI
of	O
lymphedema	O
LE	O
after	O
SLNB	O
is	O
about	B-STAT
5	I-STAT
%	I-STAT
.	O

We	O
hypothesize	O
that	O
patients	O
undergoing	O
axillary	O
excision	O
o	O
5	O
lymph	O
nodes	O
LNs	O
are	O
at	O
increased	O
risk	O
of	O
developing	O
LE	O
.	O

Methods	O
and	O
Results	O
A	O
single	O
institution	O
prospective	O
breast	B-DIS
cancer	I-DIS
database	O
was	O
retrospectively	O
reviewed	O
from	O
January	O
2013	O
to	O
December	O
2017	O
to	O
identify	O
patients	O
who	O
underwent	O
SLNB	O
and	O
were	O
diagnosed	O
with	O
LE	O
.	O

Inclusion	O
criteria	O
was	O
1	O
de	O
novo	O
breast	B-DIS
cancer	I-DIS
2	O
SLNB	O
in	O
clinically	O
node	O
negative	O
patients	O
and	O
3	O
no	O
preoperative	O
diagnosis	O
LE	O
of	O
an	O
extremity	O
.	O

Exclusion	O
criteria	O
was	O
history	O
of	O
axillary	O
lymph	O
node	O
dissection	O
.	O

Age	O
body	O
mass	O
index	O
tumor	O
-	O
node	O
-	O
metastasis	O
status	O
surgery	O
type	O
neoadjuvant	O
or	O
adjuvant	O
chemotherapy	O
radiotherapy	O
and	O
hormone	O
therapy	O
were	O
analyzed	O
.	O

Of	O
the	O
3325	O
patients	O
identified	O
2940	O
patients	O
met	O
the	O
inclusion	O
criteria	O
and	O
were	O
included	O
in	O
the	O
final	O
analysis	O
.	O

Median	O
follow	O
-	O
up	O
time	O
was	O
24	O
months	O
.	O

Forty	O
-	O
seven	O
2	O
%	O
patients	O
were	O
diagnosed	O
with	O
LE	O
and	O
nine	O
patients	O
19	B-STAT
%	I-STAT
ha	O
5	O
LNs	O
excised	O
.	O

LE	O
was	O
diagnosed	O
in	O
3.7	B-STAT
%	I-STAT
of	O
patients	O
who	O
ha	O
5	O
LNs	O
excised	O
versus	O
1.4	B-STAT
%	I-STAT
of	O
patients	O
with	O
≤5	O
LNs	O
excised	O
.	O

Incidence	B-EPI
of	O
LE	O
was	O
higher	O
in	O
patients	O
wit	O
5	O
LNs	O
excision	O
p	O
=	O
0.006	O
.	O

Conclusion	O
Our	O
study	O
showed	O
that	O
patients	O
have	O
a	O
higher	O
likelihood	O
of	O
developing	O
LE	O
whe	O
5	O
LNs	O
are	O
excised	O
.	O

BackgroundUrticaria	O
is	O
a	O
disorder	B-DIS
affecting	I-DIS
skin	I-DIS
and	I-DIS
mucosal	I-DIS
tissues	I-DIS
characterized	O
by	O
the	O
occurrence	O
of	O
wheals	O
angioedema	B-DIS
or	O
both	O
the	O
latter	O
defining	O
the	O
urticaria	B-DIS
-	I-DIS
angioedema	O
syndrome	O
.	O

It	O
is	O
estimated	O
that	O
12	B-STAT
-	I-STAT
22	I-STAT
%	I-STAT
of	O
the	O
general	O
population	O
has	O
suffered	O
at	O
least	O
one	O
subtype	O
of	O
urticaria	B-DIS
during	O
life	O
but	O
only	O
a	O
small	O
percentage	O
estimated	O
at	O
7.6	B-STAT
-	I-STAT
16	I-STAT
%	I-STAT
has	O
acute	O
urticaria	B-DIS
because	O
it	O
is	O
usually	O
self	O
-	O
limited	O
and	O
resolves	O
spontaneously	O
without	O
requiring	O
medical	O
attention	O
.	O

This	O
makes	O
likely	O
that	O
its	O
incidence	B-EPI
is	O
underestimated	O
.	O

The	O
epidemiological	O
data	O
currently	O
available	O
on	O
chronic	O
urticaria	B-DIS
in	O
many	O
cases	O
are	O
deeply	O
discordant	O
and	O
not	O
univocal	O
but	O
a	O
recent	O
Italian	O
study	O
based	O
on	O
the	O
consultation	O
of	O
a	O
national	O
registry	O
reports	O
a	O
prevalence	B-EPI
of	O
chronic	O
spontaneous	O
urticaria	B-DIS
of	O
0.02	B-STAT
%	I-STAT
to	O
0.4	B-STAT
%	I-STAT
and	O
an	O
incidence	B-EPI
of	O
0.1	O
-	O
1.5	O
cases/1000	O
inhabitants	O
/	O
year	O
.	O

MethodsWe	O
reviewed	O
the	O
recent	O
international	O
guidelines	O
about	O
urticaria	B-DIS
and	O
we	O
described	O
a	O
methodologic	O
approach	O
based	O
on	O
classification	O
pathophysiology	O
impact	O
on	O
quality	O
of	O
life	O
diagnosis	O
and	O
prognosis	O
differential	O
diagnosis	O
and	O
management	O
of	O
all	O
the	O
types	O
of	O
urticaria	B-DIS
.	O

ConclusionsThe	O
aim	O
of	O
the	O
present	O
document	O
from	O
the	O
Italian	O
Society	O
of	O
Allergology	O
Asthma	O
and	O
Clinical	O
Immunology	O
SIAAIC	O
and	O
the	O
Italian	O
Society	O
of	O
Allergological	O
Occupational	O
and	O
Environmental	O
Dermatology	O
SIDAPA	O
is	O
to	O
provide	O
updated	O
information	O
to	O
all	O
physicians	O
involved	O
in	O
diagnosis	O
and	O
management	O
of	O
urticaria	B-DIS
and	O
angioedema	B-DIS
.	O

The	O
human	O
T	B-DIS
-	I-DIS
cell	O
leukemia	O
virus	O
type	O
1	O
HTLV-1	O
and	O
type	O
2	O
HTLV-2	O
are	O
two	O
pathogenic	O
retroviruses	O
.	O

Although	O
both	O
viruses	O
share	O
a	O
common	O
genome	O
organization	O
and	O
amino	O
acid	O
homology	O
in	O
common	O
viral	O
proteins	O
the	O
incidence	B-EPI
of	O
disease	O
with	O
infection	B-DIS
is	O
distinct	O
.	O

Infection	B-DIS
with	O
HTLV-1	B-DIS
may	O
result	O
in	O
the	O
development	O
of	O
adult	O
T	B-DIS
-	I-DIS
cell	I-DIS
leukemia	O
/	B-DIS
lymphoma	I-DIS
ATL	I-DIS
an	O
aggressive	O
neoplastic	O
disease	O
or	B-DIS
a	I-DIS
variety	O
of	O
immune	O
-	O
mediated	B-DIS
/	I-DIS
inflammatory	I-DIS
disorders	I-DIS
such	O
as	B-DIS
HTLV-1	O
associated	O
myelopathy	O
/	O
tropical	O
spastic	O
paraparesis	O
HAM	O
/	O
TSP	O
whereas	O
HTLV-2	O
is	O
less	O
pathogenic	O
.	O

Our	O
studies	O
focused	O
on	O
the	O
open	O
reading	O
frame	O
II	O
encoded	O
p28	O
protein	O
of	O
HTLV-2	B-DIS
which	O
has	O
been	O
shown	O
to	O
negatively	O
regulate	O
viral	O
expression	O
by	O
the	O
nuclear	O
retention	O
of	O
the	O
tax	O
/	O
rex	O
mRNA	O
.	O

A	O
similar	O
post	O
-	O
transcriptional	O
regulatory	O
function	O
has	O
been	O
observed	O
with	O
HTLV-1	O
ORF	O
-	O
II	O
p30	O
.	O

However	O
p28	O
contrasts	O
p30	O
in	O
that	O
there	O
appears	O
to	O
be	O
no	O
significant	O
transcriptional	O
effects	O
.	O
In	O
Chapter	O
2	O
we	O
examined	O
the	O
functional	O
significance	O
of	O
p28	O
in	O
HTLV-2	B-DIS
infection	I-DIS
proliferation	O
and	O
immortalization	O
of	O
primary	O
T	O
-	O
cells	O
in	O
culture	B-DIS
and	I-DIS
viral	O
infection	O
and	O
survival	O
in	O
a	O
rabbit	O
model	B-DIS
of	I-DIS
HTLV	O
infection	O
.	O

We	O
generated	O
a	O
novel	O
HTLV-2	O
p28	O
termination	O
clone	O
HTLV2Deltap28	O
in	O
which	O
a	O
stop	O
codon	O
had	O
been	O
introduced	O
into	O
the	O
p28	O
sequence	O
without	O
altering	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
overlapping	O
regulatory	O
proteins	O
Tax	O
and	O
Rex	O
.	O

In	O
short	O
-	O
term	O
proliferation	O
and	O
long	O
-	O
term	B-DIS
immortalization	I-DIS
coculture	O
assays	O
HTLV2Deltap28	O
infected	O
and	O
immortalized	O
primary	O
human	O
T	O
-	O
cells	O
similar	O
to	O
wtHTLV-2	O
.	O

However	O
HTLV2Deltap28	O
had	O
a	O
lower	O
capacity	O
to	O
establish	O
persistent	O
infection	B-DIS
in	O
rabbits	O
indicating	O
the	O
in	O
vivo	O
importance	O
of	O
HTLV-2	B-DIS
p28	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
p28	O
repression	O
of	O
Tax	O
and	O
Rex	O
-	O
mediated	O
viral	O
gene	O
expression	O
allows	O
infected	O
cells	O
to	O
avoid	O
immune	O
recognition	O
and	O
elimination	O
or	O
acts	O
to	O
enhance	O
early	O
viral	O
spread	O
by	O
enhancing	O
the	O
survival	B-DIS
of	I-DIS
HTLV-2	O
infected	O
cells	O
.	O
In	O
Chapter	O
3	O
we	O
generated	O
and	O
characterized	O
various	O
dual	O
-	O
promoter	O
and	O
single	O
-	O
promoter	O
lentiviral	O
expression	O
vectors	O
.	O

Post	O
-	O
transduction	O
p28	O
protein	O
was	O
readily	O
detected	O
with	O
the	O
dual	O
-	O
promoter	O
vectors	O
in	O
293	O
T	O
cells	O
but	O
not	O
in	O
Jurkat	B-LOC
T	O
-	O
cells	O
.	O

The	O
differential	O
p28	O
protein	O
expression	O
was	O
found	O
to	O
be	O
due	O
to	O
cell	O
-	O
type	O
specific	O
translation	O
mechanisms	O
.	O

To	O
circumvent	O
this	O
problem	O
we	O
utilized	O
a	O
single	O
-	O
promoter	O
lentiviral	O
vector	O
that	O
expresses	O
p28	O
via	O
the	O
murine	O
stem	O
cell	O
virus	O
MSCV	O
-promoter	O
which	O
resulted	O
in	O
efficient	O
p28	O
protein	O
expression	O
in	O
both	O
T	O
-	O
cell	O
lines	O
and	O
primary	O
human	O
CD8	O
+	O
T	O
-	O
lymphocytes	O
.	O

In	O
Chapter	O
4	O
the	O
capacity	O
of	O
p28	O
to	O
modify	O
cellular	O
gene	O
expression	O
was	O
examined	O
.	O

In	O
transient	O
transfection	O
studies	O
low	O
doses	O
of	O
p28	O
modulated	O
CRE-	O
and	O
NFκB	O
-	O
driven	O
reporter	O
constructs	O
in	O
293	O
T	O
cells	O
suggesting	O
the	O
ability	O
of	O
p28	O
in	O
modulating	O
cellular	O
gene	O
expression	O
.	O

Interestingly	O
transduction	O
of	O
Jurkat	O
T	O
-	O
cells	O
with	O
the	O
lentiviral	O
p28	O
expression	O
vector	O
had	O
no	O
significant	O
effect	O
on	O
cellular	O
proliferation	O
.	O

Additionally	O
initial	O
analysis	O
of	O
global	O
cellular	O
gene	O
expression	O
by	O
microarray	O
analysis	O
suggests	O
that	O
p28	O
results	O
in	O
nominal	O
alterations	O
in	O
cellular	O
gene	O
expression	O
.	O

Collectively	O
data	O
presented	O
in	O
this	O
thesis	O
indicates	O
that	O
p28	O
is	O
critical	O
for	O
the	O
establishment	O
and	O
survival	O
of	O
HTLV-2	O
compatible	O
with	O
the	O
conclusion	O
that	O
the	O
regulation	O
of	O
HTLV	O
gene	O
expression	O
is	O
a	O
tightly	O
controlled	O
and	O
complex	O
process	O
.	O

Ultimately	O
while	O
minimal	O
the	O
impact	O
of	O
p28	O
upon	O
cellular	O
genes	O
likely	O
contributes	O
to	O
HTLV-2	O
establishment	O
of	O
infection	B-DIS
in	O
vivo	O
.	O

Adrenal	B-DIS
insufficiency	I-DIS
may	O
result	O
from	O
a	O
wide	O
variety	O
of	O
congenital	B-DIS
or	I-DIS
acquired	I-DIS
disorders	I-DIS
of	I-DIS
hypothalamus	I-DIS
pituitary	I-DIS
or	I-DIS
adrenal	I-DIS
cortex	I-DIS
.	O

Destruction	O
or	O
dysfunction	O
of	O
the	O
adrenal	O
cortex	O
is	O
the	O
cause	O
of	O
primary	B-DIS
adrenal	I-DIS
insufficiency	I-DIS
while	O
secondary	B-DIS
adrenal	I-DIS
insufficiency	I-DIS
is	O
a	O
result	O
of	O
pituitary	B-DIS
or	I-DIS
hypothalamic	I-DIS
disease	I-DIS
.	O

Timely	O
diagnosis	O
and	O
clinical	O
management	O
of	O
adrenal	B-DIS
insufficiency	I-DIS
are	O
critical	O
to	O
prevent	O
morbidity	O
and	O
mortality	O
.	O

This	O
review	O
summarizes	O
the	O
etiologies	O
presentation	O
and	O
diagnosis	O
of	O
adrenal	B-DIS
insufficiency	I-DIS
utilizing	O
different	O
dynamic	O
hormone	O
testing	O
and	O
describes	O
current	O
treatment	O
recommendations	O
and	O
new	O
therapies	O
.	O

New	O
born	O
babies	O
could	O
suffer	O
from	O
multiple	O
craniofacial	B-DIS
abnormalities	I-DIS
such	O
as	O
Pierre	B-DIS
Robin	I-DIS
syndrome	I-DIS
which	O
consists	O
of	O
micrognathia	B-DIS
and	O
relative	O
macroglossia	O
with	O
or	O
without	O
cleft	B-DIS
palate	I-DIS
.	O

Although	O
Pierre	B-DIS
Robin	I-DIS
syndrome	I-DIS
is	O
well	O
described	O
in	O
literature	O
only	O
a	O
few	O
have	O
mentioned	O
its	O
occurrence	O
in	O
identical	O
twins	O
.	O

This	O
paper	O
presents	O
a	O
rare	O
incident	O
of	O
full	O
-	O
term	O
twin	O
babies	O
born	O
with	O
the	O
sequence	B-DIS
of	I-DIS
Pierre	I-DIS
Robin	O
syndrome	O
which	O
consists	B-DIS
of	I-DIS
micrognathia	I-DIS
cleft	O
palate	B-DIS
and	O
glossoptosis	O
.	O

Although	O
it	O
is	O
a	O
rare	O
coincidence	B-DIS
Pierre	I-DIS
Robin	I-DIS
syndrome	I-DIS
still	O
can	O
occur	O
in	O
identical	O
twin	O
babies	O
.	O

The	O
treatment	O
is	O
a	O
step	O
-	O
by	O
-	O
step	O
approach	O
but	O
all	O
procedures	O
are	O
mainly	O
directed	O
to	O
widening	O
the	O
pharyngeal	O
space	O
.	O

Purpose	O
Graves	B-DIS
'	I-DIS
orbitopathy	I-DIS
GO	O
is	O
an	O
inflammatory	B-DIS
autoimmune	I-DIS
disorder	I-DIS
of	O
the	O
orbit	O
and	O
while	O
the	O
antiphospholipid	O
antibodies	O
aPL	O
Abs	O
were	O
associated	O
with	O
the	O
markers	O
of	O
inflammation	B-DIS
in	O
the	O
antiphospholipid	B-DIS
syndrome	I-DIS
APS	I-DIS
there	O
is	O
no	O
literature	O
that	O
investigate	O
the	O
presence	O
of	O
aPL	O
Abs	O
in	O
GO	O
.	O

We	O
analyzed	O
the	O
prevalence	B-EPI
of	O
aPL	O
Abs	O
and	O
the	O
differences	O
between	O
aPL	O
+	O
and	O
aPL	O
-	O
subgroups	O
of	O
GO	O
patients	O
.	O

Methods	O
Study	O
included	O
consecutive	O
patients	O
with	O
GO	O
66	O
with	O
Graves	B-DIS
'	I-DIS
GD	I-DIS
10	O
with	O
Hashimoto	B-DIS
HD	I-DIS
and	O
8	O
were	O
euthyroid	B-DIS
.	O

Anticardiolipin	O
aCL	O
and	O
anti	O
-	O
beta	O
2glycoprotein	O
I	O
aβ2gpI	O
Abs	O
were	O
measured	O
by	O
ELISA	O
.	O

Results	O
aPL	O
Abs	O
were	O
present	O
in	O
9/84	B-STAT
10.71	I-STAT
%	I-STAT
patients	O
.	O

The	O
IgM	O
aβ2gpI	O
Abs	O
were	O
present	O
in	O
8/66	B-STAT
and	O
in	O
1/10	B-STAT
patients	O
with	O
GD	O
and	O
HD	B-DIS
.	O

The	O
IgG	O
aCL	O
Abs	O
were	O
present	O
in	O
one	O
GD	O
patient	O
and	O
IgM	O
aCL	O
were	O
present	O
in	O
3/66	B-STAT
GD	O
and	O
in	O
1/10	B-STAT
patients	O
with	O
HD	B-DIS
.	O

In	O
GD	O
group	O
anti	O
-	O
Tg	O
Abs	O
were	O
in	O
positive	O
correlation	O
with	O
aβ2gpI	O
IgG	O
p	O
=	O
0.000	O
and	O
with	O
anti	O
-	O
TPO	O
Abs	O
p	O
=	O
0.016	O
.	O

In	O
HD	B-DIS
group	O
anti	O
-	O
Tg	O
Abs	O
were	O
in	O
positive	O
correlation	O
with	O
IgM	O
aCL	O
p	O
=	O
0.042	O
while	O
anti	O
-	O
TPO	O
Abs	O
were	O
in	O
positive	O
correlation	O
with	O
aβ2gpI	O
IgM	O
p	O
=	O
0.014	O
.	O

Conclusion	O
This	O
study	O
is	O
the	O
first	O
report	O
of	O
the	O
aPL	O
Abs	O
presence	O
in	O
GO	O
patients	O
.	O

The	O
anti	O
-	O
thyroid	O
Abs	O
were	O
linked	O
to	O
aPL	O
suggesting	O
that	O
their	O
presence	O
is	O
not	O
the	O
sole	O
consequence	B-DIS
of	O
hyperstimulation	O
of	O
autoreactive	O
B	O
-	O
lymphocytes	O
.	O

Larger	O
studies	O
are	O
necessary	O
to	O
confirm	O
potential	O
cause	O
-	O
effect	O
relations	O
.	O

Background	O
PURPOSE	O
Although	O
many	O
studies	O
have	O
investigated	O
the	O
relationship	O
between	O
transient	O
global	O
amnesia	B-DIS
TGA	O
and	O
migraine	B-DIS
to	O
date	O
no	O
meta	O
-	O
analysis	O
has	O
confirmed	O
the	O
existence	O
and	O
size	O
of	O
their	O
association	O
.	O

Methodology	O
Literature	O
search	O
involved	O
MEDLINE	O
EMBASE	O
CENTRAL	O
and	O
PsycINFO	B-LOC
.	O

Observational	O
controlled	O
studies	O
including	O
TGA	O
patients	O
Caplan	O
Hodges	O
and	O
Warlow	O
were	O
retrieved	O
.	O

Quality	O
evaluation	O
was	O
based	O
on	O
the	O
Newcastle	B-LOC
-	O
Ottawa	B-LOC
scale	O
.	O

The	O
prevalence	B-EPI
of	O
migraine	B-DIS
was	O
compared	O
in	O
TGA	O
patients	O
vs.	O
healthy	O
controls	O
HC	O
as	O
well	O
as	O
in	O
TGA	O
against	O
TIA	B-DIS
individuals	O
.	O

Data	O
from	O
case	O
-	O
control	O
cross	O
-	O
sectional	O
and	O
cohort	O
studies	O
were	O
pooled	O
separately	O
.	O

Results	O
Literature	O
search	O
yielded	O
1178	O
articles	O
12	O
of	O
which	O
were	O
included	O
in	O
the	O
present	O
meta	O
-	O
analysis	O
.	O

Results	O
from	O
case	O
-	O
control	O
ten	O
cohort	O
one	O
and	O
cross	O
-	O
sectional	O
one	O
studies	O
were	O
compatible	O
with	O
an	O
association	B-DIS
between	O
TGA	O
and	O
migraine	O
.	O

The	O
nationwide	O
inpatient	O
cross	O
-	O
sectional	O
study	O
was	O
of	O
lesser	O
value	O
due	O
to	O
its	O
inpatient	O
orientation	O
.	O

The	O
high	O
-	O
quality	O
population	O
-	O
based	O
retrospective	O
cohort	O
158301	O
participants	O
per	O
group	O
determined	O
a	O
higher	O
relative	O
-	B-DIS
risk	O
RR	B-DIS
of	O
TGA	O
for	O
migraine	O
vs.	O
non	O
-	O
migraine	O
individuals	O
[	O
RR	O
=	O
2.4895	B-STAT
%	I-STAT
confidence	O
-	O
interval	O
95	B-STAT
%	I-STAT
CI	O
=	O
1.32	O
4.87	O
]	O
.	O

Sensitivity	O
testing	O
based	O
on	O
stricter	O
diagnostic	O
criteria	O
strengthened	O
the	O
estimated	O
association	O
[	O
RR	O
=	O
3.8495	B-STAT
%	I-STAT
CI	O
=	O
1.57	O
9.38	O
]	O
.	O

Additionally	O
pooled	O
data	O
from	O
eight	O
case	O
-	O
control	O
studies	O
700	O
TGA	O
746	O
HC	O
yielded	O
similar	O
results	O
[	O
Odds	O
-	O
Ratio	O
OR	O
=	O
2.5195	B-STAT
%	I-STAT
CI	O
=	O
1.85	O
3.41	O
]	O
with	O
the	O
association	O
mainly	O
driven	O
by	O
the	O
three	O
high	O
-	O
quality	O
studies	O
rather	O
than	O
the	O
five	O
articles	O
of	O
moderate	O
quality	O
.	O

Finally	O
pooled	O
findings	O
from	O
four	O
case	O
-	O
control	O
studies	O
of	O
moderate	O
-	O
quality	B-EPI
revealed	O
a	B-DIS
higher	O
prevalence	O
of	O
migraine	O
among	B-DIS
TGA	O
compared	O
to	O
TIA	O
patients	O
[	O
OR	O
=	O
1.8295	B-STAT
%	I-STAT
CI	O
=	O
1.22	O
2.73	O
]	O
.	O

Conclusions	O
A	O
significant	O
association	O
between	O
TGA	O
and	O
migraine	B-DIS
was	O
established	O
.	O

The	O
underlying	O
connecting	O
mechanism	O
remains	O
undetermined	O
yet	O
.	O

Background	O
An	O
isolated	O
coronary	O
sinus	O
CS	O
atrial	B-DIS
septal	I-DIS
defect	I-DIS
ASD	I-DIS
is	O
defined	O
as	O
a	O
CS	O
unroofed	O
in	O
the	O
terminal	O
portion	O
without	O
a	O
persistent	O
left	O
superior	O
vena	O
cava	O
or	O
other	O
anomalies	B-DIS
.	O

This	O
defect	O
is	O
rare	O
and	O
part	O
of	O
the	O
wide	O
spectrum	O
of	O
unroofed	O
CS	O
syndrome	O
URCS	O
.	O

Recently	O
several	O
reports	O
have	O
described	O
this	O
finding	O
.	O

The	O
database	O
of	O
New	O
Tokyo	O
Hospital	O
was	O
searched	O
to	O
determine	O
the	O
incidence	B-EPI
of	O
this	O
defect	O
.	O

Additionally	O
to	O
raise	O
awareness	O
of	O
this	O
condition	O
the	O
findings	O
from	O
five	O
patients	O
with	O
CS	O
ASD	O
who	O
underwent	O
surgical	O
repair	O
at	O
New	O
Tokyo	O
Hospital	O
are	O
discussed	O
.	O

Case	O
presentation	O
The	O
patients	O
were	O
three	O
women	O
and	O
two	O
men	O
with	O
an	O
age	O
range	O
of	O
63	O
-	O
77	O
years	O
.	O

All	O
patients	O
underwent	O
transthoracic	O
echocardiography	O
and	O
computed	O
tomography	O
and	O
one	O
underwent	O
magnetic	O
resonance	O
imaging	O
.	O

In	O
two	O
patients	O
the	O
defect	O
was	O
found	O
unexpectedly	O
intraoperatively	O
;	O
left	O
-	O
to	O
-	O
right	O
shunting	O
was	O
apparent	O
in	O
the	O
other	O
three	O
patients	O
preoperatively	O
.	O

The	O
pulmonary	O
-	O
to	O
-	O
systemic	O
blood	O
flow	O
ratio	O
ranged	O
from	O
1.42	O
to	O
3.1	O
following	O
cardiac	O
catheterization	O
and	O
oxygen	O
saturation	O
step	O
-	O
up	O
was	O
seen	O
on	O
the	O
right	O
side	O
of	O
the	O
heart	O
.	O

Valvular	B-DIS
regurgitation	I-DIS
was	O
seen	O
in	O
4/5	B-STAT
patients	O
with	O
different	O
combinations	O
and	O
degrees	O
of	O
mitral	B-DIS
tricuspid	I-DIS
and	O
aortic	O
valve	O
involvement	O
.	O

Right	O
atrial	O
and	O
ventricular	O
dilation	O
were	O
seen	O
in	O
4/5	B-STAT
patients	O
;	O
three	O
patients	O
had	O
left	O
atrial	O
dilation	O
.	O

Three	O
patients	O
experienced	O
atrial	B-DIS
fibrillation	I-DIS
and	O
one	O
of	O
these	O
also	O
experienced	O
paroxysmal	O
ventricular	B-DIS
contractions	I-DIS
.	O

All	O
patients	O
underwent	O
surgical	O
repair	O
and	O
some	O
underwent	O
multiple	O
procedures	O
.	O

One	O
patient	O
who	O
had	O
previously	O
undergone	O
kidney	O
transplantation	O
died	O
approximately	O
1	O
year	O
postoperatively	O
;	O
the	O
remaining	O
four	O
patients	O
are	O
currently	O
experiencing	O
good	O
activities	O
of	O
daily	O
living	O
without	O
symptoms	O
.	O

Conclusions	O
CS	O
ASD	O
Kirklin	O
and	O
Barratt	O
-	O
Boyes	O
type	O
IV	O
URCS	O
comprised	O
1.3	B-STAT
%	I-STAT
of	B-DIS
adult	I-DIS
congenital	O
heart	O
surgeries	O
and	O
0.07	B-STAT
%	I-STAT
of	O
adult	O
open	O
-	O
heart	O
surgeries	O
at	O
New	O
Tokyo	O
Hospital	O
from	O
1999	O
to	O
2019	O
.	O

At	O
New	O
Tokyo	O
Hospital	O
cardiac	O
surgery	O
is	O
performed	O
mainly	O
for	O
patients	O
with	O
acquired	O
cardiac	B-DIS
disease	I-DIS
and	O
CS	O
ASD	B-DIS
is	O
rare	O
.	O

Early	O
diagnosis	O
is	O
important	O
as	O
well	O
as	O
early	O
surgical	O
repair	O
in	O
symptomatic	O
patients	O
especially	O
those	O
with	O
blood	O
access	O
shunts	O
which	O
may	O
overload	O
the	O
heart	O
.	O

The	O
case	O
of	O
a	O
poor	O
prognosis	O
in	O
this	O
series	O
is	O
noteworthy	O
as	O
similar	O
cases	O
have	O
not	O
been	O
reported	O
previously	O
.	O

Alport	B-DIS
syndrome	I-DIS
is	O
an	O
inherited	O
disorder	O
characterized	O
by	O
the	O
association	O
of	O
a	O
progressive	O
haematuric	B-DIS
nephropathy	I-DIS
with	O
ultrastructural	O
abnormalities	O
of	O
the	O
glomerular	O
basement	O
membranes	O
a	O
progressive	O
sensorineural	B-DIS
hearing	I-DIS
loss	I-DIS
and	O
sometimes	O
ocular	O
involvement	O
.	O

Its	O
incidence	B-EPI
is	O
less	O
than	O
1	B-STAT
per	I-STAT
5000	I-STAT
individuals	O
and	O
the	O
disease	O
is	O
the	O
cause	O
of	O
about	B-STAT
2	I-STAT
%	I-STAT
of	O
end	B-DIS
stage	I-DIS
renal	I-DIS
disease	I-DIS
in	O
Europe	B-LOC
and	O
the	B-LOC
United	I-LOC
States	I-LOC
.	O

Alport	B-DIS
syndrome	I-DIS
is	O
clinically	O
and	O
genetically	O
heterogeneous	O
.	O

It	O
is	O
related	O
to	O
mutations	O
in	O
the	O
genes	O
encoding	O
one	O
of	O
three	O
chains	O
α3	O
α4	O
α5	O
of	O
type	O
IV	O
collagen	O
the	O
main	O
component	O
of	O
basement	O
membranes	O
expressed	O
in	O
the	O
glomerular	O
basement	O
membrane	O
.	O

COL4A5	O
mutations	O
are	O
associated	O
with	O
X	O
-	B-DIS
linked	I-DIS
Alport	O
syndrome	O
which	O
represents	O
80	B-STAT
to	I-STAT
85	I-STAT
%	I-STAT
of	O
cases	O
and	O
is	O
more	O
severe	O
in	O
boys	O
than	O
in	O
girls	O
.	O

Mutations	O
in	O
COL4A3	O
or	O
COL4A4	O
are	O
associated	O
with	O
autosomal	O
Alport	B-DIS
syndrome	I-DIS
.	O

The	O
expression	O
of	O
collagen	O
chains	O
in	O
skin	O
and	O
kidney	O
basement	O
membranes	O
allows	O
for	O
the	O
diagnosis	O
and	O
characterization	O
of	O
the	O
mode	O
of	O
transmission	O
in	O
most	O
patients	O
.	O

It	O
is	O
necessary	O
to	O
diagnose	O
this	O
syndrome	O
because	O
its	O
family	O
involvement	O
its	O
severity	O
and	O
the	O
importance	O
of	O
genetic	O
counseling	O
.	O

Angiotensin	O
blockers	O
are	O
increasingly	O
prescribed	O
in	O
proteinuric	B-DIS
patients	O
.	O

Prospective	O
studies	O
are	O
needed	O
to	O
assess	O
the	O
effectiveness	O
of	O
these	O
treatments	O
on	O
proteinuria	B-DIS
and	O
progression	O
of	O
kidney	B-DIS
failure	I-DIS
and	O
to	O
specify	O
indications	O
.	O

Animal	O
studies	O
have	O
shown	O
the	O
potential	O
value	O
of	O
different	O
molecules	O
protease	O
inhibitors	O
chemokine	O
receptor	O
blockers	O
transforming	O
growth	O
factor	O
-	O
β1	O
inhibitors	O
hydroxy	O
-	O
methyl	O
-	O
coenzyme	O
A	O
reductase	O
inhibitors	O
bone	O
morphogenetic	O
protein-7	O
inhibitors	O
hematopoietic	O
stem	O
cells	O
and	O
of	O
a	O
anti	O
-	O
micro	O
-	O
RNA	O
.	O

The	O
prevalence	B-EPI
of	O
diabetes	B-DIS
continues	O
to	O
rise	O
worldwide	O
.	O

In	O
addition	O
to	O
rising	O
rates	O
of	O
diabetic	B-DIS
kidney	I-DIS
disease	I-DIS
we	O
are	O
also	O
seeing	O
a	O
parallel	O
rise	O
in	O
nondiabetic	O
kidney	B-DIS
disease	I-DIS
among	O
patients	O
with	O
diabetes	B-DIS
.	O

These	O
nondiabetic	O
lesions	O
include	O
focal	B-DIS
segmental	I-DIS
glomerulosclerosis	I-DIS
IgA	I-DIS
nephropathy	I-DIS
membranous	O
nephropathy	B-DIS
and	O
other	O
glomerular	B-DIS
diseases	I-DIS
.	O

The	O
management	O
of	O
diabetic	B-DIS
kidney	I-DIS
disease	I-DIS
is	O
rapidly	O
evolving	O
to	O
include	O
beyond	O
glycemic	O
control	O
and	O
renin	O
angiotensin	O
inhibition	O
the	O
use	O
of	O
sodium	O
-	O
glucose	O
cotransporter	O
2	O
SGLT2	O
inhibitors	O
and	O
mineralocorticoid	O
receptor	O
antagonists	O
.	O

These	O
and	O
other	O
new	O
treatment	O
strategies	O
should	O
be	O
applicable	O
to	O
managing	O
glomerular	B-DIS
disease	I-DIS
in	O
diabetic	B-DIS
patients	O
to	O
reduce	O
toxicities	B-DIS
associated	O
with	O
immunosuppression	O
and	O
in	O
particular	O
corticosteroids	O
.	O

The	O
prevalence	B-EPI
of	O
glomerular	B-DIS
disease	I-DIS
in	O
diabetic	B-DIS
patients	O
is	O
underappreciated	O
.	O

Diagnosis	O
and	O
appropriately	O
treating	O
these	O
diseases	O
remain	O
an	O
important	O
avenue	O
to	O
modify	O
kidney	O
outcomes	O
in	O
diabetic	B-DIS
patients	O
.	O

Over	O
2600002013	O
new	O
oral	O
squamous	B-DIS
cell	I-DIS
carcinoma	I-DIS
OSCC	I-DIS
cases	O
are	O
reported	O
annually	O
worldwide	O
.	O

Despite	O
development	O
in	O
OSCC	B-DIS
management	O
the	O
outcome	O
is	O
still	O
unsatisfactory	O
.	O

Identification	O
of	O
new	O
molecular	O
markers	O
may	O
be	O
of	O
use	O
in	O
prevention	O
prognosis	O
and	O
choice	O
of	O
an	O
appropriate	O
therapy	O
.	O

The	O
intracellular	O
molecular	O
signalling	O
pathway	O
of	O
phosphatidyl	O
-	O
inositol-3	O
-	O
kinase	O
is	O
involved	O
in	O
the	O
process	O
of	O
cell	O
growth	O
differentiation	O
migration	O
and	O
survival	O
.	O

The	O
main	O
components	O
of	O
this	O
pathway	O
PIK3CA	O
phosphatidylinositol-4	O
5	O
-	O
bisphosphate-3	O
-	O
kinase	O
catalytic	O
subunit	O
α	O
PTEN	O
phosphatase	O
and	O
tensin	O
homologue	O
deleted	O
on	O
chromosome	O
10	O
and	O
AKT	O
serine	O
-	O
threonine	O
kinase	O
are	O
potential	O
objects	O
of	O
research	O
when	O
introducing	O
new	O
therapeutic	O
agents	O
.	O

The	O
aim	O
of	O
this	O
paper	O
is	O
to	O
evaluate	O
the	O
PIK3CA	O
PTEN	O
and	O
AKT	O
gene	O
mutations	O
as	O
prognostic	O
factors	O
in	O
OSCC	B-DIS
and	O
to	O
describe	O
their	O
role	O
in	O
aggressive	B-DIS
disease	I-DIS
progression	O
.	O

This	O
is	O
crucial	O
for	O
oral	B-DIS
cancer	I-DIS
biology	O
understanding	O
and	O
for	O
indicating	O
which	O
direction	O
new	O
clinical	O
treatments	O
should	O
take	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
genetic	O
variants	O
of	O
51	O
Chinese	O
patients	O
with	O
distal	B-DIS
renal	I-DIS
tubular	I-DIS
acidosis	I-DIS
dRTA	I-DIS
and	O
explore	O
the	O
correlation	O
between	O
their	O
genotype	O
and	O
phenotype	O
.	O

Eight	O
variants	O
of	O
SLC4A119	O
variants	O
of	O
ATP6V0A4	B-DIS
and	O
16	O
variants	O
of	O
ATP6V1B1	B-DIS
have	O
been	O
identified	O
and	O
of	O
which	O
14	O
were	O
novel	O
ones	O
.	O

Eleven	O
patients	O
with	O
autosomal	B-DIS
dominant	O
dRTA	B-DIS
and	O
four	O
patients	O
with	O
autosomal	B-DIS
recessive	O
dRTA	B-DIS
were	O
caused	O
by	O
genetic	O
defects	O
in	O
SLC4A1	O
;	O
18	O
and	O
nine	O
patients	O
with	O
recessive	B-DIS
dRTA	I-DIS
were	O
resulted	O
by	O
defects	O
in	O
ATP6V0A4	B-DIS
and	O
ATP6V1B1	O
respectively	O
;	O
no	O
causal	O
gene	O
was	O
identified	O
in	O
seven	O
patients	O
.	O

Mutation	O
frequency	O
of	O
SLC4A1	O
in	O
Chinese	O
populations	O
was	O
more	O
common	O
than	O
Europeans	O
.	O

The	O
incidence	B-EPI
of	O
deafness	B-DIS
in	O
ATP6V0A4	B-DIS
and	O
ATP6V1B1	O
groups	O
was	O
16.7	B-STAT
%	I-STAT
and	O
54.5	B-STAT
%	I-STAT
respectively	O
.	O

The	O
frequency	O
of	O
CKD	O
in	O
adults	O
children	O
and	O
infants	O
was	O
100	B-STAT
%	I-STAT
51	B-STAT
%	I-STAT
and	O
3	B-STAT
%	I-STAT
separately	O
.	O

Our	O
study	O
will	O
further	O
expand	O
the	O
mutation	O
spectrum	O
of	O
primary	O
dRTA	B-DIS
and	O
provide	O
valuable	O
references	O
to	O
genetic	O
counseling	O
of	O
Chinese	O
populations	O
.	O

Background	O
Retroviruses	O
of	O
human	B-DIS
T	I-DIS
-	I-DIS
lymphotropic	I-DIS
viruses	O
HTLV-1	B-DIS
and	O
HTLV-2	O
have	O
been	O
demonstrated	O
to	O
be	O
endemic	O
in	O
the	O
north	O
-	O
eastern	O
region	O
of	O
Iran	B-LOC
.	O

This	O
study	O
was	O
aimed	O
to	O
determine	O
the	O
HTLV-1	O
and	O
HTLV-2	O
prevalence	B-EPI
among	O
healthy	O
individuals	O
in	O
Neyshabur	B-LOC
City	I-LOC
during	O
2010	O
-	O
2014	O
.	O

Methods	O
A	O
total	O
of	O
8054	O
blood	O
samples	O
were	O
collected	O
from	O
healthy	O
participants	O
in	O
Neyshabur	B-LOC
North	I-LOC
-	I-LOC
Eastern	I-LOC
Iran	B-LOC
.	O

The	O
blood	O
samples	O
were	O
screened	O
for	O
the	O
presence	O
of	O
specific	O
antibodies	O
against	O
HTLV-1	B-DIS
and	O
HTLV-2	O
by	O
using	O
ELISA	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

Results	O
The	O
overall	O
seropositivity	O
rate	O
for	O
HTLV-1	O
and	O
HTLV-2	O
was	O
found	O
to	O
be	O
6.55	B-STAT
%	I-STAT
528	O
out	O
of	O
8054	O
among	O
participants	O
.	O

Conclusion	O
Both	O
HTLV-1	O
and	O
HTLV-2	O
were	O
demonstrated	O
to	O
be	O
at	O
a	O
high	O
rate	O
in	O
healthy	O
individuals	O
.	O

However	O
a	O
smaller	O
number	O
of	O
asymptomatic	O
carriers	O
were	O
found	O
in	O
this	O
study	O
as	O
compared	O
to	O
those	O
identified	O
in	O
previous	O
investigations	O
in	O
the	O
city	O
.	O

Amoebiasis	B-DIS
is	O
a	O
common	O
infection	B-DIS
widely	O
prevalent	O
in	O
tropical	O
countries	O
with	O
low	O
income	O
and	O
poor	O
sanitation	O
.	O

The	O
clinical	O
picture	O
is	O
usually	O
nonspecific	O
;	O
however	O
invasion	O
of	O
the	O
liver	O
by	O
Entamoeba	O
histolytica	O
could	O
lead	O
to	O
an	O
amoebic	B-DIS
liver	I-DIS
abscess	I-DIS
ALA	I-DIS
.	O

It	O
is	O
relatively	O
uncommon	O
in	O
women	O
and	O
children	O
.	O

Though	O
rare	O
extension	O
of	O
ALA	O
into	O
the	O
lungs	O
pleural	O
cavity	O
and	O
pericardium	O
may	O
prove	O
fatal	O
.	O

Pericardial	B-DIS
amoebiasis	I-DIS
is	O
a	O
rare	O
complication	O
which	O
if	O
not	O
treated	O
early	O
could	O
result	O
in	O
cardiac	B-DIS
tamponade	I-DIS
and	O
subsequent	O
death	B-DIS
.	O

The	O
standard	O
management	O
option	O
is	O
eradication	O
with	O
metronidazole	O
along	O
with	O
the	O
drainage	O
of	O
fluid	O
from	O
the	O
liver	B-DIS
abscess	I-DIS
and	O
pericardial	B-DIS
effusion	I-DIS
.	O

Herein	O
we	O
present	O
a	O
case	O
of	O
a	O
seven	B-DIS
-	O
year	O
-	O
old	O
male	O
child	O
with	O
ALA	O
who	O
developed	O
signs	B-DIS
and	I-DIS
symptoms	O
suggesting	O
pericardial	O
effusion	O
within	O
a	O
few	O
days	O
of	O
hospital	O
admission	O
.	O

Early	O
diagnosis	O
of	O
pericardial	O
complication	O
and	O
successful	O
management	O
of	O
abscess	B-DIS
resolved	O
the	O
pericardial	B-DIS
effusion	I-DIS
.	O

Introduction	O
Children	O
account	O
for	O
a	O
relatively	O
small	O
proportion	O
of	O
laboratory	B-DIS
-	I-DIS
confirmed	I-DIS
SARS	O
-	O
CoV-2	O
infections	O
.	O

In	O
children	O
COVID-19	O
usually	O
has	O
a	O
relatively	O
mild	O
course	O
.	O

However	O
in	O
rare	O
cases	O
severe	O
disorders	O
can	O
be	O
observed	O
and	O
clinical	O
manifestations	O
may	O
differ	O
from	O
adults	O
.	O

Purpose	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
analyse	O
the	O
frequency	O
clinical	O
picture	O
and	O
outcome	O
of	O
COVID-19	O
in	O
children	O
based	O
on	O
the	O
experience	O
from	O
the	O
tertiary	O
care	O
centre	O
and	O
regional	O
sanitary	O
-	O
epidemiological	O
office	O
.	O

Methods	O
We	O
report	O
a	O
study	O
regarding	O
106	O
cases	O
of	O
confirmed	O
SARS	B-DIS
-	I-DIS
CoV-2	O
infection	O
cases	O
in	O
PCR	O
from	O
a	O
nasopharyngeal	O
swab	O
age	O
range	O
1	O
-	O
month	O
-	O
17	O
-	O
years	O
.	O

In	O
all	O
cases	O
history	O
was	O
taken	O
.	O

In	O
children	O
who	O
required	O
hospital	O
admission	O
physical	O
examination	O
and	O
laboratory	O
test	O
were	O
performed	O
according	O
to	O
clinical	O
indications	O
.	O

Results	O
Twelve	O
of	O
the	O
patients	O
required	O
admission	O
to	O
the	O
hospital	O
.	O

The	O
most	O
common	O
symptoms	O
were	O
anosmia	B-DIS
and	O
dysgeusia	B-DIS
75	B-STAT
%	I-STAT
and	O
headaches	B-DIS
49	B-STAT
%	I-STAT
in	O
outpatients	O
and	O
fever	B-DIS
in	O
hospitalised	O
children	O
75	B-STAT
%	I-STAT
.	O

Three	O
children	O
from	O
the	O
hospitalised	O
group	O
developed	O
a	O
severe	O
course	O
with	O
increased	O
inflammatory	O
indexes	O
.	O

The	O
clinical	O
picture	O
was	O
more	O
severe	O
in	O
younger	O
children	O
from	O
the	O
hospitalised	O
group	O
.	O

Treatment	O
options	O
were	O
regarded	O
individually	O
in	O
all	O
cases	O
.	O

Conclusion	O
Our	O
study	O
is	O
the	O
first	O
tour	O
knowledge	O
regarding	O
the	O
clinical	O
course	O
of	O
COVID-19	O
in	O
Polish	O
children	O
.	O

In	O
general	O
the	O
clinical	O
course	O
of	O
COVID-19	O
was	O
mild	O
with	O
anosmia	B-DIS
and	O
dysgeusia	B-DIS
as	O
the	O
most	O
common	O
symptoms	O
.	O

However	O
in	O
hospitalised	O
children	O
a	O
severe	O
progression	O
of	O
the	O
disease	O
and	O
less	O
typical	O
signs	O
as	O
aplastic	B-DIS
anaemia	I-DIS
may	O
be	O
developed	O
.	O

Aim	O
To	O
assess	O
the	O
prevalence	B-EPI
of	O
persistent	O
lipid	O
abnormalities	O
in	O
statin	O
-	O
treated	O
patients	B-DIS
with	O
diabetes	O
with	O
and	O
without	B-DIS
the	I-DIS
metabolic	O
syndrome	O
.	O

Methods	O
This	O
was	O
a	O
cross	O
-	O
sectional	O
study	O
of	O
22063	O
statin	O
-	O
treated	O
outpatients	O
consecutively	O
recruited	O
by	O
clinicians	O
in	O
Canada	B-LOC
and	O
11	O
European	O
countries	O
.	O

Patient	O
cardiovascular	O
risk	O
factors	O
risk	O
level	O
lipid	O
measurements	O
and	O
lipid	O
-	O
modifying	O
medication	O
regimens	O
were	O
recorded	O
.	O

Results	O
Of	O
the	O
20129	O
subjects	O
who	O
had	O
documented	O
diabetes	B-DIS
and/or	O
metabolic	B-DIS
syndrome	I-DIS
status	O
41	B-STAT
%	I-STAT
had	O
diabetes	B-DIS
of	O
whom	O
86.8	B-STAT
%	I-STAT
also	O
had	O
the	O
metabolic	B-DIS
syndrome	I-DIS
.	O

Of	O
those	O
with	O
diabetes	B-DIS
48.1	B-STAT
%	I-STAT
were	O
not	O
at	O
total	O
cholesterol	O
target	O
compared	O
with	O
58	B-STAT
%	I-STAT
of	O
those	O
without	O
diabetes	B-DIS
.	O

Amongst	O
those	O
with	O
diabetes	B-DIS
41.6	O
and	O
41.3	B-STAT
%	I-STAT
of	O
those	O
with	O
and	O
without	O
the	O
metabolic	B-DIS
syndrome	I-DIS
respectively	O
were	O
not	O
at	O
their	O
LDL	O
cholesterol	O
goal	O
relative	O
to	O
54.2	B-STAT
%	I-STAT
of	O
those	O
with	O
metabolic	B-DIS
syndrome	I-DIS
and	O
without	O
diabetes	B-DIS
and	O
52	B-STAT
%	I-STAT
of	O
those	O
with	O
neither	O
condition	O
.	O

Twenty	O
per	O
cent	O
of	O
people	O
with	O
diabetes	B-DIS
but	O
without	O
the	O
metabolic	B-DIS
syndrome	I-DIS
were	O
not	O
at	O
the	O
optimal	O
HDL	O
cholesterol	O
level	O
compared	O
with	O
9	B-STAT
%	I-STAT
of	O
those	O
with	O
neither	O
condition	O
.	O

Of	O
people	O
with	O
diabetes	B-DIS
and	O
the	O
metabolic	B-DIS
syndrome	I-DIS
49.9	B-STAT
%	I-STAT
were	O
not	O
at	O
optimal	O
triglyceride	O
level	O
relative	O
to	O
13.5	B-STAT
%	I-STAT
of	O
people	O
with	O
neither	O
diabetes	B-DIS
nor	O
the	O
metabolic	B-DIS
syndrome	I-DIS
.	O

Simvastatin	O
was	O
the	O
most	O
commonly	O
prescribed	O
statin	O
45	B-STAT
%	I-STAT
and	O
the	O
most	O
common	O
statin	O
potency	O
was	O
20	O
-	O
40	O
mg	O
/	O
day	O
simvastatin	O
equivalent	O
.	O

Approximately	B-STAT
14	I-STAT
%	I-STAT
of	O
patients	O
were	O
taking	O
ezetimibe	O
alone	O
or	O
in	O
combination	O
with	O
a	O
statin	O
.	O

Conclusions	O
Despite	O
evidence	O
supporting	O
the	O
benefits	O
of	O
lipid	O
modification	O
and	O
international	O
guideline	O
recommendations	O
statin	O
-	O
treated	O
patients	B-DIS
with	O
diabetes	O
had	O
a	B-EPI
high	O
prevalence	O
of	O
persistent	O
lipid	O
abnormalities	O
.	O

There	O
is	O
frequently	O
room	O
to	O
optimize	O
therapy	O
through	O
statin	O
dose	O
up	O
-	O
titration	O
and/or	O
addition	O
of	O
other	O
lipid	O
-	O
modifying	O
therapies	O
.	O

Background	O
Charcot	B-DIS
-	I-DIS
Marie	B-DIS
-	I-DIS
Tooth	I-DIS
disease	O
type	O
1A	O
CMT1A	O
is	O
the	O
most	B-DIS
common	I-DIS
form	O
of	O
hereditary	O
neuropathy	O
.	O

Objective	O
To	O
investigate	O
the	O
prevalence	B-EPI
and	O
characteristics	O
of	O
pain	B-DIS
in	O
patients	O
with	O
CMT1A	B-DIS
.	O

Methods	O
Nineteen	O
patients	O
with	O
a	O
diagnosis	O
of	O
CMT1A	B-DIS
were	O
evaluated	O
between	O
September	O
2018	O
and	O
October	O
2019	O
and	O
other	O
causes	O
of	O
neuropathy	B-DIS
were	O
ruled	O
out	O
.	O

The	O
following	O
tools	O
were	O
used	O
for	O
the	O
pain	B-DIS
assessment	O
neurological	O
assessment	O
LANSS	O
DN4	O
clinical	O
evaluation	O
VAS	O
CMTNS2	O
and	O
SF-36	O
.	O

Statistical	O
analysis	O
was	O
performed	O
using	O
prevalence	B-EPI
analysis	O
t	O
test	O
chi	O
-	O
square	O
test	O
and	O
Spearman	O
's	O
rho	O
.	O

Results	O
The	O
prevalence	B-EPI
of	O
pain	B-DIS
was	O
84.2	B-STAT
%	I-STAT
in	O
the	O
sample	O
of	O
this	O
study	O
with	O
moderate	O
intensity	O
and	O
nociceptive	O
characteristics	O
according	O
to	O
the	O
LANSS	O
scale	O
75	B-STAT
%	I-STAT
and	O
clinical	O
evaluation	O
50	B-STAT
%	I-STAT
but	O
differing	O
from	O
DN4	O
which	O
found	O
neuropathic	B-DIS
pain	I-DIS
in	O
the	O
majority	O
of	O
the	O
patients	O
56.2	B-STAT
%	I-STAT
.	O

Mixed	O
pain	B-DIS
was	O
also	O
observed	O
in	O
43.7	B-STAT
%	I-STAT
of	O
the	O
patients	O
according	O
to	O
clinical	O
criteria	O
.	O

There	O
was	O
a	O
statistically	O
significant	O
correlation	O
between	O
pain	B-DIS
intensity	O
and	O
SF-36	O
thus	O
demonstrating	O
that	O
the	O
lower	O
the	O
pain	B-DIS
was	O
the	O
lower	O
the	O
impairment	O
was	O
in	O
all	O
domains	O
.	O

Conclusion	O
Pain	B-DIS
is	O
a	O
prevalent	O
and	O
important	O
symptom	O
in	O
CMT1A	O
with	O
moderate	O
intensity	O
and	O
nociceptive	O
characteristics	O
according	O
to	O
two	O
tools	O
but	O
neuropathic	B-DIS
pain	I-DIS
is	O
also	O
present	O
and	O
there	O
may	O
even	O
be	O
a	O
mixed	O
pattern	O
of	O
pain	B-DIS
.	O

The	O
correlation	O
of	O
the	O
pain	B-DIS
with	O
SF-36	O
suggests	O
that	O
pain	B-DIS
relief	O
could	O
provide	O
improvements	O
to	O
the	O
quality	O
of	O
life	O
of	O
these	O
individuals	O
.	O

Background	O
Comorbidity	B-DIS
may	O
influence	O
clinical	O
aspects	O
of	O
neuromyelitis	B-DIS
optica	I-DIS
spectrum	I-DIS
disorder	I-DIS
NMOSD	I-DIS
.	O

We	O
estimated	O
the	O
prevalence	B-EPI
of	O
comorbidities	O
to	O
assess	O
their	O
association	O
with	O
outcomes	O
.	O

Methods	O
This	O
retrospective	O
study	O
assessed	O
records	O
of	O
NMOSD	B-DIS
patients	O
from	O
2008	O
to	O
2019	O
categorizing	O
comorbidities	O
into	O
three	O
groups	O
somatic	B-DIS
psychiatric	I-DIS
and	O
autoimmune	O
.	O

Severity	O
of	O
disease	O
was	O
evaluated	O
by	O
the	O
Expanded	O
Disability	O
Status	O
Scale	O
progression	O
index	O
PI	O
and	O
annualized	O
relapse	O
rate	O
.	O

The	O
frequency	O
of	O
comorbidities	O
was	O
compared	O
between	O
anti	O
-	O
aquaporin	O
4	O
antibody	O
AQP4	O
-	O
IgG	O
seropositive	O
and	O
seronegative	O
patients	O
.	O

Results	O
A	O
total	O
of	O
67	O
NMOSD	B-DIS
patients	O
were	O
enrolled	O
.	O

Thirty	O
-	O
five	O
52.2	B-STAT
%	I-STAT
patients	O
reported	O
at	O
least	O
one	O
comorbidity	O
.	O

In	O
total	O
44	O
comorbidities	O
were	O
found	O
of	O
which	O
24	O
occurred	O
prior	O
to	O
NMOSD	B-DIS
onset	O
29	O
somatic	O
13	O
psychiatric	B-DIS
and	O
2	O
autoimmune	O
entities	O
.	O

The	O
most	O
common	O
comorbidities	O
were	O
anxiety	B-DIS
disorders	I-DIS
7/67	B-STAT
10.4	I-STAT
%	I-STAT
followed	O
by	O
migraine	B-DIS
6/67	B-STAT
8.9	B-STAT
%	I-STAT
major	B-DIS
depression	I-DIS
disorder	I-DIS
6/67	B-STAT
8.9	B-STAT
%	I-STAT
iron	O
deficiency	O
anemia	B-DIS
8/54	B-STAT
14.8	I-STAT
%	I-STAT
and	O
non	B-DIS
-	I-DIS
autoimmune	B-STAT
hypothyroidism	O
4/67	B-STAT
6.0	I-STAT
%	I-STAT
.	O

Psychiatric	B-DIS
comorbidities	O
associated	O
with	O
PI	O
in	O
unadjusted	O
OR=0.53895	B-STAT
%	I-STAT
CI=0.141	O
0.935	O
P=0.009	O
and	O
adjusted	O
models	O
OR=0.38695	O
%	O
CI=0.022	O
0.751	O
P=0.038	O
.	O

A	O
significantly	O
higher	O
frequency	O
of	O
psychiatric	B-DIS
comorbidities	O
was	O
observed	O
in	O
the	O
AQP4	O
-	O
IgG	O
positive	O
patients	O
P=0.031	B-LOC
.	O

Conclusion	O
Half	O
of	O
the	O
patients	O
had	O
comorbidities	O
suggesting	O
screening	O
for	O
comorbidity	O
as	O
part	O
of	O
NMOSD	B-DIS
care	O
.	O

The	O
psychiatric	B-DIS
comorbidities	O
had	O
impact	O
on	O
clinical	O
outcome	O
.	O

Background	O
Osteogenesis	B-DIS
imperfecta	I-DIS
OI	I-DIS
is	O
a	O
rare	O
disease	O
characterized	O
by	O
increased	O
bone	O
fragility	O
and	O
susceptibility	O
for	O
fractures	B-DIS
.	O

Only	O
few	O
studies	O
have	O
compared	O
the	O
management	O
for	O
femoral	B-DIS
fractures	I-DIS
in	O
children	O
with	O
OI	B-DIS
.	O

Nevertheless	O
no	O
cohort	O
studies	O
have	O
described	O
the	O
treatment	O
for	O
femoral	B-DIS
fractures	I-DIS
in	O
adults	O
with	O
OI	O
in	O
Taiwan	B-LOC
.	O

This	O
study	O
aimed	O
to	O
investigate	O
and	O
compare	O
the	O
incidence	B-EPI
of	O
union	O
and	O
non	B-DIS
-	O
union	B-DIS
femoral	O
fractures	O
and	O
the	O
best	O
treatment	O
options	O
to	O
avoid	B-DIS
non	O
-	O
union	O
fractures	O
.	O

Methods	O
We	O
enrolled	O
72	O
patients	O
with	O
OI	O
who	O
were	O
older	O
than	O
18	O
years	O
at	O
MacKay	O
Memorial	O
Hospital	O
between	O
January	O
2010	O
and	O
December	O
2018	O
.	O

Femoral	O
fracture	O
incidence	B-EPI
non	B-DIS
-	O
union	O
rate	O
and	O
treatment	O
modality	O
were	O
analyzed	O
.	O

Results	O
Of	O
72	O
patients	O
with	O
OI	O
11	O
patients	O
had	O
femoral	O
fractures	B-DIS
and	O
4	O
patients	O
of	O
them	O
ha	O
1	O
femoral	O
fracture	O
.	O

The	O
incidence	B-EPI
for	O
all	O
types	O
of	O
femoral	O
fractures	B-DIS
was	O
651	O
fractures	B-DIS
per	O
100000	O
person	O
-	O
years	O
annually	O
.	O

In	O
15	O
total	O
fractures	B-DIS
4	O
fractures	B-DIS
resulted	O
in	O
non	B-DIS
-	O
union	O
and	O
patients	B-DIS
with	I-DIS
type	I-DIS
4	O
OI	O
mostly	O
had	B-DIS
shaft	O
fractures	O
.	O

The	O
best	O
outcomes	O
for	O
non	B-DIS
-	O
union	B-DIS
shaft	O
fracture	O
is	O
achieved	O
by	O
surgical	O
treatment	O
.	O

Conclusion	O
Adults	O
with	O
OI	O
tended	O
to	O
develop	O
femoral	O
fractures	B-DIS
and	O
non	B-DIS
-	O
unions	O
.	O

Adults	O
with	O
type	O
4	O
OI	O
were	O
particularly	O
at	O
high	O
risk	O
for	O
non	B-DIS
-	O
unions	O
in	B-DIS
shaft	O
fractures	O
with	O
conservative	O
treatment	O
.	O

With	O
increasing	O
maternal	O
age	O
in	O
this	O
decade	O
there	O
is	O
a	O
parallel	O
rise	O
in	O
the	O
number	O
of	O
pregnant	O
and	O
lactating	O
women	O
affected	O
by	O
glaucoma	B-DIS
worldwide	O
.	O

Understanding	O
the	O
diagnosis	O
and	O
management	O
of	O
glaucoma	B-DIS
during	O
pregnancy	O
and	O
lactation	O
is	O
essential	O
to	O
preventing	O
blindness	B-DIS
from	O
glaucoma	B-DIS
in	O
this	O
vulnerable	O
population	O
.	O

This	O
report	O
provides	O
a	O
review	O
of	O
the	O
current	O
literature	O
and	O
offers	O
effective	O
strategies	O
that	O
will	O
overcome	O
the	O
challenges	O
in	O
managing	O
glaucoma	B-DIS
during	O
pregnancy	O
and	O
lactation	O
.	O

Practically	O
glaucoma	B-DIS
management	O
during	O
pregnancy	O
and	O
lactation	O
presents	O
a	O
unique	O
challenge	O
for	O
the	O
physician	O
as	O
the	O
benefit	O
of	O
any	O
treatment	O
must	O
be	O
weighed	O
against	O
the	O
potential	O
risks	O
to	O
the	O
fetus	O
.	O

Prior	O
to	O
initiating	O
or	O
continuing	O
treatment	O
the	O
physician	O
should	O
be	O
familiar	O
with	O
the	O
various	O
treatment	O
options	O
to	O
manage	O
intraocular	O
pressure	O
during	O
pregnancy	O
and	O
lactation	O
including	O
the	O
safety	O
of	O
various	O
anti	O
-	O
glaucoma	O
medications	O
as	O
supported	O
by	O
the	O
existing	O
literature	O
and	O
based	O
on	O
the	O
food	O
and	O
drug	O
administration	O
guidelines	O
.	O

A	O
collaborative	O
team	O
effort	O
between	O
the	O
ophthalmologist	O
obstetrician	O
and	O
neonatologist	O
in	O
high	O
-	O
risk	O
pregnancies	O
is	O
recommended	O
to	O
optimize	O
care	O
for	O
the	O
mother	O
and	O
fetus	O
.	O

Introduction	O
New	O
neurological	O
symptoms	O
in	O
methylmalonic	B-DIS
acidemia	I-DIS
MMA	I-DIS
patients	O
after	O
liver	O
and/or	O
kidney	O
transplantation	O
LKT	O
are	O
often	O
described	O
as	O
metabolic	B-DIS
stroke	I-DIS
-	O
like	O
-	O
events	O
.	O

Since	O
calcineurin	O
inhibitors	O
CNIs	O
are	O
a	O
well	O
-	O
known	O
cause	O
of	O
new	O
neurological	O
symptoms	O
in	O
non	B-LOC
-	I-LOC
MMA	I-LOC
transplanted	O
patients	B-EPI
we	O
investigated	O
the	B-DIS
incidence	O
of	O
CNI	O
-	B-DIS
induced	O
neurotoxicity	B-DIS
including	O
posterior	O
reversible	O
encephalopathy	O
syndrome	O
PRES	O
in	O
post	O
-	O
transplanted	O
MMA	O
patients	O
.	O

Methods	O
We	O
report	O
the	O
two	O
MMA	O
patients	O
treated	O
with	O
LKT	O
in	O
our	O
center	O
.	O

Additionally	O
we	O
performed	O
a	O
systematic	O
review	O
of	O
case	O
reports	O
/	O
series	O
of	O
post	O
-	O
transplanted	O
MMA	O
patients	O
and	O
determined	O
if	O
CNI	O
-	O
induced	O
neurotoxicity	O
/	O
PRES	O
was	O
a	O
likely	O
cause	O
of	O
new	O
neurological	O
symptoms	O
.	O

Definite	O
CNI	O
-	B-DIS
induced	O
neurotoxicity	O
was	O
defined	O
as	O
new	O
neurological	O
symptoms	O
during	O
CNI	O
treatment	O
with	O
symptom	O
improvement	O
after	O
CNI	O
dose	O
reduction	O
/	O
discontinuation	O
.	O

PRES	B-DIS
was	O
defined	O
as	O
CNI	O
-	B-DIS
induced	O
neurotoxicity	O
with	O
signs	B-DIS
of	I-DIS
vasogenic	O
edema	O
on	O
brain	O
magnetic	O
resonance	O
imaging	O
MRI	O
-scan	O
post	O
-	O
transplantation	O
.	O

Results	O
Our	O
two	O
MMA	O
patients	O
both	O
developed	O
CNI	O
-	B-DIS
induced	O
neurotoxicity	O
one	B-DIS
had	O
PRES	O
.	O

In	O
literature	O
230	O
transplanted	O
MMA	O
patients	O
were	O
identified	O
.	O

Neurological	O
follow	O
-	O
up	O
was	O
reported	O
in	O
54	O
of	O
them	O
of	O
which	O
24	O
were	O
excluded	O
from	O
analysis	O
since	O
no	O
anti	O
-	O
rejection	O
medication	O
was	O
reported	O
.	O

Thirty	O
patients	O
all	O
using	O
CNI	O
were	O
included	O
.	O

Sixteen	O
patients	O
53	B-STAT
%	I-STAT
had	O
no	O
new	O
neurological	O
symptoms	O
post	O
-	O
transplantation	O
and	O
five	O
patients	O
17	B-STAT
%	I-STAT
had	O
definite	B-DIS
CNI	O
neurotoxicity	O
of	O
whom	O
two	B-DIS
had	O
PRES	O
.	O

Including	O
our	O
cases	O
this	O
results	O
in	O
a	O
pooled	O
incidence	B-EPI
of	O
22	B-STAT
%	I-STAT
7/32	B-STAT
definite	O
CNI	O
neurotoxicity	B-DIS
and	O
9	B-STAT
%	I-STAT
PRES	B-DIS
3/32	B-STAT
in	O
post	O
-	O
transplanted	O
MMA	O
patients	O
on	O
CNI	O
.	O

Conclusion	O
In	O
MMA	O
post	O
-	O
transplanted	O
patients	O
with	O
new	O
neurological	O
symptoms	O
CNI	O
-	O
induced	O
neurotoxicity	O
/	O
PRES	O
should	O
be	O
considered	O
.	O

Early	O
recognition	O
of	O
CNI	O
-	B-DIS
induced	O
neurotoxicity	O
is	O
essential	O
to	O
initiate	O
dose	O
reduction	O
/	O
discontinuation	O
of	O
CNI	B-DIS
to	I-DIS
minimize	O
persistent	O
neurologic	O
damage	O
and	O
improve	O
outcome	O
.	O

Concise	O
one	O
sentence	O
take	O
home	O
message	O
In	O
all	O
post	O
-	O
transplanted	O
MMA	O
patients	O
with	O
new	O
neurological	O
symptoms	O
CNI	O
-	O
induced	O
neurotoxicity	O
/	O
PRES	O
should	O
be	O
considered	O
and	O
directly	O
reducing	O
the	O
dose	O
/	O
discontinuation	O
of	O
CNI	O
is	O
essential	O
.	O

Pharmacological	O
technological	O
and	O
educational	O
approaches	O
have	O
advanced	O
the	O
treatment	O
of	O
Type	O
1	O
diabetes	B-DIS
in	O
the	O
last	O
four	O
decades	O
and	O
yet	O
diabetic	B-DIS
ketoacidosis	I-DIS
DKA	I-DIS
continues	O
to	O
be	O
a	O
leading	O
cause	O
of	O
admission	O
in	O
Type	O
1	O
diabetes	B-DIS
.	O

This	O
article	O
begins	O
by	O
reviewing	O
the	O
contemporary	O
epidemiological	O
evidence	O
in	O
DKA	B-DIS
.	O

It	O
highlights	O
a	O
rise	O
in	O
DKA	B-DIS
episodes	O
in	O
the	O
last	O
two	O
decades	O
with	O
DKA	B-DIS
continuing	O
to	O
be	O
the	O
leading	O
cause	O
of	O
death	B-DIS
in	O
young	O
people	O
with	O
Type	O
1	O
diabetes	B-DIS
and	O
that	O
DKA	B-DIS
episodes	O
are	O
a	O
marker	O
for	O
subsequent	O
all	O
-	O
cause	O
mortality	O
.	O

It	O
also	O
summarizes	O
the	O
limited	O
evidence	O
base	O
for	O
DKA	B-DIS
prevention	O
and	O
associations	O
with	O
psychopathology	O
.	O

To	O
emphasize	O
the	O
importance	O
of	O
this	O
group	O
with	O
high	O
-	O
risk	O
Type	B-DIS
1	O
diabetes	O
and	O
the	O
degree	O
to	O
which	O
they	O
have	O
been	O
overlooked	O
in	O
the	O
past	O
two	O
decades	O
the	O
article	O
summarizes	O
the	O
research	O
literature	O
of	B-DIS
recurrent	O
DKA	O
during	O
1976	O
-	O
1991	O
when	O
it	O
was	O
extensively	O
investigated	O
as	O
part	O
of	O
the	O
phenomenon	O
of	O
'	B-DIS
brittle	O
diabetes	O
'	O
.	O

This	O
period	O
saw	O
numerous	O
basic	O
science	O
studies	O
investigating	O
the	O
pathophysiology	O
of	O
recurrent	O
DKA	B-DIS
.	O

Subsequently	O
research	O
centres	O
published	O
their	O
experiences	O
of	O
brittle	O
diabetes	B-DIS
research	O
participants	O
manipulating	O
their	O
treatment	O
under	O
research	O
conditions	O
.	O

Unfortunately	O
the	O
driver	O
for	O
this	O
behaviour	O
and	O
whether	O
it	O
was	O
indicative	O
of	O
other	O
people	O
with	O
ketoacidosis	B-DIS
was	O
not	O
pursued	O
.	O

In	O
summary	O
we	O
suggest	O
there	O
has	O
been	O
a	O
stasis	B-DIS
in	O
the	O
approach	O
to	O
recurrent	O
DKA	B-DIS
prevention	O
which	O
is	O
likely	O
linked	O
to	O
historical	O
cases	O
of	O
mass	O
sabotage	O
of	O
brittle	O
diabetes	B-DIS
research	O
.	O

Further	O
investigation	O
is	O
required	O
to	O
clarify	O
possible	O
psychological	O
characteristics	O
that	O
increase	O
the	O
risk	O
of	O
DKA	B-DIS
and	O
thereby	O
targets	O
for	O
DKA	B-DIS
prevention	O
.	O

Purpose	O
of	O
review	O
The	O
global	O
prevalence	B-EPI
of	O
obesity	B-DIS
has	O
increased	O
rapidly	O
over	O
the	O
last	O
decades	O
posing	O
a	O
severe	O
threat	O
to	O
human	O
health	O
.	O

Currently	O
bariatric	O
surgery	O
is	O
the	O
most	O
effective	O
therapy	O
for	O
patients	O
with	O
morbid	B-DIS
obesity	I-DIS
.	O

It	O
is	O
unknown	O
whether	O
this	O
treatment	O
is	O
also	O
suitable	O
for	O
patients	O
with	O
obesity	B-DIS
due	O
to	O
a	O
confirmed	O
genetic	O
defect	O
genetic	O
obesity	B-DIS
disorders	I-DIS
.	O

Therefore	O
this	O
review	O
aims	O
to	O
elucidate	O
the	O
role	O
of	O
bariatric	O
surgery	O
in	O
the	O
treatment	O
of	O
genetic	O
obesity	B-DIS
.	O

Recent	O
findings	O
In	O
monogenic	B-DIS
non	I-DIS
-	I-DIS
syndromic	O
obesity	O
an	O
underlying	O
genetic	O
defect	O
seems	O
to	O
be	O
the	O
most	O
important	O
factor	O
determining	O
the	O
efficacy	O
of	O
bariatric	O
surgery	O
.	O

In	O
syndromic	B-DIS
obesity	I-DIS
bariatric	O
surgery	O
result	O
data	O
are	O
scarce	O
and	O
even	O
though	O
some	O
promising	O
follow	O
-	O
up	O
results	O
have	O
been	O
reported	O
caution	O
is	O
required	O
as	O
patients	O
with	O
more	O
severe	O
behavioral	O
and	O
developmental	O
disorders	O
might	O
have	O
poorer	O
outcomes	O
.	O

There	O
is	O
limited	O
evidence	O
in	O
support	O
of	O
bariatric	O
surgery	O
as	O
a	O
treatment	O
option	O
for	O
genetic	O
obesity	B-DIS
disorders	I-DIS
;	O
hence	O
no	O
strong	O
statements	O
can	O
be	O
made	O
regarding	O
the	O
efficacy	O
and	O
safety	O
of	O
these	O
procedures	O
for	O
these	O
patients	O
.	O

However	O
considering	O
that	O
patients	O
with	O
genetic	O
obesity	B-DIS
often	O
present	O
with	O
life	O
-	O
threatening	O
obesity	O
-	O
related	O
comorbidities	O
we	O
believe	O
that	O
bariatric	O
surgery	O
could	O
be	O
considered	O
a	O
last	O
-	O
resort	O
treatment	O
option	O
in	O
selected	O
patients	O
.	O

Background	O
Lichen	B-DIS
scrofulosorum	I-DIS
LS	O
represents	O
immunologic	O
reaction	O
to	O
the	O
Mycobacterium	O
tuberculosis	O
antigen	O
and	O
presents	O
with	O
subtle	O
asymptomatic	O
grouped	O
follicular	O
papules	O
over	O
the	O
trunk	O
and	O
shows	O
good	O
therapeutic	O
response	O
to	O
antitubercular	O
drugs	O
.	O

Objective	O
To	O
study	O
the	O
clinical	O
and	O
epidemiological	O
characteristics	O
of	O
patients	O
diagnosed	O
with	O
LS	O
.	O

Materials	O
and	O
methods	O
A	O
single	O
-	O
center	O
retrospective	O
review	O
of	O
patients	O
diagnosed	O
with	O
LS	O
from	O
1997	O
to	O
2018	O
was	O
conducted	O
.	O

The	O
data	O
pertained	O
to	O
clinico	O
-	O
epidemiological	O
profile	O
BCG	O
vaccination	O
Mantoux	O
positivity	O
laboratory	O
investigations	O
coexistent	O
focus	B-DIS
of	O
tuberculosis	O
and	O
response	O
to	O
antitubercular	O
treatment	O
ATT	O
.	O

Results	O
LS	O
cases	O
constituted	O
15.2	B-STAT
%	I-STAT
221/1458	B-STAT
of	O
all	O
the	O
patients	O
diagnosed	O
with	O
cutaneous	B-DIS
tuberculosis	I-DIS
CTB	O
.	O

Of	O
these	O
15670.5	B-STAT
%	I-STAT
were	O
pediatric	O
patients	O
.	O

All	O
patients	O
presented	O
with	O
multiple	O
follicular	O
and	O
perifollicular	O
grouped	O
papules	O
.	O

The	O
trunk	O
was	O
the	O
most	O
common	O
site	O
involved	O
98.6	B-STAT
%	I-STAT
followed	O
by	O
lower	O
limb	O
25.33	B-STAT
%	I-STAT
upper	O
limb	O
15.83	B-STAT
%	I-STAT
face	O
5	B-STAT
%	I-STAT
and	O
external	O
genitalia	O
3.6	B-STAT
%	I-STAT
.	O

Evidence	O
of	O
BCG	O
vaccination	O
and	O
Mantoux	O
test	O
positivity	O
was	O
observed	O
in	O
52.03	O
and	O
83.2	B-STAT
%	I-STAT
respectively	O
.	O

Coexistent	O
TB	O
focus	O
was	O
detected	O
in	O
13460.6	B-STAT
%	I-STAT
patients	O
in	O
lymph	O
nodes	O
lungs	O
abdomen	O
and	O
unusual	O
sites	O
such	O
as	O
intracranial	B-DIS
endometrium	I-DIS
and	O
eye	O
.	O

Twenty	O
-	O
eight	O
patients	O
12.66	B-STAT
%	I-STAT
had	O
coexistent	O
other	O
clinical	O
forms	O
of	O
CTB	O
.	O

Clinical	O
diagnosis	O
of	O
LS	O
was	O
confirmed	O
on	O
histology	O
that	O
revealed	O
chiefly	O
periappendageal	O
epithelioid	B-DIS
cell	I-DIS
granuloma	I-DIS
.	O

Response	O
to	O
ATT	O
was	O
good	O
with	O
complete	O
resolution	O
of	O
lesion	O
in	O
8	O
-	O
12	O
weeks	O
.	O

Conclusion	O
LS	O
appears	O
to	O
be	O
an	O
underdiagnosed	O
entity	O
.	O

Subtle	O
and	O
asymptomatic	O
lesions	O
of	O
LS	O
are	O
often	O
missed	O
thereby	O
necessitating	O
a	O
high	O
index	O
of	O
suspicion	O
and	O
appropriate	O
evaluation	O
of	O
the	O
underlying	O
TB	O
focus	O
.	O

Thiamine	O
responsive	O
megaloblastic	B-DIS
anemia	I-DIS
syndrome	I-DIS
an	O
autosomal	B-DIS
recessive	I-DIS
inherited	I-DIS
disorder	I-DIS
characterized	O
by	O
a	O
triad	O
of	O
anemia	B-DIS
diabetes	B-DIS
mellitus	I-DIS
and	O
sensorineural	B-DIS
deafness	I-DIS
is	O
caused	O
by	O
a	O
deficiency	O
of	O
a	O
thiamine	O
transporter	O
protein	O
.	O

The	O
disorder	B-DIS
is	O
rare	O
and	O
has	O
not	O
been	O
reported	O
from	O
our	O
community	O
which	O
has	O
high	O
background	O
of	O
consanguinity	B-DIS
.	O

We	O
report	O
a	O
six	O
years	O
old	O
girl	O
who	O
presented	O
with	O
diabetes	B-DIS
mellitus	I-DIS
which	O
remitted	O
after	O
thiamine	O
replacement	O
.	O

The	O
girl	O
in	O
addition	O
had	O
sensorineural	B-DIS
deafness	I-DIS
reinopathy	O
atrial	B-DIS
septal	I-DIS
defect	I-DIS
and	O
megaloblastic	B-DIS
anemia	I-DIS
which	O
responded	O
to	O
high	O
doses	O
of	O
thymine	O
.	O

This	O
is	O
the	O
first	O
case	O
reported	O
from	O
Kashmir	B-LOC
valley	I-LOC
and	O
third	O
from	O
India	B-LOC
.	O

The	O
presentation	O
and	O
management	O
in	O
such	O
cases	O
is	O
discussed	O
.	O

Purpose	O
Cataract	B-DIS
surgery	O
quantity	O
and	O
quality	O
is	O
an	O
indicator	O
of	O
ophthalmic	O
care	O
.	O

A	O
comprehensive	O
assessment	O
of	O
cataract	B-DIS
surgical	O
services	O
has	O
never	O
been	O
carried	O
out	O
in	O
Palestine	B-LOC
including	O
West	B-LOC
Bank	I-LOC
Gaza	B-LOC
Strip	I-LOC
and	O
East	B-LOC
Jerusalem	I-LOC
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
estimate	O
the	O
cataract	B-DIS
surgical	O
rate	O
in	O
2015	O
to	O
and	O
to	O
explore	O
the	O
modes	O
of	O
payment	O
and	O
referral	O
systems	O
.	O

Methods	O
A	O
cross	O
-	O
sectional	O
study	O
conducted	O
between	O
June	O
and	O
August	O
2016	O
.	O

Medical	O
Directors	O
from	O
Cataract	B-DIS
Surgical	O
Centres	O
in	O
Palestine	B-LOC
were	O
interviewed	O
using	O
a	O
structured	O
questionnaire	O
to	O
extract	O
data	O
on	O
cataract	B-DIS
output	O
and	O
surgical	O
techniques	O
.	O

Additionally	O
data	O
were	O
collected	O
on	O
modes	O
of	O
payment	O
for	O
cataract	B-DIS
services	O
.	O

The	O
cataract	B-DIS
surgical	O
rate	O
was	O
calculated	O
by	O
dividing	O
the	O
total	O
cataract	B-DIS
output	O
in	O
2015	O
by	O
the	O
estimated	O
population	O
of	O
Palestine	B-LOC
in	O
millions	O
.	O

Results	O
In	O
20159908	O
cataract	B-DIS
surgeries	O
were	O
carried	O
out	O
in	O
22	O
centres	O
.	O

The	O
cataract	B-DIS
surgical	O
rate	O
was	O
2117	O
operations	O
per	O
million	O
population	O
.	O

Phacoemulsification	O
was	O
the	O
most	O
common	O
technique	O
73.4	B-STAT
%	I-STAT
however	O
in	O
government	O
centres	O
67	B-STAT
%	I-STAT
were	O
performed	O
by	O
extracapsular	B-DIS
cataract	I-DIS
extraction	O
.	O
In	O
the	B-LOC
Gaza	I-LOC
Strip	I-LOC
56.6	B-STAT
%	I-STAT
of	O
cataract	B-DIS
surgeries	O
were	O
operated	O
at	O
government	O
centres	O
and	O
42.8	B-STAT
%	I-STAT
were	O
operated	O
at	O
NGO	B-LOC
centres	O
while	O
in	O
West	B-LOC
Bank	I-LOC
only	B-STAT
12	I-STAT
%	I-STAT
of	O
cataract	B-DIS
surgeries	O
were	O
operated	O
at	O
government	O
centres	O
with	O
two	O
-	O
thirds	B-DIS
of	O
cataracts	O
diagnosed	O
at	O
governmental	O
centres	O
being	O
referred	O
to	O
private	O
and	O
NGO	B-LOC
centres	O
.	O

Seventy	B-STAT
eight	I-STAT
percent	I-STAT
of	O
cataract	B-DIS
surgeries	O
were	O
funded	O
by	O
insurance	O
of	O
which	O
the	O
government	O
insurance	O
scheme	O
contributed	O
65	B-STAT
%	I-STAT
.	O

Conclusion	O
The	O
cataract	B-DIS
surgical	O
rate	O
in	O
Palestine	B-LOC
falls	O
short	O
of	O
the	O
required	O
WHO	O
target	O
.	O

The	O
majority	O
of	O
cataract	B-DIS
surgeries	O
are	O
funded	O
by	O
insurance	O
.	O

The	O
global	O
pandemic	O
of	O
COVID-19	O
has	O
been	O
lasting	O
for	O
more	O
than	O
one	O
year	O
and	O
there	O
is	O
little	O
known	O
about	O
the	O
long	O
-	O
term	O
health	O
effects	O
of	O
the	O
disease	O
.	O

Long	O
-	O
COVID	O
is	O
a	O
new	O
term	O
that	O
is	O
used	O
to	O
describe	O
the	O
enduring	O
symptoms	O
of	O
COVID-19	O
survivors	O
.	O

Huang	O
et	O
al	O
.	O

reported	O
that	O
fatigue	B-DIS
muscle	B-DIS
weakness	I-DIS
sleep	I-DIS
disturbances	I-DIS
anxiety	I-DIS
and	O
depression	B-DIS
were	O
the	O
most	O
common	O
complaints	O
in	O
COVID-19	O
survivors	O
after	O
6	O
months	O
of	O
the	O
infection	B-DIS
.	O

A	O
recent	O
meta	O
-	O
analysis	O
showed	O
that	O
80	B-STAT
%	I-STAT
of	O
COVID-19	O
survivors	O
have	O
developed	O
at	O
least	O
one	O
long	O
-	O
term	O
symptom	O
and	O
the	O
most	B-DIS
common	I-DIS
five	I-DIS
were	I-DIS
fatigue	I-DIS
headache	I-DIS
attention	I-DIS
deficit	O
disorder	B-DIS
hair	O
loss	O
and	O
dyspnea	O
.	O

In	O
this	O
paper	O
we	O
discuss	O
the	O
hypothesis	O
that	O
altered	O
tryptophan	O
absorption	O
and	O
metabolism	O
could	O
be	O
the	O
main	O
contributor	O
to	O
the	O
long	O
-	O
term	O
symptoms	O
in	O
COVID-19	O
survivors	O
.	O

Infection	B-DIS
of	O
a	O
maternal	O
urachal	B-DIS
cyst	I-DIS
during	O
pregnancy	O
is	O
rare	O
;	O
Sonography	O
is	O
an	O
important	O
diagnostic	O
tool	O
that	O
can	O
help	O
minimize	O
maternal	O
and	O
fetal	O
complications	O
.	O

We	O
describe	O
the	O
case	O
of	O
a	O
35	O
-	O
year	O
-	O
old	O
multiparous	O
woman	O
presenting	O
in	O
the	O
third	O
trimester	O
with	B-DIS
2	B-DIS
weeks	I-DIS
of	O
fever	O
abdominal	O
pain	O
and	O
urinary	O
symptoms	O
.	O

Imaging	O
showed	O
a	O
5	O
-	O
cm	O
complex	O
anterior	O
midline	O
mass	O
found	O
intraoperatively	O
to	O
be	O
eroding	O
into	O
the	O
uterus	O
.	O

Sonographic	O
imaging	O
aided	O
in	O
the	O
diagnosis	O
and	O
management	O
of	O
the	O
urachal	B-DIS
cyst	I-DIS
and	O
antepartum	O
sonographic	O
measurements	O
of	O
the	O
lower	O
uterine	O
segment	O
helped	O
to	O
counsel	O
regarding	O
a	O
trial	O
of	O
labor	B-DIS
.	O

Following	O
treatment	O
the	O
patient	O
stabilized	O
and	O
had	O
an	O
uncomplicated	O
vaginal	O
delivery	O
.	O

Osteogenesis	B-DIS
imperfecta	I-DIS
OI	I-DIS
is	O
a	O
heritable	O
disorder	O
that	O
mainly	O
affects	O
the	O
skeleton	O
.	O

The	O
inheritance	O
is	O
mostly	O
autosomal	O
dominant	O
and	O
associated	O
to	O
mutations	O
in	O
one	O
of	O
the	O
two	O
genes	O
COL1A1	O
and	O
COL1A2	O
encoding	O
for	O
the	O
type	O
I	O
collagen	O
α	O
chains	O
.	O

According	O
to	O
more	O
than	O
1500	O
described	O
mutation	O
sites	O
and	O
to	O
outcome	O
spanning	O
from	O
very	O
mild	O
cases	O
to	O
perinatal	B-DIS
-	O
lethality	O
OI	O
is	O
characterized	O
by	O
a	O
wide	O
genotype	O
/	O
phenotype	O
heterogeneity	O
.	O

In	O
order	O
to	O
identify	O
common	O
affected	O
molecular	O
-	O
pathways	O
and	O
disease	O
biomarkers	O
in	O
OI	O
probands	O
with	O
different	O
mutations	O
and	O
lethal	O
or	O
surviving	O
phenotypes	O
primary	O
fibroblasts	O
from	O
dominant	O
OI	O
patients	O
carrying	O
COL1A1	O
or	O
COL1A2	O
defects	O
were	O
investigated	O
by	O
applying	O
a	O
Tandem	O
Mass	O
Tag	O
labeling	O
-	O
Liquid	O
Chromatography	O
-	O
Tandem	O
Mass	O
Spectrometry	O
TMT	O
LC	O
-	O
MS	O
/	O
MS	O
proteomics	O
approach	O
and	O
bioinformatic	O
tools	O
for	O
comparative	O
protein	O
-	O
abundance	O
profiling	O
.	O

While	O
no	O
difference	O
in	O
α1	O
or	O
α2	O
abundance	O
was	O
detected	O
among	O
lethal	O
type	O
II	O
and	O
not	O
-	O
lethal	O
type	O
III	O
OI	O
patients	O
17	O
proteins	O
with	O
key	O
effects	O
on	O
matrix	O
structure	O
and	O
organization	O
cell	O
signaling	O
and	O
cell	O
and	O
tissue	O
development	O
and	O
differentiation	O
were	O
significantly	O
different	O
between	O
type	O
II	O
and	O
type	O
III	O
OI	O
patients	O
.	O

Among	O
them	O
some	O
non	O
-	O
collagenous	O
extracellular	O
matrix	O
ECM	O
proteins	O
e.g	O
.	O

decorin	O
and	O
fibrillin-1	O
and	O
proteins	O
modulating	O
cytoskeleton	O
e.g	O
.	O

nestin	O
and	O
palladin	O
directly	O
correlate	O
to	O
the	O
severity	O
of	O
the	O
disease	O
.	O

Their	O
defective	O
presence	O
may	O
define	O
proband	O
-	O
failure	O
in	O
balancing	O
aberrances	O
related	O
to	O
mutant	O
collagen	O
.	O

Purpose	O
Our	O
goal	O
was	O
to	O
assess	O
the	O
prevalence	B-EPI
of	O
ipsilateral	O
distal	O
femoral	B-DIS
osteochondritis	I-DIS
dissecans	O
OCD	B-DIS
-like	O
lesions	O
in	O
children	O
with	O
Blount	B-DIS
disease	I-DIS
including	O
factors	O
associated	O
with	O
this	O
finding	O
.	O

Materials	O
and	O
methods	O
Characteristics	O
of	O
patients	O
with	O
an	O
OCD	B-DIS
-	I-DIS
like	O
lesion	O
on	O
an	O
imaging	O
study	O
[	O
X	O
-	O
ray	O
and/or	O
magnetic	O
resonance	O
imaging	O
MRI	O
]	O
were	O
compared	O
with	O
those	O
without	O
such	O
a	O
finding	O
.	O

Results	O
Over	O
a	O
12	O
-	O
year	B-STAT
period	O
6/6310	B-STAT
%	I-STAT
skeletally	O
immature	B-STAT
patients	O
9/87	O
limbs	B-DIS
with	I-DIS
Blount	O
disease	O
had	B-DIS
an	I-DIS
OCD	O
-	O
like	O
lesion	O
visible	O
on	O
plain	O
radiographs	O
.	O

Based	O
on	O
available	O
MRI	O
7/3719	B-STAT
%	I-STAT
patients	O
or	O
10/5319	B-STAT
%	I-STAT
limbs	O
had	O
an	O
OCD	B-DIS
-	I-DIS
like	I-DIS
distal	I-DIS
femoral	O
lesion	O
.	O

All	O
lesions	O
were	O
noted	O
in	O
the	O
posterior	O
third	O
of	O
the	O
weight	O
-	O
bearing	O
portion	O
of	O
the	O
medial	O
femoral	O
condyle	O
with	O
intact	O
overlying	O
articular	O
cartilage	O
.	O

All	O
patients	O
with	O
OCD	B-DIS
-	O
like	O
lesions	O
were	O
followed	O
for	O
an	O
average	O
of	O
1.9	O
years	O
range	O
1	O
-	O
2.6	O
years	O
and	O
complete	O
radiographic	O
resolution	O
of	O
lesion	O
was	O
noted	B-STAT
in	O
7/9	O
limbs	O
78	B-STAT
%	I-STAT
.	O

There	O
was	O
no	O
association	O
of	O
the	O
presence	O
of	O
OCD	B-DIS
-	I-DIS
like	O
lesion	O
with	O
early-	B-DIS
vs	I-DIS
late	O
-	O
onset	O
disease	O
gender	O
age	O
at	O
imaging	O
laterality	O
magnitude	O
of	O
deformity	O
[	O
mean	O
mechanical	O
axis	O
deviation	O
MAD	O
63.3	O
vs	O
71.9	O
mm	O
]	O
mean	O
mechanical	O
lateral	O
distal	O
femoral	O
angle	O
mLDFA	O
;	O
91.3	O
vs	O
89.7	O
°	O
and	O
mean	O
medial	O
proximal	O
tibial	O
angle	O
MPTA	O
;	O
71.7	O
vs	O
71.8	O
°	O
.	O

Children	O
with	O
an	O
OCD	B-DIS
-	I-DIS
like	O
lesion	O
tended	O
to	O
have	O
a	O
lower	O
mean	O
body	O
mass	O
index	O
BMI	O
;	O
21	O
vs	O
36	O
p	O
=	O
0.003	O
.	O

Conclusion	O
The	O
overall	O
prevalence	B-EPI
of	O
OCD	B-DIS
-	I-DIS
like	O
lesions	O
in	O
the	O
medial	O
femoral	O
condyle	O
in	O
children	B-DIS
with	I-DIS
Blount	I-DIS
disease	O
lesions	O
is	O
10	B-STAT
%	I-STAT
using	O
plain	O
radiographs	O
and	O
at	B-STAT
least	I-STAT
19	I-STAT
%	I-STAT
on	O
MRI	O
.	O

Based	O
on	O
the	O
numbers	O
available	O
we	O
were	O
unable	O
to	O
demonstrate	O
any	O
associations	O
between	O
the	O
presence	O
of	O
such	O
lesions	O
and	O
the	O
patient	O
's	O
age	O
gender	O
or	O
magnitude	O
of	O
varus	B-DIS
deformity	I-DIS
.	O

Further	O
research	O
is	O
needed	O
to	O
fully	O
ascertain	O
the	O
aetiology	O
and	O
natural	O
history	O
of	O
these	O
benign	O
appearing	O
osteochondral	O
imaging	O
findings	O
in	O
children	O
with	O
Blount	B-DIS
disease	I-DIS
.	O

Our	O
current	O
data	O
support	O
that	O
these	O
lesions	O
do	O
resolve	O
with	O
time	O
and	O
that	O
no	O
surgical	O
intervention	O
targeted	O
at	O
the	O
femoral	B-DIS
OCD	I-DIS
-	I-DIS
like	O
lesion	O
is	O
warranted	O
.	O

Level	O
of	O
evidence	O
Diagnostic	O
study	O
Level	O
III	O
.	O

How	O
to	O
cite	O
this	O
article	O
Edobor	O
-	O
Osula	O
F	O
Wenokor	O
C	O
Bloom	O
T	O
et	O
al	O
.	O

Ipsilateral	O
Osteochondritis	B-DIS
Dissecans	O
-	O
like	O
Distal	O
Femoral	O
Lesions	O
in	O
Children	B-DIS
with	I-DIS
Blount	B-EPI
Disease	O
Prevalence	O
and	O
Associated	O
Findings	O
.	O

Strategies	O
Trauma	B-DIS
Limb	O
Reconstr	O
2019	O
;	O
143	O
121	O
-	O
125	O
.	O

Objective	O
In	O
observational	O
data	O
lower	O
levels	O
of	O
lipoprotein	O
a	O
have	O
been	O
associated	O
with	O
greater	O
prevalence	B-EPI
of	O
type	B-DIS
2	I-DIS
diabetes	I-DIS
.	O

Whether	O
pharmacologic	O
lowering	O
of	O
lipoprotein	O
a	O
influences	O
incident	O
type	O
2	O
diabetes	B-DIS
is	O
unknown	O
.	O

We	O
determined	O
the	O
relationship	O
of	O
lipoprotein	O
a	O
concentration	O
with	O
incident	O
type	O
2	O
diabetes	B-DIS
and	O
effects	O
of	O
treatment	O
with	O
alirocumab	O
a	O
PCSK9	O
inhibitor	O
.	O

Research	O
design	O
and	O
methods	O
In	O
the	O
ODYSSEY	O
OUTCOMES	O
trial	O
alirocumab	O
was	O
compared	O
with	O
placebo	O
in	O
patients	O
with	O
acute	B-DIS
coronary	I-DIS
syndrome	I-DIS
.	O

Incident	O
diabetes	B-DIS
was	O
determined	O
from	O
laboratory	O
medication	O
and	O
adverse	O
event	O
data	O
.	O

Results	O
Among	O
13480	O
patients	O
without	O
diabetes	B-DIS
at	O
baseline	O
1324	O
developed	O
type	O
2	O
diabetes	B-DIS
over	O
a	O
median	O
2.7	O
years	O
.	O

Median	O
baseline	O
lipoprotein	O
a	O
was	O
21.9	O
mg	O
/	O
dL	O
.	O

With	O
placebo	O
10	O
mg	O
/	O
dL	O
lower	O
baseline	O
lipoprotein	O
a	O
was	O
associated	O
with	O
hazard	O
ratio	O
1.0495	B-STAT
%	I-STAT
CI	O
1.02	O
-	O
1.06	O
P	O
<	O
0.001	O
for	O
incident	O
type	B-DIS
2	O
diabetes	O
.	O

Alirocumab	O
reduced	O
lipoprotein	O
a	O
by	O
a	O
median	O
23.2	B-STAT
%	I-STAT
with	O
greater	O
absolute	O
reductions	O
from	O
higher	O
baseline	O
levels	O
and	O
no	O
overall	O
effect	O
on	O
incident	O
type	O
2	O
diabetes	B-DIS
hazard	O
ratio	O
0.9595	B-STAT
%	I-STAT
CI	O
0.85	O
-	O
1.05	O
.	O

At	O
low	O
baseline	O
lipoprotein	O
a	O
levels	O
alirocumab	O
tended	O
to	O
reduce	O
incident	O
type	O
2	O
diabetes	B-DIS
while	O
at	O
high	O
baseline	O
lipoprotein	O
a	O
alirocumab	O
tended	O
to	O
increase	O
incident	O
type	O
2	O
diabetes	B-DIS
compared	O
with	O
placebo	O
treatment	O
-	O
baseline	O
lipoprotein	O
a	O
interaction	O
P	O
=	O
0.006	O
.	O

In	O
the	O
alirocumab	O
group	O
a	O
10	O
mg	O
/	O
dL	O
decrease	O
in	O
lipoprotein	O
a	O
from	O
baseline	O
was	O
associated	O
with	O
hazard	O
ratio	O
1.0795	B-STAT
%	I-STAT
CI	O
1.03	O
-	O
1.12	O
;	O
P	O
=	O
0.0002	O
for	O
incident	O
type	B-DIS
2	O
diabetes	O
.	O

Conclusions	O
In	O
patients	O
with	O
acute	B-DIS
coronary	I-DIS
syndrome	I-DIS
baseline	O
lipoprotein	O
a	O
concentration	O
associated	O
inversely	O
with	O
incident	O
type	O
2	O
diabetes	B-DIS
.	O

Alirocumab	O
had	O
neutral	O
overall	O
effect	O
on	O
incident	O
type	O
2	O
diabetes	B-DIS
.	O

However	O
treatment	O
-	B-DIS
related	I-DIS
reductions	I-DIS
in	I-DIS
lipoprotein	O
a	O
more	O
pronounced	O
from	O
high	O
baseline	O
levels	O
were	O
associated	O
with	O
increased	O
risk	O
of	O
incident	O
type	B-DIS
2	O
diabetes	O
.	O

Whether	O
these	O
findings	O
pertain	O
to	O
other	O
therapies	O
that	O
reduce	O
lipoprotein	O
a	O
is	O
undetermined	O
.	O

Smith	B-DIS
-	I-DIS
Magenis	O
syndrome	O
SMS	O
characterized	O
by	O
dysmorphic	B-DIS
features	I-DIS
neurodevelopmental	O
disorder	B-DIS
and	I-DIS
sleep	O
disturbance	O
is	O
due	O
to	O
an	O
interstitial	O
deletion	O
of	O
chromosome	O
17p11.290	B-STAT
%	I-STAT
or	O
to	O
point	O
mutations	O
in	O
the	O
RAI1	O
gene	O
.	O

In	O
this	O
retrospective	O
cohort	O
we	O
studied	O
the	O
clinical	O
cognitive	O
and	O
behavioral	O
profile	O
of	O
47	O
European	O
patients	O
with	O
SMS	O
caused	O
by	O
a	O
17p11.2	O
deletion	O
.	O

We	O
update	O
the	O
clinical	O
and	O
neurobehavioral	O
profile	O
of	O
SMS	O
.	O

Intrauterine	O
growth	O
was	O
normal	O
in	O
most	O
patients	O
.	O

Prenatal	O
anomalies	B-DIS
were	O
reported	O
in	O
15	B-STAT
%	I-STAT
.	O

60	B-STAT
%	I-STAT
of	O
our	O
patients	O
older	O
than	O
10	O
years	O
were	O
overweight	O
.	O

Prevalence	B-EPI
of	O
heart	B-DIS
defects	I-DIS
6.5	B-STAT
%	I-STAT
tetralogy	O
of	O
Fallot	O
6.5	B-STAT
%	I-STAT
pulmonary	B-DIS
stenosis	I-DIS
ophthalmological	O
problems	O
89	B-STAT
%	I-STAT
scoliosis	B-DIS
43	B-STAT
%	I-STAT
or	O
deafness	B-DIS
32	B-STAT
%	I-STAT
were	O
consistent	O
with	O
previous	O
reports	O
.	O

Epilepsy	B-DIS
was	O
uncommon	O
2	B-STAT
%	I-STAT
.	O

We	O
identified	O
a	O
high	O
prevalence	B-EPI
of	O
obstipation	B-DIS
45	B-STAT
%	I-STAT
.	O

All	O
patients	O
had	O
learning	B-DIS
difficulties	I-DIS
and	O
developmental	O
delay	O
but	O
ID	O
range	O
was	O
wide	O
and	O
10	B-STAT
%	I-STAT
of	O
patients	O
had	O
IQ	O
in	O
the	O
normal	O
range	O
.	O

Behavioral	O
problems	O
included	O
temper	O
tantrums	O
and	O
other	O
difficult	O
behaviors	O
84	B-STAT
%	I-STAT
and	O
night	O
-	O
time	O
awakenings	O
86	B-STAT
%	I-STAT
.	O

Optimal	O
care	O
of	O
SMS	O
children	O
is	O
multidisciplinary	O
and	O
requires	O
important	O
parental	O
involvement	O
.	O

In	O
our	O
series	O
half	O
of	O
patients	O
were	O
able	O
to	O
follow	O
adapted	O
schooling	O
but	O
70	B-STAT
%	I-STAT
of	O
parents	O
had	O
to	O
adapt	O
their	O
working	O
time	O
illustrating	O
the	O
medical	O
social	O
educative	O
and	O
familial	O
impact	O
of	O
having	O
a	O
child	O
with	O
SMS	O
.	O

Over	O
the	O
last	O
two	O
decades	O
improvements	O
in	O
perinatology	O
have	O
led	O
to	O
increased	O
survival	O
rates	O
of	O
preterm	O
infants	O
.	O

A	O
large	O
number	O
of	O
studies	O
and	O
meta	O
-	O
analyses	O
have	O
investigated	O
of	O
preterm	O
infants	O
and/or	O
the	O
influence	O
of	O
developmental	O
care	O
.	O

However	O
the	O
combined	O
influence	O
of	O
the	O
most	O
frequent	O
risk	O
factors	O
and	O
developmental	O
care	O
on	O
the	O
long	O
-	O
term	O
somatic	O
motor	O
and	O
cognitive	O
outcome	O
of	O
preterm	O
infants	O
remains	O
unclear	O
.	O

This	O
retrospective	O
single	O
-	O
center	O
cohort	O
study	O
includes	O
256	O
children	O
treated	O
in	O
a	O
tertiary	O
neonatal	O
intensive	O
care	O
unit	O
in	O
Rostock	B-LOC
Germany	I-LOC
between	O
2008	O
and	O
2013	O
.	O

Follow	O
-	O
up	B-DIS
examinations	I-DIS
somatic	I-DIS
psychomotor	I-DIS
and	I-DIS
mental	O
development	O
were	O
performed	O
at	O
corrected	O
24	O
months	O
using	O
Bayley	O
Scales	O
of	O
Infant	O
Development	O
II	O
BSID	O
-	O
II	O
.	O

Developmental	O
care	O
was	O
carried	O
out	O
according	O
to	O
the	O
legal	O
framework	O
and	O
national	O
guidelines	O
physiotherapy	O
and/or	O
early	O
education	O
.	O

Bronchopulmonary	B-DIS
dysplasia	I-DIS
BPD	I-DIS
and	O
an	O
exclusive	O
formula	O
feeding	O
showed	O
a	O
2.8	O
-	O
4.6	O
-	O
fold	O
higher	O
risk	O
95	B-STAT
%	I-STAT
Confidence	O
Interval	O
Mental	O
Developmental	O
Index	O
1.73	O
-	O
7.58	O
;	O
Psychomotor	O
Developmental	O
Index	O
1.44	O
-	O
14.54	O
;	O
body	O
length	O
1.20	O
-	O
6.41	O
for	B-DIS
developmental	I-DIS
deficits	I-DIS
mental	I-DIS
and	I-DIS
psychomotor	I-DIS
developmental	O
index	O
;	O
body	O
length	O
.	O

Developmental	O
care	O
after	O
discharge	O
according	O
to	O
national	O
guidelines	O
did	O
not	O
prevent	O
this	O
.	O

Since	O
this	O
is	O
a	O
retrospective	O
pilot	O
study	O
no	O
recommendations	O
can	O
be	O
made	O
based	O
on	O
this	O
analysis	O
.	O

Therefore	O
future	O
research	O
should	O
evaluate	O
whether	O
standard	O
developmental	O
care	O
should	O
be	O
extended	O
by	O
tailored	O
measures	O
depending	O
on	O
individual	O
risk	O
factors	O
.	O

Of	O
7028	O
disorders	O
with	O
suspected	O
Mendelian	O
inheritance	O
1139	O
are	O
recessive	O
and	O
have	O
an	O
established	O
molecular	O
basis	O
.	O

Although	O
individually	O
uncommon	O
Mendelian	O
diseases	O
collectively	O
account	O
for	O
~20	B-STAT
%	I-STAT
of	O
infant	O
mortality	O
and	O
~18	O
%	O
of	O
pediatric	O
hospitalizations	O
.	O

Molecular	O
diagnostic	O
testing	O
is	O
currently	O
available	O
for	O
only	O
~300	O
recessive	B-DIS
disorders	I-DIS
.	O

Preconception	O
screening	O
together	O
with	O
genetic	O
counseling	O
of	O
carriers	O
has	O
resulted	O
in	O
remarkable	O
declines	B-DIS
in	I-DIS
the	I-DIS
incidence	I-DIS
of	O
several	O
severe	O
recessive	B-DIS
diseases	I-DIS
including	O
Tay	B-DIS
-	I-DIS
Sachs	O
disease	O
and	B-DIS
cystic	O
fibrosis	O
.	O

However	O
extension	O
of	O
preconception	O
screening	O
and	O
molecular	O
diagnostic	O
testing	O
to	O
most	O
recessive	B-DIS
disease	I-DIS
genes	O
has	O
hitherto	O
been	O
impractical	O
.	O

Recently	O
we	O
reported	O
a	O
preconception	O
carrier	O
screen	O
/	O
molecular	O
diagnostic	O
test	O
for	O
448	O
recessive	O
childhood	O
diseases	O
.	O

The	O
current	O
status	O
of	O
this	O
test	O
is	O
reviewed	O
here	O
.	O

Currently	O
this	O
reports	O
analytical	O
validity	O
of	O
the	O
comprehensive	O
carrier	O
test	O
.	O

As	O
the	O
clinical	O
validity	O
and	O
clinical	O
utility	O
in	O
the	O
contexts	O
described	O
is	O
ascertained	O
this	O
article	O
will	O
be	O
updated	O
.	O

Hearing	B-DIS
loss	I-DIS
is	O
highly	O
prevalent	O
and	O
may	O
significantly	O
affect	O
how	O
we	O
age	O
.	O

Although	O
the	O
population	O
is	O
aging	O
relatively	O
few	O
adults	O
receive	O
treatment	O
for	O
hearing	B-DIS
loss	I-DIS
.	O

Internists	O
are	O
a	O
critical	O
partner	O
to	O
audiologists	O
and	O
otolaryngologists	O
in	O
caring	O
for	O
the	O
adult	O
population	O
with	O
hearing	B-DIS
loss	I-DIS
.	O

This	O
review	O
provides	O
a	O
primer	O
on	O
diagnosing	O
and	O
managing	O
hearing	B-DIS
loss	I-DIS
.	O

Herpes	B-DIS
simplex	I-DIS
virus	O
HSV	O
1	O
and	O
HSV-2	B-DIS
infections	I-DIS
are	O
highly	O
prevalent	O
worldwide	O
and	O
are	O
characterized	O
by	O
establishing	O
lifelong	O
infection	B-DIS
with	O
periods	O
of	O
latency	O
interspersed	O
with	O
periodic	O
episodes	O
of	O
reactivation	O
.	O

Acquisition	O
of	O
HSV	O
by	O
an	O
infant	O
during	O
the	O
peripartum	O
or	O
postpartum	O
period	O
results	O
in	O
neonatal	O
HSV	B-DIS
disease	I-DIS
a	O
rare	O
but	O
significant	O
infection	B-DIS
that	O
can	O
be	O
associated	O
with	O
severe	O
morbidity	O
and	O
mortality	O
especially	O
if	O
there	O
is	O
dissemination	O
or	O
central	O
nervous	O
system	O
involvement	O
.	O

Diagnostic	O
and	O
therapeutic	O
advances	O
have	O
led	O
to	O
improvements	O
in	O
mortality	O
and	O
to	O
a	O
lesser	O
extent	O
neurodevelopmental	O
outcomes	O
but	O
room	O
exists	O
for	O
further	O
improvement	O
.	O

Vitamin	O
K	O
-	O
dependent	O
factor	O
X	O
FX	O
plays	O
an	O
important	O
role	O
in	O
thrombin	O
formation	O
and	O
a	O
deficiency	O
in	O
FX	O
can	B-DIS
cause	I-DIS
impaired	O
coagulation	O
the	O
severity	O
of	O
which	O
is	O
usually	O
correlated	O
with	O
the	O
degree	O
of	O
deficiency	O
.	O

Due	O
to	O
the	O
critical	O
role	O
that	O
FX	O
plays	O
in	O
the	O
coagulation	B-DIS
cascade	I-DIS
FX	I-DIS
deficiency	I-DIS
is	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
bleeding	B-DIS
than	O
deficiencies	O
in	O
other	O
coagulation	O
factors	O
.	O

Patients	O
with	O
the	O
hereditary	B-DIS
autosomal	I-DIS
-	O
recessive	O
homozygous	O
form	B-DIS
of	I-DIS
FX	O
deficiency	O
which	O
occurs	O
in	O
approximately	O
11000000	O
individuals	O
worldwide	O
are	O
often	O
diagnosed	O
when	O
they	O
present	O
with	O
spontaneous	B-DIS
life	O
-	O
threatening	B-DIS
haemorrhage	I-DIS
most	O
often	O
intracranial	O
haemorrhage	O
during	O
the	O
first	O
month	O
of	O
life	O
.	O

In	O
addition	O
to	O
central	O
nervous	O
system	O
bleeds	O
other	O
severe	O
bleeding	B-DIS
types	O
experienced	O
by	O
such	O
patients	O
may	O
include	O
umbilical	B-DIS
cord	I-DIS
bleeding	I-DIS
gastrointestinal	I-DIS
or	O
pulmonary	B-DIS
haemorrhage	I-DIS
intramuscular	O
haematomas	B-DIS
and/or	O
haemarthrosis	B-DIS
.	O

Delayed	O
treatment	O
or	O
inadequate	O
replacement	O
of	O
FX	O
may	O
result	O
in	O
developmental	O
delays	O
musculoskeletal	B-DIS
disabilities	I-DIS
or	O
death	B-DIS
.	O

The	O
high	O
risk	O
of	O
recurrent	O
severe	O
bleeding	B-DIS
necessitates	O
prophylactic	O
replacement	O
therapy	O
for	O
many	O
individuals	O
with	O
severe	O
FX	B-DIS
deficiency	I-DIS
.	O

Available	O
products	O
for	O
replacement	O
therapy	O
include	O
plasma	O
-	O
derived	O
FX	O
concentrate	O
and	O
prothrombin	O
complex	O
concentrates	O
.	O

Fresh	O
-	O
frozen	O
plasma	O
may	O
be	O
used	O
when	O
concentrates	O
are	O
not	O
available	O
but	O
is	O
a	O
less	O
efficient	O
means	O
of	O
FX	O
replacement	O
.	O

This	O
article	O
reviews	O
the	O
literature	O
on	O
severe	O
bleeding	B-DIS
in	O
individuals	O
with	O
hereditary	B-DIS
FX	I-DIS
deficiency	I-DIS
and	O
discusses	O
current	O
treatment	O
options	O
.	O

The	O
Quebec	O
Neonatal	O
Urine	O
Screening	O
Program	O
was	O
initiated	O
in	O
1971	O
with	O
overall	O
screening	O
inception	O
of	O
newborns	O
in	O
1973	O
.	O

Forty	O
-	O
seven	O
years	O
later	O
over	O
3.5	O
million	O
babies	O
have	O
been	O
screened	O
for	O
up	O
to	B-DIS
25	I-DIS
inborn	O
errors	O
of	O
metabolism	O
divided	O
into	O
two	O
groups	O
1	O
urea	O
cycle	O
disorders	B-DIS
and	I-DIS
organic	O
acidurias	O
;	O
and	O
2	O
disorders	O
of	O
amino	O
acid	O
metabolism	O
and	O
transport	O
.	O

The	O
main	O
goal	O
of	O
this	O
preventive	O
genetic	O
medicine	O
program	O
is	O
the	O
detection	O
of	O
treatable	O
diseases	O
before	O
the	O
onset	O
of	O
clinical	O
symptoms	O
.	O

Urine	O
specimens	O
from	O
21	O
-	O
day	O
-	O
old	O
babies	O
are	O
collected	O
and	O
dried	O
on	O
filter	O
paper	O
by	O
parents	O
at	O
home	O
.	O

The	O
participation	O
is	O
voluntary	O
with	O
a	O
high	O
compliance	O
rate	O
over	O
the	O
years	O
~90	O
%	O
.	O

Specimens	O
are	O
analyzed	O
by	O
thin	O
layer	O
chromatography	O
TLC	O
.	O

The	O
main	O
objective	O
of	O
this	O
evaluative	O
research	O
project	O
was	O
to	O
assess	O
the	O
feasibility	O
of	O
a	O
technological	O
upgrade	O
towards	O
mass	O
spectrometry	O
.	O

A	O
2.85	O
-	O
min	O
flow	O
injection	O
method	O
was	O
devised	O
normal	O
values	O
established	O
and	O
abnormal	O
profiles	O
confirmed	O
using	O
second	O
-	O
tier	O
tests	O
.	O

The	O
validated	O
assays	O
are	O
sensitive	O
specific	O
and	O
suitable	O
for	O
populational	O
screening	O
as	O
well	O
as	O
for	O
high	O
-	O
risk	O
screening	O
laboratories	O
.	O

Triple	O
H	O
syndrome	O
which	O
would	O
not	O
be	O
detected	O
in	O
newborns	O
by	O
blood	O
screening	O
at	O
two	O
days	O
of	O
age	O
was	O
found	O
to	O
be	O
positive	O
in	O
the	O
urine	O
of	O
an	O
affected	O
patient	O
.	O

Background	O
and	O
purpose	O
Vascular	O
Ehlers	B-DIS
-	I-DIS
Danlos	O
syndrome	O
is	O
a	O
rare	B-DIS
inherited	I-DIS
connective	I-DIS
tissue	O
disorder	O
because	O
of	O
pathogenic	O
variants	O
in	O
the	O
COL3A1	O
gene	O
.	O

Arterial	O
complications	O
can	O
affect	O
all	O
anatomic	O
areas	O
and	O
about	B-STAT
25	I-STAT
%	I-STAT
involve	O
supra	O
-	O
aortic	O
trunks	O
SATs	O
but	O
no	O
systematic	O
assessment	O
of	O
cervical	O
artery	O
lesions	O
has	O
been	O
made	O
.	O

The	O
primary	O
objective	O
was	O
to	O
determine	O
an	O
accurate	O
prevalence	B-EPI
of	O
spontaneous	O
SAT	B-DIS
lesions	I-DIS
in	O
a	O
large	O
series	O
of	O
patients	O
with	O
vascular	B-DIS
Ehlers	I-DIS
-	I-DIS
Danlos	O
syndrome	O
at	O
diagnosis	O
and	O
during	O
follow	O
-	O
up	O
.	O

Secondary	O
objectives	O
were	O
to	O
study	O
their	O
neurological	O
consequences	O
transient	O
ischemic	O
attack	O
or	O
stroke	B-DIS
and	O
the	O
possible	O
relationships	O
with	O
sex	O
genotype	O
ascertainment	O
status	O
.	O

Methods	O
A	O
retrospective	O
review	O
of	O
a	O
monocentric	O
cohort	O
of	O
patients	O
with	O
molecularly	O
proven	O
vascular	B-DIS
Ehlers	I-DIS
-	I-DIS
Danlos	O
syndrome	O
followed	O
in	O
a	O
tertiary	O
referral	O
center	O
from	O
2000	O
to	O
2017	O
.	O

Results	O
One	O
hundred	O
forty	O
-	O
four	O
patients	O
were	O
analyzed	O
56.9	B-STAT
%	I-STAT
n=82	B-DIS
had	I-DIS
SAT	I-DIS
lesions	O
64.6	B-STAT
%	I-STAT
females	O
74.4	B-STAT
%	I-STAT
index	O
-	O
case	O
patients	O
.	O

Most	O
lesions	O
were	O
identified	O
in	O
early	O
arterial	O
assessment	O
48	B-STAT
%	I-STAT
at	O
first	O
work	O
-	O
up	O
mean	O
age	O
of	O
35.7±13.0	O
years	O
.	O

Cumulative	O
incidence	B-EPI
of	O
a	O
first	O
identification	O
of	O
a	O
SAT	B-DIS
lesion	I-DIS
was	O
41.7	B-STAT
%	I-STAT
at	O
40	O
years	O
old	O
.	O

On	O
the	O
complete	O
period	O
of	O
survey	O
183	O
SAT	O
lesions	O
with	O
132	O
dissections	O
and	O
33	O
aneurysms	B-DIS
were	O
identified	O
mainly	O
in	O
internal	O
carotid	O
arteries	O
56.3	B-STAT
%	I-STAT
and	O
vertebral	O
arteries	O
28.9	B-STAT
%	I-STAT
more	O
rarely	O
in	O
patients	O
with	O
COL3A1	O
null	O
mutations	O
P	O
=	O
0.008	O
.	O

Transient	O
ischemic	O
attack	O
or	O
stroke	B-DIS
were	O
reported	O
in	O
n=16	O
19.5	B-STAT
%	I-STAT
of	O
the	O
82	O
patients	O
with	O
SAT	B-DIS
lesions	I-DIS
without	O
relation	O
with	O
age	O
sex	O
treatment	O
or	O
hypertension	B-DIS
.	O

Conclusions	O
Cervical	O
artery	O
lesions	O
are	O
frequent	O
and	O
mostly	O
asymptomatic	O
in	O
patients	O
with	O
vascular	B-DIS
Ehlers	I-DIS
-	I-DIS
Danlos	O
syndrome	O
.	O

Local	O
dissections	O
and	O
aneurysms	B-DIS
are	O
the	O
most	O
frequent	O
type	O
of	O
lesions	O
but	O
transient	O
ischemic	O
attack	O
or	O
stroke	B-DIS
seem	O
rare	O
.	O

The	O
world	O
of	O
dermatology	O
is	O
pieced	O
together	O
by	O
clinical	O
conditions	O
unique	O
in	O
their	O
colors	O
morphology	O
and	O
configuration	O
.	O

Dermatological	O
signs	O
and	O
terms	O
are	O
influenced	O
by	O
etymology	O
language	O
and	O
history	O
.	O

Eponyms	O
also	O
make	O
dermatology	O
a	O
fascinating	O
but	O
linguistically	O
challenging	O
subject	O
.	O

This	O
article	O
reviews	O
dermatological	O
conditions	O
described	O
in	O
relation	O
to	O
fashion	O
and	O
what	O
we	O
wear	O
in	O
everyday	O
life	O
from	O
top	O
to	O
toe	O
demonstrating	O
that	O
dermatology	O
can	O
be	O
inspired	O
even	O
in	O
the	O
most	O
common	O
things	O
.	O

Background	O
and	O
objective	O
To	O
understand	O
the	O
microvascular	B-DIS
abnormalities	I-DIS
in	O
cystoid	O
macular	O
edema	B-DIS
CME	O
in	O
gyrate	B-DIS
atrophy	I-DIS
.	O

Patients	O
and	O
methods	O
Spectral	O
-	O
domain	O
optical	O
coherence	O
tomography	O
SD	O
-	O
OCT	O
and	O
OCT	O
angiography	O
OCTA	O
were	O
used	O
in	O
four	O
consecutive	O
female	O
patients	O
eight	O
eyes	O
with	O
clinically	O
and	B-DIS
biochemistry	I-DIS
-	O
confirmed	O
cases	O
of	O
gyrate	O
atrophy	O
and	O
associated	O
CME	O
.	O

Foveal	O
avascular	O
zone	O
FAZ	O
area	O
and	O
macular	O
vessel	O
density	O
percentage	O
were	O
calculated	O
and	O
compared	O
with	O
normal	O
subjects	O
.	O

Results	O
The	O
average	O
age	O
was	O
20	O
years	O
range	O
13	O
years	O
to	O
32	O
years	O
.	O

The	O
mean	O
refractive	O
error	O
was	O
-6.5	O
diopters	O
D	O
range	O
-1.0	O
D	O
to	O
-11.0	O
D	O
.	O

The	O
average	O
central	O
macular	O
thickness	O
was	O
509	O
μm	O
range	O
291	O
μm	O
to	O
750	O
μm	O
.	O

OCTA	O
showed	O
an	O
enlarged	O
FAZ	O
in	O
the	O
deep	O
capillary	O
plexus	O
DCP	O
with	O
presence	O
of	O
hyporeflective	B-DIS
cysts	I-DIS
in	O
both	O
the	O
superficial	O
and	O
deep	O
capillary	O
layers	O
corresponding	O
to	O
CME	O
.	O

Compared	O
to	O
the	O
normal	O
subjects	O
the	O
mean	O
FAZ	O
area	O
was	O
enlarged	O
and	O
macular	O
vessel	O
density	O
was	O
reduced	O
in	O
both	O
the	O
superficial	O
capillary	O
plexus	O
and	O
DCP	O
;	O
this	O
was	O
statistically	O
significant	O
P	O
<	O
.05	O
.	O

En	O
face	O
OCT	O
of	O
the	O
DCPs	O
showed	O
classical	O
hyporeflective	O
honeycomb	O
pattern	O
delineating	O
the	O
structural	O
pattern	O
of	O
CME	O
in	O
the	O
inner	O
plexiform	O
and	O
outer	O
plexiform	O
layer	O
.	O

Conclusion	O
OCTA	O
helps	O
understand	O
the	O
basic	O
pathophysiologic	O
mechanisms	O
in	O
gyrate	B-DIS
atrophy	I-DIS
of	O
choroid	O
as	O
well	O
as	O
etiology	O
for	O
CME	O
and	O
macular	O
schisis	O
.	O

[	O
Ophthalmic	O
Surg	O
Lasers	O
Imaging	O
Retina	O
.	O

2019	O
;	O
50423	O
-	O
427	O
.	O
]	O

.	O

Primary	B-DIS
hyperaldosteronism	I-DIS
PA	O
is	O
a	O
common	O
disease	O
with	O
a	O
prevalence	B-EPI
of	O
5	B-STAT
-	I-STAT
10	I-STAT
%	I-STAT
in	O
unselected	O
patients	O
with	O
hypertension	B-DIS
.	O

Medullary	B-DIS
nephrocalcinosis	I-DIS
is	O
a	O
radiological	O
diagnosis	O
and	O
refers	O
to	O
diffuse	O
calcification	B-DIS
in	I-DIS
the	I-DIS
renal	I-DIS
parenchyma	I-DIS
.	O

The	O
three	O
commonest	O
causes	O
of	O
nephrocalcinosis	B-DIS
are	O
hyperparathyroidism	B-DIS
distal	O
renal	B-DIS
tubular	I-DIS
acidosis	I-DIS
and	O
medullary	O
sponge	O
kidney	O
.	O

PA	O
is	O
not	O
a	O
recognized	O
cause	O
of	O
nephrocalcinosis	B-DIS
.	O

There	O
are	O
a	O
few	O
case	O
reports	O
linking	O
PA	O
with	O
nephrocalcinosis	B-DIS
published	O
till	O
date	O
.	O

In	O
this	O
case	O
series	O
we	O
report	O
three	O
cases	O
where	O
PA	O
was	O
possibly	O
associated	O
with	O
medullary	B-DIS
nephrocalcinosis	I-DIS
.	O

In	O
all	O
three	O
cases	O
the	O
common	O
causes	O
of	O
nephrocalcinosis	B-DIS
were	O
excluded	O
by	O
careful	O
clinical	O
history	O
biochemical	O
evaluation	O
and	O
radiological	O
findings	O
.	O

We	O
conclude	O
and	O
emphasize	O
that	O
a	O
diagnosis	O
of	O
PA	O
as	O
an	O
etiology	O
of	O
medullary	B-DIS
nephrocalcinosis	I-DIS
should	O
be	O
sought	O
after	O
common	O
causes	O
have	O
been	O
excluded	O
at	O
least	O
in	O
those	O
with	O
hypertension	B-DIS
that	O
is	O
difficult	O
to	O
control	O
.	O

Congenital	B-DIS
disorders	I-DIS
of	O
glycosylation	O
CDG	B-DIS
are	O
rare	O
diseases	O
with	O
variable	O
phenotypes	O
and	O
severity	O
.	O

Immunological	O
involvement	O
remains	O
a	O
largely	O
uncharted	O
topic	O
in	O
CDG	B-DIS
mainly	O
due	O
to	O
lack	O
of	O
robust	O
data	O
.	O

To	O
better	O
characterize	O
immune	O
-	O
related	O
manifestations	B-EPI
'	O
prevalence	O
relevance	O
and	O
quality	O
-	O
of	O
-	O
life	O
QoL	O
impact	O
we	B-DIS
developed	O
electronic	O
questionnaires	O
targeting	O
1	O
CDG	O
patients	O
and	O
2	O
the	O
general	O
`	O
`	O
healthy	O
''	O
population	O
.	O

Two	O
-	O
hundred	O
and	B-DIS
nine	O
CDG	O
patients	O
/	O
caregivers	O
and	O
349	O
healthy	O
participants	O
were	O
included	O
in	O
this	O
study	O
.	O

PMM2	O
-	O
CDG	O
was	O
the	O
most	B-DIS
represented	O
CDG	O
n	B-STAT
=	O
122/209	O
.	O

About	O
half	O
of	O
these	O
participants	O
n	O
=	O
65/122	B-STAT
described	O
relevant	O
infections	B-DIS
with	O
a	O
noteworthy	O
prevalence	B-EPI
of	O
those	O
affecting	O
the	O
gastrointestinal	B-DIS
tract	I-DIS
GI	O
63.1	B-STAT
%	I-STAT
n	O
=	O
41/65	B-STAT
.	O

Infection	B-DIS
burden	O
and	O
QoL	O
impact	O
were	O
shown	O
as	O
infections	B-DIS
correlated	O
with	O
more	O
severe	O
clinical	O
phenotypes	O
and	O
with	O
a	O
set	O
of	O
relevant	O
non	B-DIS
-	I-DIS
immune	O
PMM2	O
-	O
CDG	O
signs	O
.	O

Autoimmune	B-DIS
diseases	I-DIS
had	O
only	O
a	O
marginal	O
presence	O
in	O
PMM2	O
-	O
CDG	O
2.5	B-STAT
%	I-STAT
n	B-STAT
=	O
3/122	O
all	O
being	O
GI	O
-	O
related	O
.	O

Allergy	B-DIS
prevalence	B-EPI
was	O
also	O
low	O
in	O
PMM2	O
-	O
CDG	O
33	B-STAT
%	I-STAT
n	B-STAT
=	O
41/122	O
except	O
for	B-DIS
food	O
allergies	O
26.8	B-STAT
%	I-STAT
n	B-STAT
=	O
11/41	O
of	O
PMM2	O
-	O
CDG	O
and	O
10.8	B-STAT
%	I-STAT
n	O
=	O
17/158	O
of	O
controls	O
.	O

High	O
vaccination	O
compliance	O
with	O
greater	O
perceived	O
ineffectiveness	O
28.3	B-STAT
%	I-STAT
n	O
=	O
17/60	B-STAT
and	O
more	O
severe	O
adverse	O
reactions	O
were	O
described	O
in	O
PMM2	B-DIS
-	O
CDG	O
.	O

This	O
people	O
-	O
centric	O
approach	O
not	O
only	O
confirmed	O
literature	O
findings	O
but	O
created	O
new	O
insights	O
into	O
immunological	O
involvement	B-DIS
in	O
CDG	O
namely	O
by	O
highlighting	O
the	O
possible	O
link	O
between	O
the	O
immune	O
and	O
GI	O
systems	O
in	O
PMM2	O
-	O
CDG	O
.	O

Finally	O
our	O
results	O
emphasized	O
the	O
importance	O
of	O
patient	O
/	O
caregiver	O
knowledge	O
and	O
raised	O
several	O
red	O
flags	O
about	O
immunological	O
management	O
.	O

Autoimmune	B-DIS
thyroid	I-DIS
disease	I-DIS
ATD	O
is	O
the	O
most	O
frequent	O
cause	O
of	O
acquired	O
thyroid	B-DIS
dysfunction	I-DIS
most	O
commonly	O
presenting	O
either	O
as	O
Hashimoto	B-DIS
's	I-DIS
thyroiditis	I-DIS
or	O
Graves	B-DIS
'	I-DIS
Disease	I-DIS
.	O

Hashimoto	B-DIS
's	I-DIS
thyroiditis	I-DIS
is	O
characterized	O
by	O
the	O
presence	O
of	O
thyroid	O
-	O
specific	O
autoantibodies	O
more	O
commonly	O
anti	O
-	O
thyroperoxidase	O
antibodies	O
in	O
the	O
serum	O
and	O
the	O
typical	O
inhomogeneous	O
echostructure	O
of	O
the	O
thyroid	O
on	O
a	O
thyroid	O
ultrasound	O
examination	O
.	O

Hashimoto	B-DIS
's	I-DIS
thyroiditis	I-DIS
can	O
for	O
a	O
long	O
time	O
be	O
accompanied	O
by	O
normal	O
thyroid	O
function	O
and	O
hypothyroidism	B-DIS
can	O
only	O
progressively	O
be	O
established	O
.	O

Graves	B-DIS
'	I-DIS
disease	I-DIS
is	O
much	O
less	O
frequent	O
in	O
childhood	O
and	O
adolescence	O
and	O
presents	O
with	O
overt	O
hyperthyroidism	B-DIS
.	O

After	O
the	O
onset	O
of	O
puberty	O
ATD	O
affects	O
females	O
with	O
a	O
higher	O
incidence	B-EPI
than	O
males	O
while	O
during	O
the	O
prepubertal	O
period	O
there	O
is	O
not	O
such	O
a	O
clear	O
preponderance	O
of	O
affected	O
females	O
.	O

ATD	O
can	O
occur	O
either	O
isolated	O
or	O
in	O
the	O
context	O
of	O
other	O
autoimmune	B-DIS
disorders	I-DIS
such	O
as	O
type	O
1	O
Diabetes	B-DIS
mellitus	I-DIS
T1D	I-DIS
celiac	I-DIS
disease	I-DIS
alopecia	I-DIS
areata	I-DIS
vitiligo	I-DIS
etc	O
.	O

Especially	O
at	O
the	O
pediatric	O
age	O
a	O
higher	O
incidence	B-EPI
of	O
ATD	O
is	O
also	O
observed	O
in	O
the	O
context	O
of	O
specific	O
genetic	O
syndromes	O
such	O
as	O
trisomy	O
21	O
Down	B-DIS
syndrome	I-DIS
Klinefelter	I-DIS
syndrome	I-DIS
Turner	I-DIS
syndrome	I-DIS
or	O
22q11.2	B-DIS
deletion	O
syndrome	O
.	O

Nevertheless	O
although	O
thyroid	B-DIS
dysfunction	I-DIS
may	O
also	O
be	O
observed	O
in	O
other	O
genetic	O
syndromes	O
such	O
as	O
Prader	B-DIS
-	O
Willi	B-DIS
or	I-DIS
Williams	I-DIS
syndrome	B-DIS
the	I-DIS
thyroid	O
dysfunction	O
in	O
these	O
syndromes	O
is	O
not	O
the	O
result	B-DIS
of	I-DIS
thyroid	O
autoimmunity	O
.	O

Interestingly	O
there	O
is	O
emerging	O
evidence	O
supporting	O
a	O
possible	O
link	O
between	O
autoimmunity	B-DIS
and	O
RASopathies	B-DIS
.	O

In	O
this	O
review	O
article	O
the	O
incidence	B-EPI
as	O
well	O
as	O
the	O
clinical	O
manifestation	O
and	O
accompanied	O
pathologies	O
of	O
ATD	O
in	O
specific	O
genetic	O
syndromes	O
will	O
be	O
presented	O
and	O
regular	O
follow	O
-	O
up	O
for	O
the	O
early	O
identification	O
of	O
the	O
disorder	O
will	O
be	O
proposed	O
.	O

Autosomal	B-DIS
dominant	I-DIS
cerebellar	I-DIS
ataxia	I-DIS
type	O
I	O
is	O
a	O
heterogeneous	O
group	O
of	O
spinocerebellar	B-DIS
ataxias	I-DIS
with	O
variable	O
neurologic	O
presentations	O
with	O
age	O
of	O
onset	O
varying	O
from	O
infancy	O
to	O
adulthood	O
.	O

Autosomal	B-DIS
dominant	I-DIS
cerebellar	I-DIS
ataxia	I-DIS
type	O
I	O
is	O
composed	O
mainly	O
of	O
3	O
prevalent	O
spinocerebellar	B-DIS
ataxia	I-DIS
types	O
with	O
different	O
pathogenic	O
loci	O
specifically	O
spinocerebellar	B-DIS
ataxia	I-DIS
16p24	I-DIS
-	I-DIS
p23	I-DIS
spinocerebellar	O
ataxia	O
212q24.1	B-DIS
and	I-DIS
spinocerebellar	O
ataxia	O
314q32.1	O
.	O

The	O
shared	O
pathogenic	O
mutational	O
event	O
is	O
the	O
expansion	O
of	O
the	O
CAG	O
repeat	O
that	O
results	O
in	O
polyglutamine	O
extended	O
stretches	O
in	O
the	O
encoded	O
proteins	O
.	O

CAG	O
repeat	O
disorders	O
generally	O
show	O
the	O
phenomenon	O
of	O
anticipation	O
which	O
is	O
more	O
often	O
associated	O
with	O
paternal	O
transmission	O
.	O

In	O
this	O
report	O
we	O
describe	O
a	O
patient	O
with	O
infantile	B-DIS
-	I-DIS
onset	I-DIS
spinocerebellar	O
ataxia	O
type	O
2	O
~320	O
CAG	O
repeat	O
who	O
inherited	O
the	O
disease	O
from	O
his	O
father	O
47	O
CAG	O
repeats	O
.	O

We	O
have	O
summarized	O
the	O
clinical	O
neuroimaging	O
electroencephalographic	O
EEG	O
and	O
molecular	O
data	O
of	O
previous	O
cases	O
and	O
attempt	O
to	O
highlight	O
the	O
most	O
consistent	O
findings	O
.	O

Our	O
intent	O
is	O
to	O
help	O
treating	O
clinicians	O
to	O
suspect	O
this	O
disorder	O
and	O
to	O
offer	O
timely	O
genetic	O
counseling	O
for	O
a	O
currently	O
potentially	O
untreatable	B-DIS
disorder	I-DIS
.	O

Background	O
Tuberculosis	B-DIS
osteomyelitis	I-DIS
is	O
rarely	O
seen	O
in	O
the	O
diaphyseal	O
bones	O
.	O

It	O
may	O
be	O
confused	O
with	O
Brodie	O
's	O
abscess	B-DIS
due	O
to	O
similar	O
clinical	O
radiological	O
and	O
laboratory	O
findings	O
.	O

Late	O
diagnosis	O
of	O
the	O
disease	O
causes	O
bone	B-DIS
destruction	I-DIS
.	O

Tuberculosis	B-DIS
osteomyelitis	I-DIS
of	O
the	O
bone	O
is	O
a	O
rare	O
condition	O
caused	O
by	O
the	O
Mycobacterium	O
tuberculosis	O
.	O

Its	O
incidence	B-EPI
has	O
increased	O
in	O
Western	O
countries	O
in	O
recent	O
years	O
due	O
to	O
HIV	B-DIS
infection	I-DIS
increasing	O
elderly	O
population	O
and	O
emerging	O
resistant	O
strains	O
.	O

The	O
slow	O
progress	O
of	O
tuberculous	B-DIS
osteomyelitis	I-DIS
due	O
to	O
lack	O
of	O
significant	O
elevations	O
in	O
the	O
laboratory	O
values	O
and	O
changes	O
in	O
the	O
radiographic	O
appearance	O
often	O
leads	O
to	O
confusion	B-DIS
with	O
the	O
subtypes	O
of	O
subacute	O
osteomyelitis	B-DIS
defined	O
as	O
Brodie	O
's	O
abscess	B-DIS
.	O

These	O
two	O
low	O
-	O
virulence	O
clinical	O
cases	O
often	O
lead	O
to	O
delays	O
in	O
diagnosis	O
and	B-DIS
progressive	I-DIS
bone	O
destruction	O
.	O

Case	O
presentation	O
We	O
report	O
a	O
65	O
-	O
year	O
-	O
old	O
male	O
patient	O
who	O
presented	O
to	B-DIS
our	I-DIS
clinic	O
with	O
pain	O
swelling	O
and	O
sensitivity	O
in	O
the	O
left	O
leg	O
.	O

Diagnosed	O
with	O
infection	B-DIS
in	O
the	O
tibia	O
the	O
patient	O
had	O
undergone	O
antibiotherapy	O
.	O

However	O
the	O
patient	O
's	O
symptoms	O
were	O
not	O
resolved	O
and	O
we	O
performed	O
bone	O
curettage	O
and	O
cementation	O
.	O

M.	O
tuberculosis	B-DIS
-specific	O
DNA	O
was	O
detected	O
by	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
and	O
the	B-DIS
M.	O
tuberculosis	O
complex	O
was	O
produced	O
from	O
the	O
perioperative	O
samples	O
.	O

Conclusion	O
In	O
conclusion	O
histopathological	O
examination	O
and	O
polymerase	O
chain	O
reaction	O
are	O
essential	O
before	O
surgery	O
of	O
subacute	O
and	O
chronic	B-DIS
osteomyelitis	I-DIS
with	O
atypical	O
clinical	O
laboratory	O
and	O
radiological	O
findings	O
for	O
early	O
diagnosis	O
and	O
accurate	O
treatment	O
.	O

Objectives	O
To	O
determine	O
the	O
incidence	B-EPI
of	O
newborn	O
screening	O
NBS	B-DIS
disorders	I-DIS
and	O
to	O
study	O
the	O
key	O
performance	O
indicators	O
of	O
the	O
program	O
.	O

Methods	O
This	O
retrospective	O
single	O
-	O
center	O
study	O
enrolled	O
all	O
infants	O
who	O
underwent	O
NBS	O
from	O
January	O
2012	O
to	O
December	O
2017	O
at	O
Prince	O
Sultan	O
Military	O
Medical	O
City	O
Riyadh	O
Saudi	B-LOC
Arabia	I-LOC
.	O

We	O
screened	O
17	O
NBS	B-DIS
disorders	I-DIS
.	O

Blood	O
samples	O
were	O
collected	O
24	O
hours	O
after	O
birth	O
.	O

If	O
the	O
initial	O
result	O
was	O
positive	O
a	O
second	O
sample	O
was	O
collected	O
.	O

True	O
positive	O
cases	O
were	O
immediately	O
referred	O
for	O
medical	O
management	O
.	O

Data	O
were	O
extracted	O
from	O
laboratory	O
computerized	O
and	O
non	O
-	O
computerized	O
records	O
using	O
case	O
report	O
forms	O
.	O

Results	O
During	O
the	O
study	O
period	O
56632	O
infants	O
underwent	O
NBS	O
with	O
a	O
coverage	O
rate	O
of	O
100	B-STAT
%	I-STAT
.	O

Thirty	O
-	O
eight	O
cases	O
were	O
confirmed	O
.	O

The	O
incidence	B-EPI
of	O
congenital	B-DIS
hypothyroidism	I-DIS
was	O
13775	O
.	O

The	O
positive	O
predictive	O
value	O
for	O
the	O
detection	O
of	O
congenital	B-DIS
hypothyroidism	I-DIS
was	O
11.8	B-STAT
%	I-STAT
.	O

Propionic	O
aciduria	B-DIS
was	O
the	O
most	O
common	O
metabolic	B-DIS
disorder	I-DIS
with	O
an	O
incidence	B-EPI
of	O
114158	O
.	O

Very	O
long	O
-	O
chain	O
acyl	O
CoA	O
dehydrogenase	O
deficiency	B-DIS
and	I-DIS
glutaric	O
aciduria	O
type	O
1	O
had	B-EPI
an	O
incidence	O
of	O
118877	O
each	O
.	O

Phenylketonuria	B-DIS
biotinidase	I-DIS
deficiency	I-DIS
maple	I-DIS
syrup	I-DIS
urine	I-DIS
disease	I-DIS
and	O
citrullinemia	B-DIS
had	O
an	O
incidence	B-EPI
of	O
128316	O
each	O
.	O

However	O
galactosemia	B-DIS
and	O
3	O
-	O
methyl	O
crotonyl	O
carboxylase	O
deficiency	O
had	O
the	B-EPI
lowest	O
incidence	O
of	O
156632	O
.	O

Conclusion	O
The	O
NBS	B-DIS
coverage	O
rate	O
at	O
our	O
facility	O
was	O
100	B-STAT
%	I-STAT
.	O

Congenital	B-DIS
hypothyroidism	I-DIS
was	O
the	O
most	O
frequently	O
detected	O
disorder	O
with	O
an	O
incidence	B-EPI
that	O
matches	O
worldwide	O
figures	O
.	O

The	O
incidence	B-EPI
of	O
other	O
inherited	O
disorders	O
was	O
consistent	O
with	O
regional	O
figures	O
.	O

Group	O
B	O
Streptococcus	O
a	O
common	O
commensal	O
in	O
the	O
gut	O
of	O
humans	O
and	O
in	O
the	O
lower	O
genital	O
tract	O
in	O
women	O
remains	O
an	O
important	O
cause	O
of	O
neonatal	O
mortality	O
and	O
morbidity	O
.	O

The	O
incidence	B-EPI
of	O
early	O
onset	O
disease	O
has	O
fallen	O
markedly	O
in	O
countries	O
that	O
test	O
women	O
for	O
carriage	O
at	O
35	O
-	O
37	O
weeks	O
of	O
pregnancy	O
and	O
then	O
offer	O
intrapartum	O
prophylaxis	O
with	O
penicillin	O
during	O
labour	O
.	O

Countries	O
that	O
do	O
not	O
test	O
but	O
instead	O
employ	O
a	O
risk	O
factor	O
approach	O
have	O
not	O
seen	O
a	O
similar	O
fall	O
.	O

There	O
are	O
concerns	O
about	O
the	O
effect	O
on	O
the	O
neonatal	O
microbiome	O
of	O
widespread	O
use	O
of	O
antibiotic	O
prophylaxis	O
during	O
labour	O
but	O
so	O
far	O
the	O
effects	O
seem	O
minor	O
and	O
temporary	O
.	O

Vaccination	O
against	O
GBS	B-DIS
would	O
be	O
acceptable	O
to	O
most	O
women	O
and	O
GBS	B-DIS
vaccines	O
are	O
in	O
the	O
early	O
stages	O
of	O
development	O
.	O

Tweetable	O
abstract	O
Group	O
B	O
Strep	O
is	O
a	O
key	O
cause	O
of	O
infection	B-DIS
death	I-DIS
and	O
disability	O
in	O
young	O
babies	O
.	O

Antibiotics	O
given	O
in	O
labour	O
remain	O
the	O
mainstay	O
of	O
prevention	O
until	O
a	O
vaccine	O
is	O
available	O
.	O

Objective	O
To	O
investigate	O
the	O
prevalence	B-EPI
of	O
mutations	O
in	O
domain	O
V	O
of	O
Mycoplasma	O
pneumoniae	B-DIS
MP	I-DIS
23S	I-DIS
ribosomal	I-DIS
RNA	O
rRNA	O
and	O
the	O
clinical	O
characteristics	O
of	O
pediatric	O
MP	B-DIS
pneumonia	B-DIS
MPP	O
in	O
Nanjing	B-LOC
China	B-LOC
.	O

Methods	O
Domain	O
V	O
of	O
23S	O
rRNA	O
was	O
sequenced	O
in	O
MP	B-DIS
strains	O
collected	O
from	O
children	O
diagnosed	O
with	O
MPP	O
in	O
Nanjing	B-LOC
.	O

Clinical	O
and	O
laboratory	O
data	O
were	O
obtained	O
.	O

Results	O
Among	O
the	O
276	O
MP	O
strains	O
25592.39	B-STAT
%	I-STAT
harbored	O
mutations	O
primarily	O
A2063	O
G	O
in	O
domain	O
V	O
of	O
MP	B-DIS
23S	O
rRNA	O
.	O

When	O
children	O
were	O
stratified	O
according	O
to	O
the	O
presence	O
or	O
absence	O
of	O
mutations	O
no	O
significant	O
differences	O
were	O
found	O
in	O
sex	O
age	O
the	O
MP	B-DIS
DNA	O
load	O
at	O
enrollment	O
lymphocyte	O
counts	O
pulmonary	O
complications	O
immunomodulator	O
levels	O
fever	B-DIS
duration	O
the	O
duration	O
of	O
fever	B-DIS
after	O
macrolide	O
therapy	O
and	O
hospital	O
stay	O
.	O

The	O
prevalence	B-EPI
of	O
refractory	O
MPP	O
in	O
the	O
two	O
groups	O
was	O
similar	O
.	O

Children	O
with	O
refractory	O
MPP	O
exhibited	O
higher	O
MP	B-DIS
DNA	O
loads	O
than	O
those	O
with	O
non	O
-	O
refractory	O
MPP	O
.	O

Conclusions	O
Despite	O
the	O
high	O
prevalence	B-EPI
of	O
the	O
A2063	O
G	O
mutation	O
in	O
domain	O
V	O
of	O
MP	B-DIS
23S	O
rRNA	O
mutations	O
were	O
not	O
associated	O
with	O
the	O
clinical	O
characteristics	O
of	O
MPP	O
.	O

The	O
MP	B-DIS
DNA	O
load	O
significantly	O
differed	O
between	O
refractory	O
and	O
non	O
-	O
refractory	O
MPP	O
.	O

End	B-DIS
-	I-DIS
stage	I-DIS
renal	I-DIS
disease	O
ESRD	O
is	O
associated	O
with	O
a	O
number	O
of	O
serious	O
complications	O
including	B-DIS
increased	I-DIS
cardiovascular	I-DIS
disease	O
anaemia	B-DIS
and	I-DIS
metabolic	I-DIS
bone	O
disease	O
.	O

Optic	B-DIS
atrophy	I-DIS
secondary	O
to	O
chronic	O
anaemia	B-DIS
in	O
ESRD	B-DIS
is	O
rare	O
.	O

We	O
report	O
a	O
case	O
of	O
bilateral	O
optic	B-DIS
atrophy	I-DIS
in	O
a	O
young	O
patient	O
with	O
chronic	B-DIS
anaemia	I-DIS
secondary	O
to	O
ESRD	B-DIS
.	O

A	O
23	O
-	O
year	O
-	B-DIS
old	O
lady	O
with	O
ESRD	B-DIS
presented	I-DIS
with	I-DIS
progressive	O
blurring	O
of	O
vision	O
in	O
her	O
left	O
eye	O
for	O
a	O
period	O
of	O
six	O
months	O
.	O

Visual	O
acuity	O
in	O
the	O
left	O
eye	O
was	O
counting	O
finger	O
and	O
the	O
right	O
eye	O
was	O
6/6	B-STAT
.	O

Left	B-DIS
optic	I-DIS
nerve	I-DIS
functions	O
were	O
significantly	O
reduced	O
.	O

Bilateral	O
anterior	O
segments	O
and	O
intraocular	O
pressure	O
were	O
normal	O
.	O

Funduscopy	B-DIS
showed	O
bilateral	O
pale	O
disc	O
with	O
arteriolar	O
attenuation	O
.	O

The	O
infective	B-DIS
autoimmune	I-DIS
and	O
demyelinating	O
screening	O
were	O
negative	O
.	O

Serial	O
full	O
blood	O
count	O
indicated	O
low	O
haemoglobin	O
and	O
haematocrit	O
value	O
.	O

The	O
full	O
blood	O
picture	O
revealed	O
normocytic	B-DIS
normochromic	I-DIS
anaemia	I-DIS
.	O

Neuroimaging	O
was	O
normal	O
.	O

The	O
patient	O
was	O
diagnosed	O
as	O
having	O
bilateral	O
optic	B-DIS
atrophy	I-DIS
secondary	O
to	O
chronic	O
anaemia	B-DIS
due	O
to	O
ESRD	B-DIS
.	O

Chronic	O
anaemia	B-DIS
is	O
a	O
potential	O
cause	O
of	O
optic	B-DIS
atrophy	I-DIS
in	O
a	O
young	O
patient	O
with	O
chronic	B-DIS
disease	I-DIS
.	O

Management	O
of	O
anaemia	B-DIS
in	O
such	O
cases	O
is	O
crucial	O
to	O
prevent	O
irreversible	O
complications	O
including	O
optic	B-DIS
atrophy	I-DIS
and	O
blindness	B-DIS
.	O

Background	O
21	B-DIS
-	I-DIS
Hydroxylase	I-DIS
deficiency	O
21	O
-	O
OHD	O
caused	O
by	O
the	O
CYP21A2	O
gene	O
mutations	O
is	O
the	O
most	B-DIS
common	I-DIS
form	I-DIS
of	O
congenital	O
adrenal	O
hyperplasia	O
.	O

It	O
is	O
an	O
autosomal	O
recessive	B-DIS
disorder	I-DIS
that	O
results	O
in	O
defective	O
synthesis	O
of	O
cortisol	O
and	O
aldosterone	O
.	O

The	O
incidences	B-EPI
of	O
various	O
CYP21A2	O
gene	O
mutations	O
and	O
the	O
genotype	O
-	O
phenotype	O
correlations	O
vary	O
among	O
different	O
populations	O
.	O

Materials	O
and	O
methods	O
The	O
clinical	O
and	O
molecular	O
data	O
of	O
22	O
patients	O
were	O
analyzed	O
in	O
this	O
study	O
.	O

All	O
patients	O
were	O
recruited	O
from	O
the	O
neonatal	O
intensive	O
care	O
unit	O
.	O

Locus	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
and	O
Sanger	O
sequencing	O
were	O
applied	O
to	O
identify	O
gene	O
micro	O
-	O
conversions	O
and	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	B-DIS
was	I-DIS
used	O
to	O
detect	O
large	O
fragment	O
deletions	O
/	O
conversions	O
.	O

Then	O
the	O
genotypes	O
were	O
categorized	O
in	O
to	O
Null	O
A	O
B	O
C	O
and	O
D	O
groups	O
to	O
analyze	O
the	O
relationships	O
between	O
genotypes	O
and	O
phenotypes	O
.	O

Results	O
All	O
22	O
patients	O
were	O
classified	O
into	O
classic	O
salt	B-DIS
wasting	I-DIS
form	O
of	O
21	B-DIS
-	O
OHD	O
.	O

Molecular	O
defects	O
were	O
detected	O
in	O
44	O
alleles	O
100	B-STAT
%	I-STAT
.	O

Micro	O
-	O
conversion	O
mutation	O
IVS2	O
-	O
13A	O
G	O
70.5	B-STAT
%	I-STAT
is	O
most	O
common	O
in	O
our	O
cohort	O
followed	O
by	O
large	O
gene	O
deletions	O
and	O
conversions	O
22.7	B-STAT
%	I-STAT
.	O

The	O
other	O
mutations	O
present	O
were	O
p.	O
R357	O
W	B-STAT
4.5	I-STAT
%	I-STAT
and	O
E6	O
Cluster	O
2.3	O
%	O
.	O

Genotypes	O
of	O
22	O
patients	O
100	B-STAT
%	I-STAT
were	O
consistent	O
with	O
the	O
predictive	O
phenotypes	O
.	O

Conclusion	O
In	O
this	O
study	O
we	O
identified	O
the	O
mutation	O
spectrum	O
of	O
CYP21A2	O
gene	O
in	O
Chinese	O
patients	O
especially	O
the	O
younger	O
age	O
cohort	O
in	O
pediatrics	O
.	O

Micro	O
-	O
conversions	O
were	O
the	O
most	O
popular	O
mutations	O
.	O

Moreover	O
the	O
genotypes	O
and	O
phenotypes	O
were	O
well	O
correlated	O
in	O
this	O
cohort	O
of	O
salt	B-DIS
wasting	I-DIS
21	I-DIS
-	O
OHD	O
recruited	O
from	O
neonatal	O
intensive	O
care	O
unit	O
.	O

E.	O
histolytica	O
is	O
an	O
intestinal	O
parasite	O
that	O
causes	O
asymptomatic	O
infection	B-DIS
mostly	O
;	O
however	O
it	O
may	O
also	O
cause	O
amoebic	B-DIS
dysentery	I-DIS
and	O
liver	B-DIS
abscess	I-DIS
.	O

Molecular	O
identification	O
is	O
required	O
in	O
epidemiological	O
studies	O
due	O
to	O
the	O
presence	O
of	O
morphologically	O
identical	O
nonpathogenic	O
species	O
.	O

Therefore	O
this	O
study	O
was	O
conducted	O
to	O
first	O
evaluate	O
the	O
prevalence	B-EPI
rate	O
of	O
E.	B-DIS
histolytica	I-DIS
among	O
symptomatic	O
individuals	O
of	O
Erbil	B-LOC
city	O
and	O
to	O
investigate	O
the	O
genetic	O
diversity	O
of	O
the	O
parasite	O
in	O
a	O
limited	O
geographic	O
area	O
.	O

Accordingly	O
a	O
total	O
of	O
2026	O
samples	O
were	O
examined	O
microscopically	O
and	O
confirmed	O
by	O
nested	O
PCR	O
for	O
18s	O
rRNA	O
gene	O
.	O

The	O
results	O
showed	O
that	O
the	O
prevalence	B-EPI
rate	O
of	O
E.	B-DIS
histolytica	I-DIS
was	O
1.97	B-STAT
%	I-STAT
40	O
samples	O
among	O
symptomatic	O
patients	O
.	O

The	O
SREHP	O
gene	O
was	O
used	O
as	O
a	O
marker	O
to	O
show	O
the	O
genetic	O
polymorphism	O
of	O
E.	B-DIS
histolytica	I-DIS
;	O
however	O
to	O
compare	O
the	O
genetic	O
diversity	O
of	O
symptomatic	O
with	O
asymptomatic	O
isolates	O
57	O
asymptomatic	O
samples	O
were	O
obtained	O
from	O
our	O
previous	O
study	O
.	O

The	O
amplified	O
products	O
of	O
the	O
SREHP	O
gene	O
were	O
digested	O
by	O
AluI	O
endonuclease	O
and	O
DNA	O
banding	O
patterns	O
were	O
analysed	O
.	O

Results	O
showed	O
29	O
different	O
DNA	O
patterns	O
among	O
the	O
97	O
symptomatic	O
and	O
asymptomatic	O
samples	O
62	O
of	O
which	O
shared	O
similar	O
DNA	O
patterns	O
.	O

However	O
8	O
different	O
DNA	O
patterns	O
were	O
observed	O
among	O
asymptomatic	O
samples	O
whereas	O
15	O
distinct	O
patterns	O
were	O
observed	O
among	O
symptomatic	O
isolates	O
.	O

In	O
conclusion	O
this	O
study	O
found	O
that	O
the	O
prevalence	B-EPI
rate	O
of	O
E.	B-DIS
histolytica	I-DIS
was	O
relatively	O
low	O
;	O
relatively	O
high	O
genetic	O
diversity	O
was	O
observed	O
in	O
a	O
restricted	O
endemic	O
area	O
;	O
with	O
higher	O
rates	O
of	O
variability	O
in	O
symptomatic	O
rather	O
than	O
in	O
asymptomatic	O
isolates	O
indicating	O
a	O
possible	O
correlation	O
between	O
the	O
genotype	O
of	O
E.	O
histolytica	O
and	O
their	O
clinical	O
outcome	O
.	O

Background	O
Sleep	B-DIS
disorders	I-DIS
are	O
common	O
in	O
people	O
with	O
intellectual	B-DIS
disability	I-DIS
ID	O
and	O
autism	B-DIS
with	O
growing	O
evidence	O
of	O
diverse	O
sleep	O
profiles	O
across	O
ID	O
associated	O
genetic	O
syndromes	O
.	O

Documenting	O
the	O
prevalence	B-EPI
and	O
profile	O
of	O
specific	O
sleep	B-DIS
disorders	I-DIS
in	O
syndromes	O
will	O
quantify	O
syndrome	O
-	O
driven	O
'	O
risk	O
'	O
inform	O
prognosis	O
and	O
enhance	O
understanding	O
of	O
aetiology	B-DIS
of	I-DIS
sleep	O
disorders	O
.	O

Method	O
Following	O
PRISMA	O
guidelines	O
for	O
meta	O
-	O
analysis	O
we	O
searched	O
Ovid	O
PsycINFO	O
Ovid	O
MEDLINE	O
Ovid	O
Embase	O
Web	O
of	O
Science	O
and	O
PubMed	O
Central	O
with	O
use	O
of	O
syndrome	O
-	O
specific	B-DIS
keywords	O
and	O
60	O
sleep	O
-	O
related	O
search	O
terms	O
.	O

We	O
screened	O
and	O
extracted	O
papers	O
that	O
reported	O
sleep	B-DIS
disorder	I-DIS
prevalence	B-EPI
data	O
for	O
five	O
or	O
more	O
individuals	O
within	O
a	O
genetic	O
syndrome	O
and	O
applied	O
quality	O
criteria	O
to	O
produce	O
a	O
quality	O
-	B-EPI
effects	O
prevalence	O
model	O
of	O
six	O
types	B-DIS
of	I-DIS
sleep	O
disorder	O
across	O
nineteen	O
syndromes	O
.	O

Relative	O
risk	O
estimates	O
were	O
calculated	O
for	O
the	O
prevalence	B-EPI
of	O
each	O
sleep	B-DIS
disorder	I-DIS
in	O
each	O
syndrome	O
.	O

Results	O
Two	O
hundred	O
and	O
seventy	O
three	O
papers	O
were	O
identified	O
generating	O
463	O
prevalence	B-EPI
estimates	O
for	O
Angelman	B-DIS
CHARGE	I-DIS
Cornelia	I-DIS
de	I-DIS
Lange	I-DIS
Down	I-DIS
fragile	I-DIS
X	I-DIS
Prader	I-DIS
-	I-DIS
Willi	I-DIS
Rett	O
Smith	B-DIS
-	I-DIS
Magenis	I-DIS
and	I-DIS
Williams	I-DIS
syndromes	I-DIS
mucopolysaccharidoses	O
MPS	B-DIS
disorders	I-DIS
neurofibromatosis	O
and	O
tuberous	O
sclerosis	O
complex	O
.	O

Prevalence	B-EPI
estimates	O
were	O
higher	O
in	O
genetic	O
syndromes	O
than	O
published	O
equivalents	O
for	O
typically	O
developing	O
individuals	O
with	O
few	O
exceptions	O
.	O

Between	O
-	O
syndrome	O
differences	O
for	O
some	O
disorders	O
were	O
evident	B-DIS
;	O
sleep	O
-	O
disordered	O
breathing	O
was	B-DIS
most	I-DIS
prevalent	O
in	O
MPS	O
disorders	O
72	B-STAT
-	I-STAT
77	B-DIS
%	I-DIS
while	O
excessive	O
daytime	O
sleepiness	B-DIS
was	I-DIS
highest	O
in	O
Smith	B-LOC
-	I-LOC
Magenis	I-LOC
syndrome	O
60	B-STAT
%	I-STAT
.	O

Conversely	O
insomnia	B-DIS
which	O
was	O
reported	O
at	O
a	O
higher	O
rate	O
than	O
TD	B-DIS
estimates	O
in	O
all	O
syndromes	O
except	O
fragile	O
X	O
was	O
not	O
associated	O
with	O
specific	O
genetic	O
risk	O
.	O

This	O
suggests	O
insomnia	B-DIS
could	O
emerge	O
because	O
of	O
the	O
individual	O
's	O
environment	O
or	O
associated	O
developmental	O
delay	O
rather	O
than	O
any	O
specific	O
genetic	O
syndromes	O
.	O

Limitations	O
Due	O
to	O
the	O
broad	O
scope	O
of	O
the	O
meta	O
-	O
analysis	O
only	O
syndromes	O
previously	O
identified	O
as	O
reporting	O
preliminary	O
sleep	O
research	O
were	O
included	O
.	O

Other	O
syndromes	O
may	O
also	O
experience	O
elevated	O
prevalence	B-EPI
rates	O
of	O
specific	O
types	O
of	O
sleep	B-DIS
disorder	I-DIS
.	O

Only	O
English	O
language	O
papers	O
were	O
included	O
.	O

Conclusions	O
Differing	O
prevalence	B-EPI
rates	O
between	O
types	O
of	O
sleep	B-DIS
disorder	I-DIS
suggest	O
differing	O
causal	O
mechanisms	O
such	O
as	O
cranio	O
-	O
facial	O
morphology	B-DIS
in	O
Down	B-DIS
and	I-DIS
Prader	O
-	O
Willi	O
syndromes	O
and	O
the	O
build	O
-	O
up	O
of	O
mucopolysaccharides	O
in	O
MPS	O
disorders	O
.	O

Priorities	O
for	O
clinical	O
assessment	O
and	O
intervention	O
for	O
sleep	B-DIS
disorders	I-DIS
are	O
discussed	O
.	O

A	O
molecular	O
epidemiological	O
study	O
was	O
conducted	O
in	O
a	O
population	O
of	O
9422	O
blood	O
donors	O
in	O
the	O
province	O
of	O
Corrientes	B-LOC
Northeastern	I-LOC
Argentina	I-LOC
to	O
determine	O
the	O
prevalence	B-EPI
of	O
Human	O
T	B-DIS
-	I-DIS
cell	I-DIS
lymphotropic	O
virus	B-STAT
types	I-STAT
1	I-STAT
and	O
2	O
HTLV-1/2	O
the	O
phylogenetic	O
identification	O
of	O
HTLV-1	O
and	O
2	O
subtypes	O
/	O
subgroups	O
and	O
perform	O
a	O
mutation	O
analysis	O
.	O

Based	O
on	O
the	O
results	O
obtained	O
it	O
was	O
shown	O
that	O
both	O
HTLV-1	B-DIS
and	O
HTLV-2	O
are	O
circulating	O
in	O
a	O
low	O
-	O
risk	O
population	O
of	O
Corrientes	O
although	O
with	O
a	B-EPI
similar	O
prevalence	O
to	O
that	O
of	O
non	O
-	O
endemic	O
areas	O
.	O

Phylogenetic	O
studies	O
identified	O
the	O
HTLV-1	O
Cosmopolitan	O
subtype	O
Transcontinental	O
subgroup	O
Aa	O
and	O
the	O
HTLV-2	O
subtype	O
b	O
.	O

Infected	O
donors	O
reported	O
neither	O
a	O
history	O
of	O
risk	O
factors	O
such	O
as	O
transfusions	O
intravenous	O
drug	O
use	O
nor	O
risky	O
or	O
HTLV-1/2	O
seropositive	O
sexual	O
partners	O
.	O

These	O
results	O
suggest	O
that	O
these	O
viruses	O
were	O
transmitted	O
from	O
mother	O
to	O
child	O
possibly	O
from	O
generation	O
to	O
generation	O
and	O
that	O
these	O
strains	O
were	O
introduced	O
into	O
the	O
Caucasian	O
population	O
of	O
this	O
region	O
from	O
ancestors	O
originating	O
from	O
endemic	O
areas	O
of	O
the	O
country	O
either	O
from	O
or	O
through	O
contact	O
with	O
individuals	O
from	O
other	O
countries	O
years	O
ago	O
.	O

Our	O
results	O
demonstrate	O
for	O
the	O
first	O
time	O
the	O
presence	O
of	O
HTLV-1	O
and	O
HTLV-2	O
in	O
the	O
province	O
of	O
Corrientes	B-LOC
.	O

Moreover	O
although	O
the	O
province	O
can	O
be	O
considered	O
a	O
non	O
-	O
endemic	O
area	O
the	O
need	O
to	O
include	O
these	O
retroviruses	O
in	O
a	O
national	O
Public	O
Health	O
program	O
is	O
highlighted	O
in	O
order	O
to	O
have	O
qualified	O
professionals	O
duly	O
trained	O
to	O
make	O
their	O
diagnosis	O
and	O
provide	O
the	O
necessary	O
information	O
in	O
relation	O
to	O
primary	O
care	O
and	O
patient	O
follow	O
-	O
up	O
.	O

Since	O
it	O
was	O
first	O
documented	O
in	O
1948	O
by	O
Sir	O
William	O
Heneage	O
Ogilvie	O
numerous	O
cases	O
of	O
Ogilvie	B-DIS
syndrome	I-DIS
have	O
been	O
described	O
in	O
literature	O
due	O
to	O
various	O
medical	O
and	O
surgical	O
causes	O
.	O

Nonetheless	O
only	O
a	O
handful	O
of	O
cases	O
only	O
have	O
been	O
documented	O
due	O
to	O
underlying	O
Acquired	B-DIS
Immunodeficiency	I-DIS
Syndrome	I-DIS
AIDS	I-DIS
.	O

A	O
41	O
-	O
year	O
-	O
old	O
female	O
was	O
admitted	O
with	O
an	O
acute	O
abdomen	O
secondary	B-DIS
to	I-DIS
partial	O
mechanical	B-DIS
intestinal	I-DIS
obstruction	O
or	O
paralytic	O
ileus	O
based	O
on	O
signs	O
and	O
symptoms	O
and	O
Abdominal	O
X	O
-	O
Ray	O
AXR	O
.	O

She	O
was	O
known	O
to	O
be	O
HIV	O
/	O
AIDS	O
WHO	O
clinical	O
stage	O
II	O
on	O
treatment	O
.	O

On	O
diagnostic	O
imaging	O
studies	O
she	O
had	O
distended	O
large	O
bowels	O
without	O
features	O
of	O
mechanical	O
intestinal	B-DIS
obstruction	I-DIS
and	O
the	O
diagnosis	O
of	O
Ogilvie	B-DIS
syndrome	I-DIS
was	O
suspected	O
after	O
other	O
differentials	O
were	O
excluded	O
.	O

Early	O
recognition	O
and	O
appropriate	O
management	O
are	O
essential	O
because	O
if	O
left	O
untreated	O
the	O
bowel	O
distension	O
may	O
progress	O
to	O
caecal	O
perforation	O
and	O
fatal	O
peritonitis	B-DIS
.	O

Medical	O
imaging	O
with	O
Computer	O
Tomography	O
CT	O
scan	O
and	O
colonoscopy	O
has	O
helped	O
in	O
achieving	O
an	O
accurate	O
diagnosis	O
and	O
avoiding	O
unnecessary	O
laparotomies	O
.	O

Although	O
an	O
uncommon	O
disorder	O
for	O
earlier	O
and	O
accurate	O
diagnosis	O
a	O
high	O
index	O
of	O
suspicion	O
is	O
required	O
by	O
clinicians	O
and	O
radiologists	O
who	O
are	O
treating	O
patients	O
with	O
underlying	O
HIV	O
/	O
AIDS	O
.	O

Ogilvie	B-DIS
's	I-DIS
syndrome	I-DIS
is	O
a	O
rare	O
condition	O
and	O
if	O
missed	O
can	O
be	O
fatal	O
.	O

In	O
patients	O
with	O
HIV	O
/	O
AIDS	O
the	O
symptoms	O
may	O
be	O
directly	O
due	B-DIS
to	I-DIS
HIV	O
infection	O
secondary	B-DIS
to	I-DIS
opportunistic	O
infections	O
or	B-DIS
possible	O
neurotoxic	O
effects	O
of	O
HIV	O
treatment	O
or	O
lack	O
of	O
vitamin	O
and	O
minerals	O
.	O

It	O
is	O
important	O
to	O
exclude	O
Ogilvie	B-DIS
syndrome	I-DIS
in	O
patients	O
from	O
surgical	O
causes	O
of	O
the	O
acute	O
abdomen	O
to	O
avoid	O
unnecessary	O
surgical	O
procedures	O
.	O

Gyrate	B-DIS
Atrophy	I-DIS
GA	I-DIS
of	O
the	O
choroid	O
and	O
retina	O
MIM	O
#	O
258870	O
is	O
an	O
autosomal	O
recessive	B-DIS
disorder	I-DIS
due	O
to	O
mutations	O
of	O
the	O
OAT	O
gene	O
encoding	O
ornithine	O
-	O
delta	O
-	O
aminotransferase	O
OAT	B-DIS
associated	I-DIS
with	O
progressive	O
retinal	O
deterioration	O
and	O
blindness	O
.	O

The	O
disease	O
has	O
a	O
theoretical	O
global	O
incidence	B-EPI
of	O
approximately	O
11500000	O
.	O

OAT	O
is	O
mainly	O
involved	O
in	O
ornithine	O
catabolism	O
in	O
adults	O
thus	O
explaining	O
the	O
hyperornithinemia	B-DIS
as	O
hallmark	O
of	O
the	O
disease	O
.	O

Patients	O
are	O
treated	O
with	O
an	O
arginine	O
-	O
restricted	O
diet	O
to	O
limit	O
ornithine	O
load	O
or	O
the	O
administration	O
of	O
Vitamin	O
B6	O
a	O
precursor	O
of	O
the	O
OAT	O
coenzyme	O
pyridoxal	O
phosphate	O
.	O

Although	O
the	O
clinical	O
and	O
genetic	O
aspects	O
of	O
GA	O
are	O
known	O
for	O
many	O
years	O
the	O
enzymatic	O
phenotype	O
of	O
pathogenic	O
variants	O
and	O
their	O
response	O
to	O
Vitamin	O
B6	O
as	O
well	O
as	O
the	O
molecular	O
mechanisms	O
explaining	O
retinal	B-DIS
damage	I-DIS
are	O
poorly	O
clarified	O
.	O

Herein	O
we	O
provide	O
an	O
overview	O
of	O
the	O
current	O
knowledge	O
on	O
the	O
biochemical	O
properties	O
of	O
human	O
OAT	O
and	O
on	O
the	O
molecular	O
cellular	O
and	O
clinical	O
aspects	O
of	O
GA	O
.	O

Hearing	B-DIS
loss	I-DIS
HL	O
is	O
an	O
extra	O
-	O
skeletal	O
manifestation	O
of	B-DIS
the	I-DIS
connective	I-DIS
tissue	I-DIS
disorder	I-DIS
osteogenesis	I-DIS
imperfecta	O
OI	O
.	O

Systematic	O
evaluation	O
of	O
the	O
prevalence	B-EPI
and	O
characteristics	O
of	O
HL	B-DIS
in	O
COL1A1	O
/	O
COL1A2	O
-	O
related	O
OI	O
will	O
contribute	O
to	O
a	O
better	O
clinical	O
management	B-DIS
of	O
individuals	O
with	O
OI	O
.	O

We	O
collected	O
and	O
analyzed	O
pure	O
-	O
tone	O
audiometry	O
data	O
from	O
312	O
individuals	O
with	O
OI	O
who	O
were	O
enrolled	O
in	O
the	O
Linked	O
Clinical	O
Research	O
Centers	O
and	O
the	O
Brittle	O
Bone	O
Disorders	O
Consortium	O
.	O

The	O
prevalence	B-EPI
type	O
and	O
severity	O
of	O
HL	B-DIS
in	O
COL1A1	O
/	O
COL1A2	O
-	O
related	O
OI	O
are	O
reported	O
.	O

We	O
show	O
that	O
the	O
prevalence	B-EPI
of	O
HL	B-DIS
in	O
OI	B-DIS
is	O
28	B-STAT
%	I-STAT
and	O
increased	O
with	O
age	O
in	O
Type	O
I	O
OI	O
but	O
not	O
in	O
Types	O
III	O
and	O
IV	O
.	O

Individuals	O
with	O
OI	O
Types	O
III	O
and	O
IV	O
are	O
at	O
a	O
higher	O
risk	O
to	O
develop	O
HL	B-DIS
in	O
the	O
first	O
decade	O
of	O
life	O
when	O
compared	O
to	O
OI	O
Type	O
I	O
.	O

We	O
also	O
show	O
that	O
the	O
prevalence	B-EPI
of	O
SNHL	B-DIS
is	O
higher	O
in	O
females	O
with	O
OI	B-DIS
compared	O
to	O
males	O
.	O

This	O
study	O
reveals	O
new	O
insights	O
regarding	O
prevalence	B-EPI
of	O
HL	B-DIS
in	O
OI	O
including	O
a	O
lower	O
general	O
prevalence	B-EPI
of	O
HL	B-DIS
in	O
COL1A1	O
/	O
COL1A2	O
-	O
related	O
OI	O
than	O
previously	O
reported	O
28.3	O
vs.	O
65	B-EPI
%	I-STAT
and	B-DIS
high	O
prevalence	O
of	O
SNHL	O
in	O
females	O
.	O

Our	O
data	O
support	O
the	O
need	O
in	O
early	O
routine	O
hearing	O
evaluation	O
in	O
all	O
types	O
of	O
OI	O
that	O
can	O
be	O
adjusted	O
to	O
the	O
severity	O
of	O
the	O
skeletal	B-DIS
disease	I-DIS
.	O

Neonatal	O
herpes	B-DIS
simplex	I-DIS
virus	I-DIS
infection	I-DIS
HSV	O
is	O
rare	O
in	O
neonates	O
with	O
an	O
estimated	O
global	O
incidence	B-EPI
of	O
10	O
per	O
100000	O
live	O
births	O
.	O

Neonatal	O
HSV	B-DIS
is	O
challenging	O
to	O
diagnose	O
due	O
to	O
often	O
vague	O
signs	O
and	O
symptoms	O
.	O

Untreated	O
the	O
mortality	O
of	O
some	O
HSV	O
subtypes	O
exceeds	O
80	B-STAT
%	I-STAT
.	O

Overtesting	O
and	O
overtreatment	O
can	O
result	O
in	O
prolonged	O
hospitalizations	O
and	O
expose	O
neonates	O
to	O
medication	O
toxicity	B-DIS
.	O

In	O
contrast	O
prompt	O
evaluation	O
and	O
use	O
of	O
empiric	O
antiviral	O
therapy	O
before	O
the	O
results	O
of	O
definitive	O
testing	O
can	O
improve	O
outcomes	O
for	O
infants	O
with	O
HSV	B-DIS
.	O

A	O
wide	O
degree	O
of	O
practice	O
variation	O
exists	O
with	O
respect	O
to	O
testing	O
and	O
treatment	O
for	O
neonatal	O
HSV	O
and	O
more	O
research	O
is	O
required	O
to	O
safely	O
risk	O
-	O
stratify	O
this	O
population	O
.	O

This	O
review	O
presents	O
the	O
epidemiology	O
risk	O
factors	O
presenting	O
features	O
and	O
emergency	O
department	O
management	O
of	O
neonatal	O
HSV	B-DIS
infection	I-DIS
.	O

Georgia	B-LOC
uses	O
post	O
-	O
analytical	O
tools	O
through	O
Collaborative	O
Laboratory	O
Integrated	O
Reports	O
CLIR	O
to	O
triage	O
abnormal	O
newborn	O
screening	O
NBS	O
results	O
for	O
follow	O
-	O
up	O
.	O

Condition	O
specific	O
tools	O
are	O
used	O
to	O
assign	O
each	O
case	O
a	O
risk	O
level	O
which	O
is	O
used	O
to	O
guide	O
follow	O
-	O
up	O
recommendations	O
.	O

Follow	O
-	O
up	O
recommendations	O
include	O
assessment	O
by	O
the	O
child	O
's	O
primary	O
care	O
provider	O
as	O
well	O
as	O
testing	O
either	O
a	O
repeat	O
NBS	O
or	O
confirmatory	O
testing	O
.	O

Triaging	O
abnormal	O
cases	O
using	O
these	O
tools	O
has	O
been	O
advantageous	O
in	O
managing	O
the	O
workflow	O
for	O
the	O
follow	O
-	O
up	O
team	O
as	O
well	O
as	O
prioritizing	O
cases	O
that	O
appropriately	O
require	O
more	O
attention	O
and	O
resources	O
.	O

The	O
initial	O
goal	O
in	O
utilizing	O
these	O
tools	O
was	O
to	O
reduce	O
the	O
amount	O
of	O
confirmatory	O
testing	O
particularly	O
for	O
disorders	O
where	O
there	O
are	O
many	O
false	O
positives	O
.	O

We	O
assessed	O
the	O
performance	O
of	O
these	O
tools	O
retrospectively	O
for	O
three	O
of	O
the	O
most	O
commonly	O
detected	O
conditions	O
by	O
tandem	O
mass	O
spectrometry	O
in	O
Georgia	B-LOC
phenylketonuria	B-DIS
medium	O
chain	O
acyl	O
-	O
CoA	O
dehydrogenase	O
deficiency	O
and	O
very	O
long	O
chain	O
dehydrogenase	O
deficiency	O
.	O

The	O
post	O
-	O
analytical	O
tools	O
appropriately	O
assigned	O
all	O
true	O
positive	O
cases	O
to	O
the	O
higher	O
levels	O
of	O
follow	O
-	O
up	O
testing	O
and	O
reduced	O
the	O
level	O
of	O
intervention	O
for	O
a	O
significant	O
number	O
of	O
cases	O
as	O
well	O
.	O

Based	O
on	O
the	O
experience	O
gained	O
from	O
our	O
utilization	O
of	O
the	O
tools	O
in	O
the	O
follow	O
-	O
up	O
program	O
we	O
are	O
well	O
situated	O
to	O
move	O
forward	O
with	O
using	O
the	O
tools	O
in	O
a	O
more	O
prospective	O
manner	O
and	O
reduce	O
the	O
number	O
of	O
cases	O
that	O
will	O
be	O
reported	O
rather	O
than	O
just	O
assigning	O
resources	O
appropriately	O
at	O
follow	O
-	O
up	O
.	O

Post	O
-	O
analytical	O
tools	O
are	O
an	O
improvement	O
over	O
trying	O
to	O
capture	O
the	O
variation	O
in	O
the	O
newborn	O
population	O
using	O
multiple	O
cutoffs	O
.	O

It	O
also	O
easily	O
identifies	O
significant	O
abnormalities	O
that	O
are	O
unrelated	O
to	O
inherited	O
disease	O
such	O
as	O
large	O
amino	O
acid	O
elevations	O
due	O
to	O
total	O
parenteral	O
nutrition	O
.	O

The	O
inherited	O
bone	B-DIS
marrow	I-DIS
failure	I-DIS
syndromes	I-DIS
IBMFS	I-DIS
are	O
a	O
rare	O
yet	O
clinically	O
important	O
cause	O
of	O
neonatal	O
hematological	O
and	O
non	O
-	O
hematological	O
manifestations	O
.	O

Many	O
of	O
these	O
syndromes	O
such	O
as	O
Fanconi	B-DIS
anemia	I-DIS
dyskeratosis	I-DIS
congenita	I-DIS
and	O
Diamond	B-DIS
-	I-DIS
Blackfan	O
anemia	O
confer	O
risks	O
of	O
multiple	O
medical	O
complications	O
later	O
in	O
life	O
including	O
an	O
increased	O
risk	B-DIS
of	O
cancer	O
.	O

Some	O
IBMFS	B-DIS
may	O
present	O
with	O
cytopenias	B-DIS
in	O
the	O
neonatal	O
period	O
whereas	O
others	O
may	O
present	O
only	O
with	O
congenital	B-DIS
physical	I-DIS
abnormalities	I-DIS
and	O
progress	O
to	O
pancytopenia	B-DIS
later	O
in	O
life	O
.	O

A	O
thorough	O
family	O
history	O
and	O
detailed	O
physical	O
examination	O
are	O
integral	O
to	O
the	O
work	O
-	O
up	O
of	O
any	O
neonate	O
in	O
whom	O
there	O
is	O
a	O
high	O
index	O
of	O
suspicion	O
for	O
an	O
IBMFS	O
.	O

Correct	O
detection	O
and	O
diagnosis	O
of	O
these	O
disorders	O
is	O
important	O
for	O
appropriate	O
long	O
-	O
term	O
medical	O
surveillance	O
and	O
counseling	O
not	O
only	O
for	O
the	O
patient	O
but	O
also	O
for	O
appropriate	O
genetic	O
counselling	O
of	O
their	O
families	O
regarding	O
recurrence	O
risks	O
in	O
future	O
children	O
and	O
generations	O
.	O

Testicular	O
cancer	O
is	O
the	O
most	O
common	O
malignant	B-DIS
tumor	I-DIS
in	O
young	O
men	O
and	O
its	O
incidence	B-EPI
has	O
increased	O
in	O
recent	O
years	O
.	O

The	O
tumor	B-DIS
microenvironment	O
TME	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
development	O
and	O
progression	O
of	O
tumors	B-DIS
;	O
however	O
the	O
TME	O
of	O
testicular	O
germ	B-DIS
cell	I-DIS
tumor	I-DIS
TGCT	O
is	O
poorly	O
understood	O
.	O

In	O
this	O
study	O
we	O
downloaded	O
information	O
for	O
156	O
TGCT	B-DIS
cases	O
from	O
The	O
Cancer	B-DIS
Genome	O
Atlas	O
TCGA	B-DIS
database	O
used	O
the	O
ESTIMATE	O
method	O
to	O
determine	O
immune	O
and	O
stromal	O
scores	O
and	O
used	O
CIBERSORT	O
to	O
calculate	O
the	O
proportion	O
of	O
tumor	O
-	O
infiltrating	O
immune	O
cells	O
TICs	O
.	O

The	O
differentially	O
expressed	O
genes	O
were	O
subjected	O
to	O
a	O
COX	O
regression	O
analysis	O
and	O
used	O
for	O
the	O
construction	O
of	O
a	O
protein	O
-	O
protein	O
interaction	O
PPI	O
network	O
.	O

Toll	O
-	O
like	O
receptor	O
2	O
TLR2	O
was	O
identified	O
as	O
a	O
predictive	O
marker	O
by	O
combining	O
the	O
results	O
of	O
the	O
Cox	O
regression	O
analysis	O
and	O
PPI	O
network	O
.	O

A	O
survival	O
analysis	O
showed	O
that	O
TLR2	O
was	O
positively	O
correlated	O
with	O
TGCT	B-DIS
survival	O
.	O

A	O
gene	O
set	O
enrichment	O
analysis	O
indicated	O
that	O
genes	O
in	O
the	O
high	O
TLR2	O
expression	O
group	O
were	O
enriched	O
for	O
cell	O
adhesion	O
molecules	O
CAMs	O
and	O
the	O
chemokine	O
signaling	O
pathway	O
and	O
genes	O
in	O
the	O
low	O
TLR2	O
expression	O
group	O
were	O
mainly	O
enriched	O
in	O
the	O
spliceosome	O
.	O

Regarding	O
proportions	O
of	O
TICs	O
naive	O
B	O
cells	O
and	O
follicular	O
helper	O
T	O
cells	O
were	O
negatively	O
correlated	O
with	O
the	O
expression	O
of	O
TLR2	O
.	O

This	O
suggests	O
that	O
as	O
TLR2	O
expression	O
increases	O
the	O
immunocompetence	O
of	O
the	O
TME	O
decreases	O
.	O

The	O
expression	O
of	O
TLR2	O
may	O
affect	O
the	O
prognosis	O
of	O
TGCT	B-DIS
suggesting	O
that	O
this	O
locus	O
can	O
be	O
used	O
as	O
a	O
prognostic	O
factor	O
for	O
TGCT	B-DIS
.	O

Deficiency	O
of	O
hypoxanthine	O
-	O
guanine	O
phosphoribosyltransferase	O
HPRT	O
activity	O
is	O
an	O
inborn	O
error	O
of	O
purine	O
metabolism	O
associated	O
with	O
uric	O
acid	O
overproduction	O
and	O
a	O
continuum	O
spectrum	O
of	O
neurological	O
manifestations	O
depending	O
on	O
the	O
degree	O
of	B-DIS
the	I-DIS
enzymatic	O
deficiency	O
.	O

The	O
prevalence	B-EPI
is	O
estimated	O
at	O
1/380000	B-STAT
live	O
births	O
in	O
Canada	B-LOC
and	O
1/235000	B-STAT
live	O
births	O
in	O
Spain	B-LOC
.	O

Uric	O
acid	O
overproduction	O
is	O
present	O
inall	O
HPRT	O
-	O
deficient	O
patients	O
and	O
is	O
associated	B-DIS
with	O
lithiasis	B-DIS
and	O
gout	O
.	O

Neurological	O
manifestations	O
include	O
severe	O
action	O
dystonia	B-DIS
choreoathetosis	I-DIS
ballismus	I-DIS
cognitive	I-DIS
and	I-DIS
attention	I-DIS
deficit	I-DIS
and	O
self	B-DIS
-	O
injurious	O
behaviour	O
.	O

The	O
most	O
severe	O
forms	O
are	O
known	O
as	O
Lesch	B-DIS
-	I-DIS
Nyhan	O
syndrome	O
patients	O
are	O
normal	O
at	O
birth	O
and	O
diagnosis	O
can	O
be	O
accomplished	O
when	O
psychomotor	O
delay	O
becomes	O
apparent	O
.	O

Partial	O
HPRT	O
-	O
deficient	O
patients	O
present	O
these	O
symptoms	O
with	O
a	O
different	O
intensity	O
and	O
in	O
the	O
least	O
severe	O
forms	O
symptoms	O
may	O
be	O
unapparent	O
.	O

Megaloblastic	B-DIS
anaemia	I-DIS
is	O
also	O
associated	O
with	O
the	O
disease	O
.	O

Inheritance	O
of	O
HPRT	B-DIS
deficiency	I-DIS
is	O
X	O
-	O
linked	O
recessive	O
thus	O
males	O
are	O
generally	O
affected	O
and	O
heterozygous	O
female	O
are	O
carriers	O
usually	O
asymptomatic	O
.	O

Human	O
HPRT	O
is	O
encoded	O
by	O
a	O
single	O
structural	O
gene	O
on	O
the	O
long	O
arm	O
of	O
the	O
X	O
chromosome	O
at	O
Xq26	O
.	O

To	O
date	O
more	O
than	O
300	O
disease	O
-	O
associated	O
mutations	O
in	O
the	O
HPRT1	O
gene	O
have	O
been	O
identified	O
.	O

The	O
diagnosis	O
is	O
based	O
on	O
clinical	O
and	O
biochemical	O
findings	O
hyperuricemia	B-DIS
and	O
hyperuricosuria	B-DIS
associated	O
with	O
psychomotor	O
delay	O
and	O
enzymatic	O
HPRT	O
activity	O
determination	O
in	O
haemolysate	O
intact	O
erythrocytes	O
or	O
fibroblasts	O
and	O
molecular	O
tests	O
.	O

Molecular	O
diagnosis	O
allows	O
faster	O
and	O
more	O
accurate	O
carrier	O
and	O
prenatal	O
diagnosis	O
.	O

Prenatal	O
diagnosis	O
can	O
be	O
performed	O
with	O
amniotic	O
cells	O
obtained	O
by	O
amniocentesis	O
at	O
about	O
15	O
-	O
18	O
weeks	O
'	O
gestation	O
or	O
chorionic	O
villus	O
cells	O
obtained	O
at	O
about	O
10	O
-	O
12	O
weeks	O
'	O
gestation	O
.	O

Uric	O
acid	O
overproduction	O
can	O
be	O
managed	O
by	O
allopurinol	O
treatment	O
.	O

Doses	O
must	O
be	O
carefully	O
adjusted	O
to	O
avoid	O
xanthine	O
lithiasis	O
.	O

The	O
lack	O
of	O
precise	O
understanding	O
of	O
the	O
neurological	B-DIS
dysfunction	I-DIS
has	O
precluded	O
development	O
of	O
useful	O
therapies	O
.	O

Spasticity	B-DIS
when	O
present	O
and	O
dystonia	B-DIS
can	O
be	O
managed	O
with	O
benzodiazepines	O
and	O
gamma	O
-	O
aminobutyric	O
acid	O
inhibitors	O
such	O
as	O
baclofen	O
.	O

Physical	O
rehabilitation	O
including	O
management	O
of	O
dysarthria	B-DIS
and	O
dysphagia	B-DIS
special	O
devices	O
to	O
enable	O
hand	O
control	O
appropriate	O
walking	O
aids	O
and	O
a	O
programme	O
of	O
posture	O
management	O
to	O
prevent	O
deformities	O
are	O
recommended	O
.	O

Self	B-DIS
-	O
injurious	O
behaviour	O
must	O
be	O
managed	O
by	O
a	O
combination	O
of	O
physical	O
restraints	O
behavioural	O
and	O
pharmaceutical	O
treatments	O
.	O

The	O
use	O
of	O
proton	O
pump	O
inhibitors	O
PPIs	O
over	O
the	O
last	O
30	O
years	O
has	O
rapidly	O
increased	O
both	O
in	O
the	B-LOC
United	I-LOC
States	I-LOC
and	O
worldwide	O
.	O

PPIs	O
are	O
not	O
only	O
very	O
widely	O
used	O
both	O
for	O
approved	O
indications	O
peptic	O
ulcer	B-DIS
disease	I-DIS
gastroesophageal	I-DIS
reflux	I-DIS
disease	I-DIS
GERD	I-DIS
Helicobacter	O
pylori	O
eradication	O
regimens	O
stress	B-DIS
ulcer	I-DIS
prevention	O
but	O
are	O
also	O
one	O
of	O
the	O
most	O
frequently	O
off	O
-	O
label	O
used	O
drugs	O
25	B-STAT
-	I-STAT
70	I-STAT
%	I-STAT
of	O
total	O
.	O

An	O
increasing	O
number	O
of	O
patients	O
with	O
moderate	O
to	O
advanced	O
gastroesophageal	B-DIS
reflux	I-DIS
disease	I-DIS
are	O
remaining	O
on	O
PPI	O
indefinitely	O
.	O

Whereas	O
numerous	O
studies	O
show	O
PPIs	O
remain	O
effective	O
and	O
safe	O
most	O
of	O
these	O
studies	O
are	O
<	O
5	O
years	O
of	O
duration	O
and	O
little	O
data	O
exist	O
fo	O
10	O
years	O
of	O
treatment	O
.	O

Recently	O
based	O
primarily	O
on	O
observational	O
/	O
epidemiological	O
studies	O
there	O
have	O
been	O
an	O
increasing	O
number	O
of	O
reports	O
raising	O
issues	O
about	O
safety	O
and	O
side	O
-	O
effects	O
with	O
very	O
long	O
-	O
term	O
chronic	O
treatment	O
.	O

Some	O
of	O
these	O
safety	O
issues	O
are	O
related	O
to	O
the	O
possible	O
long	O
-	O
term	O
effects	O
of	B-DIS
chronic	O
hypergastrinemia	O
which	O
occurs	O
in	O
all	O
patients	O
taking	O
chronic	O
PPIs	O
others	O
are	O
related	O
to	O
the	O
hypo-/achlorhydria	O
that	O
frequently	O
occurs	O
with	O
chronic	O
PPI	O
treatment	O
and	O
in	O
others	O
the	O
mechanisms	O
are	O
unclear	O
.	O

These	O
issues	O
have	O
raised	O
considerable	O
controversy	O
in	O
large	O
part	O
because	O
of	O
lack	O
of	O
long	O
-	O
term	O
PPI	O
treatment	O
data	O
10	O
-	O
20	O
years	O
.	O

Zollinger	B-DIS
-	I-DIS
Ellison	O
syndrome	O
ZES	O
is	O
caused	O
by	O
ectopic	O
secretion	O
of	O
gastrin	O
from	O
a	B-DIS
neuroendocrine	O
tumor	O
resulting	O
in	B-DIS
severe	I-DIS
acid	O
hypersecretion	O
requiring	O
life	O
-	O
long	O
antisecretory	O
treatment	O
with	O
PPIs	O
which	O
are	O
the	O
drugs	O
of	O
choice	O
.	O

Because	O
in	O
<	O
30	B-STAT
%	I-STAT
of	O
patients	O
with	O
ZES	O
a	O
long	O
-	O
term	O
cure	O
is	O
not	O
possible	O
these	O
patients	O
have	B-DIS
life	O
-	O
long	O
hypergastrinemia	O
and	O
require	O
life	O
-	O
long	O
treatment	O
with	O
PPIs	O
.	O

Therefore	O
ZES	O
patients	O
have	O
been	O
proposed	O
as	O
a	O
good	O
model	O
of	O
the	O
long	O
-	O
term	O
effects	B-DIS
of	O
hypergastrinemia	O
in	O
man	O
as	O
well	O
as	O
the	O
effects	O
/	O
side	O
-	O
effects	O
of	O
very	O
long	O
-	O
term	O
PPI	O
treatment	O
.	O

In	O
this	O
article	O
the	O
insights	O
from	O
studies	O
on	O
ZES	O
into	O
these	O
controversial	O
issues	O
with	O
pertinence	O
to	O
chronic	O
PPI	O
use	O
in	O
non	B-LOC
-	I-LOC
ZES	I-LOC
patients	O
is	O
reviewed	O
primarily	O
concentrating	O
on	O
data	O
from	O
the	O
prospective	O
long	O
-	O
term	O
studies	O
of	O
ZES	O
patients	O
at	O
NIH	O
.	O

Isolated	O
cleft	B-DIS
palate	I-DIS
CPO	O
is	O
the	O
rarest	O
form	O
of	O
oral	O
clefting	O
.	O

The	O
incidence	B-EPI
of	O
CPO	O
varies	O
substantially	O
by	O
geography	O
from	O
1.3	O
to	O
25.3	O
per	O
10000	O
live	O
births	O
with	O
the	O
highest	O
rates	O
in	O
British	B-LOC
Columbia	I-LOC
Canada	I-LOC
and	O
the	O
lowest	O
rates	O
in	O
Nigeria	B-LOC
Africa	I-LOC
.	O

Stratified	O
by	O
ethnicity	O
/	O
race	O
the	O
highest	O
rates	O
of	O
CPO	O
are	O
observed	O
in	O
non	O
-	O
Hispanic	O
Whites	O
and	O
the	O
lowest	O
in	O
Africans	O
;	O
nevertheless	O
rates	O
of	O
CPO	O
are	O
consistently	O
higher	O
in	O
females	O
compared	O
to	O
males	O
.	O

Approximately	B-STAT
fifty	I-STAT
percent	I-STAT
of	O
cases	O
born	O
with	O
cleft	B-DIS
palate	I-DIS
occur	O
as	O
part	O
of	O
a	O
known	O
genetic	O
syndrome	O
or	O
with	O
another	O
malformation	O
e.g	O
.	O

congenital	B-DIS
heart	I-DIS
defects	I-DIS
and	O
the	O
other	O
half	O
occur	O
as	O
solitary	O
defects	O
referred	O
to	O
often	O
as	O
non	B-DIS
-	O
syndromic	O
clefts	O
.	O

The	O
etiology	O
of	O
CPO	O
is	O
multifactorial	O
involving	O
genetic	O
and	O
environmental	O
risk	O
factors	O
.	O

Several	O
animal	O
models	O
have	O
yielded	O
insight	O
into	O
the	O
molecular	O
pathways	O
responsible	O
for	O
proper	O
closure	O
of	O
the	O
palate	B-DIS
including	O
the	O
BMP	O
TGF	O
-	O
β	O
and	O
SHH	O
signaling	O
pathways	O
.	O

In	O
terms	O
of	O
environmental	O
exposures	O
only	O
maternal	O
tobacco	O
smoke	O
has	O
been	O
found	O
to	O
be	O
strongly	O
associated	O
with	O
CPO	O
.	O

Some	O
studies	O
have	O
suggested	O
that	O
maternal	O
glucocorticoid	O
exposure	O
may	O
also	O
be	O
important	O
.	O

Clearly	O
there	O
is	O
a	O
need	O
for	O
larger	O
epidemiologic	O
studies	O
to	O
further	O
investigate	O
both	O
genetic	O
and	O
environmental	O
risk	O
factors	O
and	O
gene	O
-	O
environment	O
interactions	O
.	O

In	O
terms	O
of	O
treatment	O
there	O
is	O
a	O
need	O
for	O
long	O
-	O
term	O
comprehensive	O
care	O
including	O
surgical	O
dental	O
and	O
speech	O
pathology	O
.	O

Overall	O
five	O
main	O
themes	O
emerge	O
as	O
critical	O
in	O
advancing	O
research	O
1	O
monitoring	O
of	O
the	O
occurrence	O
of	O
CPO	O
capacity	O
building	O
;	O
2	O
detailed	O
phenotyping	O
of	O
the	O
severity	O
biology	O
;	O
3	O
understanding	O
of	O
the	O
genetic	O
and	O
environmental	O
risk	O
factors	O
primary	O
prevention	O
;	O
4	O
access	O
to	O
early	O
detection	O
and	O
multidisciplinary	O
treatment	O
clinical	O
services	O
;	O
and	O
5	O
understanding	O
predictors	O
of	O
recurrence	O
and	O
possible	O
interventions	O
among	O
families	O
with	O
a	O
child	O
with	O
CPO	O
secondary	O
prevention	O
.	O

Objective	O
To	O
evaluate	O
the	O
safety	O
and	O
efficacy	O
of	O
radiofrequency	O
ablation	O
RFA	O
for	O
metastatic	O
lymph	O
nodes	O
LNs	O
in	O
children	O
and	O
adolescents	O
with	O
papillary	B-DIS
Thyroid	I-DIS
Carcinoma	I-DIS
PTC	I-DIS
.	O

Materials	O
and	O
methods	O
From	O
December	O
2014	O
to	O
March	O
201810	O
metastatic	O
LNs	O
mean	O
volume	O
0.30	O
±	O
0.38	O
ml	O
range	O
0.06	O
-	O
1.23ml	O
in	O
5	O
children	O
and	O
adolescents	O
3	O
females	O
2	O
males	O
;	O
mean	O
age	O
15.60	O
±	O
2.97	O
years	O
range	O
12	O
-	O
19	O
years	O
with	O
PTC	B-DIS
treated	O
by	O
RFA	O
were	O
evaluated	O
in	O
this	O
study	O
.	O

The	O
mean	O
number	O
of	O
surgical	O
procedures	O
performed	O
before	O
RFA	O
was	O
1.2	O
range	O
1	B-STAT
-	I-STAT
2	I-STAT
and	O
the	O
mean	O
number	O
of	O
treated	O
metastatic	O
LNs	O
per	O
patient	O
was	O
2	O
rang	O
1	B-STAT
-	I-STAT
3	I-STAT
.	O

RFA	O
was	O
performed	O
with	O
an	O
18	O
-	O
gauge	O
bipolar	O
RF	O
applicator	O
under	O
local	O
anesthesia	O
.	O

Follow	O
-	O
up	O
consisted	O
of	O
US	B-LOC
and	B-DIS
serum	O
thyroglobulin	O
Tg	O
level	O
at	O
136	O
12	O
months	O
and	O
every	O
12	O
months	O
thereafter	O
.	O

Results	O
All	O
the	O
patients	O
were	O
well	O
tolerant	O
to	O
RFA	O
procedure	O
and	O
no	O
procedure	O
-	O
related	O
complications	O
occurred	O
.	O

During	O
a	O
mean	O
follow	O
-	O
up	O
time	O
of	O
52.00	O
±	O
21.44	O
months	O
the	O
initial	O
volume	O
of	O
LNs	O
was	O
0.30	O
±	O
0.38	O
ml	O
which	O
significantly	O
decreased	O
to	O
0.01	O
±	O
0.03	O
ml	O
P	O
=	O
0.005	O
with	O
a	O
mean	O
VRR	O
of	O
99.28	O
±	O
2.27	O
%	O
.	O

A	O
total	O
of	O
9	O
metastatic	O
LNs	O
90.00	B-STAT
%	I-STAT
completely	O
disappeared	O
.	O

After	O
RFA	O
2	O
patients	O
developed	O
newly	O
metastases	O
.	O

One	O
patient	O
had	O
additional	O
RFA	O
.	O

The	O
other	O
one	O
with	O
multiple	O
LN	O
metastases	O
underwent	O
total	O
thyroidectomy	O
with	O
central	O
neck	O
dissection	O
.	O

Conclusion	O
As	O
a	O
less	O
invasive	O
and	O
effective	O
technique	O
RFA	O
may	O
provide	O
another	O
alternative	O
to	O
the	O
existing	O
therapeutic	O
modalities	O
for	O
cervical	O
metastatic	O
LNs	O
in	O
children	O
and	O
adolescents	O
with	O
PTC	B-DIS
.	O

Objective	O
The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
compare	O
the	O
risk	O
and	O
also	O
the	O
types	O
of	O
ictal	O
injuries	O
in	O
three	O
groups	O
of	O
people	O
with	O
seizures	B-DIS
[	O
i.e	O
.	O

IGE	B-DIS
vs.	O
TLE	B-DIS
vs.	O
FS	O
]	O
.	O

Methods	O
This	O
was	O
a	O
retrospective	O
study	O
.	O

All	O
patients	O
with	O
an	O
electro	O
-	O
clinical	O
diagnosis	B-DIS
of	I-DIS
IGE	O
TLE	O
or	O
FS	O
were	O
recruited	O
at	O
the	B-DIS
outpatient	O
epilepsy	O
clinic	O
at	O
Shiraz	O
University	O
of	O
Medical	O
Sciences	O
Shiraz	O
Iran	B-LOC
from	O
2008	O
until	O
2020	O
.	O

Age	O
sex	O
age	O
at	O
seizure	B-DIS
onset	O
seizure	B-DIS
type	O
s	O
and	O
occurrence	O
of	O
ictal	O
injury	O
at	O
any	O
time	O
since	O
the	O
onset	O
of	O
the	O
seizures	B-DIS
and	O
its	O
characteristics	O
were	O
registered	O
routinely	O
for	O
all	O
patients	O
at	O
the	O
time	O
of	O
the	O
first	O
visit	O
.	O

Results	O
One	O
thousand	O
and	O
one	O
hundred	O
seventy	O
-	O
four	O
patients	O
were	O
studied	O
481	O
patients	B-DIS
with	O
IGE	O
402	O
people	B-DIS
with	O
TLE	O
and	O
291	O
persons	O
with	O
FS	O
.	O

While	O
the	O
groups	O
differed	O
in	O
their	O
demographic	O
and	O
clinical	O
characteristics	O
the	O
rates	O
of	O
ictal	O
injury	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
groups	O
.	O

Tongue	O
injury	O
was	O
more	O
frequently	O
reported	O
by	O
patients	O
with	O
TLE	B-DIS
compared	O
with	O
that	O
by	O
people	O
with	O
IGE	B-DIS
or	O
FS	O
.	O

Other	O
types	O
/	O
locations	O
of	O
ictal	O
injury	O
were	O
more	O
or	O
less	O
reported	O
by	O
all	O
three	O
groups	O
of	O
the	O
patients	O
.	O

Conclusion	O
Ictal	O
injuries	O
may	O
happen	O
with	O
more	O
or	O
less	O
similar	O
rates	O
among	O
people	O
with	O
epilepsy	B-DIS
IGE	I-DIS
and	O
TLE	B-DIS
and	O
those	O
with	O
FS	O
.	O

Ictal	O
injury	O
rate	O
type	O
or	O
location	O
should	O
not	O
be	O
used	O
as	O
a	O
marker	O
for	O
any	O
specific	O
diagnosis	O
among	O
people	O
with	O
seizures	B-DIS
.	O

Varicella	B-DIS
is	O
a	O
highly	O
contagious	O
infectious	B-DIS
disease	I-DIS
caused	O
by	O
the	O
varicella	O
-	O
zoster	O
virus	O
.	O

Those	O
at	O
higher	O
risk	O
of	O
severe	O
complications	O
are	O
immunocompromised	O
individuals	O
adults	O
non	O
-	O
immune	O
pregnant	O
women	O
and	O
newborns	O
.	O

According	O
to	O
the	O
gestational	O
time	O
when	O
varicella	B-DIS
-	I-DIS
zoster	I-DIS
virus	O
infection	O
is	O
acquired	O
during	O
pregnancy	O
serious	O
complications	O
can	O
potentially	O
occur	O
for	O
both	O
the	O
woman	O
and	O
the	O
fetus	O
.	O

The	O
present	O
study	O
was	O
conducted	O
to	O
assess	O
the	O
profile	O
of	O
varicella	B-DIS
susceptibility	O
in	O
pregnant	O
women	O
in	O
Apulia	B-LOC
a	O
large	O
region	O
in	O
Southern	B-LOC
Italy	I-LOC
from	O
2016	O
to	O
2019	O
.	O

The	O
data	O
showed	O
that	O
pregnant	O
women	O
between	O
the	O
age	O
of	O
15	O
-	O
24	O
and	O
40	O
-	O
49	O
years	O
the	O
youngest	O
and	O
the	O
oldest	O
respectively	O
are	O
the	O
most	O
protected	O
against	O
varicella	B-DIS
-	I-DIS
zoster	I-DIS
virus	O
infection	O
exceeding	B-EPI
the	O
prevalence	O
rate	O
of	O
90	B-STAT
%	I-STAT
.	O

Conversely	O
pregnant	O
women	O
between	O
the	O
age	O
of	O
25	O
and	O
34	O
years	O
seem	O
to	O
be	O
the	O
most	O
vulnerable	O
and	O
the	O
most	O
at	O
risk	O
for	O
acquiring	O
varicella	B-DIS
-	I-DIS
zoster	I-DIS
virus	O
infection	O
during	O
pregnancy	O
.	O

Analysis	O
of	O
the	O
immunity	O
status	O
against	O
varicella	B-DIS
should	O
be	O
introduced	O
as	O
a	O
screening	O
test	O
before	O
pregnancy	O
together	O
with	O
a	O
strategic	O
vaccination	O
campaign	O
targeting	O
non	O
-	O
immune	O
women	O
of	O
childbearing	O
age	O
in	O
order	O
to	O
reduce	O
the	O
risk	B-DIS
of	I-DIS
congenital	I-DIS
and	I-DIS
perinatal	O
varicella	O
.	O

Constitutional	O
ring	O
chromosomes	O
can	O
be	O
found	O
for	O
all	O
human	O
chromosomes	O
and	O
are	O
very	O
rare	O
chromosomal	O
abnormalities	O
.	O

A	O
complete	O
ring	O
chromosome	O
without	O
loss	O
of	O
genetic	O
material	O
results	O
from	O
fusion	O
of	O
subtelomeric	O
regions	O
or	O
telomere	O
-	O
telomere	O
fusion	O
.	O

In	O
cases	O
of	O
complete	O
ring	O
chromosome	O
an	O
increased	O
incidence	B-EPI
of	O
severe	O
growth	O
failure	O
with	O
no	O
or	O
only	O
minor	O
anomalies	B-DIS
has	O
been	O
observed	O
and	O
attributed	O
to	O
ring	O
syndrome	O
.	O

Ring	O
syndrome	O
is	O
thought	O
to	O
be	O
caused	O
by	O
`	O
`	O
dynamic	O
mosaicism	O
''	O
due	O
to	O
ring	O
instability	O
.	O

We	O
report	O
a	O
6	O
-	O
year	O
-	O
old	O
boy	O
with	O
de	O
novo	O
ring	O
chromosome	O
4	O
and	O
typical	O
characteristics	O
of	O
the	O
ring	O
syndrome	O
namely	B-DIS
proportionate	I-DIS
severe	O
growth	O
failure	B-DIS
microcephaly	O
and	O
minor	O
anomalies	O
.	O

Cytogenetic	O
studies	O
showed	O
complete	O
ring	O
chromosome	O
4	O
with	O
mitotic	O
instability	O
.	O

Microarray	O
gave	O
normal	O
results	O
thus	O
excluding	O
the	O
loss	O
of	O
detectable	O
genetic	O
material	O
.	O

The	O
literature	O
of	O
complete	O
ring	O
chromosome	O
4	O
is	O
reviewed	O
.	O

Our	O
case	O
report	O
supports	O
the	O
theory	O
of	O
ring	O
syndrome	O
.	O

No	O
studies	O
about	O
the	O
effects	O
and	O
possible	O
side	O
effects	O
of	O
growth	O
hormone	O
therapy	O
on	O
patients	O
with	O
ring	O
chromosomes	O
have	O
yet	O
been	O
published	O
.	O

We	O
suggest	O
that	O
cytogenetic	O
monitoring	O
of	O
the	O
rate	O
of	O
secondary	O
aberrations	O
in	O
patients	O
with	O
ring	O
chromosome	O
undergoing	O
growth	O
hormone	O
therapy	O
might	O
be	O
feasible	O
.	O

Since	O
the	O
diagnosis	O
would	O
have	O
been	O
missed	O
by	O
molecular	O
karyotyping	O
our	O
case	O
report	O
underlines	O
the	O
continuing	O
role	O
of	O
classical	O
cytogenetics	O
for	O
the	O
evaluation	O
of	O
structural	O
chromosomal	B-DIS
abnormalities	I-DIS
in	O
patients	O
with	O
mental	O
and/or	O
physical	O
anomalies	O
.	O

Standard	O
karyotyping	O
is	O
still	O
indispensable	O
and	O
should	O
have	O
an	O
ongoing	O
role	O
as	O
first	O
-	O
tier	O
analysis	O
together	O
with	O
molecular	O
karyotyping	O
.	O

©	O
2017	O
Wiley	O
Periodicals	O
Inc	O
.	O

Dyslipidemia	B-DIS
is	O
a	O
major	O
cause	O
of	O
cardiovascular	B-DIS
diseases	I-DIS
which	O
represent	O
a	O
leading	O
cause	O
of	O
death	B-DIS
in	O
humans	O
.	O

Diverse	O
immune	O
cells	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
cardiovascular	B-DIS
diseases	I-DIS
such	O
as	O
atherosclerosis	B-DIS
.	O

Conversely	O
dyslipidemia	B-DIS
is	O
known	O
to	O
be	O
tightly	O
associated	O
with	O
immune	B-DIS
disorders	I-DIS
in	O
humans	O
as	O
evidenced	O
by	O
a	O
higher	O
incidence	B-EPI
of	O
atherosclerosis	B-DIS
in	O
patients	O
with	O
autoimmune	B-DIS
diseases	I-DIS
including	O
psoriasis	B-DIS
rheumatoid	I-DIS
arthritis	I-DIS
and	O
systemic	B-DIS
lupus	I-DIS
erythematosus	I-DIS
.	O

Given	O
that	O
the	O
dyslipidemia	B-DIS
-	I-DIS
related	I-DIS
autoimmune	O
diseases	O
are	O
caused	O
by	O
autoreactive	O
T	O
cells	O
and	O
B	B-DIS
cells	O
dyslipidemia	O
seems	O
to	O
directly	O
or	O
indirectly	O
regulate	O
the	O
adaptive	O
immunity	O
.	O

Indeed	O
accumulating	O
evidence	O
has	O
unveiled	O
that	O
proatherogenic	O
factors	O
can	O
impact	O
the	O
differentiation	O
and	O
function	O
of	O
CD4	O
+	O
<	O
/s	O
T	O
cells	O
CD8	O
+	O
<	O
/s	O
T	O
cells	O
and	O
B	O
cells	O
.	O

This	O
review	O
discusses	O
an	O
updated	O
overview	O
on	O
the	O
regulation	O
of	O
adaptive	O
immunity	O
by	O
dyslipidemia	B-DIS
and	O
proposes	O
a	O
potential	O
therapeutic	O
strategy	O
for	O
immune	B-DIS
disorders	I-DIS
by	O
targeting	O
lipid	O
metabolism	O
.	O

Background	O
The	O
Global	O
Anticoagulant	O
Registry	O
in	O
the	O
FIELD	B-DIS
-	I-DIS
Atrial	O
Fibrillation	O
GARFIELD	O
-	O
AF	O
is	O
an	O
ongoing	O
prospective	O
noninterventional	O
registry	O
which	O
is	O
providing	O
important	O
information	O
on	O
the	O
baseline	O
characteristics	O
treatment	O
patterns	O
and	O
1	O
-	O
year	O
outcomes	O
in	B-DIS
patients	I-DIS
with	I-DIS
newly	O
diagnosed	O
non	O
-	O
valvular	O
atrial	O
fibrillation	O
NVAF	O
.	O

This	O
report	O
describes	O
data	O
from	O
Indian	O
patients	O
recruited	O
in	O
this	O
registry	O
.	O

Methods	O
and	O
results	O
A	O
total	O
of	O
52014	O
patients	O
with	O
newly	O
diagnosed	O
AF	B-DIS
were	O
enrolled	O
globally	O
;	O
of	O
these	O
1388	O
patients	O
were	O
recruited	O
from	O
26	O
sites	O
within	O
India	B-LOC
2012	O
-	O
2016	O
.	O

In	O
India	B-LOC
the	O
mean	O
age	O
was	O
65.8	O
years	O
at	O
diagnosis	O
of	O
NVAF	B-DIS
.	O

Hypertension	B-DIS
was	O
the	O
most	O
prevalent	O
risk	O
factor	O
for	O
AF	O
present	O
in	O
68.5	B-STAT
%	I-STAT
of	O
patients	O
from	O
India	B-LOC
and	O
in	O
76.3	B-STAT
%	I-STAT
of	O
patients	O
globally	O
P	O
<	O
0.001	O
.	O

Diabetes	B-DIS
and	O
coronary	B-DIS
artery	I-DIS
disease	I-DIS
CAD	O
were	O
prevalent	O
in	O
36.2	B-STAT
%	I-STAT
and	O
28.1	B-STAT
%	I-STAT
of	O
patients	O
as	O
compared	O
with	O
global	O
prevalence	B-EPI
of	O
22.2	B-STAT
%	I-STAT
and	O
21.6	B-STAT
%	I-STAT
respectively	O
P	O
<	O
0.001	O
for	O
both	O
.	O

Antiplatelet	O
therapy	O
was	O
the	O
most	O
common	O
antithrombotic	O
treatment	O
in	O
India	B-LOC
.	O

With	O
increasing	O
stroke	B-DIS
risk	O
however	O
patients	O
were	O
more	O
likely	O
to	O
receive	O
oral	O
anticoagulant	O
therapy	O
[	O
mainly	O
vitamin	O
K	O
antagonist	O
VKA	O
]	O
but	O
average	O
international	O
normalized	O
ratio	O
INR	O
was	O
lower	O
among	O
Indian	O
patients	O
[	O
median	O
INR	O
value	O
1.6	O
interquartile	O
range	O
{	O
IQR	O
}	O
1.3	O
-	O
2.3	O
versus	O
2.3	O
IQR	O
1.8	O
-	O
2.8	O
P	O
<	O
0.001	O
]	O
.	O

Compared	O
with	O
other	O
countries	O
patients	O
from	O
India	B-LOC
had	O
markedly	O
higher	O
rates	O
of	O
all	O
-	O
cause	O
mortality	O
[	O
7.68	O
per	O
100	O
person	O
-	O
years	O
95	B-STAT
%	I-STAT
confidence	O
interval	O
6.32	O
-	O
9.35	O
vs	O
4.34	O
4.16	O
-	O
4.53	O
P	O
<	O
0.0001	O
]	O
while	B-DIS
rates	O
of	B-DIS
stroke	I-DIS
/	O
systemic	O
embolism	O
and	O
major	O
bleeding	O
were	O
lower	O
after	O
1	O
year	O
of	O
follow	O
-	O
up	O
.	O

Conclusion	O
Compared	O
to	O
previously	O
published	O
registries	O
from	O
India	B-LOC
the	O
GARFIELD	O
-	O
AF	O
registry	O
describes	O
clinical	O
profiles	O
and	O
outcomes	O
in	O
Indian	O
patients	O
with	O
AF	O
of	O
a	O
different	O
etiology	O
.	O

The	O
registry	O
data	O
show	O
that	O
compared	O
to	O
the	O
rest	O
of	O
the	O
world	O
Indian	O
AF	O
patients	O
are	O
younger	O
in	O
age	O
and	O
have	O
more	O
diabetes	B-DIS
and	O
CAD	B-DIS
.	O

Patients	O
with	O
a	O
higher	O
stroke	B-DIS
risk	O
are	O
more	O
likely	O
to	O
receive	O
anticoagulation	O
therapy	O
with	O
VKA	O
but	O
are	O
underdosed	O
compared	O
with	O
the	O
global	O
average	O
in	O
the	O
GARFIELD	O
-	O
AF	O
.	O

CLINICAL	O
TRIAL	O
REGISTRATION	O
-	O
URL	O
http//www.clinicaltrials.gov	O
.	O

Unique	O
identifier	O
NCT01090362	O
.	O

The	O
increasing	O
prevalence	B-EPI
of	O
AF	B-DIS
in	O
a	O
growing	O
population	O
of	O
adults	O
with	O
congenital	B-DIS
heart	I-DIS
disease	I-DIS
CHD	O
poses	O
new	O
challenges	O
to	O
clinicians	O
involved	O
in	O
the	O
management	O
of	O
these	O
patients	O
.	O

Distinctive	O
underlying	O
anatomies	O
unique	O
physiological	O
aspects	O
a	O
high	O
diversity	O
of	O
corrective	O
surgeries	O
and	O
associated	O
comorbidities	O
can	O
complicate	O
clinical	O
decision	O
-	O
making	O
.	O

In	O
this	O
review	O
the	O
authors	O
provide	O
an	O
overview	O
of	O
the	O
current	O
knowledge	O
on	O
epidemiology	O
and	O
pathophysiology	O
with	O
a	O
special	O
focus	O
on	O
the	O
differences	O
to	O
the	O
non	O
-	O
CHD	O
population	O
and	O
the	O
clinical	O
impact	O
of	O
AF	O
in	O
adults	O
with	O
CHD	O
.	O

Acute	O
and	O
long	O
-	O
term	O
management	O
strategies	O
are	O
summarised	O
including	O
the	O
use	O
of	O
antiarrhythmic	O
drugs	O
catheter	O
or	O
surgical	O
ablation	O
and	O
prophylaxis	B-DIS
of	O
thromboembolism	O
.	O

Finally	O
gaps	O
of	O
knowledge	O
and	O
potential	O
areas	O
of	O
future	O
research	O
are	O
highlighted	O
.	O

The	O
authors	O
analyse	O
descriptions	O
of	O
Greenlandic	O
and	O
Faroese	O
medicine	O
found	O
in	O
an	O
Italian	O
medical	O
publication	O
from	O
the	O
18th	O
century	O
entitled	O
Europae	O
Medicina	O
a	O
Sapientibus	O
Illustrata	O
[	O
…	O
]	O
which	O
was	O
printed	O
in	O
Brescia	B-LOC
in	O
Northern	B-LOC
Italy	I-LOC
in	O
1747	O
.	O

The	O
author	O
of	O
these	O
descriptions	O
Francesco	O
Roncalli	O
Parolino	O
1692	O
-	O
1769	O
was	O
a	O
renowned	O
European	O
physician	O
.	O

Roncalli	O
Parolino	O
focused	O
his	O
study	O
on	O
the	O
treatment	O
of	O
scurvy	B-DIS
and	O
he	O
promoted	O
the	O
inclusion	O
of	O
the	O
Greenlandic	O
and	O
Faroese	O
therapy	O
into	O
the	O
broader	O
European	O
context	O
.	O

He	O
was	O
influenced	O
to	O
do	O
this	O
due	O
to	O
the	O
already	O
integrated	O
European	O
perspective	O
of	O
medicine	O
which	O
his	O
book	O
follows	O
.	O
Like	O
now	O
medicine	O
in	O
18th	O
-	O
century	O
Europe	B-LOC
was	O
multicentric	O
and	O
characterised	O
by	O
rich	O
intellectual	O
activity	O
which	O
contributed	O
to	O
the	O
enhancement	O
of	O
clinical	O
practice	O
during	O
this	O
period	O
.	O

At	O
the	O
time	O
Greenland	B-LOC
and	O
Faroe	B-LOC
Islands	I-LOC
were	O
also	O
integrated	O
into	O
this	O
European	O
context	O
because	O
they	O
contributed	O
for	O
medical	O
-	O
scientific	O
development	O
that	O
would	O
lay	O
the	O
foundations	O
for	O
modern	O
medicine	O
.	O

Francesco	O
Roncalli	O
Parolino	O
obtained	O
just	O
recognition	O
for	O
these	O
regions	O
through	O
the	O
advancement	O
and	O
defence	O
of	O
their	O
valuable	O
medical	O
contributions	O
.	O

Background	O
Premarital	O
sex	O
practices	O
and	O
contraceptive	O
prevalence	B-EPI
rate	O
CPR	O
among	O
unmarried	O
women	O
worldwide	O
remain	O
unclear	O
even	O
though	O
unmarried	O
women	O
tend	O
to	O
have	O
multiple	O
sex	O
partners	O
over	O
time	O
which	O
makes	O
their	O
sexual	B-DIS
behaviors	I-DIS
particularly	O
important	O
to	O
the	O
sexual	O
and	O
reproductive	O
health	O
of	O
society	O
more	O
broadly	O
.	O

Methods	O
We	O
searched	O
the	O
MEDLINE	O
PubMed	O
and	O
Google	O
Scholar	O
databases	O
for	O
relevant	O
articles	O
published	O
between	O
January	O
11999	O
and	O
December	O
312018	O
.	O

Data	O
on	O
prevalence	B-EPI
of	O
premarital	O
sexual	O
intercourse	O
use	O
of	O
highly	O
prevalent	O
contraceptive	O
methods	O
as	O
well	O
as	O
CPR	O
overall	O
and	O
at	O
first	O
sexual	O
intercourse	O
were	O
extracted	O
and	O
estimated	O
using	O
a	O
DerSimonian-	O
Laird	O
random	O
effects	O
model	O
.	O

Results	O
Of	O
the	O
3918	O
articles	O
identified	O
37	O
covering	O
19	O
countries	O
were	O
included	O
.	O

The	O
estimated	O
overall	O
prevalence	B-EPI
of	O
premarital	O
sexual	O
intercourse	O
was	O
41.9	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
34.2	B-STAT
-	I-STAT
49.6	I-STAT
%	I-STAT
.	O

Pooled	O
CPR	O
was	O
57.0	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
44.3	B-STAT
-	I-STAT
69.8	I-STAT
%	I-STAT
overall	O
and	O
57.6	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
39.5-	O
75.6	B-STAT
%	I-STAT
at	O
first	O
intercourse	O
.	O

The	O
overall	O
prevalence	B-EPI
of	O
condom	O
use	O
was	O
51.2	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
42.7	O
-	O
59.7	O
%	O
followed	O
by	O
oral	O
contraceptives	O
20.5	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
13.7	B-STAT
-	I-STAT
27.3	I-STAT
%	I-STAT
withdrawal	O
12.7	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
9.4	B-STAT
-	I-STAT
15.9	I-STAT
%	I-STAT
and	O
rhythm	O
12.1	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
6.7	B-STAT
-	I-STAT
17.4	I-STAT
%	I-STAT
.	O

Conclusion	O
The	O
findings	O
of	O
this	O
global	O
study	O
indicate	O
worrying	O
trends	O
in	O
unprotected	O
intercourse	O
and	O
contraceptive	O
practices	O
suggesting	O
the	O
need	O
for	O
greater	O
attention	O
and	O
resources	O
aimed	O
at	O
educating	O
unmarried	O
adolescent	O
women	O
about	O
sexual	O
and	O
reproductive	O
health	O
.	O

Systematic	O
review	O
registration	O
number	O
CRD42019132736	O
.	O

Background	O
and	O
objective	O
Congenital	B-DIS
adrenal	I-DIS
hyperplasia	I-DIS
involves	O
a	O
series	O
of	O
autosomal	B-DIS
recessive	I-DIS
disorders	I-DIS
where	O
adrenal	O
steroidogenesis	O
is	O
affected	O
.	O

We	O
present	O
a	O
detailed	O
molecular	O
investigation	O
of	O
13	O
newborns	O
affected	O
from	O
the	O
severe	O
form	O
of	O
congenital	B-DIS
adrenal	I-DIS
hyperplasia	I-DIS
related	O
to	O
21	B-DIS
-	I-DIS
hydroxylase	O
deficiency	O
.	O

Methods	O
All	O
patients	O
were	O
diagnosed	O
with	O
classical	O
congenital	B-DIS
adrenal	I-DIS
hyperplasia	I-DIS
in	O
the	O
neonatal	O
period	O
due	O
to	O
adrenal	O
crisis	O
and/or	O
ambiguous	O
genitalia	O
presentation	O
.	O

None	O
of	O
the	O
infants	O
was	O
identified	O
through	O
a	O
congenital	B-DIS
adrenal	I-DIS
hyperplasia	I-DIS
newborn	I-DIS
screening	O
program	O
.	O

A	O
molecular	O
analysis	O
of	O
the	O
CYP21A2	O
gene	O
and	O
a	O
familiar	O
segregation	O
analysis	O
were	O
performed	O
.	O

Results	O
Adrenal	O
crisis	O
was	O
the	O
most	O
severe	O
manifestation	O
in	O
the	O
male	O
salt	O
-	O
wasting	O
newborns	O
while	O
all	O
female	O
patients	O
presented	O
with	O
atypical	O
genitalia	O
.	O

Newborns	O
were	O
correctly	O
genotyped	O
and	O
no	O
genotype	O
-	O
phenotype	O
divergences	O
were	O
found	O
.	O

Two	O
novel	O
severe	O
genotypes	O
not	O
previously	O
reported	O
were	O
identified	O
.	O

The	O
novel	O
CYP21A2	O
frameshift	O
mutations	O
c.793delG	O
and	O
c.297dupG	O
were	O
added	O
to	O
the	O
other	O
45	O
variants	O
recently	O
reported	O
in	O
the	O
literature	O
leading	O
to	O
a	O
total	O
count	O
of	O
279	O
pathogenic	O
variants	O
affecting	O
the	O
gene	O
.	O

Conclusions	O
We	O
have	O
successfully	O
genotyped	O
13	O
infants	O
diagnosed	O
with	O
classical	O
congenital	B-DIS
adrenal	I-DIS
hyperplasia	I-DIS
after	O
birth	O
.	O

Our	O
molecular	O
approach	O
led	O
to	O
the	O
identification	O
of	O
two	O
novel	O
frameshift	O
CYP21A2	O
pathogenic	O
variants	O
related	O
to	O
the	O
salt	O
-	O
wasting	O
form	B-DIS
of	I-DIS
congenital	I-DIS
adrenal	O
hyperplasia	O
.	O

Aarskog	B-DIS
-	I-DIS
Scott	O
syndrome	O
is	O
a	O
genetically	O
and	O
clinically	O
heterogeneous	O
rare	O
condition	O
caused	O
by	O
a	O
pathogenic	O
variant	O
in	O
the	O
FGD1	O
gene	O
.	O

A	O
systematic	O
review	O
was	O
carried	O
out	O
to	O
analyse	O
the	O
prevalence	B-EPI
of	O
clinical	O
manifestations	O
found	O
in	O
patients	O
as	O
well	O
as	O
to	O
evaluate	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
.	O

The	O
results	O
obtained	O
show	O
that	O
clinical	O
findings	O
of	O
the	O
craniofacial	O
orthopaedic	O
and	O
genitourinary	B-DIS
tract	I-DIS
correspond	O
to	O
the	O
highest	O
scores	O
of	O
prevalence	B-EPI
.	O

The	O
authors	O
reclassified	O
the	O
primary	O
secondary	O
and	O
additional	O
criteria	O
based	O
on	O
their	O
prevalence	B-EPI
.	O

Furthermore	O
it	O
was	O
possible	O
to	O
observe	O
in	O
accordance	O
with	O
previous	O
reports	O
that	O
the	O
reported	O
phenotypes	O
do	O
not	O
present	O
a	O
direct	O
relation	O
to	O
the	O
underlying	O
genotypes	O
.	O

Anaphylaxis	B-DIS
is	O
a	O
severe	O
allergic	B-DIS
reaction	I-DIS
rapid	O
in	O
onset	O
and	O
can	O
lead	O
to	O
fatal	O
consequences	O
if	O
not	O
promptly	O
treated	O
.	O

The	O
incidence	B-EPI
of	O
anaphylaxis	B-DIS
has	O
risen	O
at	O
an	O
alarming	O
rate	O
in	O
past	O
decades	O
and	O
continues	O
to	O
rise	O
.	O

Therefore	O
there	O
is	O
a	O
general	O
interest	O
in	O
understanding	O
the	O
molecular	O
mechanism	O
that	O
leads	O
to	O
an	O
exacerbated	O
response	O
.	O

The	O
main	O
effector	O
cells	O
are	O
mast	O
cells	O
commonly	O
triggered	O
by	O
stimuli	O
that	O
involve	O
the	O
IgE	O
-	O
dependent	O
or	O
IgE	O
-	O
independent	O
pathway	O
.	O

These	O
signaling	O
pathways	O
converge	O
in	O
the	O
release	O
of	O
proinflammatory	O
mediators	O
such	O
as	O
histamine	O
tryptases	O
prostaglandins	O
etc	O
.	O

in	O
minutes	O
.	O

The	O
action	O
and	O
cell	O
targets	O
of	O
these	O
proinflammatory	O
mediators	O
are	O
linked	O
to	O
the	O
pathophysiologic	O
consequences	O
observed	O
in	O
this	O
severe	O
allergic	B-DIS
reaction	I-DIS
.	O

While	O
many	O
molecules	O
are	O
involved	O
in	O
cellular	O
regulation	O
the	O
expression	O
and	O
regulation	O
of	O
transcription	O
factors	O
involved	O
in	O
the	O
synthesis	O
of	O
proinflammatory	O
mediators	O
and	O
secretory	O
granule	O
homeostasis	O
are	O
of	O
special	O
interest	O
due	O
to	O
their	O
ability	O
to	O
control	O
gene	O
expression	O
and	O
change	O
phenotype	O
and	O
they	O
may	O
be	O
key	O
in	O
the	O
severity	O
of	O
the	O
entire	O
reaction	O
.	O

In	O
this	O
review	O
we	O
will	O
describe	O
our	O
current	O
understanding	O
of	O
the	O
pathophysiology	O
of	O
human	O
anaphylaxis	B-DIS
focusing	O
on	O
the	O
transcription	O
factors	O
'	O
contributions	O
to	O
this	O
systemic	O
hypersensitivity	B-DIS
reaction	O
.	O

Host	O
mutation	O
in	O
transcription	O
factor	O
expression	O
or	O
deregulation	O
of	O
their	O
activity	O
in	O
an	O
anaphylaxis	B-DIS
context	O
will	O
be	O
updated	O
.	O

So	O
far	O
the	O
risk	O
of	O
anaphylaxis	B-DIS
is	O
unpredictable	O
thus	O
increasing	O
our	O
knowledge	O
of	O
the	O
molecular	O
mechanism	O
that	O
leads	O
and	O
regulates	O
mast	O
cell	O
activity	O
will	O
enable	O
us	O
to	O
improve	O
our	O
understanding	O
of	O
how	O
anaphylaxis	B-DIS
can	O
be	O
prevented	O
or	O
treated	O
.	O

The	O
10th	O
International	O
Meeting	O
on	O
Neuroacanthocytosis	B-DIS
Syndromes	O
was	O
held	O
online	O
on	O
March	O
10th12th	O
2021	O
.	O

The	O
COVID19	O
pandemic	O
situation	O
made	O
our	O
planned	O
meeting	O
in	O
Barcelona	B-LOC
on	O
March	O
2020	O
to	O
be	O
suspended	O
by	O
one	O
year	O
and	O
finally	O
took	O
place	O
online	O
.	O

The	O
meeting	O
followed	O
the	O
previous	O
nine	O
international	O
symposia	O
the	O
last	O
of	O
which	O
was	O
held	O
in	O
Dresden	B-LOC
Germany	I-LOC
in	O
March	O
2018	O
.	O

The	O
setting	O
of	O
the	O
meeting	O
encouraged	O
interactions	O
exchange	O
of	O
ideas	O
and	O
networking	O
opportunities	O
among	O
the	O
high	O
number	O
of	O
participants	O
from	O
around	O
the	O
globe	O
including	O
scientists	O
neurologists	O
and	O
specially	O
patients	O
and	O
caregivers	O
.	O

A	O
total	O
of	O
27	O
oral	O
communications	O
were	O
distributed	O
in	O
8	O
sessions	O
with	O
topics	O
ranging	O
from	O
molecular	O
and	O
cellular	O
functions	O
of	O
VPS13	O
genes	O
and	O
proteins	O
their	O
involvement	O
in	O
Neuroacanthocytosis	B-DIS
Syndromes	I-DIS
and	O
finally	O
clinical	O
aspects	O
and	O
patients	O
care	O
.	O

In	O
addition	O
5	O
posters	O
were	O
presented	O
.	O

Altogether	O
scientists	O
and	O
neurologists	O
discussed	O
recent	O
advances	O
and	O
set	O
the	O
bases	O
for	O
next	O
steps	O
action	O
points	O
and	O
future	O
studies	O
in	O
close	O
collaboration	O
with	O
the	O
patients	O
associations	O
which	O
are	O
always	O
actively	O
involved	O
in	O
the	O
whole	O
process	O
.	O

The	O
field	O
of	O
Cardio	O
-	O
oncology	O
is	O
rapidly	O
growing	O
with	O
significant	O
advances	O
in	O
research	O
leading	O
to	O
better	O
understanding	O
of	O
the	O
underlying	O
pathogenesis	O
with	O
implications	O
in	O
the	O
diagnosis	O
and	O
management	O
of	B-DIS
cancer	O
-	O
related	O
cardiomyopathy	O
.	O

Parallel	O
to	O
advancement	O
in	O
cardio	O
-	O
oncology	O
is	O
an	O
increased	O
awareness	O
of	B-EPI
the	O
incidence	B-DIS
of	I-DIS
congestive	I-DIS
heart	O
failure	B-DIS
and	O
cardiomyopathy	O
associated	B-DIS
with	O
malignancy	O
.	O

While	O
specific	O
cardiotoxic	B-DIS
profiles	O
exist	O
for	O
certain	O
chemotherapeutic	O
agents	O
there	O
is	O
increasing	O
evidence	O
of	O
unexpected	O
cardiotoxic	B-DIS
side	O
effects	O
of	O
some	O
therapeutic	O
modalities	O
combination	O
chemo-	O
and	O
radiotherapy	O
with	O
large	O
analyses	O
identifying	O
a	O
strong	O
association	O
between	O
malignancy	B-DIS
and	O
Takotsubo	B-DIS
cardiomyopathy	I-DIS
.	O

Takotsubo	B-DIS
Cardiomyopathy	I-DIS
also	O
known	O
as	O
`	O
`	O
broken	B-DIS
-	I-DIS
heart	I-DIS
''	O
syndrome	B-DIS
or	I-DIS
stress	O
cardiomyopathy	O
is	O
characterized	O
by	O
transient	O
and	O
reversible	O
regional	O
or	B-DIS
global	I-DIS
myocardial	O
dysfunction	O
without	O
inciting	O
ischemic	O
perfusion	O
defect	B-DIS
from	I-DIS
obstructive	I-DIS
coronary	I-DIS
artery	O
disease	O
.	O

While	O
direct	O
causative	O
pathophysiologic	O
mechanisms	O
continue	O
to	O
be	O
investigated	O
much	O
of	O
the	O
postulated	O
pathways	O
center	O
on	O
the	O
high	O
emotional	O
and	O
physical	O
burdens	O
of	O
cancer	B-DIS
and	O
the	O
related	O
emotional	O
stress	O
associated	O
with	O
the	O
diagnosis	O
of	O
cancer	B-DIS
as	O
well	O
as	O
the	O
corporal	O
effects	O
of	O
anti	O
-	O
neoplastic	O
therapies	O
radiation	O
and	O
oncologic	O
surgery	O
.	O

In	O
this	O
manuscript	O
we	O
review	O
the	O
most	O
current	O
data	O
in	O
this	O
rapidly	O
emerging	O
field	O
highlighting	O
the	O
epidemiology	O
the	O
postulated	O
pathogenetic	O
mechanisms	O
as	O
well	O
as	O
the	O
current	O
guidelines	O
by	O
major	O
societies	O
addressing	O
malignancy	B-DIS
-associated	O
heart	B-DIS
failure	I-DIS
and	O
cardiomyopathy	B-DIS
a	O
rather	O
complex	O
disease	O
entity	O
with	O
high	O
morbidity	O
and	O
mortality	O
.	O

Snakebites	O
in	O
Europe	B-LOC
are	O
mostly	O
due	O
to	O
bites	O
from	O
Viperidae	O
species	O
of	O
the	O
genus	O
Vipera	O
.	O

This	O
represents	O
a	O
neglected	O
public	O
health	O
hazard	O
with	O
poorly	O
defined	O
incidence	B-EPI
morbidity	O
and	O
mortality	O
.	O

In	O
Europe	B-LOC
fourteen	O
species	O
of	O
`	O
`	O
true	O
vipers	O
''	O
subfamily	O
Viperinae	O
are	O
present	O
eleven	O
of	O
which	O
belong	O
to	O
the	O
genus	O
Vipera	O
.	O

Amongst	O
these	O
the	O
main	O
medically	O
relevant	O
species	O
due	O
to	O
their	O
greater	O
diffusion	O
across	O
Europe	B-LOC
and	O
the	O
highest	O
number	O
of	O
registered	O
snakebites	B-DIS
are	O
six	O
namely	O
Vipera	B-DIS
ammodytes	I-DIS
V.	I-DIS
aspis	I-DIS
V.	I-DIS
berus	I-DIS
V.	I-DIS
latastei	I-DIS
V.	I-DIS
seoanei	I-DIS
and	I-DIS
V.	I-DIS
ursinii	I-DIS
.	O

Generally	O
speaking	O
viper	O
venom	O
composition	O
is	O
characterised	O
by	O
many	O
different	O
toxin	O
families	O
like	O
phospholipases	O
A2	O
snake	O
venom	O
serine	O
proteases	O
snake	O
venom	O
metalloproteases	O
cysteine	O
-	O
rich	O
secretory	O
proteins	O
C	O
-	O
type	O
lectins	O
disintegrins	B-DIS
haemorrhagic	I-DIS
factors	O
and	O
coagulation	O
inhibitors	O
.	O

A	O
suspected	O
snakebite	B-DIS
is	O
often	O
associated	O
with	O
severe	O
pain	B-DIS
erythema	I-DIS
oedema	I-DIS
and	O
subsequently	O
the	O
onset	O
of	O
an	O
ecchymotic	B-DIS
area	O
around	O
one	O
or	O
two	O
visible	O
fang	O
marks	O
.	O

In	O
the	O
field	O
the	O
affected	O
limb	O
should	O
be	O
immobilised	O
and	O
mildly	O
compressed	O
with	O
a	O
bandage	O
which	O
can	O
then	O
be	O
removed	O
once	O
the	O
patient	O
is	O
being	O
treated	O
in	O
hospital	O
.	O

The	O
clinician	O
should	O
advise	O
the	O
patient	O
to	O
remain	O
calm	O
to	O
reduce	O
blood	O
circulation	O
and	O
therefore	O
decrease	O
the	O
spread	O
of	O
the	O
toxins	O
.	O

In	O
the	O
case	O
of	O
pain	B-DIS
an	O
analgesic	O
therapy	O
can	O
be	O
administered	O
the	O
affected	O
area	O
can	O
be	O
treated	O
with	O
hydrogen	O
peroxide	O
or	O
clean	O
water	O
.	O

However	O
anti	O
-	O
inflammatory	O
drugs	O
and	O
disinfection	O
with	O
alcohol	O
or	O
alcoholic	O
substances	O
should	O
be	O
avoided	O
.	O

For	O
each	O
patient	O
clinical	O
chemistry	O
and	O
ECG	O
are	O
always	O
a	O
pre	O
-	O
requisite	O
as	O
well	O
as	O
the	O
evaluation	O
of	B-DIS
the	O
tetanus	O
immunisation	O
status	O
and	O
for	O
which	O
immunisation	O
may	O
be	O
provided	O
if	O
needed	O
.	O

The	O
treatment	O
of	O
any	O
clinical	O
complication	O
due	O
to	O
the	O
envenomation	B-DIS
does	O
not	O
differ	O
from	O
treatments	O
of	O
emergency	O
nature	O
.	O

Antivenom	O
is	O
recommended	O
when	O
signs	O
of	O
systemic	B-DIS
envenomation	I-DIS
exist	O
or	O
in	O
case	O
of	O
advanced	O
local	O
or	O
systemic	O
progressive	O
symptoms	O
.	O

Recommendations	O
for	O
future	O
work	O
concludes	O
.	O

The	O
aim	O
of	O
this	O
review	O
is	O
to	O
support	O
clinicians	O
for	O
the	O
clinical	O
management	O
of	O
viper	B-DIS
envenomation	I-DIS
through	O
taxonomic	O
keys	O
for	O
main	O
species	O
identification	O
description	O
of	O
venom	O
composition	O
and	O
mode	O
of	O
action	O
of	O
known	O
toxins	O
and	O
provide	O
a	O
standardised	O
clinical	O
protocol	O
and	O
antivenom	O
administration	O
.	O

Background	O
Kawasaki	B-DIS
disease	I-DIS
KD	O
incidence	B-EPI
is	O
increasing	O
in	O
Ontario	B-LOC
.	O

Cardiovascular	B-DIS
sequelae	I-DIS
following	O
KD	O
are	O
well	O
-	O
described	O
.	O

However	O
there	O
are	O
limited	O
data	O
on	O
non	O
-	O
cardiovascular	O
outcomes	O
.	O

Objectives	O
To	O
determine	O
the	O
risk	O
of	O
hearing	B-DIS
loss	I-DIS
anxiety	I-DIS
developmental	O
disorders	B-DIS
intellectual	I-DIS
disabilities	I-DIS
and	O
attention	B-DIS
-	I-DIS
deficit	I-DIS
/	O
hyperactivity	O
disorder	O
ADHD	O
among	O
KD	O
survivors	O
vs.	O
non	O
-	O
exposed	O
children	O
.	O

Methods	O
We	O
included	O
all	O
Ontario	O
children	O
≤18	O
yr	O
surviving	O
hospitalization	O
with	O
a	O
KD	O
diagnosis	O
between	O
1995	O
and	O
2018	O
using	O
population	O
-	O
based	O
health	O
administrative	O
databases	O
.	O

We	O
excluded	O
children	O
with	O
prior	O
KD	O
diagnoses	O
and	O
non	O
-	O
residents	O
.	O

KD	O
cases	O
were	O
matched	O
with	O
100	O
non	O
-	O
exposed	O
children	O
by	O
age	O
sex	O
and	O
year	O
.	O

Follow	O
-	O
up	O
continued	B-DIS
until	O
death	O
or	O
March	O
2019	O
.	O

We	O
calculated	O
the	O
prevalence	B-EPI
incidence	B-EPI
and	O
adjusted	O
hazard	O
ratios	O
aHR	O
[	O
95	B-STAT
%	I-STAT
CI	O
]	O
of	O
outcomes	O
between	O
0	O
-	O
1	B-STAT
yr	I-STAT
1	B-STAT
-	I-STAT
5	I-STAT
yr	O
5	O
-	O
10	O
yr	O
an	O
10	O
yr	O
follow	O
-	O
up	O
.	O

Results	O
Among	O
4597	O
KD	O
survivors	O
3647.9	B-STAT
%	I-STAT
were	O
diagnosed	O
with	O
hearing	B-DIS
loss	I-DIS
121326.4	B-STAT
%	I-STAT
anxiety	B-DIS
disorders	O
3988.7	B-STAT
%	I-STAT
developmental	O
disorders	O
511.1	B-STAT
%	I-STAT
intellectual	B-DIS
disability	I-DIS
and	O
210.5	B-STAT
%	I-STAT
ADHD	B-DIS
during	O
median	O
11	O
year	O
follow	O
-	O
up	O
.	O

Compared	O
to	O
459700	O
non	O
-	O
exposed	O
children	O
KD	O
survivors	O
were	O
not	O
at	O
increased	O
risk	B-DIS
of	I-DIS
hearing	O
loss	O
after	O
adjustment	O
for	O
potential	O
confounders	O
.	O

KD	O
survivors	O
were	O
at	O
increased	O
risk	O
of	O
anxiety	B-DIS
disorders	O
between	O
0	O
-	O
1	O
yr	O
aHR	O
1.75	O
[	O
1.46	O
-	O
2.10	O
]	O
1	B-STAT
-	I-STAT
5	I-STAT
yr	O
aHR	O
1.13	O
[	O
1.01	O
-	O
1.28	O
]	O
5	O
-	O
10	O
yr	O
aHR	O
1.14	O
[	O
1.03	O
-	O
1.28	O
]	O
an	O
10	O
yr	O
aHR	O
1.11	O
[	O
1.02	O
-	O
1.22	O
]	O
;	O
developmental	O
disorders	O
between	O
0	O
-	O
1	O
yr	O
aHR	O
1.49	O
[	O
1.28	O
-	O
1.74	O
]	O
and	O
1	B-STAT
-	I-STAT
5	I-STAT
yr	O
aHR	O
1.19	O
[	O
1.02	O
-	O
1.40	O
]	O
;	O
intellectual	O
disabilitie	O
10	O
yr	O
aHR	O
2.36	O
[	O
1.36	O
-	O
4.10	O
]	O
;	O
and	O
ADH	O
10	O
yr	O
aHR	O
2.01	O
[	O
1.14	O
-	O
3.57	O
]	O
.	O

Conclusions	O
KD	O
survivors	O
are	O
at	O
increased	O
risk	O
of	O
being	O
diagnosed	O
with	O
anxiety	B-DIS
disorders	I-DIS
sooner	O
being	O
diagnosed	O
with	O
developmental	B-DIS
disorders	I-DIS
between	O
0	O
and	O
5	O
yr	O
and	O
being	O
diagnosed	O
with	O
intellectual	B-DIS
disabilities	I-DIS
or	O
ADH	O
10	O
yr	O
after	O
KD	O
diagnosis	O
.	O

This	O
may	O
justify	O
enhanced	O
developmental	O
and	O
audiological	O
surveillance	O
of	O
KD	O
survivors	O
.	O

Purpose	O
of	O
review	O
Cardiovascular	B-DIS
toxicity	I-DIS
is	O
a	O
leading	O
cause	O
of	O
mortality	O
among	O
cancer	B-DIS
survivors	O
and	O
has	O
become	O
increasingly	O
prevalent	O
due	O
to	O
improved	O
cancer	B-DIS
survival	O
rates	O
.	O

In	O
this	O
review	O
we	O
synthesize	O
evidence	O
illustrating	O
how	O
common	O
cancer	O
therapeutic	O
agents	O
such	O
as	O
anthracyclines	O
human	O
epidermal	O
growth	O
factors	O
receptors	O
HER2	O
monoclonal	O
antibodies	O
and	O
tyrosine	O
kinase	O
inhibitors	O
TKIs	O
have	O
been	O
evaluated	O
in	O
cardiomyocytes	O
CMs	O
derived	O
from	O
human	O
-	O
induced	O
pluripotent	O
stem	O
cells	O
hiPSCs	O
to	O
understand	O
the	O
underlying	O
mechanisms	B-DIS
of	I-DIS
cardiovascular	O
toxicity	O
.	O

We	O
place	O
this	O
in	O
the	O
context	O
of	O
precision	O
cardio	O
-	O
oncology	O
an	O
emerging	O
concept	O
for	O
personalizing	O
the	O
prevention	O
and	O
management	B-DIS
of	I-DIS
cardiovascular	O
toxicities	B-DIS
from	O
cancer	O
therapies	O
accounting	O
for	O
each	O
individual	O
patient	O
's	O
unique	O
factors	O
.	O

We	O
outline	O
steps	O
that	O
will	O
need	O
to	O
be	O
addressed	O
by	O
multidisciplinary	O
teams	O
of	O
cardiologists	O
and	O
oncologists	O
in	O
partnership	O
with	O
regulators	O
to	O
implement	O
future	O
applications	O
of	O
hiPSCs	O
in	O
precision	O
cardio	O
-	O
oncology	O
.	O

Recent	O
findings	O
Current	O
prevention	O
of	O
cardiovascular	B-DIS
toxicity	I-DIS
involves	O
routine	O
screenings	O
and	O
management	O
of	O
modifiable	O
risk	O
factors	O
for	O
cancer	B-DIS
patients	O
as	O
well	O
as	O
the	O
initiation	O
of	O
cardioprotective	O
medications	O
.	O

Despite	O
recent	O
advancements	O
in	O
precision	O
cardio	O
-	O
oncology	O
knowledge	O
gaps	O
remain	O
and	O
limit	O
our	O
ability	O
to	O
appropriately	O
predict	O
with	O
precision	O
which	O
patients	O
will	B-DIS
develop	I-DIS
cardiovascular	O
toxicity	O
.	O

Investigations	O
using	O
patient	O
-	O
specific	O
CMs	O
facilitate	O
pharmacological	O
discovery	B-DIS
mechanistic	O
toxicity	O
studies	O
and	O
the	O
identification	O
of	O
cardioprotective	O
pathways	O
.	O

Studies	O
with	O
hiPSCs	O
demonstrate	O
that	O
patients	O
with	O
comorbidities	O
have	O
more	O
frequent	O
adverse	O
responses	O
compared	O
to	O
their	O
counterparts	O
without	O
cardiac	B-DIS
disease	I-DIS
.	O

Further	O
studies	O
utilizing	O
hiPSC	O
modeling	O
should	O
be	O
considered	O
to	O
evaluate	O
the	O
impact	O
and	O
mitigation	O
of	O
known	O
cardiovascular	O
risk	O
factors	O
including	O
blood	O
pressure	O
body	O
mass	O
index	O
BMI	O
smoking	B-DIS
status	I-DIS
diabetes	I-DIS
and	O
physical	O
activity	O
in	O
their	O
role	O
in	O
cardiovascular	B-DIS
toxicity	I-DIS
after	O
cancer	B-DIS
therapy	O
.	O

Future	O
real	O
-	O
world	O
applications	O
will	O
depend	O
on	O
understanding	O
the	O
current	O
use	O
of	O
hiPSC	O
modeling	O
in	O
order	O
for	O
oncologists	O
and	O
cardiologists	O
together	O
to	O
inform	O
their	O
potential	O
to	O
improve	O
our	O
clinical	O
collaborative	O
practice	O
in	O
cardio	O
-	O
oncology	O
.	O

When	O
applying	O
such	O
in	O
vitro	O
characterization	O
it	O
is	O
hypothesized	O
that	O
a	O
safety	O
score	O
can	O
be	O
assigned	O
to	O
each	O
individual	O
to	O
determine	O
who	O
has	O
a	O
greater	O
probability	O
of	O
developing	O
cardiovascular	B-DIS
toxicity	I-DIS
.	O

Using	O
hiPSCs	O
to	O
create	O
personalized	O
models	O
and	O
ultimately	O
evaluate	O
the	O
cardiovascular	B-DIS
toxicity	I-DIS
of	O
individuals	O
'	O
treatments	O
may	O
one	O
day	O
lead	O
to	O
more	O
patient	O
-	O
specific	O
treatment	O
plans	O
in	O
precision	O
cardio	O
-	B-DIS
oncology	I-DIS
while	O
reducing	O
cardiovascular	O
disease	O
CVD	O
morbidity	O
and	O
mortality	O
.	O

Excessive	O
daytime	B-DIS
sleepiness	I-DIS
EDS	I-DIS
is	O
a	O
highly	O
prevalent	O
condition	O
that	O
is	O
associated	O
with	O
significant	O
morbidity	O
.	O

The	O
causes	O
of	O
EDS	O
are	O
varied	O
and	O
include	O
inadequate	O
sleep	O
sleep	O
disordered	O
breathing	O
circadian	O
rhythm	B-DIS
sleep	I-DIS
-	I-DIS
wake	O
disorders	O
and	O
central	O
disorders	B-DIS
of	I-DIS
hypersomnolence	I-DIS
narcolepsy	I-DIS
idiopathic	O
hypersomnia	B-DIS
and	I-DIS
Kleine	O
-	O
Levin	O
syndrome	O
.	O

Additionally	O
EDS	O
could	O
represent	O
a	O
symptom	O
of	O
an	O
underlying	O
medical	O
or	O
psychiatric	B-DIS
disorder	I-DIS
.	O

Assessment	O
of	O
EDS	O
includes	O
a	O
thorough	O
sleep	O
medical	O
and	O
psychiatric	B-DIS
history	O
targeted	O
clinical	O
examination	O
and	O
appropriate	O
use	O
of	O
actigraphy	O
to	O
measure	O
sleep	O
duration	O
and	O
sleep	O
-	O
wake	O
patterns	O
polysomnography	O
to	O
assess	O
for	O
associated	O
conditions	O
such	B-DIS
as	O
sleep	O
-	O
related	O
breathing	O
disorders	O
or	O
other	O
factors	O
that	O
might	O
disrupt	O
nighttime	O
sleep	O
multiple	O
sleep	O
latency	O
testing	B-DIS
to	O
ascertain	O
objective	O
sleepiness	O
and	O
diagnose	B-DIS
central	O
disorders	O
of	O
hypersomnolence	O
and	O
measurement	O
of	O
cerebrospinal	O
fluid	O
hypocretin-1	O
concentration	O
.	O

Treatment	O
of	O
EDS	O
secondary	O
to	O
central	O
disorders	O
of	O
hypersomnolence	B-DIS
is	O
primarily	O
pharmacologic	O
with	O
wakefulness	O
-	O
promoting	O
agents	O
such	O
as	O
modafinil	O
stimulants	O
such	O
as	O
methylphenidate	O
and	O
amphetamines	O
and	O
newer	O
agents	O
specifically	O
designed	O
to	O
improve	O
wakefulness	O
;	O
behavioral	O
interventions	O
can	O
provide	O
a	O
useful	O
adjunct	O
to	O
pharmacologic	O
treatment	O
.	O

When	O
excessive	O
sleepiness	B-DIS
is	O
secondary	O
to	O
other	O
conditions	O
the	O
treatment	O
should	O
focus	O
on	O
targeting	O
the	O
primary	B-DIS
disorder	I-DIS
.	O

This	O
review	O
discusses	O
current	O
epidemiology	O
provides	O
guidance	O
on	O
clinical	O
assessments	O
and	O
testing	O
and	O
discusses	O
the	O
latest	O
treatment	O
options	O
.	O

For	O
this	O
review	O
we	O
collated	O
the	O
latest	O
evidence	O
using	O
the	O
search	O
terms	O
excessive	O
sleepiness	B-DIS
hypersomnia	I-DIS
hypersomnolence	O
treatment	O
from	O
PubMed	O
and	O
MEDLINE	O
and	O
the	O
latest	O
practice	O
parameters	O
from	O
the	O
American	O
Academy	O
of	O
Sleep	O
Medicine	O
.	O

Background	O
The	O
prevalence	B-EPI
of	O
perinatal	O
infection	B-DIS
from	O
maternal	O
exposure	O
is	O
increasing	O
.	O

The	O
prevalence	B-EPI
of	O
acute	O
maternal	O
infections	B-DIS
identifies	O
cytomegalovirus	B-DIS
parvovirus	I-DIS
B19	I-DIS
toxoplasmosis	B-DIS
and	O
varicella	B-DIS
as	O
the	O
most	O
common	O
organisms	O
and	O
in	O
the	O
order	O
of	O
frequency	O
.	O

Maternal	O
informed	O
consent	O
and	O
understanding	O
is	O
required	O
before	O
intrauterine	O
testing	O
for	O
fetal	O
infectious	O
and	O
possible	O
genetic	O
risk	O
assessment	O
.	O

Methods	O
This	O
structured	O
review	O
of	O
the	O
reproductive	O
published	O
literature	O
focuses	O
on	O
the	O
risks	O
of	O
amniocentesis	O
and	O
cordocentesis	O
diagnostic	O
procedure	O
-	O
related	O
fetal	O
loss	O
rates	O
and	O
fetal	O
vertical	O
transmission	O
VT	B-LOC
rates	O
from	O
published	O
infected	O
pregnant	O
cohorts	O
.	O

Results	O
The	O
total	O
postprocedure	O
fetal	O
loss	O
rate	O
for	O
diagnostic	O
amniocentesis	O
procedures	O
in	O
limited	O
infectious	O
cohorts	O
is	O
1.5	B-STAT
%	I-STAT
and	O
does	O
not	O
appear	O
to	O
be	O
increased	O
compared	O
to	O
`	O
`	O
noninfected	O
''	O
amniocentesis	O
cohorts	O
using	O
an	O
estimated	O
background	O
spontaneous	O
fetal	O
loss	O
rate	O
no	O
procedure	O
of	O
0.65	B-STAT
%	I-STAT
.	O

The	O
`	O
`	O
pooled	O
''	O
unintended	O
fetal	O
loss	O
rate	O
is	O
from	O
small	B-DIS
infected	I-DIS
population	O
cohorts	O
but	O
can	O
be	O
used	O
for	O
counseling	O
purposes	O
.	O

Postcordocentesis	O
fetal	O
loss	O
risk	O
in	O
an	O
infected	O
cohort	O
is	O
not	O
possible	O
to	O
estimate	O
due	O
to	O
limited	O
data	O
.	O

The	O
`	O
`	O
biological	O
spontaneous	O
fetal	O
loss	O
rate	O
''	O
risk	O
with	O
a	O
perinatal	O
infection	B-DIS
positive	O
or	O
negative	O
fetal	O
anomalies	O
and	O
no	O
diagnostic	O
procedure	O
before	O
20	O
weeks	O
of	O
gestation	O
is	O
reviewed	O
.	O

The	O
risk	O
of	O
VT	B-LOC
in	O
acute	B-DIS
infection	I-DIS
cohorts	O
as	O
a	O
result	O
of	O
the	O
intra	B-DIS
-	O
amniotic	O
diagnostic	O
procedure	O
is	O
not	O
found	O
to	O
be	O
increased	O
.	O

Conclusion	O
The	O
unintended	O
`	O
`	O
fetal	O
loss	O
''	O
rate	O
after	O
amniocentesis	O
for	O
perinatal	O
infected	O
cohorts	O
is	O
similar	O
to	O
that	O
of	O
noninfected	O
cohorts	O
but	O
the	O
estimate	O
is	O
based	O
on	O
limited	O
infected	O
cohorts	O
.	O

There	O
was	O
no	O
procedure	O
-	O
based	O
risk	O
of	O
fetal	O
VT	B-LOC
in	O
the	O
infected	O
cohorts	O
but	O
identification	O
of	O
postprocedure	B-DIS
maternal	O
bleeding	O
into	O
the	O
amniotic	O
cavity	O
increases	O
the	O
potential	O
risk	O
.	O

Maternal	O
knowledge	O
translation	O
and	O
an	O
informed	O
consent	O
process	O
with	O
risk	O
-	O
benefit	O
maternal	O
/	O
fetal	O
risk	O
counseling	O
are	O
required	O
prior	O
to	O
any	O
diagnostic	O
amniocentesis	O
procedure	O
.	O

Pseudoachondroplasia	B-DIS
PSACH	I-DIS
is	O
an	O
autosomal	O
dominant	B-DIS
skeletal	I-DIS
dysplasia	I-DIS
with	O
an	O
estimated	O
incidence	B-EPI
of	O
~1/60000	O
that	O
is	O
characterized	O
by	O
disproportionate	O
short	O
stature	B-DIS
brachydactyly	I-DIS
joint	I-DIS
laxity	I-DIS
and	O
early	B-DIS
-	I-DIS
onset	O
osteoarthritis	O
.	O

COMP	O
encodes	O
the	O
cartilage	O
oligomeric	O
matrix	O
protein	O
which	O
is	O
expressed	O
predominantly	O
in	O
the	O
extracellular	O
matrix	O
ECM	O
surrounding	O
the	O
cells	O
that	O
make	O
up	O
cartilage	O
ligaments	O
and	O
tendons	O
.	O

Mutations	O
in	O
COMP	O
are	O
known	O
to	O
give	O
rise	O
to	O
PSACH	B-DIS
.	O

In	O
this	O
study	O
we	O
identified	O
a	O
novel	O
nucleotide	O
mutation	O
NM_000095.2	O
c.131	O
G	O
p.	O
D439E	O
in	O
COMP	O
responsible	O
for	O
PSACH	B-DIS
in	O
a	O
Chinese	O
family	O
by	O
employing	O
whole	O
-	O
exome	O
sequencing	O
WES	O
and	O
built	O
the	O
structure	O
model	O
of	O
the	O
mutant	O
protein	O
to	O
clarify	O
its	O
pathogenicity	O
.	O

The	O
novel	O
mutation	O
cosegregated	O
with	O
the	O
affected	O
individuals	O
.	O

Our	O
study	O
expands	O
the	O
spectrum	O
of	O
COMP	O
mutations	O
and	O
further	O
provides	O
additional	O
genetic	O
testing	O
information	O
for	O
other	O
PSACH	B-DIS
patients	O
.	O

Background	O
Nonalcoholic	B-DIS
steatohepatitis	I-DIS
NASH	I-DIS
is	O
a	O
subtype	O
of	O
non	B-DIS
-	I-DIS
alcoholic	I-DIS
fatty	I-DIS
liver	I-DIS
disease	O
NAFLD	O
with	O
a	O
potentially	O
progressive	O
course	B-DIS
to	I-DIS
liver	I-DIS
fibrosis	O
cirrhosis	O
with	O
its	O
complications	O
or	B-DIS
even	I-DIS
hepatocellular	O
carcinoma	O
.	O

NAFLD	B-DIS
is	O
a	O
rapidly	O
growing	O
chronic	B-DIS
liver	I-DIS
disease	I-DIS
with	O
a	O
global	O
prevalence	B-EPI
of	O
about	B-STAT
25	I-STAT
%	I-STAT
with	O
a	O
significant	O
increase	O
in	O
the	O
last	O
2	O
decades	O
changing	O
the	O
landscape	O
of	O
hepatology	O
.	O

This	O
study	O
aimed	O
to	O
undertake	O
a	O
bibliometric	O
global	O
analysis	O
of	O
research	O
literature	O
focusing	O
on	O
NASH	B-DIS
.	O

Methods	O
We	O
searched	O
the	O
Scopus	O
database	O
to	O
identify	O
all	O
articles	O
pertaining	O
to	O
`	O
`	O
non	B-DIS
-	I-DIS
alcoholic	O
steatohepatitis	O
''	O
or	O
`	B-DIS
`	O
NASH	O
''	O
-	O
the	O
2	O
keywords	O
used	O
to	O
search	O
in	O
the	O
title	O
or	O
abstract	O
within	O
the	O
time	O
period	O
1980	O
to	O
2018	O
.	O

The	O
collected	O
data	O
included	O
document	O
type	O
author	O
journal	O
publication	O
year	O
citation	O
reports	O
country	O
and	O
were	O
analyzed	O
using	O
Microsoft	O
Excel	O
and	O
Microsoft	O
Word	O
.	O

Results	O
A	O
total	O
number	O
of	O
6632	O
articles	O
published	O
in	O
1355	O
journals	O
were	O
retrieved	O
.	O

English	O
was	O
the	O
predominant	O
language	O
of	O
publication	O
USA	B-LOC
being	O
the	O
most	O
productive	O
with	O
1937	O
articles	O
published	O
29.2	B-STAT
%	I-STAT
of	O
the	O
total	O
number	O
of	O
publications	O
followed	O
by	O
Japan	B-LOC
with	O
909	O
representing	O
13.7	B-STAT
%	I-STAT
of	O
publications	O
.	O

Hepatology	O
Journal	O
of	O
Hepatology	O
and	O
World	O
Journal	O
of	O
Gastroenterology	O
were	O
the	O
most	O
active	O
journals	O
.	O

Research	O
articles	O
were	O
the	O
most	O
common	O
type	O
of	O
publications	O
4524	O
;	O
68.22	B-STAT
%	I-STAT
followed	O
by	O
review	O
articles	O
1359	O
;	O
20.49	B-STAT
%	I-STAT
.	O

The	O
total	O
number	O
of	O
citations	O
received	O
by	O
all	O
publications	O
was	O
274041	O
with	O
an	O
average	O
of	O
41.32	O
per	O
article	O
range	O
0	O
-	O
4384	O
.	O

The	O
average	O
number	O
of	O
authors	O
per	O
article	O
has	O
increased	O
in	O
the	O
last	O
2	O
decades	O
whereas	O
the	O
trend	O
of	O
single-	O
or	O
few	O
authored	O
publications	O
has	O
decreased	O
.	O

Conclusion	O
This	O
study	O
indicates	O
that	O
NASH	B-DIS
is	O
a	O
significant	O
topic	O
in	O
the	O
hepatology	O
research	O
as	O
proved	O
by	O
the	O
huge	O
number	O
of	O
publications	O
recording	O
an	O
exponential	O
growth	O
in	O
the	O
last	O
2	O
decades	O
.	O

The	O
USA	B-LOC
stands	O
out	O
as	O
by	O
far	O
the	O
most	O
productive	O
country	O
.	O

Background	O
Human	O
lipodystrophies	O
are	O
uncommon	O
disorders	O
with	O
important	O
clinical	O
consequences	O
which	O
are	O
often	O
undiagnosed	O
.	O

The	O
Barraquer	B-DIS
-	I-DIS
Simons	O
syndrome	O
is	O
a	O
form	O
of	O
partial	O
symmetric	O
lipodystrophy	O
of	O
unknown	O
etiology	O
characterized	O
by	O
the	O
loss	O
of	O
subcutaneous	O
adipose	O
tissue	O
limited	O
to	O
upper	O
part	O
of	O
the	O
body	O
.	O

Insulin	O
resistance	O
and	O
metabolic	O
complications	O
are	O
less	O
common	O
than	O
with	O
other	O
lipodystrophy	O
subtypes	O
.	O

Patients	O
usually	O
have	O
decreased	O
serum	O
complement	O
-	O
component	O
3	O
levels	O
associated	O
with	O
complement	O
activation	O
by	O
the	O
alternative	O
pathway	O
which	O
may	O
indicate	O
the	O
presence	O
of	O
renal	O
involvement	O
.	O

Case	O
presentation	O
The	O
authors	O
report	O
a	O
case	O
of	O
a	O
31	O
-	O
year	O
-	O
old	O
woman	O
with	O
progressive	O
loss	O
of	O
subcutaneous	O
fat	O
limited	O
to	O
the	O
face	O
neck	O
and	O
thorax	O
.	O

She	O
presented	O
no	O
severe	O
metabolic	O
complications	O
neither	O
signs	O
of	O
insulin	O
resistance	O
.	O

Laboratory	O
tests	O
revealed	O
mild	O
dyslipidemia	B-DIS
and	O
low	O
serum	O
levels	O
of	O
complement	O
-	O
component	O
3	O
.	O

Clinical	O
and	O
biochemical	O
characteristics	O
were	O
consistent	O
with	O
the	O
diagnosis	O
of	O
Barraquer	B-DIS
-	I-DIS
Simons	O
syndrome	O
.	O

Conclusion	O
The	O
present	O
case	O
illustrates	O
the	O
importance	O
of	O
recognizing	O
the	O
clinical	O
features	O
of	O
this	O
lipodystrophic	B-DIS
syndrome	I-DIS
which	O
may	O
present	O
potentially	O
severe	O
consequences	O
and	O
psychological	O
distress	O
.	O

A	O
brief	O
overview	O
is	O
made	O
addressing	O
the	O
clinical	O
signs	O
of	O
the	O
disease	O
its	O
course	O
and	O
how	O
to	O
manage	O
it	O
.	O

Girls	O
with	O
Fragile	O
-	O
X	O
-	O
Syndrome	O
FXS	O
present	O
high	B-DIS
levels	O
of	O
social	O
anxiety	O
social	O
avoidance	O
extreme	O
shyness	O
tendency	O
to	O
social	O
isolation	B-DIS
poor	I-DIS
eye	O
contact	B-DIS
learning	O
difficulties	O
and	O
depression	O
.	O

The	O
aims	O
of	O
the	O
present	O
study	O
which	O
is	O
based	O
on	O
a	O
group	O
of	O
young	O
females	O
with	O
FXS	B-DIS
are	O
1	O
to	O
analyze	O
the	O
possible	O
associations	O
between	O
emotion	O
recognition	O
theory	O
of	O
mind	O
and	O
social	O
anxiety	B-DIS
and	O
adaptive	O
behavior	O
and	O
emotional	O
state	O
;	O
2	O
to	O
study	O
the	O
relationship	O
between	O
intelligence	O
quotient	O
IQ	O
and	O
adaptive	O
behavior	O
;	O
and	O
3	O
to	O
assess	O
whether	O
social	O
anxiety	B-DIS
is	O
more	O
prevalent	O
in	O
girls	O
with	O
FXS	B-DIS
.	O

The	O
study	O
has	O
40	O
female	O
participants	O
aged	O
between	O
7	O
and	O
16	O
years	O
26	O
positive	O
full	O
mutation	O
FXS	O
and	O
14	O
as	O
a	O
control	O
group	O
.	O

A	O
neuropsychological	O
assessment	O
was	O
conducted	O
using	O
the	O
following	O
tests	O
WISC	O
-	O
V	O
NEPSY	B-DIS
-	O
II	O
SENA	O
ADHD	O
Rating	O
Scale	O
BAS	O
and	O
ABAS	O
-	O
II	O
.	O

In	O
comparison	O
with	O
the	O
control	O
group	O
the	O
group	O
with	O
FXS	B-DIS
presented	O
a	O
greater	O
association	O
between	O
IQ	O
and	O
self	O
-	O
direction	O
ability	O
and	O
between	O
emotion	O
recognition	O
and	O
leadership	O
.	O

The	O
FXS	B-DIS
group	O
presented	O
higher	O
levels	O
of	O
social	O
anxiety	B-DIS
and	O
shyness	O
.	O

In	O
the	O
group	O
of	O
girls	O
with	O
FXS	B-DIS
IQ	O
may	O
have	O
prognostic	O
value	O
for	O
both	O
self	O
-	O
direction	O
ability	O
and	O
social	O
adaptation	O
level	O
.	O

Introduction	O
Patients	O
with	O
Noonan	B-DIS
and	O
Williams	B-DIS
-	I-DIS
Beuren	O
syndrome	O
present	O
similar	O
facial	O
phenotypes	O
modulated	O
by	O
their	O
ethnic	O
background	O
.	O

Although	O
distinctive	O
facial	O
features	O
have	O
been	O
reported	O
studies	O
show	O
a	O
variable	O
incidence	B-EPI
of	O
those	O
characteristics	O
in	O
populations	O
with	O
diverse	O
ancestry	O
.	O

Hence	O
a	O
differential	O
diagnosis	O
based	O
on	O
reported	O
facial	O
features	O
can	O
be	O
challenging	O
.	O

Although	O
accurate	O
diagnoses	O
are	O
possible	O
with	O
genetic	O
testing	O
they	O
are	O
not	O
available	O
in	O
developing	O
and	O
remote	O
regions	O
.	O

Methods	O
We	O
used	O
a	O
facial	O
analysis	O
technology	O
to	O
identify	O
the	O
most	O
discriminative	O
facial	O
metrics	O
between	O
286	O
patients	O
with	O
Noonan	B-DIS
and	O
161	O
with	O
Williams	B-DIS
-	I-DIS
Beuren	O
syndrome	O
with	O
diverse	O
ethnic	O
background	O
.	O

We	O
quantified	O
the	O
most	O
discriminative	O
metrics	O
and	O
their	O
ranges	O
both	O
globally	O
and	O
in	O
different	O
ethnic	O
groups	O
.	O

We	O
also	O
created	O
population	O
-	O
based	O
appearance	O
images	O
that	O
are	O
useful	O
not	O
only	O
as	O
clinical	O
references	O
but	O
also	O
for	O
training	O
purposes	O
.	O

Finally	O
we	O
trained	O
both	O
global	O
and	O
ethnic	O
-	O
specific	O
machine	O
learning	O
models	O
with	O
previous	O
metrics	O
to	O
distinguish	O
between	O
patients	B-DIS
with	O
Noonan	B-DIS
and	I-DIS
Williams	O
-	O
Beuren	O
syndromes	O
.	O

Results	O
We	O
obtained	O
a	O
classification	O
accuracy	O
of	O
85.68	B-STAT
%	I-STAT
in	O
the	O
global	O
population	O
evaluated	O
using	O
cross	O
-	O
validation	O
which	O
improved	O
to	O
90.38	B-STAT
%	I-STAT
when	O
we	O
adapted	O
the	O
facial	O
metrics	O
to	O
the	O
ethnicity	O
of	O
the	O
patients	O
p	O
=	O
0.024	O
.	O

Conclusion	O
Our	O
facial	O
analysis	O
provided	O
for	O
the	O
first	O
time	O
quantitative	O
reference	O
facial	O
metrics	O
for	O
the	O
differential	O
diagnosis	O
Noonan	B-DIS
and	O
Williams	B-DIS
-	I-DIS
Beuren	O
syndromes	O
in	O
diverse	O
populations	O
.	O

Approximately	O
one	O
-	O
third	O
of	O
the	O
world	O
's	O
population	O
is	O
infected	O
with	O
Mycobacterium	O
tuberculosis	O
and	O
it	O
is	O
a	O
leading	O
cause	B-DIS
of	O
infertility	O
in	O
endemic	O
countries	O
.	O

The	O
global	O
incidence	B-EPI
of	O
tuberculosis	B-DIS
TB	O
is	O
growing	O
at	O
approximately	B-STAT
0.4	I-STAT
%	I-STAT
per	O
year	O
and	O
much	O
faster	O
in	O
sub	O
-	O
Saharan	O
Africa	O
.	O

TB	O
causing	O
fertility	O
is	O
rare	O
in	O
developed	O
countries	O
.	O

We	O
present	O
a	O
case	O
of	O
genital	O
tuberculosis	B-DIS
causing	O
Asherman	B-DIS
's	I-DIS
syndrome	I-DIS
and	O
resultant	O
infertility	B-DIS
.	O

The	O
patient	O
is	O
a	O
34	O
-	O
year	O
-	O
old	O
P0	O
who	O
presented	O
to	O
care	O
after	O
a	O
prolonged	B-DIS
period	O
of	B-DIS
secondary	O
amenorrhea	O
and	O
infertility	O
.	O

She	O
underwent	O
a	O
hysterosalpingogram	O
which	O
demonstrated	O
no	O
free	O
spill	O
and	O
a	O
diagnostic	O
hysteroscopy	O
which	O
had	O
findings	O
of	O
mottled	O
endometrium	O
.	O

Pathology	O
returned	O
positive	O
for	O
Mycobacterium	O
tuberculosis	O
.	O

The	O
patient	O
was	O
treated	O
with	O
9	O
months	O
of	O
antituberculous	O
therapy	O
.	O

While	O
she	O
has	O
not	O
yet	O
succeeded	O
in	O
becoming	O
pregnant	O
the	O
patient	O
has	O
started	O
to	O
notice	O
cyclic	O
spotting	O
indicating	O
possible	O
return	O
of	O
menses	O
.	O

This	O
case	O
highlights	O
the	O
importance	O
of	O
TB	B-DIS
treatment	O
and	O
considering	O
TB	B-DIS
in	O
patients	O
who	O
present	O
with	O
unexplained	O
infertility	B-DIS
.	O

Ophiogomphus	O
howei	O
Bromley	B-LOC
is	O
a	O
rare	O
North	O
American	O
dragonfly	O
given	O
a	O
global	O
conservation	O
rank	O
of	O
Vulnerable	O
by	O
NatureServe	O
.	O

This	O
species	O
inhabits	O
localized	O
stretches	O
of	O
a	O
limited	O
number	O
of	O
typically	O
undisturbed	O
high	O
-	O
quality	O
forested	O
rivers	O
in	O
two	O
disjunct	O
regions	O
in	O
North	B-LOC
America	I-LOC
.	O

We	O
describe	O
a	O
new	O
population	O
in	O
between	O
the	O
known	O
ranges	O
from	O
an	O
impaired	O
river	O
in	O
a	O
largely	O
urban	O
watershed	O
in	O
southern	O
Michigan	B-LOC
United	I-LOC
States	I-LOC
.	O

We	O
also	O
report	O
a	O
previously	O
overlooked	O
specimen	O
from	O
a	O
new	O
location	O
in	O
Pennsylvania	B-LOC
United	I-LOC
States	I-LOC
and	O
provide	O
current	O
occurrence	O
and	O
conservation	O
status	O
of	O
the	O
species	O
in	O
North	B-LOC
America	I-LOC
.	O

Background	O
Wilson	B-DIS
disease	I-DIS
WD	O
is	O
an	O
autosomal	O
recessive	B-DIS
disorder	I-DIS
caused	O
by	O
mutations	O
in	O
the	O
ATP7B	O
gene	O
.	O

In	O
1984	O
Scheinberg	B-LOC
and	O
Sternlieb	O
estimated	O
the	O
prevalence	B-EPI
of	O
WD	O
to	O
be	O
130000	O
.	O

However	O
recent	O
epidemiological	O
studies	O
have	O
reported	O
increasing	O
prevalence	B-EPI
rates	O
in	O
different	O
populations	O
.	O

The	O
carrier	O
frequency	O
of	O
ATP7B	O
variants	O
and	O
the	O
prevalence	B-EPI
of	O
WD	O
in	O
the	O
Japanese	O
population	O
have	O
not	O
been	O
reported	O
using	O
multiple	O
databases	O
.	O

Methods	O
Multiple	O
public	O
databases	O
were	O
used	O
.	O

First	O
we	O
included	O
mutations	O
in	O
the	O
ATP7B	O
gene	O
that	O
were	O
registered	O
in	O
the	O
Human	O
Gene	O
Mutation	O
Database	O
HGMD	O
Professional	O
where	O
885	O
ATP7B	O
variants	O
were	O
identified	O
as	O
pathogenic	O
.	O

Next	O
we	O
investigated	O
the	O
allele	O
frequencies	O
of	O
these	O
885	O
variants	O
in	O
Japanese	O
individuals	O
using	O
the	O
Human	O
Genetic	O
Variation	O
Database	O
HGVD	O
and	O
the	O
Japanese	O
Multi	O
Omics	O
Reference	O
Panel	O
jMorp	O
.	O

Results	O
Of	O
the	O
885	O
variants	O
of	O
ATP7B	O
7	O
and	O
12	O
missense	O
and	O
nonsense	O
variants	O
0	O
and	O
3	O
splicing	O
variants	O
and	O
0	O
and	O
2	O
small	O
deletions	O
were	O
found	O
in	O
the	O
HGVD	O
and	O
in	O
jMorp	O
respectively	O
.	O

The	O
total	O
allele	O
frequencies	O
of	O
the	O
ATP7B	O
mutations	O
were	O
0.011	O
in	O
the	O
HGVD	O
and	O
0.014	O
in	O
the	O
jMorp	O
.	O

According	O
to	O
these	O
data	O
the	O
carrier	O
frequencies	O
were	O
0.022	B-STAT
2.2	I-STAT
%	I-STAT
and	O
0.028	B-STAT
2.8	I-STAT
%	I-STAT
respectively	O
and	O
patient	O
frequencies	O
were	O
0.000121	O
1.21/10000	B-STAT
individuals	O
and	O
0.000196	O
1.96/10000	B-STAT
individuals	O
respectively	O
.	O

Conclusion	O
This	O
is	O
the	O
first	O
study	O
to	O
report	O
the	O
carrier	O
frequency	O
of	O
ATP7B	O
variants	O
and	O
the	O
prevalence	B-EPI
of	O
WD	O
in	O
Japan	B-LOC
using	O
multiple	O
databases	O
.	O

The	O
calculated	O
prevalence	B-EPI
of	O
WD	O
was	O
comparatively	O
higher	O
than	O
that	O
of	O
previous	O
reports	O
indicating	O
previous	O
underdiagnosis	B-DIS
or	O
the	O
existence	O
of	O
less	O
severe	O
phenotypes	O
.	O

Microcephaly	B-DIS
is	O
a	O
prevalent	O
phenotype	O
in	O
patients	O
with	O
neurodevelopmental	O
problems	O
often	O
with	O
genetic	O
causes	O
.	O

We	O
comprehensively	O
investigated	O
the	O
clinical	O
phenotypes	O
and	O
genetic	O
background	O
of	O
microcephaly	B-DIS
in	O
40	O
Korean	O
patients	O
.	O

We	O
analyzed	O
their	O
clinical	O
phenotypes	O
and	O
radiologic	O
images	O
and	O
conducted	O
whole	O
exome	O
sequencing	O
WES	O
and	O
analysis	O
of	O
copy	O
number	O
variation	O
CNV	O
.	O

Infantile	O
hypotonia	B-DIS
and	O
developmental	O
delay	O
were	O
present	O
in	O
all	O
patients	O
.	O

Thirty	O
-	O
four	O
patients	O
85	B-STAT
%	I-STAT
showed	B-DIS
primary	O
microcephaly	O
.	O

The	O
diagnostic	O
yield	O
from	O
the	O
WES	O
and	O
CNV	O
analyses	O
was	O
47.5	B-STAT
%	I-STAT
.	O

With	O
WES	O
we	O
detected	O
pathogenic	O
or	O
likely	O
pathogenic	O
variants	O
that	O
were	O
previously	O
associated	O
with	O
microcephaly	B-DIS
in	O
12	O
patients	O
30	B-STAT
%	I-STAT
;	O
nine	O
of	O
these	O
were	O
de	O
novo	O
variants	O
with	O
autosomal	B-DIS
dominant	O
inheritance	O
.	O

Two	O
unrelated	O
patients	O
had	O
mutations	O
in	O
the	O
KMT2A	O
gene	O
.	O

In	O
10	O
other	O
patients	O
we	O
found	O
mutations	O
in	O
the	O
GNB1	O
GNAO1	O
TCF4	O
ASXL1	O
SMC1A	O
VPS13B	O
ACTG1	O
EP300	O
and	O
KMT2D	O
genes	O
.	O

Seven	O
patients	O
17.5	B-STAT
%	I-STAT
were	O
diagnosed	O
with	O
pathogenic	O
CNVs	O
.	O

Korean	O
patients	O
with	O
microcephaly	B-DIS
show	O
a	O
genetic	O
spectrum	O
that	O
is	O
different	O
from	O
that	O
of	O
patients	O
with	O
microcephaly	B-DIS
of	O
other	O
ethnicities	O
.	O

WES	O
along	O
with	O
CNV	O
analysis	O
represents	O
an	O
effective	O
approach	O
for	O
diagnosis	O
of	O
the	O
underlying	O
causes	O
of	O
microcephaly	B-DIS
.	O

Acute	B-DIS
kidney	I-DIS
injury	I-DIS
AKI	O
is	O
a	O
fatal	O
complication	O
of	O
the	O
new	O
severe	O
acute	O
respiratory	B-DIS
syndrome	I-DIS
coronavirus	I-DIS
SARS	I-DIS
-	O
CoV-2	O
which	B-DIS
causes	I-DIS
COVID-19	O
disease	O
.	O

Here	O
we	O
performed	O
a	O
scoping	O
review	O
and	O
meta	O
-	O
analysis	O
including	O
clinical	O
studies	O
on	O
patients	B-DIS
with	I-DIS
SARS	O
-	O
CoV-2	O
infection	B-DIS
with	O
data	O
on	O
AKI	O
assessment	O
and	O
characteristics	B-EPI
and	O
the	B-DIS
overall	O
prevalence	O
of	O
AKI	O
was	O
estimated	O
using	O
a	O
random	O
-	O
effects	O
model	O
.	O

We	O
identified	O
21	O
articles	O
which	O
passed	O
the	O
search	O
criteria	O
.	O

All	O
were	O
quantitative	O
observational	O
studies	O
which	O
used	O
a	O
cross	O
-	O
sectional	O
retrospective	O
case	O
report	O
or	O
cohort	O
methodology	O
.	O

This	O
showed	O
that	O
aging	O
diabetes	B-DIS
cardiovascular	I-DIS
disease	I-DIS
previous	O
chronic	B-DIS
disease	I-DIS
and	O
other	O
comorbidities	O
were	O
risk	O
factors	O
of	O
AKI	B-DIS
.	O

Although	O
the	O
prevalence	B-EPI
of	O
proteinuria	B-DIS
hematuria	I-DIS
and	O
increased	O
serum	O
creatinine	O
was	O
reported	O
for	O
up	B-STAT
to	I-STAT
60	I-STAT
%	I-STAT
of	O
the	O
patients	O
with	O
COVID-19	O
the	O
overall	O
prevalence	B-EPI
of	O
AKI	B-DIS
was	O
estimated	O
to	O
be	O
8	B-STAT
%	I-STAT
.	O

We	O
conclude	O
that	O
although	O
approximately	O
two	O
-	O
thirds	O
of	O
patients	O
with	O
COVID-19	O
had	O
symptoms	B-DIS
of	I-DIS
kidney	O
damage	O
most	O
of	O
these	O
did	O
not	O
meet	O
the	O
diagnostic	O
criteria	B-DIS
for	O
AKI	O
.	O

Further	O
studies	O
should	O
be	O
performed	O
to	O
validate	O
biomarkers	O
for	O
improved	O
AKI	B-DIS
diagnosis	O
in	O
COVID-19	O
patients	O
and	O
new	O
treatment	O
options	O
are	O
required	O
to	O
reduce	O
the	O
rate	O
of	O
mortality	O
.	O

Bubonic	O
plague	O
has	O
caused	O
three	O
deadly	O
pandemics	O
in	O
human	O
history	O
from	O
the	O
mid	O
-	O
sixth	O
to	O
mid	O
-	O
eighth	O
century	O
from	O
the	O
mid	O
-	O
fourteenth	O
to	O
the	O
mid	O
-	O
eighteenth	O
century	O
and	O
from	O
the	O
end	O
of	O
the	O
nineteenth	O
until	O
the	O
mid	O
-	O
twentieth	O
century	O
.	O

Between	O
the	O
second	O
and	O
the	O
third	O
pandemics	O
plague	O
was	O
causing	O
sporadic	O
outbreaks	O
in	O
only	O
a	O
few	O
countries	O
in	O
the	B-LOC
Middle	I-LOC
East	I-LOC
including	O
Egypt	B-LOC
.	O

Little	O
is	O
known	O
about	O
this	O
historical	O
phase	O
of	O
plague	O
even	O
though	O
it	O
represents	O
the	O
temporal	O
geographical	O
and	O
phylogenetic	O
transition	O
between	O
the	O
second	O
and	O
third	O
pandemics	O
.	O

Here	O
we	O
analysed	O
in	O
detail	O
an	O
outbreak	O
of	O
plague	O
that	O
took	O
place	O
in	O
Cairo	B-LOC
in	O
1801	O
and	O
for	O
which	O
epidemiological	O
data	O
are	O
uniquely	O
available	O
thanks	O
to	O
the	O
presence	O
of	O
medical	O
officers	O
accompanying	O
the	O
Napoleonic	O
expedition	O
into	O
Egypt	B-LOC
at	O
that	O
time	O
.	O

We	O
propose	O
a	O
new	O
stochastic	O
model	O
describing	O
how	O
bubonic	O
plague	O
outbreaks	O
unfold	O
in	O
both	O
rat	O
and	O
human	O
populations	O
and	O
perform	O
Bayesian	O
inference	O
under	O
this	O
model	O
using	O
a	O
particle	O
Markov	O
chain	O
Monte	O
Carlo	O
.	O

Rat	O
carcasses	O
were	O
estimated	O
to	O
be	O
infectious	O
for	O
approximately	O
4	O
days	O
after	O
death	B-DIS
which	O
is	O
in	O
good	O
agreement	O
with	O
local	O
observations	O
on	O
the	O
survival	O
of	O
infectious	O
rat	O
fleas	O
.	O

The	O
estimated	O
transmission	O
rate	O
between	O
rats	O
implies	O
a	O
basic	O
reproduction	O
number	O
R	O
0	O
<	O
/s	O
of	O
approximately	O
3	O
causing	O
the	O
collapse	O
of	O
the	O
rat	O
population	O
in	O
approximately	O
100	O
days	O
.	O

Simultaneously	O
the	O
force	O
of	O
infection	B-DIS
exerted	O
by	O
each	O
infected	O
rat	O
carcass	O
onto	O
the	O
human	O
population	O
increases	O
progressively	O
by	O
more	O
than	O
an	O
order	O
of	O
magnitude	O
.	O

We	O
also	O
considered	O
human	O
-	O
to	O
-	O
human	O
transmission	O
via	O
pneumonic	O
plague	O
or	O
human	O
specific	O
vectors	O
but	O
found	O
this	O
route	O
to	O
account	O
for	O
only	O
a	O
small	O
fraction	O
of	O
cases	O
and	O
to	O
be	O
significantly	O
below	O
the	O
threshold	O
required	O
to	O
sustain	O
an	O
outbreak	O
.	O

Background	O
Previous	O
research	O
has	O
suggested	O
that	O
vigorous	O
physical	O
activity	O
VPA	O
during	O
adolescence	O
and	O
early	O
adulthood	O
is	O
associated	O
with	O
ALS	B-DIS
.	O

The	O
National	O
ALS	B-DIS
Registry	O
Registry	O
collects	O
physical	O
activity	O
data	O
from	O
persons	O
with	O
ALS	B-DIS
.	O

Objective	O
To	O
examine	O
the	O
association	O
between	O
vigorous	O
VPA	O
and	O
early	O
onset	O
ALS	B-DIS
defined	O
as	O
a	O
diagnosis	O
before	O
age	O
60	O
among	O
patients	O
enrolled	O
in	O
the	O
Registry	O
.	O

VPA	O
was	O
defined	O
as	O
engaging	O
in	O
dynamic	O
exercise	O
for	O
at	O
least	O
10	O
minutes	O
in	O
a	O
session	O
that	O
caused	O
heavy	O
sweating	O
or	O
large	O
increases	O
in	O
breathing	O
or	O
heart	O
rate	O
.	O

Methods	O
A	O
cross	O
-	O
sectional	O
study	O
was	O
conducted	O
of	B-DIS
5463	O
ALS	O
patients	O
with	O
VPA	O
history	O
and	B-DIS
956	O
ALS	O
patients	O
who	O
never	O
engaged	O
in	O
VPA	O
.	O

Patient	O
characteristics	O
were	O
collected	O
via	O
online	O
surveys	O
in	O
the	O
following	O
areas	O
demographic	O
lifetime	O
VPA	O
history	O
and	O
initial	O
onset	O
of	O
symptoms	O
.	O

General	O
linear	O
modeling	O
was	O
used	O
to	O
estimate	O
mean	O
age	O
of	O
diagnosis	O
and	O
to	O
compute	O
95	B-STAT
%	I-STAT
confidence	O
intervals	O
.	O

Results	O
Patients	O
who	O
reported	O
engaging	O
in	O
VPA	O
at	O
least	O
moderately	O
three	O
times	O
a	O
week	O
during	O
early	O
adulthood	O
were	O
more	O
likely	O
to	O
have	O
an	O
ALS	B-DIS
diagnosis	O
earlier	O
compared	O
to	O
patients	O
who	O
did	O
not	O
p	O
<	O
0.0001	O
.	O

After	O
controlling	O
for	O
year	O
of	O
birth	O
statistically	O
significant	O
associations	O
between	O
those	O
reporting	O
VPA	O
at	O
age	O
15	O
-	O
24	O
and	O
25	O
-	O
34	O
and	O
diagnosis	O
of	O
ALS	B-DIS
earlier	O
p	O
=	O
0.0009	O
p	O
=	O
0.0144	O
respectively	O
.	O

Conclusion	O
Patients	O
with	O
ALS	B-DIS
who	O
had	O
a	O
history	O
of	O
VPA	O
before	O
age	O
35	O
were	O
significantly	O
more	O
likely	O
to	O
be	O
diagnosed	O
with	O
ALS	B-DIS
before	O
age	O
60	O
compared	O
to	O
patients	O
with	O
ALS	B-DIS
who	O
never	O
engaged	O
vigorously	O
.	O

More	O
research	O
is	O
needed	O
in	O
the	O
relationship	O
between	O
VPA	O
and	O
early	O
onset	O
ALS	B-DIS
.	O

Background	O
The	O
majority	O
of	O
active	O
tuberculosis	B-DIS
TB	O
cases	O
develop	O
from	O
latent	O
tuberculosis	B-DIS
infection	I-DIS
LTBI	O
.	O

Since	O
the	O
risk	O
of	O
TB	B-DIS
in	O
hemodialysis	O
HD	B-DIS
patients	O
is	O
particularly	O
high	O
interferon	O
-	O
gamma	O
release	O
assay	O
IGRA	O
for	O
LTBI	O
screening	B-DIS
in	O
HD	O
patients	O
is	O
considered	O
important	O
.	O

However	O
the	O
prevalence	B-EPI
and	O
characteristics	O
of	O
LTBI	O
in	O
Japanese	O
HD	B-DIS
patients	O
remain	O
obscure	O
.	O

Methods	O
We	O
performed	O
an	O
observational	O
cross	O
-	O
sectional	O
study	O
of	O
LTBI	O
using	O
IGRA	O
QFT-3	O
G	O
tests	O
in	B-DIS
118	O
HD	O
outpatients	O
enrolled	O
at	O
3	O
hospitals	O
of	O
varying	O
location	O
and	O
function	O
.	O

Results	O
Of	O
the	O
118	O
patients	O
96	O
were	O
QFT	O
negative	O
7	O
were	O
QFT	O
indeterminate	O
14	O
were	O
QFT	O
positive	O
and	O
1	O
was	O
QFT	O
judgment	O
impossible	O
.	O

No	O
patient	O
had	O
active	O
TB	B-DIS
.	O

Confirmed	O
QFT	O
positive	O
and	O
possible	O
QFT	O
positive	O
+	O
indeterminate	O
LTBI	O
patients	O
totaled	O
1411.9	B-STAT
%	I-STAT
and	O
2117.8	B-STAT
%	I-STAT
respectively	O
.	O

The	O
LTBI	O
possible	O
group	O
was	O
significantly	O
older	O
and	O
had	O
a	O
significantly	O
higher	O
rate	O
of	O
nephrosclerosis	B-DIS
versus	O
the	O
QFT	O
-	O
negative	O
group	O
.	O

The	O
indeterminate	O
group	O
had	O
a	O
significantly	O
longer	O
HD	O
period	O
.	O

The	O
QFT	O
results	O
were	O
not	O
remarkably	O
affected	O
by	O
other	O
clinical	O
data	O
including	O
hospital	O
characteristics	O
.	O

The	O
possible	O
LTBI	O
rate	O
increased	O
age	O
-	O
dependently	O
with	O
higher	O
values	O
from	O
60	O
years	O
of	O
age	O
.	O

Conclusions	O
The	O
prevalence	B-EPI
of	O
LTBI	O
is	O
high	O
in	O
Japanese	O
HD	B-DIS
patients	O
especially	O
from	O
the	O
age	O
of	O
60	O
years	O
.	O

Older	O
age	O
was	O
a	O
significant	O
risk	O
factor	O
for	O
LTBI	O
with	O
prediction	O
difficult	O
using	O
other	O
clinical	O
data	O
.	O

Extended	O
HD	O
may	O
mask	O
IGRA	O
results	O
.	O

Therefore	O
aggressive	O
screening	O
for	O
LTBI	O
is	O
advised	O
in	O
all	O
HD	B-DIS
patients	O
regardless	O
of	O
hospital	O
region	O
or	O
type	O
especially	O
in	O
patients	O
over	O
60	O
years	O
of	O
age	O
or	O
newly	O
commencing	O
HD	B-DIS
.	O

OBJECTIVEIntracranial	B-DIS
aneurysms	I-DIS
are	O
not	O
common	O
in	O
young	O
age	O
patients	O
.	O

We	O
sought	O
to	O
find	O
the	O
characteristics	O
of	O
the	O
intracranial	B-DIS
aneurysms	I-DIS
in	O
patients	O
under	O
20	O
years	O
of	O
age	O
.	O

METHODSWe	O
reviewed	O
23	O
consecutive	O
patients	O
≤20	O
years	O
of	O
age	O
treated	O
for	O
their	O
intracranial	B-DIS
aneurysms	I-DIS
during	O
the	O
period	O
from	O
1995	O
to	O
2017	O
.	O

From	O
medical	O
records	O
and	O
imaging	O
studies	O
we	O
gathered	O
data	O
on	O
age	O
sex	O
presentation	O
associated	O
medical	O
condition	O
location	O
and	O
characteristics	O
of	O
aneurysms	B-DIS
treatment	O
and	O
clinical	O
outcomes	O
.	O

RESULTSThe	O
patients	O
'	O
ages	O
ranged	O
from	O
13	O
months	O
to	O
20	O
years	O
median	O
14	O
years	O
.	O

There	O
were	O
16	O
males	O
and	O
seven	O
females	O
male	O
to	O
female	O
ratio	O
2.31	O
with	O
31	O
aneurysms	B-DIS
.	O

Clinical	O
presentations	O
included	O
sudden	O
severe	O
headache	B-DIS
in	O
61	B-STAT
%	I-STAT
followed	O
by	O
altered	O
mentality	O
in	O
17	B-STAT
%	I-STAT
and	O
seizure	B-DIS
in	O
17	B-STAT
%	I-STAT
.	O

More	O
than	O
one	O
-	O
fourth	O
patients	O
had	O
specific	O
medical	O
conditions	O
related	O
to	O
the	O
development	O
of	B-DIS
the	I-DIS
cerebral	O
aneurysms	O
.	O

The	O
majority	O
of	O
aneurysms	B-DIS
occurred	O
in	O
the	O
anterior	O
circulation	O
71	B-STAT
%	I-STAT
and	O
were	O
saccular	O
71	B-STAT
%	I-STAT
.	O

There	O
were	O
each	O
three	O
patients	O
with	O
false	O
aneurysms	B-DIS
13	B-STAT
%	I-STAT
and	O
giant	B-DIS
aneurysms	I-DIS
13	B-STAT
%	I-STAT
and	O
only	O
one	O
patient	O
with	O
multiple	B-DIS
aneurysms	I-DIS
4	B-STAT
%	I-STAT
.	O

We	O
treated	O
22	O
patients	O
21	O
aneurysms	B-DIS
with	O
the	O
endovascular	O
methods	O
three	O
with	O
open	O
surgery	O
and	O
one	O
with	O
combined	O
treatment	O
.	O

Good	O
functional	O
outcome	O
could	O
be	O
achieved	O
in	O
86	B-STAT
%	I-STAT
during	O
the	O
follow	O
-	O
up	O
period	O
.	O

CONCLUSIONIn	O
this	O
series	O
the	O
young	O
-	O
age	O
patients	B-DIS
with	I-DIS
intracranial	O
aneurysms	O
were	O
characterized	O
by	O
male	O
predominance	O
related	O
specific	O
medical	O
conditions	B-EPI
low	O
incidence	O
of	B-DIS
multiple	O
aneurysms	B-EPI
high	O
incidence	B-DIS
of	I-DIS
giant	O
aneurysms	O
and	O
good	O
functional	O
outcome	O
after	O
treatment	O
.	O

The	O
incidence	B-EPI
of	O
neonatal	O
varicella	B-DIS
has	O
decreased	O
dramatically	O
since	O
the	O
introduction	O
of	O
the	O
varicella	B-DIS
vaccination	O
.	O

Although	O
the	O
varicella	O
zoster	B-DIS
virus	O
is	O
often	O
associated	O
with	O
a	O
mild	O
infection	B-DIS
it	O
may	O
cause	O
severe	O
morbidity	O
and	O
mortality	O
particularly	O
in	O
the	O
neonatal	O
period	O
and	O
immunocompromised	O
hosts	O
.	O

We	O
report	O
a	O
case	O
of	O
neonatal	O
varicella	B-DIS
acquired	O
from	O
maternal	O
zoster	B-DIS
in	O
a	O
mother	O
on	O
biological	O
immunosuppressive	O
therapy	O
.	O

Following	O
the	O
diagnosis	O
the	O
baby	O
improved	O
on	O
antiviral	O
therapy	O
without	O
any	O
neurological	B-DIS
sequelae	I-DIS
.	O

This	O
case	O
highlights	O
the	O
limited	O
published	O
data	O
on	O
neonatal	O
varicella	B-DIS
following	O
herpes	B-DIS
zoster	I-DIS
reactivation	O
to	O
inform	O
practice	O
.	O

This	O
includes	O
the	O
role	O
of	O
varicella	O
zoster	B-DIS
immunoglobulin	O
in	O
neonates	O
exposed	O
to	O
maternal	O
zoster	B-DIS
the	O
degree	O
of	O
trans	O
-	O
placental	O
immunity	O
and	O
optimum	O
antiviral	O
dosing	O
and	O
duration	O
.	O

Previous	O
research	O
has	O
demonstrated	O
a	O
high	O
prevalence	B-EPI
of	O
Coxiella	O
burnetii	O
in	O
the	O
bulk	O
tank	O
milk	B-DIS
on	O
large	O
industrial	O
dairy	O
farms	O
of	O
the	O
central	O
and	O
eastern	O
European	O
region	O
.	O

The	O
aim	O
of	O
this	O
survey	O
was	O
to	O
estimate	O
the	O
prevalence	B-EPI
of	O
specific	O
IgG	O
antibodies	O
to	O
C.	O
burnetii	O
proving	O
previous	O
infection	B-DIS
among	O
dairy	O
farm	O
workers	O
and	O
to	O
determine	O
the	O
possible	O
risk	O
factors	O
.	O

Serum	O
samples	O
from	O
veterinarians	O
inseminators	O
animal	O
caretakers	O
milking	O
parlor	O
workers	O
and	O
herd	O
managers	O
working	O
on	O
dairy	O
farms	O
were	O
tested	O
for	O
the	O
presence	O
of	O
IgG	O
to	O
phase	O
I	O
and	O
phase	O
II	O
of	O
C.	O
burnetii	O
using	O
an	O
indirect	O
microimmunofluorescence	O
assay	O
.	O

Antibodies	O
phase	O
II	O
to	O
C.	O
burnetii	O
were	O
detected	O
in	O
59	O
out	O
of	O
70	O
individuals	O
tested	O
84.3	B-STAT
%	I-STAT
.	O

All	O
occupational	O
groups	O
are	O
highly	O
exposed	O
to	O
C.	B-DIS
burnetii	I-DIS
infection	I-DIS
.	O

Veterinarians	O
inseminators	O
and	O
animal	O
caretakers	O
had	O
100	B-STAT
%	I-STAT
seropositivity	O
rate	O
of	O
phase	O
II	O
whereas	O
the	O
seropositivity	O
rate	O
found	O
among	O
herd	O
managers	O
and	O
milking	O
parlor	O
workers	O
was	O
71.4	B-STAT
%	I-STAT
and	O
47	B-STAT
%	I-STAT
respectively	O
.	O

The	O
findings	O
of	O
this	O
survey	O
suggest	O
that	O
the	O
risk	O
of	O
C.	B-DIS
burnetii	I-DIS
infection	I-DIS
is	O
correlated	O
with	O
cattle	B-DIS
density	O
in	O
the	O
large	O
dairy	O
farms	O
and	O
also	O
with	O
occupational	O
groups	O
.	O

Osteogenesis	O
imperfecta	O
describes	O
a	O
group	O
of	O
genetic	O
disorders	O
that	O
result	O
from	O
a	O
defect	O
in	O
collagen	O
type	O
I	O
and	O
range	O
in	O
severity	O
from	O
a	O
subtle	O
increase	O
in	O
fracture	B-DIS
frequency	O
to	O
death	B-DIS
in	O
the	O
perinatal	O
period	O
.	O

Osteogenesis	O
imperfecta	B-DIS
is	O
mostly	O
caused	O
by	O
mutations	O
in	O
the	O
COL1A1	O
17q21.33	O
and	O
COL1A2	O
7q21.3	O
genes	O
.	O

There	O
have	O
only	O
been	O
a	O
few	O
case	O
reports	O
of	O
implant	O
-	O
prosthetic	O
treatment	O
for	O
patients	B-DIS
with	I-DIS
osteogenesis	O
imperfecta	O
.	O

These	O
reports	O
indicated	O
that	O
implants	O
and	O
augmentation	O
procedures	O
can	O
be	O
implemented	O
in	O
such	O
patients	O
.	O

However	O
for	O
patients	O
receiving	O
additional	O
antiresorptive	O
therapy	O
cautious	O
approaches	O
should	O
be	O
chosen	O
and	O
the	O
risk	O
of	O
drug	O
-	B-DIS
associated	O
osteonecrosis	O
should	O
be	O
considered	O
.	O

The	O
aim	O
of	O
this	O
article	O
is	O
to	O
report	O
on	O
the	O
implant	O
-	O
prosthetic	O
treatment	O
of	O
a	O
patient	O
with	O
type	O
I	O
osteogenesis	O
imperfecta	O
.	O

There	O
is	O
an	O
urgent	O
public	O
health	O
need	O
to	O
better	O
understand	O
Severe	O
Acute	O
Respiratory	B-DIS
Syndrome	I-DIS
SARS	I-DIS
-CoV-2	O
/	O
COVID-19	O
particularly	O
how	O
sequences	O
of	O
the	O
viruses	O
could	O
lead	O
to	B-EPI
diverse	O
incidence	O
and	O
mortality	O
of	O
COVID-19	O
in	O
different	O
countries	O
.	O

However	O
because	O
of	O
its	O
unknown	O
ancestors	O
and	O
hosts	O
elucidating	O
the	O
genetic	O
variations	O
of	O
the	O
novel	O
coronavirus	O
SARS	O
-	O
CoV-2	O
has	O
been	O
difficult	O
.	O

Without	O
needing	O
to	O
know	O
ancestors	O
we	O
identified	O
an	O
uneven	O
distribution	O
of	O
local	O
genome	O
similarities	O
among	O
the	O
viruses	O
categorized	O
by	O
geographic	O
regions	O
and	O
it	O
was	O
strongly	O
correlated	O
with	O
incidence	B-EPI
and	O
mortality	O
.	O

To	O
ensure	O
unbiased	O
and	O
origin	O
-	O
independent	O
analyses	O
we	O
used	O
a	O
pairwise	O
comparison	O
of	O
local	O
genome	O
sequences	O
of	O
virus	O
genomes	O
by	O
Basic	O
Local	O
Alignment	O
Search	O
Tool	O
BLAST	O
.	O

We	O
found	O
a	O
strong	O
statistical	O
correlation	O
between	O
dominance	O
of	O
the	O
SARS	O
-	O
CoV-2	O
in	O
distributions	O
of	O
uneven	O
similarities	O
and	B-EPI
the	O
incidence	O
and	O
mortality	B-DIS
of	O
illness	O
.	O

Genomic	O
annotation	O
of	O
the	O
BLAST	O
hits	O
also	O
showed	O
that	O
viruses	O
from	O
geographic	O
regions	O
with	O
severe	O
infections	B-DIS
tended	O
to	O
have	O
more	O
dynamic	O
genomic	O
regions	O
in	O
the	O
SARS	O
-	O
CoV-2	O
receptor	B-DIS
-	O
binding	O
domain	O
RBD	O
and	O
receptor	O
-	O
binding	O
motif	O
RBM	O
of	O
the	O
spike	O
protein	O
S	O
protein	O
.	O

Dynamic	O
domains	O
in	O
the	O
S	O
protein	O
were	O
also	O
confirmed	O
by	O
a	O
canyon	O
region	O
of	O
mismatches	O
coincident	O
with	O
RBM	B-DIS
and	O
RBD	B-DIS
without	O
hits	O
of	O
alignments	O
of	O
100	B-STAT
%	I-STAT
matching	O
.	O

Thus	O
our	O
origin	O
-	O
independent	O
analysis	O
suggests	O
that	O
the	O
dynamic	O
and	O
unstable	O
SARS	O
-	O
CoV-2	O
-	O
RBD	O
could	O
be	B-EPI
the	O
main	O
reason	O
for	B-DIS
diverse	I-DIS
incidence	O
and	O
mortality	O
of	O
COVID-19	O
infection	O
.	O

Background	O
Many	O
studies	O
reported	O
high	O
prevalence	B-EPI
of	O
antiphospholipid	B-DIS
antibodies	O
aPL	O
in	O
patients	O
with	O
COVID-19	O
raising	O
questions	O
about	O
its	O
true	O
prevalence	B-EPI
and	O
its	O
clinical	O
impact	O
on	O
the	O
disease	O
course	O
.	O

Methods	O
We	O
conducted	O
a	O
meta	O
-	O
analysis	O
and	O
a	O
systematic	O
review	O
to	O
examine	B-EPI
the	O
prevalence	O
of	O
aPL	O
and	O
its	O
clinical	O
impact	O
in	O
patients	O
with	O
COVID-19	O
.	O

Results	O
21	O
studies	O
with	O
a	O
total	O
of	O
1159	O
patients	O
were	O
included	O
in	O
our	O
meta	O
-	O
analysis	O
.	O

Among	O
patients	O
hospitalised	O
with	O
COVID-19	O
the	O
pooled	O
prevalence	B-EPI
rate	O
of	O
one	O
or	O
more	O
aPL	O
IgM	O
or	O
IgG	O
or	O
IgA	O
of	O
anticardiolipin	O
aCL	O
or	O
anti	O
-	O
ß2	O
glycoprotein	O
anti	O
-	O
ß2	O
GPI	B-DIS
or	O
antiphosphatidylserine	O
/	O
prothrombin	O
or	O
lupus	O
anticoagulant	O
LA	B-LOC
was	O
46.8	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
36.1	B-STAT
%	I-STAT
to	O
57.8	B-STAT
%	I-STAT
.	O

The	O
most	O
frequent	O
type	O
of	O
aPL	O
found	O
was	O
LA	B-LOC
with	O
pooled	O
prevalence	B-EPI
rate	O
of	O
50.7	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
34.8	B-STAT
%	I-STAT
to	O
66.5	B-STAT
%	I-STAT
.	O

Critically	B-DIS
ill	I-DIS
patients	O
with	O
COVID-19	O
had	O
significantly	O
higher	O
prevalence	B-EPI
of	O
aCL	O
IgM	O
or	O
IgG	O
28.8	B-STAT
%	I-STAT
vs	O
7.10	B-STAT
%	I-STAT
p	O
<	O
0.0001	O
and	O
anti	O
-	O
ß2	O
GPI	O
IgM	O
or	O
IgG	O
12.0	B-STAT
%	I-STAT
vs	O
5.8	B-STAT
%	I-STAT
p	O
<	O
0.0001	O
as	O
compared	O
with	O
non	O
-	O
critically	O
ill	O
patients	O
.	O

However	O
there	O
was	O
no	O
association	O
between	O
aPL	O
positivity	O
and	O
mean	O
levels	O
of	O
C	O
reactive	O
protein	O
mean	O
difference	O
was	O
3295	B-STAT
%	I-STAT
CI	O
-15	O
to	O
79	O
p=0.18	O
D	O
-	O
dimer	O
mean	O
difference	O
was	O
3495	B-STAT
%	I-STAT
CI	O
-194	O
to	O
273	O
p=0.77	O
mortality	O
1.4695	B-STAT
%	I-STAT
CI	O
0.29	O
to	O
7.29	O
p=0.65	O
invasive	O
ventilation	O
1.2295	B-STAT
%	I-STAT
CI	O
0.51	O
to	O
2.91	O
p=0.65	B-DIS
and	I-DIS
venous	O
thromboembolism	O
1.3895	B-STAT
%	I-STAT
CI	O
0.57	O
to	O
3.37	O
p=0.48	O
.	O

Conclusions	O
aPLs	B-DIS
were	O
detected	O
in	O
nearly	O
half	O
of	O
patients	O
with	O
COVID-19	O
and	O
higher	O
prevalence	B-EPI
of	O
aPL	O
was	O
found	O
in	O
severe	O
disease	O
.	O

However	O
there	O
was	O
no	O
association	O
between	O
aPL	O
positivity	O
and	O
disease	O
outcomes	O
including	O
thrombosis	B-DIS
invasive	O
ventilation	O
and	O
mortality	O
.	O

However	O
further	O
studies	O
are	O
required	O
to	O
identify	O
the	O
clinical	O
and	O
pathological	O
role	O
of	O
aPL	O
in	O
COVID-19	O
.	O

Over	O
the	O
last	O
50	O
years	O
significant	O
muskrat	O
Ondatra	O
zibethicus	O
harvest	O
declines	O
have	O
been	O
observed	O
throughout	O
North	B-LOC
America	I-LOC
.	O

Several	O
theories	O
for	O
the	O
decline	O
have	O
been	O
proposed	O
including	O
increased	O
parasite	O
infections	B-DIS
and	O
disease	O
within	O
muskrat	O
populations	O
.	O

No	O
existing	O
wholistic	O
review	O
of	O
muskrat	O
exposure	O
to	O
pathogens	O
contaminants	B-DIS
and	I-DIS
diseases	I-DIS
exists	O
.	O

To	O
address	O
this	O
knowledge	O
gap	O
we	O
conducted	O
a	O
thorough	O
review	O
of	O
existing	O
literature	O
on	O
muskrat	O
pathogens	O
contaminants	O
and	O
diseases	O
across	O
their	O
natural	O
range	O
.	O

This	O
review	O
is	O
comprised	O
of	O
131	O
articles	O
from	O
1915	O
to	O
2019	O
and	O
from	O
27	O
U.S.	B-LOC
states	O
and	O
9	O
Canadian	O
provinces	O
.	O

A	O
wide	O
diversity	O
of	O
contaminants	O
toxins	O
and	O
pathogens	O
were	O
reported	O
in	O
muskrats	O
with	O
the	O
most	O
common	O
diseases	O
being	O
cysticercosis	O
tularemia	O
Tyzzer	B-DIS
's	I-DIS
disease	I-DIS
and	O
biotoxin	O
poisoning	O
from	O
cyanobacteria	O
.	O

This	O
review	O
provides	O
a	O
summary	O
of	O
muskrat	O
pathogens	O
contaminants	O
and	O
diseases	O
over	O
a	O
century	O
that	O
has	O
observed	O
significant	O
population	O
declines	O
throughout	O
the	O
species	O
'	O
range	O
in	O
North	B-LOC
America	I-LOC
.	O

Such	O
data	O
provide	O
a	O
baseline	O
for	O
understanding	O
the	O
potential	O
role	O
of	O
disease	O
in	O
these	O
declines	O
.	O

In	O
addition	O
these	O
data	O
highlight	O
critical	O
knowledge	O
gaps	O
that	O
warrant	O
future	O
research	O
efforts	O
.	O

Neonatal	O
herpes	B-DIS
seen	O
roughly	O
in	O
1	B-STAT
of	I-STAT
3000	I-STAT
live	O
births	O
in	O
the	B-LOC
United	I-LOC
States	I-LOC
is	O
the	O
most	O
serious	O
manifestation	O
of	O
herpes	B-DIS
simplex	I-DIS
virus	O
HSV	B-DIS
infection	I-DIS
in	O
the	O
perinatal	O
period	O
.	O

Although	O
acyclovir	O
therapy	O
decreases	O
infant	O
mortality	O
associated	O
with	O
perinatal	O
HSV	O
transmission	O
development	O
of	O
permanent	O
neurological	B-DIS
disabilities	I-DIS
is	O
not	O
uncommon	O
.	O

Mother	O
-	O
to	O
-	O
neonate	O
HSV	O
transmission	O
is	O
most	O
efficient	O
when	O
maternal	O
genital	O
tract	O
HSV	O
infection	O
is	O
acquired	O
proximate	O
to	O
the	O
time	O
of	O
delivery	B-DIS
signifying	O
that	O
neonatal	O
herpes	O
prevention	O
strategies	O
need	O
to	O
focus	B-EPI
on	O
decreasing	O
the	B-DIS
incidence	O
of	O
maternal	O
infection	O
during	O
pregnancy	O
and	O
more	O
precisely	O
identifying	O
infants	O
most	O
likely	O
to	O
benefit	O
from	O
prophylactic	O
antiviral	O
therapy	O
.	O

Oculo	O
-	O
auriculo	O
-	O
vertebral	O
spectrum	B-DIS
is	I-DIS
a	O
complex	O
developmental	O
disorder	O
characterised	O
mainly	O
by	O
anomalies	B-DIS
of	I-DIS
the	I-DIS
ear	I-DIS
hemifacial	O
microsomia	B-DIS
epibulbar	I-DIS
dermoids	O
and	O
vertebral	O
anomalies	O
.	O

The	O
aetiology	O
is	O
largely	O
unknown	O
and	O
the	O
epidemiological	O
data	O
are	O
limited	O
and	O
inconsistent	O
.	O

We	O
present	O
the	O
largest	O
population	O
-	O
based	O
epidemiological	O
study	O
to	O
date	O
using	O
data	O
provided	O
by	O
the	O
large	O
network	B-DIS
of	I-DIS
congenital	O
anomalies	O
registries	O
in	O
Europe	B-LOC
.	O

The	O
study	O
population	O
included	O
infants	O
diagnosed	O
with	O
oculo	B-DIS
-	I-DIS
auriculo	O
-	O
vertebral	O
spectrum	O
during	O
the	O
1990	O
-	O
2009	O
period	O
from	O
34	O
registries	O
active	O
in	O
16	O
European	O
countries	O
.	O

Of	O
the	O
355	O
infants	O
diagnosed	O
with	O
oculo	B-DIS
-	I-DIS
auriculo	O
-	O
vertebral	O
spectrum	O
there	B-STAT
were	O
95.8	B-STAT
%	I-STAT
340/355	O
live	B-STAT
born	O
0.8	B-DIS
%	I-STAT
3/355	O
fetal	B-STAT
deaths	O
3.4	B-STAT
%	I-STAT
12/355	O
terminations	O
of	B-DIS
pregnancy	O
for	O
fetal	O
anomaly	B-STAT
and	O
1.5	B-DIS
%	I-STAT
5/340	O
neonatal	O
deaths	O
.	O

In	O
18.9	B-STAT
%	I-STAT
there	O
was	O
prenatal	O
detection	O
of	O
anomaly	O
/	O
anomalies	O
associated	B-DIS
with	I-DIS
oculo	O
-	O
auriculo	O
-	O
vertebral	O
spectrum	O
69.7	B-STAT
%	I-STAT
were	O
diagnosed	O
at	O
birth	O
3.9	B-STAT
%	I-STAT
in	O
the	O
first	O
week	O
of	O
life	O
and	O
6.1	B-STAT
%	I-STAT
within	O
1	O
year	O
of	O
life	O
.	O

Microtia	B-DIS
88.8	B-STAT
%	I-STAT
hemifacial	B-DIS
microsomia	I-DIS
49.0	B-STAT
%	I-STAT
and	O
ear	O
tags	O
44.4	B-STAT
%	I-STAT
were	O
the	O
most	O
frequent	O
anomalies	B-DIS
followed	O
by	O
atresia	B-DIS
/	I-DIS
stenosis	I-DIS
of	I-DIS
external	I-DIS
auditory	O
canal	O
25.1	B-STAT
%	I-STAT
diverse	O
vertebral	O
24.3	B-STAT
%	I-STAT
and	O
eye	O
24.3	B-DIS
%	I-STAT
anomalies	O
.	O

There	O
was	O
a	O
high	O
rate	O
69.5	B-STAT
%	I-STAT
of	O
associated	O
anomalies	B-DIS
of	O
other	O
organs	B-DIS
/	O
systems	O
.	O

The	O
most	O
common	O
were	O
congenital	B-DIS
heart	I-DIS
defects	I-DIS
present	O
in	O
27.8	B-STAT
%	I-STAT
of	O
patients	O
.	O

The	O
prevalence	B-EPI
of	O
oculo	B-DIS
-	I-DIS
auriculo	O
-	O
vertebral	O
spectrum	O
defined	O
as	O
microtia	O
/	O
ear	O
anomalies	O
and	B-DIS
at	O
least	O
one	O
major	O
characteristic	O
anomaly	O
was	O
3.8	O
per	O
100000	O
births	O
.	O

Twinning	O
assisted	O
reproductive	O
techniques	O
and	O
maternal	O
pre	O
-	B-DIS
pregnancy	O
diabetes	O
were	O
confirmed	O
as	O
risk	O
factors	O
.	O

The	O
high	O
rate	O
of	O
different	O
associated	O
anomalies	B-DIS
points	O
to	O
the	O
need	O
of	O
performing	O
an	O
early	O
ultrasound	O
screening	O
in	O
all	O
infants	O
born	O
with	O
this	O
disorder	O
.	O

Frailty	B-DIS
is	O
common	O
in	O
older	O
hospitalised	O
patients	O
and	O
may	O
be	O
associated	O
with	O
micronutrient	B-DIS
malnutrition	I-DIS
.	O

Only	O
limited	O
studies	O
have	O
explored	O
the	O
relationship	O
between	O
frailty	O
and	O
vitamin	O
C	O
deficiency	O
.	O

This	O
study	O
investigated	O
the	O
prevalence	B-EPI
of	O
vitamin	O
C	O
deficiency	O
and	O
its	O
association	O
with	O
frailty	O
severity	O
in	O
patients	O
≥75	O
years	O
admitted	O
under	O
a	O
geriatric	O
unit	O
.	O

Patients	O
n	O
=	O
160	O
with	O
a	O
mean	O
age	O
of	O
84.4	O
±	O
6.4	O
years	O
were	O
recruited	O
and	O
underwent	O
frailty	O
assessment	O
by	O
use	O
of	O
the	O
Edmonton	O
Frail	O
Scale	O
EFS	O
.	O

Patients	O
with	O
an	O
EFS	O
score	O
<	O
10	O
were	O
classified	O
as	O
non	O
-	O
frail	O
/	O
vulnerable	O
/	O
mildly	O
frail	O
and	O
those	O
with	O
≥10	O
as	O
moderate	O
-	O
severely	O
frail	O
.	O

Patients	O
with	O
vitamin	O
C	O
levels	O
between	O
11	O
-	O
28	O
μmol	O
/	O
L	O
were	O
classified	O
as	O
vitamin	O
C	O
depleted	O
while	O
those	O
with	O
levels	O
<	O
11	O
μmol	O
/	O
L	O
were	O
classified	O
as	O
vitamin	O
C	O
deficient	O
.	O

A	O
multivariate	O
logistic	O
regression	O
model	O
determined	O
the	O
relationship	O
between	O
vitamin	O
C	O
deficiency	O
and	O
frailty	O
severity	O
after	O
adjustment	O
for	O
various	O
co	O
-	O
variates	O
.	O

Fifty	O
-	O
seven	O
35.6	B-STAT
%	I-STAT
patients	O
were	O
vitamin	O
C	O
depleted	O
while	O
4226.3	B-STAT
%	I-STAT
had	O
vitamin	O
C	O
deficiency	O
.	O

Vitamin	O
C	O
levels	O
were	O
significantly	O
lower	O
among	O
patients	O
who	O
were	O
moderate	O
-	O
severely	O
frail	O
when	O
compared	O
to	O
those	O
who	O
were	O
non	O
-	O
frail	O
/	O
vulnerable	O
/	O
mildly	O
frail	O
p	O
<	O
0.05	O
.	O

After	O
adjusted	O
analysis	O
vitamin	O
C	O
deficiency	O
was	O
4.3	O
-	O
fold	O
more	O
likely	O
to	O
be	O
associated	O
with	O
moderate	O
-	O
severe	O
frailty	O
aOR	O
4.3095	B-STAT
%	I-STAT
CI	O
1.33	O
-	O
13.86	O
p	O
=	O
0.015	O
.	O

Vitamin	O
C	O
deficiency	O
is	O
common	O
and	O
is	O
associated	O
with	O
a	O
greater	O
severity	O
of	O
frailty	O
in	O
older	O
hospitalised	O
patients	O
.	O

Introduction	O
Intra	O
-	O
uterine	B-DIS
adhesion	O
IUA	O
is	O
one	O
of	O
the	O
main	O
causes	O
of	B-DIS
secondary	O
infertility	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
prevalence	B-EPI
of	O
IUA	B-DIS
developing	O
in	O
women	O
undergoing	O
hysteroscopic	O
resection	O
for	O
submucous	B-DIS
myomas	I-DIS
polyps	I-DIS
and	O
intrauterine	B-DIS
synechiae	I-DIS
and	O
test	O
the	O
efficacy	O
of	O
second	O
look	O
hysteroscopy	O
for	O
diagnosing	O
and	O
treating	O
post	B-DIS
-	I-DIS
surgical	O
adhesions	O
.	O

Materials	O
and	O
Methods	O
We	O
retrospectively	O
collected	O
data	O
from	O
reproductive	O
age	O
women	O
who	O
had	O
a	O
second	O
look	O
office	O
hysteroscopy	O
following	O
hysteroscopic	O
resection	O
for	O
myoma	B-DIS
polyp	I-DIS
or	O
IUA	B-DIS
at	O
Foch	O
hospital	O
Suresnes	O
France	B-LOC
between	O
2009	O
and	O
2017	O
.	O

Results	O
Six	O
hundred	O
and	O
twenty	O
two	O
reproductive	O
-	O
age	O
women	O
underwent	O
hysteroscopic	O
resection	B-DIS
for	I-DIS
myoma	O
polyp	B-DIS
and/or	O
IUA	O
.	O

Among	O
them	O
155	O
women	O
had	O
a	O
second	O
look	O
hysteroscopy	O
.	O

In	O
this	O
group	O
29/155	B-STAT
18.7	I-STAT
%	I-STAT
had	O
IUA	B-DIS
formation	O
17/83	B-STAT
20.5	I-STAT
%	I-STAT
women	O
who	O
underwent	O
hysteroscopic	O
myomectomy	O
5/46	B-STAT
10.9	I-STAT
%	I-STAT
women	O
who	O
underwent	O
hysteroscopic	O
polypectomy	O
and	O
7/26	B-STAT
26.9	I-STAT
%	I-STAT
women	O
who	O
underwent	O
hysteroscopic	O
lysis	O
of	O
adhesions	O
.	O

These	O
IUA	B-DIS
have	O
been	O
lysed	O
by	O
the	O
office	O
hysteroscopy	O
procedure	O
in	O
16/29	B-STAT
55.2	I-STAT
%	I-STAT
patients	O
11/17	B-STAT
64.7	I-STAT
%	I-STAT
2/540	B-STAT
%	I-STAT
and	O
3/7	B-STAT
42.9	I-STAT
%	I-STAT
in	O
women	O
who	O
underwent	O
hysteroscopic	O
myomectomy	O
polypectomy	O
and	O
lysis	O
of	O
adhesion	O
respectively	O
.	O

Conclusion	O
IUA	B-DIS
is	O
a	O
common	O
complication	O
of	O
hysteroscopic	O
surgery	O
.	O

Second	O
look	O
office	O
hysteroscopy	O
is	O
an	O
easy	O
and	O
effective	O
procedure	O
for	O
diagnosing	O
and	O
removing	O
newly	O
formed	O
IUA	B-DIS
.	O

It	O
should	O
be	O
recommended	O
for	O
all	O
women	O
undergoing	O
hysteroscopic	O
resection	O
for	O
myomas	B-DIS
polyps	O
or	O
IUA	B-DIS
.	O

Background	O
Many	O
studies	O
have	O
been	O
conducted	O
to	O
assess	O
the	O
incidence	B-EPI
of	O
congenital	B-DIS
heart	I-DIS
disease	I-DIS
CHD	O
.	O

However	O
results	O
were	O
greatly	O
inconsistent	O
among	O
these	O
studies	O
with	O
a	O
broad	O
range	O
of	O
findings	O
.	O

Methods	O
A	O
prospective	O
census	O
-	O
based	O
cohort	O
study	O
was	O
conducted	O
in	O
Qingdao	B-LOC
China	B-LOC
from	O
August	O
12018	O
to	O
April	O
302019	O
.	O

All	O
of	O
the	O
local	O
registered	O
pregnant	O
women	O
were	O
continuously	O
investigated	O
and	O
followed	O
from	O
15	O
to	O
20	O
weeks	O
of	O
gestation	O
to	O
delivery	O
tracking	O
the	O
CHD	O
cases	O
in	O
both	O
the	O
fetal	O
and	O
neonatal	O
stages	O
.	O

A	O
logistic	O
regression	O
model	O
was	O
applied	O
to	O
assess	O
the	O
association	O
between	O
CHD	O
and	O
possible	O
risk	O
factors	O
.	O

Results	O
The	O
positive	O
rate	O
of	O
prenatal	O
CHD	O
screening	O
was	O
14.36	O
per	O
1000	O
fetuses	O
and	O
the	O
incidence	B-EPI
of	O
CHD	O
was	O
9.38	O
per	O
1000	O
live	O
births	O
.	O

Results	O
from	O
logistic	O
regression	O
indicated	O
that	O
living	O
in	O
the	O
countryside	O
odds	O
ratio	O
OR	O
0.771	O
;	O
95	B-STAT
%	I-STAT
confidence	O
interval	O
CI	O
0.628	O
-	O
0.946	O
and	O
having	O
a	O
childbearing	O
history	O
OR	O
0.802	O
;	O
95	B-STAT
%	I-STAT
CI	O
0.676	O
-	O
0.951	O
were	O
negatively	O
associated	O
with	O
CHD	O
.	O

However	O
twin	O
pregnancy	O
OR	O
1.95795	B-STAT
%	I-STAT
CI	O
1.245	O
-	O
3.076	O
illness	O
in	O
the	O
first	O
trimester	O
OR	O
1.306	O
;	O
95	B-STAT
%	I-STAT
CI	O
1.048	O
-	O
1.628	O
a	O
family	O
history	O
of	O
CHD	O
OR	O
7.156	O
;	O
95	B-STAT
%	I-STAT
CI	O
3.293	O
-	O
15.552	O
and	O
having	O
a	O
child	O
with	O
a	O
birth	B-DIS
defect	I-DIS
OR	O
2.086	O
;	O
95	B-STAT
%	I-STAT
CI	O
1.167	O
-	O
3.731	O
were	O
positively	O
associated	O
with	O
CHD	O
.	O

Conclusion	O
CHD	O
is	O
a	O
serious	O
health	O
problem	O
in	O
Qingdao	B-LOC
.	O

The	O
CHD	O
incidence	B-EPI
found	O
in	O
this	O
study	O
was	O
similar	O
to	O
existing	O
research	O
.	O

The	O
positive	O
rate	O
of	O
prenatal	O
CHD	O
screening	O
was	O
higher	O
than	O
the	O
incidence	B-EPI
of	O
neonatal	O
CHD	O
.	O

Moreover	O
CHD	O
risk	O
factors	O
were	O
identified	O
in	O
our	O
study	O
and	O
our	O
findings	O
may	O
have	O
great	O
implications	O
for	O
formation	O
CHD	O
intervention	O
strategies	O
.	O

Purpose	O
of	O
review	O
Obstructive	O
sleep	O
apnea	B-DIS
syndrome	I-DIS
OSAS	I-DIS
has	O
a	O
high	O
prevalence	B-EPI
in	O
western	O
countries	O
.	O

Many	O
papers	O
have	O
been	O
published	O
with	O
the	O
purpose	O
of	O
demonstrating	O
that	O
OSAS	B-DIS
acts	O
as	O
an	O
arrhythmia	B-DIS
trigger	O
and	O
is	O
responsible	O
for	O
an	O
increase	O
in	O
cardiovascular	O
morbidity	O
and	O
mortality	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
review	O
our	O
knowledge	O
on	O
this	O
topic	O
.	O

Recent	O
findings	O
There	O
is	O
a	O
lot	O
of	O
evidence	O
demonstrating	O
the	O
relationship	O
between	O
OSAS	B-DIS
and	O
arrhythmias	B-DIS
but	O
there	O
remains	O
a	O
lack	O
of	O
an	O
interventional	O
randomized	O
trial	O
to	O
demonstrate	O
that	O
by	O
treating	O
OSAS	B-DIS
we	O
can	O
reduce	O
arrhythmia	B-DIS
burden	O
.	O

OSAS	B-DIS
is	O
a	O
highly	O
prevalent	O
illness	O
in	O
western	O
countries	O
and	O
is	O
clearly	O
related	O
to	O
an	O
increase	O
in	O
cardiovascular	O
mortality	O
and	O
morbidity	O
.	O

Cardiac	B-DIS
arrhythmias	I-DIS
are	O
triggered	O
by	O
a	O
repetitive	O
hypoxemia	B-DIS
hypercapnia	I-DIS
acidosis	I-DIS
intrathoracic	O
pressure	O
fluctuations	O
reoxygenation	O
and	O
arousals	B-DIS
during	O
apnea	B-DIS
and	O
hypopnea	B-DIS
episodes	O
.	O

Early	O
diagnosis	O
and	O
treatment	O
of	O
these	O
patients	O
can	O
reduce	O
further	O
cardiovascular	O
morbidity	O
and	O
mortality	O
.	O

BACKGROUNDThe	O
incidence	B-EPI
of	O
Taralomyces	O
marneffei	B-DIS
infection	I-DIS
in	O
HIV	O
-	O
infected	O
individuals	O
has	O
been	O
decreasing	O
whereas	O
its	O
rate	O
is	O
rising	O
among	O
non	O
-	O
HIV	O
immunodeficient	O
persons	O
particularly	O
patients	O
with	O
anti	O
-	O
interferon	O
-	O
gamma	O
autoantibodies	O
.	O

T.	O
marneffei	O
usually	O
causes	O
invasive	O
and	O
disseminated	O
infections	B-DIS
including	O
fungemia	B-DIS
.	O

T.	O
marneffei	O
oro	O
-	O
pharyngo	O
-	O
laryngitis	O
is	O
an	O
unusual	O
manifestation	O
of	O
talaromycosis	O
.	O

CASE	O
PRESENTATIONA	B-LOC
52	O
-	O
year	O
-	O
old	O
Thai	O
woman	O
had	O
been	O
diagnosed	O
anti	O
-	O
IFNɣ	O
autoantibodies	O
for	O
4	O
years	O
.	O

She	O
had	O
a	O
sore	B-DIS
throat	I-DIS
odynophagia	I-DIS
and	O
hoarseness	B-DIS
for	O
3	O
weeks	O
.	O

She	O
also	O
had	O
febrile	B-DIS
symptoms	I-DIS
and	O
lost	O
5	O
kg	O
in	O
weight	O
.	O

Physical	O
examination	O
revealed	O
marked	O
swelling	B-DIS
and	O
hyperemia	B-DIS
of	O
both	O
sides	O
of	O
the	O
tonsils	O
the	O
uvula	O
and	O
palatal	O
arches	O
including	O
a	O
swelling	O
of	O
the	O
epiglottis	B-DIS
and	O
arytenoid	O
.	O

The	O
right	B-DIS
tonsillar	I-DIS
biopsy	O
exhibited	O
a	O
few	O
intracellular	O
oval	O
and	O
elongated	O
yeast	O
-	O
like	O
organisms	O
with	O
some	O
central	O
transverse	O
septum	O
seen	O
which	O
subsequently	O
grew	O
a	O
few	O
colonies	O
of	O
T.	O
marneffei	O
on	O
fungal	O
cultures	O
.	O

The	O
patient	O
received	O
amphotericin	O
B	O
deoxycholate	O
45	O
mg	O
/	O
dayfor	O
1	O
weeks	O
followed	O
by	O
oral	O
itraconazole	O
400	O
mg	O
/	O
day	O
for	O
several	O
months	O
.	O

Her	O
symptoms	O
completely	O
resolved	O
without	O
complication	O
.	O

CONCLUSIONIn	O
patients	O
with	O
anti	O
-	O
IFN	O
-	O
ɣ	O
autoantibodies	O
T.	O
marneffei	O
can	O
rarely	B-DIS
cause	O
a	O
local	O
infection	O
involving	O
oropharynx	O
and	O
larynx	O
.	O

Fungal	O
culture	O
and	O
pathological	O
examination	O
are	O
warranted	O
for	O
diagnosis	O
T.	O
marneffei	B-DIS
oro	I-DIS
-	O
pharyngo	O
-	O
laryngitis	O
.	O

This	O
condition	O
requires	O
a	O
long	O
term	O
antifungal	O
therapy	O
.	O

Background	O
Consanguineous	B-DIS
families	O
have	O
a	O
relatively	O
high	O
prevalence	B-EPI
of	O
genetic	O
disorders	O
caused	O
by	O
bi	O
-	O
allelic	O
mutations	O
in	O
recessive	O
genes	O
.	O

This	O
study	O
aims	O
to	O
evaluate	O
the	O
effectiveness	O
and	O
efficiency	O
of	O
a	O
consanguinity	O
-	O
based	O
exome	O
sequencing	O
approach	O
to	O
capturing	O
genetic	O
mutations	O
in	B-DIS
inherited	I-DIS
retinal	O
dystrophy	O
families	B-DIS
with	O
consanguineous	O
marriages	O
.	O

Methods	O
Ten	O
unrelated	O
consanguineous	B-DIS
families	O
with	O
a	O
proband	O
affected	O
by	O
inherited	O
retinal	B-DIS
dystrophy	I-DIS
were	O
recruited	O
in	O
this	O
study	O
.	O

All	O
participants	O
underwent	O
comprehensive	O
ophthalmic	O
examinations	O
.	O

Whole	O
exome	O
sequencing	O
was	O
performed	O
followed	O
by	O
a	O
homozygote	O
-	O
prior	O
strategy	O
to	O
rapidly	O
filter	O
disease	O
-	O
causing	O
mutations	O
.	O

Bioinformatic	O
prediction	O
of	O
pathogenicity	O
Sanger	O
sequencing	O
and	O
co	O
-	O
segregation	O
analysis	O
were	O
carried	O
out	O
for	O
further	O
validation	O
.	O

Results	O
In	O
ten	O
consanguineous	B-DIS
families	O
a	O
total	O
of	O
10	O
homozygous	O
mutations	O
in	O
8	O
IRD	B-DIS
genes	O
were	O
identified	O
including	O
2	O
novel	O
mutations	O
c.1654_1655delAG	O
p.	O
R552Afs	O
*	O
5	O
in	O
gene	O
FAM161A	O
in	O
a	O
patient	O
diagnosed	O
with	O
retinitis	B-DIS
pigmentosa	I-DIS
and	O
c.830	O
C	O
p.	O
L277P	O
in	O
gene	O
CEP78	O
in	O
a	O
patient	O
diagnosed	O
with	O
cone	O
and	O
rod	O
dystrophy	O
.	O

Conclusion	O
The	O
genetic	O
etiology	O
in	O
consanguineous	B-DIS
families	O
with	O
IRD	B-DIS
were	O
successfully	O
identified	O
using	O
consanguinity	O
-	O
based	O
analysis	O
of	O
exome	O
sequencing	O
data	O
suggesting	O
that	O
this	O
approach	O
could	O
provide	O
complementary	O
insights	O
into	O
genetic	O
diagnoses	B-DIS
in	O
consanguineous	O
families	O
with	O
variant	O
genetic	O
disorders	O
.	O

The	O
inherited	O
platelet	B-DIS
glycoprotein	I-DIS
deficiencies	I-DIS
Glanzmann	I-DIS
thrombasthenia	I-DIS
GT	O
and	O
Bernard	O
Soulier	B-DIS
syndrome	I-DIS
BSS	O
are	O
rare	O
but	O
important	O
long	O
-	B-DIS
term	I-DIS
bleeding	O
disorders	O
.	O

Once	O
diagnosed	O
affected	O
patients	O
should	O
be	O
referred	O
to	O
a	O
specialist	O
centre	O
for	O
bleeding	B-DIS
disorders	O
for	O
general	O
advice	O
and	O
ongoing	O
management	O
.	O

Patients	O
do	O
not	O
require	O
prophylactic	O
treatment	O
and	O
so	O
the	O
management	O
of	O
GT	O
and	O
BSS	O
focuses	O
around	O
prophylactic	O
treatment	O
prior	O
to	O
high	O
risk	O
procedures	O
and	O
treatment	O
in	O
response	O
to	O
non	O
-	B-DIS
surgical	O
bleeding	O
events	O
and	O
in	O
women	O
the	O
management	B-DIS
of	O
menorrhagia	O
and	O
pregnancy	O
.	O

There	O
is	O
no	O
consistent	O
approach	O
to	O
the	O
treatment	O
or	O
prevention	O
of	O
bleeding	B-DIS
complications	O
.	O

Management	O
must	O
be	O
tailored	O
for	O
each	O
individual	O
and	O
the	O
approach	O
may	O
not	O
be	O
the	O
same	O
for	O
different	O
events	O
even	O
for	O
the	O
same	O
patient	O
depending	O
on	O
the	O
type	O
of	O
accident	O
or	O
invasive	O
procedure	O
the	O
extent	O
of	O
bleeding	B-DIS
and	O
the	O
presence	O
or	O
not	O
of	O
platelet	O
refractoriness	O
.	O

Marine	O
mammals	O
are	O
important	O
sources	O
of	O
food	O
for	O
indigenous	O
residents	O
of	O
northern	O
Alaska	B-LOC
.	O

Changing	O
sea	O
ice	O
patterns	O
affect	O
the	O
animals	O
themselves	O
as	O
well	O
as	O
access	O
to	O
them	O
by	O
hunters	O
.	O

Documenting	O
the	O
traditional	O
knowledge	O
of	O
Iñupiaq	O
and	O
Yupik	O
hunters	O
concerning	O
marine	O
mammals	O
and	O
sea	O
ice	O
makes	O
accessible	O
a	O
wide	O
range	O
of	O
information	O
relevant	O
to	O
understanding	O
the	O
ecosystem	O
to	O
which	O
humans	O
belong	O
.	O

We	O
interviewed	O
hunters	O
in	O
11	O
coastal	O
villages	O
from	O
the	O
northern	O
Bering	B-LOC
Sea	I-LOC
to	O
the	B-LOC
Beaufort	I-LOC
Sea	I-LOC
.	O

Hunters	O
reported	O
extensive	O
changes	O
in	O
sea	O
ice	O
and	O
weather	O
that	O
have	O
affected	O
the	O
timing	O
of	O
marine	O
mammal	O
migrations	O
their	O
distribution	O
and	O
behaviour	O
and	O
the	O
efficacy	O
of	O
certain	O
hunting	O
methods	O
.	O

Amidst	O
these	O
changes	O
however	O
hunters	O
cited	O
offsetting	O
technological	O
benefits	O
such	O
as	O
more	O
powerful	O
and	O
fuel	O
-	O
efficient	O
outboard	O
engines	O
.	O

Other	O
concerns	O
included	O
potential	O
impacts	O
to	O
subsistence	O
hunting	O
from	O
industrial	O
activity	O
such	O
as	O
shipping	O
and	O
oil	O
and	O
gas	O
development	O
.	O

While	O
hunters	O
have	O
been	O
able	O
to	O
adjust	O
to	O
some	O
changes	O
continued	O
environmental	O
changes	O
and	O
increased	O
disturbance	O
from	O
human	O
activity	O
may	O
further	O
challenge	O
their	O
ability	O
to	O
acquire	O
food	O
in	O
the	O
future	O
.	O

There	O
are	O
indications	O
however	O
that	O
innovation	O
and	O
flexibility	O
provide	O
sources	O
of	O
resilience	O
.	O

ContextThere	O
has	O
been	O
concern	O
that	O
GH	O
treatment	O
of	O
children	O
might	O
increase	B-DIS
meningioma	I-DIS
risk	O
.	O

Results	O
of	O
published	O
studies	O
have	O
been	O
inconsistent	O
and	O
limited	O
.	O

ObjectiveTo	O
examine	O
meningioma	B-DIS
risks	O
in	O
relation	O
to	O
GH	O
treatment	O
.	O

DesignCohort	O
study	O
with	O
follow	O
-	O
up	B-DIS
via	O
cancer	O
registries	O
and	O
other	O
registers	O
.	O

SettingPopulation	O
-	O
based	O
.	O

PatientsA	O
cohort	O
of	O
10403	O
patients	O
treated	O
in	O
childhood	O
with	O
recombinant	O
GH	O
in	O
five	O
European	O
countries	O
since	O
this	O
treatment	O
was	O
first	O
used	O
in	O
1984	O
.	O

Expected	O
rates	O
from	O
national	O
cancer	B-DIS
registration	O
statistics	O
.	O

Main	O
Outcome	O
MeasuresRisk	O
of	O
meningioma	B-DIS
incidence	B-EPI
.	O

ResultsDuring	O
follow	O
-	O
up	B-DIS
38	O
meningiomas	O
occurred	O
.	O

Meningioma	B-DIS
risk	O
was	O
greatly	O
raised	O
in	O
the	O
cohort	O
overall	O
[	O
standardized	O
incidence	B-EPI
ratio	O
SIR	O
=	O
75.4	O
;	O
95	B-STAT
%	I-STAT
CI	O
54.9	O
to	O
103.6	O
]	O
as	O
a	O
consequence	O
of	O
high	O
risk	O
in	O
subjects	O
who	O
had	O
received	O
radiotherapy	O
for	O
underlying	O
malignancy	B-DIS
SIR	O
=	O
658.4	O
;	O
95	B-STAT
%	I-STAT
CI	O
460.4	O
to	O
941.7	O
.	O

Risk	O
was	O
not	O
significantly	O
raised	O
in	O
patients	O
who	O
did	O
not	O
receive	O
radiotherapy	O
.	O

Risk	O
in	O
radiotherapy	O
-	O
treated	O
patients	O
was	O
not	O
significantly	O
related	O
to	O
mean	O
daily	O
dose	O
of	O
GH	O
duration	O
of	O
GH	O
treatment	O
or	O
cumulative	O
dose	O
of	O
GH	O
.	O

ConclusionsOur	O
data	O
add	O
to	O
evidence	O
of	O
very	O
high	O
risk	O
of	O
meningioma	B-DIS
in	O
patients	O
treated	O
in	O
childhood	O
with	O
GH	O
after	O
cranial	O
radiotherapy	O
but	O
suggest	O
that	O
GH	O
may	O
not	O
affect	O
radiotherapy	O
-	O
related	O
risk	O
and	O
that	O
there	O
is	O
no	O
material	O
raised	O
risk	B-DIS
of	O
meningioma	B-DIS
in	O
GH	O
-	O
treated	O
patients	O
who	O
did	O
not	O
receive	O
radiotherapy	O
.	O

Background	O
Xanthogranulomatous	O
pyelonephritis	B-DIS
XGP	I-DIS
is	O
an	O
inflammatory	O
condition	O
of	O
the	O
kidney	O
and	O
its	O
treatment	O
most	O
often	O
involves	O
a	O
combination	O
of	O
antibiotics	O
and	O
nephrectomy	O
.	O

This	O
study	O
aimed	O
to	O
define	O
the	O
clinical	O
features	O
and	O
management	O
of	O
XGP	B-DIS
focusing	O
on	O
microbiological	O
aspects	O
and	O
antibiotic	O
therapy	O
.	O

Methods	O
We	O
performed	O
a	O
retrospective	O
study	O
of	O
27	O
cases	O
of	O
XGP	B-DIS
diagnosed	O
between	O
January	O
2001	O
and	O
January	O
2020	O
to	O
analyse	O
their	O
clinical	O
and	O
management	O
characteristics	O
.	O

In	O
addition	O
a	O
literature	O
review	O
was	O
conducted	O
of	O
XGP	B-DIS
case	O
series	O
covering	O
the	O
period	O
from	O
2000	O
-	O
2020	O
.	O

We	O
searched	O
PubMed	O
for	O
case	O
series	O
through	O
April	O
2020	O
without	O
language	O
restrictions	O
.	O

Studies	O
reporting	O
case	O
series	O
of	O
XGP	B-DIS
more	O
than	O
ten	O
cases	O
were	O
included	O
if	O
they	O
were	O
relevant	O
to	O
this	O
study	O
.	O

Results	O
Twenty	O
-	O
seven	O
patients	O
were	O
diagnosed	B-DIS
with	O
XGP	O
and	O
26	O
of	O
them	O
were	O
histologically	O
proven	O
to	B-DIS
have	O
XGP	O
.	O

A	O
total	O
of	O
81.5	B-STAT
%	I-STAT
of	O
the	O
patients	O
were	O
female	O
and	O
the	O
mean	O
age	O
was	O
59.6	O
years	O
SD	B-DIS
19.2	O
.	O

The	O
most	O
frequent	O
symptoms	O
were	O
flank	O
pain	B-DIS
70.4	B-STAT
%	I-STAT
and	O
fever	B-DIS
59.3	B-STAT
%	I-STAT
while	O
77.8	B-STAT
%	I-STAT
of	O
patients	O
had	O
renal	B-DIS
stones	I-DIS
.	O

Proteus	B-DIS
mirabilis	I-DIS
was	O
detected	O
in	O
the	O
urine	O
culture	O
in	O
18.5	B-STAT
%	I-STAT
of	O
patients	O
followed	O
by	O
detection	O
of	O
Escherichia	O
coli	O
in	O
14.8	B-STAT
%	I-STAT
of	O
patients	O
.	O

The	O
computed	O
tomography	O
CT	O
findings	O
included	O
perirenal	B-DIS
29.6	B-STAT
%	I-STAT
or	O
pararenal	O
29.6	B-STAT
%	I-STAT
involvement	O
in	O
the	O
majority	O
of	O
patients	O
.	O

Twenty	O
-	O
six	O
patients	O
underwent	O
nephrectomy	O
.	O

Piperacillin	O
/	O
tazobactam	O
and	O
ceftriaxone	O
were	O
the	O
most	O
commonly	O
prescribed	O
antibiotics	O
for	O
treatment	O
.	O

The	O
reported	O
piperacillin	O
/	O
tazobactam	O
and	O
ceftriaxone	O
resistance	O
rates	O
were	O
14.3	B-STAT
%	I-STAT
and	O
16.6	B-STAT
%	I-STAT
respectively	O
.	O

Twenty	O
-	O
six	O
case	O
series	O
were	O
included	O
in	O
the	O
literature	O
review	O
reporting	O
693	O
cases	O
in	O
total	O
.	O

Conclusion	O
We	O
found	O
well	O
-	O
established	O
characteristics	B-DIS
of	O
XGP	O
patients	O
among	O
series	O
in	O
terms	O
of	O
previous	O
history	O
clinical	O
laboratory	O
and	O
imaging	O
findings	O
and	O
operative	O
and	O
postoperative	O
outcomes	O
.	O

It	O
is	O
important	O
to	O
know	O
the	O
clinical	O
presentation	O
and	O
potential	O
severity	O
of	O
XGP	B-DIS
as	O
well	O
as	O
the	O
most	O
frequently	O
involved	O
microorganisms	O
and	O
their	O
antibiotic	O
resistance	O
profiles	O
to	O
select	O
the	O
most	O
appropriate	O
antibiotic	O
therapy	O
.	O

Introduction	O
Classic	O
bladder	B-DIS
exstrophy	I-DIS
BE	O
is	O
regarded	O
as	O
an	O
isolated	O
malformation	B-DIS
without	O
any	O
further	O
anomalies	O
but	O
some	O
studies	O
have	O
indicated	O
a	O
higher	O
incidence	B-EPI
of	O
cardiac	B-DIS
anomalies	I-DIS
.	O

This	O
cross	O
-	O
sectional	O
study	O
is	O
planned	O
to	O
evaluate	B-EPI
the	O
prevalence	B-DIS
of	I-DIS
congenital	I-DIS
heart	O
defects	O
CHDs	O
and	O
the	O
clinical	O
relevance	O
for	O
patients	O
with	O
BE	O
admitted	O
for	O
primary	O
closure	O
.	O

Materials	O
and	O
methods	O
Patients	O
were	O
prospectively	O
recruited	O
between	O
March	O
2012	O
and	O
January	O
2019	O
.	O

Patients	O
'	O
profiles	O
including	O
demographic	O
data	O
results	O
of	O
transthoracic	O
echocardiography	O
TTE	O
as	O
well	O
as	O
essential	O
peri-	O
and	O
postoperative	O
data	O
were	O
assessed	O
.	O

Results	O
Thirty	O
-	O
nine	O
25	O
boys	O
and	O
14	O
girls	O
patients	O
with	O
BE	O
median	O
age	O
61	O
days	O
underwent	O
delayed	O
primary	O
bladder	O
closure	O
.	O

Thirty	O
-	O
seven	O
24	O
boys	O
and	O
13	O
girls	O
patients	O
had	O
received	O
TTE	O
1	O
day	O
before	O
surgery	O
.	O

CHD	O
was	O
detected	O
in	O
718.9	B-STAT
%	I-STAT
out	O
of	O
the	O
39	O
patients	O
but	O
no	O
clinical	O
differences	O
between	O
patients	O
with	O
and	O
without	O
CHD	O
were	O
observed	O
peri-	B-DIS
or	O
postoperatively	O
.	O

Discussion	O
and	O
conclusion	O
This	O
prospective	O
systematic	O
evaluation	O
shows	O
an	O
even	O
higher	O
rate	O
of	O
CHD	O
in	O
patients	O
with	O
BE	O
than	O
assumed	O
previously	O
.	O

Although	O
peri-	B-DIS
and	O
postoperative	O
outcome	O
did	O
not	O
differ	O
between	O
patients	O
with	O
and	O
without	O
CHD	O
we	O
consider	O
TTE	O
an	O
important	O
additional	O
method	O
for	O
ensuring	O
a	O
safe	O
peri-	B-DIS
and	O
postoperative	O
courses	O
and	O
a	O
short-	O
and	O
long	O
-	O
term	O
care	O
for	O
patients	O
with	O
CHD	O
.	O

Background	O
Endolymphatic	O
hydrops	O
EH	O
is	O
the	O
histopathological	O
hallmark	O
of	O
Ménière	O
's	O
disease	O
MD	B-LOC
and	O
has	O
been	O
found	O
by	O
in	O
vivo	O
magnetic	O
resonance	O
imaging	O
MRI	O
in	O
patients	O
with	O
several	O
inner	O
ear	O
syndromes	O
without	O
definite	O
MD	B-LOC
criteria	O
.	O

The	O
incidence	B-EPI
and	O
relevance	O
of	O
this	O
finding	O
is	O
under	O
debate	O
.	O

Purpose	O
The	O
purpose	O
of	O
the	O
study	O
is	O
to	O
evaluate	O
the	O
prevalence	B-EPI
and	O
characteristics	O
of	O
EH	O
and	O
audiovestibular	O
test	O
results	O
in	O
groups	O
of	O
patients	O
with	O
fluctuating	O
audiovestibular	O
symptoms	O
not	O
fulfilling	O
the	O
actual	O
criteria	O
for	O
definite	O
MD	B-LOC
and	O
compare	O
them	O
with	O
a	O
similar	O
group	O
of	O
patients	O
with	O
definite	O
MD	B-LOC
and	O
a	O
group	O
of	O
patients	O
with	O
recent	O
idiopathic	B-DIS
sudden	I-DIS
neurosensory	I-DIS
hearing	I-DIS
loss	I-DIS
ISSNHL	I-DIS
.	O

Material	O
and	O
Methods	O
170	O
patients	O
were	O
included	O
83	O
with	O
definite	O
MD	O
38	O
with	O
fluctuating	O
sensorineural	B-DIS
hearing	I-DIS
loss	I-DIS
34	O
with	O
recurrent	O
vertigo	B-DIS
and	O
15	O
with	O
ISSNHL	B-DIS
.	O

The	O
clinical	O
variables	O
audiovestibular	O
tests	O
and	O
EH	O
were	O
evaluated	O
and	O
compared	O
.	O

Logistic	O
proportional	O
hazard	O
models	O
were	O
used	O
to	O
obtain	O
the	O
odds	O
ratio	O
for	O
hydrops	B-DIS
development	O
including	O
a	O
multivariable	O
adjusted	O
model	O
for	O
potential	O
confounders	O
.	O

Results	O
No	O
statistical	O
differences	O
between	O
groups	O
were	O
found	O
regarding	O
disease	O
duration	O
episodes	O
Tumarkin	B-DIS
spells	I-DIS
migraine	I-DIS
vascular	O
risk	O
factors	O
or	O
vestibular	O
tests	O
;	O
only	O
hearing	B-DIS
loss	I-DIS
showed	O
differences	O
.	O

Regarding	O
EH	O
we	O
found	O
significant	O
differences	O
between	O
groups	O
with	O
odds	O
ratio	O
OR	O
for	O
EH	O
presence	O
in	O
definite	O
MD	B-LOC
group	O
vs.	O
all	O
other	O
patients	O
of	O
11.43	O
4.5	O
-	O
29.02	O
;	O
p	O
<	O
0.001	O
.	O

If	O
the	O
ISSNHL	B-DIS
group	O
was	O
used	O
as	O
reference	O
OR	O
was	O
55.2	O
11.9	O
-	O
253.9	O
;	O
p	O
<	O
0.001	O
for	O
the	O
definite	O
MD	B-LOC
group	O
9.9	O
2.1	O
-	O
38.9	O
;	O
p	O
=	O
0.003	O
for	O
the	O
recurrent	O
vertigo	B-DIS
group	O
and	O
5.1	O
1.2	O
-	O
21.7	O
;	O
p	O
=	O
0.03	O
for	O
the	O
group	O
with	O
fluctuating	O
sensorineural	B-DIS
hearing	I-DIS
loss	I-DIS
.	O

Conclusion	O
The	O
percentage	O
of	O
patients	O
with	O
EH	O
varies	O
between	O
groups	O
.	O

It	O
is	O
minimal	O
in	O
the	O
ISSNHL	B-DIS
group	O
and	O
increases	O
in	O
groups	O
with	O
increasing	O
fluctuating	O
audiovestibular	O
symptoms	O
with	O
a	O
rate	O
of	O
severe	O
EH	B-DIS
similar	O
to	O
the	O
known	O
rate	O
of	O
progression	O
to	O
definite	O
MD	B-LOC
in	O
those	O
groups	O
suggesting	O
that	O
presence	O
of	O
EH	O
by	O
MRI	O
could	O
be	O
related	O
to	O
the	O
risk	O
of	O
progression	O
to	O
definite	O
MD	B-LOC
.	O

Thus	O
EH	O
imaging	O
in	O
these	O
patients	O
is	O
recommended	O
.	O

Exstrophy	B-DIS
of	I-DIS
the	I-DIS
bladder	I-DIS
is	O
a	O
rare	O
congenital	B-DIS
anomaly	I-DIS
with	O
an	O
incidence	B-EPI
of	O
about	O
1	B-STAT
per	I-STAT
50000	I-STAT
newborns	O
.	O

The	O
malignant	O
potential	O
of	O
the	O
exstrophied	O
bladder	O
mucosa	O
is	O
well	O
known	O
;	O
95	B-STAT
%	I-STAT
are	O
adenocarcinomas	B-DIS
and	O
3	B-STAT
%	I-STAT
to	I-STAT
5	I-STAT
%	I-STAT
are	O
squamous	B-DIS
cell	I-DIS
carcinomas	I-DIS
.	O

Most	O
of	O
the	O
malignant	B-DIS
tumors	I-DIS
60	B-STAT
%	I-STAT
associated	O
with	O
an	O
exstrophy	B-DIS
of	I-DIS
the	I-DIS
bladder	I-DIS
occur	O
during	O
the	O
fourth	O
and	O
fifth	O
decades	O
of	O
life	O
.	O

Of	O
the	O
remaining	O
about	B-STAT
20	I-STAT
%	I-STAT
each	O
occur	O
after	O
60	O
years	O
and	O
before	O
40	O
years	O
.	O

Here	O
we	O
present	O
a	O
case	O
in	O
which	O
squamous	B-DIS
cell	I-DIS
carcinoma	I-DIS
developed	O
in	O
an	O
unrepaired	O
exstrophy	B-DIS
of	I-DIS
the	I-DIS
bladder	I-DIS
.	O

We	O
present	O
the	O
management	O
of	O
the	O
case	O
and	O
a	O
brief	O
review	O
of	O
the	O
literature	O
.	O

Introduction	O
Psoriatic	O
arthritis	B-DIS
PsA	O
is	O
a	O
chronic	B-DIS
immune	I-DIS
-	I-DIS
mediated	I-DIS
inflammatory	O
spondyloarthropathy	O
associated	B-DIS
with	O
psoriasis	O
.	O

PsA	B-DIS
is	O
frequently	O
associated	O
with	O
metabolic	B-DIS
disorders	I-DIS
including	O
obesity	B-DIS
metabolic	B-DIS
syndrome	I-DIS
and	O
diabetes	B-DIS
mellitus	I-DIS
DM	I-DIS
.	O

Type	O
2	O
DM	O
is	O
among	O
the	O
most	O
common	O
metabolic	B-DIS
disorders	I-DIS
with	O
a	O
prevalence	B-EPI
ranging	O
from	O
2.4	O
to	O
14.8	B-STAT
%	I-STAT
in	O
the	O
general	O
population	O
.	O

Methods	O
We	O
conducted	O
a	O
narrative	O
review	O
of	O
the	O
English	O
-	O
language	O
studies	O
from	O
January	O
1989	O
to	O
September	O
2019	O
investigating	O
the	O
risk	O
of	O
type	O
2	O
DM	O
in	O
patients	B-DIS
with	O
PsA	O
the	O
pathogenic	O
mechanism	O
linking	O
DM	B-DIS
to	O
PsA	O
and	O
the	O
effects	O
on	O
insulin	O
sensitivity	O
exerted	O
by	O
systemic	O
therapies	B-DIS
for	O
PsA	O
.	O

Results	O
The	O
prevalence	B-EPI
of	O
type	O
2	O
DM	O
in	O
patients	O
with	O
PsA	B-DIS
ranges	O
from	O
6.1	O
to	O
20.2	B-STAT
%	I-STAT
generally	O
higher	O
when	O
compared	O
to	O
the	O
general	O
population	O
.	O

The	O
higher	O
risk	O
of	O
DM	O
is	O
reported	O
in	O
women	O
with	O
more	O
severe	O
forms	O
of	O
PsA	B-DIS
.	O

Elevated	O
serum	O
levels	O
of	O
adipokines	O
including	O
TNF	O
-	O
α	O
which	O
inhibits	O
the	O
autophosphorylation	O
of	O
the	O
insulin	O
receptor	O
and	O
suppresses	O
the	O
expression	O
of	O
glucose	O
transporter	O
4	O
favor	O
insulin	O
resistance	O
and	O
could	O
partially	O
explain	O
the	O
association	B-DIS
between	O
PsA	O
and	O
DM	O
.	O

Moreover	O
adiponectin	O
and	O
omentin	O
with	O
insulin	O
-	O
sensitizing	O
and	O
anti	O
-	O
atherogenic	O
properties	O
are	O
decreased	B-DIS
in	O
patients	O
with	O
PsA	O
.	O

Some	O
of	O
the	O
treatments	O
for	O
PsA	B-DIS
could	O
affect	O
the	O
glucose	O
homeostasis	O
.	O

Systemic	O
corticosteroids	O
are	O
known	O
to	O
impair	O
insulin	O
resistance	O
whereas	O
apremilast	O
phosphodiesterase	O
type	O
4	O
inhibitor	O
and	O
TNF	O
-	O
α	O
inhibitors	O
could	O
exert	O
neutral	O
effect	O
or	O
reduce	B-DIS
the	O
insulin	O
-	O
resistance	O
.	O

The	O
role	O
of	O
IL-17	O
or	O
IL-23	O
inhibitors	O
has	O
been	O
marginally	O
investigated	O
.	O

Conclusions	O
Patients	O
affected	O
by	O
PsA	B-DIS
have	O
a	O
higher	O
prevalence	B-EPI
of	O
type	O
2	O
DM	O
compared	O
with	O
the	O
general	O
population	O
.	O

The	O
mechanism	O
linking	O
PsA	O
with	O
DM	O
has	O
not	O
been	O
completely	O
clarified	O
but	O
some	O
of	O
the	O
principal	O
mediators	O
could	O
be	O
TNF	O
-	O
α	O
and	O
adipokine	O
especially	O
adiponectin	O
and	O
omentin	O
.	O

Apremilast	O
and	O
TNF	O
-	O
α	O
inhibitor	O
may	O
have	O
a	O
favorable	O
effect	O
and	O
could	O
be	O
safely	O
used	O
in	O
patients	O
with	O
DM	O
.	O

Introduction	O
We	O
investigated	O
the	O
prevalence	B-EPI
of	O
human	B-DIS
T	I-DIS
-	I-DIS
cell	I-DIS
lymphotropic	O
virus	B-STAT
types	I-STAT
1	I-STAT
and	B-DIS
2	I-DIS
HTLV-1/2	O
infection	O
in	O
patients	B-DIS
with	I-DIS
hematological	O
diseases	O
from	O
the	O
western	O
Amazon	O
region	O
of	O
Brazil	B-LOC
.	O

Methods	O
Samples	O
from	O
306	O
patients	O
were	O
submitted	O
for	O
the	O
molecular	O
diagnosis	O
of	O
HTLV-1/2	B-DIS
infection	I-DIS
by	O
real	O
time	O
PCR	O
qPCR	O
with	O
amplification	O
sequencing	O
and	O
phylogenetic	O
analysis	O
of	O
the	O
long	O
terminal	O
repeat	O
LTR	O
region	O
.	O

Results	O
A	O
29	O
-	O
year	O
-	O
old	B-DIS
male	I-DIS
carrier	I-DIS
of	O
sickle	O
cell	O
anemia	O
with	O
a	O
history	O
of	O
multiple	O
blood	O
transfusions	O
was	O
diagnosed	O
with	O
the	O
HTLV-2c	O
subtype	O
.	O

Conclusions	O
This	O
study	O
describes	O
the	O
first	O
known	O
occurrence	O
of	O
HTLV-2c	O
in	O
the	O
urban	O
area	O
of	O
Brazil	B-LOC
's	O
western	O
Amazon	O
region	O
.	O

Skeletal	B-DIS
dysplasia	I-DIS
SD	I-DIS
a	O
heterogeneous	B-DIS
disease	I-DIS
group	O
with	O
rare	O
incidence	B-EPI
and	O
various	O
clinical	O
manifestations	O
is	O
associated	O
with	O
multiple	O
causative	O
genes	O
.	O

For	O
clinicians	O
accurate	O
diagnosis	O
of	O
SD	B-DIS
is	O
clinically	O
and	O
genetically	O
difficult	O
.	O

The	O
development	O
of	O
next	O
-	O
generation	O
sequencing	O
NGS	O
has	O
substantially	O
aided	O
in	O
the	O
genetic	O
diagnosis	B-DIS
of	O
SD	O
.	O

In	O
this	O
study	O
we	O
conducted	O
a	O
targeted	O
NGS	O
of	O
437	O
genes	O
-	O
included	O
in	O
the	O
nosology	O
of	O
SD	B-DIS
published	O
in	O
2019	O
-	O
in	O
31	O
patients	O
with	O
a	O
suspected	O
SD	B-DIS
.	O

The	O
clinical	O
and	O
genetic	O
diagnoses	O
were	O
confirmed	O
in	O
16	O
out	O
of	O
the	O
31	O
patients	O
and	O
the	O
diagnostic	O
yield	O
was	O
51.9	B-STAT
%	I-STAT
.	O

In	O
these	O
patients	O
18	O
pathogenic	O
variants	O
were	O
found	O
in	O
13	O
genes	O
COL2A1	O
MYH3	O
COMP	O
MATN3	O
CTSK	O
EBP	O
CLCN7	O
COL1A2	O
EXT1	O
TGFBR1	O
SMAD3	O
FIG4	O
and	O
ARID1B	O
of	O
which	O
four	O
were	O
novel	O
variants	O
.	O

The	O
diagnosis	O
rate	O
was	O
very	O
high	O
in	O
patients	O
with	O
a	O
suspected	O
familial	B-DIS
SD	I-DIS
and	O
with	O
radiological	O
evidence	O
indicating	O
clinical	O
SD	O
11	O
out	O
of	O
1573.3	B-STAT
%	I-STAT
.	O

In	O
patients	O
with	O
skeletal	O
involvement	O
and	O
other	O
clinical	O
manifestations	O
including	O
dysmorphism	O
or	O
multiple	O
congenital	B-DIS
anomalies	I-DIS
and	O
various	O
degrees	O
of	O
developmental	O
delay	B-DIS
/	I-DIS
intellectual	O
disability	O
the	O
diagnosis	O
rate	O
was	O
low	O
5	O
out	O
of	O
1631.2	B-STAT
%	I-STAT
but	O
rare	O
syndromic	O
SD	O
could	O
be	O
diagnosed	O
.	O

In	O
conclusion	O
NGS	O
-	O
based	O
gene	O
panel	O
sequencing	O
can	O
be	O
helpful	O
in	B-DIS
diagnosing	O
SD	O
which	O
has	O
clinical	O
and	O
genetic	O
heterogeneity	O
.	O

To	O
increase	O
the	O
diagnostic	O
yield	O
of	O
suspected	O
SD	B-DIS
patients	O
it	O
is	O
important	O
to	O
categorize	O
patients	O
based	O
on	O
the	O
clinical	O
features	O
family	O
history	O
and	O
radiographic	O
evidence	O
.	O

Objectives	O
In	O
this	O
international	O
study	O
we	O
aimed	O
to	O
investigate	O
the	O
opinions	O
of	O
physicians	O
dealing	O
with	O
patients	O
with	O
functional	B-DIS
seizures	I-DIS
FS	O
worldwide	O
on	O
working	O
restrictions	O
and	O
disability	O
benefits	O
eligibility	O
.	O

Methods	O
International	O
online	O
survey	O
of	O
neurologists	O
/	O
mental	O
health	O
professionals	O
from	O
Argentina	B-LOC
Venezuela	O
Colombia	B-LOC
Italy	B-LOC
France	B-LOC
Iran	B-LOC
Iraq	B-LOC
United	B-LOC
Arab	I-LOC
Emirates	I-LOC
UAE	O
Qatar	B-LOC
Saudi	B-LOC
Arabia	I-LOC
Georgia	B-LOC
and	O
Russia	B-LOC
.	O

Results	O
Six	O
hundred	O
and	O
twenty	O
-	O
seven	O
physicians	O
from	O
12	O
countries	O
participated	O
in	O
the	O
study	O
.	O

Working	O
as	O
a	O
neurologist	O
was	O
a	O
predictor	O
to	O
think	O
that	O
patients	O
with	O
FS	O
should	O
not	O
be	O
counseled	O
to	O
avoid	O
performing	O
all	O
jobs	O
or	O
professions	O
as	O
long	O
as	O
they	O
have	O
active	O
disease	O
OR	O
0.46	O
;	O
95	B-STAT
%	I-STAT
CI	O
0.30	O
to	O
0.68	O
;	O
p	O
<	O
0.001	O
.	O

Having	O
managed	O
more	O
than	O
200	O
patients	O
was	O
associated	O
with	O
the	O
opinion	O
that	O
patients	O
should	O
not	O
be	O
counseled	O
to	O
avoid	O
performing	O
any	O
type	O
of	O
work	O
OR	O
2.17	O
;	O
95	B-STAT
%	I-STAT
CI	O
1.02	O
to	O
4.59	O
;	O
p	O
=	O
0.043	O
.	O

Working	O
as	O
a	O
psychiatrist	O
/	O
psychologist	O
was	O
associated	O
with	O
the	O
idea	O
that	O
patients	O
with	O
FS	O
should	O
be	O
qualified	O
for	O
disability	O
benefits	O
OR	O
1.97	O
;	O
95	B-STAT
%	I-STAT
CI	O
1.21	O
-	O
3.21	O
;	O
p	O
=	O
0.006	O
and	O
receive	O
these	O
benefits	O
lifelong	O
OR	O
0.43	O
;	O
95	B-STAT
%	I-STAT
CI	O
0.22	O
-	O
0.84	O
;	O
p	O
=	O
0.014	O
.	O

Conclusion	O
Neurologists	O
and	O
mental	O
health	O
professionals	O
have	O
different	O
attitudes	O
and	O
opinions	O
toward	O
working	O
restrictions	O
and	O
disability	O
benefits	O
for	O
patients	O
with	O
FS	O
.	O

Further	O
studies	O
should	O
investigate	O
the	O
reasons	O
for	O
these	O
differences	O
and	O
propose	O
solutions	O
to	O
avoid	O
discrimination	O
and	O
unequal	O
access	O
to	O
employment	O
and	O
disability	O
benefits	O
.	O

Aim	O
To	O
assess	O
a	O
total	O
population	O
of	O
school	O
-	O
age	O
children	B-DIS
with	I-DIS
cerebral	O
palsy	O
CP	B-DIS
for	O
autism	B-DIS
and	I-DIS
attention	I-DIS
-	O
deficit	O
/	O
hyperactivity	O
disorder	O
ADHD	O
with	B-EPI
a	O
view	O
to	O
determining	O
their	O
prevalence	O
and	B-DIS
to	I-DIS
relate	I-DIS
findings	O
to	O
motor	O
function	O
intellectual	O
disability	O
and	O
other	O
associated	O
impairments	O
.	O

Method	O
Of	O
264	O
children	O
born	O
between	O
1999	O
and	O
2006	O
from	O
the	O
CP	O
register	O
of	O
western	O
Sweden	B-LOC
200	O
children	O
109	O
males	O
91	O
females	O
median	O
age	O
at	O
assessment	O
14y	O
range	O
7	O
-	O
18y	O
completed	O
comprehensive	O
screening	O
and	O
further	O
neuropsychiatric	O
clinical	O
assessments	O
.	O

Results	O
Ninety	O
children	O
45	B-STAT
%	I-STAT
were	O
diagnosed	O
with	O
autism	B-DIS
ADHD	I-DIS
or	O
both	B-STAT
5930	I-STAT
%	I-STAT
were	O
diagnosed	O
with	O
autism	B-DIS
and	O
6030	B-STAT
%	I-STAT
were	O
diagnosed	O
with	O
ADHD	B-DIS
.	O

Intellectual	O
disability	O
was	O
present	O
in	O
51	B-STAT
%	I-STAT
.	O

Two	O
-	O
thirds	B-DIS
had	I-DIS
autism	O
ADHD	B-DIS
and/or	I-DIS
intellectual	O
disability	O
.	O

In	O
regression	O
models	O
autism	B-DIS
was	O
mainly	O
predicted	O
by	O
intellectual	B-DIS
disability	I-DIS
odds	O
ratio	O
[	O
OR	O
]	O
=	O
4.1	O
and	O
ADHD	B-DIS
OR=3.2	O
and	O
ADHD	B-DIS
was	O
predicted	O
by	O
intellectual	B-DIS
disability	I-DIS
OR=2.3	O
and	O
autism	B-DIS
OR=3.0	O
.	O

Autism	B-DIS
was	O
more	O
common	O
in	O
children	O
born	O
preterm	O
OR=2.0	O
.	O

Gross	O
motor	O
function	O
was	O
not	O
associated	O
with	O
autism	B-DIS
.	O

ADHD	B-DIS
prevalence	B-EPI
was	O
low	O
in	O
children	O
with	O
severe	O
motor	B-DIS
impairment	I-DIS
possibly	O
due	O
to	O
diagnostic	O
limitations	O
.	O

Interpretation	O
Autism	B-DIS
and	O
ADHD	B-DIS
were	O
common	O
in	O
this	O
population	O
of	O
children	O
with	O
CP	O
and	O
were	O
mainlyindependent	O
of	O
motor	O
severity	O
and	O
CP	O
type	O
.	O

The	O
strongest	O
predictor	O
of	O
autism	O
/	O
ADHD	B-DIS
was	I-DIS
intellectual	O
disability	O
.	O

Assessment	O
for	O
autism	B-DIS
and	O
ADHD	B-DIS
is	O
warranted	O
as	O
part	O
of	O
the	O
evaluation	O
in	O
CP	O
.	O

What	O
this	O
paper	O
adds	O
Forty	B-STAT
-	I-STAT
five	I-STAT
percent	I-STAT
of	O
the	O
children	B-DIS
with	I-DIS
cerebral	O
palsy	O
also	B-DIS
had	I-DIS
autism	I-DIS
attention	I-DIS
-	O
deficit	O
/	O
hyperactivity	O
disorder	O
ADHD	O
or	O
both	O
.	O

Autism	B-DIS
and	O
ADHD	B-DIS
were	O
predicted	O
mainly	O
by	O
intellectual	B-DIS
disability	I-DIS
.	O

Established	O
diagnostic	O
instruments	O
worked	O
well	O
for	O
all	O
but	O
the	O
most	O
disabled	O
group	O
of	O
children	O
.	O

Unilateral	O
lung	B-DIS
agenesis	I-DIS
is	O
a	O
relatively	O
rare	O
congenital	B-DIS
anomaly	I-DIS
with	O
a	O
reported	O
incidence	B-EPI
of	O
1	B-STAT
in	I-STAT
15000	I-STAT
births	O
.	O

It	O
is	O
frequently	O
associated	O
with	O
other	O
congenital	B-DIS
malformations	I-DIS
.	O

Some	O
of	O
the	O
sequelae	O
of	O
lung	B-DIS
agenesis	I-DIS
are	O
potentially	O
life	O
-	O
threatening	O
.	O

Here	O
we	O
report	O
a	O
case	O
of	O
left	B-DIS
lung	I-DIS
agenesis	I-DIS
in	O
association	O
with	O
hiatal	B-DIS
hernia	I-DIS
and	O
atrioventricular	B-DIS
septal	I-DIS
defect	I-DIS
a	O
rare	O
combination	O
of	O
anomalies	B-DIS
which	O
have	O
not	O
been	O
described	O
previously	O
in	O
the	O
literature	O
.	O

Introduction	O
Ehlers	B-DIS
-	I-DIS
Danlos	I-DIS
syndrome	O
EDS	O
specifically	B-DIS
the	O
hypermobility	B-DIS
type	O
hEDS	O
is	O
associated	O
with	O
a	O
variety	B-DIS
of	I-DIS
gastrointestinal	O
GI	O
conditions	O
.	O

This	O
study	O
aims	O
to	O
evaluate	O
the	O
prevalence	B-EPI
of	O
and	O
factors	O
associated	O
with	O
gut	B-DIS
dysmotility	I-DIS
in	O
patients	O
with	O
hEDS	B-DIS
.	O

Methods	O
This	O
is	O
a	O
retrospective	O
study	O
of	O
hEDS	B-DIS
patients	O
conducted	O
at	O
the	O
Cleveland	O
Clinic	O
's	O
Center	O
for	O
Personalized	O
Genetic	O
Healthcare	O
between	O
January	O
2007	O
and	O
December	O
2017	O
.	O

Demographics	O
GI	O
motility	O
testing	O
endoscopic	O
and	O
imaging	O
data	O
were	O
extracted	O
from	O
the	O
patients	O
'	O
charts	O
.	O

Results	O
A	O
total	O
of	O
218	O
patients	O
with	O
hEDS	B-DIS
were	O
identified	O
.	O

Among	O
them	O
13662.3	B-STAT
%	I-STAT
patients	O
had	O
at	O
least	O
one	O
GI	O
symptom	O
at	O
the	O
time	O
of	O
EDS	O
diagnosis	O
.	O

Motility	O
testing	O
was	O
performed	O
and	O
reported	O
in	O
4219.2	B-STAT
%	I-STAT
patients	O
.	O

Out	O
of	O
them	O
five	B-STAT
11.9	I-STAT
%	I-STAT
had	O
esophageal	B-DIS
dysmotility	I-DIS
1842.8	B-STAT
%	I-STAT
had	O
gastroparesis	B-DIS
five	B-STAT
11.9	I-STAT
%	I-STAT
had	O
small	O
bowel	O
/	O
colon	O
altered	O
transit	O
time	O
and	O
four	B-STAT
9.5	I-STAT
%	I-STAT
had	B-DIS
global	O
dysmotility	O
.	O

In	O
univariable	O
analysis	O
patients	O
with	O
postural	B-DIS
orthostatic	I-DIS
tachycardia	I-DIS
syndrome	I-DIS
POTS	I-DIS
[	O
odds	O
ratio	O
OR	O
8.8895	B-STAT
%	I-STAT
CI	O
3.69	O
-	O
24.9	O
p	O
<	O
0.0001	O
]	O
fibromyalgia	B-DIS
OR	O
4.4395	B-STAT
%	I-STAT
CI	O
2.04	O
-	O
10.1	O
p=0.0002	O
history	O
of	O
irritable	B-DIS
bowel	I-DIS
syndrome	I-DIS
OR	O
5.0195	B-STAT
%	I-STAT
CI	O
2.31	O
-	O
11.2	O
p	O
<	O
0.0001	O
and	O
gastroesophageal	B-DIS
reflux	I-DIS
disease	I-DIS
OR	O
3.3395	B-STAT
%	I-STAT
CI	O
1.55	O
-	O
7.44	O
p=0.002	O
were	O
more	O
likely	O
to	O
be	O
diagnosed	O
with	O
GI	B-DIS
dysmotility	I-DIS
.	O

On	O
multivariable	O
analysis	O
only	O
POTS	O
OR	O
5.7495	B-STAT
%	I-STAT
CI	O
2.25	O
-	O
16.7	O
p=0.0005	O
was	O
significantly	O
associated	O
with	O
an	O
increased	O
likelihood	O
of	O
GI	B-DIS
dysmotility	I-DIS
.	O

Conclusions	O
This	O
study	O
suggests	O
that	O
GI	O
symptoms	O
are	O
relatively	O
common	O
among	O
patients	O
with	O
hEDS	B-DIS
.	O

Of	O
the	O
patients	O
tested	O
for	O
dysmotility	B-DIS
76.2	B-STAT
%	I-STAT
were	O
found	O
to	O
have	O
some	O
form	O
of	O
dysmotility	B-DIS
.	O

POTS	B-DIS
was	O
found	O
to	O
be	O
an	O
independent	O
predictive	O
factor	O
for	O
GI	B-DIS
dysmotility	I-DIS
.	O

Loss	O
-	O
of	O
-	O
function	O
LoF	O
mutations	O
in	O
KCNQ1	O
encoding	O
the	O
voltage	O
-	O
gated	O
K	O
+	O
<	O
/s	O
channel	O
K	O
v	B-DIS
<	I-DIS
/s	I-DIS
7.1	I-DIS
lead	B-DIS
to	O
long	O
QT	O
syndrome	O
1	O
LQT1	O
.	O

LQT1	B-DIS
patients	O
also	O
present	O
with	O
post	B-DIS
-	I-DIS
prandial	O
hyperinsulinemia	B-DIS
and	O
hypoglycaemia	O
.	O

In	O
contrast	O
KCNQ1	O
polymorphisms	O
are	O
associated	O
with	O
diabetes	B-DIS
and	O
LQTS	B-DIS
patients	O
have	O
a	O
higher	O
prevalence	B-EPI
of	O
diabetes	B-DIS
.	O

We	O
developed	O
a	O
mouse	O
model	O
with	O
a	O
LoF	O
Kcnq1	O
mutation	O
using	O
CRISPR	O
-	O
Cas9	O
and	O
hypothesized	O
that	O
this	O
mouse	O
model	O
would	O
display	O
QT	O
prolongation	O
increased	O
glucose	O
-	O
stimulated	O
insulin	O
secretion	O
and	O
allow	O
for	O
interrogation	O
of	O
K	O
v	O
<	O
/s	O
7.1	O
function	O
in	O
islets	O
.	O

Mice	O
were	O
characterized	O
by	O
electrocardiography	O
and	O
oral	O
glucose	O
tolerance	O
tests	O
.	O

Ex	O
vivo	O
islet	O
glucose	O
-	O
induced	O
insulin	O
release	O
was	O
measured	O
and	O
beta	O
-	O
cell	O
area	O
quantified	O
by	O
immunohistochemistry	O
.	O

Homozygous	O
mice	O
had	O
QT	O
prolongation	O
.	O

Ex	O
vivo	O
glucose	O
-	O
stimulated	O
insulin	O
release	O
was	O
increased	O
in	O
islets	O
from	O
homozygous	O
mice	O
at	O
12	O
-	O
14	O
weeks	O
while	O
beta	O
-	O
cell	O
area	O
was	O
reduced	O
.	O

Non	O
-	O
fasting	O
blood	O
glucose	O
levels	O
were	O
decreased	O
at	O
this	O
age	O
.	O

In	O
follow	O
-	O
up	O
studies	O
8	O
-	O
10	O
weeks	O
later	O
beta	O
-	O
cell	O
area	O
was	O
similar	O
in	O
all	O
groups	O
while	O
glucose	O
-	O
stimulated	O
insulin	O
secretion	O
was	O
now	O
reduced	O
in	O
islets	O
from	O
hetero-	O
and	O
homozygous	O
mice	O
.	O

Non	O
-	O
fasting	O
blood	O
glucose	O
levels	O
had	O
normalized	O
.	O

These	O
data	O
suggest	O
that	O
K	O
v	O
<	O
/s	O
7.1	O
dysfunction	O
is	O
involved	O
in	O
a	O
transition	O
from	O
hyper-	O
to	O
hyposecretion	B-DIS
of	O
insulin	O
potentially	O
explaining	O
the	O
association	O
with	O
both	O
hypoglycemia	B-DIS
and	O
hyperglycemia	B-DIS
in	O
LQT1	B-DIS
patients	O
.	O

Introduction	O
Angelman	B-DIS
syndrome	I-DIS
AS	O
is	O
a	O
neurodevelopmental	B-DIS
disorder	I-DIS
characterized	O
by	O
cognitive	B-DIS
disability	I-DIS
speech	O
impairment	B-DIS
hyperactivity	I-DIS
and	O
seizures	B-DIS
.	O

Movement	B-DIS
disorders	I-DIS
have	O
been	O
reported	O
in	O
almost	O
all	O
AS	O
subjects	O
and	O
they	O
are	O
described	O
as	O
`	O
`	O
tremulous	B-DIS
movements	I-DIS
of	O
limbs	B-DIS
unsteadiness	I-DIS
clumsiness	I-DIS
or	O
quick	O
jerky	O
motions	O
''	O
.	O

The	O
presence	O
of	O
dystonia	B-DIS
has	O
barely	O
been	O
mentioned	O
in	O
subjects	O
with	O
AS	O
and	O
has	O
never	O
been	O
studied	O
in	O
detail	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
evaluate	O
the	O
prevalence	B-EPI
clinical	O
features	O
and	O
severity	O
of	O
dystonia	B-DIS
in	O
a	O
series	O
of	O
adolescents	O
and	O
adults	O
with	O
AS	O
.	O

Methods	O
Whole	O
body	O
video	O
recordings	O
of	O
patients	O
with	O
genetically	O
confirmed	O
AS	O
were	O
evaluated	O
.	O

Dystonia	B-DIS
was	O
evaluated	O
by	O
mean	O
of	O
the	O
movement	O
subscale	O
of	O
Burke	O
-	B-DIS
Fahn	O
-	O
Marsden	O
Dystonia	O
Rating	O
Scale	O
BFM	O
.	O

Results	O
Forty	O
-	O
four	O
subjects	O
with	O
AS	O
were	O
evaluated	O
.	O

Fourteen	O
recordings	O
were	O
excluded	O
due	O
to	O
poor	O
cooperation	O
.	O

We	O
finally	O
analyzed	O
data	O
of	O
30	O
subjects	O
15	O
F	O
with	O
a	O
median	O
age	O
of	O
28	O
years	O
range	O
15	O
-	O
51	O
.	O

Dystonia	B-DIS
was	O
present	O
in	O
28/30	B-STAT
93.3	B-STAT
%	I-STAT
subjects	O
.	O

Among	O
these	O
dystonia	B-DIS
involved	O
the	O
upper	O
limbs	O
in	O
28/28100	B-STAT
%	I-STAT
lower	O
limbs	O
in	O
8/28	B-STAT
28.5	I-STAT
%	I-STAT
mouth	O
in	O
7/2825	B-STAT
%	I-STAT
neck	O
in	O
3/28	B-STAT
10.7	I-STAT
%	I-STAT
trunk	O
in	O
1/28	B-STAT
3.6	I-STAT
%	I-STAT
.	O

Severity	O
of	O
dystonia	B-DIS
ranged	O
from	O
slight	O
to	O
moderate	O
.	O

There	O
was	O
a	O
linear	O
correlation	O
between	O
severity	O
of	O
dystonia	B-DIS
and	O
increasing	O
age	O
.	O

There	O
was	O
no	O
difference	O
in	O
terms	O
of	O
severity	O
of	O
dystonia	B-DIS
among	O
genetic	O
subgroups	O
.	O

Conclusions	O
Dystonia	B-DIS
is	O
a	O
common	O
and	O
previously	O
underrecognized	O
clinical	O
feature	O
of	O
adults	O
and	O
adolescents	O
with	O
AS	O
.	O

Background	O
Skin	B-DIS
adnexal	I-DIS
tumors	I-DIS
SAT	O
encompass	O
wide	O
spectrum	O
of	O
benign	B-DIS
and	I-DIS
malignant	I-DIS
tumors	I-DIS
that	O
differentiate	O
toward	O
one	O
or	O
more	O
adnexal	O
structures	O
found	O
in	O
normal	O
skin	O
.	O

Overall	O
incidence	B-EPI
of	O
SATs	O
is	O
low	O
yet	O
they	O
can	O
be	O
challenging	O
to	O
diagnose	O
.	O

Aims	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
study	O
the	O
spectrum	O
and	O
microscopic	O
features	O
of	O
SATs	O
.	O

Materials	O
and	O
methods	O
It	O
was	O
a	O
retrospective	O
cross	O
-	O
sectional	O
descriptive	O
study	O
conducted	O
over	O
a	O
period	O
of	O
3	O
years	O
.	O

Formalin	O
fixed	O
paraffin	O
-	O
embedded	O
sections	O
were	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O
for	O
histopathological	O
analysis	O
.	O

Results	O
Out	O
of	O
the	O
total	O
34400	O
biopsies	O
110	O
cases	O
were	O
diagnosed	O
as	O
SATs	O
comprising	O
39.09	B-STAT
%	I-STAT
of	O
tumors	B-DIS
with	O
follicular	O
differentiation	O
followed	O
by	O
tumors	B-DIS
showing	O
sweat	O
gland	O
differentiation	O
37.27	B-STAT
%	I-STAT
and	O
sebaceous	O
differentiation	O
23.63	B-STAT
%	I-STAT
.	O

The	O
age	O
ranged	O
from	O
5	O
years	O
to	O
85	O
years	O
and	O
malefemale	O
ratio	O
was	O
1.031	O
.	O

Most	O
of	O
the	O
tumors	B-DIS
were	O
benign	O
82.73	B-STAT
%	I-STAT
while	O
only	B-STAT
17.27	I-STAT
%	I-STAT
were	O
malignant	O
.	O

Pilomatricoma	B-DIS
28.2	I-STAT
%	I-STAT
was	O
the	O
most	O
common	O
benign	O
tumor	B-DIS
while	O
sebaceous	B-DIS
carcinoma	I-DIS
11.8	B-STAT
%	I-STAT
was	O
the	O
most	O
common	O
malignant	B-DIS
tumor	I-DIS
.	O

Conclusion	O
Architectural	O
features	O
are	O
of	O
great	O
importance	O
in	O
differentiating	O
benign	O
tumors	B-DIS
from	O
malignant	O
.	O

Q	B-DIS
fever	I-DIS
is	O
a	O
zoonotic	B-DIS
disease	I-DIS
caused	O
by	O
Coxiella	O
burnetii	O
which	O
has	O
a	O
worldwide	O
distribution	O
.	O

Pneumonia	B-DIS
occurs	O
in	O
almost	O
half	O
of	O
the	O
patients	O
who	O
have	O
an	O
acute	O
C.	O
burnetii	O
infection	O
.	O

Less	O
than	O
5	O
-	O
6	O
%	O
of	O
community	O
acquired	O
pneumonia	B-DIS
CAP	O
is	O
found	O
to	O
be	O
caused	O
by	O
this	O
organism	O
.	O

Endemicity	O
of	O
C.	B-DIS
burnetii	I-DIS
infection	I-DIS
has	O
been	O
recorded	O
in	O
various	O
studies	O
carried	O
out	O
in	O
our	O
country	O
.	O

However	O
there	O
is	O
no	O
mention	O
about	O
Q	B-DIS
fever	I-DIS
as	O
a	O
cause	O
of	O
CAP	O
in	O
the	O
various	O
studies	O
done	O
to	O
identify	O
the	O
aetiological	O
agent	O
.	O

We	O
report	O
a	O
case	O
of	O
acute	B-DIS
Q	I-DIS
fever	I-DIS
related	O
pneumonia	B-DIS
and	O
this	O
appears	O
to	O
be	O
the	O
first	O
reported	O
case	O
of	O
pneumonia	B-DIS
due	O
to	O
C.	O
burnetii	B-DIS
infection	I-DIS
in	O
India	B-LOC
.	O

Background	O
The	O
VACTERL	O
association	O
VACTERL	B-DIS
is	O
the	O
nonrandom	O
occurrence	O
of	O
at	O
least	O
three	O
of	O
these	O
congenital	B-DIS
anomalies	I-DIS
vertebral	O
anal	B-DIS
cardiac	I-DIS
tracheoesophageal	I-DIS
renal	I-DIS
and	I-DIS
limb	I-DIS
anomalies	I-DIS
.	O

Despite	O
suggestions	O
for	O
involvement	O
of	O
several	O
genes	O
and	O
nongenetic	O
risk	O
factors	O
from	O
small	O
studies	O
the	O
etiology	O
of	O
VACTERL	O
remains	O
largely	O
unknown	O
.	O

Objective	O
To	O
identify	O
maternal	O
risk	O
factors	O
for	O
VACTERL	O
in	O
offspring	O
in	O
a	O
large	O
European	O
study	O
.	O

Methods	O
A	O
case	O
-	O
control	O
study	O
was	O
performed	O
using	O
data	O
from	O
28	O
EUROCAT	O
registries	O
over	O
the	O
period	O
1997	O
-	O
2015	O
with	O
case	O
and	O
control	O
ascertainment	O
through	O
hospital	B-DIS
records	I-DIS
birth	I-DIS
and	O
death	O
certificates	O
questionnaires	O
and/or	O
postmortem	O
examinations	O
.	O

Cases	O
were	O
diagnosed	O
with	O
VACTERL	O
while	O
controls	O
had	O
a	O
genetic	O
syndrome	O
and/or	O
chromosomal	B-DIS
abnormality	I-DIS
.	O

Data	O
collected	O
included	O
type	O
of	O
birth	B-DIS
defect	I-DIS
and	O
maternal	O
characteristics	O
such	O
as	O
age	O
use	O
of	O
assisted	O
reproductive	O
techniques	O
ART	O
and	O
chronic	B-DIS
illnesses	I-DIS
.	O

Multivariable	O
logistic	O
regression	O
analyses	O
were	O
performed	O
to	O
estimate	O
confounder	O
adjusted	O
odds	O
ratios	O
aOR	B-LOC
with	O
95	B-STAT
%	I-STAT
confidence	O
intervals	O
95	B-STAT
%	I-STAT
CI	O
.	O

Results	O
The	O
study	O
population	O
consisted	O
of	O
329	O
VACTERL	O
cases	O
and	O
49724	O
controls	O
with	O
recognized	O
syndromes	O
or	O
chromosomal	B-DIS
abnormality	I-DIS
.	O

For	O
couples	O
who	O
conceived	O
through	O
ART	O
we	O
found	O
an	O
increased	O
risk	O
of	O
VACTERL	O
aOR	O
2.3	B-STAT
[	I-STAT
95	I-STAT
%	I-STAT
CI	O
1.3	O
3.9	O
]	O
in	O
offspring	O
.	O

Pregestational	B-DIS
diabetes	I-DIS
aOR	O
3.1	O
[	O
95	B-STAT
%	I-STAT
CI	O
1.1	O
8.6	O
]	O
and	O
chronic	B-DIS
lower	I-DIS
obstructive	I-DIS
pulmonary	I-DIS
diseases	I-DIS
aOR	O
3.9	O
[	O
95	B-STAT
%	I-STAT
CI	O
2.2	O
6.7	O
]	O
also	O
increased	O
the	O
risk	O
of	O
having	O
a	O
child	O
with	O
VACTERL	O
.	O

Twin	O
pregnancies	O
were	O
not	O
associated	O
with	O
VACTERL	O
aOR	O
0.6	O
[	O
95	B-STAT
%	I-STAT
CI	O
0.3	O
1.4	O
]	O
.	O

Conclusion	O
We	O
identified	O
several	O
maternal	O
risk	O
factors	O
for	O
VACTERL	O
in	O
offspring	O
befitting	O
a	O
multifactorial	O
etiology	O
.	O

Objectives	O
The	O
objective	O
of	O
our	O
study	O
was	O
to	O
conduct	O
a	O
systematic	O
literature	O
review	O
of	O
estimates	O
of	O
costs	O
of	O
illness	B-DIS
of	I-DIS
spinal	I-DIS
muscular	I-DIS
atrophy	I-DIS
SMA	O
.	O

Methods	O
We	O
searched	O
MEDLINE	O
through	O
PubMed	O
CINAHL	O
Embase	O
Web	O
of	O
Science	O
National	O
Health	O
Service	O
Economic	O
Evaluation	O
Database	O
and	O
the	O
National	O
Health	O
Service	O
Health	O
Technology	O
Assessment	O
Database	O
for	O
studies	O
published	O
from	O
inception	O
up	O
until	O
31	O
August	O
2020	O
reporting	O
direct	O
medical	O
direct	O
non	O
-	O
medical	O
and/or	O
indirect	O
costs	O
of	O
any	O
phenotype	B-DIS
of	O
SMA	O
.	O

Two	O
reviewers	O
independently	O
screened	O
records	O
for	O
eligibility	O
extracted	O
the	O
data	O
and	O
assessed	O
studies	O
for	O
risk	O
of	O
bias	O
using	O
the	O
Newcastle	O
-	O
Ottawa	O
Scale	O
.	O

Costs	O
were	O
adjusted	O
and	O
converted	O
to	O
2018	O
US	O
dollars	O
.	O

Results	O
The	O
search	O
identified	O
14	O
studies	O
from	O
eight	O
countries	O
Australia	B-LOC
France	B-LOC
Germany	B-LOC
Italy	B-LOC
Spain	B-LOC
Sweden	B-LOC
the	O
UK	B-LOC
and	O
the	O
USA	B-LOC
.	O

The	O
mean	O
per	O
-	O
patient	O
annual	O
direct	O
medical	O
cost	B-DIS
of	O
illness	O
was	O
estimated	O
at	O
between	O
$	O
3320	O
SMA	O
type	O
III	O
Italy	B-LOC
and	O
$	O
324410	O
SMA	O
type	O
I	O
USA	B-LOC
mean	O
per	O
-	O
patient	O
annual	O
direct	O
non	O
-	O
medical	O
cost	O
between	O
$	O
25880	O
SMA	O
types	O
I	O
-	O
III	O
Spain	B-LOC
and	O
$	O
136800	O
SMA	O
type	O
I	O
Sweden	B-LOC
and	O
mean	O
per	O
-	O
patient	O
annual	O
indirect	O
cost	O
between	B-DIS
$	I-DIS
9440	I-DIS
SMA	O
type	O
I	O
Germany	B-LOC
and	O
$	O
74910	O
SMA	O
type	O
II	O
Australia	O
.	O

Most	O
studies	O
exhibited	O
a	O
risk	O
of	O
bias	O
.	O

Conclusions	O
The	O
current	O
body	O
of	O
evidence	O
of	O
costs	O
of	O
illness	B-DIS
of	I-DIS
SMA	I-DIS
is	O
relatively	O
scarce	O
and	O
characterized	O
by	O
considerable	O
variability	O
across	O
geographical	O
settings	O
and	O
disease	O
phenotypes	O
.	O

Our	O
review	O
provides	O
data	O
pertaining	O
to	O
the	O
economic	O
impact	O
of	O
SMA	B-DIS
which	O
is	O
of	O
particular	O
relevance	O
in	O
light	O
of	O
emerging	O
treatments	O
and	O
ongoing	O
research	O
in	O
this	O
field	O
and	O
underscores	O
the	O
substantial	O
unmet	O
medical	O
need	O
in	O
this	O
patient	O
population	O
.	O

Holoprosencephaly	B-DIS
is	O
a	O
rare	O
spectrum	O
of	O
congenital	B-DIS
malformation	I-DIS
associated	O
with	O
midline	O
facial	O
defects	O
and	O
absence	O
of	O
olfactory	O
tract	O
.	O

Sequence	O
occurs	O
at	O
4th	O
to	O
8th	O
week	O
of	O
gestational	O
age	O
due	O
to	O
failure	O
or	O
incomplete	O
diverticulation	O
and	O
cleavage	O
of	O
primitive	O
prosencephalon	O
.	O

It	O
is	O
most	O
common	O
brain	B-DIS
malformation	I-DIS
with	O
an	O
incidence	B-EPI
1250	O
in	O
conceptuses	O
and	O
associated	O
with	O
a	O
high	O
rate	O
of	O
spontaneous	O
abortion	B-DIS
and	O
prevalence	B-EPI
of	O
116000	O
in	O
live	O
borns	O
.	O

The	O
etiopathogenesis	O
of	O
holoprosencephaly	B-DIS
is	O
heterogeneous	O
and	O
multifactorial	O
may	O
be	O
environmental	O
metabolic	O
factors	O
or	O
teratogenic	O
including	O
insulin	O
-	O
dependent	B-DIS
maternal	I-DIS
diabetes	O
alcohol	O
consumption	O
.	O

In	O
this	O
study	O
we	O
described	O
a	O
case	O
of	O
holoprosencephaly	B-DIS
neonate	O
with	O
34	O
weeks	O
gestational	O
age	O
and	O
antenatal	O
ultrasonography	O
diagnosed	O
as	O
congenital	B-DIS
defects	I-DIS
in	O
the	O
central	O
nervous	O
system	O
asymmetric	O
growth	O
of	O
head	O
.	O

After	O
birth	O
the	O
infant	O
was	O
presented	O
with	O
multiple	O
congenital	B-DIS
anomalies	I-DIS
cleft	I-DIS
lip	I-DIS
cleft	I-DIS
palate	I-DIS
microphthalmia	I-DIS
absent	B-DIS
philtrum	I-DIS
absent	O
nasal	O
septum	O
with	O
single	O
naris	O
similar	O
to	O
holoprosencephaly	B-DIS
sequence	O
.	O

To	O
evaluate	O
the	O
incidence	B-EPI
and	O
predictive	O
risk	O
factors	O
of	O
complications	O
in	O
patients	O
who	O
underwent	O
thyroid	O
surgery	O
at	O
our	O
hospital	O
with	O
a	O
residency	O
training	O
program	O
.	O

This	O
retrospective	O
cohort	O
study	O
analyzed	O
the	O
complications	O
in	O
all	O
patients	O
who	O
underwent	O
thyroid	O
surgery	O
between	O
January	O
2008	O
and	O
December	O
2017	O
.	O

Demographic	O
data	O
preoperative	O
diagnosis	O
based	O
on	O
fine	O
needle	O
aspiration	O
cytology	O
surgical	O
approach	O
permanent	O
pathology	O
postoperative	O
complications	O
and	O
factors	O
associated	O
with	O
complications	O
were	O
recorded	O
.	O

At	O
our	O
hospital	O
456	O
patients	O
underwent	O
thyroidectomy	O
.	O

The	O
most	O
common	O
surgical	O
complications	O
were	O
asymptomatic	O
biochemical	O
hypocalcemia	B-DIS
and	O
symptomatic	O
hypocalcemia	B-DIS
in	O
10923.9	B-STAT
%	I-STAT
and	O
5011	B-STAT
%	I-STAT
patients	O
respectively	O
.	O

Other	O
surgical	O
complications	O
included	O
permanent	O
hypocalcemia	B-DIS
transient	O
vocal	B-DIS
cord	I-DIS
palsy	I-DIS
permanent	O
vocal	B-DIS
cord	I-DIS
palsy	I-DIS
hematoma	I-DIS
seroma	I-DIS
chyle	O
fistula	B-DIS
and	O
Horner	B-DIS
's	I-DIS
syndrome	I-DIS
.	O

Mean	O
ag	O
45	O
years	O
and	O
more	O
extensive	O
surgery	O
were	O
significantly	O
associated	O
with	O
overall	O
complications	O
P	O
=	O
0.003	O
;	O
<	O
0.001	O
.	O

Mean	O
ag	O
50	O
years	O
and	O
vitamin	O
D	O
level	O
<	O
25	O
nmol	O
/	O
L	O
<	O
10	O
ng	O
/	O
mL	O
were	B-DIS
significantly	O
associated	O
with	O
hypocalcemia	O
P	O
=	O
0.008	O
;	O
<	O
0.001	O
.	O

Moreover	O
the	O
extent	O
of	O
surgery	O
and	O
advanced	O
thyroid	B-DIS
carcinoma	I-DIS
were	O
significantly	O
associated	O
with	O
vocal	B-DIS
cord	I-DIS
palsy	I-DIS
P	O
<	O
0.001	O
;	O
0.05	O
.	O

Hypocalcemia	B-DIS
and	O
vocal	B-DIS
cord	I-DIS
palsy	I-DIS
are	O
the	O
most	O
significant	O
complications	O
.	O

Thyroid	O
surgery	O
can	O
be	O
performed	O
safely	O
by	O
senior	O
residents	O
in	O
the	O
residency	O
training	O
program	O
under	O
the	O
direct	O
supervision	O
of	O
an	O
experienced	O
surgeon	O
.	O

Over	O
the	O
last	O
10	O
years	O
evidence	O
has	O
accumulated	O
that	O
autoimmune	B-DIS
Addison	I-DIS
's	I-DIS
disease	I-DIS
AAD	O
is	O
a	O
heterogeneous	B-DIS
disease	I-DIS
.	O

Residual	O
adrenal	O
function	O
characterised	O
by	O
persistent	O
secretion	O
of	O
cortisol	O
other	O
glucocorticoids	O
and	O
mineralocorticoids	O
is	O
present	O
in	O
around	B-STAT
30	I-STAT
%	I-STAT
of	O
patients	O
with	O
established	O
AAD	O
and	O
appears	O
commoner	O
in	O
men	O
.	O

This	O
persistent	O
steroidogenesis	O
is	O
present	O
in	O
some	O
patients	O
with	O
AAD	O
for	O
more	O
than	O
20	O
years	O
but	O
it	O
is	O
commoner	O
in	O
people	O
with	O
shorter	O
disease	O
duration	O
.	O

The	O
clinical	O
significance	O
of	O
residual	O
adrenal	O
function	O
is	O
not	O
fully	O
clear	O
at	O
the	O
moment	O
but	O
as	O
it	O
signifies	O
an	O
intact	O
adrenocortical	O
stem	O
cell	O
population	O
it	O
opens	O
up	O
the	O
possibility	O
of	O
regeneration	O
of	O
adrenal	O
steroidogenesis	O
and	O
improvement	O
in	O
adrenal	B-DIS
failure	I-DIS
for	O
some	O
patients	O
.	O

Orthostatic	B-DIS
tremor	I-DIS
is	O
a	O
rare	O
condition	O
though	O
its	O
exact	O
prevalence	B-EPI
is	O
unknown	O
which	O
is	O
clinically	O
characterized	O
by	O
a	O
feeling	O
of	O
unsteadiness	O
or	O
being	O
about	O
to	O
fall	O
on	O
standing	O
and	O
which	O
disappears	O
on	O
walking	O
sitting	O
or	O
lying	O
down	O
.	O

It	O
is	O
generally	O
accepted	O
that	O
classic	O
orthostatic	B-DIS
tremor	I-DIS
manifests	O
with	O
a	O
high	O
-	B-DIS
frequency	O
tremor	O
13	O
Hz	O
of	O
the	O
legs	O
when	O
standing	O
.	O

However	O
a	O
number	O
of	O
patients	O
initially	O
reported	O
as	O
orthostatic	B-DIS
tremor	I-DIS
did	O
not	O
actually	O
have	O
such	O
electrophysiological	O
features	O
.	O

It	O
is	O
our	O
experience	O
that	O
there	O
is	O
a	O
clinical	O
spectrum	O
of	O
different	O
conditions	O
presenting	O
as	O
shaking	O
on	O
standing	O
and	O
this	O
highlights	O
the	O
importance	O
of	O
the	O
electrophysiology	O
to	O
aid	O
the	O
differential	O
diagnosis	O
of	O
these	O
disorders	O
.	O

Here	O
we	O
provide	O
a	O
critical	O
review	O
of	O
the	O
clinical	O
spectrum	O
of	O
shaking	O
on	O
standing	O
along	O
with	O
demonstrative	O
electrophysiological	O
recordings	O
of	O
some	O
of	O
these	O
conditions	O
.	O

Objective	O
To	O
demonstrate	O
that	O
delayed	O
cord	B-DIS
clamping	I-DIS
DCC	I-DIS
is	O
safe	O
in	O
mothers	O
with	O
confirmed	O
SARS	B-DIS
-	I-DIS
CoV-2	O
infection	O
.	O

Design	O
setting	O
and	O
participants	O
Prospective	O
observational	O
study	O
involving	O
epidemiological	O
information	O
from	O
403	O
pregnant	O
women	O
with	O
SARS	O
-	O
CoV-2	B-STAT
between	I-STAT
1	I-STAT
March	I-STAT
and	O
31	O
May	O
2020	O
.	O

Data	O
were	O
collected	O
from	O
70	O
centres	O
that	O
participate	O
in	O
the	O
Spanish	O
Registry	O
of	O
COVID-19	O
.	O

Methods	O
Patients	O
'	O
information	O
was	O
collected	O
from	O
their	O
medical	O
chart	O
.	O

Main	O
outcomes	O
and	O
measures	O
The	O
rate	O
of	O
perinatal	O
transmission	O
of	O
SARS	O
-	O
CoV-2	O
and	O
development	O
of	B-DIS
the	O
infection	O
in	O
neonates	O
within	O
14	O
days	O
postpartum	O
.	O

Results	O
The	O
early	O
cord	B-DIS
clamping	I-DIS
ECC	O
group	O
consisted	O
of	O
231	O
infants	O
57.3	B-STAT
%	I-STAT
and	O
the	O
DCC	O
group	O
consisted	O
of	O
172	O
infants	O
42.7	B-STAT
%	I-STAT
.	O

Five	O
positive	O
newborns	O
1.7	B-STAT
%	I-STAT
of	O
total	O
tests	O
performed	O
were	O
identified	O
with	O
the	O
nasopharyngeal	O
PCR	O
tests	O
performed	O
in	O
the	O
first	O
12	O
hours	O
postpartum	O
two	O
from	O
the	O
ECC	O
group	O
1.7	B-STAT
%	I-STAT
and	O
three	O
from	O
the	O
DCC	O
group	O
3.6	B-STAT
%	I-STAT
.	O

No	O
significant	O
differences	O
between	O
groups	O
were	O
found	O
regarding	O
neonatal	O
tests	O
for	O
SARS	O
-	O
CoV-2	O
.	O

No	O
confirmed	O
cases	O
of	O
vertical	O
transmission	O
were	O
detected	O
.	O

The	O
percentage	O
of	O
mothers	O
who	O
made	O
skin	O
-	O
to	O
-	O
skin	O
contact	O
within	O
the	O
first	O
24	O
hours	O
after	O
delivery	O
was	O
significantly	O
higher	O
in	O
the	O
DCC	O
group	O
84.3	B-STAT
%	I-STAT
versus	O
45.9	B-STAT
%	I-STAT
.	O

Breastfeeding	O
in	O
the	O
immediate	O
postpartum	O
period	O
was	O
also	O
significantly	O
higher	O
in	O
the	O
DCC	O
group	O
77.3	B-STAT
%	I-STAT
versus	O
50.2	B-STAT
%	I-STAT
.	O

Conclusions	O
The	O
results	O
of	O
our	O
study	O
show	O
no	O
differences	O
in	O
perinatal	O
outcomes	O
when	O
performing	O
ECC	O
or	O
DCC	O
and	O
skin	O
-	O
to	O
-	O
skin	O
contact	O
or	O
breastfeeding	O
.	O

Tweetable	O
abstract	O
This	O
study	O
demonstrates	O
that	O
delayed	O
cord	O
clamping	O
is	O
safe	O
in	O
mothers	O
with	O
confirmed	O
SARS	B-DIS
-	I-DIS
CoV-2	O
infection	O
.	O

Background	O
The	O
degenerative	B-DIS
cerebellar	I-DIS
ataxias	I-DIS
comprise	O
a	O
large	O
and	O
heterogeneous	O
group	O
of	O
neurological	B-DIS
diseases	I-DIS
whose	O
hallmark	O
clinical	O
feature	O
is	O
ataxia	B-DIS
and	O
which	O
are	O
accompanied	O
to	O
variable	O
degrees	O
by	O
other	O
features	O
that	O
are	O
attributable	O
to	O
cerebellar	B-DIS
dysfunction	I-DIS
.	O

Essential	O
tremor	B-DIS
ET	O
is	O
an	O
exceptionally	O
common	O
neurological	B-DIS
disease	I-DIS
whose	O
primary	O
motor	O
feature	O
is	O
action	O
tremor	B-DIS
although	O
patients	O
often	O
manifest	O
intention	O
tremor	B-DIS
mild	O
gait	B-DIS
ataxia	I-DIS
and	O
several	O
other	O
features	O
of	O
cerebellar	B-DIS
dysfunction	I-DIS
.	O

Main	O
body	O
In	O
this	O
paper	O
we	O
review	O
the	O
abundant	O
evidence	O
derived	O
from	O
clinical	O
neuroimaging	O
and	O
postmortem	O
studies	O
linking	O
ET	O
to	O
cerebellar	B-DIS
dysfunction	I-DIS
.	O

Furthermore	O
we	O
review	O
the	O
combination	O
of	O
clinical	O
natural	O
history	O
and	O
postmortem	O
features	O
suggesting	O
that	O
ET	O
is	O
neurodegenerative	O
.	O

We	O
then	O
compare	O
the	O
prevalence	B-EPI
of	O
ET	O
400	O
-	O
900	O
cases	O
per	O
100000	O
to	O
that	O
of	O
the	O
other	O
cerebellar	B-DIS
degenerations	I-DIS
ranging	O
from	O
<	O
0.5	O
-	O
9	O
cases	O
per	O
100000	O
and	O
in	O
composite	O
likely	O
to	O
be	O
on	O
the	O
order	O
of	O
20	O
cases	O
per	O
100000	O
and	O
conclude	O
that	O
ET	O
is	O
20	O
to	O
45	O
times	O
more	O
prevalent	O
than	O
all	O
other	O
forms	O
of	O
cerebellar	B-DIS
degeneration	I-DIS
combined	O
.	O

Conclusion	O
Given	O
the	O
data	O
we	O
present	O
it	O
is	O
logical	O
to	O
conclude	O
that	O
ET	O
is	O
by	O
far	O
the	O
most	O
common	O
form	O
of	O
cerebellar	B-DIS
degeneration	I-DIS
.	O

Background	O
Reported	O
birth	O
prevalences	B-EPI
of	O
congenital	B-DIS
limb	I-DIS
defects	I-DIS
CLD	I-DIS
vary	O
between	O
countries	O
from	O
13/10000	B-STAT
in	O
Finland	B-LOC
for	O
the	O
period	O
1964	O
-	O
1977	O
to	O
30.4/10000	B-STAT
births	O
in	O
Scotland	B-LOC
from	O
1964	O
-	O
1968	O
.	O

Epidemiological	O
studies	O
permit	O
the	O
timely	O
detection	O
of	O
trends	O
in	O
CLD	B-DIS
and	O
of	O
associations	O
with	O
other	O
birth	B-DIS
defects	I-DIS
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
describe	O
the	O
birth	O
prevalence	B-EPI
of	O
CLD	B-DIS
in	O
the	O
northern	O
Netherlands	B-LOC
.	O

Methods	O
In	O
a	O
population	O
-	O
based	O
epidemiological	O
study	O
we	O
investigated	O
the	B-EPI
birth	O
prevalences	B-DIS
of	O
CLD	O
for	O
1981	O
-	O
2010	O
.	O

Data	O
were	O
collected	O
by	O
the	O
European	O
Surveillance	O
of	O
Congenital	B-DIS
Anomalies	I-DIS
in	O
the	O
northern	O
Netherlands	B-LOC
EUROCAT	O
-	O
NNL	O
.	O

We	O
excluded	O
malpositions	O
club	O
foot	O
and	O
dislocation	O
/	O
dysplasia	O
of	O
hips	O
or	O
knees	O
.	O

Trends	O
were	O
analysed	O
for	O
the	O
19	O
-	O
year	O
period	O
1992	O
-	O
2010	O
using	O
χ²	O
tests	O
as	O
well	B-DIS
as	O
CLD	O
association	B-DIS
with	O
anomalies	O
affecting	O
other	O
organs	O
.	O

Results	O
The	O
birth	O
prevalence	B-EPI
of	O
CLD	B-DIS
was	O
21.1/10000	B-STAT
births	O
for	O
1981	O
-	O
2010	O
.	O

There	O
was	O
an	O
overall	O
decrease	O
in	O
non	B-DIS
-	O
syndromic	O
limb	O
defects	O
P	O
=	O
0.023	O
caused	O
by	O
a	O
decrease	O
in	B-EPI
the	O
prevalence	B-DIS
of	I-DIS
non	O
-	O
syndromic	O
syndactyly	O
P	O
<	O
0.01	O
in	O
1992	O
-	O
2010	O
.	O

Of	O
1048	O
children	O
with	O
CLD	B-DIS
55	B-STAT
%	I-STAT
were	O
males	O
57	B-STAT
%	I-STAT
had	O
isolated	O
defects	O
13	B-STAT
%	I-STAT
had	O
multiple	O
congenital	B-DIS
anomalies	I-DIS
MCA	I-DIS
and	O
30	B-STAT
%	I-STAT
had	O
a	O
recognised	O
syndrome	O
.	O

The	O
upperlower	O
limb	O
ratio	O
was	O
21	O
and	O
the	O
leftright	O
side	O
ratio	O
was	O
1.21	O
.	O

Cardiovascular	B-DIS
and	I-DIS
urinary	I-DIS
tract	I-DIS
anomalies	I-DIS
were	O
common	O
in	O
combination	O
with	O
CLD	B-DIS
37	B-STAT
%	I-STAT
and	O
25	O
%	O
of	O
cases	O
with	O
MCA	O
.	O

Digestive	O
-	O
tract	O
anomalies	O
were	O
significantly	O
associated	B-DIS
with	O
CLD	O
P	O
=	O
0.016	O
.	O

Conclusions	O
The	O
birth	O
prevalence	B-EPI
of	O
CLD	B-DIS
in	O
the	O
northern	O
Netherlands	B-LOC
was	O
21.1/10000	B-STAT
births	O
.	O

The	O
birth	O
prevalence	B-EPI
of	O
non	B-DIS
-	I-DIS
syndromic	O
syndactyly	O
dropped	B-STAT
from	O
5.2/10000	B-STAT
to	O
1.1/10000	O
in	O
1992	O
-	O
2010	O
.	O

The	O
number	O
of	O
patients	O
with	O
spinocerebellar	B-DIS
degeneration	I-DIS
SCD	I-DIS
has	O
recently	O
exceeds	O
20000	O
in	O
Japan	B-LOC
.	O

Among	O
them	O
sporadic	O
form	O
is	O
the	O
most	O
common	O
form	O
67.2	B-STAT
%	I-STAT
.	O

Among	O
the	O
hereditary	O
forms	O
of	O
SCD	B-DIS
autosomal	I-DIS
dominant	I-DIS
AD	I-DIS
form	O
comprises	O
27.0	B-STAT
%	I-STAT
while	O
autosomal	O
recessive	O
AR	O
form	O
is	O
rare	O
1.8	B-STAT
%	I-STAT
.	O

Because	O
of	O
the	O
rare	O
occurrence	O
of	O
AR	B-DIS
-	O
SCD	O
the	O
molecular	O
genetic	O
studies	O
have	O
been	O
difficult	O
to	O
conduct	O
.	O

Recent	O
progresses	O
in	O
molecular	O
genetics	O
however	O
have	O
enabled	O
identification	O
of	O
causative	O
genes	O
for	O
the	O
majority	O
of	O
AR	B-DIS
-	O
SCD	O
.	O

Although	O
Friedreich	B-DIS
's	I-DIS
ataxia	I-DIS
is	O
the	O
most	O
representative	O
form	O
of	O
AR	B-DIS
-	O
SCD	O
patients	O
with	O
molecular	O
diagnosis	B-DIS
of	I-DIS
Friedreich	I-DIS
's	O
ataxia	O
have	O
not	O
been	O
described	O
in	O
the	O
Japanese	O
population	O
.	O

Among	O
the	O
various	O
forms	O
of	O
AR	B-DIS
-	I-DIS
SCD	I-DIS
early	O
-	B-DIS
onset	I-DIS
ataxia	I-DIS
with	O
ocular	B-DIS
motor	I-DIS
apraxia	O
and	O
hypoalbuminemia	O
EAOH	O
seems	O
to	O
be	O
the	O
most	O
common	O
form	O
in	O
the	O
Japanese	O
population	O
.	O

Aprataxin	O
the	O
causative	O
gene	O
for	O
EAOH	B-DIS
has	O
been	O
suggested	O
to	O
play	O
a	O
role	O
in	O
the	O
single	O
strand	O
DNA	O
break	O
repair	O
.	O

Interestingly	O
abnormalities	O
in	O
DNA	O
break	O
repair	O
processes	O
have	O
been	O
implicated	O
in	O
several	O
forms	O
of	O
AR	B-DIS
-	O
SCD	B-DIS
including	I-DIS
AOA2	O
SCAN1	B-DIS
and	I-DIS
ataxia	O
telangiectasia	O
.	O

In	O
this	O
group	O
of	O
AR	B-DIS
-	I-DIS
SCD	I-DIS
cerebellar	O
atrophy	O
is	O
more	O
marked	O
compared	O
to	O
that	O
observed	B-DIS
in	I-DIS
Friedreich	I-DIS
's	O
ataxia	O
.	O

Taken	O
together	O
abnormalities	O
in	O
DNA	O
break	O
repair	O
processes	O
may	O
play	O
an	O
essential	O
role	O
in	O
cerebellar	B-DIS
degeneration	I-DIS
in	O
this	O
group	O
of	O
AR	B-DIS
-	O
SCD	O
.	O

Objectives	O
To	O
review	O
the	O
data	O
of	O
infants	O
and	O
children	O
with	O
suspected	O
monogenic	B-DIS
diabetes	I-DIS
who	O
underwent	O
genetic	O
testing	O
.	O

Methods	O
Monogenic	B-DIS
diabetes	I-DIS
is	O
a	O
rare	O
form	O
of	O
diabetes	B-DIS
resulting	O
from	O
mutations	O
in	O
a	O
single	O
gene	O
.	O

It	O
can	O
be	O
caused	O
by	O
dominant	O
as	O
well	O
as	O
recessive	O
modes	O
of	O
inheritance	O
.	O

In	O
a	O
country	O
like	O
Pakistan	B-LOC
where	O
interfamily	O
marriages	O
are	O
common	O
the	O
incidence	B-EPI
of	O
genetic	O
disorders	O
is	O
increased	O
.	O

As	O
Pakistan	B-LOC
a	O
resource	O
-	O
poor	O
country	O
the	O
diagnosis	B-DIS
of	I-DIS
insulin	O
-	O
dependent	O
diabetes	O
is	O
often	O
delayed	O
and	O
a	B-DIS
genetic	I-DIS
diagnosis	O
of	O
monogenic	O
diabetes	O
is	O
extremely	O
difficult	O
.	O

Children	O
with	O
clinical	O
diagnosis	O
of	O
monogenic	B-DIS
and	I-DIS
syndromic	I-DIS
diabates	I-DIS
were	O
recruited	O
and	O
blood	O
samples	O
were	O
sent	O
for	O
genetic	O
analysis	O
.	O

Results	O
One	O
thousand	O
sixty	O
four	O
new	O
cases	O
diagnosed	O
with	O
type	O
1	O
diabetes	B-DIS
were	O
registered	O
at	O
the	O
National	O
Institute	O
of	O
Child	O
Health	O
Karachi	O
in	O
the	O
last	O
10	O
years	O
.	O

Of	O
these	O
39	O
patients	O
were	O
selected	O
for	O
genetic	O
testing	O
who	O
were	O
diagnosed	O
with	O
diabetes	O
/	O
had	O
a	O
sibling	O
diagnosed	B-DIS
with	O
diabetes	O
before	O
the	O
age	O
of	O
nine	O
months	O
n	O
=	O
27	O
or	O
had	O
extra	O
pancreatic	O
features	O
n=	O
12	O
.	O

We	O
identified	O
mutations	O
in	O
18/27	B-STAT
cases	O
diagnosed	O
with	O
diabetes	B-DIS
before	O
nine	O
months	O
of	O
age	O
.	O

The	O
most	O
common	O
genetic	O
subtype	O
was	O
WolcottRallison	O
syndrome	O
caused	O
by	O
EIF2AK3	O
mutations	O
seven	O
cases	O
.	O

KCNJ11	O
mutations	O
were	O
identified	O
in	O
two	O
cases	O
ABCC8	O
mutations	O
were	O
identified	O
in	O
four	O
cases	O
from	O
three	O
families	O
GCK	O
and	O
INS	O
mutations	O
were	O
each	O
identified	O
in	O
two	O
cases	O
and	O
one	O
SLC2A2	O
mutation	O
was	O
identified	O
in	O
one	O
case	O
.	O

A	O
genetic	O
diagnosis	O
was	O
made	O
in	O
12/12	B-STAT
children	O
from	O
six	O
families	O
with	O
diabetes	B-DIS
diagnosed	O
after	O
the	O
age	O
of	O
nine	O
months	O
who	O
had	O
extrapancreatic	O
features	O
.	O

Six	O
patients	O
had	O
genetically	O
confirmed	O
Wolfram	B-DIS
syndrome	I-DIS
WFS1	I-DIS
three	O
had	O
thiamine	B-DIS
-	I-DIS
responsive	I-DIS
megaloblastic	I-DIS
anemia	O
SLC19A2	O
and	O
three	O
were	O
diagnosed	B-DIS
with	I-DIS
histocytosis	O
lymphadenopathy	O
plus	O
syndrome	O
SLC29A3	O
.	O

Conclusions	O
Genetic	O
testing	O
is	O
essential	O
to	O
confirm	O
a	O
diagnosis	O
of	O
monogenic	B-DIS
diabetes	I-DIS
which	O
guides	O
clinical	O
management	O
and	O
future	O
counselling	O
.	O

Our	O
study	O
highlights	O
the	O
importance	O
of	O
diagnosing	O
monogenic	B-DIS
diabetes	I-DIS
in	O
the	O
largely	O
consanguineously	O
-	O
married	O
population	O
of	O
Pakistan	B-LOC
.	O

Rhabdomyosarcoma	B-DIS
RMS	O
is	O
the	O
most	O
common	O
soft	B-DIS
-	I-DIS
tissue	O
sarcoma	O
in	O
children	O
yet	O
little	O
is	O
known	O
about	O
its	O
etiology	O
.	O

Studies	O
that	O
examine	O
either	O
environmental	O
exposures	O
or	O
germline	O
genetic	O
predisposition	O
in	O
RMS	O
have	O
begun	O
to	O
identify	O
factors	O
that	O
contribute	O
to	O
this	O
malignancy	B-DIS
.	O

Here	O
we	O
summarize	O
epidemiological	O
reports	O
of	O
RMS	O
incidence	B-EPI
in	O
terms	O
of	O
several	O
factors	O
including	O
age	O
at	O
diagnosis	O
biological	O
sex	O
and	O
geographic	O
location	O
.	O

We	O
then	O
describe	O
findings	O
from	O
association	O
studies	O
which	O
explore	O
the	O
role	O
of	O
parental	O
exposures	O
birth	O
and	O
perinatal	O
characteristics	O
and	O
childhood	O
exposures	O
in	O
RMS	O
.	O

Further	O
we	O
discuss	O
RMS	O
predisposition	O
syndromes	O
and	O
large	O
-	O
scale	O
sequencing	O
studies	O
that	O
have	O
further	O
identified	O
RMS	O
-	O
associated	O
genes	O
.	O

Finally	O
we	O
propose	O
future	O
directions	O
of	O
study	O
which	O
aim	O
to	O
advance	O
our	O
understanding	O
of	O
the	O
origin	O
of	O
RMS	O
and	O
can	O
provide	O
knowledge	O
for	O
novel	O
RMS	O
therapies	O
.	O

Background	O
IgA	B-DIS
nephropathy	I-DIS
IgAN	I-DIS
is	O
the	O
most	O
common	O
primary	O
glomerulonephritis	B-DIS
worldwide	O
.	O

Although	O
most	O
IgAN	B-DIS
cases	O
are	O
sporadic	O
few	O
show	O
a	O
familial	B-DIS
aggregation	I-DIS
.	O

However	O
the	O
prevalence	B-EPI
and	O
prognosis	O
of	O
IgAN	B-DIS
individuals	O
with	O
positive	O
familial	O
history	O
FH	O
of	O
renal	B-DIS
disorders	I-DIS
remains	O
uncertain	O
.	O

To	O
address	O
these	O
issues	O
we	O
conducted	O
a	O
longitudinal	O
observational	O
study	O
on	O
a	O
single	O
-	O
institution	O
cohort	O
of	O
patients	O
with	B-DIS
biopsy	O
-	O
proven	O
IgAN	O
.	O

Methods	O
A	O
total	O
of	O
467	O
IgAN	B-DIS
patients	O
who	O
underwent	O
renal	O
biopsy	O
during	O
1994	O
to	O
2019	O
were	O
ascertained	O
to	O
have	O
positive-	O
or	O
negative	O
-	O
FH	O
by	O
history	O
taking	O
and	O
were	O
followed	O
for	O
an	O
average	O
of	O
8.9	O
years	O
.	O

We	O
compared	O
the	O
clinical	O
and	O
pathological	O
features	O
of	O
the	O
two	O
subgroups	O
.	O

The	O
primary	O
outcome	O
a	O
composite	O
of	O
a	O
hard	O
endpoint	O
end	B-DIS
-	I-DIS
stage	I-DIS
renal	O
disease	B-DIS
[	O
ESRD	O
]	O
and	O
surrogate	O
endpoint	O
a	O
50	B-STAT
%	I-STAT
or	O
more	O
reduction	O
in	O
the	O
estimated	O
glomerular	O
filtration	O
rate	O
[	O
eGFR	O
]	O
from	O
baseline	O
was	O
evaluated	O
.	O

To	O
estimate	O
the	O
risk	O
for	O
progression	O
to	O
ESRD	B-DIS
a	O
Cox	O
proportional	O
hazards	O
analysis	O
was	O
performed	O
for	O
a	O
subset	O
of	O
patients	O
who	O
underwent	O
follow	O
-	O
up	O
fo	O
2	O
years	O
and	O
had	O
an	O
eGF	O
30	O
mL	O
/	O
min/1.73	O
m	O
2	O
<	O
/s	O
at	O
baseline	O
n	O
=	O
389	O
;	O
observation	O
8.7	O
years	O
.	O

Results	O
Positive	O
-	O
FH	O
subtype	O
accounted	O
for	O
11.6	B-STAT
%	I-STAT
n	O
=	O
54	O
of	B-DIS
all	O
IgAN	O
patients	O
.	O

At	O
baseline	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
positive-	O
and	O
negative	O
-	O
FH	O
subgroups	O
regarding	O
age	B-DIS
sex	I-DIS
comorbid	I-DIS
disease	O
MEST	O
-	O
C	O
score	O
observation	O
period	O
and	O
therapeutic	O
interventions	O
.	O

However	O
the	O
eGFR	O
value	O
at	O
baselines	O
was	O
significantly	O
lower	O
in	O
the	O
positive	O
-	O
FH	O
subgroup	O
than	O
in	O
the	O
negative	O
-	O
FH	O
subgroup	O
P	O
<	O
0.01	O
.	O

On	O
multivariate	O
analysis	O
positive	O
-	O
FH	O
emerged	O
an	O
independent	O
determinant	O
of	O
poorer	O
renal	O
outcomes	O
odds	O
ratio	O
2.31	O
;	O
95	B-STAT
%	I-STAT
confidence	O
interval	O
1.10	O
-	O
4.85	O
;	O
P	O
=	O
0.03	O
after	O
adjusting	O
for	O
confounding	O
factors	O
.	O

eGFR	O
at	O
follow	O
-	O
up	O
was	O
significantly	O
lower	O
in	O
the	O
positive	O
-	O
FH	O
subgroup	O
than	O
in	O
the	O
negative	O
-	O
FH	O
subgroup	O
after	O
adjustment	O
for	O
age	O
and	O
observation	O
period	O
.	O

Conclusions	O
Positive	O
-	O
FH	O
was	O
found	O
in	O
11.6	B-STAT
%	I-STAT
of	B-DIS
all	O
IgAN	O
patients	O
consistent	O
with	B-EPI
the	O
incidence	O
seen	O
in	O
previous	O
literature	O
.	O

A	O
significantly	O
lower	O
eGFR	O
at	O
baseline	O
and	O
last	O
follow	O
-	O
up	O
and	O
unfavorable	O
renal	O
outcomes	O
in	O
the	O
positive	O
-	O
FH	O
subgroup	O
suggest	O
that	O
certain	O
genetic	O
risk	B-DIS
factors	I-DIS
predisposing	O
to	O
renal	O
failure	O
may	O
exist	O
in	O
a	B-DIS
fraction	O
of	O
our	O
IgAN	O
cohort	O
.	O

331	O
words	O
.	O

Background	O
Dominant	O
optic	B-DIS
atrophy	I-DIS
DOA	O
is	O
an	O
inherited	O
optic	B-DIS
neuropathy	I-DIS
that	O
mainly	O
affects	O
visual	O
acuity	O
central	O
visual	O
fields	O
and	O
color	O
vision	O
due	O
to	O
a	O
progressive	O
loss	B-DIS
of	I-DIS
retinal	I-DIS
ganglion	I-DIS
cells	O
and	O
their	O
axons	O
that	O
form	O
the	O
optic	B-DIS
nerve	I-DIS
.	O

Approximately	O
45	O
-	O
90	O
%	O
of	O
affected	O
individuals	O
with	O
DOA	B-DIS
harbor	O
pathogenic	O
variants	O
in	O
the	O
OPA1	O
gene	O
.	O

The	O
mutation	O
spectrum	O
of	O
OPA1	O
comprises	O
nonsense	O
canonical	O
and	O
non	O
-	O
canonical	O
splice	O
site	O
frameshift	O
and	O
missense	O
as	O
well	O
as	O
copy	O
number	O
variants	O
but	O
intragenic	O
inversions	O
have	O
not	O
been	O
reported	O
so	O
far	O
.	O

Case	O
presentation	O
We	O
report	O
a	O
33	O
-	O
year	O
-	O
old	O
male	O
with	O
characteristic	B-DIS
clinical	O
features	O
of	O
DOA	O
.	O

Whole	O
-	O
genome	O
sequencing	O
identified	O
a	O
structural	O
variant	O
of	O
2.4	O
kb	O
comprising	O
an	O
inversion	O
of	O
937	O
bp	O
at	O
the	O
OPA1	O
locus	O
.	O

Fine	O
mapping	O
of	O
the	O
breakpoints	O
to	O
single	O
nucleotide	O
level	O
revealed	O
that	O
the	O
structural	O
variation	O
was	O
an	O
inversion	O
flanked	O
by	O
two	O
deletions	O
.	O

As	O
this	O
rearrangement	O
inverts	O
the	O
entire	O
first	O
exon	O
of	O
OPA1	O
it	O
was	O
classified	O
as	O
likely	O
pathogenic	O
.	O

Conclusions	O
We	O
report	O
the	O
first	O
DOA	B-DIS
case	O
harboring	O
an	O
inversion	O
in	O
the	O
OPA1	O
gene	O
.	O

Our	O
study	O
demonstrates	O
that	O
copy	O
-	O
neutral	O
genomic	O
rearrangements	O
have	O
to	O
be	O
considered	O
as	O
a	O
possible	O
cause	O
of	O
disease	B-DIS
in	O
DOA	O
cases	O
.	O

Background	O
A	O
preliminary	O
safety	O
signal	O
for	O
neural	O
-	O
tube	O
defects	O
was	O
previously	O
reported	O
in	O
association	O
with	O
dolutegravir	O
exposure	O
from	O
the	O
time	O
of	O
conception	O
which	O
has	O
affected	O
choices	O
of	O
antiretroviral	O
treatment	O
ART	B-DIS
for	I-DIS
human	I-DIS
immunodeficiency	I-DIS
virus	I-DIS
HIV	I-DIS
-infected	I-DIS
women	I-DIS
of	I-DIS
reproductive	O
potential	O
.	O

The	O
signal	O
can	O
now	O
be	O
evaluated	O
with	O
data	O
from	O
follow	O
-	O
up	O
of	O
additional	O
pregnancies	O
.	O

Methods	O
We	O
conducted	O
birth	O
-	O
outcomes	O
surveillance	O
at	O
hospitals	O
throughout	O
Botswana	B-LOC
expanding	O
from	O
8	O
to	O
18	O
sites	O
in	O
2018	O
.	O

Trained	O
midwives	O
performed	O
surface	O
examinations	O
of	O
all	O
live	O
-	O
born	O
and	O
stillborn	O
infants	O
.	O

Research	O
assistants	O
photographed	O
abnormalities	O
after	O
maternal	O
consent	O
was	O
obtained	O
.	O

The	O
prevalence	B-EPI
of	O
neural	B-DIS
-	I-DIS
tube	O
defects	O
and	O
major	O
external	O
structural	O
defects	O
according	O
to	B-DIS
maternal	I-DIS
HIV	O
infection	O
and	O
ART	O
exposure	O
status	O
was	O
determined	O
.	O

In	O
the	O
primary	O
analyses	O
we	O
used	O
the	O
Newcombe	O
method	O
to	O
evaluate	O
differences	O
in	O
prevalence	B-EPI
with	O
95	B-STAT
%	I-STAT
confidence	O
intervals	O
.	O

Results	O
From	O
August	O
2014	O
through	O
March	O
2019	O
surveillance	O
captured	O
119477	O
deliveries	O
;	O
119033	B-STAT
99.6	I-STAT
%	I-STAT
had	O
an	O
infant	O
surface	O
examination	O
that	O
could	O
be	O
evaluated	O
and	O
98	O
neural	O
-	O
tube	O
defects	O
were	O
identified	O
0.08	B-STAT
%	I-STAT
of	O
deliveries	O
.	O

Among	O
1683	O
deliveries	O
in	O
which	O
the	O
mother	O
was	O
taking	O
dolutegravir	O
at	O
conception	O
5	O
neural	O
-	O
tube	O
defects	O
were	O
found	O
0.30	B-STAT
%	I-STAT
of	O
deliveries	O
;	O
the	O
defects	O
included	O
two	O
instances	B-DIS
of	O
myelomeningocele	O
one	B-DIS
of	O
anencephaly	O
one	B-DIS
of	O
encephalocele	O
and	O
one	B-DIS
of	O
iniencephaly	O
.	O

In	O
comparison	O
15	O
neural	O
-	O
tube	O
defects	O
were	O
found	O
among	O
14792	O
deliveries	O
0.10	B-STAT
%	I-STAT
in	O
which	O
the	O
mother	O
was	O
taking	O
any	O
non	O
-	O
dolutegravir	O
ART	O
at	O
conception	O
3	O
among	O
79590.04	B-STAT
%	I-STAT
in	O
which	O
the	O
mother	O
was	O
taking	O
efavirenz	O
at	O
conception	O
1	O
among	O
38400.03	B-STAT
%	I-STAT
in	O
which	O
the	O
mother	O
started	O
dolutegravir	O
treatment	O
during	O
pregnancy	O
and	O
70	O
among	O
89372	B-STAT
0.08	I-STAT
%	I-STAT
in	O
HIV	O
-	O
uninfected	O
mothers	O
.	O

The	O
prevalence	B-EPI
of	O
neural	B-DIS
-	I-DIS
tube	O
defects	O
was	O
higher	O
in	O
association	O
with	O
dolutegravir	O
treatment	O
at	O
conception	O
than	O
with	O
non	O
-	O
dolutegravir	O
ART	O
at	O
conception	O
difference	O
0.20	O
percentage	O
points	O
;	O
95	B-STAT
%	I-STAT
confidence	O
interval	O
[	O
CI	O
]	O
0.01	O
to	O
0.59	O
or	O
with	O
other	O
types	O
of	O
ART	O
exposure	O
.	O

Major	O
external	O
structural	O
defects	O
were	O
found	O
in	O
0.95	B-STAT
%	I-STAT
of	O
deliveries	O
among	O
women	O
exposed	O
to	O
dolutegravir	O
at	O
conception	O
and	O
0.68	B-STAT
%	I-STAT
of	O
those	O
among	O
women	O
exposed	O
to	O
non	O
-	O
dolutegravir	O
ART	O
at	O
conception	O
difference	O
0.27	O
percentage	O
points	O
;	O
95	B-STAT
%	I-STAT
CI	O
-0.13	O
to	O
0.87	O
.	O

Conclusions	O
The	O
prevalence	B-EPI
of	O
neural	B-DIS
-	I-DIS
tube	O
defects	O
was	O
slightly	O
higher	O
in	O
association	O
with	O
dolutegravir	O
exposure	O
at	O
conception	O
than	O
with	O
other	O
types	O
of	O
ART	O
exposure	O
at	O
conception	O
3	O
per	O
1000	O
deliveries	B-STAT
vs.	I-STAT
1	I-STAT
per	O
1000	O
deliveries	O
.	O

Funded	O
by	O
the	O
National	O
Institutes	O
of	O
Health	O
.	O

.	O

Uveal	B-DIS
melanoma	I-DIS
UM	O
represents	O
the	O
most	O
prominent	O
primary	B-DIS
eye	I-DIS
cancer	I-DIS
in	O
adults	O
.	O

With	O
an	O
incidence	B-EPI
of	O
approximately	O
5	O
cases	O
per	O
million	O
individuals	O
annually	O
in	O
the	B-LOC
United	I-LOC
States	I-LOC
UM	I-LOC
could	O
be	O
considered	O
a	O
relatively	O
rare	O
cancer	B-DIS
.	O

The	O
90‑95	B-STAT
%	I-STAT
of	O
UM	O
cases	O
arise	O
from	O
the	O
choroid	O
.	O

Diagnosis	O
is	O
based	O
mainly	O
on	O
a	O
clinical	O
examination	O
and	O
ancillary	O
tests	O
with	O
ocular	O
ultrasonography	O
being	O
of	O
greatest	O
value	O
.	O

Differential	O
diagnosis	O
can	O
prove	O
challenging	O
in	O
the	O
case	O
of	O
indeterminate	O
choroidal	B-DIS
lesions	I-DIS
and	O
sometimes	O
monitoring	O
for	O
documented	O
growth	O
may	O
be	O
the	O
proper	O
approach	O
.	O

Fine	O
needle	O
aspiration	O
biopsy	O
tends	O
to	O
be	O
performed	O
with	O
a	O
prognostic	O
purpose	O
often	O
in	O
combination	O
with	O
radiotherapy	O
.	O

Gene	O
expression	O
profiling	O
has	O
allowed	O
for	O
the	O
grading	O
of	O
UMs	O
into	O
two	O
classes	O
which	O
feature	O
different	O
metastatic	O
risks	O
.	O

Patients	O
with	O
UM	O
require	O
a	O
specialized	O
multidisciplinary	O
management	O
.	O

Primary	O
tumor	B-DIS
treatment	O
can	O
be	O
either	O
enucleation	O
or	O
globe	O
preserving	O
.	O

Usually	O
enucleation	O
is	O
reserved	O
for	O
larger	O
tumors	B-DIS
while	O
radiotherapy	O
is	O
preferred	O
for	O
small	O
/	B-DIS
medium	O
melanomas	O
.	O

The	O
prognosis	O
is	O
unfavorable	O
due	O
to	O
the	O
high	O
mortality	O
rate	O
and	O
high	O
tendency	O
to	O
metastasize	O
.	O

Following	O
the	O
development	O
of	O
metastatic	O
disease	O
the	O
mortality	O
rate	O
increases	O
to	O
80	B-STAT
%	I-STAT
within	O
one	O
year	O
due	O
to	O
both	O
the	O
absence	O
of	O
an	O
effective	O
treatment	O
and	O
the	O
aggressiveness	O
of	O
the	O
condition	O
.	O

Novel	O
molecular	O
studies	O
have	O
allowed	O
for	O
a	O
better	O
understanding	O
of	O
the	O
genetic	O
and	O
epigenetic	O
mechanisms	O
involved	O
in	O
UM	O
biological	O
activity	O
which	O
differs	O
compared	O
to	O
skin	B-DIS
melanomas	I-DIS
.	O

The	O
most	O
commonly	O
mutated	O
genes	O
are	O
GNAQ	O
GNA11	O
and	O
BAP1	O
.	O

Research	O
in	O
this	O
field	O
could	O
help	O
to	O
identify	O
effective	O
diagnostic	O
and	O
prognostic	O
biomarkers	O
as	O
well	O
as	O
novel	O
therapeutic	O
targets	O
.	O

Aberrant	O
right	O
subclavian	O
artery	O
ARSA	O
the	O
most	O
common	O
aortic	O
arch	O
abnormality	O
occurs	O
in	O
approximately	O
0.5	O
to	O
1.8	B-STAT
%	I-STAT
of	O
the	O
general	O
population	O
with	O
prevalence	B-EPI
of	O
up	B-STAT
to	I-STAT
25	I-STAT
%	I-STAT
in	O
those	O
with	O
esophageal	B-DIS
atresia	I-DIS
.	O

Although	O
ARSA	O
is	O
often	O
asymptomatic	O
a	O
fistulous	B-DIS
tract	I-DIS
into	O
esophagus	O
may	O
develop	O
with	O
prolonged	O
nasogastric	O
tube	O
placement	O
or	O
endotracheal	O
intubation	O
and	O
lead	O
to	O
potentially	O
fatal	O
hematemesis	B-DIS
.	O

We	O
present	O
a	O
first	O
case	O
of	O
ARSA	B-DIS
-	I-DIS
esophageal	O
fistula	O
in	O
a	O
20	O
-	B-DIS
year	O
-	O
old	O
woman	O
with	O
VATER	O
association	B-DIS
in	I-DIS
the	O
absence	O
of	O
an	O
esophageal	O
anomaly	B-DIS
and	I-DIS
review	O
28	O
cases	O
of	O
ARSA	O
-	O
esophageal	O
fistula	O
reported	O
in	O
the	O
literature	O
to	O
date	O
.	O

Requiring	O
nasogastric	O
and	O
endotracheal	O
tube	O
placement	O
for	O
approximately	O
4	O
months	O
the	O
patient	O
had	O
a	O
prolonged	O
hospital	O
course	O
and	O
died	O
after	O
sudden	B-DIS
hematemesis	I-DIS
.	O

An	O
autopsy	O
demonstrated	O
an	O
ARSA	B-DIS
-	I-DIS
esophageal	O
fistula	O
and	O
no	O
other	O
source	B-DIS
of	I-DIS
upper	I-DIS
gastrointestinal	O
bleeding	O
.	O

In	O
patients	O
with	O
esophageal	B-DIS
atresia	I-DIS
requiring	O
prolonged	O
placement	O
of	O
an	O
endotracheal	O
or	O
nasogastric	O
tube	O
a	O
screening	O
imaging	O
study	O
and	O
corrective	O
surgery	O
may	O
be	O
indicated	O
.	O

Although	O
the	O
mortality	O
rate	O
is	O
still	O
high	O
timely	O
recognition	O
and	O
repair	O
of	O
ARSA	B-DIS
-	I-DIS
esophageal	O
fistula	O
appear	O
to	O
be	O
improving	O
.	O

Given	O
the	O
potentially	O
prolonged	O
latency	O
for	O
its	O
development	O
with	O
occasional	O
presence	O
of	O
heralding	O
symptoms	O
increased	O
awareness	O
may	O
facilitate	O
surgical	O
intervention	O
to	O
prevent	O
a	O
catastrophic	O
exsanguination	O
.	O

The	O
short	O
telomere	B-DIS
syndromes	I-DIS
encompass	O
a	O
spectrum	O
of	O
clinical	O
manifestations	O
that	O
present	O
from	O
infancy	O
to	O
late	O
adulthood	O
.	O

They	O
are	O
caused	O
by	O
mutations	O
in	O
telomerase	O
and	O
other	O
telomere	O
maintenance	O
genes	O
and	O
have	O
a	O
predominantly	B-DIS
degenerative	I-DIS
phenotype	I-DIS
characterized	O
by	O
organ	O
failure	O
across	O
multiple	O
systems	O
.	O

They	O
are	O
collectively	O
one	O
of	O
the	O
most	O
common	O
inherited	O
bone	B-DIS
marrow	I-DIS
failure	I-DIS
syndromes	I-DIS
;	O
however	O
their	O
most	O
prevalent	O
presentations	O
are	O
extrahematopoietic	O
.	O

This	O
review	O
focuses	O
on	O
these	O
common	O
nonhematologic	O
complications	O
including	O
pulmonary	B-DIS
fibrosis	I-DIS
liver	I-DIS
pathology	O
and	O
immunodeficiency	O
.	O

The	O
short	O
telomere	B-DIS
syndrome	I-DIS
diagnosis	O
informs	O
clinical	O
care	O
especially	O
in	O
guiding	O
diagnostic	O
evaluations	O
as	O
well	O
as	O
in	O
the	O
solid	O
organ	O
transplant	O
setting	O
.	O

Early	O
recognition	O
allows	O
an	O
individualized	O
approach	O
to	O
screening	O
and	O
management	O
.	O

This	O
review	O
illustrates	O
a	O
myriad	O
of	O
extrahematopoietic	O
presentations	O
of	O
short	O
telomere	B-DIS
syndromes	I-DIS
and	O
how	O
they	O
impact	O
clinical	O
decisions	O
.	O

Objectives	O
West	B-LOC
Nile	I-LOC
virus	O
WNV	B-DIS
is	O
a	O
re	O
-	B-DIS
emerging	I-DIS
mosquito	I-DIS
-	O
borne	O
viral	O
infection	O
.	O

This	O
study	O
investigated	O
the	O
pooled	O
prevalence	B-EPI
pattern	O
and	O
risk	O
factors	O
of	O
WNV	B-DIS
infection	I-DIS
among	O
humans	O
and	O
animals	O
in	O
Nigeria	B-LOC
.	O

Methods	O
A	O
systematic	O
review	O
was	O
conducted	O
of	O
eligible	O
studies	O
published	O
in	O
PubMed	O
Scopus	O
Google	O
Scholar	O
and	O
Web	O
of	O
Science	O
from	O
January	O
11950	O
to	O
August	O
302020	O
.	O

Peer	O
-	O
reviewed	O
cross	O
-	B-DIS
sectional	I-DIS
studies	O
describing	O
WNV	O
infections	O
in	O
humans	O
and	O
animals	O
were	O
systematically	O
reviewed	O
.	O

Heterogeneity	O
was	O
assessed	O
using	O
the	O
Cochrane	O
Q	O
statistic	O
.	O

Results	O
Eighteen	O
out	O
of	O
432	O
available	O
search	O
output	O
were	O
eligible	O
and	O
included	O
for	O
this	O
study	O
.	O

Of	O
which	O
13	O
and	O
5	O
were	O
WNV	B-DIS
studies	O
on	O
humans	O
and	O
animals	O
respectively	O
.	O

Although	O
61.5	B-STAT
%	I-STAT
of	O
the	O
human	O
studies	O
had	O
a	O
low	O
risk	O
of	O
bias	O
they	O
all	O
had	O
high	O
heterogeneity	O
.	O

The	O
South	B-LOC
West	I-LOC
geopolitical	O
zone	O
of	O
Nigeria	B-LOC
had	O
the	O
highest	O
pooled	O
prevalence	B-EPI
of	O
anti	O
-	O
WNV	O
immunoglobulin	O
M	O
IgM	O
;	O
7.8	B-STAT
%	I-STAT
in	O
humans	O
.	O

The	O
pooled	O
seroprevalence	O
of	O
anti	O
-	O
WNV	O
IgM	O
and	O
immunoglobulin	O
G	O
IgG	O
was	O
7.1	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
confidence	O
interval	O
[	O
CI	O
]	O
5.9	O
to	O
8.3	O
and	O
76.5	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
74.0	O
to	O
78.8	O
respectively	O
.	O

The	O
WNV	B-DIS
RNA	O
prevalence	B-EPI
was	O
1.9	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
1.4	O
to	O
2.9	O
while	O
14.3	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
12.9	O
to	O
15.8	O
had	O
WNV	O
-	O
neutralizing	O
antibodies	O
.	O

In	O
animals	O
the	O
pooled	O
seroprevalence	O
of	O
anti	O
-	O
WNV	O
IgM	O
and	O
IgG	O
was	O
90.3	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
84.3	O
to	O
94.6	O
and	O
3.5	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
1.9	O
to	O
5.8	O
respectively	O
while	O
20.0	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
12.9	O
to	O
21.4	O
had	O
WNV	O
-	O
neutralizing	O
antibodies	O
.	O

Age	O
odds	O
ratio	O
[	O
OR	O
]	O
3.73	O
;	O
95	B-STAT
%	I-STAT
CI	O
1.87	O
to	O
7.45	O
;	O
p	O
<	O
0.001	O
and	O
level	O
of	O
education	O
no	O
formal	O
education	O
OR	O
4.31	O
;	O
95	B-STAT
%	I-STAT
CI	O
1.08	O
to	O
17.2	O
;	O
p	O
<	O
0.05	O
;	O
primary	O
OR	O
7.29	O
;	O
95	B-STAT
%	I-STAT
CI	O
1.80	O
to	O
29.6	O
;	O
p	O
<	O
0.01	O
were	O
significant	O
risk	O
factors	O
for	O
WNV	B-DIS
IgM	O
seropositivity	O
in	O
humans	O
.	O

Conclusions	O
The	O
findings	O
of	O
this	O
study	O
highlight	O
the	O
endemicity	O
of	O
WNV	B-DIS
in	O
animals	O
and	O
humans	O
in	O
Nigeria	B-LOC
and	O
underscore	O
the	O
need	O
for	O
the	O
One	O
Health	O
prevention	O
and	O
control	O
approach	O
.	O

Oral	O
dexamethasone	O
mini	O
pulse	O
OMP	O
is	O
an	O
established	O
treatment	O
modality	O
for	O
active	O
vitiligo	B-DIS
.	O

Cyclosporine	O
may	O
have	O
therapeutic	O
role	O
in	O
active	O
vitiligo	B-DIS
but	O
current	O
evidence	O
supporting	O
its	O
role	O
is	O
scarce	O
.	O

The	O
objective	O
of	O
study	O
was	O
to	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
oral	O
cyclosporine	O
with	O
OMP	O
in	O
patients	O
of	O
active	O
vitiligo	B-DIS
.	O

Fifty	O
patients	O
with	O
active	O
vitiligo	B-DIS
were	O
randomized	O
into	O
two	O
groups	O
of	O
25	O
patients	O
.	O

Group	O
1	O
was	O
treated	O
with	O
OMP	O
2.5	O
mg	O
dexamethasone	O
on	O
two	O
consecutive	O
days	O
/	O
week	O
for	O
4	O
months	O
while	O
group	O
2	O
was	O
treated	O
with	O
cyclosporine	O
3	O
mg	O
/	O
kg	O
/	O
day	O
for	O
4	O
months	O
.	O

Laboratory	O
monitoring	O
was	O
performed	O
as	O
per	O
the	O
prevalent	O
protocol	O
.	O

The	O
patients	O
were	O
followed	O
up	O
for	O
another	O
2	O
months	O
after	O
stopping	O
treatment	O
.	O

Arrest	O
of	O
disease	O
progression	O
ADP	O
was	O
defined	O
as	O
change	O
of	O
vitiligo	B-DIS
disease	I-DIS
activity	O
score	O
from	O
4	O
+	O
to	O
3	O
+	O
time	O
elapsed	O
since	O
last	O
disease	O
activity	O
being	O
more	O
than	O
6	O
weeks	O
upto	O
3	O
months	O
during	O
the	O
study	O
period	O
6	O
months	O
.	O

ADP	O
was	O
attained	O
in	O
21	O
patients	O
in	O
group	O
1	B-STAT
and	I-STAT
22	I-STAT
patients	O
in	O
group	O
284	B-STAT
%	I-STAT
vs.	O
88	B-STAT
%	I-STAT
p	O
=	O
1.00	O
at	O
the	O
end	O
of	O
6	O
months	O
.	O

However	O
mean	O
time	O
to	O
achieve	O
ADP	O
was	O
significantly	O
lower	O
in	O
group	O
2	O
as	O
compared	O
to	O
group	O
110.92	O
[	O
4.12	O
]	O
weeks	O
vs.	O
13.90	O
[	O
3.92	O
]	O
weeks	O
p	O
=	O
0.01	O
.	O

Extent	O
of	O
repigmentation	O
improvement	O
in	O
patient	O
assessment	O
score	O
vitiligo	B-DIS
quality	O
of	O
life	O
and	O
clinical	O
markers	O
of	O
disease	O
activity	O
were	O
marginal	O
and	O
comparable	O
in	O
both	O
groups	O
.	O

Cyclosporine	O
leads	O
to	O
earlier	O
disease	O
stabilization	O
in	O
active	O
vitiligo	B-DIS
as	O
compared	O
to	O
OMP	O
.	O

Although	O
considered	O
a	O
rescue	O
drug	O
in	O
dermatology	O
low	O
dose	O
cyclosporine	O
can	O
be	O
an	O
effective	O
therapeutic	O
alternative	O
in	O
vitiligo	B-DIS
patients	O
.	O

Background	O
and	O
aims	O
Hybanthus	O
austrocaledonicus	O
Violaceae	O
is	O
a	O
nickel	O
Ni	O
hyperaccumulator	O
endemic	O
to	O
New	B-LOC
Caledonia	I-LOC
.	O

One	O
of	O
the	O
specimens	O
stored	O
at	O
the	O
local	O
herbarium	O
had	O
a	O
strip	O
of	O
bark	O
with	O
a	O
remarkably	O
green	O
phloem	O
tissue	O
attached	O
to	O
the	O
sheet	O
containing	O
over	O
4	O
wt	O
%	O
Ni	O
.	O

This	O
study	O
aimed	O
to	O
collect	O
field	O
samples	O
from	O
the	O
original	O
H.	O
austrocaledonicus	O
locality	O
to	O
confirm	O
the	O
nature	O
of	O
the	O
green	O
'	O
nickel	O
-	O
rich	O
phloem	O
'	O
in	O
this	O
taxon	O
and	O
to	O
systematically	O
assess	O
the	O
occurrence	O
of	O
Ni	O
hyperaccumulation	O
in	O
H.	O
austrocaledonicus	O
and	O
Hybanthus	O
caledonicus	O
populations	O
.	O

Methods	O
X	O
-	O
ray	O
fluorescence	O
spectroscopy	O
scanning	O
of	O
all	O
collections	O
of	O
the	O
genus	O
Hybanthus	O
236	O
specimens	O
was	O
undertaken	O
at	O
the	O
Herbarium	O
of	O
New	O
Caledonia	O
to	B-EPI
reveal	O
incidences	O
of	O
Ni	O
accumulation	O
in	O
populations	O
of	O
H.	O
austrocaledonicus	O
and	O
H.	O
caledonicus	O
.	O

In	O
parallel	O
micro	O
-	O
analytical	O
investigations	O
were	O
performed	O
via	O
synchrotron	O
X	O
-	O
ray	O
fluorescence	O
microscopy	O
XFM	O
and	O
scanning	O
electron	O
microscopy	O
with	O
X	O
-	O
ray	O
microanalysis	O
SEM	O
-	O
EDS	O
.	O

Key	O
results	O
The	O
extensive	O
scanning	O
demonstrated	O
that	O
Ni	O
hyperaccumulation	O
is	O
not	O
a	O
characteristic	O
common	O
to	O
all	O
populations	O
in	O
the	O
endemic	O
Hybanthus	O
species	O
.	O

Synchrotron	O
XFM	O
revealed	O
that	O
Ni	O
was	O
exclusively	O
concentrated	O
in	O
the	O
epidermal	O
cells	O
of	O
the	O
leaf	O
blade	O
and	O
petiole	O
conforming	O
with	O
the	O
majority	O
of	O
tropical	O
Ni	O
hyperaccumulator	O
plants	O
studied	O
to	O
date	O
.	O

SEM	O
-	O
EDS	O
of	O
freeze	O
-	O
dried	O
and	O
frozen	O
-	O
hydrated	O
samples	O
revealed	O
the	O
presence	O
of	O
dense	O
solid	O
deposits	O
in	O
the	O
phloem	O
bundles	O
that	O
containe	O
8	B-STAT
wt	I-STAT
%	I-STAT
nickel	O
.	O

Conclusions	O
The	O
occurrence	O
of	O
extremely	O
Ni	O
-	O
rich	O
green	O
phloem	O
tissues	O
appears	O
to	O
be	O
a	O
characteristic	O
feature	O
of	O
tropical	O
Ni	O
hyperaccumulator	O
plants	O
.	O

Background	O
Fulminant	B-DIS
necrotising	I-DIS
amoebic	I-DIS
colitis	I-DIS
FulNAC	O
is	O
an	O
uncommon	O
and	O
grave	O
complication	O
of	O
a	O
very	O
common	O
infectious	B-DIS
disease	I-DIS
widely	O
prevalent	O
in	O
tropical	O
countries	O
.	O

In	O
most	O
of	O
the	O
cases	O
reported	O
only	O
a	O
segment	O
of	O
large	O
bowel	O
was	O
gangrenous	B-DIS
.	O

The	O
involvement	O
of	O
the	O
whole	O
of	O
the	O
large	O
bowel	O
as	O
in	O
our	O
case	O
is	O
very	O
rare	O
and	O
has	O
very	O
high	O
mortality	O
ranging	O
from	O
55	B-STAT
%	I-STAT
to	I-STAT
100	I-STAT
%	I-STAT
.	O

Case	O
Summary	O
.	O

A	O
50	O
-	O
year	O
-	O
old	O
gentleman	O
presented	O
with	O
an	O
acute	O
abdomen	O
with	B-DIS
a	I-DIS
history	I-DIS
of	O
crampy	O
abdominal	O
pain	O
and	O
passage	O
of	O
blood	O
mixed	O
with	O
mucous	O
and	O
loose	O
stools	O
.	O

After	O
resuscitation	O
and	O
investigations	O
the	O
patient	O
was	O
taken	O
up	O
for	O
laparotomy	O
and	O
the	O
findings	O
showed	O
that	O
the	O
caecum	O
was	O
sloughed	O
off	O
and	O
the	O
entire	O
large	O
bowel	O
had	O
multiple	O
perforations	B-DIS
.	O

Subtotal	O
colectomy	O
with	O
ileostomy	O
was	O
performed	O
.	O

Histopathological	O
examination	O
showed	O
evidence	O
of	O
pancolitis	B-DIS
with	O
multiple	O
colonies	O
of	O
amoebic	B-DIS
trophozoites	O
.	O

Discussion	O
.	O

Entamoeba	O
histolytica	O
is	O
a	O
protozoon	O
that	O
affects	O
the	O
large	O
intestine	O
and	O
liver	O
in	O
humans	O
.	O

There	O
can	O
be	O
various	O
presentations	O
of	O
amoebiasis	B-DIS
asymptomatic	O
infection	B-DIS
90	B-STAT
%	I-STAT
symptomatic	O
noninvasive	O
infection	B-DIS
6	I-DIS
-	I-DIS
8	I-DIS
%	I-STAT
acute	O
amoebic	B-DIS
colitis	I-DIS
dysentery	I-DIS
or	O
fulminant	B-DIS
colitis	I-DIS
with	O
perforation	B-DIS
.	O

FulNAC	O
is	O
an	O
uncommon	O
complication	O
difficult	O
to	O
diagnose	O
and	O
treat	O
and	O
associated	O
with	O
a	O
high	O
mortality	O
rate	O
ranging	O
from	O
55	B-STAT
%	I-STAT
to	I-STAT
100	I-STAT
%	I-STAT
.	O

Conclusion	O
It	O
is	O
important	O
to	O
consider	O
the	O
possibility	O
of	O
fulminant	B-DIS
necrotising	I-DIS
amoebic	I-DIS
colitis	I-DIS
FulNAC	O
as	O
an	O
uncommon	O
and	O
fatal	O
complication	O
of	O
amoebiasis	B-DIS
especially	O
in	O
tropical	O
countries	O
where	O
amoebiasis	B-DIS
is	O
prevalent	O
.	O

Early	O
diagnosis	O
and	O
antiamoebic	O
treatment	O
along	O
with	O
urgent	O
aggressive	O
surgical	O
resection	O
of	O
the	O
involved	O
segment	O
and	O
exteriorization	O
of	O
the	O
proximal	O
and	O
distal	O
bowel	O
ends	O
are	O
shown	O
to	O
reduce	O
mortality	O
.	O

Most	O
of	O
the	O
studies	O
examining	O
the	O
impact	O
of	O
cannabis	O
use	O
in	O
first	O
episode	O
psychosis	B-DIS
FEP	O
have	O
been	O
carried	O
out	O
in	O
samples	O
with	O
adult	B-DIS
-	O
onset	O
FEP	O
.	O

Data	O
in	O
persons	O
with	O
early	O
onset	O
psychosis	B-DIS
EOP	O
is	O
scarce	O
.	O

The	O
aims	O
of	O
the	O
study	O
were	O
To	O
describe	O
the	O
prevalence	B-EPI
of	O
lifetime	O
cannabis	O
use	O
current	O
use	O
and	O
daily	O
use	O
in	O
patients	O
with	O
EOP	O
compared	O
to	O
healthy	O
controls	O
.	O

To	O
study	O
the	O
differences	O
in	O
clinical	O
presentation	O
between	O
cannabis	O
users	O
and	O
non	O
-	O
users	O
.	O

To	O
examine	O
the	O
risk	O
of	O
presenting	O
an	O
EOP	O
associated	O
with	O
cannabis	O
use	O
and	O
the	O
effect	O
of	O
doses	O
and	O
age	O
of	O
onset	O
of	O
use	O
.	O

An	O
observational	O
cross	O
-	O
sectional	O
study	O
was	O
performed	O
in	O
90	O
EOP	O
cases	O
and	O
62	O
healthy	O
controls	O
aged	O
between	O
7	O
and	O
17	O
years	O
.	O

Our	O
results	O
show	O
a	O
higher	O
prevalence	B-EPI
of	O
lifetime	O
use	O
p	O
=	O
0002	O
current	O
use	O
p	O
<	O
0.001	O
and	O
daily	O
use	O
p	O
<	O
0.001	O
in	O
EOP	O
cases	O
in	O
comparison	O
with	O
healthy	O
controls	O
.	O

Regarding	O
clinical	O
presentation	O
we	O
did	O
not	O
find	O
significant	O
differences	O
in	O
any	O
subscale	O
of	O
the	O
Positive	O
and	O
Negative	O
Syndrome	O
Scale	O
PANSS	O
.	O

Non	O
-	O
user	O
patients	O
presented	O
more	B-DIS
severe	I-DIS
depressive	I-DIS
symptoms	I-DIS
p	I-DIS
=	O
0002	O
and	O
worse	O
social	O
functioning	O
than	O
cannabis	O
users	O
p	O
=	O
0026	O
.	O

Compared	O
with	O
subjects	O
who	O
never	O
used	O
cannabis	O
the	O
risk	O
of	O
an	O
EOP	O
was	O
significantly	O
higher	O
for	O
those	O
with	O
a	O
lifetime	O
use	O
OR	O
=	O
2.88	O
p	O
=	O
0.002	O
current	O
use	O
O.R	O
=	O
6.09	O
p	O
<	O
0001	O
and	O
especially	O
in	O
those	O
with	O
daily	O
use	O
O.R	O
=	O
42.77	O
p	O
=	O
<	O
0001	O
.	O

We	O
found	O
a	O
higher	O
risk	O
of	O
EOP	O
in	O
patients	O
that	O
have	O
used	O
cannabis	O
before	O
15	O
years	O
of	O
age	O
.	O

In	O
conclusion	O
it	O
is	O
necessary	O
to	O
develop	O
early-	O
detection	O
and	O
specific	O
treatment	O
programs	O
for	O
adolescents	O
with	O
cannabis	O
use	O
.	O

The	O
clinical	O
presentation	O
except	O
age	O
of	O
onset	O
is	O
similar	O
in	O
different	O
types	O
of	O
angioedema	B-DIS
.	O

A	O
lymphoproliferative	B-DIS
disorder	I-DIS
like	O
angioimmunoblastic	O
T	B-DIS
cell	I-DIS
lymphoma	I-DIS
AITL	I-DIS
rarely	O
presents	O
with	O
symptoms	O
of	O
angioedema	B-DIS
.	O

We	O
present	O
extremely	O
rare	O
case	O
of	O
elderly	O
male	O
with	O
recurrent	O
tongue	O
swelling	O
pruritus	O
with	O
normal	O
levels	O
of	O
complements	O
and	O
C1	O
esterase	O
inhibitor	O
protein	O
featuring	O
as	O
acquired	O
angioedema	B-DIS
a	O
rare	O
manifestation	O
of	O
AITL	B-DIS
.	O

Initial	O
response	O
to	O
corticosteroids	O
may	O
be	O
misleading	O
and	O
occurs	O
as	O
a	O
result	O
of	O
immunosuppression	O
of	O
AITL	B-DIS
.	O

High	O
index	O
of	O
suspicion	O
may	O
prompt	O
need	O
for	O
histopathological	O
diagnosis	O
of	O
lymph	O
node	O
biopsy	O
.	O

Definitive	O
chemotherapeutic	O
treatment	O
may	O
achieve	O
long	O
term	O
remission	O
.	O

Background	O
To	O
evaluate	O
the	O
relationship	O
between	O
gender	O
ethnicity	O
/	O
citizenship	O
clinical	O
phenotype	B-EPI
total	O
prevalence	O
and	O
the	B-DIS
various	I-DIS
congenital	O
malformations	O
associated	O
with	O
oral	O
clefts	O
OC	O
in	O
Italy	B-LOC
across	O
the	O
period	O
2001	O
-	O
2014	O
.	O

Methods	O
A	O
retrospective	O
analysis	O
2001	O
-	O
2014	O
was	O
conducted	O
based	O
on	O
the	O
National	O
Congenital	B-DIS
Malformation	I-DIS
Registries	O
network	O
of	O
Italy	B-LOC
Emilia	O
-	O
Romagna	O
Registry	B-DIS
of	I-DIS
Birth	I-DIS
Defects	I-DIS
[	I-DIS
IMER	I-DIS
]	I-DIS
and	I-DIS
Registro	I-DIS
Toscano	I-DIS
Difetti	O
Congeniti	O
[	O
RTDC	O
]	O
which	O
were	O
analyzed	O
to	O
investigate	O
time	O
trends	O
geographical	O
/	O
ethnic	O
clusters	O
topography	O
sex	B-DIS
ratio	I-DIS
and	O
associated	O
congenital	O
anomalies	O
of	O
OC	O
phenotypes	O
.	O

Results	O
Among	O
739	O
registered	O
cases	O
29.8	B-STAT
%	I-STAT
were	O
syndromic	O
or	O
had	O
multi	O
-	O
malformed	B-DIS
associated	O
anomalies	O
compared	O
with	O
70.2	B-STAT
%	I-STAT
having	B-DIS
isolated	I-DIS
orofacial	O
cleft	O
.	O

Cleft	B-DIS
lip	I-DIS
CL	O
was	O
observed	O
in	O
22	B-STAT
%	I-STAT
cleft	B-DIS
palate	I-DIS
CP	O
in	O
40	B-STAT
%	I-STAT
and	O
cleft	B-DIS
lip	I-DIS
and	O
palate	B-DIS
CLP	O
in	O
38	B-STAT
%	I-STAT
of	O
live	O
births	O
stillbirths	O
and	O
terminations	O
of	O
pregnancy	O
for	O
fetal	O
anomaly	B-DIS
cases	O
.	O

Other	O
associated	O
conditions	O
were	O
major	B-DIS
anomalies	I-DIS
of	I-DIS
cardiovascular	I-DIS
defects	I-DIS
39	B-STAT
%	I-STAT
followed	O
by	O
defects	O
of	O
the	O
limbs	O
28	B-STAT
%	I-STAT
neuroectodermal	B-DIS
defects	I-DIS
23	B-STAT
%	I-STAT
and	O
urogenital	B-DIS
malformations	I-DIS
10	B-STAT
%	I-STAT
.	O

Male	O
-	O
to	O
-	O
female	O
sex	O
ratio	O
was	O
11.14	O
in	O
CP	O
1.221	O
in	O
CL	O
and	O
1.91	O
in	O
CLP	O
.	O

Foreigners	O
were	O
represented	O
by	O
29	B-STAT
%	I-STAT
from	O
Southeast	B-LOC
Asia	I-LOC
25	B-STAT
%	I-STAT
from	O
Balkans	B-LOC
25	B-STAT
%	I-STAT
from	O
North	O
-	O
Central	O
Africa	O
9	B-STAT
%	I-STAT
from	O
the	O
East	O
7	O
%	O
from	O
Western	B-LOC
Europe	I-LOC
and	O
5	B-STAT
%	I-STAT
from	O
South	B-LOC
America	I-LOC
.	O

Total	O
prevalence	B-EPI
of	O
OC	O
cases	O
ranged	O
from	O
0.9	O
RTDC	O
to	O
1.1	O
IMER	O
of	O
1000	O
births	O
.	O

Conclusions	O
This	O
retrospective	O
study	O
provides	O
a	O
population	O
-	O
based	O
clinical	O
-	O
epidemiological	B-DIS
description	I-DIS
of	O
the	O
orofacial	O
cleft	O
phenomenon	O
.	O

As	O
a	O
relatively	O
frequent	O
congenital	B-DIS
malformation	I-DIS
its	O
social	O
and	O
economic	O
impact	O
is	O
worthy	O
of	O
further	O
study	O
.	O

These	O
abnormalities	O
can	O
cause	O
significant	O
problems	O
that	O
may	O
be	O
solved	O
or	O
minimized	O
by	O
early	O
diagnosis	O
and	O
treatment	O
.	O

Rare	O
diseases	O
are	O
usually	O
genetic	O
chronic	O
and	O
incurable	O
disorders	O
with	O
a	O
relatively	O
low	O
incidence	B-EPI
.	O

Developments	O
in	O
the	O
diagnosis	O
and	O
management	O
of	O
rare	O
diseases	O
have	O
been	O
relatively	O
slow	O
due	O
to	O
a	O
lack	O
of	O
sufficient	O
profit	O
motivation	O
and	O
market	O
to	O
attract	O
research	O
by	O
companies	O
.	O

However	O
due	O
to	O
the	O
attention	O
of	O
government	O
and	O
society	O
as	O
well	O
as	O
economic	O
development	O
rare	O
diseases	O
have	O
been	O
gradually	O
become	O
an	O
increasing	O
concern	O
.	O

As	O
several	O
dental	O
-	O
craniofacial	O
manifestations	O
are	O
associated	O
with	O
rare	O
diseases	O
we	O
summarize	O
them	O
in	O
this	O
study	O
to	O
help	O
dentists	O
and	O
oral	O
maxillofacial	O
surgeons	O
provide	O
an	O
early	O
diagnosis	O
and	O
subsequent	O
management	O
for	O
patients	O
with	O
these	O
rare	O
diseases	O
.	O

Barth	B-DIS
syndrome	I-DIS
is	O
a	O
rare	O
X	O
-	B-DIS
linked	I-DIS
recessive	O
disorder	O
characterized	O
by	O
a	O
broad	O
spectrum	O
of	O
clinical	O
features	B-DIS
including	I-DIS
cardiac	I-DIS
and	I-DIS
skeletal	B-DIS
myopathy	O
neutropenia	O
exercise	O
intolerance	O
and	O
growth	O
delay	O
.	O

Most	O
affected	O
patients	O
are	O
diagnosed	O
during	O
childhood	O
and	O
mortality	O
is	O
highest	O
in	O
the	O
first	O
years	O
of	O
life	O
.	O

As	O
a	O
consequence	O
Barth	B-DIS
syndrome	I-DIS
is	O
often	O
considered	O
a	O
paediatric	O
disease	O
.	O

Here	O
we	O
report	O
a	O
case	O
where	O
the	O
diagnosis	O
was	O
established	O
in	O
a	O
39	O
-	O
year	O
-	B-DIS
old	I-DIS
patient	I-DIS
with	O
left	B-DIS
ventricular	O
non	O
-	O
compaction	O
and	O
neutropenia	O
.	O

The	O
clinical	O
course	O
of	O
the	O
patient	O
presented	O
here	O
was	O
relatively	O
benign	O
.	O

This	O
suggests	O
that	O
the	O
prevalence	B-EPI
of	O
Barth	B-DIS
syndrome	I-DIS
in	O
adults	O
may	O
be	O
underestimated	O
.	O

Barth	B-DIS
syndrome	I-DIS
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
of	O
male	O
patients	O
with	O
cardiomyopathy	B-DIS
and	O
neutropenia	B-DIS
.	O

In	O
our	O
previous	O
studies	O
we	O
discovered	O
the	O
congenital	B-DIS
cold	I-DIS
syndrome	I-DIS
CCS	O
which	O
is	O
characterized	O
by	O
'	O
qi	O
deficiency	O
and	O
qi	O
stagnation	O
mixed	O
cold	O
and	O
heat	O
.	O
'	O

And	O
there	O
is	O
a	O
type	O
of	O
syndrome	O
with	O
special	O
incidence	B-EPI
characteristic	O
.	O

However	O
the	O
diagnosis	O
of	O
CCS	O
still	O
lacks	O
an	O
objective	O
basis	O
.	O

In	O
this	O
study	O
we	O
performed	O
Tandem	O
Mass	O
Tag	O
TMT	O
based	O
on	O
quantitative	O
proteomics	O
technology	O
to	O
screen	O
the	O
significantly	O
differentially	O
expressed	O
proteins	O
DEPs	O
in	O
serum	O
of	O
patients	O
with	O
coronary	B-DIS
heart	I-DIS
disease	I-DIS
CHD	O
patients	O
with	O
CCS	O
patients	O
with	O
heart	B-DIS
and	I-DIS
kidney	I-DIS
yang	I-DIS
deficiency	I-DIS
and	O
healthy	O
people	O
.	O

A	O
total	O
of	O
22	O
DEPs	O
nine	O
upregulated	O
and	O
13	O
downregulated	O
were	O
identified	O
between	O
patients	O
with	O
CCS	O
and	O
healthy	O
subjects	O
.	O

Next	O
we	O
performed	O
GO	O
and	O
KEGG	O
pathway	O
enrichment	O
analysis	O
we	O
found	O
the	O
primary	O
functions	O
of	O
DEPs	O
of	O
CCS	O
were	O
binding	O
catalytic	O
activity	O
and	O
molecular	O
function	O
regulator	O
.	O

These	O
DEPs	O
were	O
mainly	O
involved	O
in	O
important	O
biological	O
processes	O
such	O
as	O
cellular	O
process	O
response	O
to	O
stimulus	O
localization	O
metabolic	O
process	O
and	O
biological	O
regulation	O
.	O

The	O
KEGG	O
analysis	O
revealed	O
that	O
the	O
DEPs	O
showed	O
significant	O
changes	O
in	O
fructose	O
and	O
mannose	O
metabolism	O
Pentose	O
phosphate	O
pathway	O
and	O
Arrhythmogenic	B-DIS
right	I-DIS
ventricular	I-DIS
cardiomyopathy	I-DIS
.	O

After	O
parallel	O
reaction	O
monitoring	O
PRM	O
verification	O
four	O
upregulated	O
target	O
proteins	O
ALDOA	O
PCYOX1	O
Crisp3	O
and	O
IGLV4	O
-	O
69	O
and	O
three	O
downregulated	O
proteins	O
ALDOC	O
ADAMTSL-2	O
and	O
C3	O
were	O
accurately	O
identified	O
.	O

These	O
proteins	O
were	O
mainly	O
related	O
to	O
immune	O
response	O
and	O
glucose	O
metabolism	O
.	O

These	O
DEPs	O
could	O
be	O
the	O
marker	O
proteins	O
of	O
coronary	B-DIS
heart	I-DIS
disease	I-DIS
with	O
CCS	O
.	O

This	O
findings	O
help	O
to	O
reveal	O
the	O
pathogenesis	O
of	O
CHD	O
with	O
CCS	O
and	O
provide	O
potential	O
therapeutic	O
targets	O
.	O

Background	O
Consanguineous	O
marriages	O
are	O
common	O
in	O
the	B-LOC
Middle	I-LOC
East	I-LOC
including	O
the	O
Gulf	B-LOC
countries	O
.	O

The	O
rate	O
of	O
consanguinity	B-DIS
in	O
Qatar	B-LOC
is	O
approximately	B-STAT
54	I-STAT
%	I-STAT
which	O
are	O
mainly	O
first	O
cousins	O
'	O
marriages	O
.	O

Previous	O
studies	O
showed	O
that	O
consanguinity	B-DIS
increases	O
the	O
prevalence	B-EPI
of	O
birth	B-DIS
defects	I-DIS
and	O
other	O
genetic	O
disorders	O
.	O

Thus	O
we	O
studied	O
the	O
effects	O
of	O
consanguinity	B-DIS
in	O
a	O
cohort	O
of	O
subjects	O
with	O
certain	O
genetic	O
disorders	O
in	O
Qatar	B-LOC
.	O

Methods	O
This	O
cross	O
-	O
sectional	O
study	O
was	O
conducted	O
at	O
two	O
centers	O
in	O
Qatar	O
Hamad	O
Medical	O
Corporation	O
`	O
`	O
HMC	O
''	O
and	O
Shafallah	O
`	O
`	O
SC	O
''	O
including	O
599	O
Qatari	O
families	O
with	O
certain	O
types	O
of	O
genetic	B-DIS
and	I-DIS
nongenetic	O
anomalies	O
.	O

Results	O
Consanguineous	O
marriages	O
were	O
seen	O
in	O
397	O
of	O
59966.2	B-STAT
%	I-STAT
Qatari	O
families	O
and	O
first	O
cousin	O
group	O
counts	O
for	O
65	B-STAT
%	I-STAT
in	O
Qatari	O
population	O
.	O

In	O
the	O
total	O
cohort	O
and	O
at	O
HMC	O
all	O
consanguineous	O
marriages	O
had	O
a	O
significantly	O
higher	O
risk	O
of	O
Autosomal	B-DIS
Recessive	I-DIS
disorders	I-DIS
than	O
nonconsanguineous	O
marriages	O
total	O
cohort	O
odds	O
ratio	O
OR	O
=	O
1.72	O
;	O
95	B-STAT
%	I-STAT
CI	O
1.10	O
2.71	O
;	O
p	O
=	O
.02	O
;	O
HMC	O
OR	O
=	O
2.98	O
;	O
95	B-STAT
%	I-STAT
CI	O
1.37	O
6.09	O
;	O
p	O
=	O
.005	O
.	O

On	O
the	O
other	O
hand	O
at	O
HMC	O
nonconsanguinity	O
was	O
significantly	O
related	O
to	O
chromosomal	B-DIS
abnormality	I-DIS
OR	O
=	O
6.36	O
;	O
95	B-STAT
%	I-STAT
CI	O
1.13	O
35.85	O
;	O
p	O
=	O
.036	O
.	O

Conclusion	O
Our	O
data	O
suggest	O
a	O
significant	O
role	O
of	O
parental	O
consanguinity	B-DIS
in	O
increasing	O
the	O
prevalence	B-EPI
of	O
genetic	O
disorders	O
;	O
mainly	O
Autosomal	O
Recessive	B-DIS
disorders	I-DIS
.	O

Chromosomal	B-DIS
abnormality	I-DIS
disorders	I-DIS
were	O
significantly	O
higher	O
among	O
nonconsanguineous	O
marriages	O
.	O

These	O
results	O
help	O
better	O
inform	O
policy	O
makers	O
on	O
social	O
educational	O
and	O
public	O
health	O
initiatives	O
that	O
might	O
mitigate	O
the	O
impact	O
of	O
genetic	O
disease	O
in	O
the	O
Qatari	O
society	O
.	O

Sjögren	O
's	O
syndrome	O
SS	O
is	O
a	O
common	O
systemic	O
autoimmune	B-DIS
disease	I-DIS
.	O

SS	O
usually	O
occurs	O
among	O
middle	O
-	O
aged	O
women	O
with	O
a	B-EPI
peak	O
incidence	O
age	O
of	O
approximately	O
50	O
years	O
old	O
.	O

Kidney	O
involvement	O
is	O
relatively	O
uncommon	O
in	O
SS	O
which	O
is	O
mostly	O
characterized	O
as	O
interstitial	B-DIS
nephritis	I-DIS
and	O
may	O
result	O
in	O
renal	B-DIS
tubular	I-DIS
acidosis	I-DIS
RTA	O
.	O

But	O
premature	O
onset	O
of	O
SS	O
seems	O
to	O
be	O
prone	O
to	O
RTA	O
.	O

Here	O
we	O
reported	O
four	O
cases	O
of	O
premature	O
onset	O
SS	O
who	O
developed	O
into	O
RTA	O
at	O
a	O
relatively	O
young	O
age	O
and	O
three	O
of	O
whom	O
suffered	O
from	O
severe	O
osteomalacia	B-DIS
.	O

All	O
of	O
them	O
shared	O
a	O
disease	O
onset	O
under	O
age	O
eighteen	O
.	O

Two	O
of	O
them	O
presented	O
hypokalemic	O
periodic	O
paralysis	B-DIS
initially	O
one	O
presented	O
purpura	B-DIS
and	O
one	O
endured	O
xerophthalmia	B-DIS
at	O
first	O
place	O
.	O

Three	O
of	O
them	O
complicated	O
with	O
osteomalacia	O
under	O
age	O
thirty	O
.	O

All	O
the	O
4	O
cases	O
did	O
n't	O
receive	O
proper	O
medical	O
care	O
in	O
time	O
due	O
to	O
a	O
prolonged	O
delay	O
of	O
diagnosis	O
.	O

We	O
aim	O
to	O
raise	O
the	O
alarm	O
over	O
misdiagnosis	O
/	O
underdiagnosis	O
of	O
the	O
disorder	O
among	O
young	O
people	O
.	O

Charcot	B-DIS
-	I-DIS
Marie	I-DIS
-	O
Tooth	O
CMT	O
disease	O
is	O
the	B-DIS
most	O
common	O
inherited	O
neuropathy	O
and	O
one	O
of	O
the	O
most	O
common	O
inherited	O
diseases	O
in	O
humans	O
.	O

The	O
diagnosis	O
of	O
CMT	B-DIS
is	O
traditionally	O
made	O
by	O
the	O
neurologic	O
specialist	O
yet	O
the	O
optimal	O
management	O
of	O
CMT	B-DIS
patients	O
includes	O
genetic	O
counselors	O
physical	O
and	O
occupational	O
therapists	O
physiatrists	O
orthotists	O
mental	O
health	O
providers	O
and	O
community	O
resources	O
.	O

Rapidly	O
developing	O
genetic	O
discoveries	O
and	O
novel	O
gene	O
discovery	O
techniques	O
continue	O
to	O
add	O
a	O
growing	O
number	O
of	O
genetic	O
subtypes	O
of	O
CMT	B-DIS
.	O

The	O
first	O
large	O
clinical	O
natural	O
history	O
and	O
therapeutic	O
trials	O
have	O
added	O
to	O
our	O
knowledge	O
of	O
each	O
CMT	O
subtype	O
and	O
revealed	O
how	O
CMT	B-DIS
impacts	O
patient	O
quality	O
of	O
life	O
.	O

In	O
this	O
review	O
we	O
discuss	O
several	O
important	O
trends	O
in	O
CMT	B-DIS
research	O
factors	O
that	O
will	O
require	O
a	O
collaborative	O
multidisciplinary	O
approach	O
.	O

These	O
include	O
the	O
development	O
of	O
large	O
multicenter	O
patient	O
registries	O
standardized	O
clinical	O
instruments	O
to	O
assess	O
disease	O
progression	O
and	O
disability	O
and	O
increasing	O
recognition	O
and	O
use	O
of	O
patient	O
-	O
reported	O
outcome	O
measures	O
.	O

These	O
developments	O
will	O
continue	O
to	O
guide	O
strategies	O
in	O
long	O
-	O
term	O
multidisciplinary	O
efforts	O
to	O
maintain	O
quality	O
of	O
life	O
and	O
preserve	O
functionality	B-DIS
in	O
CMT	O
patients	O
.	O

Coxiella	O
burnetii	O
is	O
an	O
intracellular	O
bacterium	O
and	O
the	O
cause	O
of	O
the	O
zoonotic	O
infection	B-DIS
Q	I-DIS
fever	I-DIS
.	O

National	O
surveillance	O
data	O
on	O
C.	O
burnetii	O
seroprevalence	O
is	O
currently	O
not	O
available	O
for	O
any	O
South	O
American	O
country	O
making	O
efforts	O
of	O
public	O
health	O
to	O
implement	O
strategies	O
to	O
mitigate	O
infections	B-DIS
in	O
different	O
at	O
-	O
risk	O
groups	O
within	O
the	O
population	O
extremely	O
challenging	O
.	O

In	O
the	O
current	O
study	O
we	O
used	O
two	O
commercial	O
anti-	O
C.	O
burnetii	O
immunoassays	O
to	O
screen	O
sera	O
collected	O
from	O
a	O
sample	O
of	O
the	O
Chilean	O
population	O
as	O
part	O
of	O
a	O
2016	O
-	O
2017	O
national	O
health	O
survey	O
n	O
=	O
5166	O
nationwide	O
and	O
age	O
-	O
standardized	O
.	O

The	O
seroprevalence	O
for	O
C.	O
burnetii	O
for	O
persons	O
≥	O
15	O
years	O
was	O
estimated	O
to	O
be	O
3.0	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
2.2	O
-	O
4.0	O
a	O
level	O
similar	O
to	O
national	O
surveys	O
from	O
The	O
Netherlands	B-LOC
2.4	B-STAT
%	I-STAT
and	O
USA	B-LOC
3.1	B-STAT
%	I-STAT
but	O
lower	O
than	O
Australia	B-LOC
5.6	B-STAT
%	I-STAT
.	O

A	O
linear	O
increase	O
of	O
C.	O
burnetii	O
seropositivity	O
was	O
associated	O
with	O
an	O
individual	O
's	O
age	O
with	O
the	O
peak	O
seroprevalence	O
5.6	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
3.6	O
-	O
8.6	O
observed	O
in	O
the	O
≥65	O
years	O
'	O
group	O
.	O

C.	O
burnetii	O
seropositivity	O
was	O
significantly	O
higher	O
in	O
the	O
southern	O
macro	O
-	O
zone	O
6.0	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
3.3	O
-	O
10.6	O
compared	O
to	O
metropolitan	O
region	O
1.8	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
0.9	O
-	O
3.3	O
the	O
former	O
region	O
being	O
home	O
to	O
significant	O
livestock	O
industries	O
particularly	O
dairy	O
farming	O
.	O

These	O
data	O
will	O
be	O
useful	O
to	O
inform	O
targeted	O
strategies	O
for	O
the	O
prevention	O
of	O
Q	B-DIS
fever	I-DIS
in	O
at	O
-	O
risk	O
populations	O
in	O
Chile	B-LOC
.	O

BACKGROUNDNeonatal	O
herpes	B-DIS
simplex	I-DIS
virus	I-DIS
infection	I-DIS
nHSV	O
leads	O
to	O
severe	O
morbidity	O
and	O
mortality	O
but	O
national	O
incidence	B-EPI
is	O
uncertain	O
.	O

Florida	B-LOC
regulations	O
require	O
that	O
healthcare	O
providers	O
report	O
cases	O
and	O
clinical	O
laboratories	O
report	O
test	O
results	O
when	O
herpes	B-DIS
simplex	I-DIS
virus	O
HSV	B-DIS
is	O
detected	O
.	O

We	O
estimated	O
nHSV	O
incidence	B-EPI
using	O
laboratory	O
-	O
confirmed	O
provider	O
-	O
reported	O
cases	O
and	O
electronic	O
laboratory	O
reports	O
ELR	O
stored	O
separately	O
from	O
provider	O
-	O
reported	O
cases	O
.	O

Mortality	O
was	O
estimated	O
using	O
provider	O
-	O
reported	O
cases	O
ELR	O
and	O
vital	B-DIS
statistics	O
death	O
records	O
.	O

METHODSFor	O
2011	O
-	O
2017	O
we	O
reviewed	O
provider	O
-	O
reported	O
cases	O
infants	O
<	O
60	O
days	O
of	O
age	B-DIS
with	I-DIS
HSV	O
infection	O
confirmed	O
by	O
culture	O
or	O
polymerase	O
chain	O
reaction	O
PCR	O
ELR	O
of	O
HSV	O
-	O
positive	O
culture	O
or	O
PCR	O
results	O
in	O
the	O
same	B-DIS
age	O
group	O
and	O
death	O
certificates	O
containing	B-DIS
International	O
Classification	O
of	O
Disease	O
Tenth	B-DIS
Revision	I-DIS
codes	O
for	O
herpes	O
infection	O
P35.2	O
B00.0	O
-	O
B00.9	O
and	O
A60.0	O
-	O
A60.9	O
.	O

Provider	O
-	O
reported	O
cases	O
were	O
matched	O
against	O
ELR	O
reports	O
.	O

Death	B-DIS
certificates	O
were	O
matched	O
with	O
provider	O
and	O
ELR	O
reports	O
.	O

Chapman	O
's	O
capture	O
-	O
recapture	O
method	O
was	O
used	O
to	O
estimate	B-EPI
nHSV	O
incidence	O
and	O
mortality	O
.	O

Mortality	O
from	O
all	O
three	O
sources	O
was	O
estimated	O
using	O
log	O
-	O
linear	O
modelling	O
.	O

RESULTSProviders	O
reported	O
114	O
nHSV	O
cases	O
and	O
ELR	O
identified	O
197	O
nHSV	O
cases	O
.	O

Forty	O
-	O
six	O
cases	O
were	O
common	O
to	O
both	O
datasets	O
leaving	O
265	O
unique	O
nHSV	O
reports	O
.	O

Chapman	O
's	O
estimate	O
suggests	O
48395	B-STAT
%	I-STAT
C.I	O
.	O

383	O
-	O
634	O
nHSV	O
cases	O
occurred	O
31.5	O
infections	B-DIS
per	O
100000	O
live	O
births	O
.	O

nHSV	O
deaths	B-DIS
were	O
reported	O
by	O
providers	O
n=9	O
ELR	O
n=18	O
and	O
vital	O
statistics	O
n=31	O
totaling	O
34	O
unique	O
reports	O
.	O

Log	O
-	O
linear	O
modeling	O
estimates	O
35.8	O
fatal	O
cases	O
occurred	O
95	B-STAT
%	I-STAT
CI	O
34	O
-	O
40	O
.	O

CONCLUSIONSChapman	O
's	O
estimates	O
using	O
data	O
collected	O
over	O
7	O
years	O
in	O
Florida	B-LOC
conclude	O
nHSV	O
infections	B-DIS
occurred	O
at	O
a	O
rate	O
of	O
1	B-STAT
per	I-STAT
3000	I-STAT
live	O
births	O
.	O

Background	O
/	O
aims	O
Pseudohypoparathyroidism	O
type	B-DIS
1a	O
PHP1a	O
is	O
a	O
rare	O
genetic	O
disorder	O
.	O

This	O
study	O
aimed	O
to	O
determine	O
the	O
prevalence	B-EPI
of	O
sleep	O
apnea	B-DIS
in	O
children	O
with	O
PHP1a	B-DIS
.	O

Methods	O
Nineteen	O
patients	O
with	O
PHP1a	B-DIS
between	O
the	O
age	O
of	O
2	O
and	O
21	O
years	O
were	O
enrolled	O
prospectively	O
using	O
online	O
advertisements	O
.	O

Parents	O
completed	O
a	O
medical	O
history	O
and	O
surveys	O
to	O
assess	O
sleep	B-DIS
behavior	I-DIS
.	O

Polysomnography	O
records	O
were	O
obtained	O
when	O
available	O
.	O

In	O
addition	O
18	O
subjects	O
were	O
identified	O
in	O
a	O
retrospective	O
chart	O
review	O
of	O
de	O
-	O
identified	O
medical	O
records	O
with	O
2.3	O
million	O
patient	O
charts	O
.	O

Results	O
Parents	O
reported	O
sleep	B-DIS
disturbance	I-DIS
94	B-STAT
%	I-STAT
and	O
daytime	B-DIS
somnolence	I-DIS
81	B-STAT
%	I-STAT
in	O
their	O
children	O
with	O
PHP1a	B-DIS
.	O

In	O
the	O
retrospective	O
chart	O
review	O
39	B-STAT
%	I-STAT
had	O
a	O
history	O
of	O
sleep	O
apnea	B-DIS
versus	O
8.8	B-STAT
%	I-STAT
of	O
a	O
similarly	O
obese	O
control	O
group	O
.	O

In	O
the	O
combined	O
analysis	O
n	O
=	O
3152	B-STAT
%	I-STAT
had	O
a	O
history	O
of	O
snoring	B-DIS
and	O
45	B-STAT
%	I-STAT
had	O
a	O
diagnosis	O
of	O
sleep	B-DIS
apnea	I-DIS
.	O

Patients	O
were	O
obese	O
with	O
a	O
mean	O
BMI	O
z	O
-	O
score	O
of	O
2.20	O
±	O
0.59	O
.	O

Patients	O
with	O
sleep	O
apnea	B-DIS
were	O
significantly	O
younger	O
than	O
those	O
without	O
a	O
diagnosis	O
8.1	O
±	O
5.4	O
vs.	O
12.8	O
±	O
5.0	O
years	O
p	O
=	O
0.02	O
.	O

Conclusions	O
Children	O
with	O
PHP1a	B-DIS
have	O
a	O
4.4	O
-	O
fold	O
greater	O
relative	O
risk	O
of	B-DIS
sleep	O
apnea	O
than	O
similarly	O
obese	O
children	O
.	O

Screening	O
for	O
sleep	O
apnea	B-DIS
in	O
this	O
population	O
may	O
be	O
warranted	O
to	O
prevent	O
adverse	O
health	O
outcomes	O
.	O

Q	B-DIS
fever	I-DIS
is	O
a	O
disease	O
of	O
high	O
zoonotic	O
potential	O
but	O
interest	O
in	O
its	O
causative	O
agent	O
is	O
rather	O
low	O
although	O
it	O
causes	O
some	O
public	O
health	O
problems	O
in	O
Hungary	B-LOC
.	O

The	O
prevalence	B-EPI
of	O
Q	B-DIS
fever	I-DIS
is	O
highly	O
variable	O
by	O
country	O
.	O

The	O
main	O
reservoirs	O
of	O
the	O
disease	O
are	O
the	O
same	O
domestic	O
ruminant	O
species	O
everywhere	O
but	O
the	O
epidemiological	O
profile	O
depends	O
on	O
the	O
features	O
of	O
the	O
specific	O
reservoir	O
.	O

The	O
aim	O
of	O
this	O
large	O
-	O
scale	O
study	O
was	O
to	O
demonstrate	O
the	O
importance	B-DIS
of	I-DIS
Q	O
fever	O
in	O
different	O
species	O
as	O
a	O
possible	O
source	B-DIS
for	I-DIS
human	O
infection	O
in	O
most	O
regions	O
of	O
Hungary	B-LOC
.	O

A	O
total	O
of	O
851	O
serum	O
samples	O
from	O
44	O
dairy	O
farms	O
16	O
sheep	O
flocks	O
4	O
goat	O
farms	O
and	O
3	O
zoos	O
located	O
in	O
different	O
parts	O
of	O
Hungary	B-LOC
were	O
tested	O
.	O

The	O
presence	O
of	O
antibodies	O
to	O
Coxiella	O
burnetii	O
was	O
surveyed	O
in	O
dairy	O
cattle	O
n	O
=	O
547	O
goats	O
n	O
=	O
71	O
sheep	O
n	O
=	O
200	O
and	O
zoo	O
animals	O
n	O
=	O
33	O
.	O

The	O
animal	O
species	O
tested	O
in	O
Hungary	B-LOC
showed	O
different	O
seroprevalence	O
values	O
of	O
C.	B-DIS
burnetii	I-DIS
infection	I-DIS
.	O

Seropositivity	O
by	O
the	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
was	O
found	O
in	O
258	O
out	O
of	O
54747.2	B-STAT
%	I-STAT
cows	O
and	O
in	O
69	O
out	O
of	O
27125.5	B-STAT
%	I-STAT
small	O
ruminants	O
among	O
them	O
in	O
47	O
out	O
of	O
20023.5	B-STAT
%	I-STAT
sheep	O
and	O
in	O
22	O
out	O
of	O
7131.0	B-STAT
%	I-STAT
goats	O
.	O

Antibodies	O
to	O
C.	O
burnetii	O
were	O
not	O
detected	O
in	O
zoo	O
animals	O
.	O

Seropositivity	O
was	O
demonstrated	O
in	O
44	O
out	O
of	O
44100	B-STAT
%	I-STAT
dairy	O
cattle	O
farms	O
with	O
at	O
least	O
one	O
serum	O
sample	O
found	O
to	O
be	O
positive	O
on	O
each	O
farm	O
.	O

The	O
seropositivity	O
rate	O
of	O
small	O
ruminant	O
farms	O
was	O
55.0	B-STAT
%	I-STAT
11	O
positive	O
out	O
of	O
20	O
tested	O
with	O
9	O
out	O
of	O
1656.3	B-STAT
%	I-STAT
sheep	O
flocks	O
and	O
2	O
out	O
of	O
450.0	B-STAT
%	I-STAT
goat	O
herds	O
showing	O
seropositivity	O
.	O

Purpose	O
of	O
review	O
The	O
goal	O
of	O
the	O
review	O
is	O
to	O
provide	O
a	O
comprehensive	O
overview	O
of	O
the	O
current	O
understanding	O
of	O
the	O
mechanisms	O
underlying	O
variation	O
in	O
human	B-DIS
stature	I-DIS
.	O

Recent	O
findings	O
Human	O
height	O
is	O
an	O
anthropometric	O
trait	O
that	O
varies	O
considerably	O
within	O
human	O
populations	O
as	O
well	O
as	O
across	O
the	O
globe	O
.	O

Historically	O
much	O
research	O
focus	O
was	O
placed	O
on	O
understanding	O
the	O
biology	O
of	O
growth	O
plate	O
chondrocytes	O
and	O
how	O
modifications	O
to	O
core	O
chondrocyte	O
proliferation	O
and	O
differentiation	O
pathways	O
potentially	O
shaped	O
height	O
attainment	O
in	O
normal	O
as	O
well	O
as	O
pathological	O
contexts	O
.	O

Recently	O
much	O
progress	O
has	O
been	O
made	O
to	O
improve	O
our	O
understanding	O
regarding	O
the	O
mechanisms	O
underlying	O
the	O
normal	O
and	O
pathological	O
range	O
of	O
height	O
variation	O
within	O
as	O
well	O
as	O
between	O
human	O
populations	O
and	O
today	O
it	O
is	O
understood	O
to	O
reflect	O
complex	O
interactions	O
among	O
a	O
myriad	O
of	O
genetic	O
environmental	O
and	O
evolutionary	O
factors	O
.	O

Indeed	O
recent	O
improvements	O
in	O
genetics	O
e.g	O
.	O

GWAS	O
and	O
breakthroughs	O
in	O
functional	O
genomics	O
e.g	O
.	O

whole	O
exome	O
sequencing	O
DNA	O
methylation	O
analysis	O
ATAC	O
-	O
sequencing	O
and	O
CRISPR	O
have	O
shed	O
light	O
on	O
previously	O
unknown	O
pathways	O
/	O
mechanisms	O
governing	O
pathological	O
and	O
common	O
height	O
variation	O
.	O

Additionally	O
the	O
use	O
of	O
an	O
evolutionary	O
perspective	O
has	O
also	O
revealed	O
important	O
mechanisms	O
that	O
have	O
shaped	O
height	O
variation	O
across	O
the	O
planet	O
.	O

This	O
review	O
provides	O
an	O
overview	O
of	O
the	O
current	O
knowledge	O
of	O
the	O
biological	O
mechanisms	O
underlying	O
height	O
variation	O
by	O
highlighting	O
new	O
research	O
findings	O
on	O
skeletal	O
growth	O
control	O
with	O
an	O
emphasis	O
on	O
previously	O
unknown	O
pathways	O
/	O
mechanisms	O
influencing	O
pathological	O
and	O
common	O
height	O
variation	O
.	O

In	O
this	O
context	O
this	O
review	O
also	O
discusses	O
how	O
evolutionary	O
forces	O
likely	O
shaped	O
the	O
genomic	O
architecture	O
of	O
height	O
across	O
the	O
globe	O
.	O

ContextGestational	B-DIS
trophoblastic	I-DIS
disease	I-DIS
GTD	I-DIS
is	O
a	O
rare	O
complication	O
of	O
pregnancy	O
ranging	O
from	O
molar	O
pregnancy	O
to	O
choriocarcinoma	B-DIS
.	O

Twin	O
pregnancies	O
with	O
GTD	B-DIS
and	O
coexisting	O
normal	O
fetus	O
are	O
extremely	O
rare	O
with	O
an	O
estimated	O
incidence	B-EPI
of	O
1	B-STAT
case	I-STAT
per	I-STAT
22000	I-STAT
-	O
100000	O
pregnancies	O
.	O

Molecular	O
mimicry	O
between	O
human	O
chorionic	O
gonadotrophin	O
hCG	O
and	O
thyroid	O
-	O
stimulating	O
hormone	O
TSH	O
leads	B-DIS
to	I-DIS
gestational	I-DIS
trophoblastic	O
hyperthyroidism	O
GTH	O
which	O
is	O
further	O
associated	O
with	O
increased	O
maternal	O
and	O
fetal	O
complications	O
.	O

This	O
is	O
the	O
first	O
reported	O
case	O
in	O
literature	O
describing	O
the	O
delivery	O
of	O
a	O
baby	O
with	O
biochemical	O
euthyroid	O
status	O
following	O
a	O
twin	O
pregnancy	O
with	O
hydatidiform	O
mole	O
HM	O
associated	O
with	O
gestational	B-DIS
trophoblastic	I-DIS
hyperthyroidism	I-DIS
GTH	O
.	O

Case	O
DescriptionA	O
24	O
-	O
year	O
-	O
old	O
G4	O
P3	O
Caucasian	O
female	O
with	O
twin	O
gestation	O
was	O
admitted	O
to	B-DIS
hospital	I-DIS
for	O
gestation	O
trophoblastic	O
hyperthyroidism	O
.	O

She	O
was	O
later	O
diagnosed	O
to	O
have	O
twin	O
pregnancy	O
with	O
complete	O
mole	O
and	O
coexisting	O
normal	O
fetus	O
complicated	O
by	O
gestational	B-DIS
trophoblastic	I-DIS
hyperthyroidism	I-DIS
GTH	O
.	O

Despite	O
the	O
risk	O
associated	O
with	O
the	O
continuation	O
of	O
molar	O
pregnancy	O
per	O
patient	O
request	O
pregnancy	O
was	O
continued	O
till	O
viability	O
of	O
the	O
fetus	O
.	O

The	O
patient	O
underwent	O
cesarean	O
section	O
due	O
to	O
worsening	O
preeclampsia	B-DIS
and	O
delivered	O
a	O
euthyroid	B-DIS
baby	I-DIS
at	O
the	O
24th	O
week	O
of	O
gestation	O
.	O

ConclusionsTwin	O
pregnancy	O
with	O
gestational	B-DIS
trophoblastic	I-DIS
disease	I-DIS
and	O
coexisting	O
normal	O
fetus	O
is	O
associated	O
with	O
high	O
risk	O
of	O
hyperthyroidism	B-DIS
and	O
careful	O
monitoring	O
of	O
the	O
thyroid	O
function	O
test	O
along	O
with	O
dose	O
titration	O
of	O
thionamides	O
is	O
of	O
utmost	O
importance	O
throughout	O
the	O
gestation	O
.	O

If	O
normal	O
thyroid	O
hormone	O
levels	O
are	O
maintained	O
during	O
the	O
pregnancy	O
euthyroidism	O
could	O
be	O
successfully	O
achieved	O
in	O
the	O
baby	O
.	O

Purpose	O
To	O
determine	O
if	O
there	O
is	O
an	O
increased	O
incidence	B-EPI
rate	O
of	O
post	O
-	O
cataract	O
surgery	O
pcs	O
anterior	B-DIS
ischemic	I-DIS
optic	B-DIS
neuropathy	O
AION	O
compared	O
to	B-DIS
spontaneous	O
AION	O
sAION	O
.	O

Design	O
Retrospective	O
population	O
-	O
based	O
cohort	O
.	O

Methods	O
Patients	O
diagnosed	O
with	O
AION	B-DIS
from	O
January	O
11990	O
through	O
December	O
312016	O
while	O
residing	O
in	O
Olmsted	B-LOC
County	I-LOC
Minnesota	B-LOC
.	O

Patients	O
with	O
cataract	B-DIS
surgery	O
preceding	O
AION	B-DIS
were	O
included	O
in	O
the	O
pcsAION	O
cohort	O
defined	O
in	O
2	O
ways	O
AION	B-DIS
within	O
2	O
months	O
and	O
AION	B-DIS
within	O
1	O
year	O
of	O
cataract	B-DIS
surgery	O
.	O

The	O
incidence	B-EPI
rates	O
of	O
pcsAION	B-LOC
and	O
sAION	O
were	O
compared	O
using	O
Poisson	O
regression	O
models	O
.	O

Results	O
During	O
the	O
study	O
period	O
102	O
residents	O
developed	O
AION	B-DIS
.	O

The	O
median	O
age	O
was	O
65	O
years	O
range	O
40	O
-	O
90	O
years	O
4443.1	B-STAT
%	I-STAT
were	O
female	O
.	O

Twenty	O
of	O
10219.6	B-STAT
%	I-STAT
patients	O
had	O
previous	O
cataract	B-DIS
surgery	O
of	O
which	O
2	O
and	O
9	O
developed	O
AION	B-DIS
within	O
2	O
months	O
and	O
1	O
year	O
of	O
surgery	O
respectively	O
.	O

The	O
annual	O
incidence	B-EPI
rate	O
of	O
pcsAION	B-LOC
within	O
2	O
months	O
of	O
surgery	O
8.6	O
per	O
100000	O
was	O
not	O
significantly	O
greater	O
than	O
the	O
annual	O
incidence	B-EPI
rate	O
of	O
sAION	O
6.9	O
per	O
100000	O
;	O
P	O
=	O
.78	O
.	O

However	O
the	O
annual	O
incidence	B-EPI
rate	O
of	O
pcsAION	B-LOC
within	O
1	O
year	O
of	O
surgery	O
38.9	O
per	O
100000	O
was	O
significantly	O
higher	O
than	O
the	O
incidence	B-EPI
rate	O
of	O
sAION	O
6.5	O
per	O
100000	O
;	O
P	O
<	O
.001	O
.	O

Conclusion	O
The	O
incidence	B-EPI
of	O
AION	B-DIS
is	O
increased	O
in	O
the	O
first	O
year	O
after	O
cataract	B-DIS
surgery	O
but	O
not	O
in	O
the	O
early	O
i.e	O
.	O

2	O
months	O
postoperative	O
period	O
.	O

The	O
zoonosis	B-DIS
Q	B-DIS
fever	I-DIS
is	O
caused	O
by	O
the	O
obligate	O
intracellular	O
bacterium	O
Coxiella	O
burnetii	O
.	O

Besides	O
the	O
main	O
transmission	O
route	O
via	O
inhalation	O
of	O
contaminated	O
aerosols	O
ticks	O
are	O
discussed	O
as	O
vectors	O
since	O
the	O
first	O
isolation	O
of	O
the	O
pathogen	O
from	O
a	O
Dermacentor	B-DIS
andersonii	I-DIS
tick	I-DIS
.	O

The	O
rare	O
detection	O
of	O
C.	O
burnetii	O
in	O
ticks	O
and	O
the	O
difficult	O
differentiation	O
of	O
C.	O
burnetii	O
from	O
Coxiella	O
-like	O
endosymbionts	O
CLEs	O
are	O
questioning	O
the	O
relevance	O
of	O
ticks	B-DIS
in	O
the	O
epidemiology	O
of	O
Q	B-DIS
fever	I-DIS
.	O

In	O
this	O
review	O
literature	O
databases	O
were	O
systematically	O
searched	O
for	O
recent	O
prevalence	B-EPI
studies	O
concerning	O
C.	O
burnetii	O
in	O
ticks	B-DIS
in	O
Europe	B-LOC
and	O
experimental	O
studies	O
evaluating	O
the	O
vector	O
competence	O
of	O
tick	O
species	O
.	O

A	O
total	O
of	O
72	O
prevalence	B-EPI
studies	O
were	O
included	O
and	O
evaluated	O
regarding	O
DNA	O
detection	O
methods	O
and	O
collection	O
methods	O
country	O
and	O
tested	O
tick	O
species	O
.	O

Specimens	O
of	O
more	O
than	O
25	O
different	O
tick	O
species	O
were	O
collected	O
in	O
23	O
European	O
countries	O
.	O

Overall	O
an	O
average	O
prevalence	B-EPI
of	O
4.8	B-STAT
%	I-STAT
was	O
determined	O
.	O

However	O
in	O
half	O
of	O
the	O
studies	O
no	O
Coxiella	O
-DNA	O
was	O
detected	O
.	O

In	O
Southern	O
European	O
countries	O
a	O
significantly	O
higher	O
prevalence	B-EPI
was	O
observed	O
possibly	O
related	O
to	O
the	O
abundance	O
of	O
different	O
tick	O
species	O
here	O
namely	O
Hyalomma	O
spp	O
.	O

and	O
Rhipicephalus	O
spp	O
.	O

In	O
comparison	O
a	O
similar	O
proportion	O
of	O
studies	O
used	O
ticks	O
sampled	O
by	O
flagging	O
and	O
dragging	O
or	O
tick	O
collection	O
from	O
animals	O
under	B-STAT
30	I-STAT
%	I-STAT
of	O
the	O
total	O
tick	O
samples	O
derived	O
from	O
the	O
latter	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
various	O
target	O
genes	O
used	O
for	O
the	O
molecular	O
test	O
.	O

In	O
most	O
of	O
the	O
studies	O
no	O
distinction	O
was	O
made	O
between	O
C.	O
burnetii	O
and	O
CLEs	O
.	O

The	O
application	O
of	O
specific	O
detection	O
methods	O
and	O
the	O
confirmation	O
of	O
positive	O
results	O
are	O
crucial	O
to	O
determine	O
the	O
role	O
of	O
ticks	B-DIS
in	O
Q	B-DIS
fever	I-DIS
transmission	O
.	O

Only	O
two	O
studies	O
were	O
available	O
which	O
assessed	O
the	O
vector	O
competence	O
of	O
ticks	B-DIS
for	O
C.	O
burnetii	O
in	O
the	O
last	O
20	O
years	O
demonstrating	O
the	O
need	O
for	O
further	O
research	O
.	O

Cutaneous	B-DIS
squamous	I-DIS
cell	I-DIS
carcinoma	I-DIS
cSCC	I-DIS
is	O
the	O
second	O
most	O
prevalent	O
skin	B-DIS
cancer	I-DIS
globally	O
.	O

Because	O
most	O
cSCC	O
cases	O
are	O
manageable	O
by	O
local	O
excision	O
/	O
radiotherapy	O
and	O
hardly	O
become	O
life	O
-	O
threatening	O
they	O
are	B-DIS
often	O
excluded	O
from	O
cancer	O
registries	O
in	O
most	O
countries	O
.	O

Compared	O
with	O
cutaneous	B-DIS
melanoma	I-DIS
that	O
originates	O
from	O
the	O
melanin	O
-	O
producing	O
neural	O
crest	O
-	O
derived	O
epidermal	O
resident	B-DIS
keratinocyte	O
KC	O
-derived	O
cancers	O
are	O
influenced	O
by	O
the	O
immune	O
system	O
with	O
regards	O
to	O
their	O
pathogenetic	O
behaviour	O
.	O

Congenital	B-DIS
or	I-DIS
acquired	I-DIS
immunosurveillance	I-DIS
impairments	I-DIS
compromise	O
tumoricidal	O
activity	O
and	O
raises	O
cSCC	O
incidence	B-EPI
rates	O
.	O

Intriguingly	O
expanded	O
applications	O
of	O
programmed	O
death-1	O
PD-1	O
blockade	O
therapies	O
have	O
revealed	O
cSCC	O
to	O
be	O
one	O
of	O
the	O
most	O
amenable	O
targets	O
particularly	O
when	O
compared	O
with	O
the	O
mucosal	O
counterparts	O
arisen	O
in	O
the	O
esophagus	O
or	O
the	O
cervix	O
.	O

The	O
clinical	O
observation	O
reminds	O
us	O
that	O
cutaneous	O
tissue	O
has	O
a	O
peculiarly	O
high	O
immunogenicity	O
that	O
can	O
evoke	O
tumoricidal	O
recall	O
responses	O
topically	O
.	O

Here	O
we	O
attempt	O
to	O
redefine	O
cSCC	O
biology	O
and	O
review	O
current	O
knowledge	O
about	O
cSCC	O
from	O
multiple	O
viewpoints	O
that	O
involve	O
epidemiology	O
clinicopathology	O
molecular	O
genetics	O
molecular	O
immunology	O
and	O
developmental	O
biology	O
.	O

This	O
synthesis	O
not	O
only	O
underscores	O
the	O
primal	O
importance	O
of	O
the	O
immune	O
system	O
rather	O
than	O
just	O
a	O
mere	O
accumulation	O
of	O
ultraviolet	O
-	O
induced	O
mutations	O
but	O
also	O
reinforces	O
the	O
following	O
hypothesis	O
PD-1	O
blockade	O
effectively	O
restores	O
the	O
immunity	O
specially	O
allowed	O
to	O
exist	O
within	O
the	O
fully	O
cornified	O
squamous	O
epithelium	O
that	O
is	O
the	O
epidermis	O
.	O

Inferior	B-DIS
vena	I-DIS
cava	I-DIS
IVC	I-DIS
agenesis	I-DIS
is	O
a	O
rare	O
congenital	B-DIS
abnormality	I-DIS
affecting	O
the	O
infrarenal	O
segment	O
the	O
suprarenal	O
or	O
the	O
whole	O
of	O
the	O
IVC	O
.	O

It	O
has	O
an	O
estimated	O
prevalence	B-EPI
of	O
up	B-STAT
to	I-STAT
1	I-STAT
%	I-STAT
in	O
the	O
general	O
population	O
that	O
can	O
rise	O
to	O
8.7	B-STAT
%	I-STAT
when	O
abnormalities	O
of	O
the	O
left	O
renal	O
vein	O
are	O
considered	O
.	O

Most	O
IVC	B-DIS
malformations	I-DIS
are	O
asymptomatic	O
but	O
may	O
be	O
associated	O
with	O
nonspecific	O
symptoms	O
or	O
present	O
as	O
deep	O
vein	B-DIS
thrombosis	I-DIS
DVT	I-DIS
.	O

Up	B-STAT
to	I-STAT
5	I-STAT
%	I-STAT
of	O
young	O
individuals	O
under	O
30	O
years	O
of	O
age	O
with	O
unprovoked	B-DIS
DVT	I-DIS
are	O
found	O
to	O
have	O
this	O
condition	O
.	O

Regarding	O
the	O
treatment	O
of	O
IVC	O
agenesis	O
-	B-DIS
associated	O
DVT	O
there	O
are	O
no	O
standard	O
guidelines	O
.	O

Treatment	O
is	O
directed	O
towards	O
preventing	O
thrombosis	B-DIS
or	O
its	O
recurrence	O
.	O

Low	O
molecular	O
weight	O
heparin	O
and	O
oral	O
anticoagulation	O
medication	O
in	O
particular	O
vitamin	O
K	O
antagonists	O
VKAs	O
are	O
the	O
mainstay	O
of	O
therapy	O
.	O

Given	O
the	O
high	O
risk	O
of	O
DVT	B-DIS
recurrence	O
in	O
these	O
patients	O
oral	O
anticoagulation	O
therapy	O
is	O
suggested	O
to	O
be	O
pursued	O
indefinitely	O
.	O

As	O
far	O
as	O
we	O
know	O
this	O
is	O
the	O
first	O
case	O
reporting	O
the	O
use	O
of	O
a	O
direct	O
factor	O
Xa	O
inhibitor	O
in	O
IVC	O
agenesis	O
-	B-DIS
associated	O
DVT	O
.	O

Given	O
VKA	O
monitoring	O
limitations	O
the	O
use	O
of	O
a	O
direct	O
Xa	O
inhibitor	O
could	O
be	O
an	O
alternative	O
in	O
young	O
individuals	O
with	O
anatomical	O
defects	O
without	O
thrombophilia	B-DIS
but	O
further	O
studies	O
will	O
be	O
needed	O
to	O
confirm	O
its	O
efficacy	O
and	O
safety	O
.	O

LEARNING	O
POINTSUp	O
to	O
5	B-STAT
%	I-STAT
of	O
young	O
individuals	O
under	O
30	O
years	O
of	O
age	O
with	O
unprovoked	B-DIS
deep	O
vein	B-DIS
thrombosis	I-DIS
DVT	I-DIS
are	O
found	O
to	O
have	O
this	O
condition	O
.	O

Therefore	O
these	O
types	O
of	O
anomalies	B-DIS
should	O
be	O
actively	O
looked	O
for	O
particularly	O
in	O
young	O
patients	O
with	O
DVT.Treatment	O
with	O
low	O
molecular	O
weight	O
heparin	O
or	O
oral	O
anticoagulation	O
medication	O
is	O
the	O
mainstay	O
of	O
therapy	O
directed	O
towards	O
preventing	O
thrombosis	B-DIS
or	O
its	O
recurrence	O
.	O
A	O
direct	O
factor	O
Xa	O
inhibitor	O
could	O
be	O
a	O
possible	O
alternative	O
to	O
vitamin	O
K	O
antagonists	O
in	O
these	O
patients	O
despite	O
the	O
lack	O
of	O
clinical	O
evidence	O
supporting	O
its	O
use	O
at	O
the	O
moment	O
.	O

The	O
urea	O
cycle	O
is	O
a	O
series	O
of	O
metabolic	O
reactions	O
that	O
convert	O
ammonia	O
into	O
urea	O
in	O
order	O
to	O
eliminate	O
it	O
from	O
the	O
body	O
.	O

Urea	O
cycle	O
disorders	O
are	O
characterized	O
by	O
hyperammonemia	B-DIS
which	O
can	O
cause	O
irreversible	O
damages	O
in	O
central	O
nervous	O
system	O
.	O

We	O
report	O
a	O
series	O
of	O
three	O
newborns	O
presenting	O
irritability	B-DIS
poor	O
feeding	O
and	O
tachypnea	B-DIS
.	O

Their	O
first	O
gas	O
analysis	O
revealed	O
respiratory	B-DIS
alkalosis	I-DIS
.	O

Hyperammonemia	B-DIS
was	O
confirmed	O
and	O
three	O
different	O
enzymatic	O
blocks	O
in	O
the	O
urea	O
cycle	O
were	O
diagnosed	O
.	O

Immediate	O
treatment	O
consisted	O
in	O
the	O
removal	O
of	O
ammonia	O
by	O
reduction	O
of	O
the	O
catabolic	O
state	O
dietary	O
adjustments	O
use	O
of	O
nitrogen	O
scavenging	O
agents	O
and	O
ultimately	O
hemodiafiltration	O
.	O

Hyperammonemia	B-DIS
is	O
a	O
medical	O
emergency	O
whose	O
treatment	O
should	O
not	O
be	O
delayed	O
.	O

This	O
report	O
aims	O
to	O
highlight	O
the	O
importance	O
of	O
suspecting	O
urea	O
cycle	O
disorders	O
in	O
newborns	O
with	O
aspecific	O
signs	O
of	O
hyperammonemia	B-DIS
and	O
respiratory	B-DIS
alkalosis	I-DIS
and	O
to	O
sum	O
up	O
the	O
broad	O
lines	O
of	O
hyperammonemia	B-DIS
management	O
.	O

Background	O
We	O
evaluated	O
the	O
association	O
between	O
maternal	O
antiretrovirals	O
ARVs	O
during	O
pregnancy	O
and	O
infant	O
congenital	B-DIS
anomalies	I-DIS
CAs	O
utilizing	O
data	O
from	O
the	O
National	O
Institute	O
of	O
Child	O
Health	O
and	O
Human	O
Development	O
International	O
Site	O
Development	O
Initiative	O
Perinatal	O
Study	O
.	O

Methods	O
The	O
study	O
population	O
consisted	O
of	O
first	O
singleton	O
pregnancies	O
on	O
study	O
or	O
=	O
20	O
weeks	O
gestation	O
among	O
women	O
enrolled	O
in	O
NISDI	O
from	O
Argentina	B-LOC
and	O
Brazil	B-LOC
who	O
delivered	O
between	O
September	O
2002	O
and	O
October	O
2007	O
.	O

CAs	O
were	O
defined	O
as	O
any	O
major	O
structural	O
or	O
chromosomal	B-DIS
abnormality	I-DIS
or	O
a	O
cluster	O
of	O
2	O
or	O
more	O
minor	O
abnormalities	O
according	O
to	O
the	O
conventions	O
of	O
the	O
Antiretroviral	O
Pregnancy	O
Registry	O
.	O

CAs	O
were	O
identified	O
from	O
fetal	O
ultrasound	O
study	O
visit	O
and	O
death	B-DIS
reports	O
.	O

Prevalence	B-EPI
rates	O
[	O
number	O
of	O
CAs	O
per	O
100	O
live	O
births	O
LBs	O
]	O
were	O
calculated	O
for	O
specific	O
ARVs	O
classes	O
of	O
ARVs	O
and	O
overall	O
exposure	O
to	O
ARVs	O
.	O

Results	O
Of	O
1229	O
women	O
enrolled	O
995	O
pregnancy	O
outcomes	O
974	O
LBs	O
met	O
the	O
inclusion	O
criteria	O
.	O

Of	O
these	O
60	O
infants	O
59	O
LBs	O
and	O
1	O
stillbirth	O
had	O
at	O
least	O
1	O
CA	O
.	O

The	O
overall	O
prevalence	B-EPI
of	O
CAs	O
per	O
100	O
LBs	O
was	O
6.2	B-STAT
[	I-STAT
95	I-STAT
%	I-STAT
confidence	O
interval	O
CI	O
4.6	O
to	O
7.7	O
]	O
.	O

The	O
prevalence	B-EPI
of	O
CAs	O
after	O
first	O
trimester	O
ARVs	O
6.2	O
;	O
95	B-STAT
%	I-STAT
CI	O
3.1	O
to	O
9.3	O
was	O
similar	O
to	O
that	O
after	O
second	O
6.8	O
;	O
95	B-STAT
%	I-STAT
CI	O
4.5	O
to	O
9.0	O
or	O
third	O
trimester	O
4.3	O
;	O
95	B-STAT
%	I-STAT
CI	O
1.5	O
to	O
7.2	O
exposure	O
.	O

The	O
rate	O
of	O
CAs	O
identified	O
within	O
7	O
days	O
of	O
delivery	O
was	O
2.3695	B-STAT
%	I-STAT
CI	O
1.4	O
to	O
3.3	O
.	O

Conclusions	O
The	O
prevalence	B-EPI
of	O
CAs	O
after	O
first	O
trimester	O
exposure	O
to	O
ARVs	O
was	O
similar	O
to	O
that	O
after	O
second	O
or	O
third	O
trimester	O
exposure	O
.	O

Continued	O
surveillance	O
for	O
CAs	O
among	O
children	O
exposed	O
to	O
ARVs	O
during	O
gestation	O
is	O
needed	O
.	O

Background	O
Given	O
recent	O
reports	O
of	O
percutaneous	O
closure	O
of	O
sinus	B-DIS
venosus	I-DIS
atrial	I-DIS
septal	I-DIS
defects	I-DIS
we	O
reviewed	O
our	O
experience	O
with	O
surgical	O
repair	O
.	O

Owing	O
to	O
the	O
high	O
incidence	B-EPI
of	O
arrhythmias	B-DIS
with	O
the	O
two	O
-	O
patch	O
technique	O
since	O
2001	O
we	O
have	O
used	O
either	O
one	O
-	O
patch	O
repairs	O
or	O
the	O
Warden	O
procedure	O
.	O

Methods	O
A	O
retrospective	O
review	O
was	O
performed	O
of	O
pediatric	O
patients	O
undergoing	O
sinus	O
venosus	O
atrial	O
septal	O
defect	O
repair	O
at	O
our	O
institution	O
from	O
January	O
11990	O
to	O
July	O
12018	O
.	O

Standard	O
demographic	O
data	O
such	O
as	O
echocardiographic	O
and	O
cross	O
-	O
sectional	O
imaging	O
along	O
with	O
operative	O
details	O
and	O
clinical	O
echocardiographic	O
outcomes	O
were	O
collected	O
.	O

Results	O
The	O
cohort	O
included	O
144	O
patients	O
with	O
a	O
median	O
age	O
of	O
4.3	O
years	O
interquartile	O
range	O
8.5	O
.	O

Inferior	O
SVASD	O
was	O
present	O
in	O
24	O
patients	O
17	B-STAT
%	I-STAT
.	O

A	O
single	O
autologous	O
untreated	O
pericardial	O
patch	O
was	O
used	O
for	O
114	O
patients	O
79	B-STAT
%	I-STAT
a	O
two	O
-	O
patch	O
technique	O
for	O
20	O
patients	O
14	B-STAT
%	I-STAT
last	O
performed	O
in	O
2000	O
and	O
a	O
Warden	O
procedure	O
in	O
10	O
patients	O
7	B-STAT
%	I-STAT
.	O

Median	O
length	O
of	O
stay	O
was	O
4	O
days	O
interquartile	O
range	O
2	O
.	O

On	O
echocardiogram	O
follow	O
-	O
up	O
no	O
patient	B-DIS
had	I-DIS
pulmonary	I-DIS
vein	O
stenosis	O
.	O

One	O
patient	O
who	O
had	O
the	O
Warden	O
procedure	O
required	O
a	O
balloon	O
dilation	O
of	O
the	O
superior	O
caval	O
vein	O
2	O
years	O
postoperatively	O
and	O
a	O
stent	O
3	O
years	O
later	O
.	O

Two	B-DIS
-	O
patch	O
patients	O
were	O
substantially	O
less	O
likely	O
to	O
be	O
in	O
normal	O
sinus	O
rhythm	O
41	B-STAT
%	I-STAT
on	O
postoperative	O
electrocardiograms	O
compared	O
with	O
the	O
other	O
two	O
techniques	O
81	B-STAT
%	I-STAT
one	O
-	O
patch	O
and	O
89	B-STAT
%	I-STAT
Warden	O
P	O
=	O
.02	O
.	O

Conclusions	O
The	O
great	O
majority	O
of	O
patients	O
with	O
sinus	B-DIS
venosus	I-DIS
atrial	I-DIS
septal	I-DIS
defects	I-DIS
can	O
be	O
successfully	O
repaired	O
with	O
a	O
single	O
patch	O
of	O
autologous	O
pericardium	O
.	O

We	O
transitioned	O
to	O
using	O
either	O
a	O
single	O
pericardial	O
patch	O
or	O
the	O
Warden	O
procedure	O
resulting	O
in	O
a	O
higher	O
frequency	O
of	O
normal	O
sinus	O
rhythm	O
on	O
postoperative	O
electrocardiograms	O
.	O

Background	O
Acute	O
colonic	O
pseudo	O
-	O
obstruction	O
ACPO	B-DIS
or	I-DIS
Ogilvie	I-DIS
's	O
syndrome	O
occurs	O
in	O
0.22	B-STAT
%	I-STAT
-7	O
%	O
of	O
patients	O
undergoing	O
surgery	O
with	O
a	O
mortality	O
of	O
up	B-STAT
to	I-STAT
46	I-STAT
%	I-STAT
.	O

ACPO	B-DIS
increased	O
median	O
hospital	O
days	O
versus	O
control	O
in	O
spinal	O
surgery	O
14	O
vs.	O
6	O
days	O
;	O
P	O
<	O
0.001	O
.	O

If	O
defined	O
as	O
postoperative	B-DIS
ileus	I-DIS
the	O
incidence	B-EPI
was	O
7	B-STAT
%	I-STAT
-13.4	O
%	O
.	O

Postoperative	B-DIS
ileus	I-DIS
is	O
associated	O
with	O
2.9	O
additional	O
hospital	O
days	O
and	O
an	O
$	O
80000	O
increase	O
in	O
cost	O
per	O
patient	O
.	O

We	O
present	O
a	O
case	O
of	O
ACPO	B-DIS
in	O
an	O
adult	O
patient	O
undergoing	O
spinal	O
fusion	O
for	O
correction	O
of	O
scoliosis	B-DIS
and	O
review	O
the	O
available	O
literature	O
to	O
outline	O
clinical	O
characteristics	O
and	O
surgical	O
outcomes	O
.	O

Case	O
description	O
The	O
patient	O
was	O
a	O
31	O
-	O
year	O
-	O
old	O
woman	B-DIS
with	O
untreated	O
advanced	O
scoliosis	O
with	O
no	O
history	O
of	O
neurologic	O
issues	O
.	O

T2	O
-	O
L3	O
spinal	O
instrumentation	O
and	O
fusion	O
was	O
completed	O
.	O

Plain	O
abdominal	O
radiography	O
showed	O
of	O
dilated	B-DIS
cecum	I-DIS
11	I-DIS
cm	I-DIS
and	O
the	O
department	O
of	O
general	O
surgery	O
was	O
consulted	O
.	O

Neostigmine	O
administration	O
was	O
planned	O
after	O
conservative	O
treatment	O
failure	O
after	O
transfer	O
to	O
the	O
intensive	O
care	O
unit	O
.	O

The	O
patient	O
was	O
discharged	O
home	O
with	O
no	O
recurrenc	O
60	O
days	O
.	O

Thirty	O
cases	O
were	O
found	O
in	O
our	O
literature	O
review	O
using	O
PubMed	O
and	O
Embase	O
databases	O
and	O
summarized	O
.	O

Conclusions	O
Of	O
30	O
cases	O
reviewed	O
only	O
3	O
cases	O
of	O
ACPO	B-DIS
were	O
specific	O
to	O
patients	O
undergoing	O
spinal	O
fusion	O
for	O
scoliosis	B-DIS
.	O

According	O
to	O
the	O
literature	O
20	B-STAT
%	I-STAT
of	O
patients	O
had	O
resolution	O
with	O
conservative	O
treatment	O
40	B-STAT
%	I-STAT
with	O
neostigmine	O
and	O
30	B-STAT
%	I-STAT
with	O
surgical	O
intervention	O
.	O

Other	O
noninvasive	O
treatments	O
may	O
have	O
similar	O
efficacy	O
in	O
preventing	O
complications	O
leading	O
to	O
surgical	O
invention	O
.	O

Sixty	O
clinical	O
trials	O
and	O
9	O
systematic	O
reviews	O
were	O
summarized	O
with	O
an	O
updated	O
management	O
algorithm	O
.	O

In	O
this	O
paper	O
the	O
author	O
enumerates	O
cardiac	B-DIS
defects	I-DIS
with	O
a	O
functionally	O
single	O
ventricle	O
summarizes	O
single	O
ventricle	O
physiology	O
presents	O
a	O
summary	O
of	O
management	O
strategies	O
to	O
address	O
the	O
single	O
ventricle	B-DIS
defects	I-DIS
goes	O
over	O
the	O
steps	O
of	O
staged	O
total	O
cavo	O
-	O
pulmonary	O
connection	O
cites	B-EPI
the	O
prevalence	O
of	O
inter	O
-	O
stage	O
mortality	O
names	O
the	O
causes	O
of	O
inter	O
-	O
stage	O
mortality	O
discusses	O
strategies	O
to	O
address	O
the	O
inter	O
-	O
stage	O
mortality	O
reviews	O
post	O
-	O
Fontan	O
issues	O
and	O
introduces	O
alternative	O
approaches	O
to	O
Fontan	O
circulation	O
.	O

Diarrhoea	B-DIS
lasting	O
longer	O
than	O
14	O
days	O
and	O
failing	O
to	O
respond	O
to	O
conventional	O
management	O
is	O
defined	O
as	O
severe	O
and	O
protracted	O
diarrhoea	B-DIS
SD	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
prevalence	B-EPI
pathogens	O
and	O
prognosis	O
of	O
SD	B-DIS
in	O
primary	B-DIS
immunodeficiency	I-DIS
diseases	I-DIS
PIDs	I-DIS
.	O

Among	O
246	O
patients	O
with	O
predominantly	B-DIS
paediatric	I-DIS
-	I-DIS
onset	O
PIDs	O
from	O
2003	O
-	O
201521	O
[	O
Btk	O
six	O
IL2RG	O
four	O
WASP	O
CD40L	O
gp91	O
three	O
each	O
gp47	O
RAG2	O
one	O
each	O
]	O
and	O
five	B-DIS
[	O
CVID	B-DIS
four	O
SCID	O
one	O
]	O
without	O
identified	O
mutations	B-DIS
had	O
SD	O
before	O
prophylactic	O
treatment	O
.	O

Detectable	O
pathogens	O
included	O
pseudomonas	O
salmonella	O
six	O
each	O
E.	O
coli	O
cytomegalovirus	B-DIS
coxsackie	I-DIS
virus	O
and	O
cryptosporidium	O
one	O
each	O
all	O
of	O
whom	O
improved	O
after	O
a	O
mean	O
17	O
days	O
of	O
antibiotics	O
and/or	O
IVIG	O
treatment	O
.	O

Seven	O
7/26	B-STAT
;	O
27.0	B-STAT
%	I-STAT
patients	O
died	O
[	O
respiratory	B-DIS
failure	I-DIS
four	O
lymphoma	O
sepsis	B-DIS
and	O
intracranial	B-DIS
haemorrhage	I-DIS
one	O
each	O
]	O
.	O

The	O
patients	O
with	O
WAS	B-DIS
CGD	I-DIS
and	O
CD40L	O
and	O
SD	B-DIS
had	O
a	O
higher	O
mortality	O
rate	O
than	O
those	O
without	O
.	O

Another	O
five	O
males	O
with	O
mutant	O
XIAP	O
STAT1	O
FOXP3	O
one	O
each	O
and	O
STAT3	O
two	O
had	O
undetectable	O
-	O
pathogenic	B-DIS
refractory	O
diarrhoea	O
RD	O
that	O
persiste	O
21	O
days	O
despite	O
aggressive	O
antibiotic	O
/	O
steroid	O
treatment	O
and	O
directly	O
resulted	O
in	O
mortality	O
.	O

For	O
the	O
patients	O
with	O
RD	B-DIS
without	O
anti	O
-	O
inflammatory	O
optimization	O
those	O
with	O
mutant	O
XIAP	O
and	O
FOXP3	O
died	B-DIS
of	I-DIS
Crohn's	O
-	O
like	O
colitis	O
and	O
electrolyte	O
exhaustion	O
in	O
awaiting	O
transplantation	O
while	O
transplantation	O
cured	O
the	O
STAT1	O
patient	O
.	O

Introduction	O
Obstructive	O
sleep	O
apnea	B-DIS
is	O
highly	O
prevalent	O
in	O
non	B-DIS
-	I-DIS
syndromic	I-DIS
Pierre	O
Robin	O
sequence	O
patients	O
.	O

Studies	O
have	O
found	O
a	O
probable	O
relationship	O
between	O
obstructive	B-DIS
sleep	I-DIS
apnea	I-DIS
and	O
nasal	B-DIS
obstruction	I-DIS
and	O
between	O
obstructive	B-DIS
sleep	I-DIS
apnea	I-DIS
and	O
enuresis	B-DIS
.	O

Assessment	O
of	O
the	O
relationship	O
between	O
these	O
variables	O
in	O
non	B-DIS
-	I-DIS
syndromic	I-DIS
Pierre	O
Robin	O
sequence	O
patients	O
is	O
scarce	O
.	O

Objective	O
The	O
present	O
study	O
aims	O
to	O
evaluate	O
the	O
relationship	O
between	O
symptoms	O
of	O
obstructive	B-DIS
sleep	I-DIS
apnea	I-DIS
nasal	I-DIS
obstruction	I-DIS
and	O
enuresis	B-DIS
determining	O
the	O
prevalence	B-EPI
of	O
symptoms	O
suggestive	O
of	O
these	O
conditions	O
in	O
schoolchildren	O
with	O
non	B-DIS
-	I-DIS
syndromic	I-DIS
Pierre	I-DIS
Robin	O
sequence	O
and	O
describe	B-EPI
the	O
prevalence	O
of	B-DIS
excessive	I-DIS
daytime	O
sleepiness	B-DIS
habitual	O
snoring	B-DIS
and	I-DIS
voiding	O
dysfunction	O
symptoms	O
associated	B-DIS
with	O
enuresis	O
.	O

Methods	O
This	O
was	O
a	O
prospective	O
analytical	O
cross	O
-	O
sectional	O
study	O
developed	O
at	O
a	O
reference	O
center	O
.	O

Anthropometric	O
measurements	O
and	O
a	O
structured	O
clinical	O
interview	O
were	O
carried	O
out	O
in	O
a	O
sample	O
of	O
48	O
patients	O
.	O

The	O
instruments	O
`	O
`	O
sleep	B-DIS
disorders	I-DIS
scale	O
in	O
children	O
''	O
`	O
`	O
nasal	O
congestion	O
index	O
questionnaire	O
''	O
CQ-5	O
and	O
the	O
`	O
`	O
voiding	B-DIS
dysfunction	I-DIS
symptom	O
score	O
questionnaire	O
''	O
were	O
used	O
.	O

Statistical	O
analysis	O
was	O
performed	O
for	O
p	O
<	O
0.05	O
.	O

Results	O
Positive	O
`	O
`	O
sleep	B-DIS
disorders	I-DIS
scale	O
in	O
children	O
''	O
scores	O
for	O
obstructive	B-DIS
sleep	I-DIS
apnea	I-DIS
and	O
CQ-5	O
for	O
nasal	B-DIS
obstruction	I-DIS
were	O
observed	O
in	O
38.78	B-STAT
%	I-STAT
and	O
16.33	B-STAT
%	I-STAT
respectively	O
.	O

Enuresis	B-DIS
was	O
reported	O
in	O
16.33	B-STAT
%	I-STAT
of	O
children	O
being	O
characterized	O
as	O
primary	O
in	O
71.43	B-STAT
%	I-STAT
and	O
polysymptomatic	O
in	O
55.55	B-STAT
%	I-STAT
;	O
according	O
to	O
the	O
`	O
`	O
voiding	B-DIS
dysfunction	I-DIS
symptom	O
score	O
questionnaire	O
''	O
.	O

There	O
was	O
a	O
significant	O
relationship	O
between	O
nasal	B-DIS
obstruction	I-DIS
and	O
obstructive	B-DIS
sleep	I-DIS
apnea	I-DIS
symptoms	O
p	O
<	O
0.05	O
but	O
no	O
significance	O
was	O
found	O
between	O
obstructive	B-DIS
sleep	I-DIS
apnea	I-DIS
symptoms	O
and	O
enuresis	B-DIS
and	O
between	O
nasal	B-DIS
obstruction	I-DIS
and	O
enuresis	B-DIS
.	O

The	O
prevalence	B-EPI
of	O
excessive	O
daytime	B-DIS
sleepiness	I-DIS
was	O
12.24	B-STAT
%	I-STAT
and	O
of	O
habitual	O
snoring	O
48.98	B-STAT
%	I-STAT
.	O

A	O
family	O
history	O
of	O
enuresis	B-DIS
younger	O
age	O
in	O
years	O
and	O
a	O
positive	O
`	O
`	O
voiding	B-DIS
dysfunction	I-DIS
symptom	O
score	O
questionnaire	O
''	O
score	O
were	O
associated	O
with	O
a	O
higher	O
prevalence	B-EPI
of	O
enuresis	B-DIS
p	O
<	O
0.05	O
.	O

Conclusion	O
Children	O
with	O
non	B-DIS
-	I-DIS
syndromic	I-DIS
Pierre	I-DIS
Robin	O
sequence	O
are	O
at	O
high	O
risk	B-DIS
for	I-DIS
obstructive	I-DIS
sleep	O
apnea	O
symptoms	B-DIS
and	I-DIS
habitual	O
snoring	O
with	O
a	O
correlation	O
being	O
observed	B-DIS
between	I-DIS
nasal	O
obstruction	B-DIS
and	I-DIS
obstructive	I-DIS
sleep	O
apnea	O
symptoms	O
.	O

In	O
addition	O
the	O
study	O
showed	O
that	O
non	B-DIS
-	I-DIS
syndromic	I-DIS
Pierre	I-DIS
Robin	I-DIS
sequence	I-DIS
obstructive	I-DIS
sleep	O
apnea	B-DIS
and	I-DIS
nasal	O
obstruction	O
symptoms	O
were	O
not	O
risk	O
factors	B-DIS
for	O
enuresis	O
in	O
these	O
patients	O
.	O

Aim	O
Heart	O
failure	O
is	O
increasing	O
in	O
Japan	B-LOC
in	O
particular	O
that	O
with	O
preserved	O
ejection	O
fraction	O
HFpEF	O
prevalent	O
in	O
older	O
-	O
aged	O
patients	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
pathophysiology	O
during	O
the	O
early	O
stage	O
of	O
left	O
ventricular	B-DIS
LV	I-DIS
diastolic	I-DIS
dysfunction	I-DIS
by	O
the	O
quantitative	O
proteome	O
analysis	O
of	O
human	O
myocardium	O
.	O

Methods	O
Among	O
331	O
post	O
-	O
mortem	O
autopsy	O
patients	O
we	O
selected	O
23	O
patients	O
aged	O
79	O
±	O
9.6	O
years	O
with	O
echocardiographic	O
data	O
and	O
without	O
major	O
comorbidities	B-DIS
except	O
hypertension	O
.	O

Cryopreserved	O
autopsy	O
tissue	O
of	O
the	O
LV	O
myocardium	O
was	O
subjected	O
to	O
proteome	O
analysis	O
.	O

LV	O
diastolic	O
function	O
was	O
evaluated	O
by	O
echocardiographic	O
data	O
.	O

Thirteen	O
patients	O
were	O
classified	O
into	O
the	O
impaired	O
diastolic	O
function	O
IDF	O
group	O
and	O
10	O
the	O
normal	O
cardiac	O
function	O
group	O
.	O

We	O
performed	O
comparative	O
proteome	O
analysis	O
between	O
the	O
IDF	O
and	O
normal	O
groups	O
by	O
isobaric	O
tags	O
for	O
relative	O
and	O
absolute	O
quantitation	O
iTRAQ	O
using	O
nano	O
-	O
liquid	O
chromatography	O
-	O
tandem	O
mass	O
spectrometry	O
.	O

Results	O
The	O
iTRAQ	O
-	O
based	O
proteome	O
analysis	O
revealed	O
57	O
differentially	O
expressed	O
proteins	O
in	O
the	O
IDF	O
group	O
.	O

Molecular	O
network	O
analysis	O
of	O
differentially	O
expressed	O
proteins	O
indicated	O
that	O
endoplasmic	O
reticulum	O
ER	O
stress	O
was	O
a	O
potentially	O
important	O
event	O
.	O

Furthermore	O
the	O
expressions	O
of	O
proteins	O
associated	O
with	O
the	O
ER	O
stress	O
response	O
such	O
as	O
glucose	O
-	O
regulated	O
protein	O
78	O
kDa	O
inositol	O
-	O
requiring	O
kinase	O
1α	O
and	O
spliced	O
X	O
-	O
box	O
binding	O
protein	O
1	O
were	O
significantly	O
decreased	O
in	O
the	O
IDF	O
group	O
.	O

Conclusions	O
This	O
study	O
suggested	O
that	O
reduced	O
ER	O
stress	O
responses	O
were	O
involved	O
during	O
the	O
early	O
stage	O
of	O
LV	B-DIS
diastolic	I-DIS
dysfunction	I-DIS
.	O

Geriatr	O
Gerontol	O
Int	O
••	O
;	O
••	O
••-••	O
Geriatr	O
Gerontol	O
Int	O
2021	O
;	O
••	O
••-••	O
.	O

Objective	O
To	O
assess	O
the	O
prevalence	B-EPI
and	O
patterns	O
of	O
hypodontia	B-DIS
in	I-DIS
nonsyndromic	I-DIS
Pierre	I-DIS
Robin	I-DIS
sequence	I-DIS
PRS	O
and	O
compare	O
it	O
with	O
hypodontia	B-DIS
in	I-DIS
nonsyndromic	I-DIS
isolated	I-DIS
cleft	B-DIS
palates	I-DIS
and	O
isolated	O
cleft	B-DIS
lips	I-DIS
.	O

Design	O
Retrospective	O
cohort	O
study	O
.	O

Setting	O
Alder	O
Hey	O
Children	O
's	O
Hospital	O
United	B-LOC
Kingdom	I-LOC
.	O

Patients	O
Patients	O
with	O
nonsyndromic	B-DIS
PRS	I-DIS
group	O
1	O
isolated	O
cleft	B-DIS
palate	I-DIS
group	O
2	O
and	O
isolated	O
cleft	B-DIS
lip	I-DIS
group	O
3	O
.	O

Main	O
outcome	O
measures	O
Hypodontia	B-DIS
in	O
the	O
permanent	O
dentition	O
assessed	O
from	O
orthopantomographs	O
.	O

Results	O
A	O
total	O
of	O
154	O
patients	O
were	O
included	O
.	O

Group	O
1	O
had	O
the	O
highest	O
incidence	B-EPI
of	O
hypodontia	O
with	O
47	B-STAT
%	I-STAT
having	O
at	O
least	O
one	O
tooth	O
congenitally	O
absent	O
.	O

Groups	O
2	O
and	O
3	O
had	O
reduced	O
rates	O
of	O
hypodontia	O
with	O
27	B-STAT
%	I-STAT
and	I-STAT
19	O
%	O
of	O
the	O
groups	O
missing	O
teeth	O
respectively	O
;	O
93	B-STAT
%	I-STAT
of	O
cases	O
of	O
hypodontia	O
in	O
group	O
1	O
involved	O
the	O
absence	O
of	O
at	O
least	O
one	O
second	O
premolar	O
.	O

Of	O
these	O
patients	O
there	O
was	O
found	O
to	O
be	O
bilateral	O
agenesis	O
of	O
second	O
premolars	O
in	O
50	B-STAT
%	I-STAT
of	O
cases	O
.	O

Conclusions	O
Patients	O
with	O
PRS	O
and	O
cleft	B-DIS
palates	I-DIS
are	O
more	O
likely	O
to	O
have	O
hypodontia	O
than	O
those	O
with	O
isolated	O
cleft	B-DIS
palates	I-DIS
or	O
unilateral	O
cleft	B-DIS
lips	I-DIS
.	O

Patients	O
with	O
PRS	B-DIS
have	O
more	O
severe	O
hypodontia	O
than	O
those	O
with	O
isolated	O
cleft	B-DIS
palates	I-DIS
or	O
unilateral	O
cleft	B-DIS
lips	I-DIS
.	O

Bilateral	O
agenesis	B-DIS
of	I-DIS
lower	I-DIS
second	I-DIS
premolars	O
is	O
a	O
commonly	O
seen	O
pattern	O
among	O
patients	O
with	O
PRS	O
.	O

In	O
this	O
large	O
UK	B-LOC
study	O
a	O
similar	O
prevalence	B-EPI
and	O
pattern	O
of	O
hypodontia	O
to	O
other	O
nonsyndromic	B-DIS
PRS	I-DIS
populations	O
worldwide	O
has	O
been	O
demonstrated	O
.	O

Auditory	B-DIS
neuropathy	I-DIS
spectrum	O
disorder	B-DIS
ANSD	I-DIS
refers	O
to	O
a	O
range	O
of	O
hearing	B-DIS
impairments	I-DIS
characterized	O
by	O
deteriorated	O
speech	O
perception	O
despite	O
relatively	O
preserved	O
pure	O
-	O
tone	O
detection	O
thresholds	O
.	O

Affected	O
individuals	O
usually	O
present	O
with	O
abnormal	B-DIS
auditory	I-DIS
brainstem	I-DIS
responses	O
ABRs	O
but	O
normal	O
otoacoustic	O
emissions	O
OAEs	O
.	O

These	O
electrophysiological	O
characteristics	O
have	O
led	O
to	O
the	O
hypothesis	O
that	O
ANSD	B-DIS
may	O
be	O
caused	O
by	O
various	O
dysfunctions	O
at	O
the	O
cochlear	O
inner	O
hair	O
cell	O
IHC	O
and	O
spiral	O
ganglion	O
neuron	O
SGN	O
levels	O
while	O
the	O
activity	O
of	O
outer	O
hair	O
cells	O
OHCs	O
is	O
preserved	O
resulting	O
in	O
discrepancies	O
between	O
pure	O
-	O
tone	O
and	O
speech	O
comprehension	O
thresholds	O
.	O

The	O
exact	O
prevalence	B-EPI
of	O
ANSD	B-DIS
remains	O
unknown	O
;	O
clinical	O
findings	O
show	O
a	O
large	O
variability	O
among	O
subjects	O
with	O
hearing	B-DIS
impairment	I-DIS
ranging	O
from	O
mild	O
to	O
profound	O
hearing	B-DIS
loss	I-DIS
.	O

A	O
wide	O
range	O
of	O
prenatal	O
and	O
postnatal	O
etiologies	B-DIS
have	O
been	O
proposed	O
.	O

The	O
study	O
of	O
genetics	O
and	O
of	O
the	O
implicated	O
sites	O
of	O
lesion	O
correlated	O
with	O
clinical	O
findings	O
have	O
also	O
led	O
to	O
a	O
better	O
understanding	O
of	O
the	O
molecular	O
mechanisms	O
underlying	O
the	O
various	O
forms	O
of	O
ANSD	B-DIS
and	O
may	O
guide	O
clinicians	O
in	O
better	O
screening	O
assessment	O
and	O
treatment	O
of	O
ANSD	B-DIS
patients	O
.	O

Besides	O
OAEs	O
and	O
ABRs	O
audiological	O
assessment	O
includes	O
stapedial	O
reflex	O
measurements	O
supraliminal	O
psychoacoustic	O
tests	O
electrocochleography	O
ECochG	O
auditory	O
steady	O
-	O
state	O
responses	O
ASSRs	O
and	O
cortical	O
auditory	O
evoked	O
potentials	O
CAEPs	O
.	O

Hearing	O
aids	O
are	O
indicated	O
in	O
the	O
treatment	O
of	O
ANSD	B-DIS
with	O
mild	O
to	O
moderate	O
hearing	B-DIS
loss	I-DIS
whereas	O
cochlear	O
implantation	O
is	O
the	O
first	O
choice	O
of	O
treatment	O
in	O
case	O
of	O
profound	O
hearing	B-DIS
loss	I-DIS
especially	O
in	O
case	O
of	O
IHC	O
presynaptic	O
disorders	O
or	O
in	O
case	O
of	O
poor	O
auditory	O
outcomes	O
with	O
conventional	O
hearing	O
aids	O
.	O

Tight	O
junctions	O
are	O
cellular	O
junctions	O
that	O
play	O
a	O
major	O
role	O
in	O
the	O
epithelial	O
barrier	O
function	O
.	O

In	O
the	O
inner	O
ear	O
claudins	O
occludin	O
tricellulin	O
and	O
angulins	O
form	O
the	O
bicellular	O
or	O
tricellular	O
binding	O
of	O
membrane	O
proteins	O
.	O

In	O
these	O
one	O
type	O
of	O
claudin	O
gene	O
CLDN14	O
was	O
reported	O
to	O
be	O
responsible	O
for	O
human	O
hereditary	B-DIS
hearing	I-DIS
loss	I-DIS
DFNB29	I-DIS
.	O

Until	O
now	O
nine	O
pathogenic	O
variants	O
have	O
been	O
reported	O
and	O
most	O
phenotypic	O
features	O
remain	O
unclear	O
.	O

In	O
the	O
present	O
study	O
genetic	O
screening	O
for	O
68	O
previously	O
reported	O
deafness	B-DIS
causative	O
genes	O
was	O
carried	O
out	O
to	O
identify	O
CLDN14	O
variants	O
in	O
a	O
large	O
series	O
of	O
Japanese	O
hearing	B-DIS
loss	I-DIS
patients	O
and	O
to	O
clarify	O
the	O
prevalence	B-EPI
and	O
clinical	O
characteristics	O
of	O
DFNB29	B-DIS
in	O
the	O
Japanese	O
population	O
.	O

One	O
patient	O
had	O
a	O
homozygous	O
novel	O
variant	O
c.24	B-DIS
T	I-DIS
p.	O
Arg81Cys	B-STAT
0.04	I-STAT
%	I-STAT
1/2549	B-STAT
.	O

The	O
patient	O
showed	O
progressive	O
bilateral	O
hearing	B-DIS
loss	I-DIS
with	O
post	O
-	O
lingual	O
onset	O
.	O

Pure	O
-	O
tone	O
audiograms	O
indicated	O
a	B-DIS
high	I-DIS
-	O
frequency	O
hearing	O
loss	O
type	O
and	O
the	O
deterioration	O
gradually	O
spread	O
to	O
other	O
frequencies	O
.	O

The	O
patient	O
showed	O
normal	O
vestibular	O
function	O
.	O

Cochlear	O
implantation	O
improved	O
the	O
patient	O
's	O
sound	O
field	O
threshold	O
levels	O
but	O
not	O
speech	O
discrimination	O
scores	O
.	O

This	O
report	O
indicated	O
that	O
claudin-14	O
is	O
essential	O
for	O
maintaining	O
the	O
inner	O
ear	O
environment	O
and	O
suggested	O
the	O
possible	O
phenotypic	O
expansion	O
of	O
DFNB29	B-DIS
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
patient	O
with	O
a	O
tight	O
junction	O
variant	O
receiving	O
a	O
cochlear	O
implantation	O
.	O

Few	O
studies	O
have	O
investigated	O
transient	O
global	O
amnesia	B-DIS
TGA	O
in	O
the	O
context	O
of	O
a	O
concussion	B-DIS
and	O
the	O
concussion	B-DIS
sequelae	I-DIS
following	O
TGA	O
.	O

Here	O
we	O
review	O
the	O
case	O
of	O
a	O
43	O
-	O
year	O
-	O
old	O
male	O
with	O
onset	O
of	O
transient	O
global	B-DIS
anterograde	O
and	O
retrograde	O
amnesia	O
22	O
days	B-DIS
after	O
a	O
sustained	O
concussion	O
.	O

The	O
patient	O
's	O
head	O
CT	O
MRI	O
of	O
brain	O
and	O
EEG	O
were	O
reported	O
normal	O
and	O
the	O
patient	O
regained	O
full	O
cognitive	O
function	O
8	O
h	O
after	O
the	O
TGA	O
episode	O
with	O
no	O
recollection	O
of	O
the	O
conspiring	O
events	O
.	O

Following	O
the	O
TGA	O
episode	O
the	O
patient	O
experienced	O
notable	O
worsening	O
of	O
concussive	O
symptoms	O
including	O
headache	B-DIS
head	O
pressure	O
anxiety	B-DIS
neck	O
pain	O
feeling	O
slowed	O
down	O
fogginess	B-DIS
not	O
feeling	O
right	O
difficulty	O
remembering	O
and	O
fatigue	B-DIS
.	O

The	O
patient	O
remained	O
symptomatic	O
for	O
32	O
days	O
after	O
the	O
TGA	O
episode	O
.	O

We	O
suggest	O
that	O
a	O
lingering	O
window	O
of	O
post	O
-	O
concussion	O
cerebral	O
vulnerability	O
which	O
may	O
extend	O
beyond	O
clinical	O
recovery	O
could	O
lead	O
to	O
increased	O
susceptibility	O
to	B-DIS
acute	I-DIS
cognitive	O
deficits	O
such	O
as	O
TGA	O
.	O

Background	O
and	O
aim	O
This	O
study	O
aimed	O
to	O
describe	O
the	O
clinical	O
genetic	O
and	O
epidemiological	O
features	O
of	O
Charcot	B-DIS
-	I-DIS
Marie	O
-	O
Tooth	O
disease	O
CMT	O
in	O
Brazilian	O
patients	O
from	O
a	O
tertiary	O
center	O
and	O
to	O
compare	O
our	O
data	O
with	O
previously	O
published	O
findings	O
.	O

Methods	O
This	O
retrospective	O
observational	O
study	O
conducted	O
between	O
February	O
2015	O
and	O
July	O
2020	O
evaluated	O
503	O
patients	O
94	O
families	O
and	O
192	O
unrelated	O
individuals	O
diagnosed	O
with	O
CMT	B-DIS
.	O

Clinical	O
and	O
neurophysiological	O
data	O
were	O
obtained	O
from	O
electronic	O
medical	O
records	O
and	O
blood	O
samples	O
were	O
used	O
for	O
genetic	O
analyses	O
.	O

Multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
was	O
used	O
to	O
assess	O
duplications	O
/	O
deletions	O
in	O
PMP22	O
.	O

Sanger	O
sequencing	O
of	O
GJB1	B-DIS
was	O
performed	O
in	O
cases	O
of	O
suspected	O
demyelinating	B-DIS
CMT	I-DIS
.	O

Targeted	O
gene	O
panel	O
sequencing	O
was	O
used	O
for	O
the	O
remaining	O
negative	O
demyelinating	O
cases	O
and	O
all	O
axonal	B-DIS
CMT	I-DIS
cases	O
.	O

Results	O
The	O
first	O
decade	O
of	O
life	O
was	O
the	O
most	O
common	O
period	O
of	O
disease	O
onset	O
.	O

In	O
all	O
353	O
patients	O
had	O
demyelinating	B-DIS
CMT	I-DIS
39	O
had	O
intermediate	O
CMT	B-DIS
and	O
111	O
had	O
axonal	B-DIS
CMT	I-DIS
.	O

Pathogenic	O
or	O
likely	O
pathogenic	O
variants	O
were	O
identified	O
in	O
197	O
index	O
cases	O
.	O

The	O
most	O
common	O
causative	O
genes	O
among	O
probands	O
were	O
PMP22	B-DIS
duplication	O
n=116	O
58.88	B-STAT
%	I-STAT
GJB1	O
n=23	O
11.67	B-STAT
%	I-STAT
MFN2	O
n=12	O
6.09	B-STAT
%	I-STAT
GDAP1	O
n=7	O
3.55	B-STAT
%	I-STAT
MPZ	O
n=6	O
3.05	B-STAT
%	I-STAT
PMP22	O
point	O
mutation	O
n=6	O
3.05	B-STAT
%	I-STAT
NEFL	O
n=3	O
1.52	O
%	O
SBF2	O
n=3	O
1.52	B-STAT
%	I-STAT
and	O
SH3TC2	O
n=3	B-STAT
1.52	I-STAT
%	I-STAT
.	O

Other	O
identified	O
variants	O
were	O
≤1	B-STAT
%	I-STAT
of	O
index	O
cases	O
.	O

Interpretation	O
This	O
study	O
provides	O
further	O
data	O
on	O
the	O
frequency	O
of	O
CMT	B-DIS
subtypes	O
in	O
a	O
Brazilian	O
clinical	O
-	O
based	O
population	O
and	O
highlights	O
the	O
importance	O
of	O
rarer	O
and	O
previously	O
undiagnosed	O
variants	O
in	O
clinical	O
practice	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Neuroendocrine	B-DIS
tumors	I-DIS
NETs	O
are	O
rare	O
neoplasms	B-DIS
with	O
an	O
estimated	O
annual	O
incidence	B-EPI
of	O
6.9/100000	B-STAT
.	O

They	O
arise	O
from	O
cells	O
of	O
the	O
diffuse	O
endocrine	O
system	O
which	O
are	O
mainly	O
dispersed	O
throughout	O
the	O
gastrointestinal	B-DIS
GI	I-DIS
pancreatic	I-DIS
and	I-DIS
respiratory	I-DIS
tracts	I-DIS
.	O

The	O
incidence	B-EPI
of	O
GI	B-DIS
-	O
NETs	O
has	O
recently	O
begun	O
to	O
show	O
a	O
steady	O
increase	O
.	O

According	O
to	O
the	O
Surveillance	O
Epidemiology	O
and	O
End	O
Results	O
database	O
53	B-STAT
%	I-STAT
of	O
patients	O
with	O
NETs	O
present	O
with	O
localized	O
disease	O
20	B-STAT
%	I-STAT
with	O
locoregional	B-DIS
disease	I-DIS
and	O
27	B-STAT
%	I-STAT
with	O
distant	O
metastases	O
at	O
the	O
time	O
of	O
diagnosis	O
.	O

Surgery	O
is	O
the	O
mainstay	O
for	O
the	O
treatment	O
of	O
locoregional	B-DIS
GI	I-DIS
-	O
NETs	O
.	O

Endoscopic	O
resection	O
is	O
an	O
option	O
for	O
well	O
-	O
differentiated	O
early	O
GI	O
-	O
NETs	O
which	O
are	O
thought	O
to	O
very	O
rarely	O
metastasize	O
to	O
lymph	O
nodes	O
.	O

A	O
lesion	O
that	O
is	O
technically	O
difficult	O
to	O
resect	O
via	O
endoscopy	O
is	O
an	O
indication	O
for	O
local	O
resection	O
partial	O
resection	O
without	O
lymph	O
node	O
dissection	O
.	O

GI	O
-	O
NETs	O
with	O
possible	O
lymph	O
node	O
metastasis	O
is	O
an	O
indication	O
for	O
enterectomy	O
with	O
lymph	O
node	O
dissection	O
.	O

For	O
NETs	O
with	O
metastatic	O
lesions	O
cytoreduction	O
surgery	O
can	O
control	O
hormonal	O
hypersecretion	B-DIS
and	O
alleviate	O
symptoms	O
;	O
therefore	O
cytoreduction	O
surgery	O
is	O
recommended	O
.	O

The	O
indications	O
for	O
surgery	O
vary	O
and	O
are	O
based	O
on	O
the	O
organ	O
where	O
the	O
NET	O
arose	O
;	O
therefore	O
an	O
understanding	O
of	O
the	O
patient	O
's	O
clinical	O
state	O
and	O
individualized	O
treatment	O
that	O
is	O
based	O
on	O
the	O
characteristics	O
of	O
the	O
patient	O
's	O
GI	O
-	O
NET	O
is	O
needed	O
.	O

This	O
review	O
summarizes	O
surgical	O
treatments	O
of	O
GI	O
-	O
NETs	O
in	O
each	O
organ	O
.	O

Xanthogranulomatous	B-DIS
cholecystitis	I-DIS
XGC	I-DIS
is	O
a	O
rare	O
form	O
of	O
cholecystitis	B-DIS
characterized	O
by	O
the	O
presence	O
of	O
xanthogranuloma	B-DIS
prominent	O
yellow	O
structures	O
within	O
the	O
gallbladder	O
wall	O
that	O
is	O
very	O
often	O
lithiasic	O
.	O

When	O
XGC	B-DIS
presents	O
in	O
its	O
pseudo	O
-	O
tumoral	O
form	O
with	O
occasional	O
adjacent	O
organ	O
involvement	O
it	O
can	B-DIS
mimic	I-DIS
gallbladder	O
carcinoma	O
GBC	O
.	O

The	O
etiopathogenesis	O
of	O
XGC	B-DIS
is	O
inflammatory	B-DIS
destruction	I-DIS
of	O
Rokitansky	O
-	O
Aschoff	O
sinuses	O
containing	O
biliary	O
and	O
cholesterol	O
pigments	O
within	O
the	O
gallbladder	O
wall	O
;	O
this	O
leads	O
to	O
a	B-DIS
florid	I-DIS
granulomatous	I-DIS
histiocytic	I-DIS
inflammatory	O
reaction	O
.	O

The	O
prevalence	B-EPI
ranges	O
from	O
1.3	B-STAT
%	I-STAT
to	I-STAT
8.8	I-STAT
%	I-STAT
of	O
all	O
cholecystectomies	O
and	O
varies	O
from	O
country	O
to	O
country	O
;	O
XGC	B-DIS
occurs	O
predominantly	O
in	O
patients	O
over	O
50	O
years	O
of	O
age	O
and	O
is	O
equally	O
distributed	O
between	O
males	O
and	O
females	O
.	O

Its	O
association	O
with	O
GBC	O
remains	O
a	O
topic	O
of	O
debate	O
in	O
the	O
literature	O
between	O
0	B-STAT
and	I-STAT
20	I-STAT
%	I-STAT
.	O

Symptoms	O
are	O
non	O
-	O
specific	O
and	O
generally	O
similar	O
to	O
those	O
of	O
acute	B-DIS
or	I-DIS
chronic	O
cholecystitis	O
.	O

XGC	B-DIS
when	O
associated	O
with	O
altered	O
health	O
status	O
leads	O
to	O
the	O
suspicion	O
of	O
GBC	O
.	O

XGC	B-DIS
can	O
also	O
come	O
to	O
light	O
due	O
to	O
an	O
acute	O
complication	O
of	O
cholecystolithiasis	B-DIS
in	O
particular	O
gallstone	B-DIS
migration	O
.	O

Imaging	O
by	O
sonography	O
and	O
CT	O
scan	O
is	O
suggestive	O
but	O
magnetic	O
resonance	O
imaging	O
is	O
more	O
specific	O
.	O

In	O
difficult	O
cases	O
biopsy	O
may	O
be	O
necessary	O
to	O
eliminate	O
the	O
diagnosis	O
of	O
tumor	B-DIS
.	O

In	O
case	O
of	O
pre-	O
or	O
intra	O
-	O
operative	O
diagnostic	O
doubt	O
the	O
opinion	O
of	O
a	O
hepatobiliary	O
specialty	O
center	O
can	O
be	O
of	O
help	O
.	O

When	O
diagnosis	O
of	O
GBC	O
has	O
been	O
eliminated	O
laparoscopic	O
cholecystectomy	O
is	O
recommended	O
although	O
with	O
a	O
high	O
risk	O
of	O
conversion	O
to	O
laparotomy	O
and	O
complications	O
.	O

Carbimazole	O
CMZ	O
and	O
its	O
active	O
metabolite	O
methimazole	O
MMI	O
are	O
antithyroid	O
medications	O
which	O
can	O
result	O
in	O
MMI	O
/	O
CMZ	O
embryopathy	O
in	O
susceptible	O
individuals	O
.	O

The	O
incidence	B-EPI
of	O
birth	B-DIS
defects	I-DIS
related	O
to	O
MMI	O
/	O
CMZ	O
embryopathy	O
remains	O
unclear	O
as	O
several	O
epidemiologic	O
studies	O
failed	O
to	O
prove	O
a	O
correlation	O
despite	O
positive	O
case	O
-	O
control	O
studies	O
and	O
numerous	O
case	O
reports	O
.	O

Malformations	O
reported	O
in	O
exposed	O
individuals	O
and	O
commonly	O
recognized	O
as	O
MMI	O
/	O
CMZ	O
embryopathy	B-DIS
include	I-DIS
cutis	I-DIS
aplasia	I-DIS
of	I-DIS
the	I-DIS
scalp	I-DIS
choanal	I-DIS
atresia	I-DIS
esophageal	I-DIS
atresia	O
EA	B-DIS
tracheo	O
-	O
esophageal	B-DIS
fistula	I-DIS
TEF	I-DIS
persistent	O
vitelline	O
duct	O
athelia	O
/	O
hypothelia	O
and	O
subtle	O
facial	O
dysmorphisms	O
including	O
sparse	O
or	O
arched	O
eyebrows	O
.	O

Here	O
we	O
report	O
on	O
individuals	O
with	O
early	O
pregnancy	O
exposure	O
to	O
MMI	O
with	O
microtia	B-DIS
and	O
various	O
other	O
anomalies	B-DIS
associated	O
with	O
MMI	O
embryopathy	O
suggesting	O
that	O
microtia	B-DIS
is	O
also	O
seen	O
with	O
increased	O
frequency	O
after	O
prenatal	O
MMI	O
exposure	O
.	O

Additional	O
unusual	O
malformations	O
among	O
our	O
patients	O
include	O
a	O
previously	O
unreported	O
type	O
of	O
TEF	O
with	O
three	O
separate	O
esophageal	O
pouches	O
and	O
a	O
fistula	B-DIS
connecting	O
the	O
middle	O
pouch	O
to	O
the	O
trachea	O
in	O
one	O
child	O
and	O
absence	O
of	O
the	O
gall	O
bladder	O
in	O
another	O
.	O

An	O
enlarged	O
anterior	O
fontanel	O
was	O
seen	O
in	O
three	O
patients	O
and	O
clinodactyly	B-DIS
of	I-DIS
the	I-DIS
fifth	I-DIS
finger	O
was	O
noted	O
in	O
three	O
.	O

The	O
similarities	O
between	O
our	O
three	O
patients	O
with	O
microtia	B-DIS
after	O
MMI	O
exposure	O
and	O
the	O
two	O
previously	O
reported	O
with	O
microtia	B-DIS
after	O
CMZ	O
exposure	O
support	O
the	O
concept	O
of	O
microtia	O
being	O
related	O
to	O
the	O
MMI	O
/	O
CMZ	O
exposure	O
.	O

Recognition	O
of	O
microtia	B-DIS
as	O
a	O
manifestation	O
of	O
MMI	O
/	O
CMZ	O
embryopathy	O
will	O
likely	O
increase	O
the	O
number	O
of	O
diagnosed	O
cases	O
and	O
thus	O
affect	O
ascertainment	O
.	O

We	O
propose	O
diagnostic	O
criteria	O
for	O
MMI	O
/	O
CMZ	O
embryopathy	O
including	O
the	O
presence	O
of	O
at	O
least	O
one	O
major	O
characteristic	O
finding	O
.	O

Background	O
Biatrial	O
tachycardia	B-DIS
BiAT	O
is	O
a	O
rare	O
form	O
of	O
macroreentry	O
not	O
previously	O
characterized	O
in	O
adults	O
with	O
congenital	B-DIS
heart	I-DIS
disease	I-DIS
ACHD	I-DIS
OBJECTIVE	O
To	O
determine	O
the	O
prevalence	B-EPI
mechanisms	O
and	O
outcomes	O
of	O
catheter	O
ablation	O
for	O
BiAT	O
in	O
ACHD	B-DIS
.	O

Methods	O
All	O
ACHD	B-DIS
undergoing	O
catheter	O
ablation	O
for	O
macroreentrant	O
atrial	B-DIS
tachycardia	I-DIS
over	O
a	O
10	O
-	O
year	O
period	O
were	O
evaluated	O
for	O
evidence	O
of	O
BiAT	O
.	O

Patient	O
s	O
were	O
categorized	O
as	O
prior	O
Senning	O
Fontan	O
or	O
other	O
biventricular	O
operation	O
.	O

A	O
novel	O
biatrial	O
global	O
activation	O
histogram	O
GAH	O
analysis	O
was	O
used	O
to	O
demonstrate	O
the	O
presence	O
of	O
interatrial	O
connections	O
IAC	O
.	O

Results	O
Among	O
263	O
ACHD	B-DIS
BiAT	O
was	O
identified	O
at	O
11	O
procedures	O
in	O
10	O
patients	O
4.2	B-STAT
%	I-STAT
;	O
median	O
age	O
35	O
y	O
;	O
30	B-STAT
%	I-STAT
male	O
.	O

The	O
congenital	O
category	O
was	O
Fontan	O
in	O
6	O
Senning	B-LOC
in	O
3	O
and	O
biventricular	O
in	O
2	O
.	O

Diagnosis	O
of	O
BiAT	O
was	O
associated	O
with	O
ablation	O
era	O
and	O
mapping	O
technology	O
p	O
<	O
0.001	O
and	O
could	O
be	O
confirmed	O
with	O
a	O
novel	O
GAH	O
mapping	O
approach	O
for	O
normally	O
-	O
septated	O
atrial	O
connections	O
.	O

Catheter	O
ablation	O
targeted	O
an	O
IAC	O
in	O
5	O
cases	O
Bjork	O
Fontan	O
/	O
biventricular	O
operations	O
a	O
posterior	O
isthmus	O
in	O
3	O
Senning	O
operation	O
and	O
the	O
cavo	O
-	O
tricuspid	O
isthmus	O
CTI	O
or	O
equivalent	O
in	O
3	O
LT	O
Fontan	O
.	O

Recurrence	O
was	O
isolated	O
to	O
ablation	O
to	O
sites	O
at	O
the	O
expected	O
location	O
of	O
Bachmann	O
's	O
bundle	O
BB	O
and	O
durable	O
success	O
could	O
be	O
achieved	O
after	O
repeat	O
ablation	O
.	O

Conclusion	O
BiAT	O
occurs	O
in	O
approximately	B-STAT
4	I-STAT
%	I-STAT
of	O
ACHD	B-DIS
but	O
is	O
likely	O
significantly	O
underrecognized	O
.	O

BiAT	O
could	O
be	O
targeted	O
at	O
an	O
IAC	O
after	O
biventricular	O
heart	O
/	O
Bjork	O
modified	O
Fontan	O
operations	O
and	O
at	O
a	O
conventional	O
critical	O
isthmus	O
after	O
Senning	B-LOC
and	O
LT	O
Fontan	O
operations	O
.	O

Overlapping	O
syndromes	O
such	O
as	O
Noonan	B-DIS
Cardio	I-DIS
-	I-DIS
Facio	I-DIS
-	O
Cutaneous	O
Noonan	O
syndrome	O
NS	O
with	B-DIS
multiple	I-DIS
lentigines	O
and	O
Costello	O
syndromes	O
are	O
genetically	O
heterogeneous	O
conditions	O
sharing	O
a	O
dysregulation	O
of	O
the	O
RAS	O
/	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
MAPK	B-DIS
pathway	O
and	O
are	O
known	O
collectively	O
as	O
the	O
RASopathies	O
.	O

PTPN11	O
was	O
the	O
first	O
disease	O
-	O
causing	O
gene	O
identified	O
in	O
NS	O
and	O
remains	O
the	O
more	O
prevalent	O
.	O

We	O
report	O
seven	O
patients	O
from	O
three	O
families	O
presenting	O
heterozygous	O
missense	O
variants	O
in	O
PTPN11	O
probably	O
responsible	O
for	O
a	O
disease	O
phenotype	O
distinct	O
from	O
the	O
classical	O
Noonan	B-DIS
syndrome	I-DIS
.	O

The	O
clinical	O
presentation	O
and	O
common	O
features	O
of	O
these	O
seven	O
cases	O
overlap	O
with	O
the	O
SHORT	O
syndrome	O
.	O

The	O
latter	O
is	O
the	O
consequence	O
of	O
PI3K	B-LOC
/	O
AKT	O
signaling	O
deregulation	O
with	O
the	O
predominant	O
disease	O
-	O
causing	O
gene	O
being	O
PIK3R1	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
phenotypic	O
spectrum	O
associated	O
with	O
pathogenic	O
variants	O
of	O
PTPN11	O
could	O
be	O
wider	O
than	O
previously	O
described	O
and	O
this	O
could	O
be	O
due	O
to	O
the	O
dual	O
activity	O
of	O
SHP2	O
ie	O
PTPN11	O
gene	O
product	O
on	O
the	O
RAS	O
/	O
MAPK	O
and	O
PI3K	B-LOC
/	O
AKT	O
signaling	O
.	O

Objective	O
To	O
analyze	O
the	O
prevalence	B-EPI
and	O
the	O
related	O
factors	O
of	O
dyslipidemia	B-DIS
in	O
21	B-DIS
-	I-DIS
hydroxylase	I-DIS
deficiency	O
21	O
-	O
OHD	O
patients	O
.	O

Methods	O
A	O
total	O
of	O
205	O
patients	O
with	O
21	B-DIS
-	O
OHD	O
were	O
recruited	O
in	O
Peking	O
Union	O
Medical	O
College	O
Hospital	O
from	O
January	O
2016	O
to	O
January	O
2018	O
.	O

The	O
basic	O
information	O
glucocorticoid	O
replacement	O
therapy	O
and	O
laboratory	O
examination	O
results	O
of	O
patients	O
were	O
obtained	O
from	O
medical	O
records	O
.	O

The	O
genotypes	O
of	O
CYP21A2	O
were	O
identified	O
by	O
Sanger	O
sequencing	O
and	O
multiplex	O
ligation	O
dependent	O
probe	O
amplification	O
.	O

The	O
prevalence	B-EPI
of	O
dyslipidemia	B-DIS
among	O
21	B-DIS
-	O
OHD	O
patients	O
basic	O
information	O
and	O
related	O
hormone	O
levels	B-DIS
of	O
21	O
-	O
OHD	O
patients	O
with	O
different	O
status	O
of	O
blood	O
lipid	O
were	O
described	O
.	O

Logistic	O
regression	O
model	O
was	O
used	O
to	O
analyze	O
the	O
related	O
factors	O
of	O
dyslipidemia	B-DIS
in	O
21	B-DIS
-	O
OHD	O
patients	O
.	O

Results	O
The	O
age	O
of	O
subjects	O
was	O
17.0	O
8.3	O
25.0	O
years	O
old	O
including	O
51	O
males	O
24.9	B-STAT
%	I-STAT
.	O

According	O
to	O
CYP21A2	O
genotypes	O
there	O
were	O
16	O
cases	O
in	O
Null	O
group	O
26	O
cases	O
in	O
Group	O
A	O
105	O
cases	O
in	O
group	O
B	O
27	O
cases	O
in	O
group	O
C	O
and	O
31	O
cases	O
in	O
group	O
D.	O
The	O
incidence	B-EPI
of	O
dyslipidemia	B-DIS
was	O
29.3	B-STAT
%	I-STAT
60/205	B-STAT
among	O
which	O
37.3	B-STAT
%	I-STAT
19/51	B-STAT
in	O
male	O
and	O
26.6	B-STAT
%	I-STAT
41/154	B-STAT
in	O
female	O
patients	O
respectively	O
.	O

The	O
M	O
Q	O
1	O
<	O
/s	O
Q	O
3	O
<	O
/s	O
of	O
total	O
cortisol	O
level	O
nmol	O
/	O
L	O
and	O
body	O
mass	O
index	O
kg	O
/	O
m	O
2	O
<	B-DIS
/s	O
of	O
male	B-DIS
21	O
-	O
OHD	O
patients	O
with	O
dyslipidemia	O
were	O
0.17	O
0.06	O
0.35	O
and	O
25.76	O
17.01	O
30.45	O
respectively	O
which	O
were	O
higher	O
than	O
those	O
with	O
ortholiposis	O
[	O
0.04	O
0.02	O
0.21	O
and	O
18.83	O
16.53	O
23.88	O
]	O
all	O
P	O
0.05	O
.	O

The	O
M	O
Q	O
1	O
<	O
/s	O
Q	O
3	O
<	O
/s	O
of	O
progesterone	O
level	O
nmol	O
/	O
L	O
body	O
mass	O
index	O
kg	O
/	O
m	O
2	O
<	O
/s	O
and	O
age	B-DIS
years	O
of	O
female	B-DIS
21	O
-	O
OHD	O
patients	O
with	O
dyslipidemia	O
were	O
74.40	O
50.97	O
98.52	O
23.09	O
21.78	O
27.78	O
and	O
23.00	O
16.50	O
28.00	O
respectively	O
which	O
were	O
higher	O
than	O
those	O
with	O
ortholiposis	O
[	O
52.81	O
33.41	O
68.85	O
21.55	O
18.63	O
25.71	O
and	O
18.00	O
9.50	O
25.00	O
]	O
all	O
P	O
0.05	O
.	O

The	O
risk	O
of	O
dyslipidemia	B-DIS
increased	O
by	O
5.0	B-STAT
%	I-STAT
[	O
OR	O
95	B-STAT
%	I-STAT
CI	O
1.05	O
1.01	O
1.09	O
]	O
for	O
every	O
1	O
nmol	O
/	O
L	O
increase	O
of	O
progesterone	O
.	O

Conclusion	O
The	O
incidence	B-EPI
of	O
dyslipidemia	B-DIS
is	O
high	O
in	O
21	B-DIS
-	O
OHD	O
patients	O
and	O
progesterone	O
level	O
is	O
positively	O
correlated	B-DIS
with	O
dyslipidemia	O
.	O

Background	O
Little	O
information	O
is	O
available	O
about	O
the	O
incidence	B-EPI
of	O
stiff	B-DIS
-	I-DIS
man	O
syndrome	O
SMS	O
the	O
classic	O
form	O
or	O
its	O
variants	O
or	O
about	O
long	O
-	O
term	O
treatment	O
responses	O
and	O
outcomes	O
.	O

Objective	O
To	O
comprehensively	O
describe	O
the	O
characteristics	O
of	O
a	O
cohort	O
of	O
patients	O
with	O
SMS	O
.	O

Design	O
Observational	O
study	O
.	O

Setting	O
Mayo	O
Clinic	O
Rochester	B-LOC
Minnesota	B-LOC
.	O

Patients	O
Ninety	O
-	O
nine	O
patients	O
with	O
classic	O
SMS	O
vs	O
variants	O
of	O
the	O
disorder	O
both	O
glutamic	O
acid	O
decarboxylase	O
65	O
kD	O
isoform	O
GAD65	O
antibody	O
seropositive	O
and	O
seronegative	O
.	O

Main	O
outcome	O
measures	O
Neurological	B-DIS
autoimmune	I-DIS
serological	O
and	O
oncological	O
findings	O
;	O
treatments	O
;	O
and	O
outcomes	O
between	O
January	O
1984	O
and	O
December	O
2008	O
.	O

Results	O
The	O
median	O
follow	O
-	O
up	O
duration	O
was	O
5	O
years	O
range	O
0	O
-	O
23	O
years	O
.	O

Seventy	O
-	O
nine	O
patients	O
59	O
having	O
classic	O
SMS	O
19	O
having	O
partial	O
SMS	O
and	O
1	O
having	B-DIS
progressive	O
encephalomyelitis	B-DIS
with	O
rigidity	B-DIS
and	O
myoclonus	O
[	O
PERM	O
]	O
were	O
GAD65	O
antibody	O
seropositive	O
.	O

Sixty	B-STAT
-	I-STAT
seven	I-STAT
percent	I-STAT
53	O
of	O
79	O
of	O
them	O
had	O
at	O
least	O
1	B-DIS
coexisting	I-DIS
autoimmune	O
disease	O
and	O
4	B-STAT
%	I-STAT
3	O
of	O
79	B-DIS
had	O
cancer	O
.	O

GAD65	O
antibody	O
values	O
at	O
initial	O
evaluation	O
were	O
significantly	O
higher	O
among	O
patients	O
with	O
classic	O
SMS	O
median	O
value	O
623	O
nmol	O
/	O
L	O
than	O
among	O
patients	O
with	O
partial	O
SMS	O
median	O
value	O
163	O
nmol	O
/	O
L	O
P	O
<	O
.001	O
.	O

The	O
initial	O
GAD65	O
antibody	O
value	O
was	O
positively	O
correlated	O
with	O
the	O
last	O
follow	O
-	O
up	O
Rankin	O
score	O
P	O
=	O
.03	O
.	O

Among	O
20	O
patients	O
who	O
were	O
GAD65	O
antibody	O
seronegative	O
6	O
with	O
classic	O
SMS	O
12	O
with	O
partial	O
SMS	O
and	O
2	O
with	O
PERM	O
15	B-STAT
%	I-STAT
3	O
of	O
20	O
had	O
at	O
least	O
1	O
coexisting	O
autoimmune	B-DIS
disease	I-DIS
and	O
25	B-STAT
%	I-STAT
5	O
of	O
20	O
had	O
cancer	B-DIS
3	O
with	O
amphiphysin	O
autoimmunity	O
and	O
breast	B-DIS
carcinoma	I-DIS
and	O
2	O
with	O
Hodgkin	B-DIS
lymphoma	I-DIS
.	O

Excluding	O
patients	O
with	O
PERM	O
all	O
patients	O
but	O
1	O
had	O
sustained	O
improvements	O
with	O
at	O
least	O
1	O
γ	O
-	O
aminobutyric	O
acid	O
agent	O
usually	O
diazepam	O
;	O
the	O
median	O
dosage	O
for	O
patients	O
with	O
classic	O
SMS	O
was	O
40.0	O
mg	O
/	O
d	O
.	O

Additional	O
improvements	O
occurred	O
among	O
14	O
of	O
34	O
patients	O
41	B-STAT
%	I-STAT
who	O
received	O
immunotherapy	O
intravenous	O
immune	O
globulin	O
azathioprine	O
prednisone	O
mycophenolate	O
mofetil	O
or	O
cyclophosphamide	O
.	O

Sixteen	O
of	O
25	O
patients	O
64	B-STAT
%	I-STAT
with	O
extended	O
follow	O
-	O
up	O
duration	O
remained	O
ambulatory	O
.	O

Conclusions	O
Recognition	O
of	O
classic	O
SMS	O
vs	O
variants	O
is	O
important	O
because	O
appropriate	O
therapy	O
improves	O
symptoms	O
in	O
most	O
patients	O
.	O

Classification	O
by	O
anatomical	O
extent	O
and	O
by	O
GAD65	O
antibody	O
serostatus	O
gives	O
important	O
diagnostic	O
and	O
prognostic	O
information	O
.	O

Background	O
Thyroid	B-DIS
cancer	I-DIS
is	O
a	O
common	O
malignancy	B-DIS
whose	O
detection	O
has	O
increased	O
significantly	O
in	O
past	O
decades	O
.	O

Most	O
of	O
the	O
increased	O
incidence	B-EPI
is	O
due	O
to	O
detection	O
of	O
early	O
well	O
-	B-DIS
differentiated	I-DIS
thyroid	O
cancer	O
but	B-EPI
the	O
incidence	O
of	O
more	B-DIS
advanced	I-DIS
thyroid	O
cancers	O
has	O
increased	O
as	O
well	O
.	O

Recent	O
methodological	O
advancements	O
have	O
allowed	O
for	O
a	O
deep	O
understanding	O
of	O
the	O
molecular	O
underpinnings	O
of	O
the	O
various	O
types	O
of	O
thyroid	B-DIS
cancer	I-DIS
.	O

Summary	O
Thyroid	B-DIS
cancers	I-DIS
harbor	O
a	O
high	O
frequency	O
of	O
potential	O
druggable	O
molecular	O
alterations	O
including	O
the	O
highest	O
frequency	O
of	O
oncogenic	O
driver	O
kinase	O
fusions	O
seen	O
across	O
all	O
solid	O
tumors	B-DIS
.	O

Analyses	O
of	O
poorly	O
differentiated	O
and	O
anaplastic	B-DIS
thyroid	I-DIS
carcinoma	I-DIS
confirmed	O
that	O
these	O
tumors	B-DIS
develop	O
from	O
more	O
well	O
-	O
differentiated	O
follicular	O
-	O
derived	O
thyroid	O
cancers	O
through	O
acquired	O
additional	O
mutations	O
.	O

The	O
recognition	O
of	O
driver	O
genomic	O
alterations	O
in	O
thyroid	B-DIS
cancers	I-DIS
not	O
only	O
predicts	O
tumor	B-DIS
phenotype	O
but	O
also	O
now	O
can	O
inform	O
treatment	O
approaches	O
.	O

Conclusions	O
Major	O
progress	O
in	O
understanding	O
the	O
oncogenic	O
molecular	O
underpinnings	O
across	O
the	O
array	O
of	O
thyroid	B-DIS
cancers	I-DIS
has	O
led	O
to	O
considerable	O
gains	O
in	O
gene	O
-	O
specific	O
systemic	O
therapies	O
for	B-DIS
many	O
cancers	O
.	O

This	O
article	O
focuses	O
on	O
the	O
molecular	O
characteristics	O
of	O
aggressive	B-DIS
follicular	I-DIS
-	I-DIS
derived	I-DIS
thyroid	O
cancers	B-DIS
and	I-DIS
medullary	I-DIS
thyroid	O
cancer	O
and	O
highlights	O
advancements	O
in	B-DIS
treating	I-DIS
thyroid	O
cancer	O
in	O
the	O
era	O
of	O
targeted	O
therapy	O
.	O

MYH9	O
-related	O
disease	O
MYH9	O
-RD	O
is	O
an	O
autosomal	B-DIS
-	I-DIS
dominant	O
thrombocytopenia	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
for	O
non	O
-	O
muscle	O
myosin	O
heavy	O
chain	O
IIA	O
NMMHC	O
-	O
IIA	O
.	O

Patients	O
present	O
congenital	B-DIS
macrothrombocytopenia	I-DIS
and	O
inclusions	O
of	O
NMMHC	O
-	O
IIA	O
in	O
leukocytes	O
and	O
have	O
a	O
variable	O
risk	O
of	B-DIS
developing	I-DIS
kidney	I-DIS
damage	I-DIS
sensorineural	I-DIS
deafness	I-DIS
presenile	O
cataracts	B-DIS
and/or	I-DIS
liver	I-DIS
enzymes	O
abnormalities	O
.	O

The	O
spectrum	O
of	O
mutations	O
found	O
in	O
MYH9	O
-RD	O
patients	O
is	O
limited	O
and	O
the	O
incidence	B-EPI
and	O
severity	O
of	O
the	O
non	O
-	O
congenital	O
features	O
are	O
predicted	O
by	O
the	O
causative	O
MYH9	O
variant	O
.	O

In	O
particular	O
different	O
alterations	O
of	O
the	O
C	O
-	O
terminal	O
tail	O
domain	O
of	O
NMMHC	O
-	O
IIA	O
associate	O
with	O
remarkably	O
different	O
disease	O
evolution	O
.	O

We	O
report	O
four	O
novel	O
MYH9	O
mutations	O
affecting	O
the	O
tail	O
domain	O
of	O
NMMHC	O
-	O
IIA	O
and	O
responsible	O
for	O
MYH9	O
-RD	O
in	O
four	O
families	O
.	O

Two	O
variants	O
cause	O
amino	O
acid	O
substitutions	O
in	O
the	O
coiled	O
-	O
coil	O
region	O
of	O
NMMHC	O
-	O
IIA	O
while	O
the	O
other	O
two	O
are	O
a	O
splicing	O
variant	O
and	O
a	O
single	O
nucleotide	O
deletion	O
both	O
resulting	O
in	O
frameshift	O
alterations	O
of	O
the	O
short	O
non	O
-	O
helical	O
tailpiece	O
.	O

Characterization	O
of	O
phenotypes	O
of	O
affected	O
individuals	O
shows	O
that	O
all	O
of	O
these	O
novel	O
variants	O
are	O
associated	O
with	O
a	O
mild	O
clinical	O
evolution	O
of	O
the	O
disease	O
.	O

Background	O
Cardiac	B-DIS
rupture	I-DIS
is	O
a	O
disastrous	O
but	O
uncommon	O
complication	O
of	O
acute	O
ST	B-LOC
-	O
elevation	O
myocardial	O
infarction	O
STEMI	O
.	O

The	O
incidence	B-EPI
risk	O
factors	O
and	O
in	O
-	O
hospital	O
outcomes	O
related	B-DIS
to	I-DIS
cardiac	O
rupture	O
in	O
the	O
current	O
era	O
are	O
unknown	O
.	O

Methods	O
This	O
study	O
consecutively	O
collected	O
all	O
acute	O
STEMI	B-DIS
patients	O
admitted	O
to	O
a	O
single	O
tertiary	O
center	O
in	O
China	B-LOC
from	O
January	O
2004	O
to	O
December	O
2015	O
.	O

Characteristics	O
of	O
each	O
cardiac	B-DIS
rupture	I-DIS
were	O
collected	O
and	O
analyzed	O
.	O

Results	O
Among	O
4190	O
patients	O
751.8	B-STAT
%	I-STAT
patients	O
had	O
cardiac	B-DIS
rupture	I-DIS
including	O
33	O
at	O
the	O
ventricular	O
septum	O
and	O
42	O
at	O
the	O
left	O
ventricle	O
free	O
wall	O
LVFW	O
.	O

Patients	O
with	O
cardiac	B-DIS
rupture	I-DIS
were	O
more	O
likely	O
to	O
be	O
female	O
with	O
more	O
advanced	O
age	O
lower	O
rate	O
of	O
primary	O
percutaneous	O
coronary	O
intervention	O
PPCI	O
and	O
higher	O
in	O
-	O
hospital	O
mortality	O
.	O

Compared	O
with	O
survivors	O
the	O
death	B-DIS
cases	O
were	O
older	O
had	O
a	O
higher	O
white	O
blood	O
cell	O
count	O
higher	O
rate	O
of	O
delayed	O
admission	O
12	O
h	O
from	O
symptom	O
onset	O
to	O
door	O
earlier	O
occurrence	O
of	O
cardiac	B-DIS
rupture	I-DIS
higher	O
percentage	O
of	O
LVFW	B-DIS
rupture	I-DIS
and	O
lower	O
rate	O
of	O
surgical	O
repair	O
.	O

Logistic	O
regression	O
analysis	O
showed	O
that	O
surgical	O
repair	O
served	O
as	O
the	O
most	O
valuable	O
factor	O
affecting	O
survival	O
.	O

Moreover	O
elevated	O
white	O
blood	O
cell	O
count	O
and	O
advanced	O
age	O
might	O
be	O
related	O
to	O
an	O
increased	O
in	O
-	B-DIS
hospital	O
death	O
due	B-DIS
to	I-DIS
cardiac	O
rupture	O
.	O

Conclusions	O
In	O
this	O
contemporary	O
cohort	O
female	O
sex	O
advanced	O
age	O
and	O
low	O
rate	O
of	O
PPCI	O
post	O
-	O
STEMI	O
are	O
associated	O
with	O
an	O
increased	O
risk	B-DIS
of	I-DIS
cardiac	O
rupture	O
.	O

Advanced	O
age	O
and	O
elevated	B-DIS
white	I-DIS
blood	I-DIS
cell	I-DIS
count	I-DIS
might	O
be	O
related	O
to	O
an	O
increased	O
in	O
-	O
hospital	O
mortality	B-DIS
after	I-DIS
cardiac	O
rupture	O
whereas	O
surgical	O
repair	O
served	O
as	O
the	O
most	O
valuable	O
factor	O
affecting	O
survival	O
.	O

Second	B-DIS
malignant	I-DIS
neoplasms	I-DIS
pose	O
a	O
concern	O
for	O
survivors	O
of	O
childhood	O
cancer	B-DIS
.	O

We	O
evaluated	O
incidence	B-EPI
type	O
and	O
risk	O
factors	O
for	O
second	O
malignant	O
neoplasms	O
in	O
patients	O
included	O
in	O
Berlin	B-LOC
-	O
Frankfurt	O
-	O
Muenster	B-DIS
protocols	I-DIS
for	O
childhood	O
non	O
-	O
Hodgkin	O
lymphoma	O
.	O

3590	O
patients	O
<	O
15	O
years	O
of	O
age	O
at	O
diagnosis	O
registered	O
between	O
01/1981	B-STAT
and	O
06/2010	B-STAT
were	O
analyzed	O
.	O

Second	B-DIS
malignant	I-DIS
neoplasms	I-DIS
were	O
reported	O
by	O
the	O
treating	O
institutions	O
and	O
the	O
German	O
Childhood	O
Cancer	B-DIS
Registry	O
.	O

After	O
median	O
follow	O
-	O
up	O
of	O
9.4	O
years	O
Quartile	O
Q1	O
6.7	O
and	O
Q3	O
12.195	O
second	O
malignant	O
neoplasms	O
were	O
registered	B-DIS
26	O
carcinomas	O
including	B-DIS
9	I-DIS
basal	I-DIS
cell	O
carcinomas	B-DIS
21	I-DIS
acute	I-DIS
myeloid	I-DIS
leukemias	I-DIS
/	I-DIS
myelodysplastic	I-DIS
syndromes	O
20	B-DIS
lymphoid	O
malignancies	O
12	O
CNS	O
-	O
tumors	O
and	O
16	O
other	O
.	O

Cumulative	O
incidence	B-EPI
at	O
20	O
years	O
was	O
5.7±0.7	B-STAT
%	I-STAT
standard	O
incidence	B-EPI
ratio	O
excluding	O
basal	B-DIS
cell	I-DIS
carcinomas	I-DIS
was	O
19.895	B-STAT
%	I-STAT
CI	O
14.5	O
-	O
26.5	O
.	O

Median	O
time	O
from	O
initial	O
diagnosis	O
to	O
second	O
malignancy	B-DIS
was	O
8.7	O
years	O
range	O
0.2	O
-	O
30.3	O
.	O

Acute	O
-	O
lymphoblastic	O
-	O
leukemia	O
-	O
type	O
therapy	O
cumulative	O
anthracycline	O
dose	O
and	O
cranial	O
radiotherapy	O
for	O
brain	O
tumor	O
-	O
development	O
were	O
significant	O
risk	O
factors	O
in	O
univariate	O
analysis	O
only	O
.	O

In	O
multivariate	O
analysis	O
including	O
risk	O
factors	O
significant	O
in	O
univariate	O
analysis	O
female	O
sex	O
HR	O
1.8795	B-STAT
%	I-STAT
CI	O
1.23	O
-	O
2.86	O
p=0.004	O
CNS	B-DIS
-	O
involvement	O
HR	O
2.2495	B-STAT
%	I-STAT
CI	O
1.03	B-STAT
-	B-DIS
4.88	I-DIS
p=0.042	I-DIS
lymphoblastic	O
lymphoma	O
HR	O
2.6095	B-STAT
%	I-STAT
CI	O
1.69	O
-	O
3.97	O
p	O
<	O
0.001	O
and	O
cancer	O
-	O
predisposing	O
condition	O
HR	O
11.295	B-STAT
%	I-STAT
CI	O
5.52	O
-	O
22.75	O
p	O
<	O
0.001	O
retained	O
an	O
independent	O
risk	O
.	O

Carcinomas	B-DIS
were	O
the	O
most	O
frequent	O
second	O
malignant	O
neoplasms	O
after	O
non	B-DIS
-	I-DIS
Hodgkin	O
lymphoma	O
in	O
childhood	O
followed	B-DIS
by	I-DIS
acute	I-DIS
myeloid	O
leukemia	B-DIS
and	I-DIS
lymphoid	O
malignancies	O
.	O

Female	O
sex	O
lymphoblastic	B-DIS
lymphoma	I-DIS
CNS	I-DIS
-	O
involvement	O
or	O
/	O
and	O
known	O
cancer	O
-	O
predisposing	O
condition	O
were	O
risk	O
factors	O
for	O
second	O
malignant	O
neoplasm	O
-	O
development	O
.	O

Our	O
findings	O
set	O
the	O
basis	O
for	O
individualized	O
long	O
-	O
term	O
follow	O
-	O
up	O
and	O
risk	O
assessment	O
of	O
new	O
therapies	O
.	O

Background	O
Approximately	O
70	O
%	O
of	O
congenital	B-DIS
deafness	I-DIS
is	O
attributable	O
to	O
genetic	O
causes	O
.	O

Incidence	B-EPI
of	O
congenital	B-DIS
deafness	I-DIS
is	O
known	O
to	O
be	O
higher	O
in	O
families	O
with	O
consanguineous	B-DIS
marriage	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
genetic	O
causes	O
in	O
three	O
consanguineous	B-DIS
Pakistani	O
families	O
segregating	O
with	O
prelingual	B-DIS
severe	I-DIS
-	I-DIS
to	O
-	O
profound	O
deafness	O
.	O

Results	O
Through	O
targeted	O
next	O
-	O
generation	O
sequencing	O
of	O
414	O
genes	O
known	O
to	O
be	O
associated	B-DIS
with	O
deafness	O
homozygous	O
variants	O
c.536del	O
p.	O
Leu180Serfs∗20	O
in	O
TECTA	O
c.3719	O
A	O
p.	O
Arg1240Gln	O
in	O
MYO7A	O
and	O
c.482	O
+	O
1986_1988del	O
in	O
HGF	O
were	O
identified	O
as	O
the	O
pathogenic	O
causes	O
of	O
enrolled	O
families	O
.	O

Interestingly	O
in	O
one	O
large	O
consanguineous	B-DIS
family	O
an	O
additional	O
c.70	O
A	O
p.	O
Glu236Lys	O
variant	O
in	O
the	O
X	O
-	O
linked	O
POU3F4	O
gene	O
was	O
also	O
identified	O
in	O
multiple	O
affected	O
family	O
members	B-DIS
causing	O
deafness	O
.	O

Genotype	O
-	O
phenotype	O
cosegregation	O
was	O
confirmed	O
in	O
all	O
participating	O
family	O
members	O
by	O
Sanger	O
sequencing	O
.	O

Conclusions	O
Our	O
results	O
showed	O
that	O
the	O
genetic	O
causes	O
of	O
deafness	B-DIS
are	O
highly	O
heterogeneous	O
.	O

Even	O
within	O
a	O
single	O
family	O
the	O
affected	O
members	O
with	O
apparently	O
indistinguishable	O
clinical	O
phenotypes	O
may	O
have	O
different	O
pathogenic	O
variants	O
.	O

Mandatory	O
folic	O
acid	O
fortification	O
in	O
the	B-LOC
United	I-LOC
States	I-LOC
corresponded	O
with	O
a	O
decline	O
in	O
the	O
prevalence	B-EPI
of	O
spina	B-DIS
bifida	I-DIS
SB	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
epidemiologic	O
characteristics	O
of	O
isolated	O
versus	O
non	O
-	O
isolated	O
SB	O
cases	O
in	O
both	O
pre-	O
and	O
post	O
-	O
fortification	O
periods	O
.	O

SB	O
cases	O
in	O
the	O
Slone	O
Epidemiology	O
Center	O
Birth	B-DIS
Defects	I-DIS
Study	O
from	O
1976	O
to	O
2011	O
without	O
chromosomal	B-DIS
anomalies	I-DIS
and	O
syndromes	O
were	O
included	O
.	O

A	O
maternal	O
interview	O
conducted	O
within	O
6	O
months	O
of	O
delivery	O
collected	O
information	O
on	O
demographics	O
reproductive	O
history	O
diet	O
and	O
supplement	O
use	O
.	O

Daily	O
folic	O
acid	O
intake	O
in	O
the	O
periconceptional	O
period	O
was	O
calculated	O
using	O
both	O
dietary	O
and	O
supplement	O
information	O
and	O
categorized	O
as	O
low	O
intake	O
<	O
400	O
µg	O
/	O
day	O
or	O
high	O
intake	O
≥400	O
µg	O
/	O
day	O
.	O

SB	O
cases	O
n	O
=	O
1170	O
were	O
classified	O
as	O
isolated	O
80.4	B-STAT
%	I-STAT
or	O
non	O
-	O
isolated	O
19.1	B-STAT
%	I-STAT
.	O

Non	O
-	O
isolated	O
cases	O
were	O
further	O
divided	O
into	O
subgroups	O
based	O
on	B-DIS
accompanying	I-DIS
major	I-DIS
malformations	I-DIS
midline	I-DIS
renal	I-DIS
genital	I-DIS
heart	O
laterality	O
.	O

Compared	O
to	O
non	O
-	O
isolated	O
cases	O
isolated	O
cases	O
were	O
more	O
likely	O
to	O
be	O
white	O
non	O
-	O
Hispanic	O
and	O
have	O
more	O
than	O
12	O
years	O
of	O
education	O
.	O

Cases	O
in	O
the	O
renal	B-DIS
genital	I-DIS
and	I-DIS
heart	I-DIS
subgroups	O
had	O
the	O
lowest	O
proportions	O
of	O
mothers	O
with	O
a	O
high	O
folic	O
acid	O
intake	O
.	O

The	O
change	O
from	O
pre-	O
to	O
post	O
-	O
fortification	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
the	O
proportion	O
of	O
isolated	O
cases	O
from	O
83	B-STAT
%	I-STAT
to	I-STAT
72	I-STAT
%	I-STAT
though	O
in	O
both	O
periods	O
isolated	O
cases	O
were	O
more	O
likely	O
to	O
be	O
female	O
and	O
their	O
mothers	O
were	O
more	O
likely	O
to	O
have	O
high	O
folic	O
acid	O
intake	O
.	O

These	O
findings	O
highlight	O
the	O
importance	O
of	O
separating	O
isolated	O
and	O
non	O
-	O
isolated	O
cases	O
in	O
etiologic	O
research	O
of	O
SB	O
.	O

Newborn	O
screening	O
NBS	O
in	O
Alberta	B-LOC
is	O
delivered	O
by	O
a	O
number	O
of	O
government	O
and	O
health	O
service	O
entities	O
who	O
work	O
together	O
to	O
provide	O
newborn	O
screening	O
to	O
infants	O
born	O
in	O
Alberta	B-LOC
the	O
Northwest	O
Territories	O
and	O
the	O
Kitikmeot	B-LOC
region	O
of	O
the	O
Nunavut	O
territory	O
.	O

The	O
Alberta	B-LOC
panel	O
screens	O
for	O
21	O
disorders	O
16	O
metabolic	O
two	O
endocrine	B-DIS
cystic	I-DIS
fibrosis	I-DIS
severe	O
combined	O
immunodeficiency	B-DIS
and	I-DIS
sickle	I-DIS
cell	I-DIS
disease	I-DIS
.	O

NBS	B-DIS
is	O
a	O
standard	O
of	O
care	O
but	O
is	O
not	O
mandatory	O
.	O

NBS	O
performance	O
is	O
monitored	O
by	O
the	O
Alberta	O
Newborn	O
Metabolic	O
Screening	O
NMS	O
Program	O
and	O
NMS	O
Laboratory	O
who	O
strive	O
for	O
continuous	O
quality	O
improvement	O
.	O

Performance	O
analysis	O
found	O
that	O
over	B-STAT
99	I-STAT
%	I-STAT
of	O
registered	O
infants	O
in	O
Alberta	B-LOC
received	O
a	O
newborn	O
screen	O
and	O
over	B-STAT
98	I-STAT
%	I-STAT
of	O
these	O
infants	O
received	O
a	O
screen	O
result	O
within	O
10	O
days	O
of	O
age	O
.	O

A	O
study	O
of	O
parental	O
cancer	B-DIS
in	O
326	O
children	O
referred	O
to	O
a	O
single	O
Paediatric	O
Oncology	O
Unit	O
found	O
a	O
significant	O
increase	B-DIS
in	I-DIS
breast	I-DIS
cancer	I-DIS
in	O
mothers	O
of	O
children	O
with	O
solid	O
tumours	B-DIS
.	O

The	O
5	O
tumours	B-DIS
found	O
were	O
8.9	O
times	O
the	O
expected	O
number	O
.	O

This	O
increase	O
could	O
not	O
be	O
accounted	O
for	O
by	O
any	O
of	O
the	O
known	O
risk	O
factors	O
for	O
breast	B-DIS
cancer	I-DIS
.	O

The	O
incidence	B-EPI
of	O
cancer	B-DIS
in	O
mothers	O
of	O
leukaemic	O
children	O
and	O
in	O
all	O
groups	O
of	O
fathers	O
was	O
not	O
significantly	O
raised	O
.	O

Further	O
prospective	O
studies	O
in	O
the	O
mothers	O
of	O
young	O
children	O
with	O
soft	O
tissue	O
tumours	B-DIS
are	O
needed	O
to	O
clarify	O
the	O
groups	O
at	O
risk	O
and	O
to	O
determine	O
whether	O
counselling	O
and	O
surveillance	O
of	O
these	O
mothers	O
is	O
appropriate	O
.	O

Background	O
The	O
prevalence	B-EPI
of	O
Multiple	O
Sclerosis	O
MS	O
has	O
been	O
increasing	O
worldwide	O
and	O
the	O
highest	O
prevalence	B-EPI
ratio	O
among	O
Asian	O
countries	O
was	O
reported	O
in	O
Iran	B-LOC
.	O

This	O
study	O
aims	O
to	O
estimate	O
the	O
increase	O
in	O
MS	O
occurrence	O
during	O
more	O
than	O
three	O
decades	O
in	O
Tehran	B-LOC
and	O
forecast	O
the	O
future	O
condition	O
of	O
the	O
disease	O
using	O
time	O
series	O
approaches	O
for	O
the	O
next	O
ten	O
years	O
.	O

Methods	O
The	O
cross	O
-	O
sectional	O
study	O
was	O
conducted	O
from	O
1999	O
to	O
2019	O
based	O
on	O
records	O
of	O
MS	O
cases	O
from	O
Iranian	O
MS	O
Society	O
IMSS	O
registry	O
system	O
.	O

The	O
prevalence	B-EPI
was	O
estimated	O
using	O
population	O
data	O
presented	O
by	O
the	O
Statistical	O
Centre	O
of	O
Iran	O
.	O

Through	O
Bayesian	O
Structural	O
Time	O
Series	O
BSTS	O
model	O
we	O
want	O
to	O
predict	O
the	O
prevalence	B-EPI
of	O
familial	O
and	O
sporadic	O
MS	O
in	O
the	O
next	O
ten	O
years	O
.	O

.	O

Results	O
Among	O
22421	O
cases	O
with	O
MS	O
16831	B-STAT
75.1	I-STAT
%	I-STAT
were	O
female	O
and	O
558924.9	B-STAT
%	I-STAT
were	O
male	O
.	O

Female	O
to	O
male	O
ratio	O
was	O
3.01	O
and	O
the	O
number	O
of	O
familial	O
MS	O
cases	O
were	O
298213.3	B-STAT
%	I-STAT
of	O
subjects	O
.	O

Female	O
gender	O
was	O
less	O
responsible	O
for	O
higher	O
rate	O
of	O
MS	O
in	O
familial	O
definition	O
beta	O
=	O
0.020	O
in	O
comparison	O
to	O
sporadic	O
cases	O
beta	O
=	O
0.034	O
.	O

Forecasting	O
by	O
BSTS	O
revealed	O
an	O
increase	O
in	O
MS	O
prevalence	B-EPI
for	O
the	O
next	O
ten	O
years	O
so	O
that	O
the	O
prevalence	B-EPI
rate	O
for	O
total	O
familial	O
and	O
sporadic	O
MS	B-LOC
respectively	O
begins	O
with	O
189.50	O
183.94	O
-	O
195.14	O
25.69	O
24.97	O
-	O
26.45	O
and	O
163.74	O
159.06	O
-	O
168.57	O
in	O
2020	O
and	O
ends	O
with	O
220.84	O
171.48	O
-	O
266.92	O
30.79	O
24.16	O
-	O
37.15	O
and	O
189.33	O
146.97	O
-	O
230.19	O
in	O
2029	O
.	O

Conclusions	O
According	O
to	O
the	O
findings	O
MS	O
prevalence	B-EPI
increased	O
during	O
three	O
decades	O
and	O
it	O
will	O
increase	O
over	O
the	O
next	O
ten	O
years	O
.	O

Tehran	B-LOC
province	O
is	O
one	O
of	O
the	O
regions	O
with	O
highest	O
MS	O
prevalence	B-EPI
in	O
Asia	B-LOC
.	O

The	O
results	O
of	O
present	O
study	O
indicated	O
that	O
females	O
are	O
at	O
higher	O
risk	O
for	O
MS	O
than	O
males	O
in	O
both	O
sporadic	O
and	O
familial	O
MS	O
.	O

Background	O
Adrenocortical	B-DIS
carcinoma	I-DIS
ACC	O
is	O
a	O
rare	O
endocrine	B-DIS
carcinoma	I-DIS
with	O
poor	O
5	O
-	O
year	O
survival	O
rates	O
of	O
<	O
40	B-STAT
%	I-STAT
.	O

According	O
to	O
the	O
literature	O
ACC	O
is	O
rarely	O
an	O
incidental	O
imaging	O
finding	O
.	O

However	O
presentation	O
treatment	O
and	O
outcome	O
may	O
differ	O
in	O
modern	O
series	O
.	O

Design	O
and	O
methods	O
We	O
studied	O
all	O
patients	O
n	O
=	O
47	O
four	O
children	O
from	O
a	O
single	O
centre	O
during	O
years	O
2002	O
-	O
2018	O
.	O

We	O
re	O
-	O
evaluated	O
radiologic	O
and	O
histopathological	O
findings	O
and	O
assessed	O
treatments	O
and	O
outcome	O
.	O

We	O
searched	O
for	O
possible	O
TP53	O
gene	O
defects	O
and	O
assessed	O
nationwide	O
incidence	B-EPI
of	O
ACC	O
.	O

Results	O
In	O
adults	O
incidental	O
radiologic	O
finding	O
led	O
to	O
diagnosis	O
in	O
79	B-STAT
%	I-STAT
at	O
median	O
age	O
of	O
61	O
years	O
.	O

ENSAT	B-DIS
stage	I-DIS
I	I-DIS
II	I-DIS
III	O
and	O
IV	O
was	O
19	B-STAT
%	I-STAT
40	B-STAT
%	I-STAT
19	B-STAT
%	I-STAT
and	O
21	B-STAT
%	I-STAT
respectively	O
.	O

Nonenhanced	O
CT	O
demonstrate	O
20	O
Hounsfield	O
Units	O
HU	O
for	O
all	O
tumours	B-DIS
median	O
3421	O
-	O
45	O
median	O
size	O
92	O
mm	O
20	O
-	O
196	O
Ki6717	O
%	O
1	B-STAT
-	I-STAT
40	I-STAT
%	I-STAT
Weiss	O
score	O
74	O
-	O
9	O
and	O
Helsinki	B-LOC
score	O
244	O
-	O
48	O
.	O

ACC	O
was	O
more	O
often	O
found	O
in	O
the	O
left	O
than	O
the	O
right	O
adrenal	O
p	O
<	O
0.05	O
.	O

One	O
child	O
had	O
Beckwith	B-DIS
-	O
Wiedemann	O
and	O
one	O
a	O
TP53	O
mutation	O
.	O

In	O
adults	O
the	O
primary	O
tumour	B-DIS
was	O
resected	O
in	O
88	O
and	O
79	B-STAT
%	I-STAT
received	O
adjuvant	O
mitotane	O
therapy	O
.	O

Median	O
hospital	O
stay	O
was	O
significantly	O
shorter	O
in	O
the	O
laparoscopic	O
vs.	O
open	O
surgery	O
group	O
43	O
-	O
7	O
vs.	O
85	O
-	O
38	O
days	O
respectively	O
;	O
p	O
<	O
0.001	O
.	O

In	O
3/4	B-STAT
patients	O
prolonged	O
remission	O
o	O
5	O
t	O
10	O
years	O
was	O
achieved	O
after	O
repeated	O
surgery	O
of	O
metastases	O
.	O

Overall	O
5	O
-	O
year	O
survival	O
was	O
67	B-STAT
%	I-STAT
and	O
96	B-STAT
%	I-STAT
vs.	O
26	B-STAT
%	B-DIS
for	I-DIS
ENSAT	I-DIS
stage	O
I	O
-	O
II	O
vs.	O
III	O
-	O
IV	O
p	O
<	O
0.0001	O
.	O

ENSAT	B-DIS
stage	O
and	O
Ki67	O
predicted	O
survival	O
type	O
of	O
surgery	O
did	O
not	O
.	O

Mitotane	O
associated	O
with	O
better	O
survival	O
.	O

Conclusions	O
Contemporary	O
ACC	O
predominantly	O
presents	O
as	O
an	O
incidental	O
imaging	O
finding	O
characterised	O
by	O
H	O
20	O
on	O
nonenhanced	O
CT	O
but	O
variable	O
tumour	B-DIS
size	O
20	O
-	O
196	O
mm	O
.	O

Malignancy	B-DIS
can	O
not	O
be	O
ruled	O
out	O
by	O
small	O
tumour	B-DIS
size	O
only	O
.	O

The	O
5	O
-	O
year	O
survival	O
of	O
96	B-STAT
%	B-DIS
in	O
ENSAT	O
stage	O
I	O
-	O
III	O
compares	O
favourably	O
to	O
previous	O
studies	O
.	O

Background	O
The	O
European	O
Rare	O
Kidney	B-DIS
Disease	I-DIS
Reference	O
Network	O
ERKNet	O
recently	O
established	O
ERKReg	O
a	O
Web	O
-	O
based	O
registry	O
for	O
all	O
patients	O
with	B-DIS
rare	I-DIS
kidney	O
diseases	O
.	O

The	O
main	O
objectives	O
of	O
this	O
core	O
registry	O
are	O
to	O
generate	O
epidemiological	O
information	O
identify	O
current	O
patient	O
cohort	O
for	O
clinical	O
research	O
explore	O
diagnostic	O
and	O
therapeutic	O
management	O
practices	O
and	O
monitor	O
treatment	O
performance	O
and	O
patient	O
's	O
outcomes	O
.	O

The	O
registry	O
has	O
a	O
modular	O
design	O
that	O
allows	O
to	O
integrate	O
comprehensive	O
disease	O
-	O
specific	O
registries	O
as	O
extensions	O
to	O
the	O
core	O
database	O
.	O

The	O
diagnosis	O
Orphacode	O
and	O
diagnostic	O
information	O
clinical	O
imaging	O
histopathological	O
biochemical	O
immunological	O
and	O
genetic	O
are	O
recorded	O
.	O

Anthropometric	O
kidney	O
function	O
and	O
disease	O
-	O
specific	O
management	O
and	O
outcome	O
items	O
informing	O
a	O
set	O
of	O
61	O
key	O
performance	O
indicators	O
KPIs	O
are	O
obtained	O
annually	O
.	O

Data	O
quality	O
is	O
ensured	O
by	O
automated	O
plausibility	O
checks	O
upon	O
data	O
entry	O
and	O
regular	O
offline	O
database	O
checks	O
prompting	O
queries	O
.	O

Centre	O
KPI	O
statistics	O
and	O
benchmarking	O
are	O
calculated	O
automatically	O
.	O

Results	O
Within	O
the	O
first	O
24	O
months	O
since	O
its	O
launch	O
7607	O
patients	O
were	O
enrolled	O
to	O
the	O
registry	O
at	O
45	O
pediatric	O
and	O
12	O
specialized	O
adult	O
nephrology	O
units	O
from	O
21	O
countries	O
.	O

A	O
kidney	B-DIS
disease	I-DIS
diagnosis	O
had	O
been	O
established	O
in	O
97.1	B-STAT
%	I-STAT
of	O
these	O
patients	O
at	O
time	O
of	O
enrolment	O
.	O

While	O
199	O
individual	O
disease	O
entities	O
were	O
reported	O
by	O
Orphacode	B-STAT
50	I-STAT
%	I-STAT
of	O
the	O
cohort	O
could	O
be	O
classified	O
with	O
1180	B-STAT
%	I-STAT
with	O
43	O
and	O
95	B-STAT
%	I-STAT
with	O
92	O
codes	O
.	O

Two	O
kidney	O
diagnoses	O
were	O
assigned	O
in	O
6.5	B-STAT
%	I-STAT
of	O
patients	O
;	O
5.9	B-STAT
%	I-STAT
suffered	O
from	O
syndromic	B-DIS
disease	I-DIS
.	O

Whereas	O
glomerulopathies	B-DIS
54.8	B-STAT
%	I-STAT
and	O
ciliopathies	B-DIS
including	O
autosomal	B-DIS
dominant	I-DIS
polycystic	I-DIS
kidney	I-DIS
disease	I-DIS
ADPKD	I-DIS
31.5	B-STAT
%	I-STAT
were	O
the	O
predominant	O
disease	O
groups	O
among	O
adults	O
the	O
pediatric	O
disease	O
spectrum	O
encompassed	O
congenital	B-DIS
anomalies	I-DIS
of	O
the	O
kidney	O
and	O
urinary	B-DIS
tract	I-DIS
CAKUT	I-DIS
33.7	B-STAT
%	I-STAT
glomerulopathies	B-DIS
30.7	B-STAT
%	I-STAT
ciliopathies	B-DIS
14.0	B-STAT
%	I-STAT
tubulopathies	B-DIS
9.2	B-STAT
%	I-STAT
thrombotic	B-DIS
microangiopathies	I-DIS
5.6	B-STAT
%	I-STAT
and	O
metabolic	B-DIS
nephropathies	I-DIS
4.1	B-STAT
%	I-STAT
.	O

Genetically	O
confirmed	O
diagnoses	O
were	O
reported	O
in	O
24	B-STAT
%	I-STAT
of	O
all	O
pediatric	O
and	O
12	B-STAT
%	I-STAT
adult	O
patients	O
whereas	O
glomerulopathies	B-DIS
had	O
been	O
confirmed	O
by	O
kidney	O
biopsy	O
in	O
80.4	B-STAT
%	I-STAT
adult	O
versus	O
38.5	B-STAT
%	I-STAT
pediatric	O
glomerulopathy	B-DIS
cases	O
.	O

Conclusions	O
ERKReg	O
is	O
a	O
rapidly	O
growing	O
source	O
of	O
epidemiological	O
information	O
and	O
patient	O
cohorts	O
for	O
clinical	O
research	O
and	O
an	O
innovative	O
tool	O
to	O
monitor	O
management	O
quality	O
and	O
patient	O
outcomes	O
.	O

Our	O
understanding	O
about	O
the	O
epidemiological	O
aspects	O
pathogenesis	O
molecular	O
diagnosis	O
and	O
targeted	O
therapies	O
of	O
neuroendocrine	O
neoplasms	B-DIS
NENs	I-DIS
have	O
drastically	O
advanced	O
in	O
the	O
past	O
decade	O
.	O

Gastroenteropancreatic	B-DIS
GEP	I-DIS
NENs	I-DIS
originate	O
from	O
the	O
enteroendocrine	O
cells	O
of	O
the	O
embryonic	O
gut	O
which	O
share	O
common	O
endocrine	O
and	O
neural	O
differentiation	O
factors	O
.	O

Most	O
NENs	O
are	O
well	O
-	O
differentiated	O
and	O
slow	O
growing	O
.	O

Specific	O
neuroendocrine	O
biomarkers	O
that	O
are	O
used	O
in	O
the	O
diagnosis	O
of	O
functional	B-DIS
NENs	I-DIS
include	O
insulin	O
glucagon	O
vasoactive	O
intestinal	O
polypeptide	O
gastrin	O
somatostatin	O
adrenocorticotropin	O
growth	O
hormone	O
releasing	O
hormone	O
parathyroid	O
hormone	O
-	O
related	O
peptide	O
serotonin	O
histamine	O
and	O
5	O
-	O
hydroxy	O
indole	O
acetic	O
acid	O
5	O
-	O
HIAA	O
.	O

Biomarkers	O
such	O
as	O
pancreatic	O
polypeptide	O
human	O
chorionic	O
gonadotrophin	O
subunits	O
neurotensin	O
ghrelin	O
and	O
calcitonin	O
are	O
used	O
in	O
the	O
diagnosis	O
of	O
non	B-DIS
-	I-DIS
functional	O
NENs	O
.	O

5	O
-	O
HIAA	O
levels	O
correlate	B-DIS
with	O
tumour	O
burden	O
prognosis	O
and	O
development	B-DIS
of	I-DIS
carcinoid	I-DIS
heart	O
disease	O
and	B-DIS
mesenteric	O
fibrosis	O
however	O
several	O
diseases	O
medications	O
and	O
edible	O
products	O
can	O
falsely	O
elevate	O
the	O
5	O
-	O
HIAA	O
levels	O
.	O

Organ	O
-	O
specific	O
transcription	O
factors	O
are	O
useful	O
in	O
the	O
differential	O
diagnosis	B-DIS
of	O
metastasis	O
from	O
an	O
unknown	O
primary	O
of	O
well	O
-	O
differentiated	O
NENs	O
.	O

Emerging	O
novel	O
biomarkers	O
include	O
circulating	O
tumour	B-DIS
cells	O
circulating	O
tumour	B-DIS
DNA	O
circulating	O
micro	O
-	O
RNAs	O
and	O
neuroendocrine	O
neoplasms	O
test	O
NETest	O
simultaneous	O
measurement	O
of	O
51	O
neuroendocrine	O
-	O
specific	O
marker	O
genes	O
in	O
the	O
peripheral	O
blood	O
.	O

NETest	O
has	O
high	O
sensitivity	O
85	B-STAT
%	I-STAT
-98	I-STAT
%	I-STAT
and	O
specificity	O
93	B-STAT
%	I-STAT
-97	I-STAT
%	I-STAT
for	O
the	O
detection	O
of	O
gastrointestinal	B-DIS
NENs	I-DIS
and	O
is	O
useful	O
for	O
monitoring	O
treatment	O
response	O
recurrence	O
and	O
prognosis	O
.	O

In	O
terms	O
of	O
management	O
surgery	O
radiofrequency	O
ablation	O
symptom	O
control	O
with	O
medications	O
chemotherapy	O
and	O
molecular	O
targeted	O
therapies	O
are	O
all	O
considered	O
as	O
options	O
.	O

Surgery	O
is	O
the	O
mainstay	O
of	O
treatment	O
but	O
depends	O
on	O
factors	O
including	O
age	O
of	O
the	O
individual	O
location	O
stage	O
grade	O
functional	O
status	O
and	O
the	O
heredity	B-DIS
of	O
the	O
tumour	B-DIS
sporadic	O
vs	O
inherited	O
.	O

Medical	O
management	O
is	O
helpful	O
to	O
alleviate	O
the	O
symptoms	O
manage	O
inoperable	O
lesions	O
suppress	O
postoperative	O
tumour	B-DIS
growth	O
and	O
manage	O
recurrences	O
.	O

Several	O
molecular	O
-	O
targeted	O
therapies	O
are	O
considered	O
second	O
line	O
to	O
somatostatin	O
analogues	O
.	O

This	O
review	O
is	O
a	O
clinical	O
update	O
on	O
the	O
pathophysiological	O
aspects	O
diagnostic	O
algorithm	O
and	O
management	O
of	O
GEP	O
NENs	O
.	O

Background	O
The	O
increase	O
of	O
chronic	B-DIS
diseases	I-DIS
prevalence	B-EPI
has	O
created	O
the	O
need	O
to	O
adapt	O
care	O
models	O
and	O
to	O
provide	O
greater	O
home	O
supervision	O
.	O

Objective	O
The	O
objective	O
of	O
our	O
study	O
was	O
to	O
evaluate	O
the	O
impact	O
of	O
telemonitoring	O
on	O
patients	O
with	O
long	O
-	O
term	O
conditions	O
at	O
high	O
risk	O
for	O
rehospitalization	O
or	O
an	O
emergency	O
department	O
visit	O
in	O
terms	O
of	O
target	O
disease	B-DIS
control	I-DIS
diabetes	I-DIS
hypertension	I-DIS
heart	O
failure	B-DIS
and	I-DIS
chronic	I-DIS
obstructive	I-DIS
pulmonary	O
disease	O
.	O

Methods	O
We	O
conducted	O
a	O
quasi	O
-	O
experimental	O
study	O
with	O
a	O
before	O
-	O
and	O
-	O
after	O
analysis	O
to	O
assess	O
the	O
effectiveness	O
of	O
the	O
ValCrònic	O
program	O
after	O
1	O
year	O
of	O
primary	O
care	O
monitoring	O
.	O

The	O
study	O
included	O
high	O
-	O
risk	O
patients	O
with	O
1	O
or	O
more	O
of	O
the	O
following	B-DIS
conditions	O
diabetes	O
high	O
blood	B-DIS
pressure	I-DIS
heart	O
failure	B-DIS
and	I-DIS
chronic	I-DIS
obstructive	I-DIS
pulmonary	O
disease	O
.	O

We	O
assessed	O
risk	O
according	O
to	O
the	O
Community	O
Assessment	O
Risk	O
Screen	O
.	O

Participants	O
used	O
an	O
electronic	O
device	O
tablet	O
to	O
self	O
-	O
report	O
relevant	O
health	O
information	O
which	O
was	O
then	O
automatically	O
entered	O
into	O
their	O
eHealth	O
record	O
for	O
consultation	O
.	O

Results	O
The	O
total	O
sample	O
size	O
was	O
521	O
patients	O
.	O

Compared	O
with	O
the	O
preintervention	O
year	O
there	O
were	O
significant	O
reductions	O
in	O
weight	O
82.3	O
kg	O
before	O
vs	O
80.1	O
kg	O
after	O
;	O
P=.001	O
and	O
in	O
the	O
proportion	O
of	O
people	O
with	O
high	O
systolic	O
≥140	O
mmHg	O
;	O
19036.5	B-STAT
%	I-STAT
vs	O
17032.6	B-STAT
%	I-STAT
;	O
P=.001	O
and	O
diastolic	O
≥90	O
mmHg	O
;	O
7213.8	B-STAT
%	I-STAT
vs	O
407.7	B-STAT
%	I-STAT
;	O
P=.01	O
blood	O
pressures	O
and	O
hemoglobin	O
A	O
1c	O
<	O
/s	O
≥8	O
%	O
18635.7	B-STAT
%	I-STAT
vs	O
10420.0	B-STAT
%	I-STAT
;	O
P=.001	O
.	O

There	O
was	O
also	O
a	O
decrease	O
in	O
the	O
proportion	O
of	O
participants	O
who	O
used	O
emergency	O
services	O
in	O
primary	O
care	O
6813.1	B-STAT
%	I-STAT
vs	O
336.3	B-STAT
%	I-STAT
;	O
P	O
<	O
.001	O
and	O
in	O
hospital	O
9818.8	B-STAT
%	I-STAT
vs	O
6712.8	B-STAT
%	I-STAT
;	O
P	O
<	O
.001	O
.	O

Likewise	O
fewer	O
participants	O
required	O
hospital	O
admission	O
due	O
to	O
an	O
emergency	O
10520.2	B-STAT
%	I-STAT
vs	O
7113.6	B-STAT
%	I-STAT
;	O
P	O
<	O
.001	O
or	O
disease	O
exacerbation	O
5510.5	B-STAT
%	I-STAT
vs	O
428.1	B-STAT
%	I-STAT
;	O
P	O
<	O
.001	O
.	O

Conclusions	O
The	O
ValCrònic	O
telemonitoring	O
program	O
in	O
patients	O
at	O
high	O
risk	O
for	O
rehospitalization	O
or	O
an	O
emergency	O
department	O
visit	O
appears	O
to	O
be	O
useful	O
to	O
improve	O
target	O
disease	O
control	O
and	O
to	O
reduce	O
the	O
use	O
of	O
resources	O
.	O

Background	O
and	O
Objectives	O
This	O
is	O
the	O
first	O
study	O
assessing	O
risk	O
factors	O
for	O
cerebral	B-DIS
palsy	I-DIS
CP	O
among	O
children	O
born	O
in	O
Moldova	B-LOC
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
identify	O
and	O
describe	O
risk	O
factors	O
for	O
cerebral	B-DIS
palsy	I-DIS
CP	O
among	O
children	O
born	O
in	O
Moldova	B-LOC
which	O
is	O
one	O
of	O
the	O
low	O
-	O
middle	O
income	O
countries	O
in	O
Europe	B-LOC
.	O

Materials	O
and	O
Methods	O
We	O
identified	O
351	O
children	O
with	O
CP	O
born	O
during	O
2009	O
and	O
2010	O
in	O
Moldova	B-LOC
.	O

Detailed	O
information	O
on	O
417	O
children	O
without	O
CP	O
served	O
as	O
a	O
reference	O
group	O
.	O

Logistic	O
regression	O
analyses	O
were	O
applied	O
to	O
the	O
calculate	O
crude	O
and	O
adjusted	O
odds	O
ratios	O
OR	O
for	O
CP	O
with	O
95	B-STAT
%	I-STAT
confidence	O
intervals	O
CI	O
in	O
addition	O
to	O
attributable	O
fraction	O
AF	O
.	O

Results	O
Among	O
children	O
with	O
CP	O
40.5	B-STAT
%	I-STAT
girls	O
26	B-STAT
%	I-STAT
had	O
spastic	B-DIS
unilateral	O
54	B-STAT
%	I-STAT
bilateral	O
13	B-STAT
%	I-STAT
dyskinetic	O
5	B-STAT
%	I-STAT
ataxic	B-DIS
and	O
2	B-STAT
%	I-STAT
unclassified	O
CP	O
.	O

Significant	O
risk	O
factors	O
for	O
CP	O
included	O
maternal	O
alcohol	O
consumption	O
during	O
pregnancy	O
OR	O
1.7	O
p	O
=	O
0.002	O
maternal	O
hypertension	B-DIS
OR	O
2.0	O
p	O
<	O
0.001	O
children	O
born	O
to	O
mothers	O
from	O
the	O
rural	O
areas	O
OR	O
1.6	O
p	O
<	O
0.001	O
maternal	O
age	O
≥35	O
years	O
OR	O
0.6	O
p	O
=	O
0.018	O
maternal	O
epilepsy	B-DIS
OR	O
4.3	O
p	O
<	O
0.001	O
breech	O
delivery	O
OR	O
3.1	O
p	O
=	O
0.001	O
home	O
births	O
OR	O
6.3	O
p	O
=	O
0.001	O
umbilical	O
cord	O
around	O
neck	O
OR	O
2.2	O
p	O
<	O
0.001	O
AVD	O
OR	O
3.1	O
p	O
<	O
0.001	O
male	O
gender	O
OR	O
1.3	O
p	O
<	O
0.001	O
SGA	O
OR	O
1.3	O
p	O
=	O
0.027	O
multiple	O
gestations	O
OR	O
1.7	O
p	O
<	O
0.001	O
and	O
hyperbilirubinemia	B-DIS
OR	O
4.5	O
p	O
<	O
0.001	O
.	O

Multivariable	O
analyses	O
showed	O
that	O
the	O
AF	O
of	O
CP	O
was	O
64	B-STAT
%	I-STAT
for	O
rural	O
residence	O
OR	O
2.8	O
p	O
=	O
0.00287	B-STAT
%	I-STAT
for	O
home	O
birth	O
7.6	O
p	O
=	O
0.00579	B-STAT
%	I-STAT
for	O
pre	B-DIS
-	O
labor	O
rupture	O
of	O
membrane	O
OR	O
4.9	O
p	O
=	O
0.00166	B-STAT
%	I-STAT
for	O
breech	O
delivery	O
OR	O
2.9	O
p	O
=	O
0.002	B-STAT
and	I-STAT
81	I-STAT
%	B-DIS
for	O
hyperbilirubinemia	O
OR	O
5.4	O
p	O
<	O
0.001	O
.	O

Conclusions	O
A	O
combination	O
of	O
factors	O
related	O
to	O
the	O
mother	O
the	O
delivery	O
and	O
the	O
child	O
were	O
risk	O
factors	O
for	O
CP	O
in	O
Moldova	B-LOC
many	O
of	O
them	O
possibly	O
avoidable	O
.	O

Improved	O
pregnancy	O
and	O
maternity	O
care	O
would	O
potentially	O
reduce	O
the	O
risk	O
of	O
CP	O
.	O

A	O
national	O
CP	O
registry	O
in	O
Moldova	B-LOC
is	O
suggested	O
as	O
an	O
opportunity	O
to	O
follow	O
up	O
on	O
these	O
findings	O
.	O

The	O
parkinsonian	B-DIS
syndromes	I-DIS
comprise	O
a	O
highly	O
heterogeneous	O
group	O
of	O
disorders	O
.	O

Although	O
15	O
loci	O
are	O
linked	O
to	O
predominantly	O
familial	B-DIS
Parkinson	I-DIS
's	I-DIS
disease	I-DIS
PD	I-DIS
additional	O
PD	B-DIS
loci	O
are	O
likely	O
to	O
exist	O
.	O

We	O
recently	O
identified	O
a	O
multigenerational	O
family	O
of	O
Danish	O
and	O
German	O
descent	O
in	O
which	O
five	O
males	O
in	O
three	O
generations	O
presented	O
with	O
a	O
unique	O
syndrome	O
characterized	O
by	O
parkinsonian	B-DIS
features	O
and	O
variably	O
penetrant	O
spasticity	B-DIS
for	O
which	O
X	B-DIS
-	I-DIS
linked	O
disease	O
transmission	O
was	O
strongly	O
suggested	O
XPDS	O
.	O

Autopsy	O
in	O
one	O
individual	O
failed	O
to	O
reveal	O
synucleinopathy	B-DIS
;	O
however	O
there	O
was	O
a	O
significant	O
four	B-DIS
-	I-DIS
repeat	O
tauopathy	O
in	O
the	O
striatum	O
.	O

Our	O
objective	O
was	O
to	O
identify	O
the	O
locus	O
responsible	O
for	O
this	O
unique	O
parkinsonian	B-DIS
disorder	I-DIS
.	O

Members	O
of	O
the	O
XPDS	O
family	O
were	O
genotyped	O
for	O
markers	O
spanning	O
the	O
X	O
chromosome	O
.	O

Two	O
-	O
point	O
and	O
multipoint	O
linkage	O
analyses	O
were	O
performed	O
and	O
the	O
candidate	O
region	O
refined	O
by	O
analyzing	O
additional	O
markers	O
.	O

A	O
multipoint	O
LOD	O
max	O
score	O
of	O
2.068	O
was	O
obtained	O
between	O
markers	O
DXS991	O
and	O
DXS993	O
.	O

Haplotype	O
examination	O
revealed	O
an	O
approximately	O
20	O
cM	O
region	O
bounded	O
by	O
markers	O
DXS8042	O
and	O
DXS1216	O
that	O
segregated	O
with	O
disease	O
in	O
all	O
affected	O
males	O
and	O
obligate	O
carrier	O
females	O
and	O
was	O
not	O
carried	O
by	O
unaffected	O
at	O
-	O
risk	O
males	O
.	O

To	O
reduce	O
the	O
possibility	O
of	O
a	O
false	O
-	O
positive	O
linkage	O
result	O
multiple	O
loci	O
and	O
genes	O
associated	O
with	B-DIS
other	O
parkinsonian	B-DIS
or	O
spasticity	O
syndromes	O
were	O
excluded	O
.	O

In	O
conclusion	O
we	O
have	O
identified	O
a	O
unique	O
X	O
-	B-DIS
linked	I-DIS
parkinsonian	O
syndrome	O
with	B-DIS
variable	O
spasticity	O
and	O
four	O
-	O
repeat	O
tau	O
pathology	O
and	O
defined	O
a	O
novel	O
candidate	O
gene	O
locus	O
spanning	O
approximately	O
28	O
Mb	O
from	O
Xp11.2	O
-	O
Xq13.3	O
.	O

Purpose	O
/	O
aim	O
of	O
the	O
study	O
We	O
report	O
a	O
rare	O
case	B-DIS
of	O
autosomal	O
dominant	O
genetic	O
syndrome	O
`	O
`	O
Pfeiffer	O
''	O
which	O
is	O
part	O
of	O
the	O
group	B-DIS
of	O
acrocephalosyndactyly	O
with	O
an	B-EPI
annual	O
incidence	B-STAT
<	O
1/100000	O
.	O

Three	O
forms	O
are	O
known	O
.	O

Type	O
I	O
is	O
the	O
less	O
common	O
form	O
and	O
it	O
is	O
characterized	O
by	O
moderate	O
-	B-DIS
severe	I-DIS
mediofacial	O
hypoplasia	O
usually	O
with	O
normal	O
cognitive	O
development	O
.	O

Conversely	O
types	O
2	O
and	O
3	O
are	O
more	O
common	O
and	O
they	O
are	O
associated	O
with	O
more	O
severe	O
signs	O
and	O
complications	O
with	O
a	O
more	O
unfavorable	O
prognosis	O
.	O

The	O
type	O
3	O
form	O
due	O
to	O
the	O
presence	O
of	O
a	O
cloverleaf	O
skull	O
distinguishes	O
type	O
2	O
.	O

Materials	O
and	O
methods	O
Thirty	O
-	O
eight	O
-	O
year	O
-	O
old	O
primigravida	O
was	O
referred	O
to	O
our	O
center	O
at	O
28	O
weeks	B-DIS
of	I-DIS
gestation	O
due	O
to	O
borderline	O
ventriculomegaly	O
macrocrania	O
and	O
a	O
short	O
femur	O
.	O

First	O
trimester	O
screening	O
for	O
chromosomopathies	B-DIS
and	O
CF	O
-	O
DNA	O
was	O
low	O
risk	O
;	O
II	O
trimester	O
screening	O
ultrasound	O
showed	O
the	O
presence	O
of	O
`	O
`	O
short	O
femur	O
''	B-DIS
and	O
macrocrania	O
.	O

Result	O
Our	O
ultrasound	O
evaluation	O
assisted	O
by	O
3D	O
ultrasound	O
showed	O
cloverleaf	O
skull	O
turricephaly	O
moderate	O
ventriculomegaly	B-DIS
13	O
mm	O
hypertelorism	B-DIS
and	O
exophthalmos	B-DIS
low	O
ear	O
implantation	O
mild	O
rhizomelia	B-DIS
.	O

Ultrasound	O
depicts	O
Pfeiffer	B-DIS
syndrome	I-DIS
or	O
other	O
acrocephalosyndactyly	B-DIS
syndromes	I-DIS
Apert	I-DIS
syndromes	I-DIS
Saethre	I-DIS
-	O
Chotzen	O
or	O
other	O
syndromic	O
forms	B-DIS
of	O
craniosynostosis	B-DIS
like	I-DIS
Crouzon	O
syndrome	O
.	O

The	O
NGS	O
panel	O
for	O
molecular	O
analysis	O
of	O
genes	O
involved	O
in	O
skeletal	O
dysplasias	O
showed	O
the	O
mutation	O
of	O
the	O
FGFR2	O
gene	O
de	O
novo	O
.	O

Conclusions	O
Using	O
three	O
-	O
dimensional	O
3D	O
ultrasound	O
it	O
is	O
easier	O
to	O
distinguish	O
rare	O
syndromes	O
characterized	O
by	O
facial	O
dysmorphisms	O
such	B-DIS
as	O
exophthalmos	B-DIS
mediofacial	O
hypoplasia	B-DIS
and	O
craniosynostosis	O
.	O

In	O
the	O
year	O
2000	O
the	O
discovery	O
of	O
OPA1	O
mutations	O
as	O
causative	O
for	O
dominant	O
optic	B-DIS
atrophy	I-DIS
DOA	O
was	O
pivotal	O
to	O
rapidly	O
expand	O
the	O
field	O
of	O
mitochondrial	O
dynamics	O
and	O
describe	O
the	O
complex	O
machinery	O
governing	O
this	O
pathway	O
with	O
a	O
multitude	O
of	O
other	O
genes	O
and	O
encoded	O
proteins	O
involved	O
in	O
neurodegenerative	B-DIS
disorders	I-DIS
of	I-DIS
the	I-DIS
optic	I-DIS
nerve	I-DIS
.	O

OPA1	O
turned	O
out	O
to	O
be	O
a	O
much	O
more	O
complex	O
protein	O
than	O
initially	O
envisaged	O
connecting	O
multiple	O
pathways	O
beyond	O
its	O
strict	O
role	O
in	O
mitochondrial	O
fusion	O
such	O
as	O
sensing	O
of	O
OXPHOS	O
needs	O
and	O
mitochondrial	O
DNA	O
maintenance	O
.	O

As	O
a	O
consequence	O
an	O
increasing	O
need	O
to	O
investigate	O
OPA1	O
functions	O
at	O
multiple	O
levels	O
has	O
imposed	O
the	O
development	O
of	O
multiple	O
tools	O
and	O
models	O
that	O
are	O
here	O
reviewed	O
.	O

Translational	O
mitochondrial	O
medicine	O
with	O
the	O
ultimate	O
objective	O
of	O
translating	O
basic	O
science	O
necessary	O
to	O
understand	O
pathogenic	O
mechanisms	O
into	O
therapeutic	O
strategies	O
requires	O
disease	O
modeling	O
at	O
multiple	O
levels	O
from	O
the	O
simplest	O
like	O
in	O
yeast	O
to	O
cell	O
models	O
including	O
the	O
increasing	O
use	O
of	O
reprogrammed	O
stem	O
cells	O
iPSCs	O
from	O
patients	O
to	O
animal	O
models	O
.	O

In	O
the	O
present	O
review	O
we	O
thoroughly	O
examine	O
and	O
provide	O
the	O
state	O
of	O
the	O
art	O
of	O
all	O
these	O
approaches	O
.	O

Background	O
The	O
prevalence	B-EPI
of	O
developmental	O
alterations	O
associated	O
with	O
in	O
-	O
utero	O
Zika	O
virus	O
ZIKV	O
exposure	O
in	O
children	O
is	O
not	O
well	O
understood	O
.	O

Furthermore	O
estimation	O
of	O
the	O
Population	O
Attributable	O
Fraction	O
PAF	O
of	O
developmental	O
alterations	O
attributed	O
to	O
ZIKV	O
has	O
not	O
been	O
performed	O
due	O
to	O
lack	O
of	O
population	O
-	O
based	O
cohorts	O
with	O
data	O
on	O
symptomatic	O
and	O
asymptomatic	O
ZIKV	O
exposures	O
and	O
an	O
appropriate	O
control	O
group	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
characterize	O
neurodevelopmental	O
outcomes	O
of	O
children	O
at	O
11	O
to	O
32	O
months	O
of	O
age	O
with	O
intrauterine	B-DIS
ZIKV	I-DIS
exposure	O
and	O
estimate	O
the	O
PAF	O
of	O
alterations	O
secondary	O
to	O
ZIKV	O
exposure	O
.	O

Methodology	O
/	O
principal	O
findings	O
We	O
performed	O
a	O
cohort	O
of	O
biannual	O
community	O
-	O
based	O
prospective	O
serosurveys	O
in	O
a	O
slum	O
community	O
in	O
Salvador	B-LOC
Brazil	B-LOC
.	O

We	O
recruited	O
women	O
participating	O
in	O
our	O
cohort	O
with	O
a	O
documented	O
pregnancy	O
from	O
January	O
2015	O
to	O
December	O
2016	O
and	O
children	O
born	O
to	O
those	O
mothers	O
.	O

Children	O
were	O
classified	O
as	O
ZIKV	O
exposed	O
in	O
utero	O
born	O
from	O
women	O
with	O
ZIKV	O
seroconversion	O
during	O
pregnancy	O
or	O
unexposed	O
born	O
from	O
women	O
without	O
ZIKV	O
seroconversion	O
or	O
that	O
seroconverted	O
before	O
/	O
after	O
pregnancy	O
by	O
using	O
an	O
IgG	O
monoclonal	O
antibody	O
blockade	O
-	O
of	O
-	O
binding	O
BoB	O
.	O

We	O
interviewed	O
mothers	O
and	O
performed	O
anthropometric	O
audiometric	O
ophthalmological	O
neurologic	B-DIS
and	I-DIS
neurodevelopmental	I-DIS
evaluations	O
of	O
their	O
children	O
at	O
11	O
to	O
32	O
months	O
of	O
age	O
.	O

Among	O
the	O
655	O
women	O
participating	O
in	O
the	O
cohort	O
6610	B-STAT
%	I-STAT
were	O
pregnant	O
during	O
the	O
study	O
period	O
.	O

4670	B-STAT
%	I-STAT
of	O
them	O
completed	O
follow	O
-	O
up	O
of	O
whom	O
ZIKV	O
seroconversion	O
occurred	O
before	O
during	O
and	O
after	O
pregnancy	O
in	O
2554	B-STAT
%	I-STAT
1328	B-STAT
%	I-STAT
and	I-STAT
12	I-STAT
%	I-STAT
respectively	O
.	O

The	O
rest	O
of	O
women	O
721.2	B-STAT
%	I-STAT
did	O
not	O
present	O
ZIKV	O
seroconversion	O
.	O

At	O
11	O
to	O
32	O
months	O
of	O
life	O
the	O
13	O
ZIKV	O
-	O
exposed	O
children	O
had	O
increased	O
risk	O
of	B-DIS
mild	I-DIS
cognitive	O
delay	O
RR	O
5.1	O
;	O
95	B-STAT
%	I-STAT
CI	O
1.1	O
-	O
24.4	O
compared	O
with	O
the	O
33	O
children	O
unexposed	O
with	O
a	O
PAF	O
of	O
53.5	B-STAT
%	I-STAT
.	O

Exposed	O
children	O
also	O
had	O
increased	O
risk	O
of	O
altered	O
auditory	O
behavior	O
RR	O
6.0	O
;	O
95	B-STAT
%	I-STAT
CI	O
1.3	O
-	O
26.9	O
with	O
a	O
PAF	O
of	O
59.5	B-STAT
%	I-STAT
.	O

Conclusions	O
A	O
significant	O
proportion	O
of	O
children	O
exposed	O
in	O
utero	O
to	O
ZIKV	O
developed	O
mild	O
cognitive	B-DIS
delay	I-DIS
and	I-DIS
auditory	I-DIS
behavioral	I-DIS
abnormalities	I-DIS
even	O
in	O
the	O
absence	O
of	O
gross	O
birth	B-DIS
defects	I-DIS
such	O
as	O
microcephaly	B-DIS
and	O
other	O
neurodevelopmental	O
domains	O
.	O

Furthermore	O
our	O
findings	O
suggest	O
that	O
over	O
half	O
of	O
these	O
abnormalities	O
could	O
be	O
attributed	O
to	O
intrauterine	O
ZIKV	O
exposure	O
.	O

Pierson	B-DIS
syndrome	I-DIS
an	O
autosomal	B-DIS
recessive	I-DIS
disorder	I-DIS
caused	O
by	O
a	O
mutation	O
in	O
laminin	O
ß2	O
LAMB2	O
gene	O
is	O
characterized	O
by	O
congenital	B-DIS
nephrotic	I-DIS
syndrome	I-DIS
and	O
various	O
ocular	B-DIS
abnormalities	I-DIS
.	O

The	O
ocular	O
findings	O
in	O
Pierson	B-DIS
syndrome	I-DIS
are	O
not	O
well	O
understood	O
because	O
the	O
incidence	B-EPI
of	O
this	O
syndrome	O
is	O
very	O
rare	O
.	O

We	O
report	O
ocular	O
findings	O
in	O
a	O
5	O
-	O
month	O
-	B-DIS
old	I-DIS
boy	O
with	O
Pierson	O
syndrome	O
with	O
a	O
novel	O
mutation	O
in	O
LAMB2	B-LOC
.	O

We	O
performed	O
a	O
pupilloplasty	O
for	O
his	O
microcoria	B-DIS
.	O

Ophthalmic	O
examinations	O
after	O
surgery	O
revealed	O
that	O
he	O
had	O
cataract	B-DIS
severe	O
retinal	B-DIS
degeneration	I-DIS
and	O
high	O
myopia	B-DIS
.	O

Optical	O
coherence	O
tomography	O
showed	O
the	O
collapse	B-DIS
of	I-DIS
retinal	I-DIS
layer	I-DIS
structures	I-DIS
and	O
a	O
marked	O
decrease	B-DIS
of	I-DIS
choroidal	I-DIS
thickness	I-DIS
.	O

Immunohistochemistry	O
and	O
electron	O
microscopy	O
examinations	O
revealed	O
abnormal	B-DIS
iris	I-DIS
differentiation	O
and	O
thinning	O
or	O
defect	O
of	O
basal	O
membranes	O
.	O

These	O
results	O
suggest	O
that	O
the	O
development	O
of	O
the	O
iris	B-DIS
lens	I-DIS
retina	I-DIS
and	I-DIS
choroid	I-DIS
are	O
affected	O
in	O
this	O
type	O
of	O
mutation	O
.	O

About	B-STAT
30	I-STAT
%	I-STAT
of	O
patients	O
with	O
MEN1	B-DIS
develop	O
a	O
Zollinger	B-DIS
-	I-DIS
Ellison	O
syndrome	O
.	O

Meanwhile	O
it	O
is	O
well	O
established	O
that	O
the	O
causative	O
gastrinomas	B-DIS
are	O
almost	O
exclusively	O
localized	O
in	O
the	O
duodenum	O
and	O
not	O
in	O
the	O
pancreas	B-DIS
MEN1	I-DIS
gastrinomas	I-DIS
occur	O
multicentric	O
and	O
are	O
associated	O
with	O
hyperplastic	O
gastrin	O
cell	O
lesions	O
and	O
tiny	O
gastrin	O
-	O
producing	O
micro	O
tumors	O
in	O
contrast	O
to	B-DIS
sporadic	I-DIS
duodenal	O
gastrinomas	O
.	O

Regardless	O
of	O
the	O
high	O
prevalence	B-EPI
of	O
early	O
lymphatic	O
metastases	O
the	O
survival	O
is	O
generally	O
good	O
with	O
an	O
aggressive	O
course	O
of	O
disease	O
in	O
only	B-STAT
about	I-STAT
20	I-STAT
%	I-STAT
of	O
patients	O
.	O

Symptoms	O
can	O
be	O
controlled	O
medically	O
.	O

The	O
indication	O
timing	O
type	O
and	O
extent	O
of	O
surgery	O
are	O
highly	O
controversial	O
and	O
are	O
discussed	O
in	O
detail	O
in	O
this	O
article	O
by	O
a	O
thorough	O
and	O
critical	O
review	O
of	O
literature	O
.	O

More	O
radical	O
procedures	O
like	O
partial	O
pancreaticoduodenectomy	O
are	O
weighed	O
against	O
less	O
aggressive	O
local	O
excision	O
of	O
gastrinomas	B-DIS
and	O
the	O
pros	O
and	O
cons	O
of	O
both	O
approaches	O
are	O
discussed	O
in	O
terms	O
of	O
long	O
-	O
term	O
morbidity	O
biochemical	O
cure	O
and	O
survival	O
.	O

Objective	O
To	O
determine	O
the	O
prevalence	B-EPI
profile	O
and	O
predictors	O
of	O
infections	B-DIS
in	O
an	O
Indian	O
cohort	O
of	O
IIM	B-DIS
.	O

Methods	O
We	O
reviewed	O
the	O
records	O
of	O
a	O
retrospective	O
cohort	O
of	O
IIM	B-DIS
enrolled	O
from	O
consecutive	O
patients	O
following	O
up	O
in	O
the	O
clinic	O
as	O
the	O
observation	O
cohort	O
OC	B-LOC
.	O

A	O
newly	O
diagnosed	O
inception	O
cohort	O
of	O
IIM	B-DIS
were	O
followed	O
prospectively	O
as	O
the	O
validation	O
cohort	O
VC	O
to	O
confirm	O
observations	O
and	O
compare	O
with	O
the	O
OC	O
.	O

Results	O
Among	O
68	O
patients	O
in	O
the	O
OC	O
age	O
33.4	O
years	O
F	O
M	O
4.2137	O
54.4	B-STAT
%	I-STAT
experienced	O
54	O
infections	B-DIS
of	O
which	O
2138.8	B-STAT
%	I-STAT
were	O
major	O
and	O
recurrent	O
infections	B-DIS
in	O
11	O
patients	O
16.17	B-STAT
%	I-STAT
over	O
3.08	O
years	O
.	O

Tuberculosis	B-DIS
was	O
the	O
most	O
common	O
infection	B-DIS
1222.2	B-STAT
%	I-STAT
with	O
predominance	O
of	O
extra	O
-	O
pulmonary	O
forms	O
.	O

Serum	O
protein	O
OR	O
0.44	O
platelets	O
0.44	O
at	O
disease	O
onset	O
and	O
daily	O
steroid	O
dose	O
1.04	O
predicted	O
major	O
infections	B-DIS
on	O
multivariate	O
analysis	O
.	O

A	O
higher	O
daily	O
dose	O
of	O
steroids	O
at	O
first	O
infection	B-DIS
correlated	O
with	O
number	O
of	O
recurrent	O
infections	B-DIS
.	O

Infection	B-DIS
free	O
one	O
-	O
year	O
survival	O
was	O
73.8	B-STAT
%	I-STAT
.Of	O
70	O
patients	O
in	O
VC	O
35.7	O
years	O
F	O
M	O
3.71	O
three	B-DIS
had	O
myositis	O
attributed	O
to	B-DIS
an	O
infection	O
.	O

Similar	O
proportion	O
of	O
total	O
2233.3	B-STAT
%	I-STAT
major	O
1045.4	B-STAT
%	I-STAT
and	O
recurrent	O
418	B-STAT
%	I-STAT
infections	B-DIS
were	O
recorded	O
.	O

Most	O
common	O
infection	B-DIS
was	O
community	O
acquired	O
pneumonia	B-DIS
followed	O
by	O
Tuberculosis	B-DIS
with	O
serum	O
albumin	O
OR	O
0.25	O
at	O
disease	O
onset	O
being	O
the	O
only	O
predictor	O
.	O

One	O
-	B-DIS
year	O
infection	O
free	O
survival	O
was	O
64.7	B-STAT
%	I-STAT
.	O

Those	O
who	O
had	O
a	O
major	B-DIS
infection	I-DIS
had	O
increased	O
mortality	O
at	O
1	O
year	O
with	O
survival	O
of	O
60	B-STAT
%	I-STAT
compared	O
with	O
89.09	B-STAT
%	I-STAT
in	O
those	O
without	O
.	O
In	O
both	O
cohorts	O
a	O
daily	O
prednisone	O
dos	O
6.25	O
mg	O
predisposed	O
to	O
major	O
infections	B-DIS
.	O

Conclusion	O
Major	O
and	O
recurrent	O
infections	B-DIS
are	O
common	O
in	O
Indian	O
IIM	B-DIS
patients	O
and	O
confer	O
higher	O
risk	O
for	O
future	O
infections	B-DIS
and	O
lower	O
survival	O
.	O

Respiratory	O
and	O
atypical	O
bacterial	B-DIS
infections	I-DIS
such	O
as	O
Tuberculosis	B-DIS
occur	O
throughout	O
the	O
disease	O
course	O
.	O

The	O
disease	O
and	O
the	O
case	O
reported	O
here	O
are	O
relevant	O
especially	O
because	O
of	O
their	O
varied	O
clinical	O
presentation	O
possibility	O
of	O
being	O
associated	O
with	O
other	O
disorders	O
affecting	O
several	O
organs	O
and	O
possible	O
differential	O
diagnoses	O
.	O

Congenital	B-DIS
Hepatic	I-DIS
Fibrosis	I-DIS
is	O
an	O
autosomal	B-DIS
recessive	I-DIS
disease	I-DIS
due	O
to	O
mutation	O
in	O
the	O
PKHD1	O
gene	O
which	O
encodes	O
the	O
fibrocystin	O
/	O
polyductine	O
protein	O
.	O

It	O
is	O
a	O
cholangiopathy	B-DIS
characterized	O
by	O
varying	O
degrees	O
of	O
periportal	O
fibrosis	B-DIS
and	O
irregular	O
proliferation	O
of	O
bile	O
ducts	O
.	O

Affected	O
patients	O
are	O
typically	O
diagnosed	O
in	O
childhood	O
but	O
in	O
some	O
cases	O
the	O
disease	O
may	O
remain	O
asymptomatic	O
for	O
many	O
years	O
.	O

The	O
exact	O
prevalence	B-EPI
and	O
incidence	B-EPI
of	O
the	O
disease	O
are	O
not	O
known	O
but	O
it	O
is	O
consider	O
a	O
rare	O
disease	O
with	O
a	O
few	O
hundred	O
cases	O
described	O
worldwide	O
.	O

It	O
can	O
affect	O
all	O
ethnic	O
groups	O
and	O
occur	O
associated	O
with	O
various	O
hereditary	B-DIS
and	O
non	B-DIS
-	I-DIS
hereditary	O
disorders	O
.	O

The	O
clinical	O
presentation	O
is	O
quite	O
variable	O
with	O
melena	B-DIS
and	O
hematemesis	B-DIS
being	O
initial	O
symptoms	O
in	O
30	B-STAT
%	I-STAT
-70	O
%	O
of	O
the	O
cases	O
.	O

More	O
rarely	O
they	O
may	O
present	O
episodes	O
of	O
cholangitis	B-DIS
.	O

The	O
disease	O
has	O
been	O
classified	O
into	O
four	O
types	O
portal	O
hypertension	B-DIS
cholestasis	I-DIS
/	I-DIS
cholangitis	I-DIS
mixed	O
and	O
latent	O
.	O

Diagnosis	O
begins	O
with	O
imaging	O
tests	O
but	O
the	O
definition	O
is	O
made	O
by	O
the	O
histopathological	O
sample	O
.	O

So	O
far	O
there	O
is	O
no	O
specific	O
therapy	O
that	O
can	O
stop	O
or	O
reverse	O
the	O
pathological	O
process	O
.	O

Currently	O
the	O
therapeutic	O
strategy	O
is	O
to	O
treat	O
the	O
complications	O
of	O
the	O
disease	O
.	O

The	O
Wiskott	B-DIS
-	I-DIS
Aldrich	I-DIS
syndrome	O
WAS	O
is	B-DIS
an	I-DIS
X	O
-	O
linked	O
disorder	O
caused	O
by	O
mutations	O
in	O
the	O
WAS	B-DIS
gene	I-DIS
resulting	I-DIS
in	O
congenital	B-DIS
thrombocytopenia	O
eczema	O
recurrent	O
infections	B-EPI
and	O
an	B-DIS
increased	I-DIS
incidence	O
of	O
autoimmune	O
diseases	O
and	O
malignancies	O
.	O

Without	O
curative	O
therapies	O
affected	O
patients	O
have	O
diminished	O
life	O
expectancy	O
and	O
reduced	O
quality	O
of	O
life	O
.	O

Since	O
WAS	O
protein	O
WASP	B-DIS
is	O
constitutively	O
expressed	O
only	O
in	O
hematopoietic	O
stem	O
cell	O
-	O
derived	O
lineages	O
hematopoietic	O
stem	O
cell	O
transplantation	O
HSCT	O
and	O
gene	O
therapy	O
GT	O
are	O
well	O
suited	O
to	O
correct	O
the	O
hematologic	B-DIS
and	I-DIS
immunologic	O
defects	O
.	O

Advances	O
in	O
high	O
-	O
resolution	O
HLA	O
typing	O
new	O
techniques	O
to	O
prevent	O
GvHD	O
allowing	O
the	O
use	O
of	O
haploidentical	O
donors	O
and	O
the	O
introduction	O
of	O
reduced	O
intensity	O
conditioning	O
regimens	O
with	O
myeloablative	O
features	O
have	O
increased	O
overall	O
survival	O
OS	O
to	O
over	B-STAT
90	I-STAT
%	I-STAT
.	O

The	O
development	O
of	O
GT	O
for	O
WAS	B-DIS
has	O
provided	O
basic	O
knowledge	O
into	O
vector	O
selection	O
and	O
random	O
integration	O
of	O
various	O
viral	O
vectors	O
into	O
the	O
genome	O
with	O
the	O
possibility	O
of	O
inducing	O
leukemogenesis	O
.	O

After	O
trials	O
and	O
errors	O
inactivating	O
lentiviral	O
vectors	O
carrying	O
the	O
WAS	O
gene	O
were	O
successfully	O
evaluated	O
in	O
clinical	O
trials	O
demonstrating	O
cure	O
of	O
the	O
disease	O
except	O
for	O
insufficient	O
resolution	O
of	O
the	O
platelet	O
defect	O
.	O

Thus	O
50	O
years	O
of	O
clinical	O
evaluation	O
genetic	O
exploration	O
and	O
extensive	O
clinical	O
trials	O
a	O
lethal	O
syndrome	O
has	O
turned	O
into	O
a	O
curable	B-DIS
disorder	I-DIS
.	O

Objective	O
The	O
purpose	O
of	O
this	O
meta	O
-	O
analysis	O
of	O
longitudinal	O
studies	O
is	O
to	O
determine	O
the	O
safety	O
and	O
efficacy	O
of	O
artesunate	O
combined	O
with	O
other	O
forms	O
of	O
adjunctive	O
therapies	O
for	B-DIS
severe	O
malaria	O
.	O

Methods	O
Following	O
the	O
PRISMA	O
guidelines	O
we	O
searched	O
multiple	O
databases	O
with	O
the	O
search	O
terms	O
`	O
`	O
artesunate	O
''	O
and	O
`	O
`	O
adjunctive	O
therapy	O
''	O
and	O
`	O
`	O
severe	O
malaria	B-DIS
''	O
in	O
July	O
2020	O
.	O

If	O
the	O
search	O
showed	O
a	O
randomized	O
controlled	O
trial	O
the	O
study	O
was	O
included	O
in	O
this	O
meta	O
-	O
analysis	O
.	O

The	O
random	O
-	O
effects	O
model	O
was	O
used	O
to	O
calculate	O
the	B-EPI
combined	O
incidence	O
rate	O
and	O
relative	O
risk	O
or	O
risk	O
difference	O
.	O

Results	O
This	O
meta	O
-	O
analysis	O
included	O
nine	O
longitudinal	O
studies	O
with	O
724	O
participants	O
.	O

We	O
found	O
that	O
the	O
mortality	O
rates	O
in	O
the	O
artesunate	O
monotherapy	O
group	O
and	O
the	O
artesunate	O
+	O
adjuvant	O
therapy	O
group	O
are	O
similar	O
RD	O
=	O
-0.0295	O
%	O
confidence	O
interval	O
-0.06	O
-	O
0.02	O
.	O

The	O
incidence	B-EPI
of	O
adverse	O
reactions	O
in	O
the	O
artesunate	O
monotherapy	O
group	O
and	O
the	O
artesunate	O
+	O
adjuvant	O
therapy	O
group	O
was	O
also	O
similar	O
.	O

Conclusion	O
No	O
significant	O
differences	O
in	O
safety	O
and	O
efficacy	O
were	O
observed	O
between	O
the	O
artesunate	O
monotherapy	O
group	O
and	O
the	O
artesunate	O
+	O
adjuvant	O
therapy	O
group	O
.	O

Higher	O
quality	O
and	O
rigorously	O
designed	O
randomized	O
controlled	O
studies	O
are	O
needed	O
to	O
validate	O
our	O
findings	O
.	O

Background	O
Neurological	O
involvement	O
due	O
to	O
intraspinal	O
extension	O
in	O
sacrococcygeal	B-DIS
malignant	I-DIS
germ	I-DIS
cell	I-DIS
tumors	I-DIS
SC	O
-	O
MGCTs	O
has	O
rarely	O
been	O
reported	O
.	O

Aim	O
To	O
evaluate	O
the	O
incidence	B-EPI
presentation	O
management	O
and	O
the	O
outcome	O
of	O
patients	O
of	O
SC	O
-	O
MGCT	O
with	O
intraspinal	O
extension	O
.	O

Materials	O
and	O
methods	O
Case	O
records	O
of	O
all	O
cases	O
of	O
SC	O
-	O
MGCT	O
from	O
2001	O
to	O
2008	O
were	O
reviewed	O
to	O
identify	O
cases	O
with	O
vertebral	O
involvement	O
and	O
intraspinal	O
extension	O
.	O

They	O
were	O
evaluated	O
in	O
terms	O
of	O
their	O
presentation	O
response	O
to	O
therapy	O
extent	O
of	O
surgical	O
resection	O
recovery	O
of	O
neurological	O
symptoms	O
and	O
outcome	O
.	O

Results	O
Of	O
the	O
31	O
cases	O
of	O
SC	O
-	O
MGCT	O
516	B-STAT
%	B-DIS
had	I-DIS
intraspinal	O
extension	O
.	O

Age	O
ranged	O
from	O
12	O
to	O
84	O
months	O
median	O
24	O
months	O
.	O

Four	O
patients	O
had	O
Altman	O
type	B-DIS
4	I-DIS
disease	I-DIS
stage	I-DIS
4	I-DIS
and	I-DIS
1	I-DIS
had	O
Altman	O
type	O
3	O
stage	O
3	O
disease	O
.	O

The	O
intraspinal	O
extension	O
in	O
all	O
patients	O
was	O
detected	O
on	O
contrast	O
CT	O
scan	O
.	O

Patients	O
presented	O
with	O
neurological	O
symptoms	O
in	O
the	O
form	O
of	O
lower	O
limb	O
paresis	B-DIS
80	B-STAT
%	I-STAT
bowel	O
and	O
bladder	O
20	B-STAT
%	I-STAT
incontinence	B-DIS
.	O

All	O
the	O
tumors	B-DIS
responded	O
to	O
pre	O
-	O
operative	O
chemotherapy	O
.	O

Gross	O
complete	O
local	O
resection	O
could	O
be	O
achieved	O
in	O
480	B-STAT
%	I-STAT
.	O

Neurological	O
recovery	O
was	O
complete	O
in	O
all	O
except	O
for	O
persisting	O
neurogenic	O
bladder	O
in	O
one	O
.	O

During	O
follow	O
up	O
of	O
3	O
-	O
32	O
months	O
all	O
were	O
alive	O
with	O
no	O
recurrence	O
.	O

Conclusions	O
SC	O
-	O
MGCT	O
presenting	B-DIS
with	I-DIS
neurological	O
deficits	O
due	O
to	O
intraspinal	O
extension	O
is	O
usually	O
advanced	O
disease	O
.	O

These	O
patients	O
respond	O
to	O
chemotherapy	O
and	O
surgical	O
resection	O
and	O
most	O
have	O
complete	O
neurological	O
improvement	O
.	O

Objective	O
To	O
verify	O
the	O
prevalence	B-EPI
of	O
novel	O
definitions	O
of	O
familial	O
short	O
stature	B-DIS
on	O
a	O
cross	O
-	O
sectional	O
cohort	O
of	O
children	O
referred	O
for	B-DIS
short	O
stature	O
when	O
their	O
height	O
and	O
that	O
of	O
both	O
parents	O
were	O
measured	O
.	O

Methods	O
We	O
consecutively	O
enrolled	O
65	O
individuals	O
referred	O
for	O
short	O
stature	B-DIS
when	O
both	O
parents	O
were	O
present	O
.	O

We	O
defined	O
`	O
`	O
target	O
height	O
-	O
related	O
short	O
stature	O
''	O
TH	O
-	O
SS	O
when	O
child	O
's	O
height	O
is	O
≤	O
-	O
2	O
SDS	O
and	O
included	O
in	O
the	O
range	O
of	O
target	O
height	O
;	O
suspected	O
`	O
`	O
autosomal	O
dominant	O
short	O
stature	O
''	O
AD	O
-	O
SS	O
when	O
child	O
height	O
and	O
at	O
least	O
one	O
parent	O
height	O
are	O
≤	O
-	O
2	O
SDS	O
;	O
`	O
`	O
constitutional	O
familial	O
short	O
stature	O
''	O
C	O
-	O
FSS	O
when	O
a	O
child	O
with	O
TH	O
-	O
SS	O
does	O
not	O
have	O
any	O
parents	O
with	O
height	O
≤	O
-	O
2	O
SDS	O
.	O

Results	O
Of	O
65	O
children	O
referred	O
for	O
SS	B-DIS
48	O
individuals	O
had	O
a	O
height	O
≤	O
-	O
2	O
SDS	O
.	O

Based	O
on	O
the	O
parents	O
'	O
measured	O
heights	O
24	O
children	O
had	O
TH	O
-	O
SS	O
16	O
subjects	O
AD	O
-	O
SS	O
and	O
12	O
individuals	O
C	O
-	O
FSS	O
.	O

If	O
we	O
had	O
considered	O
only	O
the	O
parents	O
'	O
reported	O
height	O
3	O
of	O
24	O
children	O
with	O
TH	O
-	O
SS	O
9	O
of	O
16	O
with	O
AD	O
-	O
SS	O
and	O
10	O
of	O
12	O
with	O
C	O
-	O
FSS	O
would	O
have	O
been	O
lost	O
.	O

Conclusion	O
We	O
suggest	O
novel	O
definitions	O
to	O
adequately	O
detect	O
and	O
approach	O
the	O
cases	O
of	O
FSS	O
since	O
C	O
-	O
FSS	O
25	B-STAT
%	I-STAT
might	O
not	O
need	O
any	O
specific	O
investigation	O
while	O
on	O
the	O
contrary	O
AD	O
-	O
SS	O
33	B-STAT
%	I-STAT
should	O
undergo	O
genetic	O
evaluation	O
.	O

Moreover	O
this	O
study	O
underlines	O
that	O
adequate	O
measurement	O
and	O
consideration	O
of	O
children	O
's	O
and	O
parents	O
'	O
heights	O
individually	O
and	O
together	O
are	O
crucial	O
in	O
the	O
clinical	O
evaluation	O
of	O
every	O
child	O
with	O
short	O
stature	B-DIS
.	O

Objective	O
This	O
study	O
aimed	O
to	O
examine	O
the	O
application	O
of	O
the	O
Objective	O
Structured	O
Clinical	O
Examination	O
OSCE	O
to	O
the	O
assessment	O
of	O
competency	O
among	O
child	O
and	O
adolescent	O
psychiatry	O
CAP	O
residents	O
and	O
to	O
analyze	O
the	O
feedback	O
from	O
the	O
residents	O
and	O
the	O
examiners	O
.	O

Methods	O
The	O
OSCE	O
was	O
administered	O
to	O
53	O
CAP	O
residents	O
based	O
on	O
three	O
seniority	O
levels	O
over	O
a	O
14	O
-	O
year	O
period	O
.	O

The	O
results	O
of	O
147	O
OSCEs	O
applied	O
to	O
residents	O
and	O
the	O
feedback	O
received	O
were	O
evaluated	O
.	O

OSCE	O
scores	O
were	O
calculated	O
based	O
on	O
the	O
scores	O
given	O
by	O
the	O
examiners	O
and	O
standardized	O
patients	O
SPs	O
.	O

Results	O
Examiners	O
'	O
communication	O
skills	O
scores	O
were	O
significantly	O
higher	O
than	O
examiners	O
'	O
task	O
performance	O
scores	O
but	O
were	O
not	O
significantly	O
different	O
than	O
the	O
SPs	O
'	O
scores	O
.	O

Intraclass	O
correlation	O
coefficients	O
indicated	O
that	O
examiners	O
and	O
SPs	O
were	O
very	O
consistent	O
in	O
their	O
assessments	O
among	O
themselves	O
.	O

The	O
scores	O
given	O
by	O
the	O
examiners	O
and	O
the	O
SPs	O
were	O
not	O
different	O
between	O
genders	O
except	O
for	O
female	O
residents	O
'	O
communication	O
skills	O
scores	O
given	O
by	O
SPs	O
in	O
the	O
OSCE	O
-	O
senior	O
.	O

With	O
regard	O
to	O
the	O
feedback	O
on	O
the	O
OSCE	O
it	O
was	O
determined	O
that	O
examiners	O
gave	O
significantly	O
higher	O
scores	O
than	O
residents	O
on	O
every	O
item	O
except	O
for	O
`	O
`	O
neutrality	O
of	O
the	O
examiners	O
.	O
''	O

Conclusions	O
A	O
standard	O
OSCE	O
including	O
different	O
station	O
types	O
was	O
structured	O
to	O
assess	O
the	O
progressive	O
clinical	O
skills	O
of	O
residents	O
over	O
the	O
years	O
.	O

Using	O
the	O
OSCE	O
contributed	O
to	O
CAP	O
residency	O
training	O
far	O
beyond	O
assessment	O
creating	O
a	O
useful	O
educational	O
experience	O
for	O
both	O
the	O
trainers	O
and	O
the	O
residents	O
.	O

Despite	O
the	O
challenge	O
experienced	O
related	O
to	O
SPs	O
the	O
OSCE	O
was	O
found	O
to	O
be	O
useful	O
in	O
improving	O
training	O
programs	O
.	O

Bullous	O
pemphigoid	B-DIS
BP	O
is	O
the	O
most	O
prevalent	O
autoimmune	B-DIS
blistering	I-DIS
skin	I-DIS
disease	I-DIS
in	O
the	O
Western	O
world	O
affecting	O
mainly	O
the	O
elderly	O
population	O
.	O

The	O
diagnosis	O
is	O
based	O
on	O
clinical	O
assessment	O
along	O
with	O
specific	O
immunopathologic	O
findings	O
on	O
skin	O
biopsy	O
.	O

Risk	O
factors	O
include	O
genetic	O
factors	O
environmental	O
exposures	O
and	O
several	O
infections	B-DIS
including	O
hepatitis	B-DIS
B	I-DIS
hepatitis	I-DIS
C	I-DIS
Helicobacter	O
pylori	O
Toxoplasma	O
gondi	O
and	O
cytomegalovirus	O
.	O

A	O
variety	O
of	O
drugs	O
have	O
been	O
associated	O
with	O
BP	O
including	O
but	O
not	O
limited	O
to	O
dipeptidyl	O
peptidase-4	O
inhibitors	O
loop	O
diuretics	O
spironolactone	O
and	O
neuroleptics	O
.	O

Associated	O
neurologic	B-DIS
disorders	I-DIS
dementia	I-DIS
Parkinson	I-DIS
's	I-DIS
disease	I-DIS
bipolar	I-DIS
disorder	I-DIS
previous	O
stroke	B-DIS
history	O
and	O
multiple	B-DIS
sclerosis	I-DIS
have	O
also	O
been	O
described	O
.	O

Common	O
clinical	O
presentation	O
consists	O
of	O
extremely	O
pruritic	O
inflammatory	O
plaques	O
that	O
resemble	O
eczematous	O
dermatitis	B-DIS
or	O
urticaria	B-DIS
followed	O
by	O
formation	O
of	O
tense	O
bullae	B-DIS
with	O
subsequent	O
erosions	B-DIS
.	O

Typical	O
distribution	O
involves	O
the	O
trunk	O
and	O
extremities	O
.	O

Mucosa	O
is	O
typically	O
spared	O
affecting	O
only	B-STAT
10	I-STAT
%	I-STAT
to	I-STAT
30	I-STAT
%	I-STAT
of	O
patients	O
.	O

Several	O
unusual	O
clinical	O
presentations	O
of	O
BP	O
have	O
been	O
described	O
such	O
as	O
nonbullous	B-DIS
forms	O
with	O
erythematous	O
excoriated	O
papules	O
plaques	O
and	O
nodules	O
.	O

Other	O
reported	O
findings	O
include	O
urticarial	B-DIS
lesions	I-DIS
prurigo	I-DIS
-	O
like	O
nodules	O
multiple	O
small	O
vesicles	B-DIS
resembling	I-DIS
dermatitis	O
herpetiformis	B-DIS
or	O
pompholyx	O
vegetating	B-DIS
and	O
purulent	O
lesions	O
localized	O
in	O
intertriginous	O
areas	O
and	O
even	B-DIS
exfoliative	O
erythroderma	O
.	O

Recognition	O
and	O
management	O
of	O
such	O
cases	O
can	O
present	O
a	O
diagnostic	O
challenge	O
to	O
clinicians	O
.	O

In	O
this	O
article	O
we	O
describe	O
another	O
variant	O
which	O
to	O
our	O
knowledge	O
is	O
the	O
first	O
case	O
to	O
present	O
with	O
a	O
cellulitis	O
-	O
like	O
presentation	O
in	O
a	O
patient	O
with	O
a	O
known	O
history	O
of	O
BP	O
.	O

Maintaining	O
proper	O
eye	O
alignment	O
is	O
necessary	O
to	O
generate	O
a	O
cohesive	O
visual	O
image	O
.	O

This	O
involves	O
the	O
coordination	O
of	O
complex	O
neural	O
networks	O
which	O
can	O
become	O
impaired	O
by	O
various	O
neurodegenerative	B-DIS
diseases	I-DIS
.	O

When	O
the	O
vergence	O
system	O
is	O
affected	O
this	O
can	O
result	O
in	O
strabismus	B-DIS
and	O
disorienting	O
diplopia	B-DIS
.	O

While	O
previous	O
studies	O
have	O
detailed	O
the	O
effect	O
of	O
these	O
disorders	O
on	O
other	O
eye	O
movements	O
such	O
as	O
saccades	O
relatively	O
little	O
is	O
known	O
about	O
strabismus	B-DIS
.	O

Here	O
we	O
focus	O
on	O
the	O
prevalence	B-EPI
clinical	O
characteristics	O
and	O
treatment	O
of	O
strabismus	B-DIS
and	O
disorders	B-DIS
of	I-DIS
vergence	I-DIS
in	O
Parkinson	B-DIS
's	I-DIS
disease	I-DIS
spinocerebellar	I-DIS
ataxia	I-DIS
Huntington	I-DIS
disease	I-DIS
and	O
multiple	O
system	O
atrophy	B-DIS
.	O

We	O
find	O
that	O
vergence	B-DIS
abnormalities	I-DIS
may	O
be	O
more	O
common	O
in	O
these	O
disorders	O
than	O
previously	O
thought	O
.	O

In	O
Parkinson	B-DIS
's	I-DIS
disease	I-DIS
the	O
evidence	O
suggests	O
that	O
strabismus	B-DIS
is	O
related	O
to	O
convergence	O
insufficiency	O
;	O
however	O
it	O
is	O
responsive	O
to	O
dopamine	O
replacement	O
therapy	O
and	O
can	O
therefore	O
fluctuate	O
with	O
medication	O
`	O
`	O
on	O
''	O
and	O
`	O
`	O
off	O
''	O
periods	O
throughout	O
the	O
day	O
.	O

Diplopia	B-DIS
is	O
also	O
established	O
as	O
a	O
side	O
effect	O
of	O
deep	O
brain	O
stimulation	O
and	O
is	O
thought	O
to	O
be	O
related	O
to	O
stimulation	O
of	O
the	O
subthalamic	O
nucleus	O
and	O
extraocular	O
motor	O
nucleus	O
among	O
other	O
structures	O
.	O

In	O
regards	O
to	O
the	O
spinocerebellar	B-DIS
ataxias	I-DIS
oculomotor	I-DIS
symptoms	I-DIS
are	O
common	O
in	O
many	O
subtypes	O
but	O
diplopia	B-DIS
is	O
most	O
common	O
in	O
SCA3	B-DIS
also	O
known	O
as	O
Machado	B-DIS
-	I-DIS
Joseph	O
disease	O
.	O

Ophthalmoplegia	B-DIS
and	O
vergence	B-DIS
insufficiency	I-DIS
have	O
both	O
been	O
implicated	O
in	O
strabismus	B-DIS
in	O
these	O
patients	O
but	O
can	O
not	O
fully	O
explain	O
the	O
properties	O
of	O
the	O
strabismus	B-DIS
suggesting	O
the	O
involvement	O
of	O
other	O
structures	O
as	O
well	O
.	O

Strabismus	B-DIS
has	O
not	O
been	O
reported	O
as	O
a	O
common	O
finding	O
in	O
Huntington	B-DIS
disease	I-DIS
or	O
atypical	O
parkinsonian	B-DIS
syndromes	I-DIS
and	O
more	O
studies	O
are	O
needed	O
to	O
determine	O
how	O
these	O
disorders	O
affect	O
binocular	O
alignment	O
.	O

Context	O
Aggrecan	O
encoded	O
by	O
the	O
ACAN	O
gene	O
is	O
the	O
main	O
proteoglycan	O
component	O
in	O
the	O
extracellular	O
cartilage	O
matrix	O
.	O

Heterozygous	O
mutations	O
in	O
ACAN	O
have	O
been	O
reported	O
to	O
cause	O
idiopathic	B-DIS
short	I-DIS
stature	I-DIS
.	O

However	O
the	O
prevalence	B-EPI
of	O
ACAN	O
pathogenic	O
variants	O
in	O
Chinese	O
short	O
stature	B-DIS
patients	O
and	O
clinical	O
phenotypes	O
remain	O
to	O
be	O
evaluated	O
.	O

Objective	O
We	O
sought	O
to	O
determine	O
the	O
prevalence	B-EPI
of	O
ACAN	O
pathogenic	O
variants	O
among	O
Chinese	O
short	O
stature	O
children	O
and	O
characterize	O
the	O
phenotypic	O
spectrum	O
and	O
their	O
responses	O
to	O
growth	O
hormone	O
therapies	O
.	O

Patients	O
and	O
methods	O
Over	O
1000	O
unrelated	O
short	O
stature	B-DIS
patients	O
ascertained	O
across	O
China	B-LOC
were	O
genetically	O
evaluated	O
by	O
next	O
-	O
generation	O
sequencing	O
-	O
based	O
test	O
.	O

Result	O
We	O
identified	O
10	O
novel	O
likely	O
pathogenic	O
variants	O
and	O
2	O
recurrent	O
pathogenic	O
variants	O
in	O
this	O
cohort	O
.	O

None	O
of	O
ACAN	O
mutation	O
carriers	O
exhibited	O
significant	O
dysmorphic	O
features	O
or	O
skeletal	O
abnormities	O
.	O

The	O
prevalence	B-EPI
of	O
ACAN	O
defect	O
is	O
estimated	O
to	O
be	O
1.2	B-STAT
%	I-STAT
in	O
the	O
whole	O
cohort	O
;	O
it	O
increased	O
to	O
14.3	B-STAT
%	I-STAT
among	O
those	O
with	O
advanced	O
bone	O
age	O
and	O
to	O
35.7	B-STAT
%	I-STAT
among	O
those	O
with	O
both	O
advanced	O
bone	O
age	O
and	O
family	O
history	O
of	O
short	O
stature	B-DIS
.	O

Nonetheless	O
5	O
of	O
11	O
ACAN	O
mutation	O
carries	O
had	O
no	O
advanced	O
bone	O
age	O
.	O

Two	O
individuals	O
received	O
growth	O
hormone	O
therapy	O
with	O
variable	O
levels	O
of	O
height	O
SD	O
score	O
improvement	O
.	O

Conclusion	O
Our	O
data	O
suggest	O
that	O
ACAN	O
mutation	O
is	O
1	O
of	O
the	O
common	O
causes	O
of	O
Chinese	O
pediatric	O
short	O
stature	B-DIS
.	O

Although	O
it	O
has	O
a	O
higher	O
detection	O
rate	O
among	O
short	O
stature	B-DIS
patients	O
with	O
advanced	O
bone	O
age	O
and	O
family	O
history	O
part	O
of	O
affected	O
probands	O
presented	O
with	O
delayed	O
bone	O
age	O
in	O
Chinese	O
short	O
stature	B-DIS
population	O
.	O

The	O
growth	O
hormone	O
treatment	O
was	O
moderately	O
effective	O
for	O
both	O
individuals	O
.	O

Objective	O
We	O
recently	O
recorded	O
a	O
high	O
prevalence	B-EPI
of	O
inclusion	O
body	O
myositis	B-DIS
IBM	O
in	O
patients	O
with	O
Sjögren	B-DIS
's	I-DIS
syndrome	I-DIS
SS	I-DIS
.	O

Whether	O
myositis	B-DIS
patients	O
with	O
SS	B-DIS
differ	O
from	O
myositis	B-DIS
patients	O
without	O
SS	B-DIS
in	O
terms	O
of	O
the	O
characteristics	O
of	O
the	O
myositis	B-DIS
is	O
currently	O
unknown	O
.	O

Anti	O
-	O
cytosolic	O
5'-nucleotidase	O
1	O
A	O
cN1A	O
has	O
recently	O
been	O
proposed	O
as	O
a	O
biomarker	O
for	O
IBM	O
but	O
is	O
also	O
frequent	B-DIS
in	O
SS	B-LOC
.	O

Whether	O
anti	O
-	O
cN1A	O
is	O
independently	O
associated	O
with	O
IBM	O
is	O
still	O
an	O
open	O
question	O
.	O

We	O
aimed	O
to	O
assess	O
the	O
significance	O
of	O
SS	O
and	O
anti	O
-	O
cN1A	B-DIS
in	O
myositis	O
patients	O
.	O

Methods	O
Cumulative	O
data	O
on	O
all	O
myositis	B-DIS
patients	O
EULAR	O
/	O
ACR	O
2017	O
criteria	O
screened	B-DIS
for	O
SS	O
ACR	O
/	O
EULAR	O
2016	O
criteria	O
in	O
a	O
single	O
center	O
were	O
analyzed	O
.	O

Ninety	O
-	O
nine	O
patients	O
were	O
included	O
covering	O
the	O
whole	O
spectrum	O
of	O
EULAR	B-DIS
/	O
ACR	O
2017	O
myositis	O
subgroups	O
and	O
with	O
a	O
median	O
follow	O
-	O
up	O
of	O
6	O
years	O
[	O
range	O
1.0	O
-	O
37.5	O
]	O
.	O

The	O
34	O
myositis	B-DIS
patients	O
with	O
SS	O
myositis	O
/	O
SS+	O
were	O
compared	O
with	O
the	B-DIS
65	O
myositis	O
patients	O
without	O
SS	O
myositis	O
/	O
SS-	O
.	O

Results	O
IBM	O
was	O
present	O
in	O
24	B-STAT
%	I-STAT
of	O
the	O
myositis	O
/	O
SS+	O
patients	O
vs	O
6	B-STAT
%	I-STAT
of	O
the	O
myositis	O
/	O
SS-	O
group	O
p	O
=	O
0.020	O
.	O

None	O
of	O
the	O
IBM	O
patients	O
responded	O
to	O
treatment	O
whether	O
they	O
had	O
SS	B-DIS
or	O
not	O
.	O

Anti	O
-	O
cN1A	O
was	O
more	O
frequent	O
in	O
myositis	O
/	O
SS+	O
patients	O
38	B-STAT
%	I-STAT
vs	O
6	B-STAT
%	I-STAT
p	O
=	O
0.0005	O
independently	B-EPI
of	O
the	O
higher	O
prevalence	O
of	O
IBM	O
in	O
this	O
group	O
multivariate	O
p	O
-	O
value	O
0.02	O
.	O

Anti	O
-	O
cN1A	O
antibody	O
specificity	O
for	O
IBM	O
was	O
0.96	O
[	O
95	B-STAT
%	I-STAT
CI	O
0.87	O
-	O
0.99	O
]	O
in	B-DIS
the	O
myositis	O
SS-	O
group	O
but	O
dropped	O
to	O
0.70	O
[	O
95	B-STAT
%	I-STAT
CI	O
0.48	O
-	O
0.85	O
]	O
in	B-DIS
the	O
myositis	O
SS/+	O
group	O
.	O

Interpretation	O
In	O
myositis	B-DIS
patients	O
SS	B-DIS
is	O
associated	O
with	O
IBM	O
and	O
with	O
anti	O
-	O
cN1A	O
antibodies	O
independently	O
of	O
the	O
IBM	O
diagnosis	O
.	O

As	O
a	O
consequence	O
anti	O
-	O
cN1A	O
has	O
limited	O
specificity	O
for	O
IBM	B-DIS
in	O
myositis	O
patients	B-DIS
with	O
SS	O
.	O

Although	O
geographic	O
information	O
system	O
-	O
based	O
studies	O
are	O
particularly	O
increasing	O
in	O
other	O
sectors	O
few	O
have	O
embraced	O
their	O
full	O
potential	O
in	O
health	O
services	O
allocation	O
in	O
Malaysia	B-LOC
.	O

This	O
study	O
aimed	O
to	O
produce	O
a	O
visual	O
map	O
on	O
the	O
distribution	O
of	O
smoking	O
cessation	O
clinics	O
SCCs	O
in	O
Malaysia	B-LOC
and	O
analyze	O
its	O
pattern	O
against	O
the	O
national	O
population	O
of	O
smokers	O
.	O

SCC	B-DIS
addresses	O
were	O
obtained	O
from	O
the	O
government	O
website	O
and	O
mapped	O
using	O
geographic	O
information	O
system	O
tools	O
.	O

A	O
total	O
of	O
199	O
and	O
449	O
private	O
and	O
public	O
SCCs	O
was	O
mapped	O
throughout	O
the	O
country	O
respectively	O
.	O

The	O
lowest	O
SCC	B-DIS
to	O
smoker	O
population	O
ratio	O
was	O
in	O
the	O
state	O
of	O
Negeri	O
Sembilan	O
with	O
13000	O
.	O

The	O
highest	O
SCC	B-DIS
to	O
smoker	O
population	O
ratio	O
was	O
in	O
Sabah	B-LOC
with	O
1	B-STAT
SCC	I-STAT
for	I-STAT
15000	I-STAT
smokers	O
.	O

Almost	B-STAT
70	I-STAT
%	I-STAT
of	O
SCCs	O
were	O
primary	O
health	O
clinics	O
.	O

Smoking	O
cessation	O
clinics	O
were	O
distributed	O
throughout	O
all	O
the	O
states	O
in	O
Malaysia	B-LOC
except	O
the	O
state	O
of	O
Sabah	B-LOC
.	O

More	O
than	O
1	B-STAT
out	I-STAT
of	I-STAT
10	I-STAT
women	O
worldwide	O
are	O
diagnosed	O
with	O
polycystic	B-DIS
ovary	I-DIS
syndrome	I-DIS
PCOS	I-DIS
the	O
leading	O
cause	O
of	O
female	O
reproductive	O
and	O
metabolic	B-DIS
dysfunction	I-DIS
.	O

Despite	O
its	O
high	O
prevalence	B-EPI
PCOS	B-DIS
and	O
its	O
accompanying	O
morbidities	O
are	O
likely	O
underdiagnosed	O
averagin	O
2	O
years	O
and	O
3	O
physicians	O
before	O
women	O
are	O
diagnosed	O
.	O

Although	O
it	O
has	O
been	O
intensively	O
researched	O
the	O
underlying	O
cause	O
s	O
of	O
PCOS	B-DIS
have	O
yet	O
to	O
be	O
defined	O
.	O

In	O
order	O
to	O
understand	O
PCOS	B-DIS
pathophysiology	O
its	O
developmental	O
origins	O
and	O
how	O
to	O
predict	O
and	O
prevent	O
PCOS	B-DIS
onset	O
there	O
is	O
an	O
urgent	O
need	O
for	O
safe	O
and	O
effective	O
markers	O
and	O
treatments	O
.	O

In	O
this	O
review	O
we	O
detail	O
which	O
animal	O
models	O
are	O
more	O
suitable	O
for	O
contributing	O
to	O
our	O
understanding	O
of	O
the	O
etiology	O
and	O
pathophysiology	O
of	O
PCOS	B-DIS
.	O

We	O
summarize	O
and	O
highlight	O
advantages	O
and	O
limitations	O
of	O
hormonal	O
or	O
genetic	O
manipulation	O
of	O
animal	O
models	O
as	O
well	O
as	O
of	O
naturally	O
occurring	O
PCOS	O
-	O
like	O
females	O
.	O

In	O
recent	O
years	O
the	O
number	O
of	O
disorders	O
known	O
to	O
affect	O
amino	O
acid	O
synthesis	O
has	O
grown	O
rapidly	O
.	O

Nor	O
is	O
it	O
just	O
the	O
number	O
of	O
disorders	O
that	O
has	O
increased	O
the	O
associated	O
clinical	O
phenotypes	O
have	O
also	O
expanded	O
spectacularly	O
primarily	O
due	O
to	O
the	O
advances	O
of	O
next	O
generation	O
sequencing	O
diagnostics	O
.	O

In	O
contrast	O
to	O
the	O
`	O
`	O
classical	O
''	O
inborn	O
errors	O
of	O
metabolism	O
in	O
catabolic	O
pathways	O
in	O
which	O
elevated	O
levels	O
of	O
metabolites	O
are	O
easily	O
detected	O
in	O
body	O
fluids	O
synthesis	O
defects	O
present	O
with	O
low	O
values	O
of	O
metabolites	O
or	O
confusingly	O
even	O
completely	O
normal	O
levels	O
of	O
amino	O
acids	O
.	O

This	O
makes	O
the	O
biochemical	O
diagnosis	O
of	O
this	O
relatively	O
new	O
group	O
of	O
metabolic	B-DIS
diseases	I-DIS
challenging	O
.	O

Defects	O
in	O
the	O
synthesis	O
pathways	O
of	O
serine	O
metabolism	O
glutamine	O
proline	O
and	O
recently	O
asparagine	O
have	O
all	O
been	O
reported	O
.	O

Although	O
these	O
amino	O
acid	O
synthesis	O
defects	O
are	O
in	O
unrelated	O
metabolic	O
pathways	O
they	O
do	O
share	O
many	O
clinical	O
features	O
.	O

In	O
children	O
the	O
central	O
nervous	O
system	O
is	O
primarily	O
affected	O
giving	O
rise	O
to	O
congenital	B-DIS
microcephaly	I-DIS
early	O
onset	O
seizures	B-DIS
and	O
varying	O
degrees	O
of	O
mental	B-DIS
disability	I-DIS
.	O

The	O
brain	B-DIS
abnormalities	I-DIS
are	O
accompanied	O
by	O
skin	B-DIS
disorders	I-DIS
such	O
as	O
cutis	B-DIS
laxa	I-DIS
in	O
defects	O
of	O
proline	O
synthesis	O
collodion	O
-	O
like	O
skin	B-DIS
and	O
ichthyosis	O
in	O
serine	O
deficiency	B-DIS
and	I-DIS
necrolytic	O
erythema	O
in	O
glutamine	O
deficiency	O
.	O

Hypomyelination	O
with	O
accompanying	O
loss	B-DIS
of	I-DIS
brain	I-DIS
volume	I-DIS
and	O
gyration	O
defects	O
can	O
be	O
observed	O
on	O
brain	O
MRI	O
in	O
all	O
synthesis	O
disorders	O
.	O

In	O
adults	O
with	O
defects	O
in	O
serine	O
or	O
proline	O
synthesis	O
spastic	B-DIS
paraplegia	I-DIS
and	O
several	O
forms	O
of	O
polyneuropathy	B-DIS
with	O
or	O
without	O
intellectual	B-DIS
disability	I-DIS
appear	O
to	O
be	O
the	O
major	O
symptoms	O
in	O
these	O
late	O
-	O
presenting	O
forms	O
of	O
amino	O
acid	O
disorders	O
.	O

This	O
review	O
provides	O
a	O
comprehensive	O
overview	O
of	O
the	O
disorders	O
in	O
amino	O
acid	O
synthesis	O
.	O

In	O
1978	O
Sohar	O
et	O
al	O
.	O

described	O
a	O
strikingly	O
peculiar	O
syndrome	O
in	O
two	O
Israeli	O
sisters	O
.	O

These	O
young	O
women	O
responded	O
to	O
environmental	O
temperatures	O
of	O
18	O
degrees	O
C-7	O
degrees	O
C	O
with	O
profuse	O
sweating	O
on	O
large	O
segments	O
on	O
their	O
back	O
and	O
chest	O
.	O

Both	O
had	O
additional	O
abnormalities	O
including	O
a	O
high	B-DIS
-	I-DIS
arched	O
palate	O
nasal	O
voice	O
depressed	O
nasal	O
bridge	O
inability	O
to	O
fully	O
extend	O
their	O
elbows	B-DIS
and	O
kyphoscoliosis	O
.	O

We	O
have	O
observed	O
this	O
disorder	O
in	O
two	O
Norwegian	O
brothers	O
.	O

Genome	O
-	O
wide	O
screening	O
in	O
the	O
two	O
families	O
followed	O
by	O
saturation	O
marker	O
studies	O
and	O
linkage	O
analysis	O
identified	O
a	O
1.4	O
-	O
Mb	O
homozygous	O
candidate	O
region	O
on	O
chromosome	O
19p12	O
.	O

The	O
maximum	O
multipoint	O
LOD	O
score	O
was	O
4.22	O
.	O

In	O
both	O
families	O
DNA	O
sequencing	O
of	O
25	O
genes	O
within	O
the	O
candidate	O
region	O
identified	O
potentially	O
deleterious	O
CRLF1	O
sequence	O
variants	O
that	O
were	O
not	O
found	O
in	O
unaffected	O
control	O
individuals	O
.	O

Our	O
findings	O
confirm	O
that	O
the	O
cold	B-DIS
-	I-DIS
induced	I-DIS
sweating	O
syndrome	O
is	O
an	B-DIS
autosomal	I-DIS
recessive	O
disorder	O
that	O
is	O
probably	O
caused	O
by	O
impaired	O
function	O
of	O
the	O
CRLF1	O
gene	O
and	O
they	O
suggest	O
important	O
developmental	O
functions	O
for	O
human	O
CRLF1	O
.	O

Background	O
To	O
evaluate	O
clinical	O
genetic	O
and	O
radiologic	O
features	O
of	O
our	O
patients	O
with	O
muscle	B-DIS
-	I-DIS
eye	O
-	O
brain	O
disease	O
.	O

Methods	O
The	O
data	O
of	O
patients	O
who	O
were	O
diagnosed	O
with	O
muscle	B-DIS
-	I-DIS
eye	O
-	O
brain	O
disease	O
from	O
a	O
cohort	B-DIS
of	I-DIS
patients	I-DIS
with	O
congenital	O
muscular	O
dystrophy	O
in	O
the	O
Division	O
of	O
Pediatric	O
Neurology	O
of	O
Dokuz	O
Eylül	O
University	O
School	O
of	O
Medicine	O
and	O
Gaziantep	O
Children	O
's	O
Hospital	O
between	O
2005	O
and	O
2013	O
were	O
analyzed	O
retrospectively	O
.	O

Results	O
From	O
a	O
cohort	O
of	O
34	O
patients	O
with	O
congenital	B-DIS
muscular	I-DIS
dystrophy	I-DIS
12	O
patients	O
from	O
10	O
families	O
were	O
diagnosed	O
with	O
muscle	B-DIS
-	I-DIS
eye	O
-	O
brain	O
disease	O
.	O

The	O
mean	O
age	O
of	O
the	O
patients	O
was	O
9	O
±	O
5.5	O
years	O
2	O
-	O
19	O
years	O
.	O

Mean	O
serum	O
creatine	O
kinase	O
value	O
was	O
2485.80	O
±	O
1308.54	O
IU	O
/	O
L	O
700	O
-	O
4267	O
IU	O
/	O
L	O
.	O

All	O
patients	O
presented	O
with	O
muscular	B-DIS
hypotonia	I-DIS
at	O
birth	O
followed	O
by	O
varying	O
degrees	O
of	O
spasticity	B-DIS
and	O
exaggerated	O
deep	O
tendon	O
reflexes	O
in	O
later	O
stages	O
of	O
life	O
.	O

Three	O
patients	O
were	O
able	O
to	O
walk	O
.	O

The	O
most	O
common	O
ophthalmologic	O
and	O
radiologic	O
abnormalities	O
were	O
cataracts	B-DIS
retinal	B-DIS
detachment	I-DIS
periventricular	O
white	B-DIS
matter	I-DIS
abnormalities	I-DIS
ventriculomegaly	I-DIS
pontocerebellar	B-DIS
hypoplasia	I-DIS
and	O
multiple	O
cerebellar	B-DIS
cysts	I-DIS
.	O

All	O
of	O
the	O
patients	O
had	O
mutations	O
in	O
the	O
POMGNT1	O
gene	O
.	O

The	O
most	O
common	O
mutation	O
detected	O
in	O
66	B-STAT
%	I-STAT
of	O
patients	O
was	O
c.1814	O
A	O
p.	O
R605H	O
.	O

Two	O
novel	O
mutations	O
were	O
identified	O
.	O

Conclusions	O
We	O
suggest	O
that	O
muscle	B-DIS
-	I-DIS
eye	O
-	O
brain	O
disease	O
is	B-DIS
a	I-DIS
relatively	O
common	O
muscular	O
dystrophy	O
in	O
Turkey	B-LOC
.	O

It	O
should	O
be	O
suspected	O
in	O
patients	O
with	O
muscular	B-DIS
hypotonia	I-DIS
increased	O
creatine	O
kinase	O
and	O
structural	O
eye	O
and	O
brain	B-DIS
abnormalities	I-DIS
.	O

The	O
c.1814	O
A	O
mutation	O
in	O
exon	O
21	O
of	O
the	O
POMGNT1	O
gene	O
is	O
apparently	O
a	O
common	O
mutation	O
in	O
the	O
Turkish	O
population	O
.	O

Individuals	O
with	O
this	O
mutation	O
show	O
classical	O
features	O
of	O
muscle	B-DIS
-	I-DIS
eye	O
-	O
brain	O
disease	O
but	O
others	O
may	O
exhibit	O
a	O
milder	O
phenotype	O
and	O
retain	O
the	O
ability	O
to	O
walk	O
independently	O
.	O

Congenital	B-DIS
muscular	I-DIS
dystrophy	I-DIS
patients	O
from	O
Turkey	B-LOC
carrying	O
the	O
clinical	O
and	O
radiologic	O
features	O
of	O
muscle	B-DIS
-	I-DIS
eye	O
-	O
brain	O
disease	O
should	O
be	O
evaluated	O
for	O
mutations	O
in	O
POMGNT1	O
gene	O
.	O

Urea	O
cycle	O
disorders	O
UCDs	O
are	O
rare	O
inherited	O
metabolic	O
conditions	O
that	O
impair	O
the	O
effectiveness	O
of	O
the	O
urea	O
cycle	O
responsible	O
for	O
removing	O
excess	O
ammonia	O
from	O
the	O
body	O
.	O

The	O
estimated	O
incidence	B-EPI
of	O
UCDs	B-DIS
is	O
135000	O
births	O
or	O
approximately	O
113	O
new	O
patients	O
with	O
UCD	O
per	O
year	O
.	O

This	O
review	O
summarizes	O
neuropsychological	O
outcomes	O
among	O
patients	O
with	O
the	O
eight	O
UCDs	B-DIS
in	O
reports	O
published	O
since	O
1980	O
.	O

Rates	O
of	O
intellectual	B-DIS
disabilities	I-DIS
published	O
before	O
and	O
including	O
2000	O
and	O
after	O
2000	O
were	O
pooled	O
and	O
compared	O
for	O
each	O
UCD	O
.	O

Since	O
diagnoses	O
for	O
UCDs	B-DIS
tended	O
to	O
occur	O
earlier	O
and	O
better	O
treatments	O
became	O
more	O
readily	O
available	O
after	O
the	O
turn	O
of	O
the	O
century	O
this	O
assessment	O
will	O
characterize	O
the	O
extent	O
that	O
current	O
management	O
strategies	O
have	O
improved	O
neuropsychological	O
outcomes	O
.	O

The	O
pooled	O
sample	O
included	O
data	O
on	O
cognitive	O
abilities	O
of	O
1649	O
individuals	O
reported	O
in	O
58	O
citations	O
.	O

A	O
total	O
of	O
556	O
patients	O
34	B-STAT
%	I-STAT
functioned	O
in	O
the	O
range	O
of	O
intellectual	B-DIS
disabilities	I-DIS
.	O

The	O
decline	O
in	O
the	O
proportion	O
of	O
intellectual	B-DIS
disabilities	I-DIS
in	O
six	O
disorders	O
ranged	O
from	O
7	B-STAT
%	I-STAT
to	I-STAT
41	I-STAT
%	I-STAT
.	O

Results	O
from	O
various	O
studies	O
differed	O
and	O
the	O
cohorts	O
varied	O
with	O
respect	O
to	O
age	O
at	O
symptom	O
onset	O
age	O
at	O
diagnosis	O
and	O
treatment	O
initiation	O
current	O
age	O
severity	O
of	O
the	O
metabolic	B-DIS
deficiency	I-DIS
management	O
strategies	O
and	O
ethnic	O
origins	O
.	O

The	O
proportion	O
of	O
cases	O
with	O
intellectual	B-DIS
disabilities	I-DIS
ranged	O
from	O
9	B-STAT
%	I-STAT
to	I-STAT
65	I-STAT
%	I-STAT
after	O
2000	O
in	O
the	O
seven	O
UCDs	B-DIS
associated	O
with	O
cognitive	B-DIS
deficits	I-DIS
.	O

Positive	O
outcomes	O
from	O
some	O
studies	O
suggest	O
that	O
it	O
is	O
possible	O
to	O
prevent	O
or	O
reverse	O
the	O
adverse	O
impact	O
of	O
UCDs	B-DIS
on	I-DIS
neuropsychological	I-DIS
functioning	I-DIS
.	O

It	O
is	O
time	O
to	O
`	O
`	O
raise	O
the	O
bar	O
''	O
in	O
terms	O
of	O
expectations	O
for	O
treatment	O
effectiveness	O
.	O

Metabolic	B-DIS
liver	I-DIS
diseases	I-DIS
MLD	I-DIS
are	O
an	O
important	O
group	O
of	O
disorders	O
presenting	O
with	O
neonatal	O
cholestasis	B-DIS
NC	B-LOC
.	O

The	O
spectrum	O
of	O
liver	O
involvement	O
is	O
wide	O
and	O
the	O
presumptive	O
diagnosis	O
is	O
traditionally	O
based	O
on	O
clinical	O
and	O
laboratory	O
findings	O
.	O

Recently	O
next	O
-	O
generation	O
sequencing	O
NGS	O
panels	O
have	O
emerged	O
as	O
an	O
appealing	O
tool	O
to	O
diagnose	B-DIS
neonatal	I-DIS
/	O
infantile	O
cholestatic	O
disorders	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
identify	O
clinical	O
phenotypes	O
of	O
liver	B-DIS
injury	I-DIS
and	O
contribute	O
to	O
find	O
a	O
diagnostic	O
methodology	O
that	O
integrates	O
new	O
molecular	O
diagnostic	O
tools	O
.	O

We	O
retrospectively	O
analyzed	O
the	O
clinical	O
and	O
biochemical	O
features	O
of	O
16	O
patients	O
with	O
MLD	B-DIS
and	O
NC	B-LOC
.	O

Patients	O
were	O
categorized	O
into	O
three	O
groups	O
A	O
-	O
NC	B-DIS
with	I-DIS
liver	I-DIS
failure	O
N	O
=	B-DIS
8	O
tyrosinemia	O
type	O
I	O
n	O
=	O
2	B-DIS
classic	O
galactosemia	O
n	O
=	O
5	O
mitochondrial	O
DNA	O
depletion	O
syndrome	O
n	O
=	O
1	O
;	O
B	O
-	B-DIS
NC	I-DIS
evolving	I-DIS
with	I-DIS
chronic	O
liver	O
disease	B-DIS
N	O
=	O
5	O
argininemia	O
n	B-DIS
=	I-DIS
2	O
;	O
mitochondrial	O
cytopathy	O
n	B-DIS
=	I-DIS
1	O
;	O
congenital	O
disorders	O
of	O
glycosylation	O
type	O
Ia	O
n	B-DIS
=	I-DIS
1	O
;	O
Zellweger	O
syndrome	O
n	O
=	O
1	O
;	O
and	O
C	O
-	O
transient	O
NC	O
N	O
=	O
3	O
Niemann	B-DIS
-	O
Pick	O
type	O
C	O
n	O
=	O
2	B-DIS
citrullinemia	O
type	O
II	O
n	O
=	O
1	O
.Conclusion	O
MLD	O
presenting	O
with	O
NC	B-LOC
can	O
be	B-DIS
categorized	I-DIS
into	O
three	O
main	O
clinical	O
phenotypes	O
of	O
liver	O
injury	O
.	O

We	O
highlight	O
transient	O
NC	B-LOC
as	O
a	O
clue	O
for	O
MLD	B-DIS
that	O
must	O
be	O
pursued	O
.	O

New	O
molecular	O
diagnostic	O
tools	O
can	O
play	O
a	O
key	O
role	O
but	O
application	O
criteria	O
must	O
be	O
established	O
to	O
make	O
them	O
cost	O
-	O
effective	O
.	O

What	O
is	O
Known	O
•	O
Metabolic	B-DIS
liver	I-DIS
diseases	I-DIS
are	O
an	O
important	O
group	O
of	O
disorders	O
presenting	O
with	O
neonatal	O
cholestasis	B-DIS
.	O

•	O
The	O
diagnostic	O
approach	O
is	O
challenging	O
and	O
traditionally	O
based	O
on	O
clinical	O
and	O
laboratory	O
findings	O
.	O

Next	O
-	O
generation	O
sequencing	O
is	O
a	O
recent	O
and	O
rapidly	O
developing	O
tool	O
in	O
pediatric	O
hepatology	O
.	O

What	O
is	O
New	O
•	O
We	O
provide	O
a	O
liver	O
-	O
targeted	O
characterization	B-DIS
of	I-DIS
metabolic	I-DIS
liver	O
diseases	O
presenting	O
with	B-DIS
neonatal	O
cholestasis	O
categorizing	O
them	O
into	O
three	O
clinical	O
phenotypes	O
that	O
may	O
narrow	O
the	O
diagnostic	O
possibilities	O
.	O

•	O
A	O
clinical	O
decision	O
-	O
making	O
algorithm	O
is	O
proposed	O
in	O
which	O
the	O
NGS	O
technology	O
is	O
integrated	O
.	O

Context	O
Because	O
the	O
skin	O
and	O
modified	O
mucosal	O
surfaces	O
of	O
the	O
vulvar	O
region	O
contain	O
dense	O
apocrine	O
glands	O
and	O
anogenital	O
mammary	O
-	O
like	O
glands	O
in	O
addition	O
to	O
eccrine	O
glands	O
and	O
folliculosebaceous	O
units	O
benign	O
as	O
well	O
as	O
malignant	O
lesions	O
derived	O
from	O
these	O
adnexal	O
structures	O
are	O
not	O
surprisingly	O
found	O
in	O
the	O
vulva	O
.	O

However	O
their	O
incidence	B-EPI
occurring	O
in	O
the	O
vulva	B-DIS
has	O
not	O
been	O
reported	O
to	O
our	O
knowledge	O
.	O

Objective	O
To	O
determine	O
the	O
incidence	B-EPI
of	O
various	O
vulvar	B-DIS
adnexal	I-DIS
lesions	I-DIS
.	O

Design	O
We	O
performed	O
a	O
retrospective	O
review	O
1978	O
-	O
2010	O
of	O
the	O
cases	O
at	O
our	O
institution	O
.	O

Results	O
A	O
total	O
of	O
189	O
vulvar	O
adnexal	O
lesions	O
were	O
identified	O
.	O

Most	O
of	O
these	O
lesions	O
were	O
benign	O
133	O
of	O
189	O
;	O
70	B-STAT
%	I-STAT
with	O
hidradenoma	B-DIS
papilliferum	I-DIS
being	O
the	O
most	O
common	O
followed	O
by	O
syringoma	B-DIS
and	O
various	O
types	O
of	O
cysts	O
.	O

Rare	O
cases	O
of	O
tubular	B-DIS
adenoma	I-DIS
poroma	I-DIS
spiradenoma	I-DIS
hidradenoma	I-DIS
cylindroma	I-DIS
sebaceoma	I-DIS
and	O
trichoepithelioma	B-DIS
were	O
identified	O
.	O

Malignant	B-DIS
adnexal	I-DIS
neoplasms	I-DIS
comprised	O
the	O
remaining	O
30	B-STAT
%	I-STAT
56	O
of	O
189	O
of	O
the	O
cases	O
.	O

Extramammary	B-DIS
Paget	I-DIS
disease	I-DIS
was	O
the	O
most	O
common	O
49	O
of	O
56	B-STAT
and	I-STAT
29	I-STAT
%	I-STAT
14	O
of	O
49	O
demonstrated	O
an	O
invasive	O
component	O
.	O

Rare	O
cases	O
of	O
basal	B-DIS
cell	I-DIS
carcinoma	I-DIS
sebaceous	I-DIS
carcinoma	I-DIS
apocrine	I-DIS
carcinoma	I-DIS
adenoid	I-DIS
cystic	I-DIS
carcinoma	I-DIS
and	O
spiradenocarcinoma	B-DIS
were	O
identified	O
.	O

Conclusions	O
In	O
this	O
retrospective	O
review	O
we	O
identified	O
several	O
benign	O
entities	O
that	O
have	O
not	O
been	O
previously	O
reported	O
on	O
the	O
vulva	O
namely	O
pilomatricoma	B-DIS
poroma	I-DIS
spiradenoma	I-DIS
and	O
sebaceoma	B-DIS
.	O

Hidradenoma	B-DIS
papilliferum	I-DIS
and	O
extramammary	B-DIS
Paget	I-DIS
disease	I-DIS
were	O
the	O
most	O
common	O
benign	B-DIS
and	I-DIS
malignant	I-DIS
adnexal	I-DIS
neoplasms	I-DIS
respectively	O
.	O

The	O
spectrum	O
of	O
various	O
vulvar	B-DIS
adnexal	I-DIS
lesions	I-DIS
appears	O
to	O
reflect	O
the	O
frequency	O
of	O
the	O
underlying	O
glandular	O
elements	O
.	O

Background	O
Chemotherapy	O
-	B-DIS
induced	O
cardiomyopathy	O
CICM	B-DIS
and	I-DIS
heart	O
failure	O
are	O
major	O
complications	B-DIS
of	O
cancer	O
therapeutics	O
and	O
can	O
result	O
in	O
significant	O
morbidity	O
and	O
mortality	O
.	O

There	O
is	O
limited	O
data	O
on	O
the	O
incidence	B-EPI
and	O
risk	O
factors	O
of	O
CICM	O
in	O
African	O
American	O
and	O
Afro	O
-	O
Caribbean	O
patients	O
.	O

Methods	O
We	O
performed	O
a	O
retrospective	O
chart	O
review	O
to	O
evaluate	O
the	O
baseline	O
characteristics	O
that	O
may	O
predispose	O
to	O
CICM	O
.	O

Patients	O
were	O
African	O
American	O
and	O
Afro	O
-	O
Caribbean	O
ethnicity	O
.	O

Data	O
was	O
collected	O
between	O
2014	O
to	O
2018	O
.	O

Patients	O
had	O
transthoracic	O
echocardiogram	O
TTE	O
or	O
multigated	O
acquisition	O
scan	O
MUGA	O
prior	O
to	O
cancer	B-DIS
therapy	O
and	O
every	O
3	O
months	O
thereafter	O
until	O
the	O
end	O
of	O
the	O
regimen	O
.	O

CICM	O
was	O
defined	O
as	O
a	O
≥16	B-STAT
%	I-STAT
reduction	O
in	O
LVEF	B-LOC
or	O
≥10	B-STAT
%	I-STAT
reduction	O
in	O
LVEF	B-LOC
to	O
a	O
value	O
<	O
50	B-STAT
%	I-STAT
.	O

Results	O
A	O
total	O
of	O
230	O
patients	O
were	O
studied	O
with	O
a	O
mean	O
age	O
of	O
54±12	O
years	O
with	O
91	B-STAT
%	I-STAT
were	O
females	O
BMI	O
30±481	B-STAT
%	I-STAT
were	O
taking	O
anthracyclines	O
87	B-STAT
%	I-STAT
were	O
on	O
Trastuzumab	B-LOC
while	O
5	B-STAT
%	I-STAT
were	O
receiving	O
both	O
medications	O
.	O

The	O
prevalence	B-EPI
of	O
comorbidities	O
was	O
as	O
follows	O
hypertension	B-DIS
8	B-STAT
%	I-STAT
diabetes	B-DIS
mellitus	I-DIS
8	B-STAT
%	I-STAT
ESRD	B-DIS
8	B-STAT
%	I-STAT
dyslipidemia	B-DIS
8	B-STAT
%	I-STAT
CAD	B-DIS
7	B-STAT
%	I-STAT
.	O

The	O
incidence	B-EPI
of	O
CICM	O
was	O
7	B-STAT
%	I-STAT
overall	O
while	O
it	O
was	O
6	B-STAT
%	I-STAT
and	I-STAT
8	I-STAT
%	I-STAT
for	O
patients	O
taking	O
Anthracyclines	O
and	O
Trastuzumab	B-LOC
respectively	O
.	O

CICM	O
was	O
associated	O
with	O
dyslipidemia	B-DIS
r=	O
.22	O
p=	O
.001	O
hypertension	B-DIS
r=	O
.12	O
p=	O
.05	O
baseline	O
ejection	O
fraction	O
r=	O
-.21	O
p=	O
.001	O
and	O
concomitant	O
use	O
of	O
radiation	O
therapy	O
r=	O
.147	O
p=	O
.02	O
but	O
not	O
with	O
age	O
gender	O
beta	O
blocker	O
use	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
use	O
number	O
of	O
chemotherapy	O
cycles	O
or	O
stage	O
of	O
the	O
malignancy	B-DIS
.	O

On	O
multivariate	O
analysis	O
CICM	O
was	O
independently	O
associated	O
with	O
baseline	O
ejection	O
fraction	O
β=	O
-.193	O
P=	O
.003	O
and	O
dyslipidemia	B-DIS
β=	O
-.20	O
P=	O
.003	O
.	O

Conclusion	O
The	O
incidence	B-EPI
of	O
CICM	O
in	O
African	O
Americans	O
and	O
Afro	O
-	O
Caribbean	O
is	O
higher	O
than	O
reported	O
in	O
the	O
general	O
population	O
.	O

Dyslipidemia	B-DIS
and	O
baseline	O
ejection	O
fraction	O
were	O
seen	O
as	O
the	O
major	O
risk	O
factors	O
associated	O
with	O
the	O
higher	O
incidence	B-EPI
of	O
CICM	O
.	O

Background	O
Craniosynostosis	B-DIS
defined	O
as	O
premature	O
fusion	O
of	O
one	O
or	O
more	O
cranial	O
sutures	O
affects	O
approximately	O
1	B-STAT
in	I-STAT
every	I-STAT
2000	I-STAT
-	O
2500	O
live	O
births	O
.	O

Sagittal	O
craniosynostosis	B-DIS
CS	O
the	O
most	O
prevalent	O
form	O
of	O
isolated	O
craniosynostosis	B-DIS
is	O
caused	O
by	O
interplay	O
between	O
genetic	O
and	O
perinatal	O
environmental	O
insults	O
.	O

However	O
the	O
underlying	O
details	O
remain	O
largely	O
unknown	O
.	O

Methods	O
The	O
proband	O
a	O
female	O
monochorionic	O
twin	O
diagnosed	O
with	O
CS	O
her	O
healthy	O
co	O
-	O
twin	O
sister	O
and	O
parents	O
were	O
enrolled	O
.	O

Obstetric	O
history	O
was	O
extracted	O
from	O
medical	O
records	O
.	O

Genetic	O
screening	O
was	O
performed	O
by	O
whole	O
exome	O
sequencing	O
WES	O
and	O
confirmed	O
by	O
Sanger	O
sequencing	O
.	O

Functional	O
annotation	O
conservation	O
and	O
structural	O
analysis	O
were	O
predicted	O
in	O
public	O
database	O
.	O

Phenotype	O
data	O
of	O
Axin2	O
knockout	O
mice	O
was	O
downloaded	O
from	O
The	O
International	O
Mouse	O
Phenotyping	O
Consortium	O
IMPC	O
http//www.mousephenotype.org	O
.	O

Results	O
Obstetric	O
medical	O
records	O
showed	O
that	O
except	O
for	O
the	O
shared	O
perinatal	O
risk	O
factors	O
by	O
the	O
twins	O
the	O
proband	O
suffered	O
additional	O
persistent	O
breech	O
presentation	O
and	O
intrauterine	O
growth	O
restriction	O
.	O

We	O
identified	O
a	O
heterozygous	O
mutation	O
of	O
Axin2	O
c.1181	O
A	O
p.	O
R394H	O
rs200899695	O
in	O
monochorionic	O
twins	O
and	O
their	O
father	O
but	O
not	O
in	O
the	O
mother	O
.	O

This	O
mutation	O
is	O
not	O
reported	O
in	O
Asian	O
population	O
and	O
results	O
in	O
replacement	O
of	O
Arg	O
at	O
residue	O
394	O
by	O
His	O
p.	O
R394H	O
.	O

Arg	O
394	O
is	O
located	O
at	O
the	O
GSK3β	O
binding	O
domain	O
of	O
Axin2	O
protein	O
which	O
is	O
highly	O
conserved	O
across	O
species	O
.	O

The	O
mutation	O
was	O
predicted	O
to	O
be	O
potentially	O
deleterious	O
by	O
in	O
silico	O
analysis	O
.	O

Incomplete	O
penetrance	O
of	O
Axin2	O
haploinsufficiency	O
was	O
found	O
in	O
female	O
mice	O
.	O

Conclusions	O
Axin2	O
c.1181	O
A	O
p.	O
R394H	O
rs200899695	O
mutation	O
confers	O
susceptibility	O
and	O
perinatal	O
risk	O
factors	O
trigger	O
the	O
occurrence	O
of	O
sagittal	O
craniosynostosis	B-DIS
.	O

Our	O
findings	O
provide	O
a	O
new	O
evidence	O
for	O
the	O
gene	O
-	O
environment	O
interplay	O
in	O
understanding	O
pathogenesis	B-DIS
of	O
craniosynostosis	O
in	O
Chinese	O
population	O
.	O

Hepatocellular	B-DIS
carcinoma	I-DIS
HCC	I-DIS
is	O
the	O
most	O
common	O
primary	B-DIS
cancer	I-DIS
of	I-DIS
the	I-DIS
liver	I-DIS
with	O
high	O
morbidity	O
and	O
mortality	O
rates	O
worldwide	O
.	O

Since	O
1963	O
when	O
alpha	O
-	O
fetoprotein	O
AFP	O
was	O
discovered	O
as	O
a	B-DIS
first	O
HCC	O
serum	O
biomarker	O
several	O
other	O
protein	O
biomarkers	O
have	O
been	O
identified	O
and	O
introduced	O
into	O
clinical	O
practice	O
.	O

However	O
insufficient	O
specificity	O
and	O
sensitivity	O
of	O
these	O
biomarkers	O
dictate	O
the	O
necessity	O
of	O
novel	O
biomarker	O
discovery	O
.	O

Remarkable	O
advancements	O
in	O
integrated	O
multiomics	O
technologies	O
for	O
the	O
identification	O
of	O
gene	O
expression	O
and	O
protein	O
or	O
metabolite	O
distribution	O
patterns	O
can	O
facilitate	O
rising	O
to	O
this	O
challenge	O
.	O

Current	O
multiomics	O
technologies	O
lead	O
to	O
the	O
accumulation	O
of	O
a	O
huge	O
amount	O
of	O
data	O
which	O
requires	O
clustering	O
and	O
finding	O
correlations	O
between	O
various	O
datasets	O
and	O
developing	O
predictive	O
models	O
for	O
data	O
filtering	O
pre	O
-	O
processing	O
and	O
reducing	O
dimensionality	O
.	O

Artificial	O
intelligence	O
AI	O
technologies	O
have	O
an	O
enormous	O
potential	O
to	O
overcome	O
accelerated	O
data	O
growth	O
complexity	O
and	O
heterogeneity	O
within	O
and	O
across	O
data	O
sources	O
.	O

Our	O
review	O
focuses	O
on	O
the	O
recent	O
progress	O
in	O
integrative	O
proteomic	O
profiling	O
strategies	O
and	O
their	O
usage	O
in	O
combination	O
with	O
machine	O
learning	O
and	O
deep	O
learning	O
technologies	O
for	O
the	O
discovery	O
of	O
novel	O
biomarker	O
candidates	O
for	O
HCC	B-DIS
early	O
diagnosis	O
and	O
prognosis	O
.	O

We	O
discuss	O
conventional	O
and	O
promising	O
proteomic	O
biomarkers	O
of	O
HCC	B-DIS
such	O
as	O
AFP	B-DIS
lens	I-DIS
culinaris	I-DIS
agglutinin	I-DIS
LCA	I-DIS
-reactive	O
L3	O
glycoform	O
of	O
AFP	O
AFP	O
-	O
L3	O
des	O
-	O
gamma	O
-	O
carboxyprothrombin	O
DCP	O
osteopontin	O
OPN	O
glypican-3	O
GPC3	B-DIS
dickkopf-1	I-DIS
DKK1	I-DIS
midkine	I-DIS
MDK	I-DIS
and	O
squamous	O
cell	O
carcinoma	O
antigen	O
SCCA	O
and	O
highlight	O
their	O
functional	O
significance	O
including	O
the	O
involvement	O
in	O
cell	O
signaling	O
such	O
as	O
Wnt	O
/	O
β	O
-	O
catenin	B-DIS
PI3K	O
/	O
Akt	O
integrin	O
αvβ3	O
/	O
NF	O
-	O
κB	O
/	O
HIF-1α	O
JAK	O
/	O
STAT3	O
and	O
MAPK	O
/	O
ERK	O
-	O
mediated	O
pathways	O
dysregulated	O
in	O
HCC	O
.	O

We	O
show	O
that	O
currently	O
available	O
computational	O
platforms	O
for	O
big	O
data	O
analysis	O
and	O
AI	O
technologies	O
can	O
both	O
enhance	O
proteomic	O
profiling	O
and	O
improve	O
imaging	O
techniques	O
to	O
enhance	O
the	O
translational	O
application	O
of	O
proteomics	O
data	O
into	O
precision	O
medicine	O
.	O

Coronavirus	B-DIS
disease	I-DIS
2019	O
COVID-19	O
is	O
emerging	O
as	O
the	O
greatest	O
public	O
health	O
crisis	O
in	O
the	O
early	O
21	O
st	O
<	O
/s	O
century	O
.	O

Its	O
causative	O
agent	O
Severe	O
Acute	O
Respiratory	B-DIS
Syndrome	I-DIS
coronavirus	I-DIS
2	I-DIS
SARS	I-DIS
-	O
CoV-2	O
is	O
an	O
enveloped	O
single	O
stranded	O
positive	O
-	O
sense	O
ribonucleic	O
acid	O
virus	O
that	O
enters	O
cells	O
via	O
the	O
angiotensin	O
converting	O
enzyme	O
2	O
receptor	O
or	O
several	O
other	O
receptors	O
.	O

While	O
COVID-19	O
primarily	O
affects	O
the	O
respiratory	O
system	O
other	O
organs	O
including	O
the	O
brain	O
can	O
be	O
involved	O
.	O

In	O
Western	O
clinical	O
studies	O
relatively	O
mild	O
neurological	B-DIS
dysfunction	I-DIS
such	O
as	O
anosmia	B-DIS
and	O
dysgeusia	B-DIS
is	O
frequent	O
~70	O
-	O
84	B-STAT
%	I-STAT
while	O
severe	O
neurologic	B-DIS
disorders	I-DIS
such	O
as	O
stroke	B-DIS
~1	O
-	O
6	O
%	O
and	O
meningoencephalitis	B-DIS
are	O
less	O
common	O
.	O

It	O
is	O
unclear	O
how	O
much	O
SARS	B-DIS
-	I-DIS
CoV-2	O
infection	O
contributes	O
to	B-EPI
the	O
incidence	B-DIS
of	O
stroke	B-DIS
given	O
co	O
-	O
morbidities	O
in	O
the	O
affected	O
patient	O
population	O
.	O

Rarely	O
clinically	O
-	O
defined	O
cases	O
of	O
acute	O
disseminated	O
encephalomyelitis	O
Guillain	O
-	B-DIS
Barré	I-DIS
syndrome	B-DIS
and	O
acute	O
necrotizing	O
encephalopathy	O
have	O
been	O
reported	O
in	O
COVID-19	O
patients	O
.	O

Common	O
neuropathological	O
findings	O
in	O
the	O
184	O
patients	O
reviewed	O
include	O
microglial	O
activation	O
42.9	B-STAT
%	I-STAT
with	O
microglial	O
nodules	O
in	O
a	O
subset	O
33.3	B-STAT
%	I-STAT
lymphoid	B-DIS
inflammation	I-DIS
37.5	B-STAT
%	I-STAT
acute	O
hypoxic	O
-	O
ischemic	O
changes	O
29.9	B-DIS
%	I-STAT
astrogliosis	O
27.7	B-STAT
%	I-STAT
acute	O
/	O
subacute	O
brain	O
infarcts	B-DIS
21.2	B-STAT
%	I-STAT
spontaneous	O
hemorrhage	O
15.8	B-STAT
%	I-STAT
and	O
microthrombi	O
15.2	B-STAT
%	I-STAT
.	O

In	O
our	O
institutional	O
cases	O
we	O
also	O
note	O
occasional	O
anterior	B-DIS
pituitary	I-DIS
infarcts	I-DIS
.	O

COVID-19	O
coagulopathy	O
sepsis	O
and	O
acute	B-DIS
respiratory	I-DIS
distress	I-DIS
likely	O
contribute	O
to	O
a	O
number	O
of	O
these	O
findings	O
.	O

When	O
present	O
central	O
nervous	O
system	O
lymphoid	O
inflammation	O
is	O
often	O
minimal	O
to	O
mild	O
is	O
detected	O
best	O
by	O
immunohistochemistry	O
and	O
in	O
one	O
study	O
indistinguishable	O
from	O
control	O
sepsis	B-DIS
cases	O
.	O

Some	O
cases	O
evince	O
microglial	O
nodules	O
or	O
neuronophagy	O
strongly	O
supporting	O
viral	B-DIS
meningoencephalitis	I-DIS
with	O
a	O
proclivity	O
for	O
involvement	O
of	O
the	O
medulla	O
oblongata	O
.	O

The	O
virus	O
is	O
detectable	O
by	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
immunohistochemistry	O
or	O
electron	O
microscopy	O
in	O
human	O
cerebrum	B-DIS
cerebellum	I-DIS
cranial	I-DIS
nerves	I-DIS
olfactory	I-DIS
bulb	I-DIS
as	O
well	O
as	O
in	O
the	O
olfactory	O
epithelium	O
;	O
neurons	O
and	O
endothelium	O
can	O
also	O
be	O
infected	O
.	O

Review	O
of	O
the	O
extant	O
cases	O
has	O
limitations	O
including	O
selection	O
bias	O
and	O
limited	O
clinical	O
information	O
in	O
some	O
cases	O
.	O

Much	O
remains	O
to	O
be	O
learned	O
about	O
the	O
effects	O
of	O
direct	O
viral	B-DIS
infection	I-DIS
of	O
brain	O
cells	O
and	O
whether	O
SARS	O
-	O
CoV-2	O
persists	O
long	O
-	O
term	O
contributing	O
to	O
chronic	O
symptomatology	O
.	O

To	O
date	O
retinal	O
implants	O
are	O
the	O
only	O
available	O
treatment	O
for	O
blind	O
individuals	O
with	O
retinal	B-DIS
degenerations	I-DIS
such	O
as	O
retinitis	B-DIS
pigmentosa	I-DIS
.	O

Argus	O
II	O
is	O
the	O
only	O
visual	O
implant	O
with	O
FDA	O
approval	O
with	O
more	O
than	O
300	O
users	O
worldwide	O
.	O

Argus	O
II	O
stimulation	O
is	O
based	O
on	O
a	O
grayscale	O
image	O
coming	O
from	O
a	O
head	O
-	O
mounted	O
visible	O
-	O
light	O
camera	O
.	O

Normally	O
the	O
11	O
°	O
<	O
/s	O
×19	O
°	O
<	O
/s	O
field	O
of	O
view	O
of	O
the	O
Argus	O
II	O
user	O
is	O
full	O
of	O
objects	O
that	O
may	O
elicit	O
similar	O
phosphenes	O
.	O

The	O
prosthesis	O
can	O
not	O
meaningfully	O
convey	O
so	O
much	O
visual	O
information	O
and	O
the	O
percept	O
is	O
reduced	O
to	O
an	O
ambiguous	O
impression	O
of	O
light	O
.	O

This	O
study	O
is	O
aimed	O
at	O
investigating	O
the	O
efficacy	O
of	O
simplifying	O
the	O
video	O
input	O
in	O
real	O
-	O
time	O
using	O
a	O
heat	O
-	O
sensitive	O
camera	O
.	O

Data	O
were	O
acquired	O
from	O
four	O
Argus	O
II	O
users	O
in	O
5	O
stationary	O
tasks	O
with	O
either	O
hot	O
objects	O
or	O
human	O
targets	O
as	O
stimuli	O
.	O

All	O
tasks	O
were	O
of	O
m	O
-	O
alternative	O
forced	O
choice	O
design	O
where	O
precisely	O
one	O
of	O
the	O
m≥2	O
response	O
alternatives	O
was	O
defined	O
to	O
be	O
`	O
`	O
correct	O
''	O
by	O
the	O
experimenter	O
.	O

To	O
compare	O
performance	O
with	O
heat	O
-	O
sensitive	O
and	O
normal	O
cameras	O
across	O
all	O
tasks	O
regardless	O
of	O
m	O
we	O
used	O
an	O
extension	O
of	O
signal	O
detection	O
theory	O
to	O
latent	O
variables	O
estimating	O
person	O
ability	O
and	O
item	O
difficulty	O
in	O
d	O
'	O
units	O
.	O

Results	O
demonstrate	O
that	O
subject	O
performance	O
was	O
significantly	O
better	O
across	O
all	O
tasks	O
with	O
the	O
thermal	O
camera	O
compared	O
to	O
the	O
regular	O
Argus	O
II	O
camera	O
.	O

The	O
future	O
addition	O
of	O
thermal	O
imaging	O
to	O
devices	O
with	O
very	O
poor	O
spatial	O
resolution	O
may	O
have	O
significant	O
real	O
-	O
life	O
benefits	O
for	O
orientation	O
personal	O
safety	O
and	O
social	O
interactions	O
thereby	O
improving	O
quality	O
of	O
life	O
.	O

Background	O
Studies	O
have	O
shown	O
that	O
the	O
human	B-DIS
T	I-DIS
-	I-DIS
lymphotropic	I-DIS
virus	I-DIS
2	O
HTLV-2	O
is	O
endemic	O
in	O
several	O
indigenous	O
populations	O
of	O
the	O
Brazilian	O
Amazon	O
and	O
molecular	O
analyses	O
have	O
shown	O
the	O
exclusive	O
presence	O
of	O
HTLV-2	O
subtype	O
2c	O
among	O
the	O
indigenous	O
groups	O
of	O
this	O
geographical	O
region	O
.	O

Methods	O
The	O
present	O
study	O
characterizes	O
the	O
prevalence	B-EPI
of	O
HTLV-2	B-DIS
infection	I-DIS
in	O
three	O
new	O
villages	O
of	O
the	O
Xikrin	O
tribe	O
in	O
the	O
Kayapo	O
group	O
according	O
to	O
their	O
distribution	O
by	O
sex	O
and	O
age	O
.	O

The	O
study	O
included	O
263	O
samples	O
from	O
individuals	O
from	O
the	O
Kateté	O
Djujeko	O
and	O
Oodjã	O
villages	O
.	O

Plasma	O
samples	O
were	O
tested	O
for	O
the	O
presence	O
of	O
anti	O
-	O
HTLV-1/2	O
antibodies	O
using	O
enzyme	O
-	O
linked	O
immunosorbent	O
assays	O
ELISA	O
.	O

Seropositive	O
samples	O
were	O
confirmed	O
using	O
real	O
-	O
time	O
PCR	O
nested	O
PCR	O
and	O
sequencing	O
.	O

Results	O
The	O
serological	O
and	O
molecular	O
results	O
confirmed	O
the	O
sole	O
presence	O
of	O
HTLV-2	B-DIS
in	O
7729	B-STAT
%	I-STAT
samples	O
with	O
a	O
prevalence	B-EPI
of	O
38	B-STAT
%	I-STAT
among	O
women	O
and	O
18	B-STAT
%	I-STAT
among	O
men	O
.	O

In	O
these	O
communities	O
it	O
was	O
found	O
that	O
the	O
prevalence	B-EPI
of	O
HTLV-2	B-DIS
infection	I-DIS
increased	O
with	O
age	O
.	O

Nucleotide	O
sequences	O
642	O
bp	O
5'LTR	O
from	O
eight	O
samples	O
were	O
subjected	O
to	O
phylogenetic	O
analysis	O
by	O
the	O
neighbor	O
-	O
joining	O
method	O
to	O
determine	O
the	O
viral	O
subtype	O
which	O
confirmed	O
the	O
presence	O
of	O
HTLV-2c	O
.	O

Conclusions	O
The	O
results	O
of	O
the	O
present	O
study	O
establish	O
the	O
presence	O
of	O
HTLV-2	B-DIS
infection	I-DIS
in	O
three	O
new	O
villages	O
of	O
the	O
Xikrin	O
tribe	O
and	O
confirm	O
the	O
high	O
endemicity	O
of	O
the	O
infection	B-DIS
in	O
the	O
Kayapo	O
indigenous	O
group	O
of	O
the	O
Brazilian	O
Amazon	O
.	O

We	O
have	O
previously	O
shown	O
that	O
67	B-STAT
%	I-STAT
of	O
patients	O
with	O
newly	O
diagnosed	O
coeliac	B-DIS
disease	I-DIS
CD	O
presenting	O
to	O
gastroenterologists	O
have	O
evidence	O
of	O
neurological	B-DIS
dysfunction	I-DIS
.	O

This	O
manifested	O
with	O
headache	B-DIS
and	O
loss	O
of	O
co	O
-	O
ordination	O
.	O

Furthermore	O
60	B-STAT
%	I-STAT
of	O
these	O
patients	O
had	O
abnormal	O
brain	O
imaging	O
.	O

In	O
this	O
follow	O
-	O
up	O
study	O
we	O
re	O
-	O
examined	O
and	O
re	O
-	O
scanned	O
30	O
patients	O
from	O
the	O
original	O
cohort	O
of	O
100	O
seven	O
years	O
later	O
.	O

There	O
was	O
significant	O
reduction	O
in	O
the	O
prevalence	B-EPI
of	O
headaches	B-DIS
47	B-STAT
%	I-STAT
to	I-STAT
20	I-STAT
%	I-STAT
but	O
an	O
increase	O
in	O
the	O
prevalence	B-EPI
of	O
incoordination	O
27	B-STAT
%	I-STAT
to	O
47	B-STAT
%	I-STAT
.	O

Although	O
those	O
patients	O
with	O
coordination	O
problems	O
at	O
baseline	O
reported	O
improvement	O
on	O
the	O
gluten	O
free	O
diet	O
GFD	O
there	O
were	O
7	O
patients	O
reporting	O
incoordination	O
not	O
present	O
at	O
baseline	O
.	O

All	O
7	O
patients	O
had	O
positive	O
serology	O
for	O
one	O
or	O
more	O
gluten	B-DIS
-	O
sensitivity	O
related	O
antibodies	O
at	O
follow	O
-	O
up	O
.	O

In	O
total	O
50	B-STAT
%	I-STAT
of	O
the	O
whole	O
follow	O
-	O
up	O
cohort	O
were	O
positive	O
for	O
one	O
or	O
more	O
gluten	O
-	O
related	O
antibodies	O
.	O

A	O
comparison	O
between	O
the	O
baseline	O
and	O
follow	O
-	O
up	O
brain	O
imaging	O
showed	O
a	O
greater	O
rate	B-DIS
of	I-DIS
cerebellar	I-DIS
grey	I-DIS
matter	O
atrophy	O
in	O
the	O
antibody	O
positive	O
group	O
compared	O
to	O
the	O
antibody	O
negative	O
group	O
.	O

Patients	O
with	O
CD	O
who	O
do	O
not	O
adhere	O
to	O
a	O
strict	O
GFD	B-DIS
and	O
are	O
serological	O
positive	O
are	O
at	O
risk	O
of	O
developing	O
ataxia	B-DIS
and	O
have	O
a	O
significantly	O
higher	O
rate	O
of	O
cerebellar	B-DIS
atrophy	I-DIS
when	O
compared	O
to	O
patients	O
with	O
negative	O
serology	O
.	O

This	O
highlights	O
the	O
importance	O
of	O
regular	O
review	O
and	O
close	O
monitoring	O
.	O

The	O
May	B-DIS
-	I-DIS
Hegglin	O
anomaly	O
is	O
characterized	O
by	B-DIS
inherited	O
thrombocytopenia	O
giant	O
platelets	O
and	O
leukocyte	O
cytoplasmic	O
inclusion	O
bodies	O
.	O

The	O
Fechtner	B-DIS
Sebastian	O
and	O
Epstein	B-DIS
syndromes	I-DIS
are	O
associated	O
with	O
mutations	O
of	O
the	O
MYH9	O
-	O
coding	O
nonmuscle	O
myosin	O
heavy	O
chain	O
ⅡA	O
similar	O
to	B-DIS
the	I-DIS
May	O
-	O
Hegglin	O
anomaly	O
and	O
are	B-DIS
together	I-DIS
classified	O
as	O
MYH9	O
disorders	O
.	O

MYH9	B-DIS
disorders	I-DIS
may	O
include	O
symptoms	O
of	O
Alport	B-DIS
syndrome	I-DIS
including	O
nephritis	B-DIS
and	O
auditory	B-DIS
and	I-DIS
ocular	I-DIS
disorders	I-DIS
.	O

A	O
6	O
-	O
year	O
-	O
old	O
boy	O
was	B-DIS
diagnosed	I-DIS
with	O
an	O
MYH9	O
disorder	O
after	B-DIS
incidental	O
discovery	B-DIS
of	O
hematuria	O
and	O
proteinuria	O
.	O

Focal	B-DIS
segmental	I-DIS
glomerulosclerosis	I-DIS
was	O
detected	O
on	O
renal	O
biopsy	O
.	O

However	O
despite	O
no	O
prior	O
bleeding	B-DIS
diatheses	O
he	O
developed	O
a	O
large	O
post	O
-	B-DIS
biopsy	O
hematoma	O
despite	O
a	O
preprocedural	O
platelet	O
transfusion	O
calculated	O
to	O
increase	O
the	O
platelet	O
count	B-STAT
from	O
54000	B-STAT
/	O
μL	O
t	O
150000	O
/	O
μL	O
.	O

Idiopathic	B-DIS
thrombocytopenic	I-DIS
purpura	I-DIS
is	O
a	O
major	O
cause	O
of	O
pediatric	O
thrombocytopenia	B-DIS
following	O
acute	B-DIS
infection	I-DIS
or	O
vaccination	O
and	O
patients	O
with	O
MYH9	B-DIS
disorders	I-DIS
may	O
be	O
misdiagnosed	O
with	O
idiopathic	B-DIS
thrombocytopenic	I-DIS
purpura	I-DIS
and	O
inappropriately	O
treated	O
with	O
corticosteroids	O
.	O

Careful	O
differential	O
diagnosis	O
is	O
important	O
in	O
thrombocytopenic	B-DIS
patients	O
with	O
hematuria	B-DIS
and	O
proteinuria	B-DIS
for	O
the	O
early	O
detection	O
of	O
thrombocytopenia	B-DIS
.	O

Patients	O
with	O
MYH9	B-DIS
disorders	I-DIS
require	O
close	O
follow	O
-	O
up	O
and	O
treatment	O
with	O
angiotensin	O
Ⅱ	O
receptor	O
blockers	O
to	O
prevent	O
the	O
onset	O
of	B-DIS
progressive	O
nephritis	O
which	O
may	O
necessitate	O
hemodialysis	O
or	O
renal	O
transplantation	O
.	O

The	O
need	O
for	O
renal	O
biopsy	O
in	O
patients	O
with	O
MYH9	B-DIS
disorders	I-DIS
should	O
be	O
carefully	O
considered	O
because	O
there	O
could	O
be	O
adverse	O
outcomes	O
even	O
after	O
platelet	O
transfusion	O
.	O

Objective	O
Dominant	O
optic	B-DIS
atrophy	I-DIS
DOA	O
is	O
the	O
most	O
common	O
inherited	O
optic	B-DIS
neuropathy	I-DIS
with	O
a	O
prevalence	B-EPI
of	O
112000	O
to	O
125000	O
.	O

OPA1	O
mutations	O
are	O
found	O
in	O
70	B-STAT
%	I-STAT
of	O
DOA	B-DIS
patients	O
with	O
a	O
significant	O
number	O
remaining	O
undiagnosed	O
.	O

Methods	O
We	O
screened	O
286	O
index	O
cases	O
presenting	O
optic	B-DIS
atrophy	I-DIS
negative	O
for	O
OPA1	O
mutations	O
by	O
targeted	O
next	O
generation	O
sequencing	O
or	O
whole	O
exome	O
sequencing	O
.	O

Pathogenicity	O
and	O
molecular	O
mechanisms	O
of	O
the	O
identified	O
variants	O
were	O
studied	O
in	O
yeast	O
and	O
patient	O
-	O
derived	O
fibroblasts	O
.	O

Results	O
Twelve	O
cases	O
4	B-STAT
%	I-STAT
were	O
found	O
to	O
carry	O
novel	O
variants	O
in	O
AFG3L2	O
a	O
gene	O
that	O
has	O
been	O
associated	O
with	O
autosomal	B-DIS
dominant	I-DIS
spinocerebellar	I-DIS
ataxia	I-DIS
28	O
SCA28	O
.	O

Half	O
of	O
cases	O
were	O
familial	O
with	O
a	O
dominant	O
inheritance	O
whereas	O
the	O
others	O
were	O
sporadic	O
including	O
de	O
novo	O
mutations	O
.	O

Biallelic	O
mutations	O
were	O
found	O
in	O
3	O
probands	O
with	O
severe	O
syndromic	B-DIS
optic	I-DIS
neuropathy	I-DIS
acting	O
as	O
recessive	O
or	O
phenotype	O
-	O
modifier	O
variants	O
.	O

All	O
the	O
DOA	O
-	O
associated	O
AFG3L2	O
mutations	O
were	O
clustered	O
in	O
the	O
ATPase	O
domain	O
whereas	O
SCA28	O
-	O
associated	O
mutations	O
mostly	O
affect	O
the	O
proteolytic	O
domain	O
.	O

The	O
pathogenic	O
role	O
of	O
DOA	O
-	O
associated	O
AFG3L2	O
mutations	O
was	O
confirmed	O
in	O
yeast	O
unraveling	O
a	O
mechanism	O
distinct	O
from	O
that	O
of	O
SCA28	O
-	O
associated	O
AFG3L2	O
mutations	O
.	O

Patients	O
'	O
fibroblasts	O
showed	O
abnormal	O
OPA1	O
processing	O
with	O
accumulation	O
of	O
the	O
fission	O
-	O
inducing	O
short	O
forms	O
leading	O
to	O
mitochondrial	O
network	O
fragmentation	O
not	O
observed	O
in	O
SCA28	O
patients	O
'	O
cells	O
.	O

Interpretation	O
This	O
study	O
demonstrates	O
that	O
mutations	O
in	O
AFG3L2	O
are	O
a	O
relevant	O
cause	O
of	O
optic	B-DIS
neuropathy	I-DIS
broadening	O
the	O
spectrum	O
of	O
clinical	O
manifestations	O
and	O
genetic	O
mechanisms	O
associated	O
with	O
AFG3L2	O
mutations	O
and	O
underscores	O
the	O
pivotal	O
role	O
of	O
OPA1	O
and	O
its	O
processing	O
in	O
the	O
pathogenesis	O
of	O
DOA	B-DIS
.	O

ANN	O
NEUROL	O
2020	O
ANN	O
NEUROL	O
2020	O
;	O
8818	O
-	O
32	O
.	O

We	O
present	O
a	O
case	O
report	O
of	O
a	O
32	O
-	O
year	O
-	O
old	B-DIS
woman	O
diagnosed	B-DIS
with	I-DIS
opticomyelitis	O
of	B-DIS
Devic	I-DIS
OMD	I-DIS
and	O
systemic	O
lupus	O
erythematosus	O
SLE	O
.	O

The	O
onset	O
of	O
neurological	O
symptoms	O
was	O
with	O
optic	B-DIS
neuritis	I-DIS
.	O

Five	O
months	O
later	O
the	O
neurological	B-DIS
deficit	I-DIS
progressed	O
within	O
a	O
few	O
days	O
to	O
lower	O
paraplegia	B-DIS
and	O
upper	B-DIS
paraparesis	I-DIS
retention	O
of	O
urine	O
and	O
faeces	O
impaired	B-DIS
somatic	I-DIS
and	I-DIS
deep	I-DIS
sensation	I-DIS
below	O
the	O
level	O
of	O
Th1	O
dermatome	O
.	O

The	O
results	O
from	O
laboratory	O
investigations	O
confirmed	O
anaemic	O
syndrome	O
increased	O
urea	O
and	O
creatinine	O
hypoproteinemia	O
and	O
severe	O
proteinuria	B-DIS
.	O

The	O
results	O
from	O
CSF	O
investigations	O
demonstrated	O
hyperproteinorachia	O
with	O
extremely	O
high	O
Ig	O
fractions	O
.	O

Serum	O
and	O
CSF	O
oligoclonal	O
bands	O
and	O
positive	O
serum	O
Aquaporin	O
IgG	O
32	O
times	O
higher	O
than	O
the	O
upper	O
referent	O
limit	O
were	O
found	O
.	O

The	O
association	O
with	O
SLE	O
was	O
confirmed	O
by	O
the	O
increased	O
levels	O
of	O
total	O
ANA	O
and	O
anti	O
-	B-DIS
ds	O
-	O
DNA	O
ANA	O
.	O

MRT	O
visualized	O
the	O
spinal	O
cord	O
as	O
non	O
-	O
homogenously	O
hypointense	O
on	O
T1	O
and	O
extremely	O
hyperintense	O
on	O
FLAIR	O
sequences	O
through	O
its	O
whole	O
length	O
up	O
to	O
the	O
bulbar	O
-	O
pontine	O
region	O
.	O

The	O
MRT	O
findings	O
and	O
the	O
serum	O
Aquaporin	O
IgG	O
confirmed	O
the	O
diagnosis	O
OMD	O
.	O

The	O
patient	O
was	O
treated	O
with	O
intravenous	O
immunomodulating	O
agents	O
.	O

We	O
consider	O
the	O
presented	O
case	O
of	O
special	O
interest	O
because	O
of	O
the	O
comorbidity	O
of	O
an	O
aggressive	B-DIS
autoimmune	I-DIS
systemic	O
and	O
an	O
organ	O
-	O
specific	O
disease	O
of	O
the	O
central	O
nervous	O
system	O
.	O

Transient	O
global	O
amnesia	B-DIS
TGA	O
is	O
an	O
uncommon	O
disease	O
characterized	O
by	O
sudden	O
onset	O
anterograde	O
amnesia	B-DIS
that	O
typically	O
improves	O
within	O
24	O
hours	O
.	O

A	O
35	O
-	O
year	O
-	O
old	O
woman	O
presented	O
with	O
complete	O
disruption	O
of	O
memory	O
that	O
had	O
started	O
on	O
the	O
previous	O
day	O
.	O

She	O
had	O
fever	B-DIS
and	O
heart	O
murmur	O
and	O
was	O
diagnosed	O
as	O
having	O
infective	B-DIS
endocarditis	I-DIS
with	O
Staphylococcus	B-DIS
lugdunensis	I-DIS
a	I-DIS
coagulase	B-DIS
-	I-DIS
negative	O
staphylococcus	O
.	O

Septic	B-DIS
embolizations	O
were	O
found	O
in	O
the	O
spleen	O
and	O
kidney	O
on	O
CT	O
scan	O
.	O

The	O
patient	O
underwent	O
aortic	O
valve	O
replacement	O
.	O

MRI	O
susceptibility	O
-	O
weighted	O
imaging	O
showed	O
a	O
dotted	O
low	O
intensity	O
area	O
in	O
the	O
right	O
hippocampus	O
.	O

Recently	O
etiology	O
of	O
TGA	O
is	O
reported	O
to	O
be	O
related	O
to	O
hippocampal	B-DIS
disorder	I-DIS
.	O

We	O
report	O
a	O
rare	O
case	O
of	O
TGA	O
with	O
hippocampal	B-DIS
infarction	I-DIS
due	O
to	O
septic	O
embolism	B-DIS
from	O
infective	B-DIS
endocarditis	I-DIS
.	O

Purpose	O
TP53germline	O
g	O
mutations	O
associated	O
with	O
the	O
Li	B-DIS
-	I-DIS
Fraumeni	I-DIS
syndrome	O
LFS	O
have	O
rarely	O
been	O
reported	O
in	O
the	O
context	B-DIS
of	I-DIS
hereditary	I-DIS
breast	I-DIS
and	I-DIS
ovarian	I-DIS
cancer	O
HBOC	O
.	O

The	O
prevalence	B-EPI
and	O
cancer	B-DIS
risks	O
in	O
this	O
target	O
group	O
are	O
unknown	O
and	O
counseling	O
remains	O
challenging	O
.	O

Notably	O
an	O
extensive	O
high	O
-	O
risk	O
surveillance	O
program	O
is	O
implemented	O
which	O
evokes	O
substantial	O
psychological	O
discomfort	O
.	O

Emphasizing	O
the	O
lack	O
of	O
consensus	O
about	O
clinical	O
implications	O
we	O
aim	O
to	O
further	O
characterize	O
TP53	O
g	O
mutations	O
in	O
HBOC	B-DIS
families	O
.	O

Methods	O
Next	O
-	O
generation	O
sequencing	O
was	O
conducted	O
on	B-DIS
1876	I-DIS
breast	O
cancer	O
BC	O
patients	O
who	O
fulfilled	O
the	O
inclusion	O
criteria	B-DIS
for	O
HBOC	O
.	O

Results	O
Likely	O
pathogenic	O
variants	O
in	O
TP53	O
gene	O
were	O
present	O
in	O
0.6	B-STAT
%	I-STAT
of	O
the	O
BC	O
cohort	O
with	O
higher	O
occurrence	O
in	O
early	O
onset	O
BC	O
<	O
36	O
years	O
.	O

1.1	B-STAT
%	I-STAT
and	O
bilateral	O
vs.	O
unilateral	O
BC	O
1.1	B-STAT
%	I-STAT
vs.	O
0.3	B-STAT
%	I-STAT
.	O

Two	O
out	O
of	O
eleven	O
patients	O
with	O
a	O
likely	O
pathogenic	O
TP53	O
g	O
variant	O
c.542	O
A	O
;	O
c.375	O
A	O
did	O
not	O
comply	O
with	O
classic	O
LFS	O
/	O
Chompret	O
criteria	O
.	O

Albeit	O
located	O
in	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
the	O
p53	O
-	O
protein	O
and	O
therefore	O
revealing	B-DIS
no	O
difference	O
to	O
LFS	O
-	O
related	O
variants	O
they	O
only	O
displayed	O
a	O
medium	O
transactivity	O
reduction	O
constituting	O
a	O
retainment	O
of	O
wildtype	O
-	O
like	O
anti	O
-	O
proliferative	O
functionality	O
.	O

Conclusion	O
Among	O
our	O
cohort	O
of	O
HBOC	B-DIS
families	O
we	O
were	O
able	O
to	O
describe	O
a	O
clinical	O
subgroup	O
which	O
is	O
distinct	O
from	O
the	O
classic	O
LFS	O
-	O
families	O
.	O

Strikingly	O
two	O
families	O
did	O
not	O
adhere	O
to	O
the	O
LFS	O
criteria	O
and	O
functional	O
analysis	O
revealed	O
a	O
reduced	O
impact	O
on	O
TP53	O
activity	O
which	O
may	O
suit	O
to	O
the	O
attenuated	O
phenotype	O
.	O

This	O
is	O
an	O
approach	O
that	O
could	O
be	O
useful	O
in	O
developing	O
individualized	O
screening	O
efforts	O
for	O
TP53	O
g	O
mutation	O
carrier	O
in	O
HBOC	B-DIS
families	O
.	O

Due	O
to	O
the	O
low	O
incidence	B-EPI
national	O
/	O
international	O
cooperation	O
is	O
necessary	O
to	O
further	O
explore	O
clinical	O
implications	O
.	O

This	O
might	O
allow	O
providing	O
directions	O
for	O
clinical	O
recommendations	O
in	O
the	O
future	O
.	O

Objectives	O
A	O
low	O
serum	O
alkaline	O
phosphatase	O
ALP	O
level	O
is	O
an	O
uncommon	O
finding	O
in	O
patients	O
with	O
chronic	B-DIS
liver	I-DIS
disease	I-DIS
CLD	I-DIS
.	O

The	O
prevalence	B-EPI
of	O
this	O
finding	O
and	O
whether	O
low	O
ALP	O
expression	O
influences	O
CLD	B-DIS
remain	O
to	O
be	O
determined	O
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
1	O
to	O
document	O
the	O
prevalence	B-EPI
of	O
low	O
serum	O
ALP	O
levels	O
in	O
adult	O
CLD	B-DIS
patients	O
and	O
2	O
compare	O
features	O
of	O
CLD	B-DIS
in	O
patients	O
with	O
low	O
versus	O
normal	O
or	O
elevated	O
serum	O
ALP	O
levels	O
.	O

Methods	O
An	O
adult	O
outpatient	O
liver	B-DIS
disease	I-DIS
database	O
was	O
searched	O
for	O
patients	O
with	O
low	O
serum	O
ALP	O
levels	O
<	O
40	O
IU	O
/	O
L	O
.	O

Hepatic	B-DIS
inflammation	I-DIS
function	O
fibrosis	B-DIS
and	O
disease	O
severity	O
were	O
determined	O
by	O
serum	O
aminotransferases	O
albumin	O
bilirubin	O
and	O
INR	O
levels	O
Fib-4	O
calculations	O
and	O
MELD	O
scores	O
respectively	O
.	O

Results	O
Of	O
19037	O
patients	O
entered	O
into	O
the	O
database	O
470.25	B-STAT
%	I-STAT
had	O
consistently	O
low	O
serum	O
ALP	O
levels	O
510.27	B-STAT
%	I-STAT
low	O
levels	O
on	O
the	O
majority	O
and	O
4692.44	B-STAT
%	I-STAT
on	O
the	O
minority	O
of	O
determinations	O
.	O

Patients	O
with	O
consistently	O
low	O
levels	O
were	O
matched	O
12	O
by	O
age	O
gender	O
and	O
nature	O
of	O
the	O
underlying	O
liver	B-DIS
disease	I-DIS
to	O
patients	O
with	O
normal	O
or	O
elevated	O
serum	O
ALP	O
levels	O
.	O

Matched	O
patients	O
with	O
consistently	O
low	O
ALP	O
levels	O
had	O
significantly	O
lower	O
serum	O
aminotransferase	O
and	O
bilirubin	O
levels	O
at	O
their	O
initial	O
visit	O
and	O
throughout	O
the	O
follow	O
-	O
up	O
period	O
p	O
<	O
0.05	O
respectively	O
while	O
Fib-4	O
levels	O
and	O
MELD	O
scores	O
were	O
similar	O
at	O
the	O
initial	O
and	O
last	O
follow	O
-	O
up	O
visit	O
.	O

Conclusions	O
These	O
results	O
establish	O
the	O
prevalence	B-EPI
of	O
low	O
serum	O
ALP	O
levels	O
in	O
adult	O
CLD	B-DIS
patients	O
and	O
describe	O
a	O
hitherto	O
unreported	O
association	O
between	O
low	O
serum	O
ALP	O
levels	O
and	O
less	O
biochemical	O
evidence	O
of	O
active	B-DIS
disease	I-DIS
.	O

The	O
term	O
NBIA	B-DIS
encompasses	O
a	O
heterogeneous	O
group	O
of	O
inherited	O
disorders	O
characterized	O
clinically	O
by	O
progressive	O
extra	O
pyramidal	B-DIS
syndrome	I-DIS
and	O
pathologically	O
by	O
excessive	O
iron	O
deposition	O
in	O
brain	O
primarily	O
affecting	O
the	O
basal	O
ganglia	O
globus	O
pallidus	O
mainly	O
.	O

The	O
hallmark	O
of	O
this	O
syndrome	O
is	O
the	O
age	O
specific	O
phenotypic	O
presentation	O
and	O
intraphenotypic	O
heterogeneity	O
.	O

NBIAs	O
at	O
present	O
include	O
ten	O
subtypes	O
with	O
genes	O
identified	O
in	O
nine	O
subtypes	O
.	O

They	O
form	O
an	O
important	O
differential	O
diagnosis	O
for	O
the	O
phenotype	O
of	O
global	O
developmental	O
delay	O
in	O
infancy	O
/	O
childhood	B-DIS
to	O
dystonia	O
-	B-DIS
parkinsonism	O
or	O
isolated	O
parkinsonism	O
at	O
all	O
ages	O
and	O
also	B-DIS
for	I-DIS
the	O
isolated	O
craniocervical	O
dystonia	O
of	O
adult	O
onset	O
.	O

There	O
needs	O
to	O
be	O
a	O
high	O
index	O
of	O
clinical	O
suspicion	O
for	O
this	O
syndrome	O
and	O
the	O
evaluation	O
includes	O
MRI	O
brain	O
T2	O
*	O
weighted	O
imaging	O
which	O
reveal	O
symmetrical	O
iron	O
deposition	O
in	O
bilateral	O
globus	O
pallidi	O
and	O
other	O
basal	O
ganglia	O
.	O

The	O
T2	O
*	O
imaging	O
pattern	O
of	O
iron	O
deposition	O
varies	O
amongst	O
the	O
different	O
subtypes	O
and	O
the	O
combination	O
of	O
clinical	O
phenotype	O
and	O
MRI	O
signature	O
makes	O
it	O
easier	O
to	O
confidently	O
make	O
a	O
diagnosis	O
of	O
NBIA	B-DIS
and	O
to	O
recommend	O
genetic	O
testing	O
.	O

The	O
treatment	O
to	O
date	O
is	O
mostly	O
symptomatic	O
with	O
targeted	O
therapies	O
on	O
the	O
horizon	O
.	O

Kuwait	B-LOC
has	O
a	O
cosmopolitan	O
population	O
of	O
1.7	O
million	O
mostly	O
Arabs	O
.	O

This	O
population	O
is	O
a	O
mosaic	O
of	O
large	O
and	O
small	O
minorities	O
representing	O
most	O
Arab	O
communities	O
.	O

In	O
general	O
Kuwait	B-LOC
's	O
population	O
is	O
characterized	O
by	O
a	O
rapid	O
rate	O
of	O
growth	O
large	O
family	O
size	O
high	O
rates	O
of	O
consanguineous	O
marriages	O
within	O
the	O
Arab	O
communities	O
with	O
low	O
frequency	O
of	O
intermarriage	O
between	O
them	O
and	O
the	O
presence	O
of	O
genetic	O
isolates	O
and	O
semi	O
-	O
isolates	O
in	O
some	O
extended	O
families	O
and	O
Bedouin	O
tribes	O
.	O

Genetic	O
services	O
have	O
been	O
available	O
in	O
Kuwait	B-LOC
for	O
over	O
a	O
decade	O
.	O

During	O
this	O
time	O
it	O
has	O
become	O
clear	O
that	O
Arabs	O
have	O
a	O
high	O
frequency	O
of	O
genetic	O
disorders	O
and	O
in	O
particular	O
autosomal	O
recessive	O
traits	O
.	O

Their	O
pattern	O
is	O
unique	O
and	O
some	O
disorders	O
are	O
relatively	O
common	O
.	O

Examples	O
are	O
Bardet	O
-	O
Biedl	B-DIS
and	I-DIS
Meckel	I-DIS
syndromes	O
phenylketonuria	O
and	O
familial	B-DIS
Mediterranean	B-LOC
fever	O
.	O

A	O
relatively	O
large	O
number	O
of	O
new	O
syndromes	O
and	O
variants	O
have	O
been	O
delineated	O
in	O
Kuwait	B-LOC
's	O
population	O
many	O
being	O
the	O
result	O
of	O
homozygosity	O
for	O
autosomal	O
recessive	O
genes	O
that	O
occurred	O
because	O
of	O
inbreeding	O
.	O

Some	O
of	O
these	O
syndromes	O
have	O
subsequently	O
been	O
found	O
in	O
other	O
parts	O
of	O
the	O
world	O
negating	O
the	O
concept	O
of	O
the	O
private	O
syndrome	O
.	O

This	O
paper	O
provides	O
an	O
overview	O
of	O
autosomal	B-DIS
recessive	I-DIS
disorders	I-DIS
among	O
the	O
Arabs	O
in	O
Kuwait	B-LOC
from	O
a	O
personal	O
perspective	O
and	O
published	O
studies	O
and	O
highlights	O
the	O
need	O
for	O
genetic	O
services	O
in	O
Arab	O
countries	O
with	O
the	O
goal	O
of	O
prevention	O
and	O
treatment	O
of	O
genetic	O
disorders	O
.	O

Objectives	O
To	O
analyse	O
the	O
characteristics	O
and	O
predictors	O
of	O
death	B-DIS
in	O
hospitalized	O
patients	O
with	O
coronavirus	B-DIS
disease	I-DIS
2019	O
COVID-19	O
in	O
Spain	B-LOC
.	O

Methods	O
A	O
retrospective	O
observational	O
study	O
was	O
performed	O
of	O
the	O
first	O
consecutive	O
patients	O
hospitalized	O
with	O
COVID-19	O
confirmed	O
by	O
real	O
-	O
time	O
PCR	O
assay	O
in	O
127	O
Spanish	O
centres	O
until	O
17	O
March	O
2020	O
.	O

The	O
follow	O
-	O
up	O
censoring	O
date	O
was	O
17	O
April	O
2020	O
.	O

We	O
collected	O
demographic	O
clinical	O
laboratory	O
treatment	O
and	O
complications	O
data	O
.	O

The	O
primary	O
endpoint	O
was	O
all	O
-	O
cause	O
mortality	O
.	O

Univariable	O
and	O
multivariable	O
Cox	O
regression	O
analyses	O
were	O
performed	O
to	O
identify	O
factors	O
associated	O
with	O
death	B-DIS
.	O

Results	O
Of	O
the	O
4035	O
patients	O
male	O
subjects	O
accounted	O
for	O
243361.0	B-STAT
%	I-STAT
of	O
3987	O
the	O
median	O
age	O
was	O
70	O
years	O
and	O
253973.8	B-STAT
%	I-STAT
of	O
3439	O
had	O
one	O
or	O
more	O
comorbidity	B-DIS
.	O

The	O
most	O
common	O
symptoms	O
were	O
a	O
history	O
of	O
fever	B-DIS
cough	I-DIS
malaise	I-DIS
and	O
dyspnoea	B-DIS
.	O

During	O
hospitalization	O
125531.5	B-STAT
%	I-STAT
of	O
3979	O
patients	O
developed	O
acute	O
respiratory	B-DIS
distress	I-DIS
syndrome	I-DIS
73618.5	B-STAT
%	I-STAT
of	O
3988	O
were	O
admitted	O
to	O
intensive	O
care	O
units	O
and	O
61915.5	B-STAT
%	I-STAT
of	O
3992	O
underwent	O
mechanical	O
ventilation	O
.	O

Virus-	O
or	O
host	O
-	O
targeted	O
medications	O
included	B-STAT
lopinavir	O
/	O
ritonavir	O
2820/4005	B-STAT
70.4	I-STAT
%	I-STAT
hydroxychloroquine	O
2618/3995	B-STAT
65.5	B-STAT
%	I-STAT
interferon	O
beta	O
1153/3950	B-STAT
29.2	I-STAT
%	I-STAT
corticosteroids	O
1109/3965	B-STAT
28.0	B-STAT
%	I-STAT
and	O
tocilizumab	O
373/3951	O
9.4	B-STAT
%	I-STAT
.	O

Overall	O
113128	B-STAT
%	I-STAT
of	O
4035	O
patients	O
died	O
.	O

Mortality	O
increased	O
with	O
age	O
85.6	B-STAT
%	I-STAT
occurring	O
in	O
older	O
than	O
65	O
years	O
.	O

Seventeen	O
factors	O
were	O
independently	O
associated	O
with	O
an	O
increased	O
hazard	O
of	O
death	B-DIS
the	O
strongest	O
among	O
them	O
including	O
advanced	O
age	O
liver	B-DIS
cirrhosis	I-DIS
low	O
age	O
-	O
adjusted	O
oxygen	O
saturation	O
higher	O
concentrations	O
of	O
C	O
-	O
reactive	O
protein	O
and	O
lower	O
estimated	O
glomerular	O
filtration	O
rate	O
.	O

Conclusions	O
Our	O
findings	O
provide	O
comprehensive	O
information	O
about	O
characteristics	O
and	O
complications	O
of	O
severe	O
COVID-19	O
and	O
may	O
help	O
clinicians	O
identify	O
patients	O
at	O
a	O
higher	O
risk	O
of	O
death	B-DIS
.	O

A	O
series	O
of	O
simplex	B-DIS
cases	O
have	O
been	O
reported	O
under	O
various	O
diagnoses	O
sharing	O
early	O
aging	O
especially	O
evident	O
in	O
congenitally	O
decreased	O
subcutaneous	O
fat	O
tissue	O
and	O
sparse	O
hair	B-DIS
bone	I-DIS
dysplasia	I-DIS
of	I-DIS
the	I-DIS
skull	I-DIS
and	O
fingers	O
a	O
distinctive	O
facial	O
gestalt	O
and	O
prenatal	O
and	O
postnatal	O
growth	O
retardation	O
.	O

For	O
historical	O
reasons	O
we	O
suggest	O
naming	O
the	O
entity	O
Fontaine	B-DIS
syndrome	I-DIS
.	O

Exome	O
sequencing	O
of	O
four	O
unrelated	O
affected	O
individuals	O
showed	O
that	O
all	O
carried	O
the	O
de	O
novo	O
missense	O
variant	O
c.64	O
T	O
p.	O
Arg217Cys	O
or	O
c.65	O
A	O
p.	O
Arg217His	O
in	O
SLC25A24	O
a	O
solute	O
carrier	O
25	O
family	O
member	O
coding	O
for	O
calcium	O
-	O
binding	O
mitochondrial	O
carrier	O
protein	O
SCaMC-1	O
also	O
known	O
as	O
SLC25A24	O
.	O

SLC25A24	O
allows	O
an	O
electro	O
-	O
neutral	O
and	O
reversible	O
exchange	O
of	O
ATP	O
-	O
Mg	O
and	O
phosphate	O
between	O
the	O
cytosol	O
and	O
mitochondria	O
which	O
is	O
required	O
for	O
maintaining	O
optimal	O
adenine	O
nucleotide	O
levels	O
in	O
the	O
mitochondrial	O
matrix	O
.	O

Molecular	O
dynamic	O
simulation	O
studies	O
predict	O
that	O
p.	O
Arg217Cys	O
and	O
p.	O
Arg217His	O
narrow	O
the	O
substrate	O
cavity	O
of	O
the	O
protein	O
and	O
disrupt	O
transporter	O
dynamics	O
.	O

SLC25A24	O
-	O
mutant	O
fibroblasts	O
and	O
cells	O
expressing	O
p.	O
Arg217Cys	O
or	O
p.	O
Arg217His	O
variants	O
showed	O
altered	O
mitochondrial	O
morphology	O
a	O
decreased	O
proliferation	O
rate	O
increased	O
mitochondrial	O
membrane	O
potential	O
and	O
decreased	O
ATP	O
-	O
linked	O
mitochondrial	O
oxygen	O
consumption	O
.	O

The	O
results	O
suggest	O
that	O
the	O
SLC25A24	O
mutations	O
lead	O
to	O
impaired	O
mitochondrial	O
ATP	O
synthesis	O
and	O
cause	O
hyperpolarization	O
and	O
increased	O
proton	O
leak	O
in	O
association	O
with	O
an	O
impaired	O
energy	O
metabolism	O
.	O

Our	O
findings	O
identify	O
SLC25A24	O
mutations	O
affecting	O
codon	O
217	O
as	O
the	O
underlying	O
genetic	O
cause	O
of	O
human	B-DIS
progeroid	I-DIS
Fontaine	I-DIS
syndrome	I-DIS
.	O

Background	O
Mitochondrial	O
diseases	O
also	O
known	O
as	O
oxidative	O
phosphorylation	O
OXPHOS	O
disorders	O
with	O
a	O
prevalence	B-EPI
rate	O
of	O
15000	O
are	O
the	O
most	O
frequent	O
inherited	O
metabolic	B-DIS
diseases	I-DIS
.	O

Leigh	B-DIS
Syndrome	I-DIS
French	O
Canadian	O
type	O
LSFC	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
nuclear	O
gene	O
2p16	O
leucine	O
-	O
rich	O
pentatricopeptide	O
repeat	O
-	O
containing	O
LRPPRC	O
.	O

It	O
is	O
an	O
autosomal	O
recessive	O
neurogenetic	B-DIS
OXPHOS	I-DIS
disorder	I-DIS
phenotypically	O
distinct	O
from	O
other	O
types	O
of	O
Leigh	B-DIS
syndrome	I-DIS
with	O
a	O
carrier	O
frequency	O
up	O
to	O
123	O
and	O
an	O
incidence	B-EPI
of	O
12063	O
in	O
the	O
Saguenay	O
-	O
Lac	O
-	O
St	O
Jean	O
region	O
of	O
Quebec	B-LOC
.	O

Recently	O
LSFC	B-DIS
has	O
also	O
been	O
reported	O
outside	O
the	O
French	O
-	O
Canadian	O
population	O
.	O

Patient	O
presentation	O
We	O
report	O
a	O
male	O
Italian	O
Sicilian	O
child	O
born	O
preterm	O
at	O
28	O
+	O
6/7	B-STAT
weeks	O
gestation	O
carrying	O
a	O
novel	O
LRPPRC	O
compound	O
heterozygous	O
mutation	O
with	O
facial	O
dysmorphisms	O
neonatal	O
hypotonia	B-DIS
non	I-DIS
-	I-DIS
epileptic	I-DIS
paroxysmal	I-DIS
motor	O
phenomena	O
and	O
absent	O
sucking	O
-	O
swallowing	O
-	O
breathing	O
coordination	O
requiring	O
at	O
4.5	O
months	O
a	O
percutaneous	O
endoscopic	O
gastrostomy	O
tube	O
placement	O
.	O

At	O
5	O
months	O
brain	O
Magnetic	O
Resonance	O
Imaging	O
showed	O
diffuse	O
cortical	B-DIS
atrophy	I-DIS
hypoplasia	I-DIS
of	O
corpus	O
callosum	B-DIS
cerebellar	I-DIS
vermis	I-DIS
hypoplasia	I-DIS
and	O
unfolded	O
hippocampi	O
.	O

Both	O
auditory	B-DIS
and	I-DIS
visual	I-DIS
evoked	O
potentials	O
were	O
pathological	O
.	O

In	O
the	O
following	O
months	O
Video	O
EEG	O
confirmed	O
the	O
persistence	O
of	O
sporadic	O
non	O
epileptic	B-DIS
motor	O
phenomena	O
.	O

No	O
episode	O
of	O
metabolic	B-DIS
decompensation	I-DIS
acidosis	I-DIS
or	O
ketosis	B-DIS
frequently	O
observed	O
in	O
LSFC	B-DIS
has	O
been	O
reported	O
.	O

Actually	O
aged	O
14	O
months	O
corrected	O
age	O
for	O
prematurity	B-DIS
the	O
child	O
shows	O
a	O
severe	O
global	O
developmental	O
delay	O
.	O

Metabolic	O
investigations	O
and	O
array	O
Comparative	O
Genomic	O
Hybridization	O
aCGH	O
results	O
were	O
normal	O
.	O

Whole	O
-	O
exome	O
sequencing	O
WES	O
found	O
a	O
compound	O
heterozygous	O
mutation	O
in	O
the	O
LRPPRC	O
gene	O
c.1921	O
-	O
7	O
G	O
and	O
c.2056	O
G	O
p.	O
Ile686Val	O
splicing	O
-	O
site	O
and	O
missense	O
variants	O
inherited	O
from	O
the	O
mother	O
and	O
the	O
father	O
respectively	O
.	O

Conclusions	O
We	O
first	O
characterized	O
the	O
clinical	O
and	O
molecular	O
features	O
of	O
a	O
novel	O
LRPPRC	O
variant	O
in	O
a	O
male	O
Sicilian	O
child	O
with	O
early	O
onset	O
encephalopathy	B-DIS
and	O
psychomotor	B-DIS
impairment	I-DIS
.	O

Our	O
patient	O
showed	O
a	O
phenotype	O
characterized	O
by	O
a	O
severe	O
neurodevelopmental	B-DIS
delay	O
and	O
absence	O
of	O
metabolic	B-DIS
decompensation	I-DIS
attributable	O
to	O
a	O
probable	O
residual	O
enzymatic	O
activity	O
.	O

LRPPRC	O
is	O
a	O
rare	O
cause	O
of	O
metabolic	B-DIS
encephalopathy	I-DIS
outside	O
of	O
Québec	B-LOC
.	O

Our	O
patient	O
adds	O
to	O
and	O
broaden	O
the	O
spectrum	O
of	O
LSFC	O
phenotypes	O
.	O

WES	O
analysis	O
is	O
a	O
pivotal	O
genetic	O
test	O
and	O
should	O
be	O
performed	O
in	O
infants	O
and	O
children	O
with	O
hypotonia	B-DIS
and	O
developmental	O
delay	O
in	O
whom	O
metabolic	O
investigations	O
and	O
aCGH	O
are	O
normal	O
.	O

Despite	O
the	O
prevalence	B-EPI
of	O
preterm	B-DIS
brain	I-DIS
injury	I-DIS
there	O
are	O
no	O
established	O
neuroprotective	O
strategies	O
to	O
prevent	O
or	O
alleviate	O
mild	O
-	O
to	B-DIS
-	I-DIS
moderate	O
inflammation	O
-	O
related	O
brain	O
injury	O
.	O

Perinatal	O
infection	B-DIS
and	O
inflammation	B-DIS
have	O
been	O
shown	O
to	O
trigger	O
acute	O
neuroinflammation	O
including	O
proinflammatory	O
cytokine	O
release	O
and	O
gliosis	B-DIS
which	O
are	O
associated	O
with	O
acute	O
and	O
chronic	O
disturbances	O
in	O
brain	O
cell	O
survival	O
and	O
maturation	O
.	O

These	O
findings	O
suggest	O
the	O
hypothesis	O
that	O
the	O
inhibition	O
of	O
peripheral	O
immune	O
responses	O
following	O
infection	B-DIS
or	O
nonspecific	O
inflammation	B-DIS
may	O
be	O
a	O
therapeutic	O
strategy	O
to	O
reduce	O
the	O
associated	O
brain	B-DIS
injury	I-DIS
and	O
neurobehavioral	B-DIS
deficits	I-DIS
.	O

This	O
review	O
provides	O
an	O
overview	O
of	O
the	O
neonatal	O
immunity	O
neuroinflammation	O
and	O
mechanisms	O
of	O
inflammation	O
-	B-DIS
related	I-DIS
brain	O
injury	O
in	O
preterm	O
infants	O
and	O
explores	O
the	O
safety	O
and	O
efficacy	O
of	O
anti	O
-	O
inflammatory	O
agents	O
as	O
potentially	O
neurotherapeutics	O
.	O

Objective	O
To	O
estimate	O
pooled	O
prevalence	B-EPI
of	O
cognitive	B-DIS
impairment	I-DIS
in	O
neuromyelitis	B-DIS
opticaspectrum	B-DIS
disorders	I-DIS
NMOSD	I-DIS
cases	O
.	O

Methods	O
We	O
searched	O
PubMed	O
Scopus	O
EMBASE	O
Web	O
of	O
Science	O
and	O
google	O
scholar	O
.	O

We	O
also	O
searched	O
the	O
gray	O
literature	O
including	O
references	O
of	O
the	O
included	O
studies	O
and	O
conference	O
abstracts	O
which	O
were	O
published	O
up	O
to	O
20th	O
October	O
2020	O
.	O

The	O
search	O
strategy	O
included	O
the	O
MeSH	O
and	O
text	O
words	O
as	O
Cognitive	O
Dysfunctions	O
OR	O
Cognitive	B-DIS
Impairment	I-DIS
OR	I-DIS
Cognitive	I-DIS
Declines	I-DIS
OR	I-DIS
Mild	I-DIS
Cognitive	B-DIS
Impairment	I-DIS
OR	I-DIS
Mental	I-DIS
Deterioration	I-DIS
AND	O
Neuromyelitis	B-DIS
Optica	I-DIS
spectrum	I-DIS
disorder	I-DIS
OR	O
NMOSD	B-DIS
OR	O
Devic	B-DIS
syndrome	I-DIS
OR	O
Neuromyelitis	B-DIS
Optica	I-DIS
spectrum	I-DIS
disorders	I-DIS
.	O

Results	O
The	O
literature	O
search	O
revealed	O
1830	O
articles	O
after	O
deleting	O
duplicates	O
1434	O
remained	O
.	O

For	O
the	O
meta	O
-	O
analysis	O
25	O
studies	O
were	O
included	O
.	O

Totally	O
761	O
NMOSD	B-DIS
patients	O
were	O
evaluated	O
and	O
329	O
patients	O
had	O
cognitive	B-DIS
impairment	I-DIS
.	O

Mean	O
age	O
ranged	O
from	O
34	O
-	O
53	O
years	O
.	O

The	O
prevalence	B-EPI
of	O
cognitive	B-DIS
impairment	I-DIS
ranged	O
from	O
3	B-STAT
%	I-STAT
to	I-STAT
75	I-STAT
%	I-STAT
.The	O
pooled	O
prevalence	B-EPI
of	O
cognitive	B-DIS
impairment	I-DIS
was	O
44	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
35	B-STAT
%	I-STAT
-54	I-STAT
%	I-STAT
I	O
2	O
<	O
/s	O
=	O
89.1	B-STAT
%	I-STAT
P	O
<	O
0.001	O
which	O
shows	O
a	O
high	O
statistical	O
heterogeneity	O
.	O

By	O
excluding	O
the	O
abstract	O
of	O
Jung	O
et	O
al	O
which	O
was	O
published	O
in	O
2009	O
we	O
found	O
that	O
the	O
pooled	O
prevalence	B-EPI
was	O
34	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI31	O
-	O
37	O
%	O
I	O
2	O
<	O
/s	O
=	O
0	O
CONCLUSION	O
Cognitive	B-DIS
impairment	I-DIS
should	O
be	O
considered	O
in	O
NMOSD	B-DIS
patients	O
as	O
its	O
pooled	O
prevalence	B-EPI
is	O
estimated	O
as	O
44	B-STAT
%	I-STAT
.	O

This	O
article	O
reports	O
the	O
intent	O
to	O
receive	O
a	O
SARS	O
-	O
COV-2	O
vaccine	O
its	O
predictors	O
and	O
willingness	O
to	O
pay	O
in	O
Bangladesh	B-LOC
.	O

We	O
carried	O
out	O
an	O
online	O
cross	O
-	O
sectional	O
survey	O
of	O
697	O
adults	O
from	O
the	O
general	O
population	O
of	O
Bangladesh	B-LOC
in	O
January	O
2021	O
.	O

A	O
structured	O
questionnaire	O
was	O
used	O
to	O
assess	O
vaccination	O
intent	O
.	O

The	O
questionnaire	O
included	O
sociodemographic	O
variables	O
and	O
health	O
belief	O
model	O
constructs	O
which	O
may	O
predict	O
vaccination	O
intent	O
.	O

Among	O
the	O
participants	O
26	B-STAT
%	I-STAT
demonstrated	O
a	O
definite	O
intent	O
43	B-STAT
%	I-STAT
probable	O
intent	O
24	B-STAT
%	I-STAT
probable	O
negative	O
and	O
7	B-STAT
%	I-STAT
a	O
definite	O
negative	O
intention	O
.	O

Multivariable	O
logistic	O
regression	O
analyses	O
suggest	O
an	O
association	O
between	O
definite	O
intent	O
and	O
previous	O
COVID-19	B-DIS
infection	I-DIS
OR	O
2.86	O
;	O
95	B-STAT
%	I-STAT
CI	O
1.71	O
-	O
4.78	O
perceiving	O
COVID-19	O
as	O
serious	O
OR	O
1.93	O
;	O
1.04	O
-	O
3.59	O
the	O
belief	O
that	O
vaccination	O
would	O
make	O
them	O
feel	O
less	O
worried	O
about	O
catching	O
COVID-19	O
OR	O
4.42	O
;	O
2.25	O
-	O
8.68	O
and	O
concerns	O
about	O
vaccine	O
affordability	O
OR	O
1.51	O
;	O
1.01	O
-	O
2.25	O
.	O

Individuals	O
afraid	O
of	O
the	O
side	O
effects	O
OR	O
0.34	O
;	O
0.21	O
-	O
0.53	O
and	O
those	O
who	O
would	O
take	O
the	O
vaccine	O
if	O
the	O
vaccine	O
were	O
taken	O
by	O
many	O
others	O
OR	O
0.44	O
;	O
0.29	O
-	O
0.67	O
are	O
less	O
likely	O
to	O
have	O
a	O
definite	O
intent	O
.	O

A	O
definite	O
negative	O
intent	O
is	O
associated	O
with	O
the	O
concern	O
that	O
the	O
vaccine	O
may	O
not	O
be	O
halal	B-DIS
OR	O
2.03	O
;	O
1.04	O
-	O
3.96	O
.	O

Furthermore	O
68.4	B-STAT
%	I-STAT
are	O
willing	O
to	O
pay	O
for	O
the	O
vaccine	O
.	O

The	O
median	O
amount	O
that	O
they	O
are	O
willing	O
to	O
pay	O
is	O
USD	O
7.08	O
.	O

The	O
study	O
findings	O
reveal	O
that	O
the	O
definite	O
intent	O
to	O
receive	O
the	O
SARS	O
-	O
CoV-2	O
vaccination	O
among	O
the	O
general	O
population	O
varies	O
depending	O
on	O
their	O
COVID-19	O
-	O
related	O
health	O
beliefs	O
and	O
no	O
significant	O
association	O
was	O
found	O
with	O
sociodemographic	O
variables	O
.	O

Background	O
21	B-DIS
-	I-DIS
hydroxylase	I-DIS
deficiency	O
21OHD	O
is	O
an	B-DIS
autosomal	I-DIS
recessive	O
disorder	O
with	B-EPI
an	O
incidence	O
of	O
110000	O
-	O
120000	O
and	O
is	O
the	O
result	O
of	O
various	O
mutations	O
in	O
the	O
CYP21A2	O
gene	O
.	O

21OHD	B-DIS
has	O
been	O
described	O
in	O
many	O
different	O
populations	O
but	O
it	O
has	O
not	O
been	O
studied	O
in	O
Roma	B-LOC
individuals	O
so	O
far	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
analyse	O
the	O
genotype	O
in	O
Roma	B-DIS
patients	O
with	O
21OHD	B-DIS
and	O
the	O
prevalence	B-EPI
of	O
the	O
disease	O
in	O
the	O
Roma	B-LOC
population	O
of	O
North	B-LOC
Macedonia	I-LOC
.	O

Methods	O
Molecular	O
analysis	O
of	O
the	O
nine	O
most	O
frequent	O
CYP21A2	O
mutations	O
in	O
all	O
known	O
Roma	B-DIS
patients	O
with	O
CAH	B-DIS
in	O
North	B-LOC
Macedonia	I-LOC
relatives	O
and	O
healthy	O
individuals	O
of	O
Roma	B-LOC
ancestry	O
using	O
the	O
PCR	O
/	O
ACRS	O
method	O
.	O

Results	O
Ten	O
Roma	B-DIS
patients	O
with	O
21OHD	B-DIS
were	O
identified	O
of	O
which	O
nine	O
had	O
the	O
salt	O
-	O
wasting	O
and	O
one	O
had	O
the	O
simple	O
virilizing	O
form	O
.	O

Calculated	O
incidence	B-EPI
of	O
21OHD	B-DIS
in	O
the	B-LOC
North	I-LOC
Macedonian	I-LOC
Roma	I-LOC
population	O
was	O
13375	O
.	O

Interestingly	O
9/10	B-STAT
patients	O
90	B-STAT
%	I-STAT
were	O
homozygous	O
for	O
the	O
In2	O
G	O
splicing	O
mutation	O
293	O
-	O
13A/	B-STAT
G	O
.	O

Standard	O
therapy	O
with	O
hydrocortisone	O
and	O
fludrocortisone	O
had	O
been	O
introduced	O
according	O
to	O
the	O
guidelines	O
.	O

In	O
16	O
healthy	O
relatives	O
investigated	O
for	O
CYP21A2	O
mutations	O
heterozygosity	O
for	O
the	O
In2	O
G	O
mutation	O
was	O
detected	O
in	O
13/32	B-STAT
40.6	I-STAT
%	I-STAT
alleles	O
.	O

In	O
100	O
healthy	O
Roma	B-LOC
individuals	O
none	O
related	O
to	O
the	O
analysed	O
families	O
no	O
CYP21A2	O
mutations	O
were	O
detected	O
.	O

Conclusion	O
The	O
Roma	O
population	O
in	O
North	B-LOC
Macedonia	I-LOC
had	O
a	O
very	O
high	O
incidence	B-EPI
of	O
classic	O
21OHD	B-DIS
.	O

Almost	O
all	O
patients	O
had	O
the	O
severe	O
salt	O
-	O
wasting	O
form	O
and	O
the	O
In2G	O
/	O
In2	O
G	O
genotype	O
.	O

Epilepsy	B-DIS
is	O
common	O
in	O
early	O
childhood	O
.	O

In	O
this	O
age	O
group	O
it	O
is	O
associated	O
with	O
high	O
rates	O
of	O
therapy	B-DIS
-	O
resistance	O
and	B-DIS
with	I-DIS
cognitive	O
motor	O
and	O
behavioural	O
comorbidity	O
.	O

A	O
large	O
number	O
of	O
genes	O
with	O
wide	O
ranging	O
functions	O
are	O
implicated	O
in	O
its	O
aetiology	O
especially	O
in	O
those	O
with	O
therapy	O
-	B-DIS
resistant	O
seizures	O
.	O

Identifying	O
the	O
more	O
common	O
single	O
-	B-DIS
gene	O
epilepsies	O
will	O
aid	O
in	O
targeting	O
resources	O
the	O
prioritization	O
of	O
diagnostic	O
testing	O
and	O
development	O
of	O
precision	O
therapy	O
.	O

Previous	O
studies	O
of	O
genetic	O
testing	O
in	O
epilepsy	B-DIS
have	O
not	O
been	O
prospective	O
and	O
population	O
-	O
based	O
.	O

Therefore	O
the	O
population	O
-	O
incidence	O
of	O
common	B-DIS
genetic	O
epilepsies	O
remains	O
unknown	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
incidence	B-EPI
and	O
phenotypic	O
spectrum	O
of	O
the	O
most	O
common	O
single	O
-	B-DIS
gene	O
epilepsies	O
in	O
young	O
children	O
and	O
to	O
calculate	O
what	O
proportion	O
are	O
amenable	O
to	O
precision	O
therapy	O
.	O

This	O
was	O
a	O
prospective	O
national	O
epidemiological	O
cohort	O
study	O
.	O

All	O
children	O
presenting	O
with	O
epilepsy	B-DIS
before	O
36	O
months	O
of	O
age	O
were	O
eligible	O
.	O

Children	O
presenting	O
with	O
recurrent	O
prolonged	O
10	O
min	O
febrile	B-DIS
seizures	I-DIS
;	O
febrile	B-DIS
or	O
afebrile	O
status	B-DIS
epilepticus	I-DIS
30	O
min	O
;	O
or	O
with	O
clusters	O
of	O
two	O
or	O
more	O
febrile	B-DIS
or	O
afebrile	O
seizures	B-DIS
within	O
a	O
24	O
-	O
h	O
period	O
were	O
also	O
eligible	O
.	O

Participants	O
were	O
recruited	O
from	O
all	O
20	O
regional	O
paediatric	O
departments	O
and	O
four	O
tertiary	O
children	O
's	O
hospitals	O
in	O
Scotland	B-LOC
over	O
a	O
3	O
-	O
year	O
period	O
.	O

DNA	O
samples	O
were	O
tested	O
on	O
a	O
custom	O
-	O
designed	O
104	O
-	O
gene	O
epilepsy	O
panel	O
.	O

Detailed	O
clinical	O
information	O
was	O
systematically	O
gathered	O
at	O
initial	O
presentation	O
and	O
during	O
follow	O
-	O
up	O
.	O

Clinical	O
and	O
genetic	O
data	O
were	O
reviewed	O
by	O
a	O
multidisciplinary	O
team	O
of	O
clinicians	O
and	O
genetic	O
scientists	O
.	O

The	O
pathogenic	O
significance	O
of	O
the	O
genetic	O
variants	O
was	O
assessed	O
in	O
accordance	O
with	O
the	O
guidelines	O
of	O
UK	O
Association	O
of	O
Clinical	O
Genetic	O
Science	O
ACGS	O
.	O

Of	O
the	O
343	O
patients	O
who	O
met	O
inclusion	O
criteria	O
333	O
completed	O
genetic	O
testing	O
and	O
80/33324	B-STAT
%	I-STAT
had	O
a	O
diagnostic	O
genetic	O
finding	O
.	O

The	O
overall	O
estimated	O
annual	O
incidence	B-EPI
of	O
single	O
-	B-DIS
gene	O
epilepsies	O
in	O
this	O
well	O
-	B-STAT
defined	I-STAT
population	I-STAT
was	O
1	O
per	B-STAT
2120	O
live	O
births	O
47.2/100000	O
;	O
95	B-STAT
%	I-STAT
confidence	O
interval	O
36.9	O
-	O
57.5	O
.	O

PRRT2	O
was	O
the	O
most	O
common	O
single	O
-	B-DIS
gene	O
epilepsy	O
with	B-EPI
an	O
incidence	B-STAT
of	I-STAT
1	I-STAT
per	O
9970	O
live	B-STAT
births	O
10.0/100000	O
;	O
95	B-STAT
%	I-STAT
confidence	O
interval	O
5.26	O
-	O
14.8	O
followed	O
by	B-STAT
SCN1A	I-STAT
1	I-STAT
per	B-STAT
12200	O
8.26/100000	O
;	O
95	B-STAT
%	I-STAT
confidence	O
interval	O
3.93	O
-	O
12.6	O
;	O
KCNQ21	O
per	B-STAT
17000	O
5.89/100000	O
;	O
95	B-STAT
%	I-STAT
confidence	O
interval	O
2.24	O
-	O
9.56	O
and	O
SLC2A11	O
per	B-STAT
24300	O
4.13/100000	O
;	O
95	B-STAT
%	I-STAT
confidence	O
interval	O
1.07	O
-	O
7.19	O
.	O

Presentation	O
before	O
the	O
age	O
of	O
6	O
months	O
and	O
presentation	O
with	O
afebrile	O
focal	O
seizures	B-DIS
were	O
significantly	O
associated	O
with	O
genetic	O
diagnosis	O
.	O

Single	B-DIS
-	I-DIS
gene	O
disorders	O
accounted	O
for	O
a	O
quarter	O
of	B-DIS
the	O
seizure	O
disorders	O
in	O
this	O
cohort	O
.	O

Genetic	O
testing	O
is	O
recommended	O
to	O
identify	O
children	O
who	O
may	O
benefit	O
from	O
precision	O
treatment	O
and	O
should	O
be	O
mainstream	O
practice	O
in	O
early	O
childhood	O
onset	O
epilepsy	B-DIS
.	O

Although	O
benzothiazole	O
and	O
its	O
derivatives	O
BTHs	O
are	O
considered	O
emerging	O
contaminants	O
in	O
diverse	O
environments	O
and	O
organisms	O
little	O
information	O
is	O
available	O
about	O
their	O
contamination	O
profiles	O
and	O
health	O
impact	O
in	O
ambient	O
particles	O
.	O

In	O
this	O
study	O
an	O
optimized	O
method	O
of	O
ultrasound	O
-	O
assisted	O
extraction	O
coupled	O
with	O
the	O
selected	O
reaction	O
monitoring	O
SRM	O
mode	O
of	O
GC	O
-	O
EI	O
-	O
MS	O
/	O
MS	O
was	O
applied	O
to	O
characterize	O
and	O
analyze	O
PM	O
2.5	O
<	O
/s	O
-bound	O
BTHs	O
from	O
three	O
cities	O
of	O
China	B-LOC
Guangzhou	B-LOC
Shanghai	B-LOC
and	O
Taiyuan	B-LOC
during	O
the	O
winter	O
of	O
2018	O
.	O

The	O
total	O
BTH	O
concentration	O
ΣBTHs	O
in	O
PM	O
2.5	O
<	O
/s	O
samples	O
from	O
the	O
three	O
cities	O
decreased	O
in	O
the	O
order	O
of	O
Guangzho	O
Shangha	O
Taiyuan	O
independently	O
of	O
the	O
PM	O
2.5	O
<	O
/s	O
concentration	O
.	O

Despite	O
the	O
large	O
variation	O
in	O
concentration	O
of	O
ΣBTHs	O
in	O
PM	O
2.5	O
<	O
/s	O
2	O
-	O
hydroxybenzothiazole	O
OTH	O
was	O
always	O
the	O
predominant	O
compound	O
among	O
the	O
PM	O
2.5	O
<	O
/s	O
-bound	O
BTHs	O
and	O
accounted	O
for	O
50	B-STAT
-	I-STAT
80	I-STAT
%	I-STAT
of	O
total	O
BTHs	O
in	O
the	O
three	O
regions	O
.	O

Results	O
from	O
human	O
exposure	O
assessment	O
and	O
toxicity	B-DIS
screening	O
indicated	O
that	O
the	O
outdoor	O
exposure	O
risk	O
of	O
PM	O
2.5	O
<	O
/s	O
-bound	O
BTHs	O
in	O
toddlers	O
was	O
much	O
higher	O
than	O
in	O
adults	O
especially	O
for	O
OTH	O
.	O

The	O
developmental	O
and	O
reproduction	O
toxicity	B-DIS
of	O
OTH	O
was	O
further	O
explored	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Exposure	O
of	O
mouse	O
embryonic	O
stem	O
cells	O
mESCs	O
to	O
OTH	O
for	O
48	O
h	O
significantly	O
increased	O
the	O
intracellular	O
reactive	O
oxygen	O
species	O
ROS	O
and	O
induced	O
DNA	O
damage	O
and	O
apoptosis	O
via	O
the	O
functionally	O
activating	O
p53	O
expression	O
.	O

In	O
addition	O
the	O
growth	O
and	O
development	O
of	O
zebrafish	O
embryos	O
were	O
found	O
to	O
be	O
severely	O
affected	O
after	O
OTH	O
treatment	O
.	O

An	O
overall	O
metabolomics	O
study	O
was	O
conducted	O
on	O
the	O
exposed	O
zebrafish	O
larvae	O
.	O

The	O
results	O
indicated	O
that	O
exposure	O
to	O
OTH	O
inhibited	O
the	O
phenylalanine	O
hydroxylation	O
reaction	O
which	O
further	O
increased	O
the	O
accumulation	O
of	O
toxic	O
phenylpyruvate	O
and	O
acetylphenylalanine	O
in	O
zebrafish	O
.	O

These	O
findings	O
provide	O
important	O
insights	O
into	O
the	O
contamination	O
profiles	O
of	O
PM	O
2.5	O
<	O
/s	O
-bound	O
BTHs	O
and	O
emphasize	O
the	O
health	O
risk	O
of	O
OTH	O
.	O

Background	O
/	O
objectives	O
This	O
retrospective	O
study	O
evaluated	B-EPI
the	O
prevalence	O
of	B-DIS
dental	O
anomalies	O
of	O
number	O
in	O
different	O
subphenotypes	O
of	B-DIS
isolated	I-DIS
cleft	O
palate	O
.	O

Materials	O
/	O
methods	O
The	O
sample	O
comprised	O
26	O
individuals	B-DIS
with	I-DIS
submucous	I-DIS
cleft	O
palate	O
group	O
S	O
and	O
68	O
individuals	O
with	B-DIS
complete	I-DIS
cleft	O
palate	O
group	O
C	O
aged	O
between	O
9	O
and	O
12	O
years	O
from	O
a	O
single	O
centre	O
.	O

Panoramic	O
radiographs	O
were	O
evaluated	O
regarding	O
the	O
presence	O
of	O
dental	O
anomalies	B-DIS
of	O
number	O
in	O
permanent	O
teeth	O
.	O

Intergroup	O
comparison	O
was	O
performed	O
using	O
chi	O
-	O
square	O
tests	O
P	O
<	O
0.05	O
.	O

Results	O
Tooth	B-DIS
agenesis	I-DIS
was	O
found	O
in	O
34.61	O
and	O
36.76	O
per	O
cent	O
of	O
group	O
S	O
and	O
group	O
C	O
respectively	O
.	O

The	O
most	O
commonly	O
missing	O
teeth	O
were	O
the	O
maxillary	O
second	O
premolar	O
maxillary	O
lateral	O
incisor	O
and	O
mandibular	O
second	O
premolar	O
.	O

Supernumerary	O
teeth	O
were	O
found	O
in	O
none	O
and	O
1.47	O
per	O
cent	O
of	O
the	O
individuals	O
with	O
submucous	B-DIS
and	O
complete	O
cleft	B-DIS
palate	I-DIS
respectively	O
.	O

No	O
statistically	O
significant	O
difference	O
was	O
found	O
between	O
groups	O
for	O
the	O
frequency	O
of	O
tooth	B-DIS
agenesis	I-DIS
and	O
supernumerary	O
teeth	O
.	O

Limitations	O
Only	O
dental	O
anomalies	O
of	O
number	O
were	O
evaluated	O
.	O

Conclusions	O
/	O
implications	O
Individuals	B-DIS
with	O
submucous	O
and	B-DIS
complete	I-DIS
cleft	O
palate	O
showed	B-EPI
similar	O
prevalence	B-DIS
for	I-DIS
tooth	O
agenesis	O
and	O
supernumerary	O
teeth	O
.	O

Dental	O
anomalies	B-DIS
frequency	O
seems	O
not	O
to	O
be	O
a	O
discriminator	O
for	O
subphenotypes	O
of	O
cleft	B-DIS
palate	I-DIS
.	O

The	O
Ehlers	B-DIS
-	I-DIS
Danlos	I-DIS
syndromes	O
EDS	O
are	O
a	O
group	O
of	O
13	O
disorders	O
clinically	O
defined	O
through	O
features	O
of	B-DIS
joint	I-DIS
hypermobility	I-DIS
skin	O
hyperextensibility	O
and	O
tissue	O
fragility	O
.	O

Most	O
subtypes	O
are	O
caused	O
by	O
mutations	O
in	O
genes	O
affecting	O
the	O
structure	O
or	O
processing	O
of	O
the	O
extracellular	O
matrix	O
ECM	O
protein	O
collagen	O
.	O

The	O
Hypermobility	B-DIS
Spectrum	O
Disorders	O
HSDs	O
are	O
clinically	O
indistinguishable	O
disorders	O
but	O
are	O
considered	O
to	O
lack	O
a	O
genetic	O
basis	O
.	O

The	O
pathogenesis	O
of	O
all	O
these	O
disorders	O
however	O
remains	O
poorly	O
understood	O
.	O

Genotype	O
-	O
phenotype	O
correlations	O
are	O
limited	O
and	O
findings	O
of	O
aberrant	O
collagen	O
fibrils	O
are	O
inconsistent	O
and	O
associate	O
poorly	O
with	O
the	O
subtype	O
and	O
severity	O
of	O
the	O
disorder	O
.	O

The	O
defective	O
ECM	O
however	O
also	O
has	O
consequences	O
for	O
cellular	O
processes	O
.	O

EDS	O
/	O
HSD	O
fibroblasts	O
exhibit	O
a	O
dysfunctional	O
phenotype	O
including	O
impairments	O
in	O
cell	O
adhesion	O
and	O
cytoskeleton	O
organization	O
though	O
the	O
pathological	O
significance	O
of	O
this	O
has	O
remained	O
unclear	O
.	O

Recent	O
advances	O
in	O
our	O
understanding	O
of	O
fibroblast	O
mechanobiology	O
suggest	O
these	O
changes	O
may	O
actually	O
reflect	O
features	O
of	O
a	O
pathomechanism	O
we	O
herein	O
define	O
.	O

This	O
review	O
departs	O
from	O
the	O
traditional	O
view	O
of	O
EDS	O
/	O
HSD	O
where	O
pathogenesis	O
is	O
mediated	O
by	O
the	O
structurally	O
defective	O
ECM	O
.	O

Instead	O
we	O
propose	O
EDS	O
/	O
HSD	O
may	O
be	O
a	O
disorder	O
of	O
membrane	O
-	O
bound	O
collagen	O
and	O
consider	O
how	O
aberrations	O
in	O
cell	O
adhesion	O
and	O
cytoskeleton	O
dynamics	O
could	O
drive	O
the	O
abnormal	O
properties	O
of	O
the	O
connective	O
tissue	O
and	O
be	O
responsible	O
for	O
the	O
pathogenesis	O
of	O
EDS	O
/	O
HSD	O
.	O

The	O
life	O
span	O
of	O
patients	O
with	O
primary	O
and	O
secondary	O
immunodeficiency	O
is	O
increasing	O
due	O
to	O
recent	O
improvements	O
in	O
therapeutic	O
strategies	O
.	O

While	O
the	O
incidence	B-EPI
of	O
primary	B-DIS
immunodeficiencies	I-DIS
PIDs	I-DIS
is	O
110000	O
births	O
that	O
of	O
secondary	O
immunodeficiencies	O
are	O
more	O
common	O
and	O
are	O
associated	O
with	O
posttransplantation	O
immune	B-DIS
dysfunction	I-DIS
with	O
immunosuppressive	O
medication	O
for	O
human	B-DIS
immunodeficiency	I-DIS
virus	I-DIS
or	O
with	O
human	B-DIS
T	I-DIS
-	I-DIS
cell	I-DIS
lymphotropic	I-DIS
virus	O
infection	O
.	O

After	O
infection	B-DIS
malignancy	I-DIS
is	O
the	O
most	O
prevalent	O
cause	O
of	O
death	B-DIS
in	O
both	O
children	O
and	O
adults	O
with	O
PIDs	B-DIS
.	O

PIDs	B-DIS
more	O
often	O
associated	O
with	O
cancer	B-DIS
include	O
common	O
variable	O
immunodeficiency	B-DIS
CVID	I-DIS
Wiskott	I-DIS
-	I-DIS
Aldrich	I-DIS
syndrome	O
ataxia	O
-	O
telangiectasia	O
and	O
severe	O
combined	O
immunodeficiency	O
.	O

This	O
suggests	O
that	O
a	O
protective	O
immune	O
response	O
against	O
both	O
infectious	B-DIS
non	I-DIS
-	O
self-	O
pathogens	B-DIS
and	I-DIS
malignant	I-DIS
self	O
-	O
challenges	O
cancer	O
exists	O
.	O

The	O
increased	O
incidence	B-EPI
of	O
cancer	B-DIS
has	O
been	O
attributed	O
to	O
defective	O
elimination	O
of	O
altered	O
or	O
`	O
`	O
transformed	O
''	O
cells	O
and/or	O
defective	O
immunity	O
towards	O
cancer	B-DIS
cells	O
.	O

The	O
concept	O
of	O
aberrant	O
immune	O
surveillance	O
occurring	O
in	O
PIDs	B-DIS
is	O
supported	O
by	O
evidence	O
in	O
mice	O
and	O
from	O
patients	O
undergoing	O
immunosuppression	O
after	O
transplantation	O
.	O

Here	O
we	O
discuss	O
the	O
importance	O
of	O
PID	B-DIS
defects	O
in	O
the	O
development	O
of	O
malignancies	B-DIS
and	O
the	O
current	O
limitations	O
associated	O
with	O
molecular	O
pathogenesis	O
of	O
these	O
diseases	O
and	O
emphasize	O
the	O
need	O
for	O
further	O
knowledge	O
of	O
how	O
specific	O
mutations	O
can	O
modulate	O
the	O
immune	O
system	O
to	O
alter	O
immunosurveillance	O
and	O
thereby	O
play	O
a	O
key	O
role	O
in	O
the	O
etiology	O
of	O
malignancies	B-DIS
in	O
PID	B-DIS
patients	O
.	O

Background	O
Childhood	O
alopecia	B-DIS
areata	O
AA	O
is	O
a	O
common	O
cause	O
of	O
dermatologic	O
consultation	O
;	O
however	O
data	O
is	O
scarce	O
in	O
the	O
present	O
set	O
-	O
up	O
.	O

Objectives	O
To	O
evaluate	O
the	O
clinico	O
-	O
epidemiological	O
profile	O
of	O
childhood	O
AA	O
along	O
with	O
dermoscopic	O
correlation	O
.	O

Methods	O
We	O
conducted	O
a	O
cross	O
-	O
sectional	O
study	O
including	O
50	O
new	O
cases	O
of	O
childhood	O
AA	O
for	O
1	O
year	O
.	O

Dermoscopy	O
was	O
performed	O
in	O
each	O
child	O
and	O
findings	O
recorded	O
.	O

Results	O
Childhood	O
AA	O
was	O
more	O
common	O
in	O
girls	O
M	O
F	O
11.4	O
mean	O
age	O
being	O
11.1	O
±	O
3.7	O
years	O
.	O

Scalp	O
was	O
commonest	O
site	O
of	O
involvement	O
in	O
86	B-STAT
%	I-STAT
cases	O
while	O
3264	B-STAT
%	I-STAT
children	O
had	O
mild	O
disease	O
<	O
25	B-STAT
%	I-STAT
involvement	O
.	O

Localized	O
circumscribed	O
patch	O
was	O
the	O
commonest	O
presentation	O
in	O
3774	B-STAT
%	I-STAT
children	O
while	O
sisaipho	O
was	O
the	B-STAT
least	I-STAT
2	I-STAT
%	I-STAT
.	O

A	O
positive	O
family	O
history	O
of	O
AA	O
was	O
noted	O
in	O
510	B-STAT
%	I-STAT
children	O
.	O

Twenty	O
-	O
four	O
children	O
48	B-STAT
%	I-STAT
provided	O
a	O
history	B-DIS
of	I-DIS
atopic	O
disorders	O
while	O
30	B-STAT
%	I-STAT
had	O
a	O
positive	O
family	O
history	B-DIS
of	O
atopy	O
.	O

Stress	O
was	O
the	O
commonest	O
precipitating	O
factor	O
in	O
1326	B-STAT
%	I-STAT
subjects	O
.	O

Nail	O
involvement	O
was	O
observed	O
in	O
1938	B-STAT
%	I-STAT
children	O
pittin	O
thinning	O
while	O
systemic	O
associations	O
like	O
vitiligo	B-DIS
and	O
thyroid	B-DIS
dysfunction	I-DIS
were	O
present	O
in	O
26	B-STAT
%	I-STAT
and	O
24	B-STAT
%	I-STAT
cases	O
respectively	O
.	O

Dermoscopy	O
revealed	O
yellow	O
-	O
dots	O
to	O
be	O
the	O
commonest	O
finding	O
in	O
4488	B-STAT
%	I-STAT
cases	O
followed	O
by	O
short	O
vellus	O
hair	O
and	O
black	O
dots	O
in	O
76	B-STAT
%	I-STAT
and	O
28	B-STAT
%	I-STAT
children	O
respectively	O
while	O
exclamation	O
-	O
mark	O
hair	O
was	O
rare	O
.	O

Conclusion	O
Female	O
gender	O
younger	O
age	O
nail	O
involvement	O
and	O
presence	O
of	O
concomitant	O
atopy	B-DIS
vitiligo	I-DIS
and	O
thyroid	B-DIS
dysfunction	I-DIS
were	O
associated	O
with	O
severe	O
disease	O
but	O
not	O
statistically	O
significant	O
0.05	O
.	O

Regression	O
model	O
failed	O
to	O
detect	O
any	O
risk	O
factors	O
for	O
severe	O
AA	O
.	O

Dermoscopy	O
is	O
an	O
important	O
non	O
-	O
invasive	O
tool	O
for	O
evaluating	O
childhood	O
AA	O
.	O

Background	O
Several	O
studies	O
have	O
shown	O
a	O
high	O
rate	O
of	O
consanguinity	B-DIS
and	O
endogamy	B-DIS
in	O
North	O
African	O
populations	O
.	O

As	O
a	O
result	O
the	O
frequency	O
of	O
autosomal	B-DIS
recessive	I-DIS
diseases	I-DIS
is	O
relatively	O
high	O
in	O
the	O
region	O
with	O
the	O
co	O
-	O
occurrence	O
of	O
two	O
or	O
more	O
diseases	O
.	O

Methods	O
We	O
report	O
here	O
on	O
a	O
consanguineous	O
Libyan	O
family	O
whose	O
child	O
was	O
initially	O
diagnosed	O
as	O
presenting	O
Fanconi	B-DIS
anemia	I-DIS
FA	O
with	O
uncommon	O
skeletal	B-DIS
deformities	I-DIS
.	O

The	O
chromosome	O
breakage	O
test	O
has	O
been	O
performed	O
using	O
mitomycin	O
C	O
MMC	O
while	O
molecular	O
analysis	O
was	O
performed	O
by	O
a	O
combined	O
approach	O
of	O
linkage	O
analysis	O
and	O
whole	O
exome	O
sequencing	O
.	O

Results	O
Cytogenetic	O
analyses	O
showed	O
that	O
the	O
karyotype	O
of	O
the	O
female	O
patient	O
is	O
46	O
XY	O
suggesting	O
the	O
diagnosis	O
of	O
a	O
disorder	O
of	O
sex	O
development	O
DSD	B-DIS
.	O

By	O
looking	O
at	O
the	O
genetic	O
etiology	O
of	O
FA	O
and	O
DSD	B-DIS
we	O
have	O
identified	O
p.	O
[	O
Arg798	O
*	O
]	O
;	O
[	O
Arg798	O
*	O
]	O
mutation	O
in	O
FANCJ	O
OMIM	O
#	O
605882	O
gene	O
responsible	O
for	O
FA	O
and	O
p.	O
[	O
Arg108	O
*	O
]	O
;	O
[	O
Arg1497Trp	O
]	O
in	O
EFCAB6	O
Gene	O
#	O
64800	O
gene	O
responsible	O
for	O
DSD	B-DIS
.	O

In	O
addition	O
we	O
have	O
incidentally	O
discovered	O
a	O
novel	O
mutation	O
p.	O
[	O
Gly1372Arg	O
]	O
;	O
[	O
Gly1372Arg	O
]	O
in	O
the	O
ERCC6	O
CSB	O
OMIM	O
#	O
609413	O
gene	O
responsible	O
for	O
COFS	B-DIS
that	O
might	O
explain	O
the	O
atypical	O
severe	O
skeletal	B-DIS
deformities	I-DIS
.	O

Conclusion	O
The	O
co	O
-	O
occurrence	O
of	O
clinical	O
and	O
overlapping	O
genetic	O
heterogeneous	O
entities	O
should	O
be	O
taken	O
into	O
consideration	O
for	O
better	O
molecular	O
and	O
genetic	O
counseling	O
.	O

Usher	B-DIS
syndrome	I-DIS
type	O
1	O
US1	O
is	O
an	O
autosomal	B-DIS
recessive	I-DIS
disease	I-DIS
characterized	O
by	O
profound	O
congenital	B-DIS
hearing	I-DIS
impairment	I-DIS
with	O
unintelligible	O
speech	O
early	O
retinitis	B-DIS
pigmentosa	I-DIS
and	O
constant	O
vestibular	B-DIS
dysfunction	I-DIS
.	O

Three	O
localizations	O
have	O
been	O
described	O
in	O
US1	O
USH1A	O
14q32	O
;	O
USH1B	O
11q13.5	O
;	O
and	O
USH1C	B-DIS
11p15	I-DIS
.	O

Studying	O
a	O
series	O
of	O
33	O
affected	O
individuals	O
belonging	O
to	O
20	O
US1	O
pedigrees	O
of	O
French	O
ancestry	O
we	O
found	O
that	O
none	O
of	O
the	O
three	O
localizations	O
accounted	O
for	O
all	O
US1	O
families	O
in	O
our	O
series	O
Zmax	O
=	O
1.48	O
at	O
theta	O
=	O
0.10	O
;	O
Zmax	O
=	O
1.45	O
at	O
theta	O
=	O
0.10	O
;	O
and	O
Zmax	O
=	O
0.36	O
at	O
theta	O
=	O
0.20	O
for	O
probes	O
MLJ14	O
Zd5	O
and	O
Mfd58	O
respectively	O
at	O
loci	O
D14S13	O
D11S527	O
and	O
D11S419	O
respectively	O
.	O

However	O
when	O
our	O
sample	O
was	O
split	O
into	O
two	O
groups	O
according	O
to	O
the	O
geographic	O
origin	O
of	O
the	O
probands	O
'	O
grandparents	O
we	O
were	O
able	O
to	O
confirm	O
the	O
presence	O
of	O
a	O
gene	O
for	O
US1	O
on	O
chromosome	O
14q32	O
USH1A	O
in	O
9	O
families	O
originating	O
from	O
the	O
Poitou	B-LOC
region	O
in	O
Western	O
France	O
Department	O
of	O
Deux	O
-	O
Sèvres	O
;	O
Zmax	O
=	O
4.46	O
at	O
theta	O
=	O
0	O
for	O
probe	O
MLJ14	O
at	O
the	O
D14S13	B-LOC
locus	O
Morton	O
likelihood	O
ratio	O
test	O
P	O
<	O
0.01	O
.	O

Moreover	O
we	O
refined	O
the	O
genetic	O
mapping	O
of	O
USH1A	O
by	O
showing	O
that	O
the	O
disease	O
gene	O
maps	O
to	O
the	O
D14S13	O
locus	O
within	O
the	O
genetic	O
interval	O
defined	O
by	O
loci	O
D14S78	O
and	O
D14S250	B-LOC
location	O
score	O
in	O
log	O
base	O
10	O
=	O
4.90	O
.	O

Consistent	O
with	O
this	O
nonsignificant	O
lod	O
score	O
values	O
for	O
linkage	O
to	O
either	O
USH1B	B-DIS
or	O
USH1C	O
were	O
found	O
in	O
this	O
group	O
.	O

ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O

Introduction	O
Cardiac	O
rehabilitation	O
CR	O
is	O
a	O
proven	O
therapy	O
for	O
reducing	O
cardiovascular	B-DIS
death	I-DIS
and	O
hospitalization	O
.	O

Whether	O
CR	O
participation	O
is	O
associated	O
with	O
improved	O
outcomes	O
in	O
patients	O
with	O
chronic	B-DIS
kidney	I-DIS
disease	I-DIS
CKD	I-DIS
is	O
unknown	O
.	O

Methods	O
We	O
obtained	O
data	O
on	O
all	O
adult	O
patients	O
in	O
Calgary	B-LOC
Alberta	O
Canada	B-LOC
with	O
angiographically	O
proven	O
coronary	B-DIS
artery	I-DIS
disease	I-DIS
from	O
1996	O
to	O
2016	O
referred	O
to	O
CR	O
from	O
The	O
Alberta	O
Provincial	O
Project	O
for	O
Outcome	O
Assessment	O
in	O
Coronary	B-DIS
Heart	I-DIS
Disease	I-DIS
and	O
TotalCardiology	O
Rehabilitation	O
.	O

An	O
estimated	O
glomerular	O
filtration	O
rate	O
eGFR	O
<	O
60	O
ml	O
/	O
min/1.73	O
m	O
2	O
<	O
/s	O
or	O
kidney	O
replacement	O
therapy	B-DIS
defined	O
CKD	O
.	O

Predictors	O
of	O
CR	O
use	O
were	O
estimated	O
with	O
multinomial	O
logistic	O
regression	O
.	O

The	O
association	O
between	O
starting	O
versus	O
not	O
starting	O
and	O
completion	O
versus	O
noncompletion	O
of	O
CR	O
and	O
clinical	O
outcomes	O
were	O
estimated	O
using	O
multivariable	O
Cox	O
proportional	O
hazards	O
models	O
.	O

Results	O
Of	O
23215	O
patients	O
referred	O
to	O
CR	O
12084	O
were	O
eligible	O
for	O
inclusion	O
.	O

Participants	O
with	O
CKD	O
N	O
=	O
1322	O
were	O
older	O
had	O
more	O
comorbidity	B-DIS
lower	O
exercise	O
capacity	O
on	O
graded	O
treadmill	O
testing	O
and	O
took	O
longer	O
to	O
be	O
referred	O
and	O
to	O
start	O
CR	O
than	O
those	O
without	O
CKD	B-DIS
.	O

CKD	O
predicted	O
not	O
starting	O
CR	O
odds	O
ratio	O
0.7395	B-STAT
%	I-STAT
confidence	O
interval	O
[	O
CI	O
]	O
0.64	O
-	O
0.83	O
.	O

Over	O
a	O
median	O
1	O
year	O
follow	O
-	O
up	O
there	O
were	B-DIS
146	O
deaths	O
400.3	B-STAT
%	I-STAT
from	O
CKD	O
and	O
1061.0	B-STAT
%	I-STAT
not	B-DIS
from	O
CKD	O
.	O

Similar	O
to	O
those	O
without	O
CKD	O
the	O
risk	O
of	O
death	B-DIS
was	O
lower	O
in	O
CR	O
completers	O
hazard	O
ratio	O
[	O
HR	O
]	O
0.24	O
[	O
95	B-STAT
%	I-STAT
CI	O
0.06	O
-	O
0.91	O
and	O
starters	O
HR	O
0.56	O
[	O
95	B-STAT
%	I-STAT
CI	O
0.29-	O
1.10	O
]	O
with	O
CKD	B-DIS
.	O

Conclusion	O
CR	O
participation	O
was	O
associated	O
with	O
comparable	O
benefits	O
in	O
people	O
with	O
moderate	O
CKD	B-DIS
as	O
those	O
without	O
who	O
survived	O
to	O
CR	O
.	O

Lower	O
rates	O
of	O
CR	O
attendance	O
in	O
this	O
high	O
-	O
risk	O
population	O
suggest	O
that	O
strategies	O
to	O
increase	O
CR	O
utilization	O
are	O
needed	O
.	O

Diastrophic	B-DIS
dysplasia	I-DIS
DTD	O
is	O
a	O
rare	O
osteochondrodysplasia	B-DIS
characterized	O
by	O
short	B-DIS
-	O
limbed	B-DIS
short	O
stature	O
and	O
joint	O
dysplasia	O
.	O

DTD	O
is	O
caused	O
by	O
mutations	O
in	O
SLC26A2	O
and	O
is	O
particularly	O
common	O
in	O
the	O
Finnish	O
population	O
.	O

However	O
the	O
disease	O
incidence	B-EPI
in	O
Finland	B-LOC
and	O
clinical	O
features	O
in	O
affected	O
individuals	O
have	O
not	O
been	O
recently	O
explored	O
.	O

This	O
registry	O
-	O
based	O
study	O
aimed	O
to	O
investigate	O
the	B-EPI
current	O
incidence	O
of	O
DTD	O
in	O
Finland	B-LOC
characterize	O
the	O
national	O
cohort	O
of	O
pediatric	O
subjects	O
with	O
DTD	O
and	O
review	O
the	O
disease	O
-	O
related	O
literature	O
.	O

Subjects	O
with	O
SLC26A2	O
-related	O
skeletal	O
dysplasia	O
born	O
between	O
2000	O
and	O
2020	O
were	O
identified	O
from	O
the	O
Skeletal	O
dysplasia	O
registry	O
and	O
from	O
hospital	O
patient	O
registry	O
and	O
their	O
clinical	O
and	O
molecular	O
data	O
were	O
reviewed	O
.	O

Fourteen	O
subjects	O
were	O
identified	O
.	O

Twelve	O
of	O
them	O
were	O
phenotypically	O
classified	O
as	O
DTD	O
and	O
two	O
as	O
recessive	O
multiple	B-DIS
epiphyseal	I-DIS
dysplasia	I-DIS
rMED	I-DIS
.	O

From	O
the	O
subjects	O
with	O
available	O
genetic	O
data	O
75	B-STAT
%	I-STAT
9/12	B-STAT
were	O
homozygous	O
for	O
the	O
Finnish	O
founder	O
mutation	B-DIS
c.-26	I-DIS
+	O
C.	O
Two	O
subjects	O
with	O
rMED	B-DIS
phenotype	O
were	O
compound	O
heterozygous	O
for	O
p.	O
Arg279Trp	O
and	O
p.	O
Thr512Lys	O
variants	O
.	O

The	O
variable	O
phenotypes	O
in	O
our	O
cohort	O
highlight	O
the	O
wide	O
spectrum	O
of	O
clinical	O
features	O
ranging	O
from	O
a	O
very	O
severe	O
form	O
of	O
DTD	O
to	O
milder	O
forms	O
of	O
DTD	O
and	O
rMED	B-DIS
.	O

The	O
incidence	B-EPI
of	O
DTD	O
in	O
Finland	B-LOC
has	O
significantly	O
decreased	O
over	O
the	O
past	O
decades	O
most	O
likely	O
due	O
to	O
increased	O
prenatal	O
diagnostics	O
.	O

Idiopathic	B-DIS
nephrotic	I-DIS
syndrome	I-DIS
newly	O
affects	O
1	B-STAT
-	I-STAT
3	I-STAT
per	O
100000	O
children	O
per	O
year	O
.	O

Approximately	B-STAT
85	I-STAT
%	I-STAT
of	O
cases	O
show	O
complete	O
remission	O
of	O
proteinuria	B-DIS
following	O
glucocorticoid	O
treatment	O
.	O

Patients	O
who	O
do	O
not	O
achieve	O
complete	O
remission	O
within	O
4	O
-	O
6	O
weeks	O
of	O
glucocorticoid	O
treatment	O
have	O
steroid	O
-	B-DIS
resistant	I-DIS
nephrotic	I-DIS
syndrome	O
SRNS	O
.	O

In	O
10	B-STAT
-	I-STAT
30	I-STAT
%	I-STAT
of	O
steroid	B-DIS
-	O
resistant	O
patients	O
mutations	O
in	O
podocyte	O
-	O
associated	O
genes	O
can	O
be	O
detected	O
whereas	O
an	O
undefined	O
circulating	O
factor	O
of	O
immune	O
origin	O
is	O
assumed	O
in	O
the	O
remaining	O
ones	O
.	O

Diagnosis	O
and	O
management	O
of	O
SRNS	B-DIS
is	O
a	O
great	O
challenge	O
due	O
to	O
its	O
heterogeneous	O
etiology	O
frequent	O
lack	O
of	O
remission	O
by	O
further	O
immunosuppressive	O
treatment	O
and	O
severe	O
complications	O
including	O
the	O
development	O
of	O
end	B-DIS
-	I-DIS
stage	I-DIS
kidney	O
disease	O
and	O
recurrence	O
after	O
renal	O
transplantation	O
.	O

A	O
team	O
of	O
experts	O
including	O
pediatric	O
nephrologists	O
and	O
renal	O
geneticists	O
from	O
the	O
International	O
Pediatric	O
Nephrology	O
Association	O
IPNA	O
a	O
renal	O
pathologist	O
and	O
an	O
adult	O
nephrologist	O
have	O
now	O
developed	O
comprehensive	O
clinical	O
practice	O
recommendations	O
on	O
the	O
diagnosis	O
and	O
management	O
of	O
SRNS	B-DIS
in	O
children	O
.	O

The	O
team	O
performed	O
a	O
systematic	O
literature	O
review	O
on	O
9	O
clinically	O
relevant	O
PICO	O
Patient	O
or	O
Population	O
covered	O
Intervention	O
Comparator	O
Outcome	O
questions	O
formulated	O
recommendations	O
and	O
formally	O
graded	O
them	O
at	O
a	O
consensus	O
meeting	O
with	O
input	O
from	O
patient	O
representatives	O
and	O
a	O
dietician	O
acting	O
as	O
external	O
advisors	O
and	O
a	O
voting	O
panel	O
of	O
pediatric	O
nephrologists	O
.	O

Research	O
recommendations	O
are	O
also	O
given	O
.	O

Mutations	O
in	O
the	O
genes	O
for	O
extracellular	O
matrix	O
ECM	O
components	O
cause	O
a	O
wide	O
range	O
of	O
genetic	O
connective	B-DIS
tissues	I-DIS
disorders	I-DIS
throughout	O
the	O
body	O
.	O

The	O
elucidation	O
of	O
mutations	O
and	O
their	O
correlation	O
with	O
pathology	O
has	O
been	O
instrumental	O
in	O
understanding	O
the	O
roles	O
of	O
many	O
ECM	O
components	O
.	O

The	O
pathological	O
consequences	O
of	O
ECM	O
protein	O
mutations	O
depend	O
on	O
its	O
tissue	O
distribution	O
tissue	O
function	O
and	O
on	O
the	O
nature	O
of	O
the	O
mutation	O
.	O

The	O
prevalent	O
paradigm	O
for	O
the	O
molecular	O
pathology	O
has	O
been	O
that	O
there	O
are	O
two	O
global	O
mechanisms	O
.	O

First	O
mutations	O
that	O
reduce	O
the	O
production	O
of	O
ECM	O
proteins	O
impair	O
matrix	O
integrity	O
largely	O
due	O
to	O
quantitative	O
ECM	O
defects	O
.	O

Second	O
mutations	O
altering	O
protein	O
structure	O
may	O
reduce	O
protein	O
secretion	O
but	O
also	O
introduce	O
dominant	O
negative	O
effects	O
in	O
ECM	O
formation	O
structure	O
and/or	O
stability	O
.	O

Recent	O
studies	O
show	O
that	O
endoplasmic	O
reticulum	O
ER	O
stress	O
caused	O
by	O
mutant	O
misfolded	O
ECM	O
proteins	O
makes	O
a	O
significant	O
contribution	O
to	O
the	O
pathophysiology	O
.	O

This	O
suggests	O
that	O
targeting	O
ER	O
-	O
stress	O
may	O
offer	O
a	O
new	O
therapeutic	O
strategy	O
in	O
a	O
range	B-DIS
of	I-DIS
ECM	O
disorders	O
caused	O
by	O
protein	O
misfolding	O
mutations	O
.	O

Anat	O
Rec	O
2019	O
.	O

©	O
2019	O
The	O
Authors	O
.	O

The	O
Anatomical	O
Record	O
published	O
by	O
Wiley	O
Periodicals	O
Inc.	O
on	O
behalf	O
of	O
American	O
Association	O
of	O
Anatomists	O
.	O

Lysosomal	O
disorders	O
are	O
diseases	O
that	O
involve	O
mutations	O
in	O
genes	O
responsible	O
for	O
the	O
coding	O
of	O
lysosomal	O
enzymes	O
transport	O
proteins	O
activator	O
proteins	O
and	O
protein	O
processing	O
enzymes	O
.	O

These	O
defects	O
lead	O
to	O
the	O
storage	O
of	O
specific	O
metabolites	O
within	O
lysosomes	O
resulting	O
in	O
a	O
great	O
variety	O
of	O
clinical	O
features	O
depending	O
on	O
the	O
tissues	O
with	O
the	O
storage	O
the	O
storage	O
products	O
and	O
the	O
extent	O
of	O
the	O
storage	O
.	O

The	O
methods	O
for	O
rapidly	O
diagnosing	O
patients	O
started	O
in	O
the	O
late	O
1960	O
's	O
when	O
the	O
enzyme	O
defects	O
were	O
identified	O
eliminating	O
the	O
need	O
for	O
tissue	O
biopsies	O
.	O

The	O
first	O
requests	O
for	O
diagnostic	O
help	O
in	O
this	O
laboratory	O
came	O
in	O
1973	O
.	O

In	O
that	O
year	O
patients	O
with	O
Krabbe	B-DIS
disease	I-DIS
and	O
Niemann	O
-	O
Pick	O
type	O
A	O
were	O
diagnosed	O
.	O

Since	O
that	O
time	O
samples	O
from	O
about	O
62000	O
individuals	O
have	O
been	O
received	O
for	O
diagnostic	O
studies	O
and	O
4900	O
diagnoses	O
have	O
been	O
made	O
.	O

The	O
largest	O
number	O
of	O
diagnosed	O
individuals	O
had	O
metachromatic	B-DIS
leukodystrophy	I-DIS
and	O
Krabbe	B-DIS
disease	I-DIS
because	O
of	O
our	O
research	O
interest	O
in	O
leukodystrophies	O
.	O

A	O
number	O
of	O
new	O
disorders	O
were	O
identified	O
and	O
the	O
primary	O
defects	O
in	O
other	O
disorders	O
were	O
clarified	O
.	O

With	O
new	O
methods	O
for	O
diagnosis	O
including	O
newborn	O
screening	O
molecular	O
analysis	O
microarrays	O
there	O
is	O
still	O
a	O
need	O
for	O
biochemical	O
confirmation	O
before	O
treatment	O
is	O
considered	O
.	O

With	O
new	O
treatments	O
including	O
gene	O
therapy	O
stem	O
cell	O
transplantation	O
enzyme	O
replacement	O
used	O
alone	O
or	O
in	O
combination	O
becoming	O
more	O
available	O
the	O
need	O
for	O
rapid	O
accurate	O
diagnosis	O
is	O
critical	O
.	O

The	O
high	O
prevalence	B-EPI
of	O
hearing	B-DIS
loss	I-DIS
among	O
older	O
adults	O
creates	O
a	O
perception	O
that	O
it	O
is	O
simply	O
a	O
benign	O
consequence	O
of	O
aging	O
which	O
leads	O
to	O
unaddressed	O
communication	O
needs	O
.	O

Strategies	O
to	O
address	O
hearing	B-DIS
loss	I-DIS
as	O
part	O
of	O
routine	O
clinical	O
care	O
are	O
pertinent	O
to	O
the	O
geriatric	O
care	O
setting	O
where	O
hearing	B-DIS
loss	I-DIS
is	O
prevalent	O
in	O
two	O
out	O
of	O
every	O
three	O
patients	O
70	O
years	O
and	O
older	O
.	O

Our	O
objectives	O
are	O
to	O
briefly	O
discuss	O
the	O
pathophysiology	O
of	O
hearing	B-DIS
loss	I-DIS
describe	O
the	O
epidemiologic	O
prevalence	B-EPI
and	O
impact	O
identify	O
statutory	O
barriers	O
facing	O
older	O
adults	O
in	O
accessing	O
hearing	O
care	O
discuss	O
current	O
progress	O
on	O
legislation	O
to	O
address	O
accessibility	O
issues	O
and	O
provide	O
actionable	O
strategies	O
for	O
addressing	O
hearing	B-DIS
loss	I-DIS
as	O
a	O
barrier	O
to	O
effective	O
communication	O
.	O

Simple	O
steps	O
can	O
be	O
taken	O
to	O
improve	O
hearing	O
care	O
accessibility	O
for	O
older	O
adults	O
with	O
hearing	B-DIS
loss	I-DIS
and	O
can	O
optimize	O
understanding	O
in	O
daily	O
communication	O
re	O
-	O
engage	O
patients	O
in	O
being	O
actively	O
involved	O
in	O
their	O
care	O
and	O
promote	O
patient	O
autonomy	O
in	O
informed	O
decision-	O
making	O
.	O

Sweden	B-LOC
has	O
one	O
neonatal	O
screening	O
laboratory	O
receiving	O
115	O
to	O
120	O
thousand	O
samples	O
per	O
year	O
.	O

Among	O
the	O
one	O
million	O
babies	O
screened	O
by	O
tandem	O
mass	O
spectrometry	O
from	O
November	O
2010	O
until	O
July	O
2019	O
a	O
total	O
of	O
665	O
babies	O
were	O
recalled	O
and	O
311	O
verified	O
as	O
having	O
one	O
of	O
the	O
diseases	O
screened	O
for	O
with	O
this	O
methodology	O
giving	O
a	O
positive	O
predictive	O
value	O
PPV	O
of	O
47	B-STAT
%	I-STAT
and	O
an	O
incidence	B-EPI
of	O
13200	O
.	O

The	O
PPV	O
was	O
high	O
41	B-STAT
%	I-STAT
already	O
in	O
the	O
first	O
year	O
after	O
start	O
of	O
screening	O
thanks	O
to	O
the	O
availability	O
of	O
the	O
collaborative	O
project	O
Region	O
4	O
Stork	O
database	O
.	O

The	O
PPV	O
is	O
presently	O
58	B-STAT
%	I-STAT
.	O

This	O
improvement	O
was	O
achieved	O
by	O
the	O
implementation	O
of	O
second	O
-	O
tier	O
analyses	O
in	O
the	O
screening	B-DIS
for	I-DIS
methylmalonic	I-DIS
aciduria	I-DIS
propionic	I-DIS
aciduria	I-DIS
isovaleric	O
aciduria	B-DIS
and	O
homocystinuria	O
and	O
the	O
employment	O
of	O
various	O
post	O
analytical	O
tools	O
of	O
the	O
Region	O
4	O
Stork	O
and	O
its	O
successor	O
the	O
collaborative	O
laboratory	O
integrated	O
reports	O
.	O

Background	O
Ehlers	B-DIS
-	I-DIS
Danlos	I-DIS
syndrome	O
EDS	O
represents	O
a	O
group	B-DIS
of	I-DIS
connective	I-DIS
tissue	O
disorders	O
characterized	O
by	O
the	O
fragility	O
of	O
the	O
soft	O
connective	O
tissues	O
resulting	O
in	O
widespread	O
skin	O
ligament	O
joint	O
blood	O
vessel	O
and	O
internal	O
organ	O
involvement	O
.	O

The	O
clinical	O
spectrum	O
is	O
highly	O
variable	O
in	O
terms	O
of	O
clinical	O
features	O
complications	O
severity	O
biochemical	O
characteristics	O
and	O
genes	O
mutations	O
.	O

The	O
kyphoscoliotic	B-DIS
type	I-DIS
EDS	I-DIS
EDS	I-DIS
VIA	O
is	O
a	O
rare	O
variant	O
of	O
the	O
disease	O
with	O
an	O
incidence	B-EPI
of	O
1100.000	O
live	O
births	O
.	O

EDS	O
VIA	O
presents	O
at	O
birth	O
as	O
severe	O
muscular	B-DIS
hypotonia	I-DIS
early	O
onset	O
of	O
progressive	O
kyphoscoliosis	B-DIS
marked	O
hyperelasticity	B-DIS
and	O
fragility	O
of	O
the	O
skin	O
with	O
abnormal	B-DIS
scarring	I-DIS
severe	O
joint	B-DIS
hypermobility	I-DIS
luxations	I-DIS
and	O
osteopenia	B-DIS
without	O
a	O
tendency	O
to	O
fractures	B-DIS
.	O

This	O
condition	O
is	O
due	O
to	O
a	O
mutation	O
in	O
the	O
PLOD1	O
gene	O
and	O
less	O
commonly	O
in	O
FKBP14	O
gene	O
which	O
results	O
in	O
the	O
erroneous	O
development	O
of	O
collagen	O
molecules	O
with	O
consequent	O
mechanical	O
instability	O
of	O
the	O
affected	O
tissue	O
.	O

Case	O
presentation	O
A	O
female	O
newborn	O
found	O
to	O
be	O
floppy	B-DIS
at	O
birth	O
presented	O
a	O
remarkable	O
physical	O
examination	O
for	O
joint	O
hypermobility	B-DIS
muscle	I-DIS
weakness	I-DIS
hyperelastic	O
skin	O
a	O
slight	O
curve	O
of	O
the	O
spine	O
the	O
absence	O
of	O
the	O
inferior	O
labial	O
and	O
lingual	O
frenulum	O
.	O

Due	O
to	O
severe	O
hypotonia	B-DIS
neuromuscular	I-DIS
disorders	I-DIS
such	O
as	O
Spinal	B-DIS
Muscular	I-DIS
Atrophy	I-DIS
SMA	I-DIS
genetic	O
diseases	O
such	O
as	O
Prader	B-DIS
Willi	I-DIS
syndrome	I-DIS
PWS	I-DIS
myopathies	I-DIS
and	O
connective	B-DIS
tissue	I-DIS
disorders	I-DIS
were	O
considered	O
in	O
the	O
differential	O
diagnosis	O
.	O

Targeted	O
gene	O
sequencing	O
were	O
performed	O
for	O
SMN1	B-DIS
PLOD1	I-DIS
FKBP14	I-DIS
COL6A1	I-DIS
COL6A2	O
COL6A3	O
.	O

The	O
urinary	O
lysyl	O
and	O
hydroxy	O
-	O
lysyl	O
pyridinoline	O
ratio	O
was	O
diagnostic	O
before	O
discovering	O
the	O
homozygous	O
duplication	O
in	O
the	O
PLOD1	O
gene	O
which	B-DIS
confirmed	I-DIS
kyphoscoliotic	O
EDS	O
diagnosis	O
.	O

Conclusion	O
In	O
front	O
of	O
a	O
floppy	B-DIS
infant	O
a	O
large	O
variety	O
of	O
disorders	O
should	O
be	O
considered	O
including	O
some	O
connective	B-DIS
diseases	I-DIS
.	O

The	O
presence	O
at	O
the	O
birth	B-DIS
of	I-DIS
kyphoscoliosis	I-DIS
associated	O
with	O
joint	O
hypermobility	B-DIS
and	O
the	O
absence	O
of	O
the	O
lingual	O
and	O
lower	O
lip	O
frenulum	O
should	O
suggest	O
an	O
EDS	O
.	O

Purpose	O
We	O
evaluated	O
the	O
various	O
accompanied	O
malformations	B-DIS
in	O
patients	O
with	O
anal	B-DIS
atresia	I-DIS
or	O
tracheoesophageal	B-DIS
fistula	I-DIS
TEF	O
.	O

Furthermore	O
we	O
determined	O
the	O
prevalence	B-EPI
of	O
VACTERL	O
association	O
and	O
compared	O
the	O
clinical	O
findings	O
with	O
those	O
of	O
patients	O
without	O
VACTERL	O
association	O
.	O

Methods	O
We	O
enrolled	O
the	O
patients	O
with	O
anal	B-DIS
atresia	I-DIS
or	O
TEF	O
with	O
/	B-DIS
without	I-DIS
esophageal	O
atresia	O
.	O

We	O
collected	O
the	O
patient	O
data	O
pertaining	O
to	O
accompanied	O
vertebral	B-DIS
cardiovascular	I-DIS
renal	I-DIS
or	I-DIS
limb	I-DIS
anomalies	I-DIS
single	O
umbilical	O
artery	O
maternal	O
diabetes	B-DIS
mellitus	I-DIS
or	O
drug	O
history	O
and	O
gene	O
research	O
.	O

Results	O
A	O
total	O
155	O
patients	O
65	O
boys	O
and	O
90	O
girls	O
were	O
enrolled	O
with	O
147	O
cases	O
of	O
anal	B-DIS
atresia	I-DIS
3	O
cases	O
of	O
TEF	O
and	O
5	O
cases	O
of	O
anal	B-DIS
atresia	I-DIS
with	O
TEF	O
.	O

The	O
prevalence	B-EPI
of	O
accompanied	O
anomalies	B-DIS
was	O
67.1	B-STAT
%	I-STAT
in	O
cardiovascular	O
27.1	B-STAT
%	I-STAT
in	O
renal	O
9.7	B-STAT
%	I-STAT
in	O
vertebral	O
2.6	B-STAT
%	I-STAT
in	O
limb	O
anomalies	B-DIS
and	O
3.9	B-STAT
%	I-STAT
in	O
single	O
umbilical	O
artery	O
.	O

Thirty	O
-	O
six	O
23.2	B-STAT
%	I-STAT
patients	O
were	O
diagnosed	O
with	O
VACTERL	O
association	O
.	O

The	O
patients	O
with	O
VACTERL	O
association	O
had	O
a	O
significantly	O
higher	O
number	O
of	O
male	O
patients	O
58.3	O
vs.	O
37.0	B-STAT
%	I-STAT
p	O
=	O
.033	O
and	O
single	O
umbilical	O
artery	O
11.1	O
vs.	O
1.7	B-STAT
%	I-STAT
p	O
=	O
.026	O
and	O
had	O
a	O
significantly	O
lower	O
birth	O
weight	O
2.8	O
vs.	O
3.1	O
kg	O
p	O
=	O
.033	O
than	O
the	O
patients	O
without	O
VACTERL	O
association	O
.	O

Genetic	O
studies	O
were	O
performed	O
in	O
111	O
patients	O
and	O
87.2	B-STAT
%	I-STAT
had	O
chromosomal	O
abnormalities-3	O
in	O
VACTERL	O
and	O
5	O
in	O
no	O
VACTERL	O
group	O
.	O

Conclusion	O
We	O
recommend	O
a	O
careful	O
evaluation	O
for	O
VACTERL	O
association	O
in	O
patients	O
with	O
anal	B-DIS
atresia	I-DIS
or	O
TEF	O
.	O

It	O
is	O
particularly	O
important	O
to	O
screen	O
for	O
a	O
single	O
umbilical	O
artery	O
for	O
features	O
of	O
VACTERL	O
association	O
as	O
well	O
as	O
for	O
other	O
congenital	B-DIS
anomalies	I-DIS
.	O

Purpose	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
review	O
patients	O
with	O
xanthogranulomatous	B-DIS
cholecystitis	I-DIS
XGC	I-DIS
.	O

Methods	O
A	O
total	O
of	O
79	O
patients	O
diagnosed	O
with	O
XGC	B-DIS
were	O
included	O
in	O
the	O
study	O
.	O

The	O
criteria	O
for	O
XGC	B-DIS
in	O
the	O
pathology	O
specimens	O
were	O
the	O
presence	O
of	O
histiocytes	O
cholesterol	O
deposits	O
lipids	O
and	O
focal	O
or	O
widespread	O
wall	O
enlargement	O
.	O

Results	O
Patients	O
were	O
diagnosed	O
with	O
XGC	B-DIS
of	O
which	O
5265.8	B-STAT
%	I-STAT
were	O
male	O
and	O
2734.2	B-STAT
%	I-STAT
were	O
female	O
creating	O
a	O
male	O
-	O
to	O
-	O
female	O
ratio	O
of	O
21	O
.	O

The	O
mean	O
age	O
was	O
65.8	O
±	O
14.3	O
years	O
range	O
36	O
-	O
97	O
years	O
.	O

The	O
most	O
common	O
presenting	O
symptom	O
was	O
abdominal	B-DIS
pain	I-DIS
63.3	B-STAT
%	I-STAT
and	O
the	O
least	O
common	O
presenting	O
symptom	O
was	O
jaundice	B-DIS
8.9	B-STAT
%	I-STAT
.	O

Of	O
the	O
total	O
25	O
patients	O
were	O
found	O
to	O
have	O
pathological	O
conditions	O
with	O
the	O
potential	O
to	O
obstruct	O
the	O
bile	O
duct	O
or	O
to	O
slow	O
bile	O
flow	O
.	O

A	O
frozen	O
section	O
examination	O
was	O
performed	O
on	O
20	O
patients	O
due	O
to	O
suspicion	O
of	O
a	O
tumor	B-DIS
by	O
intraoperative	O
macroscopic	O
examination	O
.	O

However	O
no	O
malignancy	B-DIS
was	O
detected	O
in	O
the	O
cases	O
who	O
underwent	O
a	O
frozen	O
section	O
examination	O
.	O

An	O
increase	O
in	O
wall	O
thickness	O
of	O
the	O
gallbladder	O
was	O
observed	O
in	O
81.6	B-STAT
%	I-STAT
n	O
=	O
31	O
of	O
the	O
patients	O
on	O
computed	O
tomography	O
scans	O
and	O
in	O
81.8	B-STAT
%	I-STAT
n	O
=	O
18	O
of	O
the	O
patients	O
on	O
magnetic	O
resonance	O
imaging	O
scans	O
in	O
which	O
possible	O
tumor	B-DIS
lesions	O
were	O
reported	O
but	O
no	O
tumor	B-DIS
was	O
detected	O
.	O

Conclusion	O
It	O
is	O
difficult	O
to	O
diagnose	O
XGC	B-DIS
either	O
preoperatively	O
or	O
intraoperatively	O
and	O
further	O
imaging	O
methods	O
are	O
needed	O
in	O
the	O
preoperative	O
period	O
other	O
than	O
ultrasonography	O
.	O

However	O
a	O
definitive	O
diagnosis	O
depends	O
exclusively	O
on	O
pathologic	O
examination	O
.	O

Background	O
Vitamin	O
C	O
has	O
anti	O
-	O
oxidant	O
properties	O
and	O
acts	O
as	O
a	O
cofactor	O
for	O
several	O
enzymes	O
.	O

Hypovitaminosis	O
C	O
has	O
been	O
associated	O
with	O
bleeding	B-DIS
endothelial	O
dysfunction	O
and	O
death	B-DIS
.	O

The	O
prevalence	B-EPI
of	O
hypovitaminosis	O
C	O
is	O
unknown	O
in	O
Australian	O
hospitalised	O
patients	O
and	O
its	O
clinical	O
relevance	O
is	O
uncertain	O
.	O

Aims	O
To	O
determine	O
the	O
prevalence	B-EPI
characteristics	O
and	O
clinical	O
outcomes	O
of	O
hospitalised	O
patients	O
with	O
hypovitaminosis	O
C.	O
Methods	O
This	O
observational	O
study	O
included	O
general	O
-	O
medical	O
inpatients	O
in	O
a	O
tertiary	O
-	O
level	O
hospital	O
in	O
Australia	B-LOC
.	O

High	O
-	O
performance	O
liquid	O
chromatography	O
HPLC	O
was	O
used	O
to	O
determine	O
plasma	O
vitamin	O
C	O
levels	O
.	O

As	O
per	O
Johnston	O
's	O
criteria	O
vitamin	O
C	O
levels	O
of	O
≥28	O
μmol	O
/	O
L	O
were	O
classified	O
as	O
normal	O
and	O
<	O
28	O
μmol	O
/	O
L	O
as	O
low	O
.	O

Clinical	O
outcomes	O
determined	O
included	O
length	O
of	O
hospital	O
stay	O
LOS	B-LOC
nosocomial	O
complications	O
intensive	O
care	O
unit	O
admission	O
and	O
in	O
-	O
hospital	O
mortality	O
.	O

Results	O
A	O
total	O
of	O
200	O
patients	O
participated	O
in	O
this	O
study	O
and	O
vitamin	O
C	O
levels	O
were	O
available	O
for	O
149	O
patients	O
of	O
whom	O
3523.5	B-STAT
%	I-STAT
had	O
normal	O
vitamin	O
C	O
levels	O
and	O
11476.5	B-STAT
%	I-STAT
had	O
hypovitaminosis	O
C.	O
Patients	O
with	O
hypovitaminosis	O
C	O
were	O
older	O
and	O
had	O
higher	O
C	O
-	O
reactive	O
protein	O
CRP	O
levels	O
.	O

Median	O
LOS	O
was	O
2	O
days	O
longer	O
in	O
patients	O
with	O
hypovitaminosis	O
C	O
6	O
days	O
interquartile	O
range	O
IQR	O
48	O
vs	O
4	O
days	O
IQR	O
36	O
P	O
=	O
0.02	O
and	O
they	O
had	O
fourfold	O
higher	O
odds	O
of	O
staying	O
in	O
hospital	O
fo	O
5	O
days	O
than	O
those	O
with	O
normal	O
vitamin	O
C	O
levels	O
.	O

Other	O
clinical	O
outcomes	O
were	O
similar	O
between	O
the	O
two	O
groups	O
.	O

Conclusions	O
Hypovitaminosis	O
C	O
is	O
common	O
in	O
hospitalised	O
patients	O
and	O
is	O
associated	O
with	O
prolonged	O
LOS	B-LOC
.	O

Further	O
research	O
is	O
needed	O
to	O
ascertain	O
the	O
benefits	O
of	O
vitamin	O
C	O
supplementation	O
in	O
vitamin	O
C	O
-	O
depleted	O
patients	O
.	O

Background	O
Mucopolysaccharidoses	O
MPS	O
are	O
rare	O
inherited	O
lysosomal	O
storage	O
disorders	O
characterized	O
by	O
progressive	O
multiorgan	O
involvement	O
.	O

Previous	O
studies	O
on	O
incidence	B-EPI
and	O
prevalence	B-EPI
of	O
MPS	O
mainly	O
focused	O
on	O
countries	O
other	O
than	O
the	B-LOC
United	I-LOC
States	I-LOC
US	B-LOC
showing	O
considerable	O
variation	O
by	O
country	O
.	O

This	O
study	O
aimed	O
to	O
identify	O
MPS	O
incidence	B-EPI
and	O
prevalence	B-EPI
in	O
the	O
US	B-LOC
at	O
a	O
national	O
and	O
state	O
level	O
to	O
guide	O
clinicians	O
and	O
policy	O
makers	O
.	O

Methods	O
This	O
retrospective	O
study	O
examined	O
all	O
diagnosed	O
cases	O
of	O
MPS	O
from	O
1995	O
to	O
2015	O
in	O
the	O
US	B-LOC
using	O
the	O
National	O
MPS	O
Society	O
database	O
records	O
.	O

Data	O
included	O
year	O
of	O
birth	O
patient	O
geographic	O
location	O
and	O
MPS	O
variant	O
type	O
.	O

US	B-LOC
population	O
information	O
was	O
obtained	O
from	O
the	O
National	O
Center	O
for	O
Health	O
Statistics	O
.	O

The	O
incidence	B-EPI
and	O
prevalence	B-EPI
rates	O
were	O
calculated	O
for	O
each	O
disease	O
.	O

Incidence	B-EPI
rates	O
were	O
calculated	O
for	O
each	O
state	O
.	O

Results	O
We	O
obtained	O
information	O
from	O
789	O
MPS	O
patients	O
during	O
a	O
20	O
-	O
year	O
period	O
.	O

Incidence	B-EPI
of	O
MPS	O
in	O
the	O
US	B-LOC
was	O
found	O
to	O
be	O
0.98	O
per	O
100000	O
live	O
births	O
.	O

Prevalence	B-EPI
was	O
found	O
to	O
be	O
2.67	O
per	O
1	O
million	O
.	O

MPS	O
I	O
II	O
and	O
III	O
had	O
the	O
highest	O
incidence	B-EPI
rate	O
at	O
birth	O
0.26/100000	B-STAT
and	O
prevalence	B-EPI
rates	O
of	O
0.70	O
-	O
0.71	O
per	O
million	O
.	O

Birth	O
incidences	B-EPI
of	O
MPS	O
IV	O
VI	O
and	O
VII	O
were	O
0.14	O
0.04	O
and	O
0.027	O
per	O
100000	O
live	O
births	O
.	O

Conclusions	O
This	O
is	O
the	O
most	O
comprehensive	O
review	O
of	O
MPS	O
incidence	B-EPI
and	O
prevalence	B-EPI
rates	O
in	O
the	O
US	B-LOC
.	O

Due	O
to	O
the	O
large	O
US	B-LOC
population	O
and	O
state	O
fragmentation	O
US	B-LOC
incidence	B-EPI
and	O
prevalence	B-EPI
were	O
found	O
to	O
be	O
lower	O
than	O
other	O
countries	O
.	O

Nonetheless	O
state	O
-	O
level	O
studies	O
in	O
the	O
US	B-LOC
supported	O
these	O
figures	O
.	O

Efforts	O
should	O
be	O
focused	O
in	O
the	O
establishment	O
of	O
a	O
national	O
rare	O
disease	O
registry	O
with	O
mandated	O
reporting	O
from	O
every	O
state	O
as	O
well	O
as	O
newborn	O
screening	O
of	O
MPS	O
.	O

Background	O
Primary	O
and	O
secondary	O
aortopathy	O
are	O
frequently	O
encountered	O
in	O
patients	O
with	O
congenital	B-DIS
heart	I-DIS
disease	I-DIS
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
present	O
our	O
experience	O
and	O
the	O
incidence	B-EPI
of	O
primary	O
and	O
secondary	O
adult	O
CHD	O
-	O
associated	O
aortopathy	O
.	O

Methods	O
The	O
cohort	O
is	O
comprised	O
of	O
adult	O
patients	O
with	O
congenital	B-DIS
heart	I-DIS
disease	I-DIS
from	O
the	O
registry	O
of	O
the	O
Eastern	O
Slovakia	O
Institute	O
of	O
Cardiovascular	B-DIS
Diseases	I-DIS
.	O

Data	O
from	O
the	O
last	O
follow	O
-	O
up	O
examinations	O
are	O
included	O
in	O
this	O
study	O
.	O

In	O
the	O
primary	O
and	O
secondary	O
aortopathy	O
groups	O
were	O
35	O
and	O
12	O
patients	O
respectively	O
.	O

As	O
a	O
control	O
group	O
were	O
selected	O
64	O
patients	O
with	O
non	O
aortopathy	O
associated	O
congenital	B-DIS
heart	I-DIS
disease	I-DIS
atrial	O
and	O
ventricular	B-DIS
septal	I-DIS
defect	I-DIS
.	O

Results	O
Patients	O
with	O
primary	O
and	O
secondary	O
aortopathy	O
had	O
larger	O
ascending	O
aorta	O
/	O
aortic	O
root	O
diameters	O
than	O
the	O
control	O
group	O
36.28	O
26	O
-	O
49	O
mm	O
vs	O
30.25	O
21	O
-	O
41	O
mm	O
p	O
=	O
0.000113	O
33.82	O
27	O
-	O
49	O
mm	O
vs	O
29.03	O
19	O
-	O
38	O
mm	O
p	O
=	O
0.000366	O
and	O
42.1	O
30	O
-	O
50	O
mm	O
vs	O
30.25	O
21	O
-	O
41	O
mm	O
p	O
=	O
0.000106	O
35.67	O
27	O
-	O
48	O
mm	O
vs	O
29.03	O
19	O
-	O
38	O
mm	O
p	O
=	O
0.000119	O
respectively	O
.	O

Moreover	O
patients	O
with	O
secondary	O
aortopathy	O
had	O
statistically	O
significant	O
larger	O
ascending	O
aorta	O
diameter	O
compared	O
to	O
the	O
patients	O
with	O
primary	O
aortopathy	O
42.1	O
30	O
-	O
50	O
mm	O
vs	O
36.28	O
26	O
-	O
49	O
mm	O
p	O
=	O
0.030	O
.	O

During	O
the	O
follow	O
-	O
up	O
period	O
were	O
performed	O
only	O
in	O
2	O
patients	O
one	O
from	O
each	O
group	O
operations	O
on	O
the	O
aortic	O
root	O
and	O
the	O
ascending	O
aorta	O
due	O
to	O
aortic	O
root	O
or	O
ascending	O
aorta	O
dilatation	O
.	O

Conclusion	O
More	O
patients	O
with	O
secondary	O
aortopathy	O
had	O
dilated	B-DIS
ascending	I-DIS
aorta/	I-DIS
aortic	O
root	O
as	O
well	O
as	O
larger	O
aortic	O
diameters	O
compare	O
to	O
the	O
patients	O
with	O
primary	O
aortopathy	O
.	O

Routine	O
follow	O
-	O
up	O
of	O
these	O
patients	O
with	O
attention	O
to	O
aortic	O
diameter	O
is	O
necessary	O
.	O

Seizures	B-DIS
are	O
the	O
most	O
acute	O
evident	O
manifestation	O
of	O
central	O
nervous	O
system	O
dysfunction	O
in	O
neonates	O
.	O

The	O
incidence	B-EPI
is	O
higher	O
in	O
very	O
low	O
weight	O
neonates	O
about	O
58/100	B-STAT
live	O
births	O
as	O
opposed	O
to	O
full	O
-	O
term	O
infants	O
estimated	B-STAT
about	O
3.5/100	O
live	O
births	O
.	O

Neonatal	O
seizures	B-DIS
represent	O
the	O
clinical	O
manifestation	O
of	O
a	O
non	O
-	B-DIS
specific	I-DIS
disorder	I-DIS
of	I-DIS
cortical	I-DIS
cerebral	O
dysfunction	O
which	O
could	O
lead	O
to	B-DIS
permanent	I-DIS
brain	O
injury	O
.	O

The	O
etiology	O
is	O
multifactorial	O
and	O
requires	O
a	O
judicious	O
assessment	O
of	O
each	O
clinical	O
scenario	O
.	O

The	O
diagnosis	O
and	O
its	O
management	O
are	O
further	O
complicated	O
as	O
most	O
neonatal	O
seizures	B-DIS
may	O
have	O
very	O
subtle	O
or	O
no	O
clinical	O
changes	O
and	O
the	O
diagnosis	O
may	O
be	O
just	O
based	O
on	O
EEG	O
findings	O
so	O
-	O
called	O
subclinical	O
.	O

The	O
treatment	O
is	O
dependent	O
on	O
the	O
etiology	O
but	O
early	O
and	O
opportune	O
intervention	O
can	O
prevent	O
further	O
brain	B-DIS
damage	I-DIS
and	O
improve	O
prognosis	O
.	O

Although	O
early	O
identification	O
and	O
treatment	O
are	O
essential	O
the	O
diagnosis	O
of	O
neonatal	O
seizures	B-DIS
can	O
be	O
further	O
complicated	O
by	O
the	O
clinical	O
presentations	O
possible	O
etiologies	B-DIS
and	O
treatments	O
.	O

Nevertheless	O
research	O
studies	O
and	O
clinical	O
evidence	O
have	O
shown	O
that	O
early	O
treatment	O
with	O
anti	O
-	O
seizure	O
medications	O
can	O
change	O
the	O
outcome	O
.	O

Background	O
Community	B-DIS
-	I-DIS
acquired	B-DIS
pneumonia	O
CAP	O
is	O
the	O
major	O
manifestation	B-DIS
of	I-DIS
Q	O
fever	O
an	O
emerging	O
disease	O
in	O
French	O
Guiana	B-LOC
.	O

Consequently	O
the	O
empirical	O
antibiotherapy	O
used	O
for	O
the	O
treatment	O
of	O
CAP	O
combines	O
doxycycline	O
and	O
the	O
recommended	O
amoxicillin	O
.	O

Our	O
objectives	O
were	O
to	O
estimate	O
the	O
prevalence	B-EPI
of	O
Q	B-DIS
fever	I-DIS
pneumonia	I-DIS
and	O
to	O
build	O
a	O
prediction	O
rule	O
to	O
identify	O
patients	O
with	O
Q	B-DIS
fever	I-DIS
pneumonia	I-DIS
for	O
empirical	O
antibiotic	O
guidance	O
.	O

Methods	O
A	O
retrospective	O
case	O
-	O
control	O
study	O
was	O
conducted	O
on	O
inpatients	O
admitted	O
with	O
CAP	O
in	O
the	O
Department	O
of	B-DIS
Infectious	I-DIS
Diseases	I-DIS
of	O
Cayenne	O
Hospital	O
from	O
2004	O
to	O
2007	O
.	O

Serodiagnosis	O
for	O
Coxiella	O
burnetii	O
was	O
performed	O
for	O
all	O
patients	O
.	O

Risk	O
factor	O
analysis	O
was	O
performed	O
using	O
multivariate	O
logistic	O
regression	O
and	O
a	O
prognostic	O
score	O
was	O
computed	O
using	O
bootstrap	O
procedures	O
.	O

The	O
score	O
performance	O
characteristics	O
were	O
used	O
to	O
choose	O
the	O
best	O
prediction	O
rule	O
to	O
identify	O
patients	O
with	O
Q	B-DIS
fever	I-DIS
pneumonia	I-DIS
.	O

Results	O
One	O
hundred	O
thirty	O
-	O
one	O
patients	B-DIS
with	O
CAP	O
were	O
included	O
and	B-DIS
the	I-DIS
Q	I-DIS
fever	B-EPI
pneumonia	O
prevalence	O
was	O
24.4	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
confidence	O
interval	O
[	O
CI	O
]	O
17.1	O
-	O
31.9	O
.	O

In	O
multivariate	O
analysis	O
male	O
sex	O
middle	O
age	O
age	O
30	O
-	O
60	O
years	O
headache	B-DIS
leukocyte	O
count	O
<	O
10	O
×	O
109	O
/L	O
and	O
C	O
-	O
reactive	O
protein	O
leve	O
185	O
mg	O
/	O
L	O
were	B-DIS
independently	I-DIS
associated	I-DIS
with	O
Q	O
fever	O
pneumonia	O
.	O

Patients	O
with	O
a	O
predictive	O
score	O
≤3	O
had	O
a	O
low	O
risk	O
of	O
Q	B-DIS
fever	I-DIS
pneumonia	I-DIS
with	O
a	O
negative	O
predictive	O
value	O
of	O
0.9795	B-STAT
%	I-STAT
CI	O
.90	O
-	O
1	O
and	O
a	O
sensitivity	O
of	O
0.9795	B-STAT
%	I-STAT
CI	O
.89	O
-	O
1	O
.	O

Conclusions	O
The	O
prediction	O
rule	O
described	O
here	O
accurately	O
identifies	O
patients	O
with	O
low	O
risk	O
of	O
Q	B-DIS
fever	I-DIS
pneumonia	I-DIS
and	O
may	O
help	O
physicians	O
to	O
make	O
more	O
rational	O
decisions	O
about	O
the	O
empirical	O
use	O
of	O
antibiotherapy	O
.	O

Further	O
prospective	O
studies	O
should	O
be	O
performed	O
to	O
validate	O
this	O
score	O
.	O

Aim	O
Psychogenic	B-DIS
nonepileptic	I-DIS
seizures	I-DIS
PNES	O
or	O
functional	O
seizures	B-DIS
are	O
universal	O
phenomena	O
.	O

However	O
data	O
on	O
their	O
epidemiology	O
is	O
limited	O
.	O

The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
review	O
the	O
literature	O
on	O
the	O
epidemiology	O
of	O
PNES	O
and	O
to	O
provide	O
analytical	O
estimates	O
of	O
its	O
incidence	B-EPI
and	O
prevalence	B-EPI
based	O
on	O
the	O
direct	O
data	O
that	O
are	O
available	O
from	O
previous	O
studies	O
on	O
PNES	O
.	O

Methods	O
The	O
methods	O
of	O
this	O
work	O
had	O
two	O
parts	O
1	O
MEDLINE	O
PsycINFO	O
and	O
Scopus	O
from	O
inception	O
to	O
19	O
October	O
2019	O
were	O
systematically	O
searched	O
.	O

2	O
The	O
analytical	O
study	O
of	O
the	O
incidence	B-EPI
and	O
prevalence	B-EPI
of	O
PNES	O
was	O
performed	O
based	O
on	O
the	O
following	O
data	O
from	O
previous	O
studies	O
incidence	B-EPI
of	O
PNES	O
duration	O
of	O
PNES	O
before	O
making	O
a	O
diagnosis	O
outcome	O
and	O
mortality	O
of	O
PNES	O
.	O

Results	O
The	O
search	O
strategy	O
yielded	O
five	O
articles	O
;	O
three	O
were	O
on	O
the	O
incidence	B-EPI
and	O
two	O
on	O
the	O
prevalence	B-EPI
.	O

In	O
the	O
analytical	O
part	O
of	O
the	O
study	O
the	O
incidence	B-EPI
of	O
PNES	O
was	O
calculated	O
to	O
be	O
3.195	B-STAT
%	I-STAT
Confidence	O
Interval	O
1.1	O
-	O
5.1	O
per	O
100000	O
population	O
per	O
year	O
.	O

The	O
calculated	O
prevalence	B-EPI
rate	O
of	O
PNES	O
in	O
2019	O
was	O
108.595	B-STAT
%	I-STAT
Confidence	O
Interval	O
39.2	O
-	O
177.8	O
per	O
100000	O
population	O
in	O
the	O
USA	B-LOC
.	O

Conclusion	O
While	O
the	O
generalizability	O
of	O
these	O
calculated	O
incidence	B-EPI
and	O
prevalence	B-EPI
rates	O
to	O
other	O
places	O
in	O
the	O
world	O
is	O
limited	O
they	O
give	O
us	O
a	O
reasonable	O
hint	O
that	O
PNES	O
is	O
a	O
common	O
condition	O
and	O
the	O
prevalence	B-EPI
is	O
much	O
more	O
than	O
that	O
it	O
was	O
thought	O
before	O
.	O
Supplemental	O
data	O
for	O
this	O
article	O
is	O
available	O
online	O
at	O
https//doi.org/10.1080/00207454.2021.1942870	O
.	O

Charcot	B-DIS
-	I-DIS
Marie	I-DIS
-	O
Tooth	O
CMT	O
disease	O
is	B-DIS
a	I-DIS
common	O
inherited	O
peripheral	O
neuropathy	O
.	O

The	O
CMT2	B-DIS
K	I-DIS
axonal	O
form	O
is	O
associated	O
with	O
GDAP1	B-DIS
dominant	I-DIS
mutations	I-DIS
which	O
according	O
to	O
the	O
affected	O
domain	O
cause	O
a	O
gradient	O
of	O
severity	O
.	O

Indeed	O
the	O
p.	O
C240Y	O
mutation	O
located	O
within	O
GDAP1	O
glutathione	O
S	O
-	O
transferase	O
GST	O
domain	O
and	O
associated	O
to	O
a	O
mitochondrial	O
complex	O
I	O
defect	O
is	O
related	O
to	O
a	O
faster	O
disease	O
progression	O
compared	O
to	O
other	O
mutations	O
such	O
as	O
the	B-DIS
p.	O
R120W	O
located	O
outside	O
the	O
GST	O
domain	O
.	O

Here	O
we	O
analysed	O
the	O
pathophysiology	O
of	O
six	O
CMT2	B-DIS
K	I-DIS
fibroblast	O
cell	O
lines	O
carrying	O
either	O
the	O
p.	O
C240Y	O
or	O
p.	O
R120W	B-DIS
mutations	O
.	O

We	O
show	O
that	O
complex	O
I	O
deficiency	O
leads	O
to	O
a	O
redox	O
potential	O
alteration	O
and	O
a	O
significant	O
reduction	O
of	O
sirtuin	O
1	O
SIRT1	O
expression	O
a	O
major	O
deacetylase	O
sensitive	O
to	O
the	O
cellular	O
redox	O
state	O
and	O
NRF1	O
the	O
downstream	O
target	O
of	O
SIRT1	O
.	O

In	O
addition	O
we	O
disclosed	O
that	O
the	O
p.	O
C240Y	O
mutation	O
is	O
associated	O
with	O
a	O
greater	O
mitochondrial	O
oxidative	O
stress	O
than	O
the	O
p.	O
R120W	O
mutation	O
.	O

Moreover	O
complex	O
I	O
activity	O
is	O
further	O
restored	O
in	O
CMT2	B-DIS
K	I-DIS
mutant	O
cell	O
lines	O
exposed	O
to	O
resveratrol	O
.	O

Together	O
these	O
results	O
suggest	O
that	O
the	O
reduction	O
of	O
oxidative	O
stress	O
may	O
constitute	O
a	O
promising	O
therapeutic	O
strategy	O
for	O
CMT2	B-DIS
K	I-DIS
.	O

Purpose	O
Inflammatory	B-DIS
bowel	I-DIS
diseases	I-DIS
IBD	I-DIS
including	O
Crohn	B-DIS
's	I-DIS
disease	I-DIS
CD	O
and	O
ulcerative	B-DIS
colitis	I-DIS
UC	I-DIS
are	O
chronic	B-DIS
diseases	I-DIS
.	O

The	O
aim	O
was	O
to	O
validate	O
diagnoses	O
of	O
IBD	B-DIS
among	O
patients	O
aged	O
50	O
+	O
years	O
in	O
the	O
Danish	O
National	O
Patient	O
Registry	O
NPR	O
by	O
comparison	O
with	O
patient	O
medical	O
records	O
.	O

Patients	O
and	O
methods	O
Men	O
and	O
women	O
in	O
the	O
Diet	O
Cancer	B-DIS
and	O
Health	O
DCH	O
cohort	O
were	O
linked	O
to	O
NPR	O
and	O
cases	O
with	O
a	O
diagnosis	O
of	O
IBD	B-DIS
and	O
their	O
respective	O
hospital	O
records	O
were	O
identified	O
.	O

Validation	O
was	O
performed	O
by	O
comparing	O
patient	O
medical	O
records	O
with	O
information	O
on	O
discharge	O
diagnoses	O
of	O
IBD	B-DIS
from	O
the	O
NPR	O
.	O

Results	O
Of	O
57053	O
individuals	O
in	O
the	O
DCH	O
-	O
cohort	O
339	O
were	O
registered	O
with	B-DIS
an	O
IBD	O
diagnosis	O
in	O
NPR	O
with	O
27782	B-STAT
%	I-STAT
records	O
available	O
for	O
review	O
.	O

Among	O
277	O
patients	O
the	O
positive	O
predictive	O
values	O
PPVs	O
of	O
one	O
CD	O
or	O
UC	B-DIS
registration	O
in	O
NPR	O
were	O
78	B-STAT
%	I-STAT
for	O
IBD	B-DIS
overall	O
51	B-STAT
%	I-STAT
for	O
CD	O
and	O
54	B-STAT
%	I-STAT
for	O
UC	B-DIS
.	O

One	O
hundred	O
fifty	O
-	O
seven	O
patients	O
had	O
at	O
least	O
two	O
CD	B-DIS
and/or	O
UC	O
registrations	O
with	O
PPVs	O
of	O
90	B-STAT
%	B-DIS
for	O
IBD	O
overall	O
65	B-STAT
%	I-STAT
for	O
CD	O
and	O
73	B-STAT
%	B-DIS
for	O
UC	O
.	O

One	O
hundred	O
and	O
two	O
patients	O
had	O
at	O
least	O
three	O
registrations	O
with	O
PPVs	O
of	O
97	B-STAT
%	I-STAT
for	O
IBD	B-DIS
overall	O
75	B-STAT
%	I-STAT
for	O
CD	O
and	O
88	B-STAT
%	I-STAT
for	O
UC	B-DIS
.	O

96	B-STAT
%	I-STAT
were	O
diagnosed	O
at	O
a	O
specialized	O
department	O
.	O

Other	O
diagnoses	O
coded	O
as	O
IBD	B-DIS
mostly	O
included	O
microscopic	O
colitis	O
irritable	B-DIS
bowel	I-DIS
syndrome	I-DIS
and	O
cancer	B-DIS
.	O

Conclusion	O
Validity	O
of	O
IBD	B-DIS
diagnoses	O
in	O
the	O
registry	O
of	O
individuals	O
aged	O
50	O
+	O
years	O
increased	O
with	O
the	O
number	O
of	O
registrations	O
.	O

It	O
is	O
recommended	O
that	O
these	O
results	O
are	O
taken	O
into	O
consideration	O
in	O
future	O
studies	O
especially	O
in	O
epidemiology	O
research	O
using	O
NPR	O
as	O
a	O
data	O
source	O
for	O
patients	O
diagnosed	O
with	O
IBD	B-DIS
.	O

Objective	O
Health	O
-	O
related	O
quality	O
of	O
life	B-DIS
is	I-DIS
impaired	I-DIS
in	I-DIS
idiopathic	I-DIS
inflammatory	O
myopathies	O
.	O

This	O
study	O
aimed	O
to	O
identify	O
the	O
main	O
areas	O
of	O
the	O
health	O
-	O
related	O
quality	O
of	O
life	O
environment	O
domain	O
that	O
are	O
affected	O
in	O
patients	B-DIS
with	O
myositis	O
.	O

Methods	O
A	O
qualitative	O
study	O
was	O
performed	O
using	O
focus	O
groups	O
and	O
applying	O
the	O
International	O
Classification	O
of	O
Functioning	B-DIS
Disability	I-DIS
and	O
Health	O
.	O

Participants	O
were	O
recruited	O
from	O
a	O
cohort	O
of	O
323	O
adult	O
inflammatory	O
myopathy	B-DIS
patients	O
consulting	O
at	O
a	O
reference	O
center	O
for	O
idiopathic	B-DIS
inflammatory	I-DIS
myopathy	I-DIS
in	O
Spain	B-LOC
selected	O
by	O
the	O
maximum	O
variation	O
strategy	O
and	O
placed	O
in	O
focus	O
groups	O
with	O
5	O
to	O
7	O
patients	O
per	O
group	O
.	O

The	O
number	O
of	O
focus	O
groups	O
required	O
was	O
determined	O
by	O
data	O
saturation	O
.	O

Results	O
Twenty	O
-	O
five	O
patients	O
distributed	O
in	O
4	O
focus	O
groups	O
were	O
interviewed	O
.	O

The	O
verbatim	O
provided	O
54	O
categories	O
directly	O
related	O
with	O
environmental	O
factors	O
.	O

Those	O
associated	O
with	O
products	O
or	O
substances	O
for	O
personal	O
consumption	O
e110	O
health	O
professionals	O
e355	O
health	O
services	O
systems	O
and	O
policies	O
e580	O
products	O
and	O
technology	O
for	O
personal	O
use	O
in	O
daily	O
living	O
e115	O
and	O
immediate	O
family	O
e310	O
were	O
the	O
ones	O
most	O
frequently	O
reported	O
.	O

Conclusion	O
The	O
results	O
of	O
this	O
study	O
led	O
to	O
identification	O
of	O
several	O
environmental	O
factors	O
that	O
affect	O
the	O
health	O
-	O
related	O
quality	O
of	O
life	O
of	O
patients	B-DIS
with	O
myositis	O
.	O

Remedial	O
interventions	O
should	O
be	O
designed	O
to	O
address	O
some	O
of	O
these	O
factors	O
.	O

Background	O
Most	O
epidemiological	O
data	O
on	O
vitiligo	B-DIS
refer	O
to	O
selected	O
environments	O
or	O
focus	O
on	O
the	O
prevalence	B-EPI
of	O
comorbidity	O
unrelated	O
to	O
the	O
population	O
.	O

Objective	O
Aim	O
of	O
the	O
study	O
was	O
to	O
gain	O
robust	O
representative	O
prevalence	B-EPI
data	O
on	O
vitiligo	B-DIS
and	O
on	O
associated	O
dermatologic	O
comorbidity	O
in	O
the	O
German	O
adult	O
population	O
.	O

Methods	O
A	O
dual	O
population	O
-	O
based	O
approach	O
was	O
applied	O
with	O
1	O
primary	O
data	O
obtained	O
between	O
2004	O
and	O
2014	O
from	O
dermatological	O
exams	O
in	O
the	O
general	O
working	O
population	O
;	O
2	O
claims	O
data	O
from	O
a	O
large	O
German	O
statutory	O
health	O
insurance	O
reference	O
year	O
2010	O
.	O

Results	O
In	O
the	O
working	O
cohort	O
N	O
=	O
121783	O
;	O
57	B-STAT
%	I-STAT
male	O
;	O
mean	O
age	O
43	O
years	O
the	O
prevalence	B-EPI
of	O
vitiligo	B-DIS
was	O
0.77	B-STAT
%	I-STAT
0.84	B-STAT
%	I-STAT
in	O
men	O
;	O
0.67	B-STAT
%	I-STAT
in	O
women	O
.	O

In	O
the	O
claims	O
data	O
N	O
=	O
1619678	O
;	O
38	B-STAT
%	I-STAT
male	O
;	O
mean	O
age	O
46	O
years	O
prevalence	B-EPI
was	O
0.17	B-STAT
%	I-STAT
0.14	B-STAT
%	I-STAT
in	O
men	O
;	O
0.18	B-STAT
%	I-STAT
in	O
women	O
.	O

In	O
the	O
working	O
cohort	O
vitiligo	B-DIS
was	O
significantly	O
more	O
common	O
in	O
people	O
with	O
fair	O
skin	O
type	O
ephelides	O
and	O
port	B-DIS
-	O
wine	O
stains	O
and	O
less	O
common	O
in	O
people	B-DIS
with	O
acne	O
and	O
solar	O
lentigines	O
.	O

In	O
the	O
claims	O
data	O
vitiligo	B-DIS
was	O
associated	O
with	O
a	O
variety	O
of	O
skin	O
conditions	O
eg	O
atopic	B-DIS
dermatitis	I-DIS
psoriasis	I-DIS
and	O
alopecia	B-DIS
areata	I-DIS
.	O

Conclusion	O
The	O
resulting	O
discrepancy	O
of	O
claims	O
vs	O
primary	O
data	O
between	B-STAT
0.17	I-STAT
%	I-STAT
and	O
0.77	B-STAT
%	I-STAT
indicates	O
the	O
most	O
probable	O
spectrum	O
of	O
vitiligo	B-DIS
prevalence	B-EPI
in	O
Germany	B-LOC
.	O

It	O
is	O
more	O
frequently	O
observed	O
in	O
clinical	O
exams	O
than	O
recorded	O
in	O
claims	O
data	O
indicating	O
a	O
marked	O
proportion	O
of	O
people	O
seeking	O
no	O
medical	O
help	O
.	O

Such	O
nonattendance	O
may	O
result	O
from	O
the	O
fact	O
that	O
many	O
treatment	O
options	O
do	O
not	O
provide	O
satisfying	O
benefits	O
to	O
the	O
patients	O
.	O

Background	O
Repeated	O
inflammation	B-DIS
of	O
the	O
pancreas	O
can	O
cause	O
pancreatitis	B-DIS
or	O
diabetes	B-DIS
.	O

It	O
is	O
well	O
recognized	O
that	O
the	O
organic	B-DIS
acidemias	I-DIS
may	O
be	O
complicated	O
by	O
pancreatitis	B-DIS
but	O
less	O
recognized	O
are	O
other	O
metabolic	B-DIS
disorders	I-DIS
in	O
which	O
pancreatitis	B-DIS
can	O
occur	O
.	O

This	O
study	O
shows	O
that	O
long	O
-	O
term	O
follow	O
-	O
up	O
of	B-DIS
patients	I-DIS
with	O
various	O
metabolic	O
disorders	O
in	O
Korea	B-LOC
revealed	O
several	O
with	B-DIS
episodes	O
of	B-DIS
isolated	O
pancreatitis	O
or	B-DIS
diabetes	O
concomitantly	O
with	O
pancreatitis	O
.	O

Results	O
and	O
discussion	O
In	O
this	O
study	O
two	O
patients	O
with	O
methylmalonic	B-DIS
aciduria	I-DIS
MMA	I-DIS
two	O
with	O
propionic	O
acidemia	O
PPA	O
one	O
with	O
fatty	O
acid	O
oxidation	O
disorder	O
FAOD	O
and	O
one	O
with	O
hyperornithinemia	B-DIS
gyrate	I-DIS
atrophy	I-DIS
and	O
juvenile	O
onset	O
diabetes	B-DIS
mellitus	I-DIS
DM	I-DIS
were	O
clinically	O
followed	O
for	O
up	O
to	O
10	O
-	O
21	O
years	O
.	O

Two	O
Korean	O
siblings	O
with	O
MMA	O
showed	O
recurrent	O
pancreatitis	B-DIS
from	O
the	O
age	O
of	O
15	O
and	O
19	O
respectively	O
.	O

The	O
frequency	O
of	O
admission	O
due	O
to	O
pancreatitis	B-DIS
was	O
up	O
to	O
11	O
times	O
.	O

One	O
patient	O
with	O
MMA	O
developed	O
diabetes	B-DIS
mellitus	I-DIS
at	O
the	O
age	O
of	O
20	O
.	O

The	O
other	O
patient	O
with	O
MMA	O
developed	O
recurrent	O
pancreatitis	B-DIS
at	O
4	O
years	O
and	O
diabetes	B-DIS
at	O
8	O
years	O
of	O
age	O
.	O

One	O
of	O
the	O
patients	O
with	O
PPA	O
presented	O
with	O
diabetic	B-DIS
ketoacidosis	I-DIS
.	O

The	O
other	O
PPA	O
patient	O
died	O
of	O
cardiac	B-DIS
arrest	I-DIS
at	O
age	O
10	O
.	O

The	O
patient	O
with	O
FAOD	O
presented	O
with	O
pancreatitis	B-DIS
at	O
10	O
years	O
and	O
died	O
at	O
the	O
age	O
of	O
15	O
years	O
due	O
to	O
cardiac	B-DIS
arrest	I-DIS
.	O

A	O
35	O
-	O
year	O
-	O
old	O
woman	O
with	O
hyperornithinemia	O
/	O
gyrate	O
atrophy	B-DIS
was	O
diagnosed	O
with	O
juvenile	O
onset	O
diabetes	O
at	O
the	O
age	O
of	O
7	O
years	O
.	O

No	O
pancreatitis	B-DIS
occurred	O
during	O
the	O
follow	O
-	O
up	O
period	O
.	O

Conclusions	O
We	O
conclude	O
that	O
various	O
metabolic	B-DIS
disorders	I-DIS
can	O
trigger	O
acute	O
or	O
chronic	O
pancreatitis	B-DIS
.	O

Proper	O
and	O
prompt	O
multidisciplinary	O
management	O
of	O
metabolic	B-DIS
derangement	I-DIS
is	O
crucial	O
for	O
preventing	O
pancreatic	B-DIS
damage	I-DIS
.	O

Further	O
clinical	O
and	O
investigational	O
studies	O
are	O
required	O
to	O
elucidate	O
the	O
pathogenesis	O
of	O
pancreatitis	B-DIS
and	O
diabetes	B-DIS
mellitus	I-DIS
in	O
patients	O
with	O
inborn	B-DIS
errors	I-DIS
in	O
metabolism	O
.	O

The	O
global	O
spread	O
of	O
COVID-19	O
constitutes	O
the	O
most	O
dangerous	O
pandemic	B-DIS
to	O
emerge	O
during	O
the	O
last	O
one	O
hundred	O
years	O
.	O

About	O
seventy	O
-	O
nine	B-DIS
million	O
infections	O
and	O
more	O
than	O
1.7	B-DIS
million	O
death	O
have	O
been	O
reported	O
to	O
date	O
along	O
with	O
destruction	O
of	O
the	O
global	O
economy	O
.	O

With	O
the	O
uncertainty	O
evolved	O
by	O
alarming	O
level	O
of	O
genome	O
mutations	O
coupled	O
with	O
likelihood	O
of	O
generating	O
only	O
a	O
short	O
lived	O
immune	O
response	O
by	O
the	O
vaccine	O
injections	O
the	O
identification	O
of	O
antiviral	O
drugs	O
for	O
direct	O
therapy	O
is	O
the	O
need	O
of	O
the	O
hour	O
.	O

Strategies	O
to	O
inhibit	O
virus	O
infection	B-DIS
and	O
replication	O
focus	O
on	O
targets	O
such	O
as	O
the	O
spike	O
protein	O
and	O
non	O
-	O
structural	O
proteins	O
including	O
the	O
highly	O
conserved	O
RNA	O
-	O
dependent	O
-	O
RNA	O
-	O
polymerase	O
nucleotidyl	O
-	O
transferases	O
main	O
protease	O
and	O
papain	O
-	O
like	O
proteases	O
.	O

There	O
is	O
also	O
an	O
indirect	O
option	O
to	O
target	O
the	O
host	O
cell	O
recognition	O
systems	O
such	O
as	O
angiotensin	O
-	O
converting	O
enzyme	O
2	O
ACE2	O
transmembrane	O
protease	O
serine	O
2	O
host	O
cell	O
expressed	O
CD147	O
and	O
the	O
host	O
furin	O
.	O

A	O
drug	O
search	O
strategy	O
consensus	O
in	O
tandem	O
with	O
analysis	O
of	O
currently	O
available	O
information	O
is	O
extremely	O
important	O
for	O
the	O
rapid	O
identification	O
of	O
anti	O
-	O
viral	O
.	O

An	O
unprecedented	O
display	O
of	O
cooperation	O
among	O
the	O
scientific	O
community	O
regarding	O
SARS	O
-	O
CoV-2	O
research	O
has	O
resulted	O
in	O
the	O
accumulation	O
of	O
an	O
enormous	O
amount	O
of	O
literature	O
that	O
requires	O
curation	O
.	O

Drug	O
repurposing	O
and	O
drug	O
combinations	O
have	O
drawn	O
tremendous	O
attention	O
for	O
rapid	O
therapeutic	O
application	O
while	O
high	O
throughput	O
screening	O
and	O
virtual	O
searches	O
support	O
de	O
novo	O
drug	O
identification	O
.	O

Here	O
we	O
examine	O
how	O
certain	O
approved	O
drugs	O
targeting	O
different	O
viruses	O
can	O
play	O
a	O
role	O
in	O
combating	O
this	O
new	O
virus	O
and	O
analyze	O
how	O
they	O
demonstrate	O
efficacy	O
under	O
clinical	O
assessment	O
.	O

Suggestions	O
on	O
repurposing	O
and	O
de	O
novo	O
strategies	O
are	O
proposed	O
to	O
facilitate	O
the	O
fight	O
against	O
the	O
COVID-19	O
pandemic	O
.	O

Coronavirus	B-DIS
2019	I-DIS
COVID-19	I-DIS
is	O
responsible	O
for	O
the	O
current	O
pandemic	O
which	O
has	O
already	O
resulted	O
in	O
considerable	O
mortality	O
worldwide	O
.	O

This	O
systematic	O
review	O
was	O
conducted	O
to	O
summarize	O
the	O
results	O
of	O
the	O
published	O
articles	O
assessing	O
the	O
incidence	B-EPI
of	O
heart	B-DIS
diseases	I-DIS
in	O
patients	O
infected	O
with	O
COVID-19	O
.	O

The	O
electronic	O
databases	O
Scopus	O
Web	O
of	O
Science	O
Pubmed	O
Science	O
Direct	O
and	O
ProQuest	O
were	O
used	O
to	O
search	O
for	O
potentially	O
relevant	O
articles	O
.	O

Articles	O
published	O
from	O
Dec	O
2019	O
to	O
April	O
2020	O
were	O
included	O
.	O

All	O
cross	O
-	O
sectional	O
retrospective	O
or	O
prospective	O
observational	O
cohort	O
and	O
case	O
-	O
control	O
studies	O
were	O
selected	B-EPI
which	O
reported	B-EPI
the	O
incidence	B-DIS
or	I-DIS
prevalence	I-DIS
of	I-DIS
myocardial	O
injury	B-DIS
myocardial	I-DIS
infarction	O
or	O
cardiovascular	O
disease	O
in	B-DIS
patients	I-DIS
with	O
confirmed	O
COVID-19	O
infection	O
.	O

Based	O
on	O
the	O
inclusion	O
criteria	O
12	O
articles	O
were	O
selected	O
.	O

The	O
incidence	B-EPI
of	O
cardiac	B-DIS
injury	I-DIS
was	O
reported	O
in	O
8	O
articles	O
and	O
8	O
articles	O
focused	O
on	O
the	O
cardiovascular	O
outcomes	O
of	O
COVID-19	B-DIS
infection	I-DIS
.	O

The	O
incidence	B-EPI
of	O
new	O
cardiac	B-DIS
injury	I-DIS
was	O
reported	O
to	O
be	O
7.2	B-STAT
-	I-STAT
77	I-STAT
%	I-STAT
in	O
live	O
and	O
dead	O
patients	O
respectively	O
.	O

The	O
results	O
showed	O
that	O
patients	O
with	O
cardiac	B-DIS
injury	I-DIS
had	O
worse	O
outcomes	O
including	O
higher	O
mortality	O
than	O
those	O
without	O
cardiac	B-DIS
injury	I-DIS
.	O

The	O
most	O
common	O
cardiac	B-DIS
injury	I-DIS
outcomes	O
were	O
shock	B-DIS
and	O
malignant	B-DIS
arrhythmias	I-DIS
.	O

The	O
most	O
common	O
radiographic	O
findings	O
in	O
patients	O
with	O
cardiac	B-DIS
injury	I-DIS
were	O
multiple	O
mottling	O
and	O
ground	B-DIS
-	I-DIS
glass	O
opacities	O
in	O
the	O
lungs	O
64.6	B-STAT
%	I-STAT
.	O

A	O
significant	O
number	O
of	O
patients	O
with	O
cardiac	B-DIS
injury	I-DIS
required	O
noninvasive	O
mechanical	O
ventilation	O
46.3	B-STAT
%	I-STAT
or	O
invasive	O
mechanical	O
ventilation	O
22.0	B-STAT
%	I-STAT
.	O

Acute	O
respiratory	B-DIS
distress	I-DIS
syndrome	O
was	O
seen	O
in	O
58.5	B-STAT
%	I-STAT
acute	B-DIS
kidney	I-DIS
injury	I-DIS
in	O
8.5	B-STAT
%	I-STAT
electrolyte	O
disturbances	O
in	O
15.9	B-STAT
%	I-STAT
hypoproteinemia	B-DIS
in	O
13.4	B-STAT
%	I-STAT
and	O
coagulation	B-DIS
disorders	I-DIS
in	O
7.3	B-STAT
%	I-STAT
of	O
patients	O
with	O
cardiac	B-DIS
injuries	I-DIS
.	O

In	O
addition	O
survival	O
days	O
were	O
negatively	O
correlated	O
with	O
cardiac	O
troponin	O
I	O
levels	O
r	O
=	O
-0.4295	O
%	O
p	O
=	O
0.005	O
.	O

The	O
results	O
of	O
this	O
review	O
showed	O
that	O
myocardial	B-DIS
injury	I-DIS
in	O
patients	O
with	O
COVID	O
19	O
has	O
a	O
poor	O
prognosis	O
.	O

Hence	O
cardiac	O
investigation	O
and	O
management	O
in	O
these	O
patients	O
are	O
crucial	O
.	O

The	O
periampullary	B-DIS
neuroendocrine	I-DIS
tumour	I-DIS
is	O
an	O
infrequently	O
occurring	O
tumour	B-DIS
.	O

Its	O
prevalence	B-EPI
among	O
gastrointestinal	B-DIS
neuroendocrine	I-DIS
neoplasms	I-DIS
is	O
less	B-STAT
than	I-STAT
0.3	I-STAT
%	I-STAT
and	O
less	B-STAT
than	I-STAT
2	I-STAT
%	I-STAT
out	O
of	O
periampullary	B-DIS
tumours	I-DIS
.	O

These	O
neoplasms	B-DIS
have	O
relatively	O
poor	O
prognosis	O
.	O

Jaundice	B-DIS
and	O
pain	B-DIS
in	O
the	O
abdomen	O
are	O
the	O
early	O
and	O
most	O
commonly	O
occurring	O
symptoms	O
with	O
weight	B-DIS
loss	I-DIS
being	O
a	O
late	O
event	O
.	O

The	O
carcinoid	B-DIS
syndrome	I-DIS
presents	O
infrequently	O
in	O
periampullary	B-DIS
neuroendocrine	I-DIS
tumour	I-DIS
and	O
happens	O
only	O
if	O
hepatic	B-DIS
metastasis	I-DIS
occurs	O
.	O

In	O
this	O
scenario	O
histopathology	O
plays	O
a	O
paramount	O
role	O
in	O
the	O
diagnosis	O
.	O

Specific	O
immunohistochemical	O
staining	O
is	O
used	O
for	O
diagnosis	O
while	O
the	O
treatment	O
options	O
are	O
local	O
excision	O
endoscopic	O
excision	O
and	O
pancreaticoduodenectomy	O
.	O

Here	O
is	O
a	O
case	O
report	O
of	O
a	O
42	O
-	O
year	O
-	O
old	O
patient	O
who	O
presented	B-DIS
with	I-DIS
complaint	O
of	O
obstructive	O
jaundice	O
for	O
one	O
month	O
.	O

Periampullary	B-DIS
carcinoid	I-DIS
tumour	I-DIS
was	O
diagnosed	O
on	O
biopsy	O
and	O
she	O
underwent	O
Pancreaticoduodenectomy	O
as	O
treatment	O
.	O

Literature	O
shows	O
that	O
there	O
is	O
poor	O
precision	O
of	O
preoperative	O
and	O
intraoperative	O
lymph	O
node	O
metastatic	O
involvement	O
regardless	O
of	O
the	O
size	O
of	O
the	O
tumour	B-DIS
.	O

Hence	O
radical	O
resection	O
must	O
be	O
considered	O
the	O
standard	O
approach	O
.	O

Rationale	O
Women	O
with	O
congenital	B-DIS
adrenal	I-DIS
hyperplasia	I-DIS
CAH	I-DIS
can	O
suffer	O
from	O
impaired	B-DIS
fertility	I-DIS
rates	O
as	O
a	O
result	O
of	O
increased	O
androgen	O
secretion	O
or	O
impaired	O
sex	O
steroid	O
production	O
.	O

CAH	B-DIS
patients	O
have	O
lower	O
pregnancy	O
rate	O
compared	O
to	O
normal	O
women	O
.	O

Only	O
a	O
few	O
cases	O
with	O
successful	O
pregnancy	O
have	O
been	O
reported	O
in	O
the	O
literature	O
.	O

This	O
report	O
described	O
a	O
case	O
of	O
CAH	B-DIS
with	O
successful	O
pregnancy	O
and	O
live	O
birth	O
.	O

Patient	O
concerns	O
A	O
23	O
-	O
year	O
-	O
old	O
woman	O
visited	O
our	B-DIS
endocrinology	I-DIS
department	O
for	B-DIS
clitoral	I-DIS
hypertrophy	O
and	O
primary	O
amenorrhea	O
.	O

Diagnoses	O
The	O
patient	O
was	O
diagnosed	O
as	O
CAH	B-DIS
.	O

Intervention	O
Prednisone	O
was	O
initially	O
started	O
to	O
improve	O
the	O
patient	O
's	O
symptoms	O
.	O

Then	O
she	O
underwent	O
clitoral	O
resection	O
and	O
vaginoplasty	O
several	O
months	O
later	O
.	O

She	O
continuously	O
took	O
the	O
prednisolone	O
after	O
the	O
operation	O
and	O
had	O
been	O
undergoing	O
regular	O
checkups	O
.	O

Outcomes	O
She	O
was	O
pregnant	O
spontaneously	O
without	O
assisted	O
reproductive	O
technology	O
and	O
had	O
a	O
successful	O
live	O
birth	O
.	O

Her	O
baby	O
had	O
shown	O
normal	O
external	O
genitalia	O
with	O
normal	O
karyotype	O
and	O
normal	O
development	O
up	O
to	O
6	O
years	O
of	O
age	O
.	O

Lessons	O
Some	O
mild	O
CAH	B-DIS
patients	O
with	O
certain	O
types	O
can	O
achieved	O
successful	O
pregnancy	O
without	O
any	O
assisted	O
reproductive	O
technology	O
after	O
treatment	O
with	O
steroid	O
.	O

The	O
pregnancy	O
rate	O
among	O
CAH	O
women	O
who	O
wish	O
to	O
conceive	O
may	O
be	O
much	O
more	O
optimistic	O
than	O
previous	O
researches	O
.	O

Li	B-DIS
-	I-DIS
Fraumeni	O
syndrome	O
LFS	O
is	B-DIS
a	I-DIS
hereditary	I-DIS
cancer	I-DIS
predisposition	O
syndrome	O
with	O
the	O
characteristics	O
of	O
early	O
onset	B-DIS
of	O
cancer	B-DIS
and	I-DIS
high	B-EPI
cancer	O
incidence	O
.	O

TP53	O
is	O
widely	O
accepted	O
as	O
a	O
pathogenic	O
gene	O
of	O
LFS	O
.	O

A	O
2	O
years	O
and	O
6	O
months	O
old	O
boy	O
is	O
reported	O
in	O
this	O
article	O
who	O
was	O
diagnosed	O
with	O
embryonal	B-DIS
rhabdomyosarcoma	I-DIS
RMS	O
in	O
the	O
left	O
submandibular	O
region	O
.	O

His	O
brother	O
died	O
of	O
RMS	O
and	O
his	O
grandmother	O
was	O
diagnosed	O
with	O
breast	B-DIS
cancer	I-DIS
.	O

TP53	O
gene	O
mutation	O
detection	O
was	O
performed	O
in	O
this	O
patient	O
and	O
some	O
family	O
members	O
indicating	O
a	O
missense	O
mutation	O
in	O
exon	O
8	O
of	O
the	O
patient	O
c.84	O
T	O
p.	O
Arg282Trp	O
heterozygous	O
.	O

TP53	O
mutation	O
was	O
also	O
found	O
in	O
his	O
mother	O
and	O
sister	O
.	O

The	O
boy	O
met	O
the	O
diagnostic	O
criteria	O
for	O
LFS	O
.	O

Among	O
pediatric	O
patients	O
the	O
most	O
common	O
LFS	B-DIS
diseases	I-DIS
include	O
osteosarcoma	B-DIS
adrenocortical	I-DIS
cancer	I-DIS
central	I-DIS
nervous	I-DIS
system	I-DIS
tumor	I-DIS
and	O
soft	O
tissue	O
tumor	B-DIS
.	O

Additionally	O
leukemia	B-DIS
and	I-DIS
lymphoma	I-DIS
are	O
also	O
involved	O
.	O

LFS	O
patients	O
have	O
a	O
high	O
risk	O
to	O
suffer	O
secondary	O
or	O
even	O
multiple	O
cancers	B-DIS
.	O

Therefore	O
it	O
is	O
necessary	O
to	O
perform	O
genetic	O
detection	O
for	O
pediatric	O
cancer	B-DIS
patients	O
especially	O
those	O
with	O
hereditary	B-DIS
predisposition	O
cancers	B-DIS
.	O

TP53	O
mutation	O
often	O
indicates	O
poor	O
prognosis	O
so	O
it	O
is	O
important	O
to	O
take	O
active	O
treatment	O
and	O
systematic	O
monitoring	O
for	O
LFS	O
family	O
.	O

Identifying	O
which	O
factors	O
contribute	O
to	O
vitiligo	B-DIS
severity	O
and	O
determining	O
their	O
individual	O
weight	O
are	O
important	O
in	O
the	O
management	O
of	O
vitiligo	B-DIS
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
the	O
predictive	O
variables	O
concerning	O
vitiligo	B-DIS
severity	O
as	O
perceived	O
by	O
the	O
patients	O
.	O

Based	O
on	O
a	O
questionnaire	O
several	O
factors	O
that	O
may	O
contribute	O
to	O
the	O
Patient	O
Global	O
Assessment	O
PtGA	O
of	O
severity	O
were	O
investigated	O
within	O
a	O
Belgian	O
vitiligo	B-DIS
population	O
n	O
=	O
291	O
.	O

In	O
addition	O
possible	O
factors	O
influencing	O
vitiligo	B-DIS
severity	O
were	O
scored	O
and	O
ranked	O
.	O

The	O
strongest	O
correlations	O
with	O
the	O
PtGA	O
of	O
severity	O
were	O
found	O
for	O
impact	O
Dermatology	O
Life	O
Quality	O
Index	O
and	O
disease	O
extent	O
.	O

Based	O
on	O
multivariable	O
regression	O
analyses	O
64.7	B-STAT
%	I-STAT
of	O
PtGA	O
of	O
severity	O
could	O
be	O
predicted	O
by	O
subjective	O
and	O
objective	O
variables	O
while	O
32	B-STAT
%	I-STAT
could	O
be	O
explained	O
by	O
objective	O
clinical	O
features	O
only	O
.	O

Patients	O
considered	O
lesion	O
location	O
extent	O
and	O
disease	O
activity	O
as	O
the	O
most	O
important	O
contributing	O
factors	O
to	O
severity	O
.	O

Vitiligo	B-DIS
severity	O
is	O
determined	O
by	O
objective	O
clinical	O
features	O
but	O
also	O
for	O
a	O
significant	O
part	O
by	O
the	O
perceived	O
impact	O
of	O
the	O
disease	O
.	O

Although	O
West	B-LOC
Nile	I-LOC
virus	O
WNV	B-DIS
is	O
endemic	O
to	O
South	B-LOC
Africa	I-LOC
RSA	I-LOC
it	O
has	O
only	O
become	O
recognized	O
as	O
a	O
significant	O
cause	O
of	O
neurological	B-DIS
disease	I-DIS
in	O
humans	O
and	O
horses	O
locally	O
in	O
the	O
past	O
2	O
decades	O
as	O
it	O
emerged	O
globally	O
.	O

This	O
article	O
describes	O
the	O
epidemiological	O
and	O
clinical	O
presentation	O
of	O
WNV	B-DIS
in	O
horses	O
across	O
RSA	O
during	O
2016	O
-	O
2017	O
.	O

In	O
total	O
54	O
WNV	O
-	O
positive	O
cases	O
were	O
identified	O
by	O
passive	O
surveillance	O
in	O
horses	B-DIS
with	O
febrile	O
and/or	O
neurological	O
signs	O
at	O
the	O
Centre	O
for	O
Viral	O
Zoonoses	O
University	O
of	O
Pretoria	O
.	O

They	O
were	O
followed	O
up	O
and	O
compared	O
to	O
120	O
randomly	O
selected	O
WNV	O
-	O
negative	O
controls	O
with	O
the	O
same	O
case	O
definition	O
and	O
during	O
the	O
same	O
time	O
period	O
.	O

Of	O
the	O
WNV	O
-	O
positive	O
cases	O
52	B-STAT
%	B-DIS
had	O
fever	O
92	B-STAT
%	I-STAT
displayed	O
neurological	O
signs	O
and	O
39	B-STAT
%	I-STAT
experienced	O
mortality	O
.	O

Cases	O
occurred	O
mostly	O
in	O
WNV	O
-	O
unvaccinated	O
horses	O
<	O
5	O
years	O
old	O
during	O
late	O
summer	O
and	O
autumn	O
after	O
heavy	O
rain	O
in	O
the	O
temperate	O
to	O
warm	O
eastern	O
parts	O
of	O
RSA	O
.	O

WNV	O
-	O
positive	O
cases	O
that	O
had	O
only	O
neurological	O
signs	B-DIS
without	O
fever	O
were	O
more	O
likely	O
to	O
die	O
.	O

In	O
the	O
multivariable	O
analysis	O
the	O
odds	O
of	O
WNV	B-DIS
infection	I-DIS
were	O
associated	O
with	O
season	O
late	O
summer	O
higher	O
altitude	O
more	O
highly	O
purebred	O
animals	O
younger	O
age	O
and	O
failure	O
to	O
vaccinate	O
against	O
WNV	B-DIS
.	O

Vaccination	O
is	O
currently	O
the	O
most	O
effective	O
prophylactic	O
measure	O
to	O
reduce	O
WNV	B-DIS
morbidity	O
and	O
mortality	O
in	O
horses	O
.	O

Adrenocortical	B-DIS
carcinoma	I-DIS
ACC	O
is	O
a	O
rare	O
endocrine	B-DIS
malignancy	I-DIS
arising	O
from	O
the	O
adrenal	O
cortex	O
often	O
with	O
unexpected	O
biological	O
behavior	O
.	O

It	O
can	O
occur	O
at	O
any	O
age	O
with	O
two	O
peaks	O
of	O
incidence	B-EPI
in	O
the	O
first	O
and	O
between	O
fifth	O
and	O
seventh	O
decades	O
of	O
life	O
.	O

Although	O
ACC	O
are	O
mostly	O
hormonally	O
active	O
precursors	O
and	O
metabolites	O
rather	O
than	O
end	O
products	O
of	O
steroidogenesis	O
are	O
produced	O
by	O
dedifferentiated	O
and	O
immature	O
malignant	O
cells	O
.	O

Distinguishing	O
the	O
etiology	O
of	O
adrenal	B-DIS
mass	I-DIS
between	O
benign	O
adenomas	B-DIS
which	O
are	O
quite	O
frequent	O
in	O
general	O
population	O
and	O
malignant	B-DIS
carcinomas	I-DIS
with	O
dismal	O
prognosis	O
is	O
often	O
unfeasible	O
.	O

Even	O
after	O
pathohistological	O
analysis	O
diagnosis	O
of	O
adrenocortical	B-DIS
carcinomas	I-DIS
is	O
not	O
always	O
straightforward	O
and	O
represents	O
a	O
great	O
challenge	O
for	O
experienced	O
and	O
multidisciplinary	O
expert	O
teams	O
.	O

No	O
single	O
imaging	O
method	O
hormonal	O
work	O
-	O
up	O
or	O
immunohistochemical	O
labelling	O
can	O
definitively	O
prove	O
the	O
diagnosis	O
of	O
ACC	O
.	O

Over	O
several	O
decades	O
'	O
great	O
efforts	O
have	O
been	O
made	O
in	O
finding	O
novel	O
reliable	O
and	O
available	O
diagnostic	O
and	O
prognostic	O
factors	O
including	O
steroid	O
metabolome	O
profiling	O
or	O
target	O
gene	O
identification	O
.	O

Despite	O
these	O
achievements	O
the	O
5	O
-	O
year	O
mortality	O
rate	O
still	O
accounts	O
for	O
approximately	B-STAT
75	I-STAT
%	I-STAT
to	I-STAT
90	I-STAT
%	I-STAT
ACC	O
is	O
frequently	O
diagnosed	O
in	O
advanced	O
stages	O
and	O
therapeutic	O
options	O
are	O
unfortunately	O
limited	O
.	O

Therefore	O
imperative	O
is	O
to	O
identify	O
new	O
biological	O
markers	O
that	O
can	O
predict	O
patient	O
prognosis	O
and	O
provide	O
new	O
therapeutic	O
options	O
.	O

Background	O
Vitamin	O
D	O
deficiency	O
is	O
highly	O
prevalent	O
in	O
children	O
with	O
intestinal	B-DIS
failure	I-DIS
IF	O
who	O
receive	O
parenteral	O
nutrition	O
PN	O
but	O
data	O
on	O
vitamin	O
D	O
status	O
after	O
achieving	O
enteral	O
autonomy	O
EA	O
are	O
limited	O
.	O

We	O
aimed	O
to	O
evaluate	O
the	O
prevalence	B-EPI
of	O
vitamin	O
D	O
deficiency	O
in	O
this	O
population	O
while	O
exploring	O
clinical	O
variables	O
that	O
may	O
be	O
associated	O
with	O
its	O
development	O
.	O

Methods	O
A	O
retrospective	O
review	O
was	O
performed	O
on	O
29	O
children	O
with	O
IF	O
who	O
had	O
achieved	O
EA	O
.	O

Deficiency	O
was	O
defined	O
as	O
a	O
mean	O
serum	O
25	O
-	O
hydroxyvitamin	O
D	O
<	O
30	O
ng	O
/	O
ml	O
.	O

Data	O
results	O
Sixty	B-STAT
-	I-STAT
six	I-STAT
percent	I-STAT
of	O
children	O
had	O
at	O
least	O
one	O
deficient	O
level	O
during	O
the	O
study	O
period	O
with	O
38	B-STAT
%	I-STAT
being	O
deficient	O
based	O
on	O
the	O
mean	O
vitamin	O
D	O
levels	O
.	O

Eighty	B-STAT
-	I-STAT
four	I-STAT
percent	I-STAT
had	O
radiologic	O
evidence	B-DIS
of	O
osteopenia	O
.	O

Compared	O
with	O
the	O
sufficient	O
group	O
n=18	O
the	O
deficient	O
group	O
n=11	O
received	O
higher	O
daily	O
mean	O
vitamin	O
D	O
doses	O
2246	O
vs	O
920	O
IU	O
;	O
P=.02	O
had	O
shorter	O
remnant	O
small	O
-	O
bowel	O
length	O
53.8	O
vs	O
82.1	O
cm	O
;	O
P=.03	O
and	O
were	O
PN	O
dependent	O
for	O
a	O
longer	O
duration	O
1.3	O
vs	O
0.58	O
years	O
;	O
P=.01	O
.	O

Univariate	O
analyses	O
revealed	O
longer	O
remnant	O
gut	O
length	O
odds	O
ratio	O
[	O
OR	O
]	O
=	O
1.03	O
;	O
P=.04	O
and	O
shorter	O
duration	O
of	O
PN	O
OR	O
=	O
0.26	O
;	O
P=.04	O
to	O
be	O
significantly	O
associated	O
with	O
sufficient	O
vitamin	O
D	O
status	O
.	O

Conclusion	O
Vitamin	O
D	O
deficiency	O
and	O
osteopenia	B-DIS
are	O
highly	O
prevalent	O
in	O
pediatric	O
patients	O
with	O
a	O
history	O
of	O
IF	O
who	O
have	O
achieved	O
EA	O
despite	O
enteral	O
supplementation	O
with	O
higher	O
than	O
standard	O
doses	O
.	O

Shorter	O
remnant	O
small	O
-	O
bowel	O
length	O
and	O
longer	O
duration	O
of	O
PN	O
were	O
associated	O
with	O
vitamin	O
D	O
deficiency	O
.	O

These	O
findings	O
emphasize	O
the	O
importance	O
of	O
prolonged	O
surveillance	O
and	O
highlight	O
the	O
need	O
for	O
alternate	O
dosing	O
regimens	O
.	O

Background	O
Metabolic	B-DIS
syndrome	I-DIS
MetS	O
is	O
a	O
major	O
risk	O
factor	O
for	O
cardiovascular	B-DIS
diseases	I-DIS
.	O

The	O
objective	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
the	O
updated	O
prevalence	B-EPI
of	O
MetS	O
and	O
provide	O
a	O
comprehensive	O
illustration	O
of	O
the	O
possible	O
temporal	O
changes	O
in	O
MetS	O
prevalence	B-EPI
in	O
China	B-LOC
from	O
2011	O
to	O
2015	O
.	O

Methods	O
The	O
data	O
for	O
this	O
study	O
are	O
from	O
the	O
2011	O
and	O
2015	O
waves	O
of	O
the	O
China	O
Health	O
and	O
Retirement	O
Longitudinal	O
Study	O
CHARLS	O
.	O

CHARLS	O
is	O
a	O
nationally	O
representative	O
survey	O
targeting	O
populations	O
aged	O
45	O
and	O
above	O
from	O
28	O
provinces	O
in	O
mainland	O
China	B-LOC
.	O

A	O
total	O
of	O
11847	O
and	O
13013	O
participants	O
were	O
eligible	O
for	O
data	O
analysis	O
at	O
the	O
two	O
time	O
points	O
.	O

Results	O
The	O
estimated	O
prevalence	B-EPI
of	O
MetS	B-DIS
in	O
2015	O
was	O
20.41	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
19.02	B-STAT
-	I-STAT
21.8	I-STAT
%	I-STAT
by	O
the	O
National	O
Cholesterol	O
Education	O
Program	O
NCEP	O
Expert	O
Panel	O
on	O
Detection	O
Evaluation	O
and	O
Treatment	O
of	O
High	O
Blood	O
Cholesterol	O
in	O
Adults	O
ATP	O
III	O
criteria	O
34.77	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
33.12	O
-	O
36.42	B-STAT
%	I-STAT
by	O
the	O
International	O
Diabetes	B-DIS
Federation	O
IDF	O
criteria	O
39.68	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
37.88	B-STAT
-	I-STAT
41.47	I-STAT
%	I-STAT
by	O
the	O
revised	O
ATP	O
III	O
criteria	O
and	O
25.55	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
24.19	B-STAT
-	I-STAT
26.91	I-STAT
%	I-STAT
by	O
the	O
Chinese	O
Diabetes	B-DIS
Society	O
CDS	O
criteria	O
.	O

The	O
prevalence	B-EPI
was	O
higher	O
among	O
women	O
and	O
elderly	O
adults	O
and	O
in	O
urban	O
and	O
northern	O
populations	O
.	O

Furthermore	O
the	O
trends	O
in	O
the	O
prevalence	B-EPI
decreased	O
significantly	O
between	O
2011	O
and	O
2015	O
by	O
the	O
ATP	O
III	O
revised	O
ATP	O
III	O
and	O
CDS	O
criteria	O
.	O

However	O
trends	O
increased	O
significantly	O
from	O
2011	O
to	O
2015	O
by	O
the	O
IDF	O
criteria	O
.	O

Conclusions	O
A	O
higher	O
prevalence	B-EPI
of	O
MetS	B-DIS
is	O
found	O
in	O
those	O
who	O
reported	O
being	O
middle	O
aged	O
and	O
elderly	O
women	O
residing	O
in	O
northern	O
China	B-LOC
or	O
living	O
in	O
urban	O
areas	O
.	O

Additionally	O
temporal	O
changes	O
in	O
the	O
prevalence	B-EPI
of	O
MetS	O
varied	O
according	O
to	O
different	O
criteria	O
.	O

Increased	O
attention	O
to	O
the	O
causes	O
associated	O
with	O
populations	O
who	O
have	O
higher	O
levels	O
of	O
MetS	B-DIS
is	O
warranted	O
.	O

Q	B-DIS
fever	I-DIS
can	O
present	O
as	O
a	O
fever	B-DIS
of	O
unknown	O
aetiology	O
and	O
can	O
be	O
challenging	O
to	O
diagnose	O
because	O
of	O
the	O
rare	O
incidence	B-EPI
.	O

It	O
can	O
present	O
as	O
an	O
acute	O
illness	O
with	O
manifestations	O
including	O
influenza	O
-	O
like	B-DIS
symptoms	I-DIS
hepatitis	O
pneumonia	B-DIS
or	I-DIS
chronic	O
disease	O
involving	O
the	O
cardiovascular	O
system	O
.	O

We	O
present	O
a	O
case	O
of	O
a	O
39	O
-	O
year	O
-	O
old	O
woman	O
in	O
the	B-DIS
USA	I-DIS
who	I-DIS
developed	O
acute	O
Q	B-DIS
fever	O
with	O
associated	B-DIS
sepsis	O
and	O
severe	O
hepatitis	O
.	O

She	O
received	O
treatment	O
with	O
recovery	O
from	O
acute	B-DIS
infection	I-DIS
but	O
currently	O
has	O
symptoms	O
of	O
post	O
Q	B-DIS
fever	I-DIS
syndrome	I-DIS
.	O

Purpose	O
To	O
describe	O
the	O
molecular	O
epidemiology	O
of	O
nonsyndromic	B-DIS
retinitis	I-DIS
pigmentosa	I-DIS
RP	I-DIS
and	O
Usher	B-DIS
syndrome	I-DIS
US	B-LOC
in	O
Italian	O
patients	O
.	O

Methods	O
A	O
total	O
of	O
591	O
probands	O
315	O
with	O
family	O
history	O
and	O
276	O
sporadics	O
were	O
analyzed	O
.	O

For	O
155	O
of	O
them	O
we	O
performed	O
a	O
family	O
segregation	O
study	O
considering	O
a	O
total	O
of	O
382	O
relatives	O
.	O

Probands	O
were	O
analyzed	O
by	O
a	O
customized	O
multigene	O
panel	O
approach	O
.	O

Sanger	O
sequencing	O
was	O
used	O
to	O
validate	O
all	O
genetic	O
variants	O
and	O
to	O
perform	O
family	O
segregation	O
studies	O
.	O

Copy	O
number	O
variants	O
of	O
selected	O
genes	O
were	O
analyzed	O
by	O
multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
.	O

Four	O
patients	O
who	O
tested	O
negative	O
to	O
targeted	O
next	O
-	O
generation	O
sequencing	O
analysis	O
underwent	O
clinical	O
exome	O
sequencing	O
.	O

Results	O
The	O
mean	O
diagnostic	O
yield	O
of	O
molecular	O
testing	O
among	O
patients	O
with	O
a	O
family	O
history	O
of	O
retinal	B-DIS
disorders	I-DIS
was	O
55.2	B-STAT
%	I-STAT
while	O
the	O
diagnostic	O
yield	O
including	O
sporadic	O
cases	O
was	O
37.4	B-STAT
%	I-STAT
.	O

We	O
found	O
468	O
potentially	O
pathogenic	O
variants	O
147	O
of	O
which	O
were	O
unpublished	O
in	O
308	O
probands	O
and	O
66	O
relatives	O
.	O

Mean	O
ages	O
of	O
onset	O
of	O
the	O
different	O
classes	O
of	O
RP	O
were	O
autosomal	B-DIS
dominant	I-DIS
RP	I-DIS
19.3	O
±	O
12.6	O
years	O
;	O
autosomal	O
recessive	B-DIS
RP	I-DIS
23.2	O
±	O
16.6	O
years	O
;	O
X	O
-	O
linked	O
RP	O
13.9	O
±	O
9.9	O
years	O
;	B-DIS
and	I-DIS
Usher	O
syndrome	O
18.9	O
±	O
9.5	O
years	O
.	O

We	O
reported	O
potential	O
new	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
three	O
probands	O
two	O
revealed	O
by	O
TruSight	O
One	O
testing	O
.	O

All	O
three	O
probands	O
showed	O
isolated	O
RP	O
caused	O
by	O
biallelic	O
variants	O
in	O
genes	O
usually	O
associated	O
with	O
syndromes	O
such	O
as	O
PERCHING	O
and	O
Senior	O
-	O
Loken	O
or	B-DIS
with	I-DIS
retinal	I-DIS
dystrophy	I-DIS
iris	O
coloboma	O
and	B-DIS
comedogenic	O
acne	O
syndrome	O
.	O

Conclusions	O
This	O
is	O
the	O
largest	O
molecular	O
study	O
of	O
Italian	O
patients	O
with	O
RP	B-DIS
in	O
the	O
literature	O
thus	O
reflecting	O
the	O
epidemiology	O
of	O
the	O
disease	O
in	O
Italy	B-LOC
with	O
reasonable	O
accuracy	O
.	O

Diabetes	B-DIS
is	O
a	O
chronic	B-DIS
illness	I-DIS
.	O

Hyperglycemia	B-DIS
is	O
the	O
characteristic	O
of	O
this	O
disorder	O
.	O

Diabetes	B-DIS
is	O
a	O
global	O
crisis	O
which	O
affects	O
the	O
economy	O
and	O
health	O
of	O
all	O
nations	O
.	O

Over	O
the	O
last	O
decades	O
the	O
number	O
of	O
individuals	O
living	O
with	O
diabetes	B-DIS
has	O
significantly	O
increased	O
worldwide	O
.	O

Asia	B-LOC
is	O
a	O
key	O
epicenter	O
of	O
the	O
emerging	O
diabetes	B-DIS
epidemic	O
with	O
China	B-LOC
and	O
India	B-LOC
the	O
two	O
nations	O
having	O
the	O
highest	O
number	O
of	O
diabetic	B-DIS
people	O
.	O

Economic	O
development	O
modernization	O
unhealthy	O
diet	O
population	O
aging	O
and	O
sedentary	O
lifestyles	O
are	O
the	O
major	O
factors	O
responsible	O
for	O
the	O
increasing	O
diabetes	B-DIS
epidemic	O
.	O

Diabetes	B-DIS
is	O
associated	O
with	O
several	O
complications	O
and	O
cardiovascular	B-DIS
disease	I-DIS
is	O
the	O
most	O
important	O
cause	O
of	O
morbidity	O
and	O
mortality	O
among	O
people	O
with	O
diabetes	B-DIS
.	O

These	O
life	O
-	O
threatening	O
problems	O
can	O
be	O
prevented	O
or	O
delayed	O
by	O
proper	O
management	B-DIS
of	O
diabetes	O
.	O

Lifestyle	O
modification	O
is	O
an	O
important	O
factor	O
to	O
decrease	O
the	O
diabetes	B-DIS
risk	O
.	O

The	O
frequency	O
of	O
diabetic	B-DIS
complications	I-DIS
will	O
rise	O
if	O
there	O
is	O
a	O
lack	O
of	O
cost	O
-	O
effective	O
and	O
sustainable	O
interventions	O
.	O

Hence	O
prevention	O
of	O
diabetes	B-DIS
and	O
its	O
complications	O
such	O
as	O
diabetic	B-DIS
retinopathy	I-DIS
and	O
cardiovascular	B-DIS
disease	I-DIS
should	O
be	O
a	O
crucial	O
part	O
of	O
all	O
future	O
health	O
-	O
related	O
public	O
policies	O
among	O
all	O
nations	O
.	O

This	O
review	O
summarizes	O
current	O
epidemiological	O
aspects	O
of	O
diabetes	B-DIS
in	O
the	O
world	O
along	O
with	O
its	O
complications	O
preventive	O
measures	O
and	O
treatment	O
.	O

Genetic	O
testing	O
is	O
used	O
to	O
optimise	O
the	O
management	O
of	O
inherited	O
cardiovascular	B-DIS
disorders	I-DIS
that	O
can	O
cause	O
sudden	B-DIS
cardiac	I-DIS
death	I-DIS
.	O

Yet	O
more	O
genotype	O
-	O
phenotype	O
correlation	O
studies	O
from	O
populations	O
not	O
ascertained	O
on	O
clinical	O
symptoms	O
or	O
family	O
history	O
of	O
disease	O
are	O
required	O
to	O
improve	O
understanding	O
of	O
gene	O
penetrance	O
.	O

We	O
performed	O
targeted	O
sequencing	O
of	O
25	O
genes	O
used	O
routinely	O
in	O
clinical	O
genetic	O
testing	O
for	O
inherited	O
cardiovascular	B-DIS
disorders	I-DIS
in	O
a	O
population	O
of	O
13131	O
asymptomatic	O
older	O
individuals	O
mean	O
age	O
75	O
years	O
enrolled	O
in	O
the	O
ASPREE	O
trial	O
.	O

Participants	O
had	O
no	O
prior	O
history	O
of	O
cardiovascular	B-DIS
disease	I-DIS
events	O
dementia	B-DIS
or	O
physical	B-DIS
disability	I-DIS
at	O
enrolment	O
.	O

Variants	O
were	O
classified	O
following	O
ACMG	O
/	O
AMP	O
standards	O
.	O

Sudden	O
and	O
rapid	O
cardiac	B-DIS
deaths	I-DIS
were	O
clinically	O
adjudicated	O
as	O
ASPREE	O
trial	O
endpoints	O
and	O
assessed	O
during	O
mean	O
4.7	O
years	O
of	O
follow	O
-	O
up	O
.	O

In	O
total	O
119	O
participants	O
had	O
pathogenic	O
/	O
deleterious	O
variants	B-STAT
in	I-STAT
one	I-STAT
of	I-STAT
the	O
25	O
genes	O
analysed	O
carrier	O
rate	B-STAT
of	I-STAT
1	I-STAT
in	O
110	O
or	O
0.9	B-STAT
%	I-STAT
.	O

Participants	O
carried	O
variants	O
associated	O
with	O
hypertrophic	B-DIS
cardiomyopathy	I-DIS
N	I-DIS
=	O
24	O
dilated	B-DIS
cardiomyopathy	I-DIS
N	O
=	O
29	O
arrhythmogenic	B-DIS
right	I-DIS
-	I-DIS
ventricular	I-DIS
cardiomyopathy	O
N	O
=	O
22	O
catecholaminergic	B-DIS
polymorphic	I-DIS
ventricular	O
tachycardia	B-DIS
N	I-DIS
=	I-DIS
4	I-DIS
aortopathies	O
N	O
=	O
1	B-DIS
and	I-DIS
long	I-DIS
-	O
QT	O
syndrome	O
N	O
=	O
39	O
.	O

Among	O
119	O
carriers	O
two	O
died	O
from	O
presumed	O
sudden	O
/	O
rapid	O
cardiac	O
deaths	O
during	O
follow	O
-	O
up	O
1.7	B-STAT
%	I-STAT
;	O
both	O
with	B-DIS
pathogenic	I-DIS
variants	O
in	O
long	O
-	O
QT	O
syndrome	O
genes	O
KCNQ1	O
SCN5A	O
.	O

Among	O
non	O
-	O
carriers	O
the	O
rate	O
of	O
sudden	O
/	O
rapid	O
cardiac	O
deaths	O
was	O
significantly	B-STAT
lower	O
0.08	B-STAT
%	I-STAT
11/12936	O
p	O
<	O
0.001	O
.	O

Variants	O
associated	O
with	O
inherited	O
cardiovascular	B-DIS
disorders	I-DIS
are	O
found	O
in	O
asymptomatic	O
individuals	O
aged	O
70	O
years	O
and	O
older	O
without	O
a	O
history	O
of	O
cardiovascular	B-DIS
disease	I-DIS
.	O

Study	O
objectives	O
The	O
primary	O
objective	O
was	O
to	O
describe	O
trends	O
in	O
the	O
2	O
-	O
year	O
limited	B-EPI
duration	O
prevalence	B-DIS
of	O
narcolepsy	O
from	O
2013	O
-	O
2016	O
in	O
a	O
large	O
insured	O
population	O
with	O
claims	O
activity	O
.	O

Secondary	O
objectives	O
were	O
to	O
assess	O
the	O
prevalence	B-EPI
of	O
other	O
sleep	B-DIS
disorders	I-DIS
and	O
the	O
frequency	O
of	O
diagnostic	O
sleep	O
testing	O
.	O

Methods	O
Nationwide	O
medical	O
/	O
prescription	O
claims	O
Symphony	O
Health	O
were	O
analyzed	O
to	O
estimate	O
the	B-EPI
annual	O
prevalence	O
per	O
100000	O
persons	B-DIS
of	O
narcolepsy	O
and	B-DIS
other	I-DIS
sleep	I-DIS
disorders	I-DIS
obstructive	I-DIS
sleep	I-DIS
apnea	I-DIS
idiopathic	O
hypersomnia	O
rapid	B-DIS
eye	I-DIS
movement	I-DIS
sleep	I-DIS
behavior	O
disorder	O
periodic	B-DIS
limb	I-DIS
movement	O
disorder	O
and	O
the	O
frequency	O
of	O
diagnostic	O
sleep	O
testing	O
.	O

Prevalence	B-EPI
was	O
adjusted	O
to	O
the	O
age	O
/	O
sex	O
distribution	O
of	O
the	O
2016	O
US	B-LOC
census	O
estimates	O
.	O

Results	O
The	O
prevalence	B-EPI
of	O
narcolepsy	B-DIS
per	O
100000	O
persons	O
increased	O
14	B-STAT
%	I-STAT
from	O
38.9	O
in	O
2013	O
to	O
44.3	O
in	O
2016	O
.	O

Obstructive	O
sleep	O
apnea	B-DIS
prevalence	B-EPI
increased	O
41	B-STAT
%	I-STAT
over	O
the	O
study	O
period	O
from	O
2429	O
to	O
3420	O
per	O
100000	O
.	O

Large	O
increases	O
in	O
prevalence	B-EPI
were	O
also	O
seen	O
for	O
idiopathic	B-DIS
hypersomnia	I-DIS
32	B-STAT
%	I-STAT
periodic	O
limb	O
movement	B-DIS
disorder	I-DIS
30	B-STAT
%	I-STAT
and	O
rapid	O
eye	O
movement	B-DIS
sleep	I-DIS
behavior	I-DIS
disorder	I-DIS
64	B-STAT
%	I-STAT
.	O

For	O
each	O
sleep	B-DIS
disorder	I-DIS
prevalence	B-EPI
was	O
higher	O
for	O
those	O
with	O
commercial	O
insurance	O
versus	O
Medicare	O
/	O
Medicaid	O
and	O
markedly	B-EPI
lower	O
prevalence	O
was	O
observed	O
for	O
the	O
Northeast	B-LOC
compared	O
with	O
the	B-LOC
Midwest	I-LOC
South	I-LOC
and	O
Western	B-LOC
US	I-LOC
regions	O
.	O

The	O
frequency	O
of	O
multiple	O
sleep	O
latency	O
/	O
maintenance	O
of	O
wakefulness	O
testing	O
declined	O
by	O
20	B-STAT
%	I-STAT
and	O
polysomnography	O
declined	O
by	O
15	B-STAT
%	I-STAT
.	O

Conversely	O
home	O
sleep	O
apnea	B-DIS
testing	O
increased	O
by	O
117	B-STAT
%	I-STAT
.	O

Conclusions	O
The	O
prevalence	B-EPI
of	O
narcolepsy	B-DIS
obstructive	I-DIS
sleep	I-DIS
apnea	I-DIS
and	O
the	O
other	O
sleep	B-DIS
disorders	I-DIS
increased	O
appreciably	O
over	O
the	O
2013	O
-	O
2016	O
period	O
.	O

It	O
remains	O
to	O
be	O
determined	O
whether	O
the	O
trends	O
seen	O
in	O
our	O
analyses	O
are	O
due	O
to	O
increased	O
incidence	B-EPI
or	O
increased	O
awareness	O
of	O
these	O
conditions	O
.	O

Significant	O
part	O
of	O
Southeastern	B-LOC
Europe	I-LOC
with	O
a	O
population	O
of	O
76	O
million	O
has	O
newborn	O
screening	O
NBS	O
programs	O
non	O
-	O
harmonized	O
with	O
developed	O
European	O
countries	O
.	O

Initial	O
survey	O
was	O
conducted	O
in	O
2013/2014	B-STAT
among	O
11	O
countries	O
from	O
the	O
region	O
Albania	B-LOC
Bulgaria	B-LOC
Bosnia	I-LOC
and	O
Herzegovina	B-LOC
BIH	I-LOC
Croatia	B-LOC
Kosovo	B-LOC
Macedonia	B-LOC
Moldova	B-LOC
Montenegro	B-LOC
Romania	B-LOC
Serbia	I-LOC
and	O
Slovenia	B-LOC
to	O
assess	O
the	O
main	O
characteristics	O
of	O
their	O
NBS	O
programs	O
and	O
their	O
future	O
plans	O
.	O

Their	O
cumulative	O
population	O
at	O
that	O
time	O
was	O
~525	O
million	O
.	O

At	O
that	O
time	O
none	O
of	O
the	O
countries	O
had	O
an	O
expanded	O
NBS	O
program	O
while	O
phenylketonuria	O
screening	O
was	O
not	O
introduced	O
in	O
four	O
and	O
congenital	B-DIS
hypothyroidism	I-DIS
in	O
three	O
of	O
11	O
countries	O
.	O

We	O
repeated	O
the	O
survey	O
in	O
2020	O
inviting	O
the	O
same	O
11	O
countries	O
adding	O
Cyprus	B-LOC
Greece	I-LOC
Hungary	I-LOC
and	O
Malta	B-LOC
due	O
to	O
their	O
geographical	O
position	O
in	O
the	O
wider	O
region	O
.	O

The	O
aims	O
were	O
to	O
assess	O
the	O
current	O
state	O
to	O
evaluate	O
the	O
change	O
in	O
the	O
period	O
and	O
to	O
identify	O
the	O
main	O
obstacles	O
impacting	O
the	O
implementation	O
of	O
expanded	O
NBS	O
and/or	O
reaching	O
a	O
wider	O
population	O
.	O

Responses	O
were	O
collected	O
from	O
12	O
countries	O
BIH	O
-	O
Federation	O
of	O
BIH	O
BIH	O
-	O
Republic	O
of	O
Srpska	B-LOC
Bulgaria	B-LOC
Croatia	B-LOC
Greece	B-LOC
Hungary	B-LOC
Kosovo	B-LOC
North	B-LOC
Macedonia	I-LOC
Malta	B-LOC
Montenegro	B-LOC
Romania	B-LOC
Serbia	O
Slovenia	B-LOC
with	O
a	O
population	O
of	O
68.5	O
million	O
.	O

The	O
results	O
of	O
the	O
survey	O
showed	O
that	O
the	O
regional	O
situation	O
regarding	O
NBS	O
only	O
modestly	O
improved	O
in	O
this	O
period	O
.	O

All	O
of	O
the	O
surveyed	O
countries	O
except	O
Kosovo	B-LOC
screened	O
for	O
at	O
least	O
congenital	B-DIS
hypothyroidism	I-DIS
while	O
phenylketonuria	B-DIS
was	O
not	O
screened	O
in	O
four	O
of	O
12	O
countries	O
.	O

Croatia	B-LOC
and	O
Slovenia	B-LOC
implemented	O
an	O
expanded	O
NBS	O
program	O
using	O
tandem	O
mass	O
spectrometry	O
from	O
the	O
time	O
of	O
last	O
survey	O
.	O

In	O
conclusion	O
the	O
current	O
status	O
of	O
NBS	O
programs	O
in	O
Southeastern	B-LOC
Europe	I-LOC
is	O
very	O
variable	O
and	O
is	O
still	O
underdeveloped	O
or	O
even	O
non	O
-	O
existent	O
in	O
some	O
of	O
the	O
countries	O
.	O

We	O
suggest	O
establishing	O
an	O
international	O
task	O
-	O
force	O
to	O
assist	O
with	O
implementation	O
and	O
harmonization	O
of	O
basic	O
NBS	O
services	O
where	O
needed	O
.	O

Sexual	O
activity	O
during	O
adolescence	O
can	O
lead	O
to	O
unwanted	O
pregnancy	O
which	O
in	O
turn	O
can	O
result	O
in	O
serious	O
maternal	O
and	O
fetal	O
complications	O
.	O

The	O
present	O
study	O
aimed	O
to	O
evaluate	O
the	O
complications	O
related	O
to	O
adolescent	O
pregnancy	O
through	O
a	O
systematic	O
review	O
using	O
the	O
Medical	O
Subject	O
Headings	O
`	O
`	O
pregnancy	O
complication	O
''	O
AND	O
`	O
`	O
adolescent	O
''	O
OR	O
`	O
`	O
pregnancy	O
in	O
adolescence	O
''	O
.	O

Only	O
full	O
original	O
articles	O
in	O
English	O
or	O
Portuguese	O
with	O
a	O
clearly	O
described	O
methodology	O
were	O
included	O
.	O

No	O
qualitative	O
studies	O
reviews	O
or	O
meta	O
-	O
analyses	O
editorials	O
case	O
series	O
or	O
case	O
reports	O
were	O
included	O
.	O

The	O
sample	O
consisted	O
of	O
15	O
articles	O
;	O
in	O
that	O
10	O
were	O
cross	O
-	O
sectional	O
and	O
5	O
were	O
cohort	O
studies	O
.	O

The	O
overall	O
prevalence	B-EPI
of	O
adolescent	O
pregnancy	O
was	O
10	B-STAT
%	I-STAT
and	O
among	O
the	O
Brazilian	O
studies	O
the	O
adolescent	O
pregnancy	O
rate	O
was	O
26	B-STAT
%	I-STAT
.	O

The	O
cesarean	O
delivery	O
rate	O
was	O
lower	O
than	O
that	O
reported	O
in	O
the	O
general	O
population	O
.	O

The	O
main	O
maternal	O
and	O
neonatal	O
complications	O
were	O
hypertensive	B-DIS
disorders	I-DIS
of	I-DIS
pregnancy	I-DIS
prematurity	I-DIS
and	O
low	O
birth	O
weight	O
respectively	O
.	O

Adolescent	O
pregnancy	O
is	O
related	O
to	O
increased	O
frequency	O
of	O
neonatal	O
and	O
maternal	O
complications	O
and	O
lower	O
prevalence	B-EPI
of	O
cesarean	O
delivery	O
.	O

Genetic	O
predisposition	O
has	O
been	O
always	O
noted	O
in	O
the	O
context	O
of	O
familial	B-DIS
hematological	I-DIS
malignancies	I-DIS
.	O

Epidemiological	O
studies	O
have	O
provided	O
evidence	O
consisting	O
of	O
an	O
increased	O
risk	O
to	O
develop	O
blood	B-DIS
cancer	I-DIS
in	O
relatives	O
diagnosed	O
with	O
the	O
same	O
pathology	O
and	O
characterized	O
by	O
early	O
age	O
at	O
diagnosis	O
and	O
higher	O
severity	O
compared	O
to	O
sporadic	O
forms	O
.	O

With	O
the	O
emergence	O
of	O
new	O
genomic	O
testing	O
approaches	O
the	O
prevalence	B-EPI
of	O
familial	B-DIS
aggregations	I-DIS
of	I-DIS
hematological	I-DIS
malignancies	I-DIS
seems	O
to	O
be	O
under	O
estimated	O
.	O

The	O
heterogeneity	O
of	O
clinical	O
features	O
explains	O
the	O
wide	O
number	O
of	O
genes	O
'	O
mutations	O
reported	O
to	O
date	O
and	O
the	O
variable	O
penetrance	O
of	O
variants	O
.	O

Nevertheless	O
the	O
genetic	O
basis	O
of	O
familial	B-DIS
hematological	I-DIS
malignancies	I-DIS
is	O
still	O
not	O
well	O
understood	O
.	O

Identifying	O
the	O
genetic	O
background	O
in	O
familial	B-DIS
aggregations	I-DIS
provides	O
a	O
valuable	O
tool	O
for	O
prognostic	O
evaluation	O
personalized	O
treatment	O
and	O
better	O
genetic	O
counseling	O
in	O
high	O
-	O
risk	O
families	O
.	O

Herein	O
we	O
provide	O
an	O
overview	O
of	O
genes	O
reported	O
in	O
the	O
last	O
few	O
years	O
in	O
association	O
to	O
hematological	B-DIS
malignancies	I-DIS
including	O
familial	O
form	O
of	O
Hodgkin	B-DIS
Lymphoma	I-DIS
Non	I-DIS
-	I-DIS
Hodgkin	O
Lymphoma	B-DIS
Chronic	I-DIS
Lymphocytic	I-DIS
Leukemia	I-DIS
acute	I-DIS
Myeloid	O
Leukemia	B-DIS
and	I-DIS
acute	I-DIS
Lymphoblastic	O
Leukemia	O
.	O

AIMThe	O
aim	O
of	O
this	O
study	O
was	O
to	O
develop	O
an	O
algorithm	O
to	O
prompt	O
early	O
clinical	O
suspicion	O
of	O
mucopolysaccharidosis	B-DIS
type	O
I	O
MPS	O
I	O
.	O

METHODSAn	O
international	O
working	O
group	O
was	O
established	O
in	O
2016	O
that	O
comprised	O
11	O
experts	O
in	O
paediatrics	O
rare	O
diseases	O
and	O
inherited	O
metabolic	B-DIS
diseases	I-DIS
.	O

They	O
reviewed	O
real	O
-	O
world	O
clinical	O
cases	O
selected	O
key	O
signs	O
or	O
symptoms	O
based	O
on	B-EPI
their	O
prevalence	O
and	O
specificity	O
and	O
reached	O
consensus	O
about	O
the	O
algorithm	O
.	O

The	O
algorithm	O
was	O
retrospectively	O
tested	O
.	O

RESULTSAn	O
algorithm	O
was	O
developed	O
.	O

In	O
patients	O
under	O
two	O
years	O
of	O
age	O
kyphosis	B-DIS
or	O
gibbus	B-DIS
deformity	O
were	O
the	O
key	O
symptoms	O
that	O
raised	O
clinical	O
suspicion	O
of	O
MPS	O
I	O
and	O
in	O
those	O
over	O
two	O
years	O
they	O
were	O
kyphosis	B-DIS
or	O
gibbus	B-DIS
deformity	O
or	O
joint	O
stiffness	O
or	O
contractures	O
without	O
inflammation	B-DIS
.	O

The	O
algorithm	O
was	O
tested	O
on	O
35	O
cases	O
comprising	O
16	O
Hurler	O
10	O
Hurler	B-DIS
-	O
Scheie	O
and	B-DIS
nine	O
Scheie	O
patients	O
.	O

Of	O
these	O
35	O
cases	O
3291	B-STAT
%	I-STAT
-	O
16	O
Hurler	B-DIS
nine	O
Hurler	B-DIS
-	O
Scheie	O
and	B-DIS
seven	O
Scheie	O
patients	O
-	O
would	O
have	O
been	O
referred	O
earlier	O
if	O
the	O
algorithm	O
had	O
been	O
used	O
.	O

CONCLUSIONThe	O
expert	O
panel	O
developed	O
and	O
tested	O
an	O
algorithm	O
that	O
helps	O
raise	O
clinical	O
suspicion	O
of	O
MPS	O
I	O
and	O
would	O
lead	O
to	O
a	O
more	O
prompt	O
final	O
diagnosis	O
and	O
allow	O
earlier	O
treatment	O
.	O

Background	O
The	O
incidence	B-EPI
of	O
hydrocephalus	B-DIS
in	O
the	O
spinal	B-DIS
muscular	I-DIS
atrophy	I-DIS
SMA	O
population	O
relative	O
to	O
the	O
general	O
population	O
is	O
currently	O
unknown	O
.	O

Since	O
the	O
approval	O
of	O
nusinersen	O
an	O
intrathecally	O
administered	O
drug	O
for	O
SMA	B-DIS
a	I-DIS
small	I-DIS
number	I-DIS
of	O
hydrocephalus	B-DIS
cases	O
among	O
nusinersen	O
users	O
have	O
been	O
reported	O
.	O

Currently	O
the	O
incidence	B-EPI
of	O
hydrocephalus	B-DIS
in	O
untreated	O
SMA	B-DIS
patients	O
is	O
not	O
available	O
thereby	O
making	O
it	O
difficult	O
to	O
determine	O
if	O
hydrocephalus	B-DIS
is	O
a	O
side	O
effect	O
of	O
nusinersen	O
or	O
part	O
of	O
SMA	O
's	O
natural	O
history	O
.	O

This	O
retrospective	O
matched	O
cohort	O
study	O
used	O
electronic	O
health	O
records	O
EHRs	O
to	O
estimate	O
and	O
compare	O
the	O
incidence	B-EPI
of	O
hydrocephalus	B-DIS
in	O
both	O
SMA	B-DIS
patients	O
and	O
matched	O
non	O
-	O
SMA	O
controls	O
in	O
the	O
time	O
period	O
prior	O
to	O
the	O
approval	O
of	O
nusinersen	O
.	O

Methods	O
The	O
U.S.	B-LOC
Optum	O
®	O
de	O
-	O
identified	O
EHR	O
database	O
contains	O
records	O
for	O
approximately	O
100	O
million	O
persons	O
.	O

The	O
current	O
study	O
period	O
spanned	O
January	O
12007	O
-	O
December	O
222016	O
.	O

Patients	O
with	O
SMA	B-DIS
were	O
identified	O
by	O
one	O
or	O
more	O
International	O
Classification	O
of	O
Diseases	B-DIS
ICD	I-DIS
-9	I-DIS
and/or	I-DIS
ICD-10	I-DIS
codes	I-DIS
for	O
SMA	O
appearing	O
as	O
primary	O
admission	O
or	O
discharge	O
diagnoses	O
without	O
a	O
pregnancy	O
diagnostic	O
code	O
in	O
the	O
1	O
-	O
year	O
time	O
before	O
and	O
after	O
the	O
first	O
occurrence	B-DIS
of	O
SMA	O
.	O

The	O
first	O
occurrence	O
of	O
SMA	B-DIS
defined	O
the	O
index	O
date	O
and	O
non	O
-	O
SMA	O
controls	O
were	O
matched	O
to	O
cases	O
.	O

Incident	O
cases	O
of	O
hydrocephalus	B-DIS
were	O
identified	O
with	O
one	O
or	O
more	O
ICD-9	B-LOC
and/or	O
ICD-10	O
code	O
for	O
any	O
type	O
of	O
hydrocephalus	B-DIS
following	O
the	O
index	O
date	O
.	O

Hydrocephalus	B-DIS
incidence	B-EPI
rates	O
per	O
person	O
-	O
months	O
and	B-EPI
the	O
incidence	O
rate	O
ratio	O
comparing	O
SMA	O
cases	O
with	O
non	O
-	O
SMA	O
controls	O
were	O
calculated	O
.	O

Results	O
There	O
were	O
5354	O
SMA	O
cases	O
and	O
an	O
equal	O
number	O
of	O
matched	O
non	O
-	O
SMA	O
controls	O
.	O

Incident	O
hydrocephalus	B-DIS
events	O
were	O
identified	O
in	O
42	O
SMA	B-DIS
cases	O
and	O
9	O
non	O
-	O
SMA	O
controls	O
.	O

Hydrocephalus	B-DIS
incidence	B-EPI
rates	O
per	O
100000	O
person	O
-	O
months	O
were	O
15.595	B-STAT
%	I-STAT
CI	O
11.2	O
-	O
20.9	O
among	O
SMA	O
cases	O
and	O
3.395	B-STAT
%	I-STAT
CI	O
1.5	O
-	O
6.3	O
among	O
non	O
-	O
SMA	O
controls	O
.	O

The	O
incidence	B-EPI
rate	O
ratio	O
was	O
4.795	B-STAT
%	I-STAT
CI	O
2.4	O
-	O
10.2	O
.	O

Conclusions	O
Based	O
on	O
this	O
retrospective	O
analysis	O
utilizing	O
US	B-LOC
EHR	O
data	O
SMA	B-DIS
patients	O
had	O
an	O
approximately	O
fourfold	O
increased	O
risk	O
of	O
hydrocephalus	B-DIS
compared	O
with	O
non	O
-	O
SMA	O
controls	O
in	O
the	O
era	O
preceding	O
nusinersen	O
treatment	O
.	O

This	O
study	O
may	O
assist	O
in	O
properly	O
evaluating	O
adverse	O
events	O
in	O
nusinersen	O
-	B-DIS
treated	O
SMA	O
patients	O
.	O

Context	O
Patients	O
with	O
pseudohypoparathyroidism	B-DIS
type	O
1b	O
PHP1b	O
show	O
disordered	O
imprinting	O
of	O
the	O
maternal	O
GNAS	B-DIS
allele	O
or	O
paternal	O
uniparental	O
disomy	O
UPD	B-DIS
.	O

Genetic	O
deletions	O
in	O
STX16	O
or	O
in	O
upstream	O
exons	O
of	O
GNAS	B-DIS
are	O
present	O
in	O
many	O
familial	O
but	O
not	O
sporadic	O
cases	O
.	O

Objective	O
Characterization	O
of	O
epigenetic	O
and	O
genetic	O
defects	O
in	O
patients	O
with	O
PHP1b	B-DIS
.	O

Design	O
and	O
patients	O
DNA	O
from	O
84	O
subjects	O
including	O
26	O
subjects	O
with	O
sporadic	O
PHP1b	O
27	O
affected	O
subjects	O
and	O
17	O
unaffected	O
and/or	O
obligate	O
gene	O
carriers	O
from	O
12	O
PHP1b	B-DIS
families	O
11	O
healthy	O
individuals	O
and	O
3	O
subjects	O
with	O
PHP1a	B-DIS
was	O
subjected	O
to	O
quantitative	O
pyrosequencing	O
of	O
GNAS	B-DIS
differentially	O
methylated	O
regions	O
DMRs	O
microarray	O
analysis	O
and	O
microsatellite	O
haplotype	O
analysis	O
.	O

Setting	O
Academic	O
medical	O
center	O
.	O

Main	O
outcome	O
measurements	O
Molecular	O
pathology	O
of	O
PHP1b	B-DIS
.	O

Results	O
Healthy	O
subjects	O
unaffected	O
family	O
members	O
and	O
obligate	O
carriers	O
of	O
paternal	B-DIS
PHP1b	I-DIS
alleles	O
and	O
subjects	O
with	O
PHP1a	B-DIS
showed	O
normal	O
methylation	O
of	O
all	O
DMRs	O
.	O

All	O
PHP1b	B-DIS
subjects	O
showed	O
loss	O
of	O
methylation	O
LOM	O
at	O
the	O
exon	O
A	O
/	O
B	O
DMR	O
.	O

Affected	O
members	O
of	O
nine	O
PHP1b	B-DIS
kindreds	I-DIS
showed	O
LOM	O
only	O
at	O
the	O
exon	O
A	O
/	O
B	O
DMR	O
which	O
was	O
associated	O
with	O
a	O
3	O
-	O
kb	O
deletion	O
of	O
STX16	O
exons	O
4	O
-	O
6	O
in	O
seven	O
families	O
and	O
a	O
novel	O
deletion	O
of	O
STX16	O
and	O
adjacent	O
NEPEPL1	O
in	O
one	O
family	O
.	O

A	O
novel	O
NESP	O
deletion	O
was	O
found	O
in	O
one	O
of	O
two	O
other	O
families	O
with	O
more	O
extensive	O
methylation	O
defects	O
.	O

One	O
sporadic	O
PHP1b	B-DIS
had	O
UPD	B-DIS
of	I-DIS
20q	I-DIS
two	O
had	O
3	O
-	O
kb	O
STX16	O
deletions	O
and	O
five	O
had	O
apparent	O
epigenetic	O
mosaicism	O
.	O

Conclusions	O
We	O
found	O
diverse	O
patterns	O
of	O
defective	O
methylation	O
and	O
identified	O
novel	O
or	O
previously	O
known	O
mutations	O
in	O
9	O
of	O
12	O
PHP1b	B-DIS
families	O
.	O

Purpose	O
of	O
review	O
In	O
this	O
review	O
we	O
report	O
on	O
the	O
state	O
of	O
knowledge	O
about	O
human	B-DIS
Q	I-DIS
fever	I-DIS
in	O
Brazil	B-LOC
and	O
on	O
the	O
Guiana	O
Shield	O
an	O
Amazonian	O
region	O
located	O
in	O
northeastern	O
South	B-LOC
America	I-LOC
.	O

There	O
is	O
a	O
contrast	O
between	O
French	O
Guiana	B-LOC
where	O
the	O
incidence	B-EPI
of	O
this	O
disease	O
is	O
the	O
highest	O
in	O
the	O
world	O
and	O
other	O
countries	O
where	O
this	O
disease	O
is	O
practically	O
non	O
-	O
existent	O
.	O

Recent	O
findings	O
Recent	O
findings	O
are	O
essentially	O
in	O
French	O
Guiana	B-LOC
where	O
a	O
unique	O
strain	O
MST17	O
has	O
been	O
identified	O
;	O
it	O
is	O
probably	O
more	O
virulent	O
than	O
those	O
usually	O
found	O
with	O
a	O
particularly	O
marked	O
pulmonary	B-DIS
tropism	I-DIS
a	O
mysterious	O
animal	O
reservoir	O
a	O
geographical	O
distribution	O
that	O
raises	O
questions	O
.	O

Summary	B-DIS
Q	I-DIS
fever	I-DIS
is	O
a	O
bacterial	B-DIS
zoonosis	I-DIS
due	O
to	O
Coxiella	O
burnetii	O
that	O
has	O
been	O
reported	O
worldwide	O
.	O

On	O
the	O
Guiana	O
Shield	O
a	O
region	O
mostly	O
covered	O
by	O
Amazonian	O
forest	O
which	O
encompasses	O
the	O
Venezuelan	O
State	O
of	O
Bolivar	O
Guyana	O
Suriname	B-LOC
French	O
Guiana	B-LOC
and	O
the	O
Brazilian	O
State	O
of	O
Amapá	O
the	O
situation	O
is	O
very	O
heterogeneous	O
.	O

While	O
French	O
Guiana	B-LOC
is	O
the	O
region	O
reporting	O
the	O
highest	O
incidence	B-EPI
of	O
this	O
disease	O
in	O
the	O
world	O
with	O
a	O
single	O
infecting	O
clone	O
MST	O
117	O
and	O
a	O
unique	O
epidemiological	O
cycle	O
it	O
has	O
hardly	O
ever	O
been	O
reported	O
in	O
other	O
countries	O
in	O
the	O
region	O
.	O

This	O
absence	O
of	O
cases	O
raises	O
many	O
questions	O
and	O
is	O
probably	O
due	O
to	O
massive	O
under	O
-	O
diagnosis	O
.	O

Studies	O
should	O
estimate	O
comprehensively	O
the	O
true	O
burden	O
of	O
this	O
disease	O
in	O
the	O
region	O
.	O

Aims	O
Medullary	B-DIS
carcinoma	I-DIS
is	O
an	O
uncommon	O
colorectal	B-DIS
tumour	I-DIS
which	O
appears	O
poorly	O
differentiated	O
histologically	O
.	O

Consequently	O
it	O
may	O
be	O
confused	O
with	O
poorly	O
differentiated	O
adenocarcinoma	B-DIS
not	O
otherwise	O
specified	O
NOS	O
.	O

The	O
principal	O
aim	O
of	O
this	O
study	O
was	O
to	O
review	O
a	O
large	O
series	O
of	O
poorly	O
differentiated	O
colorectal	B-DIS
cancers	I-DIS
resected	O
at	O
a	O
large	O
National	O
Health	O
Service	O
NHS	O
Teaching	O
Hospital	O
to	O
determine	O
how	O
often	O
medullary	B-DIS
carcinomas	I-DIS
were	O
misclassified	O
.	O

Secondary	O
aims	O
were	O
to	O
investigate	O
how	O
often	O
neuroendocrine	O
differentiation	O
or	O
metastatic	O
tumours	B-DIS
were	O
considered	O
in	O
the	O
differential	O
diagnosis	O
and	O
compare	O
clinico	O
-	O
pathological	O
features	O
between	O
medullary	O
and	O
poorly	B-DIS
differentiated	O
adenocarcinoma	O
NOS	O
.	O

Methods	O
and	O
results	O
Histology	O
slides	O
from	O
302	O
colorectal	B-DIS
cancer	I-DIS
resections	O
originally	O
reported	O
as	O
poorly	O
differentiated	O
adenocarcinoma	B-DIS
were	O
reviewed	O
and	O
cases	O
fulfilling	O
World	O
Health	O
Organisation	O
WHO	O
criteria	O
for	O
medullary	B-DIS
carcinoma	I-DIS
identified	O
.	O

The	O
original	O
pathology	O
report	O
was	O
examined	O
for	O
any	O
mention	O
of	O
medullary	O
phenotype	O
consideration	O
of	O
neuroendocrine	O
differentiation	O
or	O
consideration	O
of	O
metastasis	B-DIS
from	O
another	O
site	O
.	O

Clinico	O
-	O
pathological	O
features	O
were	O
compared	O
to	O
poorly	B-DIS
differentiated	O
adenocarcinoma	O
NOS	O
.	O

Only	O
one	O
-	O
third	B-DIS
of	I-DIS
medullary	O
carcinomas	O
were	O
correctly	O
identified	O
between	O
1997	O
and	O
2018	O
.	O

The	O
other	O
two	O
-	O
thirds	O
were	O
reported	O
as	O
poorly	B-DIS
differentiated	O
adenocarcinoma	O
NOS	O
.	O

The	O
possibility	O
of	O
an	O
extracolonic	B-DIS
origin	O
or	O
neuroendocrine	B-DIS
carcinoma	I-DIS
was	O
considered	O
in	O
21	O
and	O
27	B-STAT
%	I-STAT
of	O
reports	O
.	O

Most	O
medullary	B-DIS
carcinomas	I-DIS
exhibited	O
mismatch	B-DIS
repair	I-DIS
deficiency	I-DIS
were	O
located	O
in	O
ascending	O
colon	B-DIS
and	I-DIS
caecum	I-DIS
and	I-DIS
had	O
a	O
lower	O
rate	O
of	O
vascular	O
channel	O
invasion	O
and	O
lymph	O
node	O
metastasis	O
compared	O
to	O
poorly	O
differentiated	O
adenocarcinoma	B-DIS
.	O

Conclusions	O
Medullary	B-DIS
carcinoma	I-DIS
of	I-DIS
the	I-DIS
colon	I-DIS
is	O
often	O
mistaken	O
for	O
poorly	O
differentiated	O
adenocarcinoma	B-DIS
NOS	O
and	O
occasionally	O
for	O
neuroendocrine	O
or	O
metastatic	O
carcinoma	B-DIS
.	O

Greater	O
familiarity	O
with	O
morphological	O
criteria	O
and	O
use	O
of	O
mismatch	O
repair	O
protein	O
staining	O
should	O
improve	O
diagnosis	O
.	O

The	O
recent	O
discovery	O
of	O
genes	O
involved	O
in	O
familial	O
forms	O
of	O
nephrotic	B-DIS
syndrome	I-DIS
represents	O
a	O
break	O
-	O
through	O
in	O
nephrology	O
.	O

To	O
date	O
15	O
genes	O
have	O
been	O
characterized	O
and	O
several	O
new	O
loci	O
have	O
been	O
identified	O
with	O
a	O
potential	O
for	O
discovery	O
of	O
new	O
genes	O
.	O

Overall	O
these	O
genes	O
account	O
for	O
a	O
large	O
fraction	O
of	O
familial	O
forms	O
of	O
nephrotic	B-DIS
syndrome	I-DIS
but	O
they	O
can	O
also	O
be	O
recognized	O
in	O
10	B-STAT
-	I-STAT
20	I-STAT
%	I-STAT
of	O
sporadic	O
cases	O
.	O

These	O
advances	O
increase	O
diagnostic	O
and	O
therapeutic	O
potentials	O
but	O
also	O
add	O
higher	O
complexity	O
to	O
the	O
scenario	O
requiring	O
clear	O
definitions	O
of	O
clinical	O
histopathological	O
and	O
molecular	O
signatures	O
.	O

In	O
general	O
genetic	O
forms	O
of	O
nephrotic	B-DIS
syndrome	I-DIS
are	O
resistant	O
to	O
common	O
therapeutic	O
approaches	O
that	O
include	O
steroids	O
and	O
calcineurin	O
inhibitors	O
but	O
in	O
a	O
few	O
cases	O
drug	O
response	O
or	O
spontaneous	O
remission	O
suggest	O
a	O
complex	O
pathogenesis	O
.	O

Finally	O
syndromic	O
variants	O
can	O
be	O
recognized	O
on	O
the	O
basis	O
of	O
the	O
associated	O
extra	O
-	O
renal	O
manifestations	O
.	O

In	O
this	O
educational	O
review	O
clinical	O
histological	O
and	O
molecular	O
aspects	O
of	O
various	O
forms	O
of	O
familial	B-DIS
nephrotic	I-DIS
syndrome	I-DIS
have	O
been	O
reviewed	O
in	O
an	O
attempt	O
to	O
define	O
a	O
rational	O
diagnostic	O
approach	O
.	O

The	O
proposed	O
model	O
focuses	O
on	O
practical	O
and	O
economic	O
issues	O
taking	O
into	O
consideration	O
the	O
impossibility	O
of	O
using	O
genetic	O
testing	O
as	O
starting	O
diagnostic	O
tool	O
.	O

The	O
final	O
objective	O
of	O
this	O
review	O
is	O
to	O
outline	O
a	O
diagnostic	O
flow	O
-	O
chart	O
for	O
clinicians	O
and	O
geneticists	O
and	O
to	O
generate	O
a	O
rational	O
scheme	O
for	O
molecular	O
testing	O
.	O

Fanconi	B-DIS
anemia	I-DIS
FA	O
is	O
a	O
recessive	O
DNA	O
instability	B-DIS
disorder	I-DIS
associated	O
with	O
developmental	O
abnormalities	B-DIS
bone	I-DIS
marrow	I-DIS
failure	I-DIS
and	O
a	O
predisposition	O
to	O
cancer	B-DIS
.	O

Based	O
on	O
their	O
sensitivity	O
to	O
DNA	O
cross	O
-	O
linking	O
agents	O
FA	O
cells	O
have	O
been	O
assigned	O
to	O
15	O
complementation	O
groups	O
and	O
the	O
associated	O
genes	O
have	O
been	O
identified	O
.	O

Founder	O
mutations	O
have	O
been	O
found	O
in	O
different	O
FA	O
genes	O
in	O
several	O
populations	O
.	O

The	O
majority	O
of	O
Dutch	O
FA	O
patients	O
belongs	O
to	O
complementation	O
group	O
FA	O
-	O
C	O
.	O

Here	O
we	O
report	O
15	O
patients	O
of	O
Dutch	O
ancestry	O
and	O
a	O
large	O
Canadian	O
Manitoba	B-LOC
Mennonite	O
kindred	O
carrying	O
the	O
FANCC	O
c.67delG	O
mutation	O
.	O

Genealogical	O
investigation	O
into	O
the	O
ancestors	O
of	O
the	O
Dutch	O
patients	O
shows	O
that	O
these	O
ancestors	O
lived	O
in	O
four	O
distinct	O
areas	O
in	O
The	B-LOC
Netherlands	I-LOC
.	O

We	O
also	O
show	O
that	O
the	O
Dutch	O
and	O
Manitoba	B-LOC
Mennonite	I-LOC
FANCC	O
c.67delG	O
patients	O
share	O
the	O
same	O
haplotype	O
surrounding	O
this	O
mutation	O
indicating	O
a	O
common	O
founder	O
.	O

In	O
contrast	O
to	O
acute	O
peripheral	B-DIS
nerve	I-DIS
injury	I-DIS
the	O
molecular	O
response	O
of	O
Schwann	O
cells	O
in	O
chronic	B-DIS
neuropathies	I-DIS
remains	O
poorly	O
understood	O
.	O

Onion	O
bulb	O
structures	O
are	O
a	O
pathological	O
hallmark	O
of	O
demyelinating	B-DIS
neuropathies	I-DIS
but	O
the	O
nature	O
of	O
these	O
formations	O
is	O
unknown	O
.	O

Here	O
we	O
show	O
that	O
Schwann	O
cells	O
induce	O
the	O
expression	O
of	O
Neuregulin-1	O
type	O
I	O
NRG1	O
-	O
I	O
a	O
paracrine	O
growth	O
factor	O
in	B-DIS
various	I-DIS
chronic	I-DIS
demyelinating	O
diseases	O
.	O

Genetic	O
disruption	O
of	O
Schwann	O
cell	O
-	O
derived	O
NRG1	O
signalling	O
in	O
a	O
mouse	O
model	B-DIS
of	I-DIS
Charcot	O
-	O
Marie	O
-	O
Tooth	O
Disease	O
1A	O
CMT1A	O
suppresses	O
hypermyelination	O
and	O
the	O
formation	O
of	O
onion	O
bulbs	O
.	O

Transgenic	O
overexpression	O
of	O
NRG1	O
-	O
I	O
in	O
Schwann	O
cells	O
on	O
a	O
wildtype	O
background	O
is	O
sufficient	O
to	O
mediate	O
an	O
interaction	O
between	O
Schwann	O
cells	O
via	O
an	O
ErbB2	O
receptor	O
-	O
MEK	O
/	O
ERK	O
signaling	O
axis	O
which	O
causes	O
onion	O
bulb	B-DIS
formations	I-DIS
and	O
results	O
in	B-DIS
a	O
peripheral	O
neuropathy	O
reminiscent	O
of	O
CMT1A	O
.	O

We	O
suggest	O
that	O
diseased	O
Schwann	O
cells	O
mount	O
a	O
regeneration	O
program	O
that	O
is	O
beneficial	O
in	O
acute	B-DIS
nerve	I-DIS
injury	I-DIS
but	O
that	O
overstimulation	O
of	O
Schwann	O
cells	O
in	O
chronic	B-DIS
neuropathies	I-DIS
is	O
detrimental	O
.	O

A	O
57	O
-	O
year	O
-	O
old	O
male	O
presented	O
to	O
the	O
emergency	O
department	O
with	B-DIS
right	O
upper	O
quadrant	O
pain	O
and	O
constitutional	O
symptoms	O
.	O

Initial	O
investigation	O
revealed	O
biliary	B-DIS
sepsis	I-DIS
with	O
features	O
of	O
chronic	B-DIS
cholecystitis	I-DIS
multiple	O
liver	B-DIS
abscesses	I-DIS
and	O
a	O
fistulous	O
connection	O
between	O
the	O
gallbladder	B-DIS
and	I-DIS
colon	I-DIS
.	O

He	O
was	O
subsequently	O
diagnosed	O
with	O
a	O
cholecysto	O
-	B-DIS
colonic	O
fistula	O
an	O
unusual	O
complication	O
of	O
biliary	O
pathology	O
with	B-EPI
an	O
incidence	O
of	O
0.06	B-STAT
-	I-STAT
0.14	I-STAT
%	I-STAT
at	O
cholecystectomy	O
.	O

It	O
is	O
the	O
second	O
most	O
common	O
form	O
of	O
cholecystoenteric	B-DIS
fistula	I-DIS
the	O
first	O
of	O
which	O
is	O
cholecystoduodenal	O
.	O

A	O
preoperative	O
diagnosis	O
was	O
suggested	O
using	O
computed	O
tomography	O
and	O
sinogram	O
imaging	O
.	O

The	O
associated	O
liver	B-DIS
abscesses	I-DIS
together	O
with	O
the	O
xanthogranulomatous	B-DIS
inflammation	I-DIS
found	O
on	O
histopathology	O
makes	O
the	O
case	O
particularly	O
exceptional	O
.	O

Mutations	O
in	O
the	O
COL4A5	O
gene	O
located	O
at	O
Xq22	O
cause	O
Alport	B-DIS
syndrome	I-DIS
AS	O
a	O
nephritis	O
characterized	O
by	O
progressive	O
deterioration	B-DIS
of	I-DIS
the	I-DIS
glomerular	I-DIS
basement	O
membrane	O
and	O
usually	O
associated	O
with	O
progressive	O
hearing	B-DIS
loss	I-DIS
.	O

We	O
have	O
identified	O
a	O
novel	O
mutation	O
L1649R	O
present	O
in	O
9	O
of	O
121	O
independently	O
ascertained	O
families	O
.	O

Affected	O
males	O
shared	O
the	O
same	O
haplotype	O
of	O
eight	O
polymorphic	O
markers	O
tightly	O
linked	O
to	O
COL4A5	O
indicating	O
common	O
ancestry	O
.	O

Genealogical	O
studies	O
place	O
the	O
birth	O
of	O
this	O
ancesto	O
200	O
years	O
ago	O
.	O

The	O
L1649R	B-DIS
mutation	O
is	O
a	O
relatively	O
common	O
cause	O
of	O
Alport	B-DIS
syndrome	I-DIS
in	O
the	O
western	O
United	B-LOC
States	I-LOC
in	O
part	O
because	O
of	O
the	O
rapid	O
growth	O
and	O
migratory	O
expansion	O
of	O
mid	O
-	O
nineteenth	O
-	O
century	O
pioneer	O
populations	O
carrying	O
the	O
gene	O
.	O

L1649R	B-DIS
affects	O
a	O
highly	O
conserved	O
residue	O
in	O
the	O
NC1	O
domain	O
which	O
is	O
involved	O
in	O
key	O
inter-	O
and	O
intramolecular	O
interactions	O
but	O
results	O
in	O
a	O
relatively	O
mild	O
disease	O
phenotype	O
.	O

Renal	B-DIS
failure	I-DIS
in	O
an	O
L1649R	B-DIS
male	O
typically	O
occurs	O
in	O
the	O
4th	O
or	O
5th	O
decade	O
and	O
precedes	O
the	O
onset	O
of	O
significant	O
hearing	B-DIS
loss	I-DIS
by	O
approximately	O
10	O
years	O
.	O

Most	O
amyotrophic	B-DIS
lateral	I-DIS
sclerosis	I-DIS
ALS	I-DIS
cases	O
are	O
considered	O
sporadic	O
without	O
a	O
known	O
genetic	O
basis	O
and	O
lifestyle	O
factors	O
are	O
suspected	O
to	O
play	O
an	O
etiologic	O
role	O
.	O

We	O
previously	O
observed	O
increased	O
risk	O
of	O
ALS	B-DIS
associated	O
with	O
high	B-DIS
nail	I-DIS
mercury	I-DIS
levels	O
as	O
an	O
exposure	O
biomarker	O
and	O
thus	O
hypothesized	O
that	O
mercury	O
exposure	O
via	O
fish	O
consumption	O
patterns	O
increases	O
ALS	O
risk	O
.	O

Lifestyle	O
surveys	O
were	O
obtained	O
from	O
ALS	B-DIS
patients	O
n	O
=	O
165	O
and	O
n	O
=	O
330	O
age-	O
and	O
sex	O
-	O
matched	O
controls	B-DIS
without	O
ALS	O
enrolled	O
in	O
New	B-LOC
Hampshire	I-LOC
Vermont	B-LOC
or	O
Ohio	B-LOC
USA	I-LOC
.	O

We	O
estimated	O
their	O
annual	O
intake	O
of	O
mercury	O
and	O
omega-3	O
polyunsaturated	O
fatty	O
acid	O
PUFA	O
via	O
self	O
-	O
reported	O
seafood	O
consumption	O
habits	O
including	O
species	O
and	O
frequency	O
.	O

In	O
our	O
multivariable	O
model	O
family	O
income	O
showed	O
a	O
significant	O
positive	O
association	O
with	O
ALS	B-DIS
risk	O
p	O
=	O
0.0003	O
adjusted	O
for	O
age	O
sex	O
family	O
history	O
education	O
and	O
race	O
.	O

Neither	O
the	O
estimated	O
annual	O
mercury	O
nor	O
omega-3	O
PUFA	O
intakes	O
via	O
seafood	O
were	O
associated	O
with	O
ALS	B-DIS
risk	O
.	O

ALS	B-DIS
incidence	B-EPI
is	O
associated	O
with	O
socioeconomic	O
status	O
;	O
however	O
consistent	O
with	O
a	O
prior	O
international	O
study	O
this	O
relationship	O
is	O
not	O
linked	O
to	O
mercury	O
intake	O
estimated	O
via	O
fish	O
or	O
seafood	O
consumption	O
patterns	O
.	O

Standardized	O
screening	O
assessments	O
and	O
sex	O
differences	O
in	O
autism	B-DIS
spectrum	I-DIS
disorder	I-DIS
ASD	I-DIS
are	O
still	O
under	O
-	O
explored	O
in	O
Poland	B-LOC
.	O

This	O
study	O
investigated	O
the	O
differences	O
between	O
Polish	O
ASD	O
females	O
and	O
males	O
based	O
on	O
the	O
responses	O
provided	O
by	O
parents	O
/	O
caregivers	O
to	O
a	O
Polish	O
adaptation	O
of	O
the	O
Social	O
Communication	O
Questionnaire	O
SCQ	O
Lifetime	O
and	O
SCQ	O
Current	O
.	O

The	O
study	O
included	O
90	O
ASD	O
participants	O
from	O
Mental	O
Health	O
Services	O
and	O
Autism	B-DIS
Clinics	O
in	O
Poland	B-LOC
with	O
no	O
intellectual	B-DIS
disability	I-DIS
and	O
no	O
profound	O
communication	B-DIS
difficulties	I-DIS
.	O

Parents	O
provided	O
information	O
on	O
the	O
SCQ	O
items	O
which	O
were	O
compared	O
under	O
three	O
domains	O
of	O
the	O
Autism	B-DIS
Diagnostic	O
Interview	B-DIS
-	I-DIS
Revised	O
ADI	O
-	O
R	O
.	O

Four	O
SCQ	O
items	O
with	O
the	O
examples	O
were	O
investigated	O
.	O

No	O
significant	O
differences	O
were	O
found	O
between	O
the	O
two	O
sexes	O
in	O
the	O
three	O
domains	O
.	O

The	O
repetitive	O
use	O
of	O
objects	O
declined	O
with	O
age	O
in	O
ASD	O
males	O
.	O

Although	O
the	O
findings	O
of	O
the	O
present	O
study	O
did	O
not	O
reveal	O
substantial	O
gender	O
biases	O
in	O
the	O
Polish	O
adaptation	O
of	O
the	O
SCQ	O
it	O
is	O
necessary	O
to	O
take	O
into	O
account	O
potential	O
gender	O
differences	O
in	O
the	O
clinical	O
presentation	O
of	O
ASD	B-DIS
and	O
in	O
the	O
adaptation	O
of	O
screening	O
and	O
diagnostic	O
tools	O
.	O

Syndactyly	B-DIS
and	O
polydactyly	O
-	O
respectively	O
characterized	O
by	O
fused	O
and	O
supernumerary	O
digits	O
-	O
are	O
among	B-DIS
the	I-DIS
most	I-DIS
common	O
congenital	B-DIS
limb	O
malformations	O
with	O
syndactyly	O
presenting	B-EPI
at	O
an	B-STAT
estimated	I-STAT
incidence	I-STAT
of	O
1	O
in	O
2000	O
-	O
3000	B-DIS
live	O
births	O
and	O
polydactyly	O
at	B-STAT
a	I-STAT
frequency	I-STAT
of	I-STAT
1	O
in	O
approximately	O
700	O
-	O
1000	O
live	O
births	O
.	O

Despite	O
their	O
relatively	O
regular	O
manifestation	O
in	O
the	O
clinic	O
the	O
etiologies	O
of	O
syndactyly	B-DIS
and	O
polydactyly	B-DIS
remain	O
poorly	O
understood	O
because	O
of	O
their	O
phenotypic	O
and	O
genetic	O
diversity	O
.	O

Further	O
even	O
though	O
concrete	O
knowledge	O
of	O
genotypic	O
links	O
has	O
been	O
established	O
for	O
some	O
variants	O
of	O
syndactyly	B-DIS
and	O
polydactyly	B-DIS
there	O
appears	O
to	O
be	O
no	O
single	O
comprehensive	O
published	O
summary	O
of	O
all	O
syndromic	O
and	O
nonsyndromic	B-DIS
syndactyly	I-DIS
and	O
polydactyly	B-DIS
presentations	O
and	O
there	O
is	O
decidedly	O
no	O
resource	O
that	O
maps	O
all	O
syndromic	O
and	O
nonsyndromic	B-DIS
syndactylies	I-DIS
and	O
polydactylies	B-DIS
to	O
their	O
genetic	O
bases	O
.	O

This	O
gap	O
in	O
the	O
literature	O
problematizes	O
comprehensive	O
carrier	O
screening	O
and	O
prenatal	O
diagnosis	O
and	O
complicates	O
novel	O
diagnostic	O
attempts	O
.	O

This	O
review	O
thus	O
attempts	O
to	O
collect	O
all	O
that	O
is	O
known	O
about	O
the	O
genetic	O
bases	O
of	O
syndromic	O
and	O
nonsyndromic	B-DIS
syndactylies	I-DIS
and	O
polydactylies	O
as	O
well	O
as	O
to	O
highlight	O
the	O
dactyly	O
manifestations	O
for	O
which	O
no	O
genetic	O
bases	O
are	O
as	O
yet	O
known	O
.	O

Then	O
having	O
established	O
a	O
summation	O
of	O
existing	O
and	O
missing	O
knowledge	O
this	O
work	O
briefly	O
outlines	O
the	O
diagnostic	O
techniques	O
that	O
a	O
genetics	O
-	O
reinforced	O
understanding	B-DIS
of	O
syndactyly	B-DIS
and	O
polydactyly	O
could	O
inform	O
.	O

Background	O
Pierre	B-DIS
Robin	I-DIS
sequence	I-DIS
PRS	O
is	O
a	O
rare	O
congenital	B-DIS
anomaly	I-DIS
.	O

Respiratory	B-DIS
disorders	I-DIS
and	O
feeding	O
difficulties	O
represent	O
the	O
main	O
burden	O
.	O

Objective	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
epidemiology	O
of	O
PRS	O
using	O
a	O
cohort	O
of	O
cases	O
from	O
EUROCAT	O
the	O
European	O
network	O
of	O
population	O
-	O
based	O
registries	B-DIS
of	I-DIS
congenital	O
anomalies	O
.	O

Methods	O
We	O
analysed	O
cases	O
of	O
PRS	O
born	O
in	O
the	O
period	O
1998	O
-	O
2017	O
collected	O
by	O
29	O
population	O
-	B-DIS
based	I-DIS
congenital	O
anomaly	O
registries	O
in	O
17	O
different	O
countries	O
.	O

We	O
calculated	O
prevalence	B-EPI
estimates	O
prenatal	O
detection	O
rate	O
survival	O
up	O
to	O
1	O
week	O
and	O
proportions	O
of	O
associated	O
anomalies	B-DIS
.	O

The	O
effect	O
of	O
maternal	O
age	O
was	O
tested	O
using	O
a	O
Poisson	O
regression	O
model	O
.	O

Results	O
Out	O
of	O
11669155	O
surveyed	O
births	O
a	O
total	O
of	O
1294	O
cases	O
of	O
PRS	O
were	O
identified	O
.	O

The	O
estimate	O
of	O
the	O
overall	O
prevalence	B-EPI
was	O
12.0	O
per	O
100000	O
births	O
95	B-STAT
%	I-STAT
CI	O
9.9	O
14.5	O
.	O

There	O
was	O
a	O
total	O
of	O
88268.2	B-STAT
%	I-STAT
isolated	O
cases	O
and	O
the	O
prevalence	B-EPI
was	O
7.8	O
per	O
100000	O
births	O
95	B-STAT
%	I-STAT
CI	O
6.7	O
9.2	O
.	O

A	O
total	O
of	O
250	O
cases	O
19.3	B-STAT
%	I-STAT
were	O
associated	O
with	O
other	O
structural	O
congenital	B-DIS
anomalies	I-DIS
77	O
cases	O
6.0	B-STAT
%	I-STAT
were	O
associated	O
with	O
chromosomal	B-DIS
anomalies	I-DIS
and	O
776.0	B-STAT
%	I-STAT
with	O
genetic	O
syndromes	O
.	O

The	O
prenatal	O
detection	O
rate	O
in	O
isolated	O
cases	O
was	O
12.0	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
9.8	O
14.5	O
and	O
increased	O
to	O
16.0	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
12.7	O
19.7	O
in	O
the	O
sub	O
-	O
period	O
2008	O
-	O
2017	O
.	O

The	O
prevalence	B-EPI
rate	O
ratio	O
of	O
non	B-DIS
-	O
chromosomal	O
cases	O
with	O
maternal	O
age	O
≥35	O
was	O
higher	O
than	O
in	O
cases	O
with	O
maternal	O
age	O
<	O
25	O
for	O
total	O
PRR	O
1.2695	B-STAT
%	I-STAT
CI	O
1.05	O
1.51	O
and	O
isolated	O
cases	O
PRR	O
1.3395	B-STAT
%	I-STAT
CI	O
1.00	O
1.64	O
.	O

Survival	O
of	O
chromosomal	O
cases	O
94.2	B-STAT
%	I-STAT
and	O
multiple	O
anomaly	B-DIS
cases	O
95.3	B-STAT
%	I-STAT
were	O
lower	O
than	O
survival	O
of	O
isolated	O
cases	O
99.4	B-STAT
%	I-STAT
.	O

Conclusions	O
This	O
epidemiological	O
study	O
using	O
a	O
large	O
series	O
of	O
cases	O
of	O
PRS	O
provides	O
insights	O
into	O
the	O
epidemiological	O
profile	O
of	O
PRS	O
in	O
Europe	B-LOC
.	O

We	O
observed	O
an	O
association	O
with	O
higher	O
maternal	O
age	O
but	O
further	O
investigations	O
are	O
needed	O
to	O
test	O
potential	O
risk	O
factors	O
for	O
PRS	B-DIS
.	O

Inherited	O
forms	O
of	O
deafness	B-DIS
account	O
for	O
a	O
sizable	O
portion	O
of	O
hearing	B-DIS
loss	I-DIS
among	O
children	O
and	O
adult	O
populations	O
.	O

Many	O
patients	O
with	O
sensorineural	B-DIS
deficits	I-DIS
have	O
pathological	O
manifestations	O
in	O
the	O
peripheral	O
auditory	O
system	O
the	O
inner	O
ear	O
.	O

Within	O
the	O
hearing	O
organ	O
the	O
cochlea	O
most	O
of	O
the	O
genetic	O
forms	O
of	O
hearing	B-DIS
loss	I-DIS
involve	O
defects	O
in	O
sensory	O
detection	O
and	O
to	O
some	O
extent	O
signaling	O
to	O
the	O
brain	O
via	O
the	O
auditory	O
cranial	O
nerve	O
.	O

This	O
review	O
focuses	O
on	O
peripheral	O
forms	O
of	O
hereditary	B-DIS
hearing	I-DIS
loss	I-DIS
and	O
how	O
these	O
impairments	O
can	O
be	O
studied	O
in	O
diverse	O
animal	O
models	O
or	O
patient	O
-	O
derived	O
cells	O
with	O
the	O
ultimate	O
goal	O
of	O
using	O
the	O
knowledge	O
gained	O
to	O
understand	O
the	O
underlying	O
biology	O
and	B-DIS
treat	I-DIS
hearing	O
loss	O
.	O

Osteoporosis	B-DIS
characterized	O
by	O
reduced	O
bone	O
mass	O
and	O
increased	O
bone	O
fragility	O
is	O
a	O
disease	O
prevalent	O
in	O
women	O
.	O

Likewise	O
breast	B-DIS
cancer	I-DIS
is	O
a	O
multifactorial	B-DIS
disease	I-DIS
and	O
considered	O
the	O
major	O
cause	O
of	O
mortality	O
in	O
premenopausal	O
and	O
postmenopausal	O
women	O
worldwide	O
.	O

Our	O
data	O
demonstrated	O
the	O
association	O
of	O
the	O
MYLK	O
gene	O
and	O
PTGS1	O
gene	O
variants	O
with	O
osteoporosis	B-DIS
and	O
benign	O
breast	B-DIS
tumor	I-DIS
risk	O
and	O
the	O
impact	O
of	O
ovariectomy	O
on	O
osteoporosis	B-DIS
in	O
Korean	O
women	O
.	O

We	O
performed	O
a	O
genome	O
-	O
wide	O
association	O
study	O
GWAS	O
of	O
women	B-DIS
with	O
osteoporosis	O
and	B-DIS
benign	I-DIS
breast	O
tumors	O
.	O

There	O
were	O
60	O
single	O
nucleotide	O
polymorphisms	O
SNPs	O
and	O
12	O
SNPs	O
in	O
the	O
MYLK	O
and	O
PTGS1	O
genes	O
associated	O
with	O
benign	O
breast	B-DIS
tumors	I-DIS
and	O
osteoporosis	B-DIS
.	O

Our	O
study	O
showed	O
that	O
women	O
with	O
homozygous	O
MYLK	O
rs12163585	O
major	O
alleles	O
had	O
an	O
increased	O
risk	O
of	O
osteoporosis	B-DIS
following	O
ovariectomy	O
compared	O
to	O
those	O
with	O
minor	O
alleles	O
.	O

Women	O
carrying	O
the	O
minor	O
PTGS1	O
rs1213265	O
allele	O
and	O
not	O
treated	O
via	O
ovariectomy	O
carried	O
a	O
higher	O
risk	O
of	O
osteoporosis	B-DIS
than	O
those	O
who	O
underwent	O
ovariectomy	O
with	O
a	O
homozygous	O
genotype	O
at	O
the	O
major	O
alleles	O
.	O

Our	O
results	O
suggest	O
that	O
both	O
the	O
MYLK	O
and	O
PTGS1	O
genes	O
are	O
genetic	O
factors	O
associated	O
with	O
the	O
phenotypes	O
and	O
these	O
associations	O
appear	O
to	O
be	O
modulated	O
by	O
ovariectomy	O
.	O

Objectives	O
Determine	O
the	O
types	O
incidence	B-EPI
mortality	O
rate	O
and	O
clinical	O
status	O
of	O
youth	O
diabetes	B-DIS
at	O
Bach	O
Christian	O
Hospital	O
BCH	B-LOC
Qalandarabad	B-LOC
Pakistan	B-LOC
.	O

Methods	O
Analysis	O
of	O
incidence	B-EPI
and	O
mortality	O
data	O
of	O
all	O
patients	O
<	O
25	O
year	O
y	O
diagnosed	O
from	O
January	O
2014	O
-	O
June	O
2019	O
and	O
also	O
analysis	O
of	O
clinical	O
status	O
of	O
patients	O
<	O
25y	O
seen	B-STAT
in	O
2018/2019	O
.	O

Results	O
Ninety	O
-	O
three	O
patients	O
were	O
seen	O
over	O
the	O
study	O
period	O
.	O

Eighty	O
-	O
eight	O
were	O
type	B-DIS
1	I-DIS
diabetes	O
T1D	O
51.1	B-STAT
%	I-STAT
female	O
.	O

Age	O
of	O
diagnosis	O
was	O
0.8	O
-	O
24.5	O
years	O
y	O
mean	O
=	O
11.4	O
y	O
SD	O
=	O
6.2y	O
.	O

15.1	B-STAT
%	I-STAT
were	O
0	B-STAT
-	I-STAT
4y	I-STAT
31.4	I-STAT
%	I-STAT
5	O
-	O
9	O
y	O
24.4	B-STAT
%	I-STAT
10	O
-	O
14y	O
19.8	B-STAT
%	I-STAT
15	O
-	O
19y	O
and	O
9.3	B-STAT
%	I-STAT
20	O
-	O
24y	O
.	O

Minimum	O
incidence	B-EPI
for	O
the	O
Mansehra	O
tehsil	O
administrative	O
district	O
was	O
calculated	O
as	O
1.0	O
per	O
100000	O
population	O
<	O
15y	B-STAT
/	O
y	O
1.2	O
per	O
100000	B-STAT
<	O
20y	O
/	O
y	O
and	O
1.1	B-STAT
per	O
100000	O
<	O
25y	O
/	O
y	O
;	O
the	O
degree	O
of	O
ascertainment	O
could	O
not	O
be	O
assessed	O
.	O

A	O
further	O
four	O
patients	O
were	O
diagnosed	O
with	O
thiamine	B-DIS
-	I-DIS
responsive	I-DIS
megaloblastic	I-DIS
anaemia	O
TRMA	O
all	O
male	O
three	O
from	O
the	O
same	O
consanguineous	O
family	O
and	O
were	O
treated	O
with	O
high	O
-	O
dose	O
thiamine	O
.	O

One	O
other	O
patient	O
was	O
diagnosed	O
with	O
type	O
2	O
diabetes	B-DIS
.	O

Three	O
T1D	B-DIS
and	O
one	O
TRMA	B-DIS
patient	O
died	O
during	O
the	O
study	O
period	O
.	O

The	O
standardised	O
mortality	O
rate	O
for	O
T1D	B-DIS
was	O
9.4	O
but	O
vital	O
status	O
was	O
unknown	O
for	O
13	O
patients	O
.	O

The	O
mean	O
/	O
median	O
HbA1c	B-DIS
of	O
T1D	O
patients	O
seen	B-STAT
in	O
2018/2019	O
was	O
9.1	B-STAT
%	I-STAT
/9.2	B-STAT
%	O
76/77	O
mmol	O
/	O
mol	O
.	O

Conclusions	O
Minimum	O
T1D	B-DIS
incidence	B-EPI
in	O
Mansehra	O
tehsil	O
is	O
double	O
the	O
previously	O
reported	O
value	O
for	O
Pakistan	B-LOC
from	O
1990	O
to	O
1999	O
although	O
is	O
still	O
low	O
compared	O
to	O
most	O
other	O
countries	O
.	O

Considering	O
the	O
limited	O
resources	O
available	O
patients	O
attending	O
BCH	B-LOC
are	O
achieving	O
fair	O
glycemic	O
control	O
.	O

The	O
TRMA	B-DIS
cases	O
show	O
the	O
importance	O
of	O
genetic	O
testing	O
in	O
atypical	O
cases	O
.	O

We	O
aimed	O
to	O
explore	O
the	O
genetic	O
and	O
environmental	O
contributions	O
to	O
variation	O
in	O
the	O
risk	O
of	O
hematologic	B-DIS
malignancies	I-DIS
and	O
characterize	O
familial	B-DIS
dependence	I-DIS
within	O
and	O
across	O
hematologic	B-DIS
malignancies	I-DIS
.	O

The	O
study	O
base	O
included	O
316397	O
individual	O
twins	O
from	O
the	O
Nordic	O
Twin	O
Study	O
of	O
Cancer	B-DIS
with	O
a	O
median	O
of	O
41	O
years	O
of	O
follow	O
-	O
up	O
8861828	B-STAT
%	I-STAT
of	O
the	O
twins	O
were	O
monozygotic	O
and	B-DIS
3459	I-DIS
hematologic	O
malignancies	O
were	O
reported	O
.	O

We	O
estimated	O
the	O
cumulative	O
incidence	B-EPI
by	O
age	O
familial	O
risk	O
and	O
genetic	O
and	O
environmental	O
variance	O
components	O
of	O
hematologic	B-DIS
malignancies	I-DIS
accounting	O
for	O
competing	O
risk	O
of	O
death	B-DIS
.	O

The	O
lifetime	O
risk	O
of	O
any	O
hematologic	O
malignancy	B-DIS
was	O
2.5	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
2.4	B-STAT
-	I-STAT
2.6	I-STAT
%	I-STAT
as	O
in	O
the	O
background	O
population	O
.	O

This	O
risk	O
was	O
elevated	O
to	O
4.5	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
3.1	B-STAT
-	I-STAT
6.5	I-STAT
%	I-STAT
conditional	O
on	O
hematologic	O
malignancy	B-DIS
in	O
a	O
dizygotic	O
co	O
-	O
twin	O
and	O
was	O
even	O
greater	O
at	O
7.6	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
4.8	B-STAT
-	I-STAT
11.8	I-STAT
%	I-STAT
if	O
a	O
monozygotic	O
co	O
-	O
twin	B-DIS
had	O
a	O
hematologic	O
malignancy	O
.	O

Heritability	O
of	O
the	O
liability	O
to	O
develop	O
any	O
hematologic	O
malignancy	B-DIS
was	O
24	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
14	B-STAT
-	I-STAT
33	I-STAT
%	I-STAT
.	O

This	O
estimate	O
decreased	O
across	O
age	O
from	O
approximately	B-STAT
55	I-STAT
%	I-STAT
at	O
age	O
40	O
to	O
about	O
20	O
-	O
25	O
%	O
after	O
age	O
55	O
when	O
it	O
seems	O
to	O
stabilize	O
.	O

In	O
this	O
largest	O
ever	O
studied	O
twin	O
cohort	O
with	O
the	O
longest	O
follow	O
-	O
up	O
we	O
found	O
evidence	O
for	O
familial	O
risk	B-DIS
of	I-DIS
hematologic	O
malignancies	O
.	O

The	O
discovery	O
of	O
decreasing	O
familial	O
predisposition	O
with	O
increasing	O
age	O
underscores	O
the	O
importance	O
of	O
cancer	B-DIS
surveillance	O
in	O
families	O
with	O
hematological	B-DIS
malignancies	I-DIS
.	O

COVID-19	O
coronavirus	B-DIS
disease	I-DIS
2019	O
represents	O
a	O
prothrombotic	O
disorder	O
and	O
there	O
have	O
been	O
several	O
reports	O
of	O
platelet	O
factor	O
4	B-STAT
/	O
heparin	O
antibodies	O
being	O
present	O
in	O
COVID-19	O
-	O
infected	O
patients	O
.	O

This	O
has	O
thus	O
been	O
identified	O
in	O
some	O
publications	O
as	O
representing	O
a	O
high	O
incidence	B-EPI
of	O
heparin	B-DIS
-	I-DIS
induced	I-DIS
thrombocytopenia	O
HIT	O
whereas	O
in	O
others	O
findings	O
have	O
been	O
tempered	O
by	O
general	O
lack	O
of	O
functional	O
reactivity	O
using	O
confirmation	O
assays	O
of	O
serotonin	O
release	O
assay	O
SRA	B-DIS
or	B-DIS
heparin	I-DIS
-	O
induced	O
platelet	O
aggregation	O
HIPA	O
.	O

Moreover	O
in	O
at	O
least	O
two	O
publications	O
data	O
are	O
provided	O
suggesting	O
that	O
antibodies	O
can	O
arise	O
in	O
heparin	O
naïve	O
patients	O
or	O
that	O
platelet	O
activation	O
may	O
not	O
be	O
heparin	O
-	O
dependent	O
.	O

From	O
this	O
literature	O
we	O
would	O
conclude	O
that	O
platelet	O
factor	O
4	B-STAT
/	O
heparin	O
antibodies	O
can	O
be	O
observed	O
in	O
COVID-19	O
-	O
infected	O
patients	O
and	O
they	O
may	B-EPI
occur	O
at	O
higher	O
incidence	O
than	O
in	O
historical	O
non	O
-	O
COVID-19	O
-	O
infected	O
cohorts	O
.	O

However	O
the	O
situation	O
is	O
complex	O
since	O
not	O
all	O
platelet	O
factor	O
4	B-STAT
/	O
heparin	O
antibodies	O
may	O
lead	O
to	O
platelet	O
activation	O
and	O
not	O
all	O
identified	O
antibodies	O
are	O
heparin	O
-	O
dependent	O
such	O
that	O
they	O
do	O
not	O
necessarily	O
reflect	O
`	B-DIS
`	O
true	O
''	O
HIT	O
.	O

Most	O
recently	O
a	O
`	O
`	O
HIT	O
-	O
like	O
''	O
syndrome	O
has	O
reported	O
in	O
patients	O
who	O
have	O
been	O
vaccinated	O
against	O
COVID-19	O
.	O

Accordingly	O
much	O
more	O
is	O
yet	O
to	O
be	O
learnt	O
about	O
the	O
insidious	B-DIS
disease	I-DIS
that	O
COVID-19	O
represents	O
including	O
autoimmune	O
outcomes	O
in	O
affected	O
patients	O
.	O

Background	O
Unilateral	O
lung	B-DIS
agenesis	I-DIS
is	O
an	O
uncommon	O
congenital	B-DIS
abnormality	I-DIS
with	O
a	O
lack	O
of	O
reported	O
accurate	O
incidence	B-EPI
estimates	O
.	O

Prognosis	O
is	O
also	O
uncertain	O
with	O
older	O
literature	O
reporting	O
poor	O
outcomes	O
.	O

Methods	O
The	O
North	O
of	O
England	O
register	O
of	O
congenital	B-DIS
anomalies	I-DIS
Northern	O
Congenital	B-DIS
Abnormality	I-DIS
Survey	O
records	O
cases	O
of	O
congenital	B-DIS
anomalies	I-DIS
to	O
mothers	O
'	O
resident	O
in	O
the	O
region	O
.	O

We	O
used	O
the	O
register	O
to	O
identify	O
all	O
patients	O
with	O
congenital	B-DIS
lung	I-DIS
agenesis	I-DIS
born	O
between	O
2004	O
and	O
2013	O
to	O
calculate	O
an	O
accurate	O
incidence	B-EPI
estimate	O
and	O
report	O
clinical	O
outcomes	O
with	O
contemporary	O
management	O
.	O

Results	O
Four	O
patients	O
with	O
congenital	B-DIS
lung	I-DIS
agenesis	I-DIS
were	O
born	O
during	O
the	O
study	O
period	O
giving	O
an	O
estimated	O
incidence	B-EPI
in	O
the	B-LOC
North	I-LOC
of	I-LOC
England	I-LOC
of	O
1.22	O
per	O
100000	O
live	O
births	O
95	B-STAT
%	I-STAT
confidence	O
interval	O
0.33	O
-	O
3.11	O
.	O

Two	O
patients	O
had	O
associated	O
congenital	B-DIS
heart	I-DIS
disease	I-DIS
requiring	O
corrective	O
surgery	O
and	O
one	O
had	O
musculoskeletal	B-DIS
anomalies	I-DIS
.	O

All	O
four	O
patients	O
are	O
alive	O
and	O
well	O
without	O
a	O
regular	O
oxygen	O
requirement	O
.	O

Conclusion	O
Contrary	O
to	O
previous	O
reports	O
the	O
medium	O
term	O
outcomes	O
in	O
our	O
patients	O
have	O
been	O
good	O
even	O
when	O
lung	B-DIS
agenesis	I-DIS
is	O
associated	O
with	O
other	O
congenital	B-DIS
anomalies	I-DIS
.	O

Long	O
-	O
term	O
prognosis	O
with	O
modern	O
management	O
remains	O
unknown	O
and	O
the	O
potential	O
for	O
the	O
development	B-DIS
of	I-DIS
pulmonary	O
hypertension	O
remains	O
a	O
concern	O
.	O

Birth	B-DIS
Defects	I-DIS
Research	O
109857	O
-	O
8592017	O
.	O

©	O
2017	O
Wiley	O
Periodicals	O
Inc	O
.	O

Craniosynostosis	B-DIS
is	O
a	O
heterogeneous	O
condition	O
caused	O
by	O
the	O
premature	O
fusion	O
of	O
cranial	O
sutures	O
occurring	O
mostly	O
as	O
an	O
isolated	O
anomaly	B-DIS
.	O

Pathogenesis	O
of	O
non	B-DIS
-	O
syndromic	O
forms	B-DIS
of	O
craniosynostosis	O
is	O
largely	O
unknown	O
.	O

In	O
about	O
15	O
-	O
30	O
%	O
of	O
cases	O
craniosynostosis	B-DIS
occurs	O
in	O
association	O
with	O
other	O
physical	O
anomalies	O
and	O
it	O
is	O
referred	O
to	O
as	O
syndromic	B-DIS
craniosynostosis	I-DIS
.	O

Syndromic	O
forms	O
of	O
craniosynostosis	B-DIS
arise	O
from	O
mutations	O
in	O
genes	O
belonging	O
to	O
the	O
Fibroblast	O
Growth	O
Factor	O
Receptor	O
FGFR	O
family	O
and	O
the	O
interconnected	O
molecular	O
pathways	O
in	O
most	O
cases	O
.	O

However	O
it	O
can	O
occur	O
in	O
association	O
with	O
other	O
gene	O
variants	O
and	O
with	O
a	O
variety	O
of	O
chromosome	O
abnormalities	O
as	O
well	O
usually	O
in	O
association	O
with	O
intellectual	B-DIS
disability	I-DIS
ID	O
and	O
additional	O
physical	O
anomalies	O
.	O

Evaluating	O
the	O
molecular	O
properties	O
of	O
the	O
genes	O
undergoing	O
intragenic	O
mutations	O
or	O
copy	O
number	O
variations	O
CNVs	O
along	O
with	O
prevalence	B-EPI
of	O
craniosynostosis	B-DIS
in	O
different	O
conditions	O
and	O
animal	O
models	O
if	O
available	O
we	O
made	O
an	O
attempt	O
to	O
define	O
two	O
distinct	O
groups	O
of	O
unusual	O
syndromic	O
craniosynostosis	O
which	O
can	O
reflect	O
direct	O
effects	O
of	O
emerging	O
new	O
candidate	O
genes	O
with	O
roles	O
in	O
suture	O
homeostasis	O
or	O
a	O
non	O
-	O
specific	O
phenotypic	O
manifestation	O
of	O
pleiotropic	O
genes	O
respectively	O
.	O

RASopathies	O
and	O
9p23p22.3	O
deletions	O
are	O
reviewed	O
as	O
examples	O
of	O
conditions	O
in	O
the	O
first	O
group	O
.	O

In	O
particular	O
we	O
found	O
that	O
craniosynostosis	B-DIS
is	O
a	O
relatively	O
common	O
component	O
manifestation	O
of	O
cardio	B-DIS
-	I-DIS
facio	I-DIS
-	O
cutaneous	O
CFC	O
syndrome	O
.	O

Chromatinopathies	O
and	O
neurocristopathies	O
are	O
presented	O
as	O
examples	O
of	O
conditions	O
in	O
the	O
second	O
group	O
.	O

We	O
observed	O
that	O
craniosynostosis	B-DIS
is	O
uncommon	O
on	O
average	O
in	O
these	O
conditions	O
.	O

It	O
was	O
randomly	O
associated	O
with	O
Kabuki	B-DIS
Koolen	I-DIS
-	I-DIS
de	I-DIS
Vries	O
/	B-DIS
KANSL1	I-DIS
haploinsufficiency	O
and	O
Mowat	O
-	O
Wilson	O
syndromes	O
and	O
in	O
KAT6B	B-LOC
-	O
related	O
disorders	O
.	O

As	O
an	O
exception	O
trigonocephaly	B-DIS
in	O
Bohring	B-DIS
-	I-DIS
Opitz	O
syndrome	O
reflects	O
specific	O
molecular	O
properties	O
of	O
the	O
chromatin	O
modifier	O
ASXL1	O
gene	O
.	O

Surveillance	O
for	O
craniosynostosis	B-DIS
in	O
syndromic	O
forms	O
of	O
intellectual	B-DIS
disability	I-DIS
as	O
well	O
as	O
ascertainment	O
of	O
genomic	O
CNVs	O
by	O
array	O
-	O
CGH	O
in	B-DIS
apparently	I-DIS
non	O
-	O
syndromic	O
craniosynostosis	O
is	O
recommended	O
to	O
allow	O
for	O
improvement	O
of	O
both	O
the	O
clinical	O
outcome	O
of	O
patients	O
and	O
the	O
accurate	O
individual	O
diagnosis	O
.	O

Babies	O
in	O
Neonatal	O
Intensive	O
Care	O
Units	O
NICU	O
have	O
an	O
additional	O
risk	O
for	O
hearing	B-DIS
loss	I-DIS
due	O
to	O
various	O
risk	O
factors	O
like	O
prematurity	B-DIS
low	O
birth	O
weight	O
mechanical	O
ventilation	O
hyperbillirubinemia	B-DIS
ototoxic	I-DIS
drugs	O
low	O
APGAR	O
score	O
etc	O
.	O

as	O
compared	O
to	O
the	O
babies	O
from	O
well	O
baby	O
nursery	O
WBN	O
who	O
poses	O
risk	O
factors	O
mostly	O
family	O
history	O
syndromic	B-DIS
deafness	I-DIS
.	O

So	O
the	O
present	O
study	O
was	O
aimed	O
know	O
the	O
risk	O
factors	O
responsible	O
for	O
hearing	B-DIS
loss	I-DIS
in	O
NICU	O
and	O
WBN	O
babies	O
and	O
to	O
assess	O
the	O
incidence	B-EPI
of	O
deafness	B-DIS
.	O

A	O
total	O
of	O
800	O
babies	O
from	O
NICU	O
n	O
=	O
402	O
and	O
WBN	O
n	O
=	O
398	O
underwent	O
hearing	O
screening	O
from	O
a	O
tertiary	O
care	O
center	O
.	O

Hearing	O
screening	O
was	O
done	O
using	O
two	O
staged	O
screening	O
protocol	O
as	O
per	O
JCIH	O
guidelines	O
with	O
Distortion	O
product	O
Evoked	O
Otoacoustic	O
Emissions	O
DPOAE	O
and	O
Automated	O
Auditory	O
Brainstem	O
Responses	O
A	O
-	O
ABR	O
.	O

According	O
to	O
DPOAE	O
test	O
311	O
from	O
NICU	O
and	O
383	O
from	O
WBN	O
passed	O
the	O
test	O
and	O
during	O
second	O
screening	O
80	O
out	O
of	O
91	O
from	O
NICU	O
and	O
11	O
out	O
of	O
13	O
from	O
WBN	O
passed	O
the	O
DPOAE	O
test	O
.	O

Further	O
BERA	O
was	O
done	O
at	O
the	O
3	O
rd	O
<	O
/s	O
month	O
of	O
corrected	O
age	O
where	O
6	O
out	O
of	O
11	O
showed	O
positive	O
responses	O
from	O
NICU	O
and	O
3	O
babies	O
from	O
WBN	O
had	O
profound	O
hearing	B-DIS
loss	I-DIS
.	O

Data	O
analysis	O
revealed	O
that	O
family	O
history	O
of	O
deafness	B-DIS
anemia	I-DIS
and	O
hypertension	B-DIS
in	O
ANC	O
TORCH	B-DIS
in	O
mother	O
low	O
Apgar	O
score	O
and	O
hyperbillirubinemia	B-DIS
in	O
newborns	O
were	O
a	O
major	O
risk	O
factor	O
for	O
hearing	B-DIS
impairment	I-DIS
.	O

We	O
conclude	O
that	O
the	O
diagnoses	O
of	O
auditory	B-DIS
disorders	I-DIS
at	O
early	O
stage	O
due	O
to	O
various	O
risk	O
factors	O
are	O
important	O
since	O
appropriate	O
therapeutic	O
intervention	O
and	O
rehabilitation	O
would	O
help	O
in	O
better	O
development	O
of	O
children	O
.	O

Although	O
many	O
nutritional	B-DIS
deficiencies	I-DIS
are	O
associated	O
with	O
Crohn	B-DIS
's	I-DIS
disease	I-DIS
CD	O
vitamin	O
C	O
deficiency	O
is	O
less	O
frequently	O
diagnosed	O
and	O
reported	O
despite	O
its	O
prevalence	B-EPI
.	O

Vitamin	O
C	O
deficiency	O
may	O
be	O
more	O
difficult	O
to	O
diagnose	O
in	O
patients	O
with	O
CD	O
because	O
symptoms	O
from	O
active	O
CD	O
may	O
overlap	O
with	O
scurvy	B-DIS
.	O

Identification	O
of	O
the	O
deficiency	O
is	O
vital	O
however	O
because	O
treatment	O
can	O
lead	O
to	O
swift	O
marked	O
resolution	O
of	O
symptoms	O
.	O

We	O
present	O
a	O
patient	O
with	O
long	O
-	O
standing	O
CD	O
who	O
presented	O
with	O
gum	O
bleeding	O
and	O
was	O
found	O
to	B-DIS
have	O
scurvy	O
.	O

Background	O
In	O
South	B-LOC
Korea	I-LOC
the	O
number	O
of	O
Q	B-DIS
fever	I-DIS
cases	O
has	O
rapidly	O
increased	O
since	O
2015	O
.	O

Therefore	O
this	O
study	O
aimed	O
to	O
characterize	O
the	O
epidemiological	O
and	O
clinical	O
features	O
of	O
Q	B-DIS
fever	I-DIS
in	O
South	B-LOC
Korea	I-LOC
between	O
2011	O
and	O
2017	O
.	O

Methods	O
/	O
principal	O
findings	O
We	O
analyzed	O
the	O
epidemiological	O
investigations	O
and	O
reviewed	O
the	O
medical	O
records	O
from	O
all	O
hospitals	O
that	O
had	O
reported	O
at	O
least	O
one	O
case	B-DIS
of	I-DIS
Q	O
fever	O
from	O
2011	O
to	O
2017	O
.	O

We	O
also	O
conducted	O
an	O
online	O
survey	O
to	O
investigate	O
physicians	O
'	O
awareness	O
regarding	O
how	O
to	O
appropriately	O
diagnose	O
and	O
manage	O
Q	B-DIS
fever	I-DIS
.	O

The	O
nationwide	O
incidence	B-EPI
rate	O
of	O
Q	B-DIS
fever	I-DIS
was	O
annually	O
0.07	O
cases	O
per	O
100000	O
persons	O
.	O

However	O
there	O
has	O
been	O
a	O
sharp	O
increase	O
in	O
its	O
incidence	B-EPI
reaching	O
up	O
to	O
0.19	O
cases	O
per	O
100000	O
persons	O
in	O
2017	O
.	O

Q	B-DIS
fever	I-DIS
sporadically	O
occurred	O
across	O
the	O
country	O
with	O
the	O
highest	O
incidences	B-EPI
in	O
Chungbuk	O
0.53	O
cases	O
per	O
100000	O
persons	O
per	O
year	O
and	O
Chungnam	O
0.27	O
cases	O
per	O
100000	O
persons	O
per	O
year	O
areas	O
.	O

Patients	O
with	O
acute	B-DIS
Q	I-DIS
fever	I-DIS
primarily	O
presented	O
with	O
mild	O
illnesses	O
such	O
as	O
hepatitis	B-DIS
64.5	B-STAT
%	I-STAT
and	O
isolated	O
febrile	B-DIS
illness	I-DIS
24.0	B-STAT
%	I-STAT
whereas	O
those	O
with	O
chronic	B-DIS
Q	I-DIS
fever	I-DIS
were	O
likely	O
to	O
undergo	O
surgery	O
41.2	B-STAT
%	I-STAT
and	O
had	O
a	O
high	O
mortality	O
rate	O
23.5	B-STAT
%	I-STAT
.	O

Follow	O
-	O
up	O
for	O
6	O
months	B-DIS
after	I-DIS
acute	I-DIS
Q	O
fever	O
was	O
performed	O
by	O
24.0	B-STAT
%	I-STAT
of	O
the	O
physician	O
respondents	O
and	O
only	B-STAT
22.3	I-STAT
%	I-STAT
of	O
them	O
reported	O
that	O
clinical	O
and	O
serological	O
evaluations	O
were	O
required	B-DIS
after	I-DIS
acute	I-DIS
Q	O
fever	O
diagnosis	O
.	O

Conclusions	B-DIS
Q	I-DIS
fever	I-DIS
is	O
becoming	O
an	O
endemic	O
disease	O
in	O
the	O
midwestern	O
area	O
of	O
South	B-LOC
Korea	I-LOC
.	O

Given	O
the	O
clinical	O
severity	O
and	O
mortality	O
of	O
chronic	B-DIS
Q	I-DIS
fever	I-DIS
physicians	O
should	O
be	O
made	O
aware	O
of	O
appropriate	O
diagnosis	O
and	O
management	O
strategies	O
for	O
Q	B-DIS
fever	I-DIS
.	O

Background	O
Cobalamin	O
cbl	O
C	O
is	O
a	O
treatable	O
rare	O
hereditary	B-DIS
disorder	I-DIS
of	O
cbl	O
metabolism	O
with	O
autosomal	B-DIS
recessive	B-DIS
inheritance	I-DIS
.	O

It	O
is	O
the	O
most	O
common	O
organic	O
acidemia	B-DIS
manifested	O
as	O
methylmalonic	B-DIS
academia	I-DIS
combined	O
with	O
homocysteinemia	B-DIS
.	O

Early	O
screening	O
and	O
diagnosis	O
are	O
important	O
.	O

The	O
mutation	O
spectrum	O
of	O
the	O
MMACHC	O
gene	O
causing	O
cblC	B-DIS
varies	O
among	O
populations	O
.	O

The	O
mutation	O
spectrum	O
in	O
Chinese	O
population	O
is	O
notably	O
different	O
from	O
that	O
in	O
other	O
populations	O
.	O

Methods	O
A	O
PCR	O
followed	O
by	O
high	O
-	O
resolution	O
melting	O
curve	O
analysis	O
PCR	O
-	O
HRM	O
method	O
covering	O
all	O
coding	O
exons	O
of	O
MMACHC	O
gene	O
was	O
designed	O
to	O
verify	O
14	O
pathogenic	O
MMACHC	O
gene	O
variants	O
found	B-DIS
in	O
patients	O
with	O
cblC	O
including	O
all	O
common	O
mutations	O
in	B-DIS
Chinese	O
patients	O
with	O
cblC	O
.	O

Result	O
By	O
PCR	O
-	O
HRM	O
analysis	O
14	O
pathogenic	O
variants	O
of	O
MMACHC	O
showed	O
distinctly	O
different	O
melting	O
curves	O
which	O
were	O
consistent	O
with	O
Sanger	O
sequencing	O
.	O

The	O
homozygous	O
type	O
of	O
the	O
most	O
common	O
mutation	O
c.609	O
A	O
p.	O
Trp203Ter	O
can	O
also	O
be	O
analyzed	O
by	O
specially	O
designed	O
PCR	O
-	O
HRM	O
.	O

Conclusion	O
The	O
established	O
PCR	O
-	O
HRM	O
method	O
for	O
screening	O
common	O
pathogenic	O
MMACHC	O
variants	O
in	O
Chinese	O
patients	B-DIS
with	O
cblC	O
has	O
the	O
advantages	O
of	O
high	O
accuracy	O
high	O
throughput	O
low	O
cost	O
and	O
high	O
speed	O
.	O

It	O
is	O
suitable	O
for	O
the	O
large	O
-	O
sample	O
screening	O
of	O
suspected	O
children	B-DIS
with	I-DIS
methylmalonic	O
acidemia	O
and	O
carriers	O
in	O
population	O
.	O

Background	O
Juvenile	B-DIS
idiopathic	I-DIS
arthritis	I-DIS
JIA	O
is	O
a	O
heterogeneous	O
group	O
of	O
chronic	B-DIS
arthritides	I-DIS
presenting	O
in	O
patients	O
aged	O
≤16	O
years	O
with	O
a	O
prevalence	B-EPI
of	O
16	O
to	O
150	O
per	O
100000	O
.	O

Juvenile	B-DIS
osteochondritis	I-DIS
dissecans	O
OCD	B-DIS
is	O
an	O
idiopathic	B-DIS
disease	I-DIS
of	O
articular	O
cartilage	O
and	O
subchondral	O
bone	O
has	O
an	O
onset	O
age	O
of	O
10	O
to	O
16	O
years	O
and	O
often	O
affects	O
the	O
knee	O
with	O
a	O
prevalence	B-EPI
of	O
2	O
to	O
18	O
per	O
100000	O
.	O

Currently	O
there	O
are	O
few	O
studies	O
that	O
have	O
evaluated	O
the	O
relationship	O
between	O
JIA	B-DIS
and	O
OCD	B-DIS
.	O

Hypothesis	O
OCD	B-DIS
is	O
more	O
prevalent	O
in	O
children	O
with	O
JIA	B-DIS
and	O
when	O
diagnosed	O
in	O
such	O
patients	O
OCD	B-DIS
often	O
presents	O
at	O
an	O
advanced	O
state	O
.	O

Study	O
design	O
Case	O
series	O
;	O
Level	O
of	O
evidence	O
4	O
.	O

Methods	O
The	O
medical	O
records	O
of	O
patients	O
with	O
diagnoses	O
of	O
both	O
JIA	B-DIS
and	O
OCD	B-DIS
treated	O
between	O
January	O
2008	O
and	O
March	O
2019	O
at	O
a	O
single	O
children	O
's	O
hospital	O
were	O
retrospectively	O
reviewed	O
.	O

Associations	O
between	O
timing	O
of	O
diagnoses	O
number	O
and	O
types	O
of	O
corticosteroid	O
treatments	O
category	O
of	O
arthritis	B-DIS
timing	O
of	O
diagnoses	O
and	O
lesion	O
stability	O
were	O
examined	O
with	O
Spearman	O
correlation	O
coefficients	O
.	O

Results	O
A	O
total	O
of	O
2021	O
patients	O
with	O
JIA	B-DIS
were	O
identified	O
20	O
of	O
whom	O
19	O
female	O
1	O
male	O
had	O
OCD	B-DIS
of	O
the	O
knee	O
and/or	O
talus	O
for	O
a	O
prevalence	B-EPI
of	O
1	B-STAT
in	I-STAT
100	I-STAT
or	O
1000	O
in	O
100000	O
or	O
approximately	O
50	O
to	O
500	O
times	O
that	O
of	O
the	O
general	O
population	O
.	O

These	O
20	O
patients	O
had	O
a	O
total	O
of	O
28	O
OCD	B-DIS
lesions	O
43	B-STAT
%	I-STAT
9	O
femur	O
3	O
talus	O
were	O
radiographically	O
stable	O
over	O
time	O
50	B-STAT
%	I-STAT
10	O
femur	O
2	O
patella	O
2	O
talus	O
were	O
unstable	O
at	O
initial	O
diagnosis	O
and	O
7	B-STAT
%	I-STAT
2	O
femur	O
were	O
initially	O
stable	O
but	O
progressed	O
to	O
unstable	O
lesions	O
despite	O
drilling	O
.	O

Twelve	O
patients	O
60	B-STAT
%	I-STAT
underwent	O
surgery	O
420	B-STAT
%	I-STAT
with	O
stable	O
femoral	O
lesions	O
for	O
persistent	O
symptoms	O
despite	O
prolonged	O
nonoperative	O
treatment	O
and	O
840	B-STAT
%	I-STAT
for	O
treatment	O
of	O
their	O
unstable	O
lesions	O
femoral	O
and	O
patellar	O
.	O

Within	O
our	O
study	O
design	O
we	O
could	O
identify	O
no	O
significant	O
associations	O
between	O
lesion	O
stability	O
and	O
timing	O
of	O
diagnoses	O
number	O
of	O
joint	O
injections	O
or	O
limb	O
deformities	O
nor	O
were	O
there	O
associations	O
between	O
timing	O
of	O
JIA	B-DIS
and	O
OCD	B-DIS
diagnoses	O
and	O
category	O
of	O
arthritis	B-DIS
.	O

Conclusion	O
In	O
our	O
population	O
of	O
patients	O
with	O
JIA	B-DIS
OCD	I-DIS
lesions	O
were	O
found	O
to	O
be	O
50	O
to	O
500	O
times	O
more	O
prevalent	O
when	O
compared	O
with	O
published	O
rates	O
in	O
the	O
general	O
population	O
and	O
often	O
presented	O
at	O
an	O
advanced	O
state	O
with	O
instability	O
or	O
delayed	O
healing	O
requiring	O
surgery	O
for	O
stabilization	O
or	O
resolution	O
of	O
symptoms	O
.	O

Middle	O
ear	O
barotrauma	B-DIS
MEB	I-DIS
is	O
a	O
common	O
complication	O
of	O
hyperbaric	O
oxygen	O
HBO2	O
therapy	O
.	O

It	O
has	O
been	O
reported	O
in	O
more	B-STAT
than	I-STAT
40	I-STAT
%	I-STAT
of	O
HBO2	O
treatments	O
and	O
can	O
interrupt	O
the	O
sequence	O
of	O
HBO2	O
.	O

MEB	B-DIS
may	O
lead	O
to	O
pain	B-DIS
tympanic	O
membrane	O
rupture	O
and	O
even	O
hearing	B-DIS
loss	I-DIS
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
pretreatment	O
with	O
intranasal	O
fluticasone	O
and	O
oxymetazoline	O
affected	O
the	O
incidence	B-EPI
of	O
MEB	B-DIS
.	O

We	O
conducted	O
a	O
retrospective	O
chart	O
review	O
of	O
subjects	O
undergoing	O
HBO2	O
at	O
our	O
institution	O
between	O
February	O
12014	O
and	O
May	O
312019	O
.	O

Subjects	O
in	O
the	O
fluticasone	O
/	O
oxymetazoline	O
FOT	O
treatment	O
group	O
used	O
intranasal	O
fluticasone	O
50	O
mcg	O
two	O
times	O
per	O
day	O
and	O
oxymetazoline	O
0.05	B-STAT
%	I-STAT
one	O
spray	O
two	O
times	O
per	O
day	O
beginning	O
48	O
hours	O
prior	O
to	O
initial	O
HBO2	O
.	O

Oxymetazoline	O
was	O
discontinued	O
after	O
four	O
days	O
.	O

Fluticasone	O
was	O
continued	O
for	O
the	O
duration	O
of	O
HBO2	O
therapy	O
.	O

A	O
total	O
of	O
154	O
unique	O
subjects	O
underwent	O
5683	O
HBO2	O
treatments	O
39	O
unique	O
subjects	O
in	O
the	O
FOT	O
group	O
underwent	O
1501	O
HBO2	O
;	O
115	O
unique	O
subjects	O
in	O
the	O
nFOT	O
no	O
oxymetazoline	O
or	O
fluticasone	O
treatment	O
group	O
underwent	O
4182	O
HBO2	O
treatments	O
.	O

The	O
incidence	B-EPI
of	O
MEB	B-DIS
was	O
15.4	B-STAT
%	I-STAT
in	O
the	O
FOT	O
group	O
and	O
16.2	B-STAT
%	I-STAT
in	O
the	O
nFOT	O
group	O
.	O

This	O
was	O
not	O
a	O
statistically	O
significant	O
difference	O
OR	O
=	O
0.77	O
;	O
p	O
=	O
0.636	O
.	O

Treatment	O
pressure	O
age	O
over	O
65	O
years	O
male	O
sex	O
and	O
BMI	O
were	O
not	O
associated	O
with	O
a	O
difference	O
in	O
MEB	B-DIS
incidence	B-EPI
.	O

In	O
summary	O
pretreatment	O
with	O
intranasal	O
oxymetazoline	O
and	O
fluticasone	O
in	O
patients	O
undergoing	O
HBO2	O
did	O
not	O
significantly	O
reduce	O
MEB	B-DIS
.	O

More	O
investigation	O
with	O
larger	O
numbers	O
of	O
participants	O
and	O
prospective	O
studies	O
could	O
further	O
clarify	O
this	O
issue	O
.	O

Background	O
Hereditary	B-DIS
cancer	I-DIS
susceptibility	O
syndrome	O
HCSS	O
contributes	O
to	O
the	O
cancer	B-DIS
predisposition	O
at	O
an	O
early	O
age	O
therefore	O
identification	O
of	O
HCSS	O
has	O
found	O
to	O
be	O
crucial	O
for	O
surveillance	O
managing	O
therapeutic	O
interventions	O
and	O
refer	O
the	O
patients	O
and	O
their	O
families	O
for	O
genetic	O
counselling	O
.	O

The	O
study	O
aimed	O
to	O
identify	O
ALL	B-DIS
patients	O
who	O
meet	O
the	O
American	O
College	O
of	O
Medical	O
Genetics	O
ACMG	O
criteria	O
and	O
refer	O
them	O
for	O
the	O
genetic	O
testing	O
for	O
HCSS	O
as	O
hereditary	B-DIS
leukemia	I-DIS
and	O
hematologic	O
malignancy	B-DIS
syndrome	I-DIS
and	O
to	O
elucidate	O
the	O
significance	O
of	O
high	O
consanguinity	O
with	O
the	O
prevalence	B-EPI
of	O
inherited	O
leukemia	B-DIS
in	O
Pakistani	O
population	O
.	O

Methods	O
A	O
total	O
of	O
300	O
acute	B-DIS
lymphoblastic	I-DIS
leukemia	I-DIS
patients	O
were	O
recruited	O
from	O
the	O
Children	O
's	O
Hospital	O
Lahore	O
Pakistan	O
from	O
December	O
2018	O
to	O
September	O
2019	O
.	O

A	O
structured	O
self	O
-	O
reporting	O
questionnaire	O
based	O
on	O
family	O
and	O
medical	O
history	O
of	O
the	O
disease	O
was	O
utilized	O
for	O
the	O
data	O
collection	O
.	O

Results	O
In	O
our	O
cohort	O
60.40	B-STAT
%	I-STAT
of	O
ALL	B-DIS
patients	O
were	O
identified	O
to	O
meet	O
ACMG	O
criteria	O
.	O

Among	O
them	O
a	O
large	O
number	O
of	O
patients	O
40.65	B-STAT
%	I-STAT
solely	O
fulfil	O
the	O
criteria	O
due	O
to	O
the	O
presence	O
of	O
parental	O
consanguinity	B-DIS
.	O

However	O
parental	O
consanguinity	B-DIS
showed	O
protective	O
impact	O
on	O
the	O
onset	O
at	O
early	O
age	O
of	O
disease	O
[	O
OD	O
=	O
0.44	O
0.25	O
-	O
0.77	O
p	O
-	O
value	O
=	O
0.00	O
]	O
while	O
a	O
family	O
history	B-DIS
of	O
cancer	O
increased	O
the	O
risk	B-DIS
of	O
cardiotoxicity	O
[	O
OD	O
=	O
2.46	O
1.15	O
-	O
5.24	O
p	O
-	O
value	O
=	O
0.02	O
]	O
.	O

Parental	O
consanguinity	B-DIS
shows	O
no	O
significant	O
impact	O
on	O
the	O
family	O
history	O
of	O
cancer	B-DIS
and	O
the	O
number	O
of	O
relatives	O
with	O
cancer	B-DIS
.	O

Conclusions	O
More	B-STAT
than	I-STAT
50	I-STAT
%	I-STAT
of	O
the	O
ALL	B-DIS
patients	O
were	O
considered	O
the	O
strong	O
candidates	O
'	O
for	O
genetic	O
testing	O
of	O
HCSS	O
in	O
the	O
Pakistani	O
population	O
and	O
parental	O
consanguinity	B-DIS
was	O
the	O
leading	O
criteria	O
fulfilled	O
by	O
the	O
individuals	O
when	O
assessed	O
through	O
ACMG	O
guidelines	O
.	O

Our	O
study	O
suggests	O
revisiting	O
ACMG	O
guidelines	O
especially	O
for	O
the	O
criterion	O
of	O
parental	O
consanguinity	B-DIS
and	O
formulating	O
the	O
score	O
based	O
criteria	O
based	O
on	O
;	O
genetic	O
research	O
the	O
toxicology	O
profile	O
physical	O
features	O
personal	O
and	O
family	O
history	O
of	O
cancer	B-DIS
for	O
the	O
identification	O
of	O
patients	O
for	O
the	O
genetic	O
testing	O
.	O

Background	O
Moebius	B-DIS
syndrome	I-DIS
is	O
a	O
disorder	O
characterized	O
by	O
facial	O
and	O
abducens	B-DIS
nerve	I-DIS
paralysis	I-DIS
.	O

Patients	O
can	O
present	O
a	O
wide	O
range	O
of	O
upper	B-DIS
extremity	I-DIS
malformations	I-DIS
.	O

Literature	O
focused	O
on	O
orthopedic	O
manifestations	O
of	O
Moebius	B-DIS
syndrome	I-DIS
shows	O
variability	O
in	O
the	O
prevalence	B-EPI
and	O
clinical	O
presentation	O
of	O
upper	B-DIS
extremity	I-DIS
anomalies	I-DIS
.	O

The	O
aim	O
of	O
this	O
work	O
is	O
to	O
evaluate	O
the	O
prevalence	B-EPI
of	O
upper	B-DIS
extremity	I-DIS
malformations	I-DIS
in	O
patients	O
with	O
Moebius	B-DIS
syndrome	I-DIS
clarify	O
its	O
various	O
clinical	O
presentations	O
and	O
present	O
treatment	O
strategies	O
for	O
their	O
management	O
.	O

Methods	O
This	O
is	O
a	O
retrospective	O
cross	O
-	O
sectional	O
study	O
including	O
patients	B-DIS
with	I-DIS
Moebius	O
syndrome	B-DIS
and	I-DIS
upper	I-DIS
extremity	O
malformations	O
between	O
2012	O
and	O
2019	O
.	O

Data	O
include	O
demographic	O
characteristics	O
Moebius	B-DIS
syndrome	I-DIS
subtype	O
type	O
of	O
malformation	B-DIS
affected	O
extremity	O
and	O
surgical	O
procedures	O
underwent	O
.	O

Quantitative	O
data	O
were	O
recorded	O
as	O
mean	O
standard	O
deviation	O
[	O
SD	O
]	O
and	O
qualitative	O
data	O
were	O
expressed	O
in	O
terms	O
of	O
totals	O
and	O
percentages	O
.	O

Statistical	O
association	O
between	O
Moebius	B-DIS
syndrome	I-DIS
subtype	O
and	O
development	O
of	O
upper	B-DIS
extremity	I-DIS
anomalies	I-DIS
was	O
evaluated	O
using	O
binary	O
logistic	O
regression	O
.	O

Results	O
Twenty	O
-	O
five	O
out	O
of	O
153	O
patients	O
16.3	B-STAT
%	B-DIS
presented	I-DIS
upper	I-DIS
extremity	O
malformations	O
48	B-STAT
%	I-STAT
male	O
.	O

Mean	O
age	O
of	O
presentation	O
was	O
9.08	O
±	O
9.43	O
years	O
.	O

Sixty	B-STAT
-	I-STAT
eight	I-STAT
percent	I-STAT
of	B-DIS
the	O
malformations	O
were	O
unilateral	O
.	O

The	O
most	O
common	O
presentations	O
included	O
Poland	B-LOC
syndrome	O
and	O
simple	O
syndactyly	O
with	O
8	O
cases	O
each	O
32	B-STAT
%	I-STAT
followed	O
by	O
5	O
cases	O
of	O
brachysyndactyly	B-DIS
20	I-STAT
%	I-STAT
3	O
cases	O
of	O
amniotic	O
band	O
syndrome	O
12	B-STAT
%	I-STAT
and	O
1	O
case	O
of	O
cleft	O
hand	O
4	B-STAT
%	I-STAT
.	O

No	O
statistical	O
association	O
was	O
found	O
between	O
Moebius	B-DIS
syndrome	I-DIS
subtype	O
and	O
odds	O
ratio	O
for	O
development	O
of	O
upper	B-DIS
extremity	I-DIS
anomalies	I-DIS
.	O

Thirteen	O
patients	O
52	B-STAT
%	I-STAT
underwent	O
reconstructive	O
procedures	O
.	O

Conclusion	O
Poland	B-LOC
syndrome	O
and	O
syndactyly	B-DIS
are	O
the	O
most	O
common	O
anomalies	B-DIS
in	O
patients	O
with	O
Moebius	B-DIS
syndrome	I-DIS
.	O

Patients	O
may	O
present	O
with	O
a	O
wide	O
range	O
of	O
hand	B-DIS
malformations	I-DIS
each	O
patient	O
should	O
be	O
carefully	O
evaluated	O
in	O
order	O
to	O
determine	O
whether	O
surgical	O
treatment	O
is	O
needed	O
and	O
to	O
optimize	O
rehabilitation	O
protocols	O
.	O

Urea	O
cycle	O
disorders	O
UCDs	O
are	O
inherited	O
metabolic	B-DIS
disorders	I-DIS
with	O
impaired	B-DIS
nitrogen	I-DIS
detoxification	O
caused	O
by	O
defects	O
in	O
urea	O
cycle	O
enzymes	O
.	O

They	O
often	O
manifest	O
with	O
hyperammonemic	B-DIS
attacks	O
resulting	O
in	O
significant	O
morbidity	O
or	O
death	B-DIS
.	O

We	O
performed	O
a	O
nationwide	O
questionnaire	O
-	O
based	O
study	O
between	O
January	O
2000	O
and	O
March	O
2018	O
to	O
document	B-DIS
all	O
UCDs	O
in	O
Japan	B-LOC
including	O
diagnoses	O
treatments	O
and	O
outcomes	O
.	O

A	O
total	O
of	O
229	O
patients	O
with	O
UCDs	B-DIS
were	O
enrolled	O
in	O
this	O
study	O
73	O
males	O
and	O
53	O
females	O
with	O
ornithine	O
transcarbamylase	O
deficiency	O
OTCD	O
33	O
patients	O
with	O
carbamoylphosphate	O
synthetase	O
1	B-STAT
deficiency	I-STAT
48	I-STAT
with	O
argininosuccinate	O
synthetase	O
deficiency	O
14	O
with	O
argininosuccinate	O
lyase	O
deficiency	O
and	O
8	O
with	O
arginase	O
deficiency	O
.	O

Survival	O
rates	O
at	O
20	O
years	O
of	O
age	O
of	O
male	O
and	O
female	O
patients	O
with	O
late	B-DIS
-	I-DIS
onset	O
OTCD	O
were	O
100	B-STAT
%	I-STAT
and	O
97.7	B-STAT
%	I-STAT
respectively	O
.	O

Blood	O
ammonia	O
levels	O
and	O
time	O
of	O
onset	O
had	O
a	O
significant	O
impact	O
on	O
the	O
neurodevelopmental	O
outcome	O
P	O
<	O
.001	O
and	O
P	O
=	O
.028	O
respectively	O
.	O

Hemodialysis	O
and	O
liver	O
transplantation	O
did	O
not	O
prevent	O
poor	O
neurodevelopmental	O
outcomes	O
.	O

While	O
treatment	O
including	O
medication	O
hemodialysis	O
and	O
liver	O
transplantation	O
may	O
aid	O
in	O
decreasing	O
blood	O
ammonia	O
and/or	O
preventing	O
severe	O
hyperammonemia	B-DIS
a	O
blood	O
ammonia	O
level	O
≥	O
360	O
μmol	O
/	O
L	O
was	O
found	O
to	O
be	O
a	O
significant	O
indicator	O
for	O
a	O
poor	O
neurodevelopmental	O
outcome	O
.	O

In	O
conclusion	O
although	O
current	O
therapy	O
for	O
UCDs	B-DIS
has	O
advanced	O
and	O
helped	O
saving	O
lives	O
patients	O
with	O
blood	O
ammonia	O
levels	O
≥	O
360	O
μmol	O
/	O
L	O
at	O
onset	O
often	B-DIS
have	I-DIS
impaired	O
neurodevelopmental	O
outcomes	O
.	O

Novel	O
neuroprotective	O
measures	O
should	O
therefore	O
be	O
developed	O
to	O
achieve	O
better	O
neurodevelopmental	O
outcomes	O
in	O
these	O
patients	O
.	O

This	O
study	O
aimed	O
to	O
analyze	O
the	O
epidemiology	O
of	O
congenital	B-DIS
upper	I-DIS
limb	I-DIS
anomalies	I-DIS
CULA	O
in	O
Korea	B-LOC
.	O

We	O
evaluated	O
the	O
incidence	B-EPI
of	O
each	O
type	O
of	O
CULA	O
the	O
presence	O
of	O
coexisting	O
anomalies	B-DIS
and	O
the	O
surgical	O
treatment	O
status	O
in	O
CULA	O
patients	O
.	O

We	O
conducted	O
a	O
retrospective	O
cohort	O
study	O
of	O
patients	O
aged	O
<	O
1	B-STAT
year	I-STAT
between	I-STAT
2007	I-STAT
and	O
2016	O
who	O
were	O
registered	O
with	O
CULA	O
in	O
the	O
Health	O
Insurance	O
Review	O
and	O
Assessment	O
Service	O
of	O
Korea	O
.	O

In	O
total	O
10704	O
patients	O
had	O
CULA	O
including	O
6174	B-DIS
boys	O
57.7	B-STAT
%	I-STAT
and	O
4530	O
girls	O
42.3	B-STAT
%	I-STAT
.	O

The	O
mean	O
annual	O
incidence	B-EPI
of	O
CULA	O
was	O
23.5	O
per	O
10000	O
live	O
births	O
;	O
it	O
was	O
significantly	O
higher	O
in	O
boys	O
than	O
in	O
girls	O
26.3	O
vs.	O
20.5	O
p	O
<	O
0.001	O
.	O

Among	O
the	O
four	O
categories	O
of	O
CULA	O
-	B-DIS
polydactyly	O
syndactyly	O
limb	O
deficiency	O
and	O
other	O
anomalies	O
-	O
polydactyly	O
was	O
the	O
most	O
common	O
.	O

In	O
total	O
4149	O
patients	O
38.8	B-STAT
%	I-STAT
had	O
other	O
congenital	B-DIS
anomalies	I-DIS
and	O
coexisting	O
anomalies	O
of	O
the	O
circulatory	O
system	O
24.9	B-STAT
%	I-STAT
were	O
the	O
most	O
common	O
.	O

In	O
total	O
4776	O
patients	O
44.6	B-STAT
%	I-STAT
underwent	O
operative	O
treatment	O
for	O
CULA	O
within	O
minimum	O
three	O
years	O
of	O
the	O
diagnosis	O
.	O

The	O
proportion	O
of	O
patients	O
who	O
underwent	O
surgical	O
treatment	O
was	O
significantly	O
higher	O
for	O
polydactyly	O
73.4	B-STAT
%	I-STAT
vs.	O
16.8	B-STAT
%	I-STAT
p	O
<	O
0.001	O
and	O
syndactyly	B-DIS
65.3	B-STAT
%	I-STAT
vs.	O
41.5	B-STAT
%	I-STAT
p	O
<	O
0.001	O
but	O
it	O
was	O
significantly	O
lower	O
in	O
limb	O
deficiency	O
27.6	B-STAT
%	I-STAT
vs.	O
45.4	B-STAT
%	I-STAT
p	O
<	O
0.001	O
and	O
other	O
anomalies	B-DIS
10.0	B-STAT
%	I-STAT
vs.	O
69.8	B-STAT
%	I-STAT
p	O
<	O
0.001	O
than	O
rest	O
of	O
CULA	O
patients	O
.	O

Among	O
the	O
patients	O
who	O
had	O
operations	O
21.5	B-STAT
%	I-STAT
underwent	O
multiple	O
operations	O
.	O

The	O
proportion	O
of	O
patients	O
who	O
underwent	O
multiple	O
operations	O
was	O
significantly	O
higher	O
in	O
syndactyly	B-DIS
35.6	B-STAT
%	I-STAT
vs.	O
18.1	B-STAT
%	I-STAT
p	O
<	O
0.001	O
but	O
it	O
was	O
significantly	O
lower	O
in	O
polydactyly	O
4.0	B-STAT
%	I-STAT
vs.	O
95.5	B-STAT
%	I-STAT
p	O
<	O
0.001	O
and	O
other	O
anomalies	O
17.9	B-STAT
%	I-STAT
vs.	O
21.9	B-STAT
%	I-STAT
p	O
<	O
0.001	O
than	O
rest	O
of	O
CULA	O
patients	O
.	O

These	O
results	O
could	O
provide	O
a	O
basis	O
for	O
estimating	O
the	O
national	O
healthcare	O
costs	O
for	O
CULA	O
and	O
the	O
required	O
number	O
of	O
CULA	O
specialists	O
.	O

An	O
accurate	O
diagnosis	O
of	O
syndromic	B-DIS
craniosynostosis	I-DIS
CS	O
is	O
important	O
for	O
personalized	O
treatment	O
surveillance	O
and	O
genetic	O
counselling	O
.	O

We	O
describe	O
detailed	O
clinical	O
criteria	O
for	O
syndromic	O
CS	O
and	O
the	O
distribution	O
of	O
genetic	O
diagnoses	O
within	O
the	O
cohort	O
.	O

The	O
prospective	O
registry	O
of	O
the	O
Norwegian	O
National	O
Unit	O
for	O
Craniofacial	O
Surgery	O
was	O
used	O
to	O
retrieve	O
individuals	O
with	O
syndromic	O
CS	O
born	O
between	O
1	B-STAT
January	I-STAT
2002	I-STAT
and	O
30	O
June	O
2019	O
.	O

All	O
individuals	O
were	O
assessed	O
by	O
a	O
clinical	O
geneticist	O
and	O
classified	O
using	O
defined	O
clinical	O
criteria	O
.	O

A	O
stepwise	O
approach	O
consisting	O
of	O
single	O
-	O
gene	O
analysis	O
comparative	O
genomic	O
hybridization	O
aCGH	O
and	O
exome	O
-	O
based	O
high	O
-	O
throughput	O
sequencing	O
first	O
filtering	O
for	O
72	O
genes	O
associated	O
with	O
syndromic	O
CS	O
followed	O
by	O
an	O
extended	O
trio	O
-	O
based	O
panel	O
of	O
1570	O
genes	O
were	O
offered	O
to	O
all	O
syndromic	O
CS	O
cases	O
.	O

A	O
total	O
of	O
381	O
individuals	O
were	O
registered	O
with	O
CS	O
of	O
whom	O
10427	B-STAT
%	I-STAT
were	O
clinically	O
classified	O
as	O
syndromic	O
CS	O
.	O

Using	O
the	O
single	O
-	O
gene	O
analysis	O
aCGH	O
and	O
custom	O
-	O
designed	O
panel	O
a	O
genetic	O
diagnosis	O
was	O
confirmed	O
in	O
73	B-STAT
%	I-STAT
of	O
the	O
individuals	O
n	O
=	O
94	O
.	O

The	O
diagnostic	O
yield	O
increased	O
to	O
84	B-STAT
%	I-STAT
after	O
adding	O
the	O
results	O
from	O
the	O
extended	O
trio	O
-	O
based	O
panel	O
.	O

Common	O
causes	O
of	O
syndromic	O
CS	O
were	O
found	O
in	O
53	O
individuals	O
56	B-STAT
%	I-STAT
whereas	O
2628	B-STAT
%	I-STAT
had	O
other	O
genetic	O
syndromes	O
including	O
17	O
individuals	O
with	O
syndromes	O
not	O
commonly	O
associated	O
with	O
CS	O
.	O

Only	O
15	O
individuals	O
16	B-STAT
%	I-STAT
had	O
negative	O
genetic	O
analyses	O
.	O

Using	O
the	O
defined	O
combination	O
of	O
clinical	O
criteria	O
we	O
detected	O
among	O
the	O
highest	O
numbers	O
of	O
syndromic	O
CS	O
cases	O
reported	O
confirmed	O
by	O
a	O
high	O
genetic	O
diagnostic	O
yield	O
of	O
84	B-STAT
%	I-STAT
.	O

The	O
observed	O
genetic	O
heterogeneity	O
encourages	O
a	O
broad	O
genetic	O
approach	O
in	O
diagnosing	O
syndromic	O
CS	O
.	O

The	O
sexually	O
transmitted	O
enteric	O
infections	B-DIS
topic	O
is	O
one	O
of	O
the	O
chapters	O
of	O
the	O
Clinical	O
Protocol	O
and	O
Therapeutic	O
Guidelines	O
for	O
Comprehensive	O
Care	O
for	O
People	O
with	O
Sexually	O
Transmitted	O
Infections	B-DIS
published	O
by	O
the	O
Brazilian	O
Ministry	O
of	O
Health	O
in	O
2020	O
.	O

The	O
document	O
was	O
developed	O
based	O
on	O
scientific	O
evidence	O
and	O
validated	O
in	O
discussions	O
with	O
specialists	O
.	O

This	O
article	O
presents	O
epidemiological	O
and	O
clinical	O
aspects	O
of	O
these	O
infections	B-DIS
and	O
guidance	O
for	O
service	O
managers	O
on	O
their	O
programmatic	O
and	O
operational	O
management	O
.	O

The	O
aim	O
is	O
to	O
assist	O
health	O
professionals	O
with	O
screening	O
diagnosis	O
and	O
treatment	O
of	O
people	O
with	O
sexually	O
transmitted	O
enteric	O
infections	B-DIS
and	O
their	O
sexual	O
partners	O
in	O
addition	O
to	O
supporting	O
strategies	O
for	O
their	O
surveillance	O
prevention	O
and	O
control	O
.	O

The	O
incidence	B-EPI
of	O
anorectal	O
sexually	O
transmitted	O
infections	B-DIS
has	O
increased	O
over	O
the	O
last	O
years	O
mainly	O
due	O
to	O
the	O
increase	O
in	O
the	O
practice	O
of	O
unprotected	B-DIS
receptive	I-DIS
anal	I-DIS
sexual	I-DIS
intercourse	I-DIS
.	O

Background	O
Chronic	B-DIS
kidney	I-DIS
disease	I-DIS
CKD	I-DIS
in	O
childhood	O
and	O
adolescence	O
occurs	O
with	O
a	O
median	O
incidence	B-EPI
of	O
9	O
per	O
million	O
of	O
the	O
age	O
-	O
related	O
population	O
.	O

Over	B-STAT
70	I-STAT
%	I-STAT
of	O
CKD	O
cases	O
under	O
the	O
age	O
of	O
25	O
years	O
can	O
be	O
attributed	O
to	O
a	O
hereditary	B-DIS
kidney	I-DIS
disease	I-DIS
.	O

Among	O
these	O
are	O
hereditary	B-DIS
podocytopathies	I-DIS
ciliopathies	I-DIS
and	O
monogenic	B-DIS
congenital	I-DIS
anomalies	I-DIS
of	O
the	O
kidney	O
and	O
urinary	B-DIS
tract	I-DIS
CAKUT	O
.	O

These	O
disease	O
entities	O
can	O
present	O
with	O
a	O
vast	O
variety	O
of	O
extrarenal	O
manifestations	O
.	O

So	O
far	O
skeletal	O
anomalies	O
SA	O
have	O
been	O
infrequently	O
described	O
as	O
extrarenal	O
manifestation	O
in	O
these	O
entities	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
retrospectively	O
investigate	O
a	O
cohort	O
of	O
individuals	O
with	O
hereditary	B-DIS
podocytopathies	I-DIS
ciliopathies	I-DIS
or	O
CAKUT	O
in	O
which	O
molecular	O
genetic	O
testing	O
had	O
been	O
performed	O
for	O
the	O
extrarenal	O
manifestation	O
of	O
SA	B-DIS
.	O

Material	O
and	O
Methods	O
A	O
cohort	O
of	O
65	O
unrelated	O
individuals	O
with	O
a	O
clinically	O
presumed	O
hereditary	B-DIS
podocytopathy	I-DIS
focal	I-DIS
segmental	I-DIS
glomerulosclerosis	I-DIS
steroid	I-DIS
resistant	O
nephrotic	B-DIS
syndrome	I-DIS
ciliopathy	I-DIS
nephronophthisis	I-DIS
Bardet	I-DIS
-	I-DIS
Biedl	I-DIS
syndrome	I-DIS
autosomal	I-DIS
recessive	I-DIS
/	I-DIS
dominant	O
polycystic	O
kidney	O
disease	O
or	O
CAKUT	O
was	O
screened	O
for	O
SA	O
.	O

Data	O
was	O
acquired	O
using	O
a	O
standardized	O
questionnaire	O
and	O
medical	O
reports	O
.	O

57/6588	B-STAT
%	I-STAT
of	O
the	O
index	O
cases	O
were	O
analyzed	O
using	O
exome	O
sequencing	O
ES	O
.	O

Results	O
8/6512	B-STAT
%	I-STAT
index	O
individuals	O
presented	O
with	O
a	O
hereditary	B-DIS
podocytopathy	I-DIS
ciliopathy	I-DIS
or	O
CAKUT	O
and	O
an	O
additional	O
skeletal	O
phenotype	O
.	O

In	O
5/8	B-STAT
families	O
63	B-STAT
%	I-STAT
pathogenic	O
variants	O
in	O
known	O
disease	O
-	O
associated	O
genes	O
1x	O
BBS1	O
1x	O
MAFB	O
2x	O
PBX1	O
1x	O
SIX2	O
could	O
be	O
identified	O
.	O

Conclusions	O
This	O
study	O
highlights	O
the	O
genetic	O
heterogeneity	O
and	O
clinical	O
variability	O
of	O
hereditary	B-DIS
nephropathies	I-DIS
in	O
respect	O
of	O
skeletal	O
anomalies	O
as	O
extrarenal	O
manifestation	O
.	O

While	O
the	O
epidemiology	O
of	O
Flaviviruses	O
has	O
been	O
extensively	O
studied	O
in	O
most	O
of	O
the	O
Mediterranean	B-LOC
basin	O
little	O
is	O
known	O
about	O
the	O
current	O
situation	O
in	O
Algeria	B-LOC
.	O

In	O
order	O
to	O
detect	O
the	O
circulation	O
of	O
West	B-LOC
Nile	I-LOC
WNV	I-LOC
and	O
Usutu	B-DIS
viruses	I-DIS
USUV	I-DIS
in	O
Kabylia	B-LOC
165	O
sera	O
were	O
collected	O
from	O
two	O
wild	O
birds	O
species	O
namely	O
the	O
long	O
distance	O
migrant	O
Turdus	O
philomelos	O
song	O
thrush	B-DIS
n	O
=	O
92	O
and	O
the	O
resident	O
Passer	O
domesticus	O
house	O
sparrow	O
n	O
=	O
73	O
.	O

A	O
total	O
of	O
154	O
sera	O
were	O
first	O
analyzed	O
by	O
commercial	O
competition	O
ELISA	O
.	O

WNV	B-DIS
and	O
USUV	B-DIS
micro	O
-	O
neutralization	O
tests	O
were	O
performed	O
on	O
all	O
c	O
-	O
ELISA	O
positive	O
sera	O
and	O
all	O
samples	O
with	O
poor	O
volume	O
.	O

Overall	O
7.8	B-STAT
%	I-STAT
CI95	B-STAT
%	I-STAT
3.5	O
-	O
11.9	O
were	O
positive	O
by	O
c	O
-	O
ELISA	O
.	O

Positive	O
results	O
were	O
detected	O
in	O
12.5	B-STAT
%	I-STAT
CI95	B-STAT
%	I-STAT
5.6	O
-	O
19.4	O
of	O
song	O
thrushes	O
and	O
1.5	B-STAT
%	I-STAT
CI95	B-STAT
%	I-STAT
0.0	O
-	O
4.5	O
for	O
sparrow	O
.	O

Micro	O
-	O
neutralization	O
tests	O
revealed	O
an	O
overall	O
seroprevalence	O
of	O
6.7	B-STAT
%	B-DIS
for	O
WNV	O
CI95	B-STAT
%	I-STAT
2.9	O
-	O
10.3	O
Neutralizing	O
antibodies	O
were	O
found	O
in	O
8.7	B-STAT
%	I-STAT
CI95	B-STAT
%	I-STAT
3.0	O
-	O
14.4	O
for	O
song	O
thrushes	O
and	O
in	O
4.1	B-STAT
%	I-STAT
CI95	B-STAT
%	I-STAT
0.0	O
-	O
8.7	O
of	O
sparrows	O
.	O

The	O
current	O
study	O
demonstrates	O
significant	O
seroprevalence	O
of	O
WNV	B-DIS
antibodies	O
in	O
wild	O
birds	O
in	O
Algeria	B-LOC
.	O

Background	O
Kindler	B-DIS
poikiloderma	I-DIS
is	O
an	O
inherited	O
autosomal	O
genodermatosis	O
characterized	O
by	O
blistering	O
of	O
the	O
epidermis	O
and	O
mucosae	O
.	O

Its	O
prevalence	B-EPI
is	O
unknown	O
.	O

Case	O
report	O
We	O
monitored	O
two	O
brothers	O
suffering	O
from	O
this	O
pathology	O
.	O

Oral	O
manifestations	O
mainly	O
take	O
the	O
form	O
of	O
periodontal	O
lesions	O
.	O

In	O
our	O
patients	O
we	O
noted	O
gingivitis	B-DIS
progressing	O
to	O
periodontitis	B-DIS
as	O
follow	O
-	O
up	O
care	O
was	O
not	O
effective	O
.	O

We	O
also	O
diagnosed	O
enamel	B-DIS
hypoplasia	I-DIS
described	O
more	O
rarely	O
in	O
this	O
pathology	O
.	O

Conclusion	O
Periodontitis	O
in	O
Kindler	B-DIS
Syndrome	I-DIS
responds	O
to	O
maintenance	O
therapy	O
but	O
the	O
absence	O
of	O
surveillance	O
is	O
penalized	O
by	O
a	O
deterioration	O
in	O
periodontal	O
condition	O
and	O
complication	O
of	O
management	O
.	O

All	O
restorative	O
endodontic	O
surgical	O
periodontal	O
and	O
orthodontic	O
treatments	O
should	O
be	O
performed	O
with	O
appropriate	O
precautions	O
.	O

Congenital	B-DIS
hepatic	I-DIS
fibrosis	I-DIS
CHF	I-DIS
is	O
a	O
rare	O
autosomal	B-DIS
recessive	I-DIS
disease	I-DIS
derived	O
from	O
biliary	B-DIS
dysgenesis	I-DIS
secondary	O
to	O
ductal	B-DIS
plate	I-DIS
malformation	I-DIS
;	O
it	O
often	O
coexists	O
with	O
Caroli	B-DIS
's	I-DIS
disease	I-DIS
von	O
Meyenburg	B-DIS
complexes	I-DIS
autosomal	I-DIS
dominant	I-DIS
polycystic	I-DIS
kidney	I-DIS
disease	I-DIS
ADPKD	I-DIS
and	O
autosomal	B-DIS
recessive	I-DIS
polycystic	I-DIS
kidney	I-DIS
disease	I-DIS
ARPKD	I-DIS
.	O

Although	O
CHF	B-DIS
was	O
first	O
named	O
and	O
described	O
in	O
detail	O
by	O
Kerr	O
et	O
al	O
.	O

in	O
1961	O
.	O

Its	O
pathogenesis	O
still	O
remains	O
unclear	O
.	O

The	O
exact	O
incidence	B-EPI
and	O
prevalence	B-EPI
are	O
not	O
known	O
and	O
only	O
a	O
few	O
hundred	O
patients	O
with	O
CHF	B-DIS
have	O
been	O
reported	O
in	O
the	O
literature	O
to	O
date	O
.	O

However	O
with	O
the	O
development	O
of	O
noninvasive	O
diagnostic	O
techniques	O
such	O
as	O
ultrasound	O
computed	O
tomography	O
CT	O
and	O
magnetic	O
resonance	O
imaging	O
MRI	O
CHF	B-DIS
may	O
now	O
be	O
more	O
frequently	O
detected	O
.	O

Anatomopathological	O
examination	O
of	O
liver	O
biopsy	O
is	O
the	O
gold	O
standard	O
in	O
diagnosis	O
of	O
CHF	B-DIS
.	O

Patients	O
with	O
CHF	B-DIS
exhibit	O
variable	O
clinical	O
presentations	O
ranging	O
from	O
no	O
symptoms	O
to	O
severe	O
symptoms	O
such	O
as	O
acute	B-DIS
hepatic	I-DIS
decompensation	I-DIS
and	O
even	O
cirrhosis	B-DIS
.	O

The	O
most	O
common	O
presentations	O
in	O
these	O
patients	O
are	O
splenomegaly	B-DIS
esophageal	B-DIS
varices	I-DIS
and	O
gastrointestinal	B-DIS
bleeding	I-DIS
due	O
to	O
portal	O
hypertension	B-DIS
.	O

In	O
addition	O
in	O
younger	O
children	O
CHF	B-DIS
often	O
is	O
accompanied	O
by	O
renal	B-DIS
cysts	I-DIS
or	O
increased	O
renal	O
echogenicity	O
.	O

Great	O
variability	O
exists	O
among	O
the	O
signs	O
and	O
symptoms	O
of	O
the	O
disease	O
from	O
early	O
childhood	O
to	O
the	O
5	O
th	O
<	O
/s	O
or	O
6	O
th	O
<	O
/s	O
decade	O
of	O
life	O
and	O
in	O
most	O
patients	O
the	O
disorder	B-DIS
is	O
diagnosed	O
during	O
adolescence	O
or	O
young	O
adulthood	O
.	O

Here	O
we	O
present	O
two	O
cases	O
of	O
congenital	B-DIS
hepatic	I-DIS
fibrosis	I-DIS
in	O
2	O
-	O
years	O
-	O
old	O
girl	O
and	O
12	O
-	O
year	O
-	O
old	O
male	O
who	B-DIS
had	I-DIS
been	O
referred	O
for	B-DIS
evaluation	O
of	B-DIS
an	O
abdominal	O
distension	O
with	O
persistent	O
hyper	O
-	O
transaminasemia	O
and	O
cholestasis	O
the	O
diagnostic	O
was	O
made	O
according	O
to	O
the	O
results	O
of	O
medical	O
imaging	O
CT	O
or	O
MRI	O
a	O
liver	O
biopsy	O
and	O
genetic	O
testing	O
.	O

Talaromyces	O
marneffei	O
causes	O
life	O
-	B-DIS
threatening	I-DIS
opportunistic	O
infections	O
mainly	O
in	O
Southeast	B-LOC
Asia	I-LOC
and	O
South	B-LOC
China	I-LOC
.	O

T.	O
marneffei	O
mainly	O
infects	O
patients	O
with	O
human	B-DIS
immunodeficiency	I-DIS
virus	I-DIS
HIV	I-DIS
but	O
also	O
infects	O
individuals	O
without	O
known	O
immunosuppression	O
.	O

Here	O
we	O
investigated	O
the	O
involvement	O
of	O
anti	O
-	O
IFN	O
-	O
γ	O
autoantibodies	O
in	B-DIS
severe	O
T.	O
marneffei	O
infections	O
in	O
HIV	O
-	O
negative	O
patients	O
.	O

We	O
enrolled	O
58	O
HIV	O
-	O
negative	O
adults	O
with	O
severe	O
T.	B-DIS
marneffei	O
infections	O
who	O
were	O
otherwise	O
healthy	O
.	O

We	O
found	O
a	O
high	O
prevalence	B-EPI
of	O
neutralizing	O
anti	O
-	O
IFN	O
-	O
γ	O
autoantibodies	O
94.8	B-STAT
%	I-STAT
in	O
this	O
cohort	O
.	O

The	O
presence	O
of	O
anti	O
-	O
IFN	O
-	O
γ	O
autoantibodies	O
was	O
strongly	O
associated	O
with	O
HLA	O
-	O
DRB1	O
*	O
1602	O
and	O
-DQB1	O
*	O
0502	O
alleles	O
in	O
these	O
patients	O
.	O

We	O
demonstrated	O
that	O
adult	B-DIS
-	O
onset	B-DIS
acquired	O
immunodeficiency	O
due	O
to	O
autoantibodies	O
against	O
IFN	O
-	O
γ	O
is	O
the	O
major	O
cause	O
of	B-DIS
severe	O
T.	O
marneffei	O
infections	O
in	O
HIV	O
-	O
negative	O
patients	O
in	O
regions	O
where	O
this	O
fungus	O
is	O
endemic	O
.	O

The	O
high	O
prevalence	B-EPI
of	O
anti	O
-	O
IFN	O
-	O
γ	O
autoantibody	O
-	O
associated	O
HLA	O
class	O
II	O
DRB1	O
*	O
1602	O
and	O
DQB1	O
*	O
0502	O
alleles	O
may	B-DIS
account	O
for	O
severe	O
T.	O
marneffei	O
infections	O
in	O
Southeast	B-LOC
Asia	I-LOC
.	O

Our	O
findings	O
clarify	O
the	O
pathogenesis	O
of	O
T.	O
marneffei	B-DIS
infection	I-DIS
and	O
pave	O
the	O
way	O
for	O
developing	O
novel	O
treatments	O
.	O

Renal	B-DIS
and	I-DIS
hepatic	I-DIS
functions	I-DIS
are	O
often	O
mingled	O
through	O
both	O
the	O
existence	O
of	O
associated	O
primary	B-DIS
organ	I-DIS
diseases	I-DIS
and	O
hemodynamic	O
co	O
-	O
relationship	O
.	O

The	O
primary	O
objective	O
of	O
this	O
study	O
was	O
to	O
sum	O
up	O
the	O
relationship	O
between	O
autoimmune	B-DIS
hepatitis	I-DIS
AIH	I-DIS
on	O
renal	B-DIS
tubular	I-DIS
acidosis	I-DIS
RTA	O
and	O
the	O
stages	O
of	O
the	O
disease	O
.	O

A	O
systematic	O
review	O
was	O
performed	O
for	O
24	O
trials	O
.	O

A	O
total	O
of	O
3687	B-DIS
patients	O
were	O
included	O
.	O

The	O
incidence	B-EPI
of	O
RTA	O
occurring	O
and	O
short	O
-	O
term	O
mortality	O
reduction	O
was	O
seen	O
in	O
two	O
groups	O
;	O
for	O
an	O
overall	O
effect	O
Z	O
=	O
2.85	O
P	O
=	O
0.004	O
a	O
total	O
95	B-STAT
%	I-STAT
CI	O
of	O
0.53	O
[	O
0.34	O
0.82	O
]	O
.	O

Only	O
one	O
patient	O
with	O
alcoholic	B-DIS
liver	I-DIS
cirrhosis	I-DIS
was	O
found	O
to	O
have	O
an	O
incomplete	O
type	O
of	O
RTA	O
.	O

Test	O
for	O
overall	O
effect	O
Z	O
=	O
2.28	O
P	O
=	O
0.0295	B-STAT
%	I-STAT
CI	O
of	O
2.83	O
[	O
1.16	O
6.95	O
]	O
.	O

A	O
reduction	O
in	O
fatal	O
infections	B-DIS
with	O
dual	O
therapy	O
of	O
corticosteroid	O
plus	O
N	O
-	O
acetylcysteine	O
NAC	O
test	O
for	O
overall	O
effect	O
Z	O
=	O
3.07	O
P	O
=	O
0.002	O
with	O
95	B-STAT
%	I-STAT
CI	O
of	O
0.45	O
[	O
0.27	O
0.75	O
]	O
.	O

Autoimmune	B-DIS
diseases	I-DIS
are	O
the	O
most	O
frequent	O
underlying	O
cause	O
of	O
secondary	O
RTA	O
in	O
adults	O
.	O

The	O
primary	B-DIS
renal	I-DIS
disease	I-DIS
must	O
be	O
actively	O
excluded	O
in	O
all	O
patients	O
with	O
hepatic	B-DIS
failure	I-DIS
by	O
aggressive	O
clinical	O
and	O
laboratory	O
evaluations	O
.	O

Introduction	O
A	O
congenital	B-DIS
lung	I-DIS
abnormality	I-DIS
CLA	O
is	O
often	O
found	O
in	O
conjunction	O
with	O
other	O
abnormalities	O
but	O
screening	O
guidelines	O
for	O
newborns	O
with	O
CLA	O
have	O
not	O
yet	O
been	O
reported	O
.	O

We	O
aimed	O
to	O
assess	O
the	O
incidence	B-EPI
of	O
associated	O
anomalies	B-DIS
in	O
CLA	O
patients	O
born	O
or	O
followed	O
up	O
at	O
our	O
centre	O
and	O
the	O
need	O
for	O
additional	O
screening	O
of	O
newborns	O
with	O
a	O
CLA	O
.	O

Methods	O
From	O
a	O
retrospective	O
chart	O
review	O
of	O
all	O
patients	O
born	O
with	O
a	O
CLA	O
between	O
January	O
1999	O
and	O
January	O
2019	O
we	O
identified	O
patients	O
diagnosed	O
with	O
a	O
congenital	B-DIS
pulmonary	I-DIS
airway	I-DIS
malformation	I-DIS
bronchopulmonary	I-DIS
sequestration	O
congenital	B-DIS
lobar	I-DIS
overinflation	I-DIS
bronchogenic	I-DIS
cyst	I-DIS
or	I-DIS
lung	I-DIS
agenesis	I-DIS
.	O

Associated	O
anomalies	B-DIS
were	O
noted	O
and	O
categorized	O
according	O
to	O
the	O
affected	O
organ	O
system	O
.	O

Results	O
Twenty	B-STAT
-	I-STAT
eight	I-STAT
14	I-STAT
%	I-STAT
of	O
196	O
CLA	O
patients	O
had	O
a	O
major	B-DIS
associated	O
anomaly	O
.	O

This	O
was	O
most	O
frequent	O
in	O
conjunction	O
with	O
a	O
lung	B-DIS
agenesis	I-DIS
100	B-STAT
%	I-STAT
or	O
bronchogenic	O
cyst	O
29	B-STAT
%	I-STAT
.	O

Congenital	B-DIS
heart	I-DIS
defects	I-DIS
32	B-STAT
%	I-STAT
and	O
gastrointestinal	B-DIS
defects	I-DIS
18	B-STAT
%	I-STAT
were	O
the	O
most	O
frequently	O
associated	O
anomalies	B-DIS
.	O

Examination	O
of	O
newborns	O
with	O
a	O
CLA	O
should	O
focus	O
on	O
the	O
cardiovascular	B-DIS
and	I-DIS
gastrointestinal	I-DIS
tract	I-DIS
and	O
a	O
chest	B-DIS
and	I-DIS
abdominal	I-DIS
radiograph	I-DIS
may	O
be	O
useful	O
to	O
assess	O
signs	O
of	O
major	O
associated	O
anomalies	B-DIS
regardless	O
of	O
the	O
clinical	O
course	O
.	O

Background	O
The	O
prevalence	B-EPI
of	O
metabolic	B-DIS
disease	I-DIS
in	O
Nepal	B-LOC
is	O
largely	O
unknown	O
.	O

Some	O
consideration	O
has	O
been	O
given	O
by	O
the	O
nepalese	O
government	O
for	O
high	O
prevalence	B-EPI
of	O
congenital	B-DIS
disorders	I-DIS
in	O
some	O
populations	O
but	O
disorders	O
due	O
to	O
enzymatic	O
deficiencies	O
have	O
not	O
been	O
considered	O
as	O
a	O
class	O
of	O
diseases	O
where	O
timely	O
diagnosis	O
and	O
intervention	O
might	O
be	O
possible	O
.	O

No	O
case	O
for	O
these	O
disorders	O
has	O
been	O
made	O
so	O
far	O
however	O
findings	O
of	O
many	O
rare	O
metabolic	B-DIS
diseases	I-DIS
have	O
been	O
reported	O
in	O
literature	O
by	O
the	O
nepalese	O
medical	O
fraternity	O
.	O

Methods	O
A	O
search	O
for	O
case	O
reports	O
on	O
metabolic	B-DIS
disorders	I-DIS
listed	O
according	O
to	O
International	O
Classification	O
of	O
Diseases	O
-11	O
was	O
performed	O
using	O
the	O
google	O
search	O
engine	O
.	O

Results	O
A	O
total	O
of	O
443	O
cases	O
have	O
been	O
discovered	O
presented	O
in	O
the	O
literature	O
.	O

This	O
does	O
not	O
include	O
disorders	O
that	O
might	O
be	O
due	O
to	O
lifestyle	O
and	O
behaviour	O
.	O

Most	O
of	O
the	O
reported	O
cases	O
have	O
been	O
identified	O
based	O
on	O
clinical	O
acumen	O
radiological	O
and	O
histopathological	O
findings	O
.	O

Conclusions	O
Glucose	O
6	O
phosphate	O
dehydrogenase	O
deficiency	O
Wilson	B-DIS
's	I-DIS
disease	I-DIS
and	O
lysosomal	O
disorders	O
should	O
be	O
considered	O
for	O
early	O
diagnosis	O
through	O
newborn	O
screening	O
along	O
with	O
the	O
acknowledged	O
disorders	B-DIS
hypothyroidism	I-DIS
and	O
hemoglobinopathies	B-DIS
in	O
Nepal	B-LOC
.	O

Early	O
intervention	O
in	O
these	O
disorders	O
can	O
significantly	O
reduce	O
morbidity	O
and	O
mortality	O
in	O
infancy	O
.	O

Down	B-DIS
syndrome	I-DIS
DS	O
is	O
the	O
most	O
common	O
chromosome	O
abnormality	O
with	O
a	O
unique	O
cancer	B-DIS
predisposition	I-DIS
syndrome	I-DIS
pattern	O
a	O
higher	O
risk	O
to	O
develop	O
acute	B-DIS
leukemia	I-DIS
and	O
a	O
lower	O
incidence	B-EPI
of	O
solid	O
tumors	B-DIS
.	O

In	O
particular	O
brain	B-DIS
tumors	I-DIS
are	O
rarely	O
reported	O
in	O
the	O
DS	O
population	O
and	O
biological	O
behavior	O
and	O
natural	O
history	O
are	O
not	O
well	O
described	O
and	O
identified	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
10	O
-	O
year	O
-	O
old	O
child	O
with	O
DS	O
who	B-DIS
presented	O
with	O
a	O
medulloblastoma	O
MB	O
.	O

Histological	O
examination	O
revealed	O
a	O
classic	O
MB	O
with	O
focal	B-DIS
anaplasia	I-DIS
and	O
the	O
molecular	O
profile	O
showed	O
the	O
presence	O
of	O
a	O
CTNNB1	O
variant	O
associated	O
with	O
the	O
wingless	O
WNT	O
molecular	O
subgroup	O
with	O
a	O
good	O
prognosis	O
in	O
contrast	O
to	O
our	O
case	O
report	O
that	O
has	O
shown	O
an	O
early	O
metastatic	O
relapse	O
.	O

The	O
nearly	O
seven	O
-	O
fold	O
decreased	O
risk	O
of	O
MB	O
in	O
children	O
with	O
DS	O
suggests	O
the	O
presence	O
of	O
protective	O
biological	O
mechanisms	O
.	O

The	O
cerebellum	B-DIS
hypoplasia	I-DIS
and	O
the	O
reduced	O
volume	B-DIS
of	I-DIS
cerebellar	I-DIS
granule	I-DIS
neuron	I-DIS
progenitor	I-DIS
cells	O
seem	O
to	O
be	O
a	O
possible	O
favorable	O
condition	O
to	O
prevent	O
MB	O
development	O
via	O
inhibition	O
of	O
neuroectodermal	B-DIS
differentiation	O
.	O

Moreover	O
the	O
NOTCH	O
/	O
WNT	O
dysregulation	O
in	O
DS	O
which	O
is	O
probably	O
associated	O
with	O
an	O
increased	O
risk	B-DIS
of	O
leukemia	O
suggests	O
a	O
pivotal	O
role	O
of	O
this	O
pathway	O
alteration	O
in	O
the	O
pathogenesis	O
of	O
MB	O
;	O
therefore	O
this	O
condition	O
should	O
be	O
further	O
investigated	O
in	O
future	O
studies	O
by	O
molecular	O
characterizations	O
.	O

Background	O
.	O

Vitamin	O
C	O
E	O
D	O
A	O
zinc	O
are	O
considered	O
to	O
be	O
essential	O
in	O
preventing	O
and	O
treating	O
of	O
acute	O
respiratory	B-DIS
infections	I-DIS
ARI	O
including	O
COVID-19	O
.	O

Methods	O
.	O

We	O
reviewed	O
published	O
studies	O
evaluating	O
the	O
potential	O
roles	O
of	O
these	O
vitamin	O
and	O
zinc	O
for	O
ARIs	B-DIS
and	O
COVID-19	O
using	O
Medline	O
database	O
medRxiv	O
and	O
bibliographic	O
references	O
.	O

Results	O
.	O

Vitamins	O
C	O
D	O
and	O
E	O
did	O
not	O
reduce	O
incidence	B-EPI
of	O
common	O
cold	O
in	O
general	O
but	O
vitamin	O
C	O
reduced	O
by	O
half	O
in	O
population	O
with	O
physical	O
and	O
environment	O
stresses	O
.	O

Vitamins	O
C	O
and	O
E	O
shortened	O
duration	O
and	O
reduced	O
severity	O
of	O
common	O
cold	O
.	O

A	O
large	O
-	O
dose	O
vitamin	O
A	O
had	O
no	O
effect	O
on	O
recovery	B-DIS
from	O
pneumonia	O
.	O

Zinc	O
improved	O
clinical	O
deterioration	O
and	O
pneumonia	B-DIS
duration	O
in	O
under	O
five	O
.	O

The	O
effect	O
on	O
preventing	O
COVID-19	O
morbidity	O
and	O
related	O
-	O
death	O
was	O
lacking	O
.	O

Conclusions	O
.	O

Although	O
the	O
effects	O
of	O
vitamins	O
and	O
zinc	O
on	O
ARIs	B-DIS
including	O
COVID-19	O
were	O
inconclusive	O
taking	O
these	O
for	O
a	O
short	O
period	O
during	O
pandemic	B-DIS
may	O
be	O
beneficial	O
when	O
there	O
is	O
risks	O
of	O
deficiency	O
.	O

Methylmalonic	B-DIS
acidemia	I-DIS
MMA	O
is	O
a	O
lethal	O
severe	O
heterogeneous	B-DIS
disorder	I-DIS
of	O
methylmalonate	O
and	O
cobalamin	O
cbl	O
;	O
vitamin	O
B12	O
metabolism	O
with	O
poor	O
prognosis	O
.	O

Two	O
main	O
forms	O
of	O
the	O
disease	O
have	O
been	O
identified	O
isolated	O
methylmalonic	B-DIS
acidurias	I-DIS
and	O
combined	O
methylmalonic	B-DIS
aciduria	I-DIS
and	O
homocystinuria	B-DIS
which	O
is	O
respectively	O
caused	O
by	O
different	O
gene	O
mutations	O
.	O

Here	O
we	O
review	O
the	O
improvement	O
of	O
pathogenesis	O
diagnosis	O
and	O
treatment	O
in	O
MMA	B-LOC
.	O

Importantly	O
the	O
reported	O
epidemiological	O
data	O
of	O
MMA	O
patients	O
in	O
China	B-LOC
and	O
the	O
hot	O
mutation	O
sites	O
in	O
Chinese	O
patients	O
are	O
listed	O
which	O
will	O
aid	O
in	O
improving	O
healthcare	O
of	O
Chinese	O
patients	O
in	O
the	O
future	O
.	O

c.729_730insTT	O
was	O
the	O
most	O
common	O
mutation	O
in	O
Chinese	O
isolated	O
MMA	O
patients	O
while	O
c.60	O
A	O
and	O
c.658_660delAAG	O
were	O
in	O
Chinese	O
cblC	B-DIS
type	O
patients	O
according	O
to	O
unrelated	O
studies	O
.	O

The	O
estimated	O
newborn	O
screening	O
incidence	B-EPI
was	O
reported	O
to	O
be	O
12600013	O
920111	O
16016	O
032	O
respectively	O
in	O
Beijing	B-LOC
and	O
Shanghai	B-LOC
Shandong	I-LOC
province	O
Taian	B-LOC
district	O
and	O
Henan	B-LOC
province	I-LOC
of	I-LOC
China	B-LOC
.	O

Alternatively	O
when	O
patients	O
with	O
suspected	O
inherited	O
metabolic	B-DIS
diseases	I-DIS
were	O
used	O
as	O
the	O
screened	O
sample	O
the	O
relatively	O
high	O
incidence	B-EPI
0.3	B-STAT
%	I-STAT
and	O
1.32	B-STAT
%	I-STAT
were	O
respectively	O
obtained	O
in	O
southern	O
China	B-LOC
and	O
throughout	O
all	O
the	O
provinces	O
of	O
mainland	O
China	B-LOC
and	O
Macao	B-LOC
with	O
the	O
exception	O
of	O
five	O
provinces	O
Hainan	B-LOC
Neimenggu	I-LOC
Tibet	B-LOC
Ningxia	I-LOC
and	O
Hong	B-LOC
Kong	I-LOC
.	O

BACKGROUNDLesch	O
-	O
Nyhan	O
syndrome	O
LNS	O
is	B-DIS
a	I-DIS
congenital	I-DIS
X	I-DIS
-	I-DIS
linked	O
recessive	O
neurogenetic	O
disorder	O
caused	O
by	O
mutations	O
in	O
the	O
hypoxanthine	O
-	O
guanine	O
phosphoribosyltransferase	O
HPRT	O
gene	O
.	O

The	O
main	O
clinical	O
manifestation	O
includes	O
hyperuricemia	B-DIS
juvenile	I-DIS
-	I-DIS
onset	I-DIS
gouty	O
arthritis	B-DIS
and	I-DIS
neurological	I-DIS
developmental	O
disorders	O
.	O

Studies	O
have	O
reported	O
more	O
than	O
400	O
HPRT	O
gene	O
mutation	O
sites	O
but	O
the	O
incidence	B-EPI
of	O
LNS	O
in	O
the	O
Chinese	O
population	O
is	O
extremely	O
low	O
.	O

METHODSHere	O
we	O
report	O
a	O
16	O
-	O
year	O
-	O
old	O
male	B-DIS
patient	I-DIS
who	O
suffered	O
neurological	O
dysfunction	O
at	O
an	B-DIS
early	I-DIS
age	O
and	O
gouty	O
arthritis	O
in	O
his	O
youth	O
.	O

RESULTSNo	O
activity	O
of	O
the	O
HPRT	O
enzyme	O
was	O
detected	O
in	O
the	O
erythrocytes	O
.	O

Furthermore	O
we	O
found	O
a	O
mutation	O
on	O
exon	O
3	O
of	O
the	O
HPRT	O
gene	O
in	O
the	O
patient	O
and	O
his	O
mother	O
exon	O
3	O
c.14	O
A	O
which	O
resulted	O
in	O
arginine	O
to	O
histidine	O
p.	O
R48H	O
substitution	O
in	O
the	O
encoded	O
protein	O
.	O

The	O
same	O
mutation	O
was	O
reported	O
in	O
several	O
European	O
families	O
but	O
was	O
found	O
for	O
the	O
first	O
time	O
in	O
a	O
Chinese	O
family	O
.	O

CONCLUSIONSClinicians	O
in	O
China	B-LOC
have	O
poor	O
experience	O
in	O
diagnosing	O
LNS	O
cases	O
due	O
to	O
the	O
low	O
incidence	B-EPI
in	O
China	B-LOC
.	O

Therefore	O
LNS	O
screening	O
for	O
infants	O
or	O
adolescents	O
with	O
hyperuricemia	B-DIS
gouty	I-DIS
arthritis	I-DIS
and	O
neurological	B-DIS
dysfunction	I-DIS
should	O
be	O
performed	O
.	O

The	O
congenital	B-DIS
long	I-DIS
QT	I-DIS
syndrome	I-DIS
LQTS	I-DIS
is	O
an	O
inherited	O
cardiac	B-DIS
disorder	I-DIS
characterized	O
by	O
increased	O
QT	O
intervals	O
and	O
a	O
tendency	O
to	O
experience	O
ventricular	B-DIS
tachycardia	I-DIS
which	O
can	O
cause	O
fainting	B-DIS
heart	I-DIS
failure	I-DIS
or	O
sudden	O
death	O
.	O

A	O
4	O
-	O
year	O
-	O
old	O
female	O
patient	O
undergoing	O
velopharyngeal	O
correction	O
surgery	O
under	O
general	B-DIS
anesthesia	I-DIS
suddenly	I-DIS
developed	O
Torsades	O
de	O
pointes	O
.	O

Although	O
the	O
patient	O
spontaneously	O
resolved	O
to	O
sinus	O
rhythm	O
without	O
treatment	O
subsequent	O
QT	O
prolongation	O
persisted	O
.	O

Here	O
we	O
report	O
a	O
case	O
of	O
concealed	O
LQTS	B-DIS
with	O
a	O
literature	O
review	O
.	O

OBJECTIVESThe	O
incidence	B-EPI
of	O
neonatal	O
herpes	B-DIS
simplex	I-DIS
virus	O
nHSV	O
infections	B-DIS
is	O
monitored	O
periodically	O
in	O
the	O
Netherlands	B-LOC
yet	O
management	O
and	O
outcome	O
is	O
unknown	O
.	O

Comprehensive	O
national	O
guidelines	O
are	O
lacking	O
.	O

We	O
aim	O
to	O
describe	O
management	O
and	O
outcome	O
in	O
the	O
last	O
decade	O
to	O
explore	O
current	O
diagnostic	O
and	O
therapeutic	O
challenges	O
.	O

We	O
aim	O
to	O
identify	O
possible	O
variability	O
in	O
management	O
of	O
patients	O
with	O
a	O
suspected	O
nHSV	O
infection	B-DIS
.	O

METHODSWe	O
conducted	O
a	O
retrospective	O
case	O
series	O
of	O
management	O
and	O
outcome	O
of	O
nHSV	O
infections	B-DIS
at	O
2	O
tertiary	O
care	O
center	O
locations	O
in	O
the	O
Netherlands	B-LOC
.	O

RESULTSAn	O
nHSV	O
infection	O
was	O
diagnosed	O
in	O
1	B-STAT
%	I-STAT
12	I-STAT
of	O
1348	O
of	O
patients	O
in	O
whom	O
polymerase	O
chain	O
reaction	O
for	O
HSV	O
was	O
performed	O
.	O

Of	O
the	O
patients	O
with	O
nHSV	O
infection	O
3	O
of	O
12	O
died	O
and	O
4	O
of	O
944	B-STAT
%	I-STAT
survivors	O
suffered	O
neurologic	B-DIS
sequelae	I-DIS
.	O

Neurologic	O
symptoms	O
at	O
presentation	O
were	O
seen	O
in	O
only	O
2	O
of	O
8	O
patients	O
with	O
nHSV	O
encephalitis	B-DIS
.	O

A	O
cerebral	O
spinal	O
fluid	O
analysis	O
was	O
performed	O
in	O
3	O
of	O
6	O
patients	O
presenting	O
with	O
skin	O
lesions	O
.	O

Only	O
3	O
of	O
6	O
patients	O
with	O
neurologic	O
symptoms	O
received	O
suppressive	O
therapy	O
.	O

nHSV	O
infection	B-DIS
was	O
diagnosed	O
in	O
8	O
of	O
1894	B-STAT
%	I-STAT
patients	O
who	O
were	O
empirically	O
treated	O
.	O

CONCLUSIONSManagement	O
of	O
nHSV	O
infection	O
particularly	O
when	O
presented	O
with	O
skin	B-DIS
lesions	I-DIS
is	O
inconsistent	O
.	O

Many	O
infants	O
without	O
a	O
HSV	B-DIS
infection	I-DIS
are	O
exposed	O
to	O
antiviral	O
medication	O
.	O

There	O
is	O
substantial	O
interhospital	O
variation	O
in	O
diagnostic	O
and	O
therapeutic	O
management	O
of	O
a	O
suspected	O
infection	B-DIS
.	O

Comprehensive	O
guidelines	O
need	O
to	O
be	O
developed	O
to	O
standardize	O
management	O
of	O
suspected	O
nHSV	O
infection	B-DIS
.	O

Diseases	B-DIS
of	I-DIS
the	I-DIS
retina	I-DIS
are	O
major	O
causes	O
of	O
visual	B-DIS
impairment	I-DIS
and	O
blindness	O
in	O
developed	O
countries	O
and	O
due	O
to	O
an	O
ageing	O
population	O
their	O
prevalence	B-EPI
is	O
continually	O
rising	O
.	O

The	O
lack	O
of	O
effective	O
therapies	O
and	O
the	O
limitations	O
of	O
those	O
currently	O
in	O
use	O
highlight	O
the	O
importance	O
of	O
continued	O
research	O
into	O
the	O
pathogenesis	O
of	O
these	O
diseases	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
VEGF	O
plays	O
a	O
major	O
role	O
in	O
driving	O
vascular	B-DIS
dysfunction	I-DIS
in	O
retinal	B-DIS
disease	I-DIS
and	O
has	O
therefore	O
become	O
a	O
key	O
therapeutic	O
target	O
.	O

Recent	O
evidence	O
also	O
points	O
to	O
a	O
potentially	O
similarly	O
important	O
role	O
of	O
galectins	O
a	O
family	O
of	O
β	O
-	O
galactoside	O
-	O
binding	O
proteins	O
.	O

Indeed	O
they	O
have	O
been	O
implicated	O
in	O
regulating	O
fundamental	O
processes	O
including	O
vascular	O
hyperpermeability	O
angiogenesis	O
neuroinflammation	B-DIS
and	O
oxidative	O
stress	O
all	O
of	O
which	O
also	O
play	O
a	O
prominent	O
role	O
in	O
retinopathies	B-DIS
.	O

Here	O
we	O
review	O
direct	O
evidence	O
for	O
pathological	O
roles	O
of	O
galectins	O
in	O
retinal	B-DIS
disease	I-DIS
.	O

In	O
addition	O
we	O
extrapolate	O
potential	O
roles	O
of	O
galectins	O
in	O
the	O
retina	O
from	O
evidence	O
in	O
cancer	B-DIS
immune	I-DIS
and	O
neuro	O
-	O
biology	O
.	O

We	O
conclude	O
that	O
there	O
is	O
value	O
in	O
increasing	O
understanding	O
of	O
galectin	O
function	O
in	O
retinal	O
biology	O
in	O
particular	O
in	O
the	O
context	O
of	O
the	O
retinal	O
vasculature	O
and	O
microglia	O
.	O

With	O
greater	O
insight	O
recent	O
clinical	O
developments	O
of	O
galectin	O
-	O
targeting	O
drugs	O
could	O
potentially	O
also	O
be	O
of	O
benefit	O
to	O
the	O
clinical	O
management	O
of	O
many	O
blinding	O
diseases	O
.	O

This	O
study	O
aims	O
to	O
identify	O
the	O
baseline	O
patient	O
characteristics	O
clinical	O
presentation	O
and	O
response	O
to	O
treatment	O
of	O
11	O
patients	O
who	O
were	O
diagnosed	O
with	O
thrombotic	B-DIS
thrombocytopenic	I-DIS
purpura	I-DIS
TTP	I-DIS
between	O
2014	O
and	O
2020	O
at	O
Brookdale	O
University	O
Hospital	O
Medical	O
Center	O
Brooklyn	O
NY	B-LOC
.	O

Laboratory	O
and	O
clinical	O
parameters	O
were	O
recorded	O
for	O
29	O
patients	O
who	O
received	O
plasmapheresis	O
in	O
this	O
time	O
period	O
.	O

Of	O
29	O
patients	O
11	O
had	O
confirmed	O
TTP	B-DIS
and	O
one	O
was	O
diagnosed	O
with	O
hereditary	B-DIS
TTP	I-DIS
.	O

Young	O
black	O
and	O
female	O
patients	O
made	O
up	O
the	O
majority	O
of	O
our	O
patient	O
population	O
.	O

A	O
high	O
prevalence	B-EPI
of	O
obesity	B-DIS
and	O
drug	B-DIS
abuse	I-DIS
were	O
seen	O
among	O
our	O
patients	O
.	O

Five	O
out	O
of	O
11	O
were	O
obese	O
and	O
four	O
of	O
them	O
were	O
morbidly	O
obese	O
;	O
six	O
out	O
of	O
11	O
patients	O
were	O
positive	O
for	O
the	O
drug	O
screen	O
including	O
cannabinoids	O
3	O
opiates	O
2	O
benzodiazepines	O
1	B-STAT
PCP	B-DIS
1	B-STAT
and	I-STAT
methadone	I-STAT
1	I-STAT
.	O

Four	O
patients	O
with	O
a	O
positive	O
drug	O
screen	O
had	O
acute	B-DIS
kidney	I-DIS
injury	I-DIS
AKI	I-DIS
and	O
plasmapheresis	O
helped	O
them	O
enhance	O
their	O
kidney	O
function	O
.	O

We	O
observed	O
a	O
high	O
incidence	B-EPI
of	O
AKI	B-DIS
and	O
high	O
TTP	B-DIS
exacerbation	O
rates	O
in	O
patients	O
who	O
were	O
drug	O
abusers	O
and	O
those	O
who	O
were	O
morbidly	O
obese	O
.	O

There	O
is	O
a	O
paucity	O
of	O
data	O
on	O
the	O
relationship	O
of	O
TTP	B-DIS
with	O
obesityor	B-DIS
drug	I-DIS
abuse	I-DIS
and	O
this	O
needs	O
further	O
study	O
.	O

CT	O
-	O
based	O
quantitative	O
analysis	O
of	O
any	O
ossification	O
center	O
in	O
the	O
cranium	O
has	O
not	O
previously	O
been	O
carried	O
out	O
due	O
to	O
the	O
limited	O
availability	O
of	O
human	O
fetal	O
material	O
.	O

Detailed	O
morphometric	O
data	O
on	O
the	O
development	O
of	O
ossification	O
centers	O
in	O
the	O
human	O
fetus	O
may	O
be	O
useful	O
in	O
the	O
early	O
detection	O
of	O
congenital	B-DIS
defects	I-DIS
.	O

Ossification	B-DIS
disorders	I-DIS
in	O
the	O
cranium	O
are	O
associated	O
with	O
either	O
a	O
delayed	O
development	O
of	O
ossification	O
centers	O
or	O
their	O
mineralization	O
.	O

These	O
aberrations	O
may	O
result	O
in	O
the	O
formation	O
of	O
accessory	O
skull	O
bones	O
that	O
differ	O
in	O
shape	O
and	O
size	O
and	O
the	O
incidence	B-EPI
of	O
which	O
may	O
be	O
misdiagnosed	O
as	O
e.g	O
.	O

skull	B-DIS
fractures	I-DIS
.	O

The	O
study	O
material	O
comprised	O
37	O
human	O
fetuses	O
of	O
both	O
sexes	O
16	O
♂	O
21	O
♀	B-LOC
aged	O
18	O
-	O
30	O
weeks	O
.	O

Using	O
CT	O
digital	O
image	O
analysis	O
software	O
3D	O
reconstruction	O
and	O
statistical	O
methods	O
the	O
linear	O
planar	O
and	O
spatial	O
dimensions	O
of	O
the	O
occipital	O
squama	O
ossification	O
center	O
were	O
measured	O
.	O

The	O
morphometric	O
characteristics	O
of	O
the	O
fused	O
ossification	O
center	O
of	O
the	O
occipital	O
squama	O
show	O
no	O
right	O
-	O
left	O
differences	O
.	O

In	O
relation	O
to	O
gestational	O
age	O
the	O
ossification	O
center	O
of	O
the	O
occipital	O
squama	O
grows	O
linearly	O
in	O
its	O
right	O
and	O
left	O
vertical	O
diameters	O
logarithmically	O
in	O
its	O
transverse	O
diameters	O
of	O
both	O
the	O
interparietal	O
and	O
supraoccipital	O
parts	O
and	O
projection	O
surface	O
area	O
and	O
according	O
to	O
a	O
quadratic	O
function	O
in	O
its	O
volume	O
.	O

The	O
obtained	O
numerical	O
findings	O
of	O
the	O
occipital	O
squama	O
ossification	O
center	O
may	O
be	O
considered	O
age	O
-	O
specific	O
references	O
of	O
relevance	O
in	O
both	O
the	O
estimation	O
of	O
gestational	O
age	O
and	O
the	O
diagnostic	O
process	B-DIS
of	I-DIS
congenital	O
defects	O
.	O

Antiretroviral	O
therapy	O
ART	O
has	O
significantly	O
improved	O
life	O
expectancy	O
of	O
infected	O
subjects	O
generating	O
a	O
new	O
epidemiological	O
setting	O
of	O
people	O
aging	O
withHuman	O
Immunodeficiency	O
Virus	O
HIV	O
.	O

People	O
living	O
with	O
HIV	O
PLWH	O
having	O
longer	O
life	O
expectancy	O
now	O
face	O
several	O
age	O
-	O
related	O
conditions	O
as	O
well	O
as	O
side	O
effects	O
of	O
long	O
-	O
term	O
exposure	O
of	O
ART	O
.	O

Chronic	B-DIS
kidney	I-DIS
disease	I-DIS
CKD	I-DIS
is	O
a	O
common	O
comorbidity	B-DIS
in	O
this	O
population	O
.	O

CKD	O
is	O
a	O
relentlessly	O
progressive	O
disease	O
that	O
may	O
evolve	O
toward	O
end	B-DIS
-	I-DIS
stage	I-DIS
renal	I-DIS
disease	O
ESRD	O
and	O
significantly	O
affect	O
quality	O
of	O
life	O
and	O
risk	B-DIS
of	O
death	O
.	O

Herein	O
we	O
review	O
current	O
understanding	O
of	O
renal	O
involvement	O
in	O
PLWH	O
mechanisms	O
and	O
risk	O
factors	O
for	O
CKD	O
as	O
well	O
as	O
strategies	O
for	O
early	O
recognition	O
of	O
renal	B-DIS
dysfunction	I-DIS
and	O
best	O
care	O
of	O
CKD	B-DIS
.	O

The	O
diagnosis	O
of	O
autoimmune	B-DIS
polyglandular	I-DIS
syndrome	I-DIS
APS	I-DIS
types	O
1/2	B-STAT
is	O
difficult	O
due	O
to	O
their	O
rarity	O
and	O
nonspecific	O
clinical	O
manifestations	O
.	O

APS-1	O
development	O
can	O
be	O
identified	O
with	O
assays	O
for	O
autoantibodies	O
against	O
cytokines	O
and	O
APS-2	O
development	O
with	O
organ	O
-	O
specific	O
antibodies	O
.	O

In	O
this	O
study	O
a	O
microarray	O
-	O
based	O
multiplex	O
assay	O
was	O
proposed	O
for	O
simultaneous	O
detection	O
of	O
both	O
organ	O
-	O
specific	O
anti-21	O
-	O
OH	O
anti	O
-	O
GAD-65	O
anti	O
-	O
IA2	O
anti	O
-	O
ICA	O
anti	O
-	O
TG	O
and	O
anti	O
-	O
TPO	O
and	O
APS-1	O
-	O
specific	O
anti	O
-	O
IFN	O
-	O
ω	O
anti	O
-	O
IFN	O
-	O
α-2a	O
and	O
anti	O
-	O
IL-22	O
autoantibodies	O
.	O

Herein	O
206	O
serum	O
samples	O
from	O
adult	O
patients	O
with	O
APS-1	B-DIS
APS-2	I-DIS
isolated	O
autoimmune	B-DIS
endocrine	I-DIS
pathologies	I-DIS
or	O
non	B-DIS
-	I-DIS
autoimmune	I-DIS
endocrine	O
pathologies	O
and	O
from	O
healthy	O
donors	O
were	O
analyzed	O
.	O

The	O
prevalence	B-EPI
of	O
autoantibodies	O
differed	O
among	O
the	O
groups	O
of	O
healthy	O
donors	O
and	O
patients	O
with	O
non-	O
mono-	O
and	O
multi	B-DIS
-	I-DIS
endocrine	O
diseases	O
.	O

APS-1	B-DIS
patients	O
were	O
characterized	O
by	O
the	O
presence	O
of	O
at	O
least	O
two	O
specific	O
autoantibodies	O
specificity	O
99.5	B-STAT
%	I-STAT
sensitivity	O
100	B-STAT
%	I-STAT
.	O

Furthermore	O
in	O
16	O
of	O
the	O
18	O
patients	O
the	O
APS-1	O
assay	O
revealed	O
triple	O
positivity	O
for	O
autoantibodies	O
against	O
IFN	O
-	O
ω	O
IFN	O
-	O
α-2a	O
and	O
IL-22	O
specificity	O
100	B-STAT
%	I-STAT
sensitivity	O
88.9	B-STAT
%	I-STAT
.	O

No	O
anti	O
-	O
cytokine	O
autoantibodies	O
were	O
found	O
in	O
the	O
group	O
of	O
patients	O
with	B-DIS
non	I-DIS
-	O
APS-1	O
polyendocrine	O
autoimmunity	O
.	O

The	O
accuracy	O
of	O
the	O
microarray	O
-	O
based	O
assay	O
compared	O
to	O
ELISA	O
for	O
organ	O
-	O
specific	O
autoantibodies	O
was	O
88.8	B-STAT
-	I-STAT
97.6	I-STAT
%	I-STAT
.	O

This	O
multiplex	O
assay	O
can	O
be	O
part	O
of	O
the	O
strategy	O
for	O
diagnosing	O
and	O
predicting	O
the	O
development	O
of	O
APS	B-DIS
.	O

Background	O
Lipodystrophy	B-DIS
syndromes	I-DIS
are	O
a	O
group	O
of	O
disorders	O
characterized	O
by	O
a	O
loss	B-DIS
of	I-DIS
adipose	I-DIS
tissue	O
once	O
other	O
situations	O
of	O
nutritional	O
deprivation	O
or	O
exacerbated	O
catabolism	O
have	O
been	O
ruled	O
out	O
.	O

With	O
the	O
exception	O
of	O
the	O
HIV	B-DIS
-	I-DIS
associated	O
lipodystrophy	O
they	O
have	O
a	O
very	B-EPI
low	O
prevalence	O
which	O
together	O
with	O
their	O
large	O
phenotypic	O
heterogeneity	O
makes	O
their	O
identification	O
difficult	O
even	O
for	O
endocrinologists	O
and	O
pediatricians	O
.	O

This	O
leads	O
to	O
significant	O
delays	O
in	O
diagnosis	O
or	O
even	O
to	O
misdiagnosis	O
.	O

Our	O
group	O
has	O
developed	O
an	O
algorithm	O
that	O
identifies	O
the	O
more	O
than	O
40	O
rare	O
lipodystrophy	O
subtypes	O
described	O
to	O
date	O
.	O

This	O
algorithm	O
has	O
been	O
implemented	O
in	O
a	O
free	O
mobile	O
application	O
LipoDDx	O
®	O
.	O

Our	O
aim	O
was	O
to	O
establish	O
the	O
effectiveness	O
of	O
LipoDDx	O
®	O
.	O

Forty	O
clinical	O
records	O
of	O
patients	O
with	O
a	O
diagnosis	O
of	O
certainty	O
of	O
most	O
lipodystrophy	B-DIS
subtypes	O
were	O
analyzed	O
including	O
subjects	O
without	O
lipodystrophy	B-DIS
.	O

The	O
medical	O
records	O
blinded	O
for	O
diagnosis	O
were	O
evaluated	O
by	O
13	O
physicians	O
1	B-STAT
biochemist	I-STAT
and	I-STAT
1	I-STAT
dentist	O
.	O

Each	O
evaluator	O
first	O
gave	O
his	O
/	O
her	O
results	O
based	O
on	O
his	O
/	O
her	O
own	O
criteria	O
.	O

Then	O
a	O
second	O
diagnosis	O
was	O
given	O
using	O
LipoDDx	O
®	O
.	O

The	O
results	O
were	O
analysed	O
based	O
on	O
a	O
score	O
table	O
according	O
to	O
the	O
complexity	O
of	O
each	O
case	O
and	O
the	O
prevalence	B-EPI
of	O
the	O
disease	O
.	O

Results	O
LipoDDx	O
®	O
provides	O
a	O
user	O
-	O
friendly	O
environment	O
based	O
on	O
usually	O
dichotomous	O
questions	O
or	O
choice	O
of	O
clinical	O
signs	O
from	O
drop	O
-	O
down	O
menus	O
.	O

The	O
final	O
result	O
provided	O
by	O
this	O
app	O
for	O
a	O
particular	O
case	O
can	O
be	O
a	O
low	O
/	O
high	O
probability	O
of	O
suffering	O
a	O
particular	O
lipodystrophy	O
subtype	O
.	O

Without	O
using	O
LipoDDx	O
®	O
the	O
success	O
rate	O
was	O
17	B-STAT
±	I-STAT
20	I-STAT
%	I-STAT
while	O
with	O
LipoDDx	O
®	O
the	O
success	O
rate	O
was	O
79	B-STAT
±	I-STAT
20	I-STAT
%	I-STAT
p	O
<	O
0.01	O
.	O

Conclusions	O
LipoDDx	O
®	O
is	O
a	O
free	O
app	O
that	O
enables	O
the	O
identification	O
of	O
subtypes	O
of	O
rare	O
lipodystrophies	B-DIS
which	O
in	O
this	O
small	O
cohort	O
has	O
around	B-STAT
80	I-STAT
%	I-STAT
effectiveness	O
which	O
will	O
be	O
of	O
help	O
to	O
doctors	O
who	O
are	O
not	O
experts	O
in	O
this	O
field	O
.	O

However	O
it	O
will	O
be	O
necessary	O
to	O
analyze	O
more	O
cases	O
in	O
order	O
to	O
obtain	O
a	O
more	O
accurate	O
efficiency	O
value	O
.	O

Pathogenic	O
variants	O
in	O
the	O
fibroblast	O
growth	O
factor	O
receptor	O
3	O
FGFR3	O
gene	O
are	O
responsible	O
for	O
a	O
broad	O
spectrum	O
of	O
skeletal	O
dysplasias	O
including	O
achondroplasia	B-DIS
ACH	O
.	O

The	O
classic	O
phenotype	O
of	O
ACH	O
is	O
caused	O
by	O
two	O
highly	O
prevalent	O
mutations	O
c.1138	O
A	O
and	O
c.1138	O
C	O
p.	O
Gly380Arg	O
.	O

In	O
the	O
homozygous	O
state	O
these	O
variant	O
results	O
in	O
a	O
severe	O
skeletal	B-DIS
dysplasia	I-DIS
neurologic	I-DIS
deficits	I-DIS
and	O
early	O
demise	O
from	O
respiratory	B-DIS
insufficiency	I-DIS
.	O

Although	O
homozygous	O
biallelic	O
mutations	O
have	O
been	O
reported	O
in	O
patients	O
with	O
ACH	O
in	O
combination	O
with	O
hypochondroplasia	B-DIS
or	O
other	O
dominant	B-DIS
skeletal	I-DIS
dysplasias	I-DIS
thus	O
far	O
no	O
cases	O
of	O
heterozygous	O
biallelic	O
pathogenic	O
ACH	O
-	O
related	O
variants	O
in	O
FGFR3	O
have	O
been	O
reported	O
.	O

We	O
describe	O
a	O
novel	O
phenotype	O
of	O
an	O
infant	O
with	O
two	O
ACH	O
-	O
related	O
mutations	O
in	O
FGFR3	O
p.	O
Gly380Arg	O
and	O
p.	O
Ser344Cys	O
.	O

Discordant	O
features	O
from	O
classic	O
ACH	O
include	O
atypical	O
radiographic	O
findings	O
severe	O
obstructive	B-DIS
sleep	I-DIS
apnea	I-DIS
and	O
focal	O
migrating	O
seizures	B-DIS
.	O

We	O
also	O
report	O
the	O
long	O
-	O
term	O
clinical	O
course	O
of	O
her	O
father	O
who	O
harbors	O
the	O
p.	O
Ser344Cys	O
mutation	O
that	O
has	O
only	O
been	O
reported	O
once	O
previously	O
in	O
a	O
Japanese	O
patient	O
.	O

The	O
phenotype	O
of	O
heterozygous	O
biallelic	O
mutations	O
in	O
FGFR3	O
associated	O
with	O
ACH	O
is	O
variable	O
underscoring	O
the	O
importance	O
of	O
recognition	O
and	O
accurate	O
diagnosis	O
to	O
ensure	O
appropriate	O
management	O
.	O

Cone	B-DIS
-	I-DIS
rod	O
dystrophy	O
CORD	O
is	O
one	O
of	O
the	B-DIS
inherited	I-DIS
retinal	O
diseases	O
that	O
result	O
in	B-DIS
central	I-DIS
visual	I-DIS
field	O
deterioration	O
and	O
decreased	O
visual	O
acuity	O
VA	B-LOC
.	O

In	O
CORD	O
patients	O
impaired	O
photoreceptor	O
cells	O
are	O
observed	O
as	O
the	O
disruption	O
of	O
ellipsoid	O
zone	O
EZ	O
on	O
optical	O
coherence	O
tomography	O
OCT	O
images	O
.	O

In	O
the	O
present	O
study	O
we	O
calculated	O
the	O
index	O
of	O
residual	O
EZ	O
rEZ	O
to	O
quantify	O
the	O
function	O
of	O
photoreceptor	O
cells	O
and	O
investigated	O
the	O
correlation	O
between	O
rEZ	O
index	O
and	O
visual	O
functions	O
.	O

Twenty	O
-	O
six	O
eyes	O
of	O
13	O
patients	O
with	O
clinical	O
suspicion	O
of	O
CORD	O
were	O
examined	O
.	O

Visual	O
field	O
was	O
tested	O
with	O
the	O
Humphrey	O
Visual	O
Field	O
Analyzer	O
HFA	O
10	O
-	O
2	O
program	O
.	O

We	O
simultaneously	O
obtained	O
OCT	O
images	O
and	O
calculated	O
the	O
area	O
of	O
decreased	O
EZ	O
intensity	O
EZa	O
.	O

Using	O
the	O
binarized	O
OCT	O
images	O
the	O
percentage	O
of	O
the	O
rEZ	O
in	O
a	O
3	O
×	O
3	O
mm	O
area	O
surrounding	O
the	O
macula	O
was	O
analyzed	O
.	O

To	O
clarify	O
interrator	O
reproducibility	O
intraclass	O
correlation	O
coefficient	O
ICC	O
was	O
calculated	O
.	O

Moreover	O
we	O
investigated	O
the	O
association	O
between	O
OCT	O
parameters	O
and	O
VA	B-LOC
as	O
well	O
as	O
the	O
mean	O
deviation	O
MD	O
value	O
measured	O
with	O
HFA	O
.	O

The	O
mean	O
age	O
of	O
the	O
patients	O
was	O
48.5	O
±	O
16.9	O
years	O
.	O

The	O
mean	O
central	O
retinal	O
thickness	O
was	O
122.7	O
±	O
73.2	O
μm	O
.	O

The	O
mean	O
EZa	O
and	O
rEZ	O
were	O
22.2	O
±	O
23.6	O
μm	O
2	O
<	O
/s	O
and	O
0.35	B-STAT
±	I-STAT
0.31	I-STAT
respectively	O
.	O

The	O
ICC	O
of	O
each	O
rEZ	O
index	O
was	O
0.9195	B-STAT
%	I-STAT
CI	O
0.89	O
<	O
ICC	O
<	O
0.93	O
.	O

Multivariate	O
analysis	O
indicated	O
rEZ	O
was	O
significantly	O
related	O
to	O
logMAR	O
VA	B-LOC
p	O
=	O
0.05	O
and	O
rEZ	O
and	O
EZa	O
were	O
associated	O
with	O
the	O
MD	B-LOC
value	O
p	O
=	O
0.014	O
and	O
p	O
=	O
0.009	O
linear	O
mixed	O
model	O
.	O

Furthermore	O
rEZ	O
was	O
also	O
associated	O
with	O
photopic	O
a-	O
and	O
b	O
-	O
wave	O
amplitudes	O
p	O
=	O
0.027	O
and	O
p	O
=	O
0.0024	O
respectively	O
linear	O
mixed	O
model	O
.	O

Taken	O
together	O
the	O
current	O
results	O
suggested	O
the	O
usefulness	O
of	O
rEZ	O
quantification	O
for	O
predicting	O
visual	O
functions	O
in	O
CORD	O
patients	O
.	O

Nontuberculous	B-DIS
mycobacterial	I-DIS
NTM	I-DIS
infections	I-DIS
in	O
humans	O
have	O
increased	O
in	O
prevalence	B-EPI
in	O
recent	O
decades	O
.	O

Mycobacterium	O
kansasii	O
is	O
one	O
of	O
the	O
most	O
prevalent	O
human	O
pathogenic	O
NTM	O
species	O
worldwide	O
.	O

Herein	O
we	O
report	O
the	O
first	O
isolation	O
of	O
M.	O
kansasii	O
from	O
an	O
indoor	O
domestic	O
cat	O
in	O
Japan	B-LOC
.	O

Comparative	O
genome	O
sequence	O
analysis	O
of	O
the	O
feline	O
isolate	O
showed	O
this	O
pathogen	O
is	O
genetically	O
identical	O
to	O
human	O
pathogenic	O
M.	O
kansasii	O
.	O

This	O
finding	O
suggests	O
that	O
M.	O
kansasii	O
has	O
a	O
potential	O
risk	O
of	O
zoonoses	O
and	O
requires	O
the	O
`	O
`	O
One	O
Health	O
''	O
approach	O
to	O
control	O
NTM	B-DIS
infection	I-DIS
.	O

OBJECTIVESTo	O
examine	O
the	O
incidence	B-EPI
mortality	O
and	O
health	O
care	O
use	O
related	O
to	O
neonatal	O
herpes	B-DIS
simplex	I-DIS
virus	O
HSV	B-DIS
infection	I-DIS
.	O

METHODSA	O
retrospective	O
longitudinal	O
cohort	O
study	O
using	O
a	O
multistate	O
Medicaid	O
claims	O
database	O
.	O

We	O
identified	O
neonates	O
hospitalized	O
with	O
HSV	B-DIS
infection	I-DIS
from	O
2009	O
to	O
2015	O
by	O
using	O
discharge	O
diagnosis	O
codes	O
and	O
managed	O
them	O
for	O
6	O
months	O
after	O
discharge	O
.	O

Incidence	B-EPI
rates	O
were	O
corrected	O
for	O
the	O
imperfect	O
sensitivity	O
and	O
specificity	O
of	O
thediagnosis	O
codes	O
for	O
identifying	O
HSV	B-DIS
infection	I-DIS
.	O

RESULTSOf	O
2107124	O
births	O
from	O
2009	O
to	O
2015900	O
neonates	O
were	O
identified	O
with	O
HSV	B-DIS
infection	I-DIS
with	O
a	O
corrected	O
incidence	B-EPI
rate	O
of	O
4.595	B-STAT
%	I-STAT
confidence	O
interval	O
[	O
CI	O
]	O
4.2	O
-	O
4.8	O
per	O
10000	O
births	O
.	O

The	O
yearly	O
disease	O
incidence	B-EPI
increased	O
by	O
56	B-STAT
%	I-STAT
from	O
3.495	B-STAT
%	I-STAT
CI	O
2.8	O
-	O
4.2	O
per	O
10000	O
births	O
or	O
1	B-STAT
in	I-STAT
2941	I-STAT
births	O
in	O
2009	O
to	O
5.395	B-STAT
%	I-STAT
CI	O
4.6	B-STAT
-	I-STAT
6.1	I-STAT
per	O
10000	O
births	O
or	O
1	B-STAT
in	I-STAT
1886	I-STAT
births	O
in	O
2015	O
P	O
<	O
.001	O
.	O

Of	O
the	O
900	O
neonates	O
with	O
HSV	B-DIS
infection	I-DIS
546.0	B-STAT
%	I-STAT
[	O
95	B-STAT
%	I-STAT
CI	O
4.4	B-STAT
%	I-STAT
-7.6	O
%	O
]	O
died	O
during	O
the	O
index	O
hospitalization	O
;	O
there	O
was	O
no	O
increase	O
in	O
the	O
yearly	O
mortality	O
rate	O
.	O

Of	O
the	O
69281.2	B-STAT
%	I-STAT
infants	O
with	O
follow	O
-	O
up	O
data	O
31645.7	B-STAT
%	I-STAT
had	O
an	O
emergency	O
department	O
visit	O
and	O
11216.2	B-STAT
%	I-STAT
had	O
a	O
hospital	O
readmission	O
.	O

Total	O
payments	O
at	O
6	O
months	O
amounted	O
to	O
$	O
60620431	O
a	O
median	O
of	O
$	O
87602	O
per	O
case	O
of	O
neonatal	O
HSV	B-DIS
infection	I-DIS
.	O

CONCLUSIONSWe	O
observed	O
an	O
increase	O
in	O
neonatal	O
HSV	B-DIS
infection	I-DIS
incidence	B-EPI
over	O
a	O
recent	O
7	O
-	O
year	O
period	O
in	O
a	O
Medicaid	O
population	O
.	O

Associated	O
health	O
care	O
use	O
and	O
payments	O
were	O
substantial	O
.	O

Public	O
health	O
interventions	O
targeting	O
disease	O
prevention	O
and	O
early	O
diagnosis	O
are	O
needed	O
.	O

Objective	O
To	O
determine	O
the	O
prevalence	B-EPI
of	O
Barth	B-DIS
syndrome	I-DIS
in	O
the	O
pediatric	O
population	O
.	O

Study	O
design	O
Data	O
were	O
collected	O
from	O
the	O
Barth	B-DIS
Syndrome	I-DIS
Foundation	O
Registry	O
and	O
relevant	O
literature	O
.	O

With	O
the	O
advent	O
of	O
genetic	O
testing	O
and	O
whole	O
-	O
exome	O
sequencing	O
a	O
multipronged	O
Bayesian	O
analysis	O
was	O
used	O
to	O
estimate	B-EPI
the	O
prevalence	B-DIS
of	I-DIS
Barth	O
syndrome	O
based	O
on	O
published	O
data	O
on	B-EPI
the	O
incidence	B-EPI
and	O
prevalence	B-DIS
of	O
cardiomyopathy	B-DIS
and	O
neutropenia	O
and	O
the	O
respective	O
subpopulations	O
of	O
patients	B-DIS
with	I-DIS
Barth	O
syndrome	O
indicated	O
in	O
these	O
publications	O
.	O

Results	O
Based	O
on	O
7	O
published	O
studies	O
of	O
cardiomyopathy	B-DIS
and	O
2	O
published	O
studies	O
of	O
neutropenia	B-DIS
the	O
estimated	O
prevalence	B-EPI
of	O
Barth	B-DIS
syndrome	I-DIS
is	O
approximately	O
1	O
case	O
per	O
million	O
male	O
population	O
.	O

This	O
contrasts	O
with	O
99	O
cases	O
in	O
the	O
Barth	B-DIS
Syndrome	I-DIS
Foundation	O
Registry	O
58	O
of	O
which	O
indicate	O
a	O
US	B-LOC
location	O
and	O
only	O
230	O
-	O
250	O
cases	O
known	O
worldwide	O
.	O

Conclusions	O
It	O
appears	O
that	O
Barth	B-DIS
syndrome	I-DIS
is	O
greatly	O
underdiagnosed	O
.	O

There	O
is	O
a	O
need	O
for	O
better	O
education	O
and	O
awareness	O
of	O
this	O
rare	O
disease	O
to	O
move	O
toward	O
early	O
diagnosis	O
and	O
treatment	O
.	O

Childhood	O
wasting	B-DIS
is	O
among	O
the	O
most	O
prevalent	O
forms	O
of	O
undernutrition	O
globally	O
.	O

The	O
Southeast	B-LOC
Asia	I-LOC
region	O
is	O
home	O
to	O
many	O
wasted	O
children	O
but	O
wasting	B-DIS
is	O
not	O
recognized	O
as	O
a	O
public	O
health	O
problem	O
and	O
its	O
epidemiology	O
is	O
yet	O
to	O
be	O
fully	O
examined	O
.	O

This	O
analysis	O
aimed	O
to	O
determine	O
the	O
burden	O
of	O
wasting	B-DIS
its	O
predictors	O
and	O
the	O
level	O
of	O
wasting	B-DIS
and	O
stunting	B-DIS
concurrence	O
.	O

Datasets	O
from	O
Demographic	O
and	O
Health	O
Surveys	O
and	O
Multiple	O
Indicator	O
Cluster	O
Surveys	O
in	O
six	O
countries	O
in	O
the	O
region	O
were	O
analyzed	O
.	O

The	O
pooled	O
weighted	O
prevalence	B-EPI
for	O
wasting	B-DIS
and	O
concurrent	O
wasting	B-DIS
and	O
stunting	O
among	O
children	O
0	O
-	O
59	O
months	O
in	O
the	O
six	O
countries	O
was	O
8.9	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
8.0	O
-	O
9.9	O
and	O
1.6	B-STAT
%	I-STAT
95	B-STAT
%	I-STAT
CI	O
1.5	O
-	O
1.8	O
respectively	O
.	O

This	O
prevalence	B-EPI
is	O
approximately	O
12	O
-	O
fold	O
higher	O
than	O
the	O
0.7	B-EPI
%	I-STAT
prevalence	O
of	O
high	O
-	O
income	O
countries	O
;	O
and	O
translated	O
into	O
an	O
absolute	O
number	O
of	O
1088747	B-DIS
children	O
affected	O
by	O
wasting	B-DIS
and	O
272563	O
concurrent	O
wasting	O
and	O
stunting	O
.	O

Wasting	B-DIS
prevalence	B-EPI
was	O
50	B-STAT
percent	I-STAT
higher	O
in	O
the	O
0	O
-	O
23	O
-	O
month	O
age	O
group	O
.	O

Predictors	O
for	O
wasting	B-DIS
included	O
source	O
of	O
drinking	O
water	O
wealth	O
index	O
urban	O
residence	O
child	O
's	O
age	O
and	O
history	O
of	O
illness	B-DIS
and	O
mother	O
's	O
body	O
mass	O
index	O
.	O

In	O
conclusion	O
our	O
analysis	O
showed	O
that	O
wasting	B-DIS
is	O
a	O
serious	O
public	O
health	O
problem	O
in	O
the	O
region	O
that	O
should	O
be	O
addressed	O
urgently	O
using	O
both	O
preventive	O
and	O
curative	O
approaches	O
.	O

Massachusetts	B-LOC
began	O
newborn	O
screening	O
NBS	O
for	O
Spinal	B-DIS
Muscular	I-DIS
Atrophy	I-DIS
SMA	I-DIS
following	O
the	O
availability	O
of	O
new	O
treatment	O
options	O
.	O

The	O
New	O
England	O
Newborn	O
Screening	O
Program	O
developed	O
validated	O
and	O
implemented	O
a	O
screening	O
algorithm	O
for	O
the	O
detection	O
of	O
SMA	O
-	O
affected	O
infants	O
who	B-DIS
show	I-DIS
absent	I-DIS
SMN1	I-DIS
Exon	O
7	O
by	O
Real	O
-	O
Time	O
™	O
quantitative	O
PCR	O
qPCR	O
.	O

We	O
screened	O
179467	O
neonates	O
and	O
identified	O
9	O
SMA	O
-	O
affected	O
infants	O
all	O
of	O
whom	O
were	O
referred	O
to	O
a	O
specialist	O
by	O
day	O
of	O
life	O
6	O
average	O
and	O
median	O
4	O
days	O
of	O
life	O
.	O

Another	O
ten	O
SMN1	O
hybrids	O
were	O
observed	O
but	O
never	O
referred	O
.	O

The	O
nine	O
referred	O
infants	O
who	O
were	O
confirmed	O
to	O
have	O
SMA	B-DIS
were	O
entered	O
into	O
treatment	O
protocols	O
.	O

Early	O
data	O
show	O
that	O
some	O
SMA	O
-	O
affected	O
children	O
have	O
remained	O
asymptomatic	O
and	O
are	O
meeting	O
developmental	O
milestones	O
and	O
some	O
have	O
mild	O
to	O
moderate	O
delays	O
.	O

The	O
Massachusetts	B-LOC
experience	O
demonstrates	O
that	O
SMA	B-DIS
NBS	O
is	O
feasible	O
can	O
be	O
implemented	O
on	O
a	O
population	O
basis	O
and	O
helps	O
engage	O
infants	O
for	O
early	O
treatment	O
to	O
maximize	O
benefit	O
.	O

Despite	O
numerous	O
studies	O
in	O
the	O
field	O
of	O
congenital	B-DIS
adrenal	I-DIS
hyperplasia	I-DIS
CAH	I-DIS
due	O
to	O
21	B-DIS
-	I-DIS
hydroxylase	O
deficiency	O
some	O
clinical	O
variability	O
of	O
the	O
presentation	O
and	O
discrepancies	O
in	O
the	O
genotype	O
/	O
phenotype	O
correlation	O
are	O
still	O
unexplained	O
.	O

Some	O
but	O
not	O
all	O
discordant	O
phenotypes	O
caused	O
by	O
mutations	O
with	O
known	O
enzyme	O
activity	O
have	O
been	O
explained	O
by	O
in	O
silico	O
structural	O
changes	O
in	O
the	O
21	O
-	O
hydroxylase	O
protein	O
.	O

The	O
incidence	B-EPI
of	O
P30L	O
mutation	O
varies	O
in	O
different	O
populations	O
and	O
is	O
most	O
frequently	O
found	O
in	O
several	O
Central	O
and	O
Southeast	O
European	O
countries	O
as	O
well	O
as	O
Mexico	B-LOC
.	O

Patients	O
carrying	O
P30L	O
mutation	O
present	O
predominantly	O
as	O
non	O
-	O
classical	O
CAH	O
;	O
however	O
simple	O
virilizing	O
forms	O
are	O
found	O
in	O
up	B-STAT
to	I-STAT
50	I-STAT
%	I-STAT
of	O
patients	O
.	O

Taking	O
into	O
consideration	O
the	O
residual	O
21	O
-	O
hydroxulase	O
activity	O
present	O
with	O
P30L	O
mutation	O
this	O
is	O
unexpected	O
.	O

Different	O
mechanisms	O
for	O
increased	O
androgenization	O
in	O
patients	O
carrying	O
P30L	O
mutation	O
have	O
been	O
proposed	O
including	O
influence	O
of	O
different	O
residues	O
accompanying	O
promotor	O
allele	O
variability	O
or	O
mutations	O
and	O
individual	O
androgene	O
sensitivity	O
.	O

Early	O
diagnosis	O
of	O
patients	O
who	O
would	O
present	O
with	O
SV	O
is	O
important	O
in	O
order	O
to	O
improve	O
outcome	O
.	O

Outcome	O
studies	O
of	O
CAH	B-DIS
have	O
confirmed	O
the	O
uniqueness	O
of	O
this	O
mutation	O
such	O
as	O
difficulties	O
in	O
phenotype	O
classification	O
different	O
fertility	O
growth	O
and	O
psychologic	O
issues	O
in	O
comparison	O
with	O
other	O
genotypes	O
.	O

Additional	O
studies	O
of	O
P30L	O
mutation	O
are	O
warranted	O
.	O

It	O
has	O
been	O
well	O
-	O
established	B-DIS
that	O
cancer	O
cells	O
are	O
under	O
constant	O
oxidative	O
stress	O
as	O
reflected	O
by	O
elevated	O
basal	O
level	O
of	O
reactive	O
oxygen	O
species	O
ROS	O
due	O
to	O
increased	O
metabolism	O
driven	O
by	O
aberrant	O
cell	O
growth	O
.	O

Cancer	B-DIS
cells	O
can	O
adapt	O
to	O
maintain	O
redox	O
homeostasis	O
through	O
a	O
variety	O
of	O
mechanisms	O
.	O

The	O
prevalent	O
perception	O
about	O
ROS	O
is	O
that	O
they	O
are	O
one	O
of	O
the	O
key	O
drivers	O
promoting	O
tumor	B-DIS
initiation	O
progression	O
metastasis	B-DIS
and	O
drug	O
resistance	O
.	O

Based	O
on	O
this	O
notion	O
numerous	O
antioxidants	O
that	O
aim	O
to	O
mitigate	O
tumor	B-DIS
oxidative	O
stress	O
have	O
been	O
tested	O
for	O
cancer	B-DIS
prevention	O
or	O
treatment	O
although	O
the	O
effectiveness	O
of	O
this	O
strategy	O
has	O
yet	O
to	O
be	O
established	O
.	O

In	O
recent	O
years	O
it	O
has	O
been	O
increasingly	O
appreciated	O
that	O
ROS	O
have	O
a	O
complex	O
multifaceted	O
role	O
in	O
the	O
tumor	B-DIS
microenvironment	O
TME	O
and	O
that	O
tumor	B-DIS
redox	O
can	O
be	O
targeted	O
to	O
amplify	O
oxidative	O
stress	O
inside	O
the	O
tumor	B-DIS
to	O
cause	O
tumor	B-DIS
destruction	O
.	O

Accumulating	O
evidence	O
indicates	O
that	O
cancer	B-DIS
immunotherapies	O
can	O
alter	O
tumor	B-DIS
redox	O
to	O
intensify	O
tumor	B-DIS
oxidative	O
stress	O
resulting	O
in	O
ROS	O
-	B-DIS
dependent	O
tumor	O
rejection	O
.	O

Herein	O
we	O
review	O
the	O
recent	O
progresses	O
regarding	O
the	O
impact	O
of	O
ROS	O
on	O
cancer	O
cells	O
and	O
various	O
immune	O
cells	O
in	O
the	O
TME	O
and	O
discuss	O
the	O
emerging	O
ROS	O
-	O
modulating	O
strategies	O
that	O
can	O
be	O
used	O
in	O
combination	B-DIS
with	O
cancer	O
immunotherapies	O
to	O
achieve	O
enhanced	O
antitumor	O
effects	O
.	O

Transient	O
global	O
amnesia	B-DIS
TGA	O
is	O
a	O
neurological	B-DIS
syndrome	I-DIS
with	O
rather	O
distinctive	O
brain	O
MRI	O
features	O
namely	O
hyperintense	O
lesion	O
in	O
hippocampus	O
on	O
diffusion	O
-	O
weighted	O
imaging	O
DWI	O
and	O
fluid	O
-	O
attenuated	O
inversion	O
recovery	O
FLAIR	O
sequences	O
.	O

Post	B-DIS
-	I-DIS
traumatic	O
amnesia	O
is	B-DIS
another	I-DIS
amnestic	O
syndrome	O
which	O
can	O
also	O
show	O
hyperintense	O
lesions	O
in	O
brain	O
MRI	O
due	O
to	B-DIS
cytotoxic	O
oedema	O
caused	B-DIS
by	B-DIS
traumatic	I-DIS
brain	O
injury	O
.	O

We	O
present	O
a	O
case	O
of	O
a	O
patient	O
with	O
post	B-DIS
-	I-DIS
traumatic	O
amnesia	O
with	O
a	O
brain	O
MRI	O
image	O
mimic	O
of	O
TGA	O
.	O

Transient	O
global	O
amnesia	B-DIS
TGA	O
is	O
a	O
benign	O
memory	B-DIS
disorder	I-DIS
with	O
etiologies	B-DIS
that	O
have	O
been	O
debated	O
for	O
a	O
long	O
time	O
.	O

The	O
prevalence	B-EPI
of	O
stressful	O
events	O
before	O
a	O
TGA	O
attack	O
makes	O
it	O
hard	O
to	O
overlook	O
these	O
precipitating	O
factors	O
given	O
that	O
stress	O
has	O
the	O
potential	O
to	O
organically	O
effect	O
the	O
brain	O
.	O

Cortical	O
spreading	O
depression	B-DIS
CSD	O
was	O
proposed	O
as	O
a	O
possible	O
cause	O
decades	O
ago	O
.	O

Being	O
a	O
regional	O
phenomenon	O
CSD	O
seems	O
to	O
affect	O
every	O
aspect	O
of	O
the	O
micro	O
-	O
mechanism	O
in	O
maintaining	O
the	O
homeostasis	O
of	O
the	O
central	O
nervous	O
system	O
CNS	O
.	O

Corresponding	O
evidence	O
regarding	O
hemodynamic	O
and	O
morphological	O
changes	O
from	O
TGA	O
and	O
CSD	B-DIS
have	O
been	O
accumulated	O
separately	O
but	O
the	O
resemblance	O
between	O
the	O
two	O
has	O
not	O
been	O
systematically	O
explored	O
so	O
far	O
which	O
is	O
surprising	O
especially	O
considering	O
that	O
CSD	B-DIS
had	O
been	O
confirmed	O
to	O
cause	O
secondary	B-DIS
damage	I-DIS
in	I-DIS
the	I-DIS
human	I-DIS
brain	I-DIS
.	O

Thus	O
by	O
deeply	O
delving	O
into	O
the	O
anatomic	O
and	O
electrophysiological	O
properties	O
of	O
the	O
CNS	O
the	O
CSD	O
-	O
TGA	O
model	O
may	O
render	O
insights	O
into	O
the	O
basic	O
pathophysiology	O
behind	O
the	O
façade	O
of	O
the	O
enigmatic	O
clinical	O
presentation	O
.	O

Although	O
AOA1	B-DIS
ataxia	I-DIS
oculomotor	I-DIS
apraxia1	I-DIS
is	O
one	O
of	O
the	O
most	O
common	O
causes	O
of	O
autosomal	B-DIS
recessive	I-DIS
cerebellar	I-DIS
ataxias	I-DIS
in	O
Japanese	O
population	O
it	O
is	O
reported	O
from	O
all	O
over	O
the	O
world	O
.	O

The	O
clinical	O
manifestations	O
are	O
similar	O
to	O
ataxia	B-DIS
telangiectasia	I-DIS
in	O
which	O
non	O
-	O
neurological	O
manifestations	O
are	O
absent	O
and	O
include	O
almost	B-STAT
10	I-STAT
%	B-DIS
of	I-DIS
autosomal	I-DIS
recessive	I-DIS
cerebellar	O
ataxias	O
.	O

Dysarthria	B-DIS
and	O
gait	B-DIS
disorder	I-DIS
are	O
the	O
most	O
two	O
common	O
and	O
typical	O
manifestations	O
.	O

Oculomotor	B-DIS
apraxia	I-DIS
is	O
usually	O
seen	O
a	O
few	O
years	O
after	O
the	O
manifestations	O
start	O
.	O

APTX	O
gene	O
on	O
9p13.3	O
chromosome	O
is	O
expressed	O
in	O
the	O
cells	O
of	O
all	O
human	O
body	O
tissues	O
and	O
different	O
mutations	O
had	O
been	O
discovered	O
.	O

Here	O
we	O
report	O
two	O
siblings	O
a	O
girl	O
and	O
a	O
boy	O
of	O
consanguineous	B-DIS
parents	O
visited	O
at	O
Mofid	O
Pediatrics	O
Hospital	O
in	O
2015	O
with	O
history	O
of	O
gait	B-DIS
ataxia	I-DIS
titubation	I-DIS
tremor	B-DIS
and	O
oculomotor	B-DIS
apraxia	I-DIS
around	O
five	O
yr	O
old	O
and	O
after	O
that	O
.	O

The	O
brother	O
showed	O
symptoms	O
of	O
disease	O
earlier	O
and	O
more	O
severe	O
than	O
his	O
sister	O
did	O
.	O

After	O
ruling	O
out	O
the	O
common	O
etiologies	O
of	O
progressive	O
ataxia	B-DIS
we	O
did	O
genetic	O
study	O
for	O
AOA1	B-DIS
that	O
showed	O
a	O
homozygous	O
frameshift	O
mutation	O
as	O
c.418_418	O
del	O
was	O
found	O
.	O

This	O
mutation	O
was	O
not	O
reported	O
before	O
so	O
this	O
was	O
a	O
new	O
mutation	O
in	O
APTX	O
gene	O
.	O

Charcot	B-DIS
-	I-DIS
Marie	O
-	O
Tooth	O
disease	O
CMT	O
is	O
a	B-DIS
group	I-DIS
of	O
inherited	O
neurological	B-DIS
disorders	I-DIS
of	I-DIS
the	O
peripheral	O
nervous	O
system	O
.	O

CMT	B-DIS
is	O
subdivided	O
into	O
two	O
main	O
types	O
a	O
demyelinating	B-DIS
form	O
known	O
as	O
CMT1	B-DIS
and	O
an	O
axonal	O
form	O
known	O
as	O
CMT2	B-DIS
.	O

Nearly	O
30	O
genes	O
have	O
been	O
identified	O
as	O
a	O
cause	O
of	O
CMT2	B-DIS
.	O

One	O
of	O
these	O
is	O
the	O
'	O
dehydrogenase	O
E1	O
and	O
transketolase	O
domain	O
containing	O
1	O
'	O
DHTKD1	O
gene	O
.	O

We	O
previously	O
demonstrated	O
that	O
a	O
nonsense	O
mutation	O
[	O
c.1455	O
G	O
p.	O
Y485	O
*	O
]	O
in	O
exon	O
8	O
of	O
DHTKD1	O
is	O
one	O
of	O
the	O
disease	O
-	O
causing	O
mutations	O
in	O
CMT2Q	O
MIM	O
615025	O
.	O

The	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
investigate	O
whether	O
human	O
disease	O
-	O
causing	O
mutations	O
in	O
the	O
Dhtkd1	O
gene	O
cause	O
CMT2Q	O
phenotypes	O
in	O
a	O
mouse	O
model	O
in	O
order	O
to	O
investigate	O
the	O
physiological	O
function	O
and	O
pathogenic	O
mechanisms	O
associated	O
with	O
mutations	O
in	O
the	O
Dhtkd1	O
gene	O
in	O
vivo	O
.	O

Therefore	O
we	O
generated	O
a	O
knock	O
-	O
in	O
mouse	O
model	O
with	O
the	O
Dhtkd1	O
Y486	O
*	O
<	O
/s	O
point	O
mutation	O
.	O

We	O
observed	O
that	O
the	O
Dhtkd1	O
expression	O
level	O
in	O
sciatic	O
nerve	O
of	O
knock	O
-	O
in	O
mice	O
was	O
significantly	O
lower	O
than	O
in	O
wild	O
-	O
type	O
mice	O
.	O

Moreover	O
a	O
histopathological	O
phenotype	O
was	O
observed	O
reminiscent	O
of	O
a	O
peripheral	B-DIS
neuropathy	I-DIS
including	O
reduced	O
large	O
axon	O
diameter	O
and	O
abnormal	O
myelination	O
in	O
peripheral	O
nerves	O
.	O

The	O
knock	O
-	O
in	O
mice	O
also	B-DIS
displayed	I-DIS
clear	I-DIS
sensory	O
defects	O
while	O
no	O
abnormalities	O
in	O
the	O
motor	O
performance	O
were	O
observed	O
.	O

In	O
addition	O
accumulation	O
of	O
mitochondria	O
and	O
an	O
elevated	O
energy	O
metabolic	O
state	O
was	O
observed	O
in	O
the	O
knock	O
-	O
in	O
mice	O
.	O

Taken	O
together	O
our	O
study	O
indicates	O
that	O
the	O
Dhtkd1	O
Y486	O
*	O
<	O
/s	O
knock	O
-	O
in	O
mice	O
partially	O
recapitulate	O
the	O
clinical	O
phenotypes	O
of	O
CMT2Q	O
patients	O
and	O
we	O
hypothesize	O
that	O
there	O
might	O
be	O
a	O
compensatory	O
effect	O
from	O
the	O
elevated	O
metabolic	O
state	O
in	O
the	O
knock	O
-	O
in	O
mice	O
that	O
enables	O
them	O
to	O
maintain	O
their	O
normal	O
locomotor	O
function	O
.	O

Background	O
Congenital	B-DIS
malformations	I-DIS
are	O
described	O
in	O
about	B-STAT
3	I-STAT
%	I-STAT
of	O
live	O
births	O
and	O
20	B-STAT
%	I-STAT
of	O
stillbirths	B-DIS
in	O
the	O
industrialized	O
countries	O
.	O

The	O
prevalence	B-EPI
of	O
congenital	B-DIS
anomalies	I-DIS
in	O
developing	O
countries	O
including	O
Morocco	B-LOC
is	O
not	O
well	O
known	O
at	O
the	O
national	O
level	O
.	O

The	O
aim	O
of	O
our	O
study	O
is	O
to	O
conduct	O
a	O
descriptive	O
exploratory	O
analysis	O
of	O
congenital	B-DIS
malformations	I-DIS
cases	O
diagnosed	O
at	O
the	O
`	O
`	O
Les	O
Orangers	O
''	O
Maternity	O
and	O
Reproductive	O
Health	O
Hospital	O
in	O
Rabat	B-LOC
.	O

Methods	O
We	O
collected	O
all	O
the	O
cases	O
of	O
congenital	B-DIS
malformations	I-DIS
diagnosed	O
at	O
the	O
`	O
`	O
Les	O
Orangers	O
''	O
Maternity	O
and	O
Reproductive	O
Health	O
Hospital	O
in	O
Rabat	B-LOC
from	O
January	O
1st	O
2011	O
to	O
June	O
31st	O
2016	O
.	O

Data	O
were	O
reported	O
on	O
pre	O
-	O
established	O
sheets	O
and	O
on	O
a	O
registry	B-DIS
of	O
malformations	O
.	O

Total	O
and	O
specific	O
prevalences	B-EPI
were	O
calculated	O
for	O
each	O
malformation	O
.	O

A	O
principal	O
component	O
analysis	O
PCA	O
was	O
then	O
conducted	O
followed	O
by	O
a	O
Varimax	O
rotation	O
in	O
order	O
to	O
identify	O
the	O
different	O
associations	O
of	O
malformations	B-DIS
in	O
our	O
series	O
.	O

Results	O
We	O
registred	O
245	O
cases	O
of	O
congenital	B-DIS
malformations	I-DIS
out	O
of	O
a	O
total	O
of	O
43923	O
recorded	O
births	O
;	O
a	O
prevalence	B-EPI
of	O
5.58	O
per	O
thousand	O
births	O
of	O
which	O
19.2	B-STAT
%	I-STAT
were	O
FDIU	O
fetal	O
deaths	B-DIS
in	O
utero	O
.	O

A	O
polymalformative	O
syndrome	O
was	O
found	O
in	O
26.5	B-STAT
%	I-STAT
of	O
cases	O
which	O
makes	O
a	O
total	O
number	O
of	O
470	O
anomalies	B-DIS
.	O

The	O
musculoskeletal	B-DIS
anomalies	I-DIS
predominate	O
with	O
a	O
rate	O
of	O
33	B-STAT
%	I-STAT
followed	O
by	O
neurological	B-DIS
abnormalities	I-DIS
18	B-STAT
%	I-STAT
of	O
whom	O
31	B-STAT
%	I-STAT
were	O
hydrocephalus	B-DIS
26.2	B-STAT
%	I-STAT
anencephaly	B-DIS
and	O
20.24	B-STAT
%	I-STAT
spina	B-DIS
bifida	I-DIS
.	O

Malformations	O
of	O
the	O
eye	O
ear	O
face	O
and	O
neck	O
were	O
described	O
in	O
12	B-STAT
%	I-STAT
of	O
the	O
cases	O
while	O
genetic	O
abnormalities	O
were	O
observed	O
in	O
85	B-STAT
%	I-STAT
of	O
which	O
87.5	B-STAT
%	I-STAT
represented	O
Down	B-DIS
syndrome	I-DIS
.	O

The	O
antenatal	O
diagnosis	O
of	O
congenital	B-DIS
malformations	I-DIS
was	O
performed	O
in	O
28.6	B-STAT
%	I-STAT
of	O
cases	O
.	O

Conclusions	O
Our	O
study	O
provides	O
a	O
general	O
overview	O
of	O
the	O
epidemiological	O
situation	O
related	O
to	O
different	O
types	O
of	O
congenital	B-DIS
anomalies	I-DIS
for	O
a	O
specific	O
area	O
in	O
Morocco	B-LOC
.	O

It	O
represents	O
a	O
database	O
that	O
should	O
be	O
complemented	O
by	O
other	O
multicenter	O
studies	O
and	O
the	O
implementation	O
of	O
a	O
national	O
registry	O
to	O
determine	O
the	O
prevalence	B-EPI
of	O
congenital	B-DIS
malformations	I-DIS
at	O
a	O
national	O
level	O
.	O

Non	O
-	B-DIS
obstructive	O
azoospermia	O
accounts	O
for	O
10	B-STAT
-	I-STAT
15	I-STAT
%	I-STAT
of	B-DIS
male	O
infertility	O
resulting	O
in	O
60	B-STAT
%	I-STAT
of	O
all	O
cases	B-DIS
of	O
azoospermia	O
and	O
affecting	O
about	B-STAT
1	I-STAT
%	I-STAT
of	O
the	O
male	O
population	O
.	O

About	B-STAT
30	I-STAT
%	I-STAT
of	O
these	O
cases	O
are	O
due	O
to	O
Y	O
chromosome	O
microdeletions	O
chromosome	O
abnormalities	O
or	O
hormonal	O
disorders	O
.	O

Pathogenic	O
variants	O
in	O
genes	O
on	O
the	O
sex	O
chromosomes	O
have	O
key	O
roles	O
in	O
spermatogenic	B-DIS
failure	I-DIS
.	O

The	O
co	O
-	O
occurrence	B-DIS
of	O
azoospermia	B-DIS
and	I-DIS
congenital	O
cataracts	O
ranges	B-STAT
between	I-STAT
1	I-STAT
in	O
165000	B-STAT
and	I-STAT
1	I-STAT
in	O
500000	O
.	O

Our	O
28	O
-	O
year	O
-	O
old	O
patient	O
with	O
normal	O
intelligence	O
and	O
abnormally	O
shaped	O
teeth	O
presented	O
with	O
both	O
disorders	O
.	O

A	O
microarray	O
revealed	O
a	O
microdeletion	O
at	O
Xp23.13	O
with	O
a	O
whole	O
NHS	O
gene	O
deletion	O
as	O
well	O
as	O
a	O
contiguous	O
deletion	O
of	O
two	O
other	O
genes	O
[	O
SCML1	O
and	O
RAI2	O
]	O
.	O

This	O
observation	O
represents	O
the	O
first	O
report	O
of	O
non	O
-	B-DIS
obstructive	O
azoospermia	B-DIS
with	I-DIS
congenital	O
cataracts	O
and	O
a	O
contiguous	O
deletion	O
of	O
the	O
SCML1	O
gene	O
a	O
transcript	O
of	O
which	O
is	O
exclusively	O
expressed	O
in	B-DIS
the	O
testis	O
.	O

SCML1	O
is	O
the	O
putative	O
culprit	O
gene	O
which	O
requires	O
functional	O
study	O
or	O
animal	O
experiments	O
.	O

Our	O
analysis	O
of	O
60	O
known	O
spermatogenesis	O
failure	O
-	O
related	O
genes	O
by	O
whole	O
-	O
exome	O
sequencing	O
revealed	O
no	O
other	O
candidate	O
.	O

The	O
Nance	B-DIS
-	I-DIS
Horan	O
syndrome	O
due	O
to	O
pathogenic	O
variants	O
in	O
the	O
NHS	O
gene	O
at	O
Xp23.13	O
including	O
whole	O
gene	O
deletion	O
does	O
not	B-DIS
have	O
azoospermia	O
as	O
a	O
feature	O
.	O

Our	O
report	O
adds	O
to	O
the	O
completeness	O
of	O
genetic	O
counseling	O
for	O
an	O
individual	O
with	O
azoospermia	B-DIS
and	O
congenital	B-DIS
cataracts	I-DIS
.	O

Objective	O
Renal	B-DIS
tubular	I-DIS
acidosis	I-DIS
RTA	O
is	O
a	O
clinical	O
manifestation	O
that	O
occurs	O
with	O
insufficiency	B-DIS
in	O
restoring	O
bicarbonate	O
or	O
disruption	O
in	O
hydrogen	O
ion	O
elimination	O
as	O
a	O
result	O
of	O
a	O
disruption	O
in	O
tubulus	O
functions	O
causing	O
normal	O
anion	O
gap	O
-	B-DIS
opening	I-DIS
metabolic	O
acidosis	O
.	O

In	O
the	O
present	O
study	O
we	O
aimed	O
to	O
investigate	O
the	O
prevalence	B-EPI
of	O
RTA	O
in	O
the	O
largest	O
systemic	O
lupus	O
erythematosus	O
SLE	O
patient	O
population	O
to	O
date	O
.	O

Materials	O
and	O
methods	O
SLE	O
patients	O
who	O
were	O
followed	O
up	O
in	O
2	O
different	O
healthcare	O
centers	O
were	O
included	O
.	O

Patients	O
with	O
metabolic	B-DIS
acidosis	I-DIS
pH	O
<	O
7.35	O
and	O
HCO3	O
<	O
22	O
mEq	O
/	O
L	O
in	O
venous	O
blood	O
gas	O
analysis	O
were	O
determined	O
.	O

The	O
serum	O
and	O
urine	O
anion	O
GAP	O
of	O
these	O
patients	O
were	O
estimated	O
and	O
the	O
urine	O
pH	O
was	O
assessed	O
.	O

RTA	O
presence	O
was	O
evaluated	O
as	O
metabolic	B-DIS
acidosis	I-DIS
with	O
a	O
normal	O
serum	O
anion	O
gap	O
and	O
a	O
positive	O
urine	O
anion	O
GAP	O
.	O

Results	O
A	O
total	O
of	O
108	O
patients	O
were	O
included	O
in	O
the	O
present	O
study	O
.	O

The	O
mean	O
age	O
of	O
the	O
patients	O
was	O
41.5	O
±	O
1.2	O
and	O
87	B-STAT
%	I-STAT
were	O
female	O
.	O

The	O
SLE	O
diagnosis	O
duration	O
was	O
75	O
±	O
5	O
months	O
.	O

The	O
mean	O
creatinine	O
value	O
​​was	O
0.6	O
±	O
0.1	O
mg	O
/	O
dL	O
and	O
the	O
mean	O
eGFR	O
was	O
111	O
±	O
2	O
mL	O
/	O
min	O
.	O

According	O
to	O
the	O
blood	O
gas	O
analysis	O
18	O
patients	O
16.7	B-STAT
%	I-STAT
of	O
the	O
total	O
had	O
RTA	O
.	O

Sixteen	O
of	O
these	O
patients	O
had	O
type	O
1	B-STAT
RTA	I-STAT
and	I-STAT
2	I-STAT
had	O
type	O
2	O
RTA	O
;	O
type	O
4	O
RTA	O
was	O
not	O
determined	O
in	O
any	O
of	O
the	O
patients	O
.	O

Conclusion	O
RTA	O
should	O
be	O
considered	O
in	O
SLE	O
patients	O
even	O
if	O
they	O
have	O
normal	O
eGFR	O
values	O
.	O

This	O
is	O
the	O
largest	O
study	O
to	O
examine	O
the	O
prevalence	B-EPI
of	O
RTA	B-DIS
in	I-DIS
SLE	I-DIS
patients	O
in	O
the	O
literature	O
.	O

Transient	O
congenital	B-DIS
hypothyroidism	I-DIS
CH	O
refers	O
to	O
a	O
temporary	B-DIS
deficiency	I-DIS
of	I-DIS
thyroid	I-DIS
hormone	I-DIS
identified	O
after	O
birth	O
with	O
low	O
thyroxine	O
T4	O
and	O
elevated	O
thyrotropin	O
TSH	O
which	O
later	O
recovers	O
to	O
improved	O
thyroxine	O
production	O
typically	O
in	O
first	O
few	O
months	O
of	O
infancy	O
.	O

Approximately	B-STAT
17	I-STAT
%	I-STAT
to	I-STAT
40	I-STAT
%	I-STAT
of	O
children	O
diagnosed	O
with	O
CH	O
by	O
newborn	O
screening	O
NBS	O
programs	O
were	O
later	O
determined	O
to	O
have	O
transient	O
hypothyroidism	B-DIS
.	O

Causes	O
of	O
transient	O
CH	O
are	O
prematurity	O
iodine	O
deficiency	O
maternal	O
thyrotropin	O
receptor	O
blocking	O
antibodies	O
maternal	O
intake	O
of	O
anti	O
-	O
thyroid	O
drugs	O
maternal	O
or	O
neonatal	O
iodine	O
exposure	O
loss	O
of	O
function	O
mutations	B-DIS
and	I-DIS
hepatic	O
hemangiomas	O
.	O

The	O
classic	O
clinical	O
symptoms	O
and	O
signs	O
of	O
CH	O
are	O
usually	O
absent	O
immediately	O
after	O
birth	O
in	O
vast	O
majority	O
of	O
infants	O
due	O
to	O
temporary	O
protection	O
from	O
maternal	O
thyroxine	O
.	O

NBS	O
has	O
been	O
largely	O
successful	O
in	O
preventing	O
intellectual	B-DIS
disability	I-DIS
by	O
early	O
detection	O
of	O
CH	O
by	O
performing	O
thyroid	O
function	O
tests	O
in	O
infants	O
with	O
abnormal	O
screening	O
results	O
.	O

In	O
this	O
review	O
we	O
present	O
the	O
evidence	O
for	O
decision	O
making	O
regarding	O
treatment	O
vs.	O
withholding	O
treatment	O
in	O
infants	O
with	O
transient	O
CH	O
and	O
present	O
a	O
rational	O
approach	O
to	O
identifying	O
transient	O
CH	O
based	O
on	O
American	O
Academy	O
of	O
Pediatrics	O
AAP	O
recommendation	O
.	O

Microcephalic	B-DIS
osteodysplastic	I-DIS
primordial	I-DIS
dwarfism	I-DIS
type	I-DIS
II	I-DIS
OMIM	I-DIS
210720	I-DIS
is	O
a	O
rare	O
autosomal	O
recessive	O
condition	O
frequently	O
associated	O
with	O
early	B-DIS
-	I-DIS
onset	I-DIS
cerebrovascular	O
disease	O
.	O

Presymptomatic	O
detection	O
and	O
intervention	O
could	O
prevent	O
the	O
adverse	O
consequences	O
associated	O
with	O
this	O
.	O

We	O
reviewed	O
published	O
cases	O
of	O
microcephalic	B-DIS
osteodysplastic	I-DIS
primordial	I-DIS
dwarfism	I-DIS
type	O
II	O
to	O
ascertain	O
prevalence	B-EPI
and	O
characteristics	O
of	O
cerebrovascular	B-DIS
disease	I-DIS
and	O
use	O
these	O
data	O
to	O
propose	O
an	O
evidence	O
-	O
based	O
approach	O
to	O
cerebrovascular	O
screening	O
.	O

Of	O
147	O
cases	O
identified	O
47	O
had	O
cerebrovascular	B-DIS
disease	I-DIS
32	B-STAT
%	I-STAT
including	O
occlusive	O
arteriopathy	O
including	O
moyamoya	B-DIS
and	I-DIS
cerebral	I-DIS
aneurysmal	I-DIS
disease	I-DIS
.	O

Occlusive	B-DIS
disease	I-DIS
occurred	O
in	O
younger	O
individuals	O
and	O
progression	O
can	O
be	O
both	O
rapid	O
and	O
clinically	O
silent	O
.	O

A	O
reasonable	O
screening	O
approach	O
would	O
be	O
magnetic	O
resonance	O
imaging	O
and	O
angiography	O
of	O
the	O
cervical	O
and	O
intracranial	O
circulation	O
at	O
diagnosis	O
repeated	O
at	O
yearly	O
intervals	O
until	O
10	O
years	O
and	O
every	O
2	O
years	O
thereafter	O
unless	O
clinical	O
concerns	O
occur	O
earlier	O
.	O

At	O
present	O
it	O
would	O
appear	O
that	O
this	O
needs	O
to	O
be	O
life	O
-	O
long	O
.	O

Families	O
and	O
professionals	O
should	O
be	O
alerted	O
to	O
the	O
potential	O
significance	O
of	O
neurologic	O
symptoms	O
and	O
measures	O
should	O
be	O
taken	O
to	O
maintain	O
good	O
vascular	O
health	O
in	O
affected	O
individuals	O
.	O

Background	O
National	O
neonatal	O
surveillance	O
for	O
herpes	B-DIS
simplex	I-DIS
virus	I-DIS
HSV	I-DIS
disease	I-DIS
suggests	O
that	O
the	O
incidence	B-EPI
of	O
HSV	B-DIS
disease	I-DIS
may	O
be	O
higher	O
in	O
Queensland	B-LOC
QLD	I-LOC
than	O
in	O
other	O
Australian	O
States	O
.	O

We	O
sought	O
to	O
investigate	O
the	O
incidence	B-EPI
via	O
a	O
retrospective	O
13	O
-	O
year	O
evaluation	O
of	O
statewide	O
laboratory	O
data	O
autopsy	O
data	O
and	O
linked	O
clinical	O
records	O
of	O
infants	O
with	O
laboratory	B-DIS
confirmed	O
infection	O
.	O

Methods	O
All	O
positive	O
polymerase	O
chain	O
reaction	O
HSV	O
1	B-STAT
and	I-STAT
2	I-STAT
results	O
were	O
obtained	O
for	O
infants	O
0	O
-	O
3	O
months	O
of	O
age	O
from	O
January	O
12005	O
to	O
December	O
312017	O
.	O

Clinical	O
data	O
were	O
obtained	O
from	O
patient	O
records	O
and	O
parent	O
questionnaires	O
were	O
used	O
to	O
evaluate	O
long	O
-	O
term	O
sequelae	O
.	O

Results	O
One	O
hundred	O
seventy	O
-	O
two	O
infants	O
with	O
HSV	O
positive	O
polymerase	O
chain	O
reaction	O
results	O
12170.3	B-STAT
%	I-STAT
with	O
HSV	O
1	O
.	O

Of	O
10460.5	B-STAT
%	I-STAT
infants	O
with	O
signs	O
of	O
HSV	B-DIS
disease	I-DIS
7673.1	B-STAT
%	I-STAT
were	O
neonates	O
≤28	O
days	O
of	O
age	O
[	O
incidence	B-EPI
9.695	B-STAT
%	I-STAT
confidence	O
interval	O
7.0	O
-	O
11.5	O
per	O
100000	O
live	O
births	O
]	O
and	O
2826.9	B-STAT
%	I-STAT
were	O
young	O
infants	O
29	O
-	O
90	O
days	O
of	O
age	O
[	O
3.695	B-STAT
%	I-STAT
confidence	O
interval	O
2.4	O
-	O
5.4	O
per	O
100000	O
live	O
births	O
]	O
.	O

The	O
annual	O
incidence	B-EPI
of	O
neonatal	O
HSV	B-DIS
disease	I-DIS
increased	O
significantly	O
in	O
Queensland	B-LOC
over	O
the	O
study	O
period	O
P	O
<	O
0.01	O
.	O

Of	O
the	O
76	O
neonates	O
with	O
HSV	B-DIS
disease	I-DIS
5876.3	B-STAT
%	I-STAT
presented	O
with	O
the	O
skin	B-DIS
eye	I-DIS
mouth	I-DIS
SEM	I-DIS
disease	I-DIS
1722.4	B-STAT
%	I-STAT
with	O
HSV	B-DIS
encephalitis	I-DIS
and	O
1114.5	B-STAT
%	I-STAT
had	O
disseminated	O
disease	O
.	O

Young	O
infants	O
presented	O
with	O
HSV	B-DIS
skin	I-DIS
eye	I-DIS
mouth	I-DIS
disease	I-DIS
2175.0	B-STAT
%	I-STAT
or	O
HSV	B-DIS
encephalitis	I-DIS
621.4	B-STAT
%	I-STAT
.	O

Death	B-DIS
occurred	O
in	O
12/104	B-STAT
11.5	B-STAT
%	I-STAT
infants	O
all	O
neonates	O
with	O
10	O
attributable	O
to	O
HSV	B-DIS
disease	I-DIS
.	O

Conclusion	O
The	O
incidence	B-EPI
of	O
neonatal	O
HSV	B-DIS
disease	I-DIS
in	O
QLD	B-LOC
is	O
almost	O
3	O
times	O
the	O
national	O
reported	O
incidence	B-EPI
.	O

Further	O
research	O
is	O
being	O
undertaken	O
to	O
explore	O
reasons	O
for	O
this	O
change	O
and	O
implications	O
for	O
practice	O
.	O

Craniofacial	B-DIS
anomalies	I-DIS
are	O
among	O
the	O
most	O
common	O
birth	B-DIS
defects	I-DIS
and	O
are	O
associated	O
with	O
increased	O
mortality	O
and	O
in	O
many	O
cases	O
the	O
need	O
for	O
lifelong	O
treatment	O
.	O

Over	O
the	O
past	O
few	O
decades	O
dramatic	O
advances	O
in	O
the	O
surgical	O
and	O
medical	O
care	O
of	O
these	O
patients	O
have	O
led	O
to	O
marked	O
improvements	O
in	O
patient	O
outcomes	O
.	O

However	O
none	O
of	O
the	O
treatments	O
currently	O
in	O
clinical	O
use	O
address	O
the	O
underlying	O
molecular	O
causes	O
of	O
these	O
disorders	O
.	O

Fortunately	O
the	O
field	O
of	O
craniofacial	O
developmental	O
biology	O
provides	O
a	O
strong	O
foundation	O
for	O
improved	O
diagnosis	O
and	O
for	O
therapies	O
that	O
target	O
the	O
genetic	O
causes	O
of	O
birth	B-DIS
defects	I-DIS
.	O

In	O
this	O
chapter	O
we	O
discuss	O
recent	O
advances	O
in	O
our	O
understanding	O
of	O
the	O
embryology	O
of	O
craniofacial	O
conditions	O
and	O
we	O
focus	O
on	O
the	O
use	O
of	O
animal	O
models	O
to	O
guide	O
rational	O
therapies	O
anchored	O
in	O
genetics	O
and	O
biochemistry	O
.	O

The	O
temperate	O
United	B-LOC
States	I-LOC
has	O
experienced	O
increasing	O
incidence	B-EPI
of	O
mosquito	B-DIS
-	I-DIS
borne	O
diseases	O
.	O

Recent	O
studies	O
conducted	O
in	O
Baltimore	B-LOC
MD	O
have	O
demonstrated	O
a	O
negative	O
relationship	O
between	O
abundances	O
of	O
Aedes	O
albopictus	O
Skuse	O
and	O
Culex	O
mosquitoes	O
and	O
mean	O
neighborhood	O
income	O
level	O
but	O
have	O
not	O
looked	O
at	O
the	O
presence	O
of	O
pathogens	O
.	O

Mosquitoes	O
collected	O
from	O
five	O
socioeconomically	O
variable	O
neighborhoods	O
were	O
tested	O
for	O
infection	B-DIS
by	O
West	B-LOC
Nile	I-LOC
chikungunya	O
and	O
Zika	O
viruses	O
in	O
2015	O
and	O
2016	O
and	O
again	O
from	O
four	O
of	O
the	O
neighborhoods	O
in	O
2017	O
.	O

Minimum	O
infection	B-DIS
rates	O
of	O
pooled	O
samples	O
were	O
compared	O
among	O
neighborhoods	O
for	O
each	O
year	O
as	O
well	O
as	O
among	O
individual	O
blocks	O
in	O
2017	O
.	O

West	B-LOC
Nile	I-LOC
virus	O
was	O
detected	O
in	O
both	O
Ae	O
.	O

albopictus	O
and	O
Culex	O
pools	O
from	O
all	O
neighborhoods	O
sampled	O
in	O
2015	O
and	O
2017	O
.	O

No	O
infected	O
pools	O
were	O
detected	O
in	O
any	O
year	O
for	O
chikungunya	O
or	O
Zika	O
viruses	O
and	O
none	O
of	O
the	O
target	O
viruses	O
were	O
detected	O
in	O
2016	O
.	O

Infection	B-DIS
rates	O
were	O
consistently	O
higher	O
for	O
Culex	O
than	O
for	O
Ae	O
.	O

albopictus	O
.	O

Minimum	O
infection	B-DIS
rate	O
was	O
negatively	O
associated	O
with	O
mean	O
neighborhood	O
income	O
for	O
both	O
species	O
in	O
2015	O
.	O

Although	O
earlier	O
work	O
has	O
shown	O
a	O
positive	O
association	O
between	O
block	O
-	O
level	O
abandonment	O
and	O
mosquito	O
abundance	O
no	O
association	O
was	O
detected	O
in	O
this	O
study	O
.	O

Still	O
we	O
demonstrate	O
that	O
viral	B-DIS
infection	I-DIS
in	O
mosquito	O
pools	O
can	O
differ	O
substantially	O
across	O
adjacent	O
urban	O
neighborhoods	O
that	O
vary	O
by	O
income	O
.	O

Though	O
trap	O
security	O
and	O
accessibility	O
often	O
inform	O
city	O
sampling	O
locations	O
detecting	O
and	O
managing	O
arboviral	O
risk	O
requires	O
surveillance	O
across	O
neighborhoods	O
that	O
vary	O
in	O
socioeconomics	O
including	O
lower	O
income	O
areas	O
that	O
may	O
be	O
less	O
accessible	O
and	O
secure	O
but	O
have	O
higher	O
infection	B-DIS
rates	O
.	O

Background	O
Insight	O
into	O
type	O
6	O
long	B-DIS
-	I-DIS
QT	I-DIS
syndrome	O
LQT6	O
stemming	O
from	O
mutations	O
in	O
the	O
KCNE2	O
-encoded	O
voltage	O
-	O
gated	O
channel	O
β	O
-	O
subunit	O
is	O
limited	O
.	O

We	O
sought	O
to	O
further	O
characterize	O
its	O
clinical	O
phenotype	O
.	O

Methods	O
and	O
results	O
Individuals	O
with	O
reported	O
pathogenic	O
KCNE2	O
mutations	O
identified	O
during	O
arrhythmia	B-DIS
evaluation	O
were	O
collected	O
from	O
inherited	O
arrhythmia	B-DIS
clinics	O
and	O
the	O
Rochester	O
long	B-DIS
-	I-DIS
QT	I-DIS
syndrome	O
LQTS	O
registry	O
.	O

Previously	O
reported	O
LQT6	B-DIS
cases	O
were	O
identified	O
through	O
a	O
search	O
of	O
the	O
MEDLINE	O
database	O
.	O

Clinical	O
features	O
were	O
assessed	O
while	O
reported	O
KCNE2	O
mutations	O
were	O
evaluated	O
for	O
genotype	O
-	O
phenotype	O
segregation	O
and	O
classified	O
according	O
to	O
the	O
contemporary	O
American	O
College	O
of	O
Medical	O
Genetics	O
guidelines	O
.	O

Twenty	O
-	O
seven	O
probands	O
possessed	O
reported	O
pathogenic	O
KCNE2	O
mutations	O
while	O
a	O
MEDLINE	O
search	O
identified	O
17	O
additional	O
LQT6	O
cases	O
providing	O
clinical	O
and	O
genetic	O
data	O
.	O

Sixteen	O
probands	O
had	O
normal	O
resting	O
QTc	O
values	O
and	O
only	O
developed	O
QT	O
prolongation	O
and	O
malignant	B-DIS
arrhythmias	I-DIS
after	O
exposure	O
to	O
QT	O
-	O
prolonging	O
stressors	O
10	O
had	B-DIS
other	O
LQTS	O
pathogenic	O
mutations	O
and	O
10	O
did	O
not	O
have	B-DIS
an	O
LQTS	O
phenotype	O
.	O

Although	O
the	O
remaining	O
8	O
subjects	O
had	O
an	O
LQTS	B-DIS
phenotype	O
evidence	O
suggested	O
that	O
the	O
KCNE2	O
variant	O
was	O
not	O
the	O
underlying	O
culprit	O
.	O

The	O
collective	O
frequency	O
of	O
KCNE2	O
variants	O
implicated	O
in	O
LQT6	B-DIS
in	O
the	O
Exome	O
Aggregation	O
Consortium	O
database	O
was	O
1.4	B-STAT
%	I-STAT
in	O
comparison	O
with	O
a	O
0.0005	B-STAT
%	I-STAT
estimated	O
clinical	O
prevalence	B-EPI
for	O
LQT6	B-DIS
.	O

Conclusions	O
On	O
the	O
basis	O
of	O
clinical	O
phenotype	O
the	O
high	O
allelic	O
frequencies	O
of	O
LQT6	B-DIS
mutations	O
in	O
the	O
Exome	O
Aggregation	O
Consortium	O
database	O
and	O
absence	O
of	O
previous	O
documentation	O
of	O
genotype	O
-	O
phenotype	O
segregation	O
our	O
findings	O
suggest	O
that	O
many	O
KCNE2	O
variants	O
and	O
perhaps	O
all	O
have	O
been	O
erroneously	O
designated	O
as	O
LQTS	O
-	O
causative	O
mutations	O
.	O

Instead	O
KCNE2	O
variants	O
may	O
confer	O
proarrhythmic	O
susceptibility	O
when	O
provoked	O
by	O
additional	O
environmental	O
/	O
acquired	O
or	O
genetic	O
factors	O
or	O
both	O
.	O

ImportanceCongenital	O
retinal	B-DIS
macrovessel	I-DIS
CRM	O
is	O
a	O
rarely	O
reported	O
venous	B-DIS
malformation	I-DIS
of	O
the	O
retina	O
that	O
is	O
associated	O
with	O
venous	B-DIS
anomalies	I-DIS
of	O
the	O
brain	O
.	O

ObjectiveTo	O
study	O
the	O
multimodal	O
imaging	O
findings	O
of	O
a	O
series	O
of	O
eyes	O
with	O
congenital	B-DIS
retinal	I-DIS
macrovessel	I-DIS
and	O
describe	O
the	O
systemic	O
associations	O
.	O

Design	O
Setting	O
and	O
ParticipantsIn	O
this	O
cross	O
-	O
sectional	O
multicenter	O
study	O
medical	O
records	O
were	O
retrospectively	O
reviewed	O
from	O
7	O
different	O
retina	O
clinics	O
worldwide	O
over	O
a	O
10	O
-	O
year	O
period	O
2007	O
-	O
2017	O
.	O

Patients	O
with	O
CRM	O
defined	O
as	O
an	O
abnormal	O
large	O
macular	O
vessel	O
with	O
a	O
vascular	O
distribution	O
above	O
and	O
below	O
the	O
horizontal	O
raphe	O
were	O
identified	O
.	O

Data	O
were	O
analyzed	O
from	O
December	O
2016	O
to	O
August	O
2017	O
.	O

Main	O
Outcomes	O
and	O
MeasuresClinical	O
information	O
and	O
multimodal	O
retinal	O
imaging	O
findings	O
were	O
collected	O
and	O
studied	O
.	O

Pertinent	O
systemic	O
information	O
including	O
brain	O
magnetic	O
resonance	O
imaging	O
findings	O
was	O
also	O
noted	O
if	O
available	O
.	O

ResultsOf	O
the	O
49	O
included	O
patients	O
3265	B-STAT
%	I-STAT
were	O
female	O
and	O
the	O
mean	O
SD	O
age	O
at	O
onset	O
was	O
44.0	O
20.9	O
years	O
.	O

A	O
total	O
of	O
49	O
eyes	O
from	O
49	O
patients	O
were	O
studied	O
.	O

Macrovessel	O
was	O
unilateral	O
in	O
all	O
patients	O
.	O

Color	O
fundus	O
photography	O
illustrated	O
a	O
large	O
aberrant	B-DIS
dilated	I-DIS
and	O
tortuous	O
retinal	B-DIS
vein	I-DIS
in	O
all	O
patients	O
.	O

Early	O
-	O
phase	O
frames	O
of	O
fluorescein	O
angiography	O
further	O
confirmed	O
the	O
venous	O
nature	O
of	B-DIS
the	O
macrovessel	O
in	O
40	O
of	O
40	O
eyes	O
.	O

Optical	O
coherence	O
tomography	O
angiography	O
available	O
in	O
17	O
eyes	O
35	B-STAT
%	I-STAT
displayed	O
microvascular	O
capillary	O
abnormalities	O
around	O
the	O
CRM	O
which	O
were	O
more	O
evident	O
in	O
the	O
deep	O
capillary	O
plexus	O
.	O

Of	O
the	O
49	O
patients	O
with	O
CRM	O
3980	B-STAT
%	I-STAT
did	O
not	O
illustrate	O
any	O
evidence	O
of	O
ophthalmic	O
complications	O
.	O

Ten	O
patients	O
20	B-STAT
%	I-STAT
presented	O
with	O
retinal	B-DIS
complications	I-DIS
typically	O
an	O
incidental	O
association	O
with	O
CRM	O
.	O

Twelve	O
patients	O
24	B-STAT
%	I-STAT
were	O
noted	O
to	O
have	O
venous	B-DIS
malformations	I-DIS
of	O
the	O
brain	O
with	O
associated	O
magnetic	O
resonance	O
imaging	O
.	O

Of	O
these	O
location	O
of	O
the	O
venous	B-DIS
anomaly	I-DIS
in	O
the	O
brain	O
was	O
ipsilateral	O
to	O
the	O
CRM	O
in	O
10	O
patients	O
83	B-STAT
%	I-STAT
and	O
contralateral	O
in	O
2	O
patients	O
17	B-STAT
%	I-STAT
mainly	O
located	O
in	O
the	O
frontal	O
lobe	O
in	O
9	O
patients	O
75	B-STAT
%	I-STAT
.	O

Conclusions	O
and	O
RelevanceOur	O
study	O
has	O
identified	O
an	O
association	O
between	O
macrovessels	O
in	O
the	O
retina	O
and	O
venous	B-DIS
anomalies	I-DIS
of	O
the	O
brain	O
24	B-STAT
%	I-STAT
compared	O
with	O
0.2	B-STAT
%	I-STAT
to	O
6.0	B-STAT
%	I-STAT
in	O
the	O
normal	O
population	O
.	O

Thus	O
we	O
recommend	O
new	O
guidelines	O
for	O
the	O
systemic	O
workup	O
of	O
patients	O
with	O
CRM	O
to	O
include	O
brain	O
magnetic	O
resonance	O
imaging	O
with	O
contrast	O
.	O

These	O
lesions	O
may	O
be	O
more	O
accurately	O
referred	O
to	O
as	O
retinal	B-DIS
venous	I-DIS
malformations	I-DIS
which	O
may	O
raise	O
awareness	O
regarding	O
potential	O
cerebral	O
associations	O
.	O

Background	O
Primary	O
immune	B-DIS
deficiencies	I-DIS
PIDs	I-DIS
are	O
a	O
heterogeneous	O
group	O
of	O
disorders	O
resulting	O
from	O
defects	O
in	O
immune	O
system	O
.	O

They	O
lead	O
to	O
increased	O
susceptibility	O
to	O
infections	B-DIS
and	O
immune	O
dysregulation	O
.	O

The	O
resulting	O
chronic	B-DIS
inflammation	I-DIS
can	O
induce	O
long	O
-	O
term	O
complications	O
including	O
AA	O
amyloidosis	O
AAA	O
.	O

Objectives	O
To	O
present	O
the	O
French	O
cases	O
of	O
PID	O
-	O
related	O
AAA	O
and	O
perform	O
a	O
systematic	O
literature	O
review	O
to	O
determine	O
its	O
main	O
features	O
and	O
predisposing	O
factors	O
.	O

Methods	O
A	O
systematic	O
literature	O
review	O
was	O
performed	O
by	O
searching	O
MEDLINE	O
up	O
until	O
2019	O
.	O

New	O
French	O
cases	O
were	O
identified	O
with	O
the	O
help	O
of	O
the	O
Reference	O
Center	O
for	O
Auto	B-DIS
-	B-DIS
Inflammatory	I-DIS
Diseases	I-DIS
and	I-DIS
AA	O
Amyloidosis	O
and	O
the	O
Reference	O
Center	O
for	O
Hereditary	O
Immune	O
Deficiencies	O
.	O

Results	O
Forty	O
patients	O
were	O
identified	O
including	O
2	O
new	O
French	O
cases	O
.	O

PIDs	B-DIS
were	O
varied	O
immunoglobulin	O
deficits	O
n	O
=	O
30	O
chronic	O
granulomatous	B-DIS
disease	I-DIS
n	O
=	O
3	O
hyper	B-DIS
-	I-DIS
IgM	O
syndrome	O
n	O
=	O
3	O
hereditary	O
complete	O
C4	O
deficiency	O
n	O
=	O
1	O
leucocyte	O
adhesion	O
deficiency	B-STAT
type	I-STAT
1	I-STAT
n	I-STAT
=	B-DIS
1	I-DIS
hyper	O
-	O
IgE	O
syndrome	O
n	B-DIS
=	I-DIS
1	O
and	O
Chediak	O
-	O
Higashi	O
syndrome	O
n	O
=	O
1	O
.	O

The	O
mean	O
age	O
at	O
PID	O
diagnosis	O
was	O
22.2	O
±	O
16.02	O
years	O
.	O

Renal	O
involvement	O
was	O
the	O
most	O
common	O
manifestation	O
of	O
AAA	O
80	B-STAT
%	I-STAT
.	O

Infections	B-DIS
were	O
extremely	O
heterogeneous	O
;	O
bacterial	B-DIS
infection	I-DIS
with	O
pulmonary	O
involvement	O
was	O
the	O
most	O
frequent	O
.	O

Bronchiectasis	O
was	O
particularly	O
common	O
52.5	B-STAT
%	I-STAT
.	O

The	O
delay	O
between	O
the	O
first	O
symptoms	O
of	O
PID	B-DIS
and	O
AAA	O
diagnosis	O
was	O
16.18	O
±	O
7	O
years	O
.	O

Thirteen	O
concomitant	O
diagnoses	O
were	O
made	O
.	O

Twenty	O
patients	O
died	O
during	O
follow	O
-	O
up	O
.	O

Conclusion	O
AAA	O
is	O
a	O
rare	O
life	O
-	O
threatening	O
complication	O
of	O
PID	O
especially	O
in	O
cases	O
of	O
long	O
diagnostic	O
and	O
therapeutic	O
delays	O
.	O

Bronchiectasis	O
should	O
be	O
considered	O
as	O
a	O
warning	O
sign	O
of	O
chronic	O
inflammation	O
and	O
increased	O
risk	O
of	O
AAA	O
.	O

Autosomal	B-DIS
recessive	I-DIS
interleukin-1	I-DIS
receptor	O
-	O
associated	O
kinase	O
IRAK	O
-4	O
and	O
myeloid	O
differentiation	B-DIS
factor	O
MyD	O
88	O
deficiencies	O
impair	O
Toll	O
-	O
like	O
receptor	O
TLR	O
-	O
and	O
interleukin-1	O
receptor	O
-	O
mediated	O
immunity	O
.	O

We	O
documented	O
the	O
clinical	O
features	O
and	O
outcome	O
of	O
48	O
patients	O
with	O
IRAK-4	O
deficiency	O
and	O
12	O
patients	O
with	O
MyD88	O
deficiency	O
from	O
37	O
kindreds	O
in	O
15	O
countries	O
.	O
The	O
clinical	O
features	O
of	O
IRAK-4	O
and	O
MyD88	O
deficiency	O
were	O
indistinguishable	O
.	O

There	O
were	O
no	O
severe	O
viral	B-DIS
parasitic	I-DIS
and	I-DIS
fungal	I-DIS
diseases	I-DIS
and	O
the	O
range	O
of	O
bacterial	B-DIS
infections	I-DIS
was	O
narrow	O
.	O

Noninvasive	O
bacterial	B-DIS
infections	I-DIS
occurred	O
in	O
52	O
patients	O
with	O
a	O
high	O
incidence	B-EPI
of	O
infections	B-DIS
of	O
the	O
upper	O
respiratory	O
tract	O
and	O
the	O
skin	O
mostly	O
caused	O
by	O
Pseudomonas	B-DIS
aeruginosa	I-DIS
and	O
Staphylococcus	B-DIS
aureus	I-DIS
respectively	O
.	O

The	O
leading	O
threat	O
was	O
invasive	O
pneumococcal	B-DIS
disease	I-DIS
documented	O
in	O
41	O
patients	O
68	B-STAT
%	I-STAT
and	O
causing	O
72	O
documented	O
invasive	O
infections	B-DIS
52.2	B-STAT
%	I-STAT
.	O

P.	B-DIS
aeruginosa	I-DIS
and	O
Staph	O
.	O

aureus	B-DIS
documented	O
invasive	O
infections	B-DIS
also	O
occurred	O
16.7	B-STAT
%	I-STAT
and	O
16	B-STAT
%	I-STAT
respectively	O
in	O
13	O
and	O
13	O
patients	O
respectively	O
.	O

Systemic	O
signs	O
of	O
inflammation	B-DIS
were	O
usually	O
weak	O
or	O
delayed	O
.	O

The	O
first	O
invasive	O
infection	B-DIS
occurred	O
before	O
the	O
age	O
of	O
2	O
years	O
in	O
5388.3	B-STAT
%	I-STAT
and	O
in	O
the	O
neonatal	O
period	O
in	O
1932.7	B-STAT
%	I-STAT
patients	O
.	O

Multiple	O
or	O
recurrent	O
invasive	O
infections	B-DIS
were	O
observed	O
in	O
most	O
survivors	O
n	O
=	O
36/5072	B-STAT
%	I-STAT
.Clinical	O
outcome	O
was	O
poor	O
with	O
24	O
deaths	B-DIS
in	O
10	O
cases	O
during	O
the	O
first	O
invasive	O
episode	O
and	O
in	O
16	O
cases	O
of	O
invasive	O
pneumococcal	B-DIS
disease	I-DIS
.	O

However	O
no	O
death	B-DIS
and	O
invasive	O
infectious	B-DIS
disease	I-DIS
were	O
reported	O
in	O
patients	O
after	O
the	O
age	O
of	O
8	O
years	O
and	O
14	O
years	O
respectively	O
.	O

Antibiotic	O
prophylaxis	O
n	O
=	O
34	O
antipneumococcal	O
vaccination	O
n	O
=	O
31	O
and/or	O
IgG	O
infusion	O
n	O
=	O
19	O
when	O
instituted	O
had	O
a	O
beneficial	O
impact	O
on	O
patients	O
until	O
the	O
teenage	O
years	O
with	O
no	O
seemingly	O
detectable	O
impact	O
thereafter	O
.	O
IRAK-4	O
and	O
MyD88	O
deficiencies	O
predispose	O
patients	O
to	O
recurrent	O
life	O
-	B-DIS
threatening	I-DIS
bacterial	O
diseases	O
such	O
as	B-DIS
invasive	I-DIS
pneumococcal	O
disease	O
in	O
particular	O
in	O
infancy	O
and	O
early	O
childhood	O
with	O
weak	O
signs	B-DIS
of	O
inflammation	O
.	O

Patients	O
and	O
families	O
should	O
be	O
informed	O
of	O
the	O
risk	O
of	O
developing	O
life	O
-	B-DIS
threatening	O
infections	O
;	O
empiric	O
antibacterial	O
treatment	O
and	O
immediate	O
medical	O
consultation	O
are	O
strongly	O
recommended	O
in	O
cases	O
of	B-DIS
suspected	O
infection	O
or	B-DIS
moderate	O
fever	O
.	O

Prophylactic	O
measures	O
in	O
childhood	O
are	O
beneficial	O
until	O
spontaneous	O
improvement	O
occurs	O
in	O
adolescence	O
.	O

Glucose-6	O
-	O
phosphate	O
dehydrogenase	O
G6PD	O
deficiency	O
is	O
the	O
most	O
common	O
enzymatic	O
disorder	O
of	O
red	O
blood	O
cells	O
worldwide	O
.	O

The	O
severity	O
of	O
hemolytic	B-DIS
anemia	I-DIS
varies	O
among	O
individuals	O
with	O
G6PD	O
deficiency	O
depending	O
on	O
the	O
genetic	O
variant	O
in	O
the	O
G6PD	O
gene	O
;	O
this	O
makes	O
the	O
diagnosis	O
of	O
the	O
condition	O
more	O
challenging	O
in	O
some	O
cases	O
.	O

In	O
this	O
report	O
we	O
present	O
a	O
case	O
of	O
severe	O
hemolytic	B-DIS
anemia	I-DIS
and	O
methemoglobinemia	B-DIS
in	O
a	O
patient	O
with	O
G6PD	B-DIS
deficiency	I-DIS
who	O
had	O
been	O
exposed	O
to	O
hydroxychloroquine	O
prescribed	O
for	O
severe	O
acute	B-DIS
respiratory	I-DIS
syndrome	I-DIS
coronavirus	I-DIS
2	I-DIS
SARS	I-DIS
-	I-DIS
CoV-2	O
infection	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
and	O
based	O
on	O
a	O
literature	O
search	O
this	O
is	O
one	O
of	O
the	O
first	O
case	O
reports	O
in	O
the	O
literature	O
about	O
hemolytic	B-DIS
crisis	O
and	O
methemoglobinemia	B-DIS
in	O
a	O
patient	O
with	O
critical	O
illness	O
due	O
to	O
severe	O
coronavirus	B-DIS
disease	I-DIS
2019	O
COVID-19	O
who	O
was	O
exposed	O
to	O
hydroxychloroquine	O
.	O

It	O
is	O
critical	O
for	O
physicians	O
and	O
caregivers	O
to	O
recognize	O
the	O
effects	O
of	O
oxidative	O
stressors	O
such	O
as	O
hydroxychloroquine	O
particularly	O
in	O
this	O
era	O
of	O
the	O
COVID-19	O
pandemic	O
and	O
in	O
regions	O
with	O
a	O
high	O
prevalence	B-EPI
of	O
G6PD	B-DIS
deficiency	I-DIS
for	O
the	O
appropriate	O
management	O
of	O
this	O
unique	O
subset	O
of	O
patients	O
.	O

Rates	O
of	O
eating	B-DIS
disorders	I-DIS
EDs	O
are	O
increasing	O
in	O
Australia	B-LOC
as	O
are	O
rates	O
of	O
bariatric	O
and	O
cosmetic	O
surgery	O
including	O
weight	O
-	O
related	O
procedures	O
.	O

It	O
is	O
known	O
that	O
binge	B-DIS
eating	I-DIS
disorder	I-DIS
BED	O
is	O
common	O
in	O
bariatric	O
surgery	O
candidates	O
and	O
that	O
people	O
with	O
EDs	O
are	O
likely	O
to	O
undergo	O
weight	O
-	O
related	O
cosmetic	O
procedures	O
however	O
most	O
of	O
the	O
literature	O
is	O
based	O
on	O
clinic	O
samples	O
and	O
focuses	O
on	O
young	O
women	O
and	O
BED	O
.	O

Aims	O
of	O
this	O
study	O
were	O
to	O
determine	O
the	O
prevalence	B-EPI
of	O
1	O
actual	O
or	O
intended	O
bariatric	O
surgery	O
and	O
2	O
actual	O
or	O
intended	O
cosmetic	O
surgery	O
including	O
weight	O
-	O
related	O
procedures	O
in	O
people	O
with	O
a	O
current	O
ED	O
and	O
a	O
lifetime	O
history	O
of	O
BED	B-DIS
or	I-DIS
bulimia	O
nervosa	O
BN	O
and	O
the	O
associations	O
with	O
actual	O
or	O
intended	O
bariatric	O
or	O
cosmetic	O
surgery	O
and	O
demographic	O
features	O
.	O

Using	O
a	O
general	O
population	O
survey	O
2977	O
individuals	O
were	O
interviewed	O
regarding	O
sociodemographic	O
status	O
ED	O
symptoms	O
mental	O
health	O
-	O
related	O
quality	O
of	O
life	O
MHRQoL	O
and	O
actual	O
or	O
intended	O
use	O
of	O
bariatric	O
and	O
cosmetic	B-EPI
surgery	O
prevalence	O
estimates	O
of	O
which	O
were	O
2.0	B-STAT
%	I-STAT
and	O
1.1	B-STAT
%	I-STAT
respectively	O
.	O

People	O
who	O
had	O
planned	O
or	O
received	O
either	O
type	O
of	O
surgery	O
were	O
more	O
likely	O
to	O
be	O
1	B-STAT
women	I-STAT
and	I-STAT
2	I-STAT
have	O
a	O
higher	O
BMI	O
3	O
poorer	O
MHRQoL	O
and	O
4	O
a	O
current	O
ED	O
lifetime	O
BN	O
or	O
BED	O
or	O
features	O
of	O
EDs	O
all	O
p	O
<	O
0.05	O
.	O

Age	O
and	O
household	O
income	O
were	O
not	O
significantly	O
associated	O
with	O
increased	O
use	O
of	O
either	O
type	O
of	O
surgery	O
.	O

Given	O
the	O
potential	O
for	O
an	O
ED	O
to	O
affect	O
outcomes	O
of	O
surgery	O
screening	O
and	O
treatment	O
for	O
EDs	O
should	O
be	O
considered	O
in	O
such	O
surgical	O
candidates	O
.	O

On	O
3	O
August	O
1900	O
bubonic	O
plague	O
Yersinia	B-DIS
pestis	O
broke	O
out	O
in	O
Glasgow	B-LOC
for	O
the	O
first	O
time	O
during	O
the	O
Third	O
Pandemic	O
.	O

The	O
local	O
sanitary	O
authorities	O
rigorously	O
tracked	O
the	O
spread	O
of	O
the	O
disease	O
and	O
they	O
found	O
that	O
nearly	O
all	O
of	O
the	O
35	O
cases	O
could	O
be	O
linked	O
by	O
contact	O
with	O
a	O
previous	O
case	O
.	O

Despite	O
trapping	O
hundreds	O
of	O
rats	O
in	O
the	O
area	O
there	O
was	O
no	O
evidence	O
of	O
a	O
rat	O
epizootic	O
and	O
the	O
investigators	O
speculated	O
that	O
the	O
outbreak	O
could	O
be	O
due	O
to	O
human	O
-	O
to	O
-	B-DIS
human	I-DIS
transmission	O
of	O
bubonic	O
plague	O
.	O

Here	O
we	O
use	O
a	O
likelihood	O
-	O
based	O
method	O
to	O
reconstruct	O
transmission	O
trees	O
for	O
the	O
outbreak	O
.	O

From	O
the	O
description	O
of	O
the	O
outbreak	O
and	O
the	O
reconstructed	O
trees	O
we	O
infer	O
several	O
epidemiological	O
parameters	O
.	O

We	O
found	O
that	O
the	O
estimated	O
mean	O
serial	O
interval	O
was	O
7.4	O
-	O
9.2	O
days	O
and	O
the	O
mean	O
effective	O
reproduction	O
number	O
dropped	O
below	O
1	O
after	O
implementation	O
of	O
control	O
measures	O
.	O

We	O
also	O
found	O
a	O
high	O
rate	O
of	O
secondary	O
transmissions	O
within	O
households	O
and	O
observations	O
of	O
transmissions	O
from	O
individuals	O
who	O
were	O
not	O
terminally	O
septicaemic	B-DIS
.	O

Our	O
results	O
provide	O
important	O
insights	O
into	O
the	O
epidemiology	O
of	O
a	O
bubonic	O
plague	O
outbreak	O
during	O
the	O
Third	O
Pandemic	O
in	O
Europe	B-LOC
.	O

Mayer	O
Rokitansky	O
Kuster	B-DIS
Hauser	I-DIS
MRKH	I-DIS
syndrome	I-DIS
is	O
a	O
congenital	B-DIS
disorder	I-DIS
involving	O
reproductive	B-DIS
genitourinary	I-DIS
bone	O
and	O
cardiac	B-DIS
malformation	I-DIS
.	O

The	O
incidence	B-EPI
is	O
1	B-STAT
in	I-STAT
4000	I-STAT
-	O
5000	O
females	O
livebirths	O
.	O

The	O
phenotype	O
is	O
female	O
46	O
XX	O
karyotype	O
normal	O
secondary	O
sexual	O
characteristics	O
and	O
normal	O
functional	O
ovaries	O
.	O

The	O
occurrence	O
of	O
leiomyoma	B-DIS
in	O
uterine	O
remnant	O
in	O
MRKH	B-DIS
syndrome	I-DIS
is	O
a	O
very	O
rare	O
case	O
even	O
though	O
several	O
cases	O
have	O
been	O
reported	O
.	O

The	O
diagnosis	O
and	O
management	O
approach	O
in	O
this	O
case	O
is	O
quite	O
challenging	O
.	O

Here	O
we	O
report	O
a	O
38	O
years	O
old	O
female	O
who	O
represents	O
multiple	O
leiomyomas	B-DIS
on	O
the	O
rudimentary	O
uterus	O
then	O
we	O
did	O
laparoscopic	O
removal	O
of	O
the	O
fibroids	B-DIS
and	O
adjacent	O
rudimentary	O
uterus	O
.	O

Objective	O
To	O
determine	O
whether	O
the	O
two	O
most	O
common	O
genetic	O
mutations	O
seen	O
in	O
Stickler	B-DIS
Syndrome	I-DIS
SS	I-DIS
COL2A1	O
and	O
COL11A1	O
affect	O
the	O
incidence	B-EPI
of	O
mandibular	B-DIS
distraction	I-DIS
osteogenesis	I-DIS
MDO	I-DIS
and	O
what	O
impact	O
Robin	B-DIS
sequence	I-DIS
RS	I-DIS
has	O
on	O
diagnosis	O
.	O

SS	O
is	O
an	O
autosomal	B-DIS
dominant	I-DIS
connective	I-DIS
tissue	I-DIS
disorder	I-DIS
characterized	O
by	O
almost	O
complete	O
penetrance	O
.	O

COL2A1	O
and	O
COL11A1	O
are	O
the	O
two	O
most	O
common	O
mutations	O
seen	O
in	O
SS	B-DIS
patients	O
.	O

SS	O
often	O
presents	O
at	O
birth	O
with	O
RS	B-DIS
which	O
is	O
characterized	O
by	O
the	O
triad	O
of	O
micrognathia	B-DIS
glossoptosis	I-DIS
and	O
tongue	B-DIS
-	B-DIS
based	I-DIS
airway	O
obstruction	O
.	O

MDO	O
is	O
one	O
surgical	O
intervention	O
that	O
has	O
been	O
shown	O
to	O
be	O
successful	O
in	O
relieving	O
tongue	O
base	B-DIS
obstruction	I-DIS
and	O
is	O
the	O
surgical	O
intervention	O
of	O
choice	O
for	O
this	O
condition	O
.	O

Methods	O
A	O
retrospective	O
chart	O
review	O
was	O
performed	O
on	O
all	O
patients	O
with	O
a	O
diagnosis	O
of	O
SS	B-DIS
at	O
a	O
tertiary	O
pediatric	O
hospital	O
between	O
January	O
12003	O
and	O
December	O
312018	O
.	O

The	O
included	O
patient	O
charts	O
were	O
reviewed	O
for	O
demographic	O
information	O
SS	O
mutation	O
and	O
history	O
of	O
MDO	O
.	O

Forty	O
-	O
six	O
patients	O
had	O
a	O
clinical	O
diagnosis	B-DIS
of	O
SS	O
.	O

Of	O
those	O
31	O
met	O
inclusion	O
criteria	O
which	O
involved	O
having	O
a	O
molecular	O
diagnosis	O
of	O
SS	O
and	O
sufficient	O
follow	O
up	O
information	O
to	O
determine	O
if	O
MDO	O
was	O
indicated	O
or	O
performed	O
.	O

Twenty	O
-	O
two	O
of	O
the	O
31	O
included	O
patients	O
had	O
a	O
diagnosis	B-DIS
of	O
RS	O
70.96	B-STAT
%	I-STAT
.	O

Thirteen	O
of	O
the	O
31	O
patients	O
41.94	B-STAT
%	I-STAT
included	O
in	O
this	O
study	O
required	O
MDO	O
as	O
a	O
neonate	O
.	O

Results	O
Fifty	B-STAT
-	I-STAT
percent	I-STAT
of	O
patients	O
with	O
type	O
I	O
COL2A1	O
required	O
MDO	O
as	O
a	O
neonate	O
compared	O
to	O
only	B-STAT
31	I-STAT
%	I-STAT
of	O
patients	O
with	O
type	O
II	O
COL11A1	O
though	O
the	O
difference	O
between	O
the	O
two	O
groups	O
was	O
not	O
statistically	O
significant	O
.	O

Conclusion	O
The	O
findings	O
of	O
this	O
study	O
suggest	O
that	O
patients	O
with	O
type	O
I	O
mutation	O
may	O
have	O
a	O
higher	O
incidence	B-EPI
of	O
MDO	B-DIS
than	O
patients	O
with	O
a	O
type	O
II	O
mutation	O
though	O
further	O
research	O
with	O
larger	O
sample	O
sizes	O
is	O
needed	O
.	O

This	O
information	O
is	O
helpful	O
in	O
counseling	O
those	O
with	O
SS	B-DIS
or	O
family	O
history	O
of	O
SS	O
about	O
what	O
they	O
can	O
expect	O
related	O
to	O
RS	B-DIS
and	O
need	O
for	O
MDO	O
based	O
on	O
genetic	O
findings	O
.	O

Level	O
of	O
evidence	O
3	O
.	O

Most	O
of	O
the	O
knowledge	O
in	O
pediatric	O
antiphospholipid	B-DIS
syndrome	I-DIS
APS	I-DIS
is	O
derived	O
from	O
studies	O
performed	O
on	O
the	O
adult	O
population	O
.	O

As	O
in	O
adults	O
antiphospholipid	O
antibodies	O
aPL	O
can	O
contribute	O
to	O
thrombosis	B-DIS
especially	O
cerebrovascular	B-DIS
thrombosis	I-DIS
in	O
neonates	O
and	O
children	O
.	O

Since	O
aPL	O
have	O
the	O
potential	O
to	O
cross	O
the	O
placental	O
barrier	O
and	O
since	O
the	O
pediatric	O
population	O
is	O
prone	O
to	O
infections	B-DIS
re	O
-	O
testing	O
for	O
their	O
positivity	O
is	O
essential	O
to	O
specify	O
their	O
role	B-DIS
in	I-DIS
cerebrovascular	O
thrombosis	O
.	O
In	O
this	O
review	O
we	O
aimed	O
at	O
assessing	B-EPI
the	O
prevalence	O
of	O
aPL	O
criteria	B-DIS
or	O
non	O
-	O
criteria	O
in	B-DIS
neonatal	I-DIS
and	O
childhood	B-DIS
ischemic	I-DIS
stroke	O
and	O
sinovenous	O
thrombosis	O
trying	O
to	O
find	O
an	O
association	B-DIS
between	I-DIS
aPL	O
and	O
cerebrovascular	O
thrombosis	O
in	O
the	O
neonatal	O
and	O
pediatric	O
population	O
.	O

Also	O
we	O
looked	O
into	O
the	O
effect	O
of	O
aPL	O
and	O
anticoagulants	O
/	O
antiplatelets	O
on	O
the	O
long	O
term	O
neurological	O
outcomes	O
of	O
affected	O
neonates	O
or	O
children	O
.	O

The	O
questions	O
regarding	O
the	O
prevalence	B-EPI
of	O
aPL	O
among	O
pediatric	O
patients	O
with	O
cerebrovascular	B-DIS
thrombosis	I-DIS
the	O
relationship	O
between	O
the	O
titers	O
of	O
aPL	O
and	O
incidence	B-EPI
and	O
recurrence	O
of	O
cerebrovascular	O
events	O
the	O
predictability	O
of	O
the	O
long	O
term	O
neurological	O
outcomes	O
and	O
the	O
most	O
optimal	O
anticoagulation	O
plan	O
are	O
still	O
to	O
be	O
answered	O
.	O

However	O
it	O
is	O
crucial	O
for	O
clinicians	O
to	O
screen	O
neonates	O
and	O
children	O
with	O
cerebrovascular	B-DIS
thrombosis	I-DIS
for	O
aPL	O
and	O
confirm	O
their	O
presence	O
if	O
positive	O
.	O

The	O
Xp22.31	O
segment	O
of	O
the	O
short	O
arm	O
of	O
the	O
human	O
X	O
chromosome	O
is	O
a	O
region	O
of	O
high	O
instability	O
with	O
frequent	O
rearrangement	O
.	O

The	O
duplication	O
of	O
this	O
region	O
has	O
been	O
found	O
in	O
healthy	O
people	O
as	O
well	O
as	O
in	O
individuals	O
with	O
varying	O
degrees	O
of	O
neurological	B-DIS
impairment	I-DIS
.	O

The	O
incidence	B-EPI
has	O
been	O
reported	O
in	O
a	O
range	O
of	O
0.4	B-STAT
-	I-STAT
0.44	I-STAT
%	I-STAT
of	O
the	O
patients	O
with	O
neurological	B-DIS
impairment	I-DIS
.	O

Moreover	O
there	O
is	O
evidence	O
that	O
Xp22.31	O
duplication	O
may	O
cause	O
a	O
common	O
phenotype	O
including	O
developmental	O
delay	O
intellectual	B-DIS
disability	I-DIS
feeding	O
difficulty	O
autistic	B-DIS
spectrum	I-DIS
disorders	I-DIS
hypotonia	I-DIS
seizures	I-DIS
and	O
talipes	B-DIS
.	O

We	O
report	O
on	O
a	O
patient	O
with	O
microcephaly	B-DIS
and	O
trigonocephaly	B-DIS
moderate	O
intellectual	B-DIS
disability	I-DIS
speech	O
and	O
language	O
delay	O
and	O
poor	O
social	O
interaction	O
in	O
addition	O
to	O
minor	O
but	O
atypical	O
dysmorphic	O
features	O
.	O

This	O
report	O
provides	O
further	O
insight	O
into	O
the	O
pathogenicity	O
of	O
the	O
Xp22.31	O
duplication	O
by	O
extending	O
knowledge	O
of	O
its	O
clinical	O
features	O
.	O

This	O
case	O
in	O
association	O
with	O
those	O
reported	O
in	O
the	O
literature	O
indicates	O
that	O
the	O
Xp22.31	O
duplication	O
may	O
contribute	O
to	O
cause	O
pathological	O
phenotypes	O
with	O
minor	O
facial	O
dysmorphisms	O
microcephaly	O
and	O
intellectual	B-DIS
disability	I-DIS
as	O
main	O
features	O
.	O

Inherited	O
retinal	B-DIS
diseases	I-DIS
IRDs	O
which	O
are	O
among	O
the	O
most	O
common	O
genetic	O
diseases	O
in	O
humans	O
define	O
a	O
clinically	O
and	O
genetically	O
heterogeneous	O
group	O
of	O
disorders	O
.	O

Over	O
80	O
forms	O
of	O
syndromic	B-DIS
IRDs	I-DIS
have	O
been	O
described	O
.	O

Approximately	O
200	O
genes	O
are	O
associated	O
with	O
these	O
syndromes	O
.	O

The	O
majority	O
of	O
syndromic	B-DIS
IRDs	I-DIS
are	O
recessively	O
inherited	O
and	O
rare	O
.	O

Many	O
although	O
not	O
all	O
syndromic	O
IRDs	O
can	O
be	O
classified	O
into	O
one	O
of	O
two	O
major	B-DIS
disease	I-DIS
groups	O
inborn	B-DIS
errors	I-DIS
of	O
metabolism	O
and	O
ciliopathies	B-DIS
.	O

Besides	O
the	O
retina	O
the	O
systems	O
and	O
organs	O
most	O
commonly	O
involved	O
in	O
syndromic	O
IRDs	O
are	O
the	O
central	O
nervous	O
system	O
ophthalmic	O
extra	O
-	O
retinal	O
tissues	O
ear	O
skeleton	O
kidney	O
and	O
the	O
cardiovascular	O
system	O
.	O

Due	O
to	O
the	O
high	O
degree	O
of	O
phenotypic	O
variability	O
and	O
phenotypic	O
overlap	O
found	O
in	O
syndromic	O
IRDs	O
correct	O
diagnosis	O
based	O
on	O
phenotypic	O
features	O
alone	O
may	O
be	O
challenging	O
and	O
sometimes	O
misleading	O
.	O

Therefore	O
genetic	O
testing	O
has	O
become	O
the	O
benchmark	O
for	O
the	O
diagnosis	O
and	O
management	O
of	O
patients	O
with	O
these	O
conditions	O
as	O
it	O
complements	O
the	O
clinical	O
findings	O
and	O
facilitates	O
an	O
accurate	O
clinical	O
diagnosis	O
and	O
treatment	O
.	O

This	O
study	O
is	O
to	O
describe	O
current	O
incidence	B-EPI
of	O
childhood	O
clear	B-DIS
cell	I-DIS
sarcoma	I-DIS
of	I-DIS
kidney	I-DIS
CCSK	I-DIS
and	O
to	O
investigate	O
the	O
present	O
survival	O
of	O
this	O
cancer	B-DIS
.	O

Surveillance	O
Epidemiology	O
and	O
End	O
Result	O
SEER	O
data	O
was	O
used	O
to	O
identify	O
children	O
with	O
CCSK	B-DIS
and	O
Wilms	O
tumor	B-DIS
WT	O
aged	O
0	O
-	O
19	O
years	O
in	O
the	O
US	B-LOC
.	O

Age	O
-	B-EPI
adjusted	O
incidences	O
were	O
estimated	O
over	O
the	O
decades	O
.	O

Age-	O
and	O
sex	O
-	O
specific	O
epidemiology	O
was	O
also	O
presented	O
.	O

Propensity	O
score	O
matching	O
was	O
used	O
to	O
balance	O
features	O
of	O
CCSK	B-DIS
and	O
WT	O
cases	O
.	O

Log	O
rank	O
test	O
was	O
used	O
to	O
compare	O
survivals	O
and	O
Cox	O
regression	O
was	O
used	O
to	O
evaluate	O
independent	O
effects	O
of	O
factors	O
.	O

The	O
present	O
age	O
-	B-EPI
adjusted	O
incidence	O
of	B-DIS
childhood	O
CCSK	O
was	O
0.205	O
per	O
million	O
which	O
remained	O
stable	O
for	O
years	O
and	O
ranked	O
third	O
in	O
all	B-DIS
pediatric	I-DIS
renal	O
tumors	O
.	O

The	O
incidence	B-EPI
rate	O
ratios	O
for	O
boy	O
and	O
age	O
under	O
4	O
were	O
3	O
and	O
21	O
respectively	O
.	O

The	O
current	O
5	O
-	O
year	O
overall	O
survival	O
OS	O
rate	B-DIS
for	O
CCSK	O
was	O
87	B-STAT
%	I-STAT
which	O
is	O
not	O
evidently	O
inferior	O
to	O
that	O
for	O
WT	B-STAT
90	I-STAT
%	I-STAT
;	O
however	O
the	O
outcome	B-DIS
of	O
CCSK	O
was	O
significantly	O
poorer	O
if	O
both	O
groups	O
were	O
well	O
-	O
balanced	O
OS	O
rate	O
was	O
86	O
vs.	O
95	B-STAT
%	I-STAT
.	O

Early	O
year	O
of	O
diagnosis	O
and	O
distant	O
metastasis	B-DIS
were	O
independent	O
survival	O
factors	O
.	O

In	O
conclusion	O
occurrence	O
of	O
CCSK	B-DIS
remains	O
stable	O
over	O
the	O
years	O
with	O
an	O
age	O
-	B-EPI
adjusted	O
incidence	O
of	O
0.205	O
per	O
million	O
.	O

Boy	O
and	O
age	O
under	O
4	O
are	O
risk	O
factors	O
for	O
tumor	B-DIS
development	O
.	O

CCSK	B-DIS
currently	O
has	O
a	O
favorable	O
outcome	O
but	O
its	O
nature	O
may	O
be	O
more	O
aggressive	B-DIS
than	I-DIS
common	I-DIS
kidney	I-DIS
tumor	I-DIS
which	O
in	O
turn	O
proves	O
efficacy	O
of	O
modern	O
treatment	O
.	O

Background	O
Using	O
data	O
from	O
the	O
GARFIELD	O
-	O
AF	O
Global	O
Anticoagulant	O
Registry	O
in	O
the	O
FIELD	O
-Atrial	O
Fibrillation	B-DIS
we	O
evaluated	O
the	O
impact	O
of	O
chronic	B-DIS
kidney	I-DIS
disease	I-DIS
CKD	I-DIS
stage	I-DIS
on	O
clinical	O
outcomes	O
in	O
patients	O
with	O
newly	O
diagnosed	O
atrial	B-DIS
fibrillation	I-DIS
AF	O
.	O

Methods	O
and	O
Results	O
GARFIELD	O
-	O
AF	O
is	O
a	O
prospective	O
registry	O
of	O
patients	O
from	O
35	O
countries	O
including	O
patients	O
from	O
Asia	B-LOC
China	I-LOC
India	I-LOC
Japan	B-LOC
Singapore	B-LOC
South	B-LOC
Korea	I-LOC
and	O
Thailand	B-LOC
.	O

Consecutive	O
patients	O
enrolled	O
2013	O
-	O
2016	O
were	O
classified	O
with	O
no	O
mild	O
or	O
moderate	O
-	O
to	O
-	O
severe	O
CKD	O
based	O
on	O
the	O
National	B-DIS
Kidney	I-DIS
Foundation	O
's	O
Kidney	O
Disease	O
Outcomes	O
Quality	O
Initiative	O
guidelines	O
.	O

Data	O
on	O
CKD	O
status	O
and	O
outcomes	O
were	O
available	O
for	O
33024	O
of	O
34854	O
patients	O
including	O
9491	B-DIS
patients	O
from	O
Asia	B-LOC
;	O
10.9	B-STAT
%	I-STAT
n=3613	O
had	O
moderate	O
-	B-DIS
to	O
-	O
severe	O
CKD	O
16.9	B-DIS
%	I-STAT
n=5595	O
mild	O
CKD	O
and	O
72.1	B-STAT
%	I-STAT
n=23816	O
no	O
CKD	O
.	O

The	O
use	O
of	O
oral	O
anticoagulants	O
was	O
influenced	O
by	O
stroke	B-DIS
risk	O
ie	O
post	O
hoc	O
assessment	O
of	O
CHA	O
2	O
<	O
/s	O
DS	O
2	O
<	O
/s	O
-	O
VAS	O
c	O
score	O
but	O
not	O
by	O
CKD	O
stage	O
.	O

The	O
quality	O
of	O
anticoagulant	O
control	O
with	O
vitamin	O
K	O
antagonists	O
did	O
not	O
differ	O
with	O
CKD	B-DIS
stage	I-DIS
.	O

After	O
adjusting	O
for	O
baseline	O
characteristics	O
and	O
antithrombotic	O
use	O
both	O
mild	O
and	O
moderate	O
-	B-DIS
to	O
-	O
severe	O
CKD	O
were	O
independent	O
risk	O
factors	O
for	O
all	O
-	O
cause	O
mortality	O
.	O

Moderate	O
-	B-DIS
to	O
-	O
severe	O
CKD	O
was	O
independently	O
associated	O
with	O
a	O
higher	B-DIS
risk	O
of	B-DIS
stroke	O
/	B-DIS
systemic	I-DIS
embolism	I-DIS
major	O
bleeding	O
new	O
-	O
onset	B-DIS
acute	I-DIS
coronary	O
syndrome	O
and	O
new	O
or	O
worsening	O
heart	O
failure	O
.	O

The	O
impact	O
of	O
moderate	O
-	B-DIS
to	O
-	O
severe	O
CKD	O
on	O
mortality	O
was	O
significantly	O
greater	O
in	O
patients	O
from	O
Asia	B-LOC
than	O
the	O
rest	O
of	O
the	O
world	O
P=0.001	O
.	O

Conclusions	O
In	O
GARFIELD	O
-	O
AF	O
moderate	O
-	B-DIS
to	O
-	O
severe	O
CKD	O
was	O
independently	B-DIS
associated	O
with	B-DIS
stroke	O
/	O
systemic	O
embolism	O
major	O
bleeding	O
and	O
mortality	O
.	O

The	O
effect	O
of	O
moderate	O
-	B-DIS
to	O
-	O
severe	O
CKD	O
on	O
mortality	O
was	O
even	O
greater	O
in	O
patients	O
from	O
Asia	B-LOC
than	O
the	O
rest	O
of	O
the	O
world	O
.	O

Clinical	O
Trial	O
Registration	O
URL	O
http//www.clinicaltrials.gov	O
.	O

Unique	O
identifier	O
NCT	O
01090362	O
.	O

Background	O
Hypertension	B-DIS
is	O
prevalent	O
in	O
35	B-STAT
%	I-STAT
-46	I-STAT
%	O
of	O
the	O
general	O
population	O
;	O
1	B-STAT
%	I-STAT
of	O
them	O
experience	O
accelerated	O
hypertension	B-DIS
.	O

Among	O
patients	O
with	O
accelerated	O
hypertension	B-DIS
acute	O
worsening	O
of	O
renal	O
functions	O
occur	O
in	O
22	B-STAT
%	I-STAT
-55	O
%	O
.	O

Morbidity	O
and	O
mortality	O
rates	O
are	O
high	O
.	O

Partial	O
renal	O
recovery	O
is	O
seen	O
in	O
some	O
while	O
others	O
rapidly	O
progress	O
to	O
end	B-DIS
-	I-DIS
stage	I-DIS
renal	O
disease	O
.	O

Methods	O
Patients	O
who	O
presented	O
with	O
accelerated	O
hypertension	B-DIS
renal	I-DIS
dysfunction	I-DIS
and	O
had	O
undergone	O
renal	O
biopsy	O
were	O
evaluated	O
and	O
their	O
clinical	O
profile	O
was	O
analyzed	O
.	O

Those	O
who	O
became	O
dialysis	O
dependent	O
were	O
excluded	O
from	O
further	O
follow	O
-	O
up	O
.	O

Study	O
outcome	O
were	O
blood	O
pressure	O
control	O
renal	O
functions	O
requirement	O
of	O
renal	O
replacement	O
and	O
mortality	O
.	O

Results	O
Of	O
the	O
30	O
patients	O
evaluated	O
age	O
at	O
presentation	O
was	O
41.2	O
±	O
15.46	O
years	O
and	O
2686.7	B-STAT
%	I-STAT
were	O
males	O
1033	B-STAT
%	I-STAT
had	O
presented	O
with	O
nonspecific	O
complaints	O
.	O

Mean	O
duration	O
of	O
hypertension	B-DIS
and	O
blood	O
pressure	O
were	O
21.93	O
months	O
and	O
196	O
±	O
20.8/129	B-STAT
±	O
12.4	O
mmHg	O
respectively	O
.	O

Glomerulonephritis	B-DIS
and	O
hypertensive	B-DIS
nephrosclerosis	I-DIS
had	O
similar	O
characteristics	O
except	O
proteinuria	B-DIS
P	O
=	O
0.04	O
.	O

Average	O
follow	O
-	O
up	O
n	O
=	O
25	O
duration	O
was	O
3.69	O
years	O
range	O
0.05	O
-	O
9.6	O
.	O

At	O
the	O
end	O
of	O
study	O
6	O
were	O
dialysis	O
dependent	O
while	O
in	O
others	O
mean	O
e	O
-	O
GFR	O
was	O
23.96	O
ml	O
/	O
min/1.73	O
m	O
2	O
<	O
/s	O
.	O

Poor	O
renal	O
prognosis	O
was	O
predicted	O
by	O
glomerulonephritis	B-DIS
relative	O
risk-4.6	O
and	O
degree	O
of	O
interstitial	B-DIS
fibrosis	I-DIS
.	O

Five	O
-	O
year	O
patient	O
and	O
renal	O
survival	O
were	O
94.4	B-STAT
%	I-STAT
and	O
71.9	B-STAT
%	I-STAT
respectively	O
.	O

Conclusion	O
Accelerated	O
hypertension	B-DIS
occurs	O
among	O
patients	O
with	O
both	O
primary	O
and	O
secondary	O
hypertension	B-DIS
.	O

It	O
leaves	O
permanent	O
renal	B-DIS
sequelae	I-DIS
.	O

Though	O
some	O
patients	O
recover	O
renal	O
function	O
partially	O
further	O
progression	O
is	O
rapid	O
especially	O
among	O
those	O
with	O
chronic	O
glomerulonephritis	B-DIS
.	O

After	O
a	O
female	O
patient	O
had	O
presented	O
with	O
advanced	O
renal	B-DIS
failure	I-DIS
bilateral	O
enormous	O
increase	B-DIS
in	I-DIS
kidney	I-DIS
size	I-DIS
radiologically	I-DIS
urinary	I-DIS
tract	I-DIS
infection	I-DIS
E.	O
coli	O
and	O
septicemia	B-DIS
autopsy	O
disclosed	B-DIS
megalocytic	I-DIS
interstitial	I-DIS
nephritis	I-DIS
MIN	O
.	O

Clinical	O
and	O
pathological	O
differentiation	O
from	O
renal	B-DIS
parenchymal	I-DIS
malakoplakia	I-DIS
RPM	O
is	O
discussed	O
.	O

A	O
literature	O
survey	O
of	O
15	O
cases	O
of	O
MIN	O
and	O
35	O
observations	O
of	O
RPM	O
points	O
to	O
certain	O
differences	O
between	O
the	O
two	O
entities	O
i.e	O
.	O

an	O
increased	O
incidence	B-EPI
of	O
bilateral	O
pathology	O
in	O
MIN	O
mor	O
frequent	O
extrarenal	O
localizations	O
in	O
RPM	O
absent	O
Michaelis	O
-	O
Gutmann	O
bodies	O
and	O
a	O
predominantly	O
cortical	O
distribution	O
in	O
MIN	O
.	O

The	O
similarities	O
however	O
suggest	O
that	O
the	O
two	O
conditions	O
might	O
represent	O
different	O
stages	O
of	O
one	O
and	O
the	O
same	O
disease	O
process	O
.	O

Background	O
The	O
data	O
in	O
the	O
literature	O
suggests	O
that	O
Methimazole	O
MMI	O
/Carbimazole	O
CMZ	O
embryopathy	O
is	O
rare	O
.	O

This	O
study	O
examined	O
the	O
incidence	B-EPI
of	O
CMZ	O
embryopathy	O
in	O
the	B-LOC
Hong	I-LOC
Kong	I-LOC
Chinese	O
population	O
and	O
the	O
factors	O
associated	O
with	O
its	O
development	O
.	O

Methods	O
Of	O
the	O
145	O
pregnant	O
women	O
with	O
hyperthyroidism	B-DIS
managed	O
from	O
2008	O
to	O
20102920	B-STAT
%	I-STAT
had	O
taken	O
CMZ	O
during	O
pregnancy	O
.	O

The	O
presence	O
and	O
details	O
of	O
birth	B-DIS
defects	I-DIS
the	O
dosage	O
of	O
CMZ	O
and	O
the	O
period	O
of	O
exposure	O
during	O
pregnancy	O
were	O
examined	O
in	O
these	O
29	O
pregnancies	O
.	O

All	O
cases	O
of	O
CMZ	O
embryopathy	O
in	O
the	O
English	O
literature	O
were	O
reviewed	O
in	O
the	O
same	O
way	O
.	O

Results	O
Of	O
the	O
27	O
babies	O
93.1	B-STAT
%	I-STAT
with	O
known	O
outcome	O
3	O
had	O
aplasia	B-DIS
cutis	I-DIS
and	O
1	O
had	O
an	O
omphalocele	B-DIS
in	O
addition	O
and	O
1	O
affected	O
baby	O
had	O
a	O
sibling	O
with	O
aplasia	B-DIS
cutis	I-DIS
and	O
patent	O
vitellointestinal	B-DIS
duct	I-DIS
.	O

The	O
incidence	B-EPI
of	O
CMZ	O
embryopathy	O
in	O
our	O
study	O
group	O
is	O
11.1	B-STAT
%	I-STAT
.	O

Amongst	O
the	O
21	O
cases	O
of	O
CMZ	O
embryopathy	O
in	O
the	O
literature	O
85	B-STAT
%	I-STAT
were	O
exposed	O
to	O
a	O
CMZ	O
dosage	O
of	O
≥20	O
mg	O
/	O
day	O
and	O
the	O
minimum	O
duration	O
of	O
exposure	O
being	O
7	O
weeks	O
from	O
last	O
menstrual	O
period	O
.	O

The	O
most	O
common	O
abnormality	O
is	O
ectodermal	B-DIS
anomaly	I-DIS
62	B-STAT
%	I-STAT
followed	O
by	O
oro	O
-	B-DIS
nasal	O
anomaly	O
48	B-STAT
%	I-STAT
facial	O
dysmorphism	O
38	B-DIS
%	I-DIS
gastrointestinal	O
anomaly	O
33	B-STAT
%	I-STAT
and	O
abdominal	O
wall	O
defect	O
19	B-STAT
%	I-STAT
.	O

There	O
was	O
no	O
relationship	O
between	O
the	O
type	O
of	O
abnormality	O
and	O
the	O
dosage	O
or	O
duration	O
of	O
exposure	O
to	O
CMZ	O
.	O

Conclusions	O
The	O
incidence	B-EPI
of	O
CMZ	O
embryopathy	O
in	O
our	O
study	O
group	O
is	O
11.1	B-STAT
%	I-STAT
.	O

Critical	O
factors	O
for	O
its	O
development	O
are	O
exposure	O
to	O
a	O
CMZ	O
dosage	O
of	O
≥20	O
mg	O
/	O
day	O
before	O
7	O
weeks	O
of	O
gestation	O
.	O

Genetic	O
susceptibility	O
may	O
also	O
play	O
a	O
role	O
.	O

Background	O
Little	O
is	O
known	O
about	O
the	O
prognosis	O
regarding	O
shunt	O
revision	O
and	O
mortality	O
among	O
hydrocephalus	B-DIS
patients	O
below	O
2	O
years	O
of	O
age	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
investigate	O
1	O
the	O
cumulative	O
risks	O
of	O
shunt	O
revision	O
SR	O
and	O
mortality	O
and	O
2	O
the	O
potential	O
associations	O
between	O
prematurity	B-DIS
low	O
weight	O
for	O
gestational	O
age	O
LWGA	O
underlying	O
aetiology	O
sex	O
age	O
of	O
the	O
child	O
at	O
shunt	O
placement	O
and	O
the	O
risk	O
of	O
SR	O
.	O

Method	O
This	O
was	O
a	O
purely	O
register	O
-	O
based	O
cohort	O
study	O
including	O
all	B-DIS
shunted	O
hydrocephalic	O
infants	O
in	O
Denmark	B-LOC
1996	O
-	O
2015	O
.	O

The	O
cumulative	O
risks	O
of	O
SR	O
and	O
mortality	O
were	O
estimated	O
using	O
the	O
Aalen	O
-	O
Johansen	O
and	O
Kaplan	O
-	O
Meier	O
estimators	O
respectively	O
.	O

A	O
multivariable	O
Cox	O
-	O
regression	O
model	O
was	O
used	O
to	O
estimate	O
hazard	O
ratios	O
HRs	O
for	O
SR	O
according	O
to	O
the	O
listed	O
patient	O
-	O
related	O
risk	O
factors	O
.	O

Results	O
Among	O
374	O
shunted	O
infantile	B-DIS
hydrocephalus	I-DIS
patients	O
accounting	O
for	O
1047	O
SRs	O
the	O
3	O
-	O
month	O
and	O
1	O
-	O
year	O
cumulative	O
risks	O
of	O
SR	O
were	O
36	B-STAT
%	I-STAT
and	I-STAT
50	I-STAT
%	I-STAT
respectively	O
.	O

The	O
overall	O
10	O
-	O
year	O
cumulative	O
mortality	O
was	O
12	B-STAT
%	I-STAT
and	O
for	O
non	O
-	O
tumour	O
subgroups	O
7	B-STAT
-	B-DIS
16	I-STAT
%	I-STAT
isolated	O
hydrocephalus	O
7	B-STAT
%	I-STAT
.	O

The	O
10	O
-	O
year	O
cumulative	O
mortality	O
for	O
children	O
born	O
with	O
LWGA	O
was	O
21	B-STAT
%	I-STAT
.	O

Except	O
for	O
aetiology	O
we	O
observed	O
no	O
strong	O
overall	O
associations	O
between	O
the	O
investigated	O
risk	O
factors	O
and	O
the	O
risk	O
of	O
SR	O
but	O
interaction	O
analyses	O
for	O
aetiology	O
showed	O
that	O
patients	O
with	O
Dandy	B-DIS
-	I-DIS
Walker	O
malformation	O
born	O
with	O
LWGA	O
had	O
a	O
higher	O
risk	O
of	O
SR	O
compared	O
to	O
patients	O
of	O
similar	O
aetiology	O
with	O
normal	O
WGA	O
HR	O
2.4795	B-STAT
%	I-STAT
CI	O
1.39	O
-	O
4.40	O
.	O

Conclusions	O
We	O
found	O
very	O
high	O
cumulative	O
risks	O
of	O
SR	O
and	O
mortality	O
among	O
this	O
youngest	O
group	O
of	O
hydrocephalus	B-DIS
patients	O
disregarding	O
aetiology	O
but	O
none	O
of	O
them	O
were	O
strongly	O
related	O
to	O
the	O
investigated	O
risk	O
factors	O
.	O

